imatinib mesylate has been researched along with Granulocytic Leukemia, Chronic in 4602 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (0.22) | 18.2507 |
| 2000's | 2003 (43.52) | 29.6817 |
| 2010's | 2070 (44.98) | 24.3611 |
| 2020's | 519 (11.28) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Biagioni, S; Brancaccio, D; Bufano, M; Ceramella, J; Coluccia, A; Coluccia, AML; Da Pozzo, E; Hamel, E; Iacopetta, D; La Regina, G; Liu, T; Martini, C; Nalli, M; Orlando, V; Puxeddu, M; Sebastiani, J; Shen, H; Silvestri, R; Sinicropi, MS; Tremolanti, C | 1 |
| Itoh, H; Nakahara, R; Ogata, M; Sumimoto, T; Suzuki, Y; Tanaka, R; Yoshida, N | 1 |
| Gao, L; Peng, ZY; Ren, MQ; Shi, G; Tian, ZG; Yuan, Z | 1 |
| Erçalışkan, A; Eşkazan, AE; Seyhan Erdoğan, D | 1 |
| Baccarani, M; Efficace, F | 1 |
| Bankar, A; Lipton, JH | 2 |
| Sakaida, E | 1 |
| Abruzzese, E; Annunziata, M; Bonifacio, M; Breccia, M; Bucelli, C; Carmosino, I; Colafigli, G; Crugnola, M; Di Raimondo, F; Fava, C; Feo, C; Galimberti, S; Gozzini, A; Guarini, A; Gugliotta, G; Iurlo, A; Latagliata, R; Leonetti Crescenzi, S; Luciano, L; Mauro, E; Rosti, G; Russo Rossi, A; Sgherza, N; Sorà, F; Stagno, F; Tiribelli, M; Trawinska, MM | 1 |
| Himuro, N; Ito, K; Masutani, K; Miyake, K; Morita, N; Nakayama, T; Nawata, A; Ozaki, T; Sasaki, H; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T; Yokota, S | 1 |
| Aoki, M; Ishikawa, M; Kanda, Y; Maki, A; Matsumura, I; Nakamae, H; Ohmine, K; Ono, T; Sakaida, E; Shibayama, H; Yamamoto, M | 1 |
| Abdullah, SM; Ahmad, I; Akhter, J; Ali Beg, MM; Goyal, Y; Guru, SA; Rizvi, A; Verma, AK | 1 |
| Berman, E | 2 |
| Ahmad, M; Bucci, T; Cass, AS; Crona, DJ; Deal, A; Foster, MC; Kemper, R; Muluneh, B; Sketch, MR; Szeto, AH; Zeidner, JF; Zhu, A | 1 |
| Attrotto, C; Capuano, E; Ceci Ginistrelli, L; de Pretis, S; Fatica, A; Fazi, F; Franceschini, L; Iaiza, A; Ianniello, Z; Marchioni, M; Masciarelli, S; Ottone, T; Pelizzola, M; Rizzo, M; Sorci, M; Tito, C; Voso, MT | 1 |
| Akahane, K; Björn, N; Inukai, T; Keszei, M; Lotfi, K; Madapura, HS; Malyukova, A; Nagy, N; Nguyen, TTT; Salamon, D; Stenke, L; Tamai, M; Ujvari, D; Wallvik, J; Yektaei-Karin, E; Zovko, A | 1 |
| Hu, C; Lin, Y; Ren, Y; Xu, X; Yin, S; Zhang, A | 1 |
| Chan, CK; Mohamed, S; Szeto, SK; Tsang, CW | 1 |
| Agha, IY; Aljurf, M; Blok, HJ; Browne, P; Chalandon, Y; De Witte, T; Ganser, A; Hayden, P; Helbig, G; Hoek, J; Iacobelli, S; Kroeger, N; Masouridi-Levrat, S; Morozova, E; Nagler, A; Niittyvuopio, R; Olavarria, E; Passweg, J; Reményi, P; Robin, M; Sengeloev, H; Snowden, JA; Van Gorkom, G; Wallet, HL | 1 |
| Martins, JBL; Nascimento, ÉCM; Rocha, KML | 1 |
| Chang, PY; Chen, JH; Chen, YC; Chen, YG; Chiu, YL; Dai, MS; Ho, CL; Huang, TC; Lai, HF; Lai, SW; Lee, CH; Liu, WN; Wu, YY; Ye, RH | 1 |
| Snyder, D | 1 |
| Cao, YJ; Rao, GW; Xu, XL; Zhang, W | 1 |
| Capannacci, J; Carvalho, RF; Cury, SS; Hokama, NK; Hokama, POM; Martins, JRB; Moraes, LN; Nogueira, CR | 1 |
| Chen, CN; Chou, AK; Fu, CM; Kung, PJ; Li, MJ; Liao, LC; Su, PY; Tan, BF | 1 |
| Ben Said, F; Elloumi, M; Kallel, F; Kassar, O; Khabir, A; Ksouda, K; Mallek, R | 1 |
| Amesty, A; Aranda-Tavío, H; Blanco, R; Brito-Casillas, Y; Estévez-Braun, A; Fernández-Pérez, L; Gandullo-Sánchez, L; Guerra, B; Guerra-Rodríguez, M; Junco, V; León, J; Martín-Acosta, P; McNaughton-Smith, G; Montero, JC; Pandiella, A; Recio, C; Zapata, JM | 1 |
| An, F; Brümmendorf, TH; Cortes, JE; Crescenzo, RJ; Ferdinand, R; Gambacorti-Passerini, C; Kim, DW; Kota, V; Leip, E; Lipton, JH | 1 |
| Bakhshayesh, M; Barati, M; Gohari, LH; Safa, M | 1 |
| Corral Alaejos, Á; Jiménez Cabrera, S; Otero, MJ; Pérez-Blanco, JS; Sánchez-Guijo, F; Zarzuelo Castañeda, A | 1 |
| Abdel Hamid, M; Aref, S; Ayed, M; El-Sokkary, AMA; Fathy El-Metwaly, N | 1 |
| Abraham, I; De Geest, S; Lee, CS; MacDonald, K; Obeng-Kusi, M; van Lierde, MA | 1 |
| Go, TH; Jang, J; Kim, Y; Kong, JH; Lee, JB; Lee, JI; Lim, ST; Shim, KY | 1 |
| Albanese, SK; Berger, BT; Chodera, JD; Guo, J; Knapp, S; Lyczek, A; Paung, Y; Philipose, H; Rangwala, AM; Robers, MB; Seeliger, MA; Tom, J | 1 |
| Kalodimos, CG; Miller, D; Rossi, P; Saleh, T; Xie, T | 1 |
| Afacan Öztürk, HB; Albayrak, M; Maral, S; Reis Aras, M; Sağlam, B; Tığlıoğlu, M; Tığlıoğlu, P; Yılmaz, F | 1 |
| Guo, JJ; Hincapie, AL; Li, Y; Yue, X | 1 |
| Huang, ZY; Lu, YH | 1 |
| Chang, YS; Fu, SL; Huang, CF; Jiang, JH; Kuo, YH; Lin, WJ; Liu, MY; Wei, SH | 1 |
| Bai, D; Chen, K; Chen, Q; Deng, M; Ding, L; Gao, D; Jiang, Y; Li, G; Xu, B; Zhang, H | 1 |
| Bouscary, D; Coiteux, V; Dekiouk, S; Fovez, Q; Germain, N; Ghesquiere, B; Idziorek, T; Jean-Pierre, S; Joncquel, M; Khamari, R; Kluza, J; Laine, W; Maboudou, P; Maguer-Satta, V; Mahon, FX; Marchetti, P; Quesnel, B; Trinh, A; Turcq, B | 1 |
| Baerlocher, GM; Egeli, DB; Hanfstein, B; Lauseker, M; Müller, MC; Pfirrmann, M; Saussele, S | 1 |
| Deng, ZK; Han, X; Liu, XN; Yu, L; Zhang, CW | 1 |
| Cao, SY; Huang, JX; Jiang, YQ; Liu, XL; Wang, JS; Weng, JY; Xiao, SS; Xu, N; Yuan, Z; Zhu, HQ | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Hussain, S; Klugar, M; Sharma, M; Singh, AK | 1 |
| Aranguren, PN; Belli, CB; Bestach, Y; Bordone, J; Enrico, A; Larripa, IB; Lincango-Yupanki, M; Mariano, R; Pérez, M; Tarqui, M; Toloza, MJ | 1 |
| Jang, EJ; Kee, KM; Kim, DW; Kim, HT; Kim, SH; Lee, SM; Nam, YW; Park, SH; Shin, JU; Yang, SY | 1 |
| Ai, Z; Chen, L; Li, G; Li, Y; Ma, C; Wan, R; Yin, J | 1 |
| Castro Hernández, C; de la Torre-Luján, AH; Fabian-Morales, E; Frias, S; González-Barrios, R; Gudiño, A; Herrera, LA; López Saavedra, A; Oliva-Rico, DA; Ornelas Guzmán, EC; Rodríguez Torres, YL; Rodríguez, A; Vallejo-Escamilla, D | 1 |
| Gan, L; Ge, W; Guo, T; Liu, K; Liu, W; Sun, Y; Zhang, F; Zhu, Y | 1 |
| Autore, F; Chiusolo, P; Colangelo, M; Minnella, G; Rossi, E; Sica, S; Sora', F | 1 |
| Funakoshi-Tago, M; Mashino, T; Nakazawa, Y; Ohe, T; Sumi, K; Tago, K; Takahashi, K | 1 |
| Huang, Z; Liang, Y; Liu, M; Zhang, J; Zhang, M | 1 |
| Chang, LS; Chiou, JT; Huang, CH; Huang, PW; Lee, YC; Wang, LJ; Wu, TH | 1 |
| Aguzzi, C; Amantini, C; Maggi, F; Marinelli, O; Morelli, MB; Nabissi, M; Santoni, G; Tomassoni, D; Zeppa, L | 1 |
| Apperley, JF; Claudiani, S; Dominy, KM; Foroni, L; Foskett, P; Gerrard, G; Khorashad, J; Milojkovic, D; O'Hare, M; Szydlo, R | 1 |
| Dahlén, T; Dreimane, A; Edgren, G; Flygt, H; Höglund, M; Ljungman, P; Myhr-Eriksson, K; Olsson-Strömberg, U; Richter, J; Själander, A; Stenke, L; Wadenvik, H; Zhao, J | 1 |
| Kesselheim, AS; Rome, BN; Sarpatwari, A; Walsh, BS | 1 |
| Adachi, K; Araki, M; Asada, S; Fukushima, T; Fukuyama, T; Goyama, S; Imai, M; Ito, R; Kitamura, T; Komatsu, N; Lamagna, C; Masuda, ES; Mikami, K; Morishita, S; Nagata, M; Takaku, T; Takeda, R; Takizawa, H; Tamura, M; Tanaka, Y; Tsuchiya, S; Umemoto, T; Watanabe, N | 1 |
| Fan, S; Fu, J; Li, D; Li, H; Liu, Y; Zhang, Q; Zhao, Y | 1 |
| Barbosa, ADP; Carneiro, WJ; Cruz, AC; Cunha, LCD; Cunha, MMBD; Dewulf, NLS; Lemes, GA; Oliveira, FNM; Rodrigues Martins, M | 1 |
| Anila, KN; Jayakumar, S; Krishna, A; Mahima, A; Merin, D; Sidharthan, N | 1 |
| Chen, X; Chen, Y; Cheng, H; Liu, S; Mai, H; Wen, F; Xu, H; Yi, M; Yuan, X; Zhang, M | 1 |
| Bett, Y; Ezzi, M; McLigeyo, A; Mwanzi, S; Odhiambo, A; Ong'ondi, M; Othieno-Abinya, N; Oyiro, P; Rajab, J | 1 |
| Lv, K; Tong, W | 1 |
| Gilreath, JA; Pokorny, R; Stenehjem, DD | 1 |
| Al Nahedh, M; Aljurf, M; Baqal, OJ; Binzaid, AA; Samarkandi, HH; Soheib, M | 1 |
| Koyakutty, M; Melge, AR; Mohan, CG; Parate, S; Pavithran, K | 1 |
| Joubert, AM; Karodia, M; Pool, R; Repsold, L; Tintinger, G | 1 |
| Ali, R; Alnıgeniş, E; Ayyıldız, O; Eşkazan, AE; Haznedaroğlu, İ; Kırkızlar, O; Kurtoğlu, E; Malhan, S; Öksüz, E; Polat, Ö; Saydam, G; Sönmez, M; Toprak, SK; Toptaş, T; Turgut, M | 1 |
| Gale, RP; Huang, XJ; Jiang, Q; Zhang, MJ; Zhang, XS | 1 |
| Havanur, P; Kharkar, V; Khopkar, U; Mahajan, S; Pardeshi, SS | 1 |
| Assumpção, PP; Azevedo, TCB; Barros, MCDC; Burbano, RMR; Carvalho, DC; Cereja Pantoja, KBC; Cohen Paes, AN; Fernandes, MR; Freitas, ARS; Monte, N; Santos, NPCD; Santos, SEBD; Vinagre, LWMS | 1 |
| Balogun, MO; Bamgboje, AO; Durosinmi, MA; Fagbayimu, MO; Fajobi, O; Mene-Afejuku, TO | 1 |
| Ahn, JS; Kim, HJ; Ko, GH; Park, SG; Sim, KY; Yang, T | 1 |
| Roskoski, R | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Kumar, A; Sharma, M; Singh, AK | 1 |
| Angkasa, YK; Rajabto, W | 1 |
| Cao, H; Li, Y; Liang, D; Rong, S; Sun, G; Sun, H; Sun, Y; Wang, R; Wang, X; Xie, S; Yan, Y; Zhou, X | 1 |
| Cui, MM; Fu, PY; Huang, L; Liu, X; Wang, GC; Zhu, HZ | 1 |
| Beck, JC; Patel, SA | 1 |
| Ji, C; Li, P; Liu, N; Liu, Q; Ma, D; Sun, Y; Wang, Y; Ye, J; Yu, S; Zhang, J; Zhu, X | 1 |
| Friedman, R; Lindström, HJG | 1 |
| Akmal Hisham, H; Chang, KM; Ibrahim, L; Mat Yusoff, Y; Mohd Yacob, A; Muhamad, NA | 1 |
| Eldin, SMK; Gohar, SF; Muharram, NM; Shehata, AMF | 1 |
| Chen, W; Pathak, A; Yang, D; Yang, Y; Zhai, Y; Zhang, Y | 1 |
| Beg, MMA; Guru, SA; Koner, BC; Mir, R; Saxena, A; Sumi, MP | 1 |
| Hirabayashi, K; Minagawa, A; Morita, D; Nakazawa, H; Nakazawa, Y; Okura, E; Saito, S; Tanaka, M; Uchida, E | 1 |
| Fajar, JK; Rahayu, P; Susianti, H; Wardhani, SO; Yueniwati, YP | 1 |
| Belfrak, F; Beloufa, S; Benlazar, M; Benmehimda, NC; Mahi, E; Matmour, D; Merad, Y; Si-Ali, N; Toumi, H | 1 |
| Andrianov, AM; Bosko, IP; Ignatovich, ZV; Karpenko, AD; Kornoushenko, YV; Koroleva, EV; Siniutsich, JV | 1 |
| Chen, Y; Cheng, F; He, W; Li, W; Liu, Z; Meng, L; Wang, D; Zhang, Y; Zou, J | 1 |
| Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Iwanaga, E; Kawaguchi, T; Kimura, Y; Kizaki, M; Komatsu, N; Nakazato, T; Nishiyama-Fujita, Y; Sato, E; Sugimoto, K; Takaku, T; Tokuhira, M; Tsuchiya, S | 1 |
| Cenda, A; Chukwu, O; Jakóbczyk, M; Kamińska, M; Sacha, T; Szczepanek, E; Wącław, J; Wysogląd, H; Zawada, M | 1 |
| Camacho Zamora, A; Castillo-Martínez, L; Castillo-Martínez, MJ; Milke-García, MDP; Tuna-Aguilar, EJ; Villegas Cervantes, V | 1 |
| Akahane, K; Goi, K; Harama, D; Inukai, T; Kagami, K; Kasai, S; Nguyen, TTT; Tamai, M; Watanabe, A | 1 |
| Hao, RR; Huang, WH; Liang, MH; Pan, YL; Shen, ZR; Zeng, SX | 1 |
| Gale, RP; Huang, XJ; Jiang, Q; Yang, S; Zhang, XS | 1 |
| Ali, V; Gupta, SK; Kumar, V; Singh, P; Verma, M | 1 |
| Asgaritarghi, G; Farsani, SSM; Najafi, F; Sadeghizadeh, D; Sadeghizadeh, M | 1 |
| Berger, MG; Cayssials, E; Charbonnier, A; Coiteux, V; Cony-Makhoul, P; Dubruille, V; Dulucq, S; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Guerci-Bresler, A; Henni, T; Ianotto, JC; Jardel, H; Johnson-Ansah, H; Joly, B; Legros, L; Lenain, P; Liu, J; Mahon, FX; Martiniuc, J; Morisset, S; Nicolini, FE; Rea, D; Rigal-Huguet, F; Robbesyn, F; Rousselot, P; Turlure, P; Villemagne, B; Zunic, P | 1 |
| Akıncı, S; Bakanay, ŞM; Çavdarlı, B; Ceran, F; Dağdaş, S; Dilek, İ; Falay, M; Gündüz, M; Korkmaz, G; Özet, G; Uçar, MA | 1 |
| Ciaffaglione, V; Consoli, V; Floresta, G; Greish, K; Intagliata, S; Marrazzo, A; Pittalà, V; Rescifina, A; Romeo, G; Salerno, L; Sorrenti, V; Vanella, L | 1 |
| Chan, GC; Cheng, FW; Cheuk, DK; Chiu, KH; Ho, KK; Leung, AW; Leung, WY; Li, CH | 1 |
| Chen, CW; Chen, YC; Fan, CK; Huang, HM; Huang, NK; Lee, YL; Liu, CW | 1 |
| Gale, RP; Huang, XJ; Jiang, Q; Li, ZY; Zhang, MY; Zhang, XS | 1 |
| Gokarn, A; Gota, V; Govalkar, R; Jadhav, S; Khattry, N; Krishnamurthy, MN; Kumar, S; Mehta, P; Patil, A; Punatar, S; Puri, AS; Shriyan, B | 1 |
| Atallah, EL; Pettit, K; Radich, J; Rezazadeh, A | 1 |
| Abdelfattah, R; Hamza, MS; Moussa, HS; Omran, MM; Shouman, SA | 1 |
| Benesova, A; Cerveira, N; Colomer, D; Coriu, D; Cross, NCP; Ernst, T; Franke, GN; Glauche, I; Gottardi, E; Gottschalk, A; Hochhaus, A; Hovorkova, L; Izzo, B; Jurcek, T; Klamova, H; Koblihova, J; Lion, T; Markova, MS; Mayer, J; Motlova, E; Polakova, KM; Polivkova, V; Roeder, I; Salmon, M; Schäfer, V; Srbova, D; Venturi, C; Vigneri, P; White, HE; Zackova, D; Zawada, M; Zizkova, H; Zuna, J | 1 |
| Chen, YL; Li, WM; Zhang, YL; Zou, J | 1 |
| Dai, B; Du, X; Gong, Z; Ji, Y; Li, S; Ma, W; Shi, X; Wang, B; Wang, Y; Yang, T; Zhan, Y; Zhang, D; Zhang, Y; Zhu, M | 1 |
| Gao, L; Tian, ZG; Weng, LC; Xu, Y | 1 |
| Biray Avci, C; Gunduz, C; Karatekin, I; Kipcak, S; Ozel, B; Sabour Takanlou, L; Sabour Takanlou, M; Selvi Gunel, N; Tezcanli Kaymaz, B | 1 |
| Ammerpohl, O; Böhm, R; Bruckmueller, H; Cascorbi, I; Kaehler, M; Kolarova, J; Litterst, M; Nagel, I | 1 |
| Abd El Hai, D; Allam, AA; Hodeib, H; Mansour, W; Sabry, NM; Sarhan, ME; Selim, A; Selim, AF; Tawfik, MA; Youssef, A | 1 |
| Alonso, RA; Ayala, R; Calbacho, M; Carreño-Tarragona, G; Colmenares, R; Cruz-Rojo, J; de la Cruz, J; García-Barrio, N; Gil, R; Gil-Alos, D; Hernández, G; Lopez, N; Martínez-López, J; Meloni, L; Pedrera-Jiménez, M; Pérez-Rey, D; Sánchez-Pina, J; Sanz, A; Serrano-Balazote, P | 1 |
| Jabbour, E; Kantarjian, H | 3 |
| Doytchinova, I; Iwanov, I; Momekov, G; Montesi, M; Naydenova, E; Panseri, S; Rossi, A; Sargsyan, A | 1 |
| Akhtar, J; Gupta, N; Khan, AA; Nafees, S; Rahman, AU; Sharma, A | 1 |
| Breccia, M; Cortes, JE; García-Gutiérrez, V; Jabbour, E; Mauro, M | 1 |
| Bigirimana, JB; Bihizimana, P; DeBoer, RJ; Lehmann, LE; Morgan, J; Mugabo, F; Nguyen, C; Nsabimana, N; Paciorek, A; Ruhangaza, D; Shulman, LN; Shyirambere, C; Umwizerwa, A; Villaverde, C | 1 |
| Du, X; Jin, J; Liu, P; Lou, J; Meng, L; Wang, W; Yu, W | 1 |
| Copland, M | 1 |
| Chang, H; Chen, CC; Chen, TY; Hsiao, PC; Kuo, MC; Lin, TH; Lin, TL; Ma, MC; Shih, LY; Su, YJ; Teng, CJ; Wang, MC; Wang, PN; Yang, Y | 1 |
| Hwang, EJ; Kim, DW; Kim, DY; Kim, E; Kim, JY; Lee, J | 1 |
| Arenas-Ramírez, A; Cervera-Ceballos, E; Garcia-Lopez, P; Jurado, R; Llaguno-Munive, M; Pérez-Rojas, J; Prado-Carrillo, O | 1 |
| Huang, M; Lu, D; Wang, H; Wang, M; Zhang, Q; Zhou, W; Zhu, Y | 1 |
| Aftandilian, C; Ford, M; Hijiya, N; Mauro, M; Sakamoto, KM | 1 |
| Bauduer, F; Bris, YL; Cayuela, JM; Chabane, K; Chevallier, P; Cony-Makhoul, P; Dulucq, S; Flandrin-Gresta, P; Hayette, S; Jeune, CL; Legros, L; Mahon, FX; Maisonneuve, H; Nicolini, FE; Rea, D; Roy, L; Sloma, I | 1 |
| Fukuoka, N; Goto, H; Kawabe, K; Koike, H; Nakayama, T; Ooba, N; Sahashi, Y; Sakamoto, Y; Suzuki, T | 1 |
| Akashi, K; Haji, S; Hirata, A; Kato, K; Kimura, D; Masuda, T; Miyamoto, T; Nakashima, N; Nakashima, Y; Nojiri, C; Ogawa, Y; Shiratsuchi, M; Tokunaga, S; Tsuda, M | 1 |
| Angelucci, A; Aronne, R; Carbone, A; Cianciusi, A; Crespan, E; Deplano, S; Di Maria, S; Dreassi, E; Maccioni, E; Maga, G; Molinari, A; Mori, M; Musumeci, F; Perini, C; Picarazzi, F; Poggialini, F; Sabetta, S; Schenone, S | 1 |
| Aizawa, M; Fujisawa, S; Hino, M; Ishizawa, K; Koide, Y; Matsumura, I; Ono, C; Ono, T; Sakaida, E; Sekiguchi, N; Takahashi, N; Tanetsugu, Y | 1 |
| Björn, N; Keszei, M; Lotfi, K; Madapura, HS; Malyukova, A; Nagy, N; Salamon, D; Stenke, L; Ujvari, D; Wallvik, J; Yektaei-Karin, E; Zovko, A | 1 |
| Abedi, E; Lak, ER; Ramzi, M; Ranjbaran, R; Sharifzadeh, S; Tamaddon, G | 1 |
| Fabarius, A; Haferlach, C; Hehlmann, R; Hochhaus, A; Lauseker, M; Saußele, S; Voskanyan, A | 1 |
| Ansah, HJ; Berger, MG; Daguenet, E; Guerci-Bresler, A; Hamroun, D; Hermet, E; Huguet, F; Lambert, C; Pereira, B; Saugues, S; Tchirkov, A; Turhan, A | 1 |
| El-Haggar, SM; Elkholy, MM; Fahmi, MW | 1 |
| Feng, W; Jiang, G; Liang, Y; Peng, Y; Qin, Y; Wang, J | 1 |
| Huang, Y; Liu, Q; Wang, L; Yuan, C | 1 |
| Boni, C; Calvanese, D; Carpentieri, B; Dewik, NA; Ferracin, M; Ismail, MA; Latorre, RV; Lecca, P; Lombardi, G; Mosca, A; Negrini, M; Sorio, C; Tomasello, L; Yassin, M | 1 |
| Allan, JM; Blair, HJ; Dannoura, A; Dueñas, ME; Heidenreich, O; Heunis, T; Inns, J; Marín-Rubio, JL; Martin, MP; Peltier-Heap, RE; Saxty, B; Scott, J; Simpson, AJ; Trost, M; Watt, JE | 1 |
| Adattini, JA; Gross, AS; McLachlan, AJ; Wong Doo, N | 1 |
| Acharjee, M; Basu, S; Bhattacharyya, D; Dey, S; Gupta, PP; Nath, S; Roychoudhury, S; Shah, S | 1 |
| Jabbour, E; Kantarjian, H; Paul, S; Thakkar, J | 1 |
| Feng, W; Jiang, G; Liang, Y; Qin, Y; Yuan, Y | 1 |
| Agrawal, R; Corbin, R; Negi, H; Rajput, T; Ryan, J; Viana, R; Vieira, J | 1 |
| Chen, Y; Cheng, F; Cui, Z; Li, Q; Li, W; Zeng, F; Zhang, Y | 2 |
| Appelmann, I; Brümmendorf, TH; Koschmieder, S; Maletzke, S; Masouleh, BK; Salimi, A; Schemionek, M; Schroeder, KM; Vieri, M | 1 |
| Aksel, M; Alankuş, Ö; Bölükbaşı, SŞ; Çiftçi, H; Emirdağ, S; Fujita, M; Karayıldırım, T; Otsuka, M; Özmen, A; Radwan, MO; Sever, B; Sözer, E; Tateishi, H; Ulusoy, NG; Yaylı, N | 1 |
| Badhan, RKS; Yu, H | 1 |
| Bertorelle, R; Binotto, G; Bonifacio, M; Calistri, E; D'Amore, F; Damiani, D; De Matteis, G; Di Giusto, S; Ermacora, A; Fanin, R; Griguolo, D; Krampera, M; Miggiano, MC; Scaffidi, L; Scotton, G; Semenzato, G; Stella, R; Stulle, M; Tiribelli, M; Toffoletti, E | 1 |
| Chen, X; Ding, W; Hu, M; Jiang, L; Lan, X; Liao, S; Liu, A; Liu, B; Liu, J; Meng, Y; Peng, G; Shi, X; Wang, J; Zhang, H; Zhou, H | 1 |
| Aljurf, M; Apperley, J; Broers, AEC; Byrne, J; Chalandon, Y; Choi, G; Gras, L; Hayden, PJ; Helbig, G; Kinsella, F; Koster, L; Kröger, N; Lenhoff, S; McLornan, DP; Mielke, S; Passweg, J; Reményi, P; Robin, M; Salmenniemi, U; Sbianchi, G; Sengeloev, H; Snowden, JA; Tan, SM; Yakoub-Agha, I; Yegin, ZA | 1 |
| Antunes, MV; de Souza Guterres, F; Fogliatto, LM; Kohlrausch, R; Krützmann, ME; Linden, R; Martini, RR; Mattevi, VS; Torriani, MS; Wagner, SC | 1 |
| Fukuhara, N; Onodera, K | 1 |
| Biswas, G; Biswas, S; Chakraborty, S; Chanda, S; Mohapatra, S; Singh, VK; Vinothkumar, K | 1 |
| Cheng, F; Li, Q; Liu, W; Shen, N; Tang, L; You, Y; Yuan, G; Zhu, X; Zou, P | 1 |
| Ishida, T; Jobu, K; Kawada, K; Miyamura, M; Morisawa, S; Okazaki, M; Sugimoto, S; Tamura, N; Yoshioka, S | 1 |
| Ando, T; Itamura, H; Kamachi, K; Katsuya, H; Kimura, S; Okamoto, S; Sano, H; Ureshino, H; Yoshimura, M | 1 |
| Kawaguchi, T; Kizaki, M; Matsumura, I; Naoe, T; Ohnishi, K; Ono, T; Suzuki, R; Takahashi, N; Yamamoto, K | 2 |
| Amor, IB; Elloumi, M; Kahla, AB; Kallel, F; Kassar, O; Koubaa, A | 1 |
| Akın, MG; Çiftçiler, R; Erat, Z; Eşkazan, AE | 1 |
| Su, Y; Sun, H; Yi, H; Zhang, X | 1 |
| Briant, A; Brossier, D; De Moerloose, B; Delehaye, F; Dworzak, M; Güneş, AM; Hraskova, A; Kalwak, K; Lausen, B; Li, CK; Millot, F; Parienti, JJ; Rouger, J; Roula, F; Sedlacek, P; Srdjana, C; Suttorp, M; Versluys, B | 1 |
| Itoh, Y; Nakamura, Y; Wakimoto, N | 1 |
| Jurajda, M; Knight, A; Mayer, J; Piskacek, M; Prochazkova, J; Racil, Z; Zackova, D | 1 |
| Basal, FB; Bilgetekin, I; Karacin, C; Oksuzoglu, OB | 1 |
| Achakzai, NM; Ali, I; Asif, M; Baloch, Z; Hussain, A; Rasool, M | 1 |
| Balabanov, S; Cantoni, N; Kahn, S; Kulenkampff, E; Lambert, JF; Schmidt, A; Seitz, P; Sommavilla, R; Zenhaeusern, R | 1 |
| Brewinska-Olchowik, M; Dudka, W; Hoser, G; Klejman, A; Kominek, A; Kusio-Kobialka, M; Machnicki, MM; Mondal, SS; Piwocka, K; Seferynska, I; Stoklosa, T; Swatler, J; Turos-Korgul, L; Wiech, M; Wołczyk, M | 1 |
| Eşkazan, AE | 8 |
| Beninati, S; Brunello, A; Feriotto, G; Mischiati, C; Tabolacci, C; Tagliati, F | 1 |
| Altmann, DM; Apperley, JF; Boyton, RJ; Claudiani, S; Gibbons, JM; Innes, AJ; Liu, S; Loaiza, S; McKnight, Á; Milojkovic, D; Pade, C; Palanicawander, R; Pieper, FP; Reynolds, CJ; Sandoval, DM | 1 |
| Artus, J; Bennaceur-Griscelli, A; Coignard, S; de Souza, LEB; Desterke, C; Foudi, A; Hugues, P; Ijjeh, Y; Riccaldi, S; Rittavee, Y; Simanic, I; Turhan, AG | 1 |
| Breccia, M; Chiodi, F; Coco, P; Degli Esposti, L; Giacomini, E; Nardozza, AP; Perrone, V; Premoli, E; Rendace, MC; Sangiorgi, D; Valsecchi, D | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Chandra Patra, P; Halder, R; Kapoor, J; Singh, R | 1 |
| Cao, W; Jia, L; Liu, L; Qiu, Y; Shi, L; Wang, X; Xiao, Y; Yu, Y; Zhang, H; Zhang, R | 1 |
| Feng, W; Jiang, G; Peng, Y; Qin, Y; Wang, J; Yuan, Y; Zeng, F | 1 |
| Aizuddin, AN; Mohamad Selamat, E; Sathar, J; Tumian, NR; Wan Puteh, SE | 2 |
| Böttcher, M; Häselbarth, L; Jitschin, R; Karow, A; Krumbholz, M; Mentz, K; Metzler, M; Mougiakakos, D; Roche-Lancaster, O | 1 |
| Abdelfattah, R; Allam, RM; Azim, SA; Omran, MM; Sabri, A; Shouman, SA | 1 |
| Arai, H; Matsubara, T; Mii, A; Minamiguchi, S; Miyake, T; Muso, E; Shimizu, A; Tochio, A; Yamamoto, S; Yanagita, M | 1 |
| Adattini, JA; Doo, NW; Gross, AS; McLachlan, AJ | 1 |
| Eckart, F; Knöfler, R; Suttorp, M; Tauer, JT | 1 |
| Allard, NAE; Blijlevens, NMA; Boss, M; Gotthardt, M; Hopman, MTE; Janssen, L; Lobeek, D; Schirris, TJJ; Swaans, GJA; Timmers, S | 1 |
| Azizi, M; Bahmani, H; Hamid, M; Mohammadi, F; Rostami, G; Shafiei, M | 1 |
| Prasad, V; Walia, A | 1 |
| Dang, HB; Jiang, Q; Li, WM; Liang, LX; Liu, BC; Liu, XL; Song, YP; Xu, N; Yang, YF; Zhang, Y; Zhao, HF | 1 |
| Chen, JS; Chen, SH; Chen, TY; Cheng, CN; Jaing, TH; Kuo, MC; Lin, TH; Lin, TL; Liu, HC; Ma, MC; Sheen, JM; Shih, LY; Wang, MC; Wang, PN; Wang, SC; Wu, KH; Yang, Y; Yeh, TC | 1 |
| Cai, F; Ding, Y; Huang, F; Li, B; Li, J; Xu, D | 1 |
| Allahyari, A; Jafari-Nozad, AM; Maharati, A; Zangooie, A | 1 |
| Cao, YP; Li, ZZ; Luo, L; Shi, PC; Song, YF; Zhang, TG; Zhu, XJ | 1 |
| Fang, Q; Hu, TZ; Liu, P; Luo, H; Pan, CY; Shang, Q; Wang, JS; Zhang, TZ; Zhao, NQ | 1 |
| Ballarò, D; Buffolino, S; Lapietra, G; Limongi, MZ; Mancini, M; Martelli, M; Nanni, M | 1 |
| Baron, J; Fu, K; Hernandez-Ilizaliturri, F; Jani Sait, SN; Kashef, F; Przespolewski, ER; Thompson, J | 1 |
| Deng, Y; Gao, Q; Huang, R; Li, X; Rao, J; Wang, R; Wang, X; Xiao, Y; Yang, S; Zhang, X | 1 |
| Cui, X; Feng, Y; He, W; Hu, Y; Huang, J; Li, M; Li, N; Li, Q; Li, Z; Pan, C; Qiu, H; Qiu, Q; Sample, KM; Sun, Y; Wang, B; Wang, Z; Yang, L; Yin, Y; Zheng, L | 1 |
| Bari, S; Chan, ZE; Cheung, AMS; Chng, WJ; Chuah, C; Hwang, WYK; Krishnan, V; Lee, KL; Lim, MGL; Makheja, M; Nawaz, Z; Ong, ST; Ouyang, J; Prabhakar, S; Rackham, O; Rayan, NA; Ren, X; Schmidt, F; Tan, TZ; Than, H; Venkatesh, PN; Yu, M | 1 |
| Agrawal, N; Ahmed, R; Bhurani, D; Sharma, M; Singh, AK; Vidyadhari, A | 1 |
| Aleem, A; AlFaifi, A; Alotaibi, G; Iqbal, Z | 1 |
| Mlejnek, P | 1 |
| Altamura, H; Braley, J; Branford, S; Feng, J; Grigg, AP; Hughes, TP; Kenyon, RR; King, RM; Kok, CH; Lin, M; Mills, AK; Pagani, IS; Ross, DM; Saunders, V; Schreiber, AW; Schwarer, AP; Scott, HS; Shahrin, N; Shanmuganathan, N; Thomson, D; Wadham, C; Wang, P; Yeung, DT; Yong, ASM | 1 |
| Cao, J; Chen, F; Chen, Y; Feng, XH; Gao, C; Gu, S; Li, X; Liang, T; Lin, X; Liu, X; Qin, J; Tong, H; Wang, L; Xu, P; Yu, Y; Yuan, S; Zhao, B | 1 |
| Cony-Makhoul, P; De Mas, V; Dulucq, S; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Hayette, S; Klein, E; Lacoste-Roussillon, C; Legros, L; Liu, J; Mahon, FX; Morisset, S; Nicolini, FE; Raynaud, S; Rea, D; Rigal-Huguet, F; Robbesyn, F; Rousselot, P | 1 |
| Bhattacharya, M; Cronin, KA; de Claro, RA; Ehrlich, LA; Gormley, NJ; Howlader, N; Mariotto, AB; Richardson, NC; Sharon, E; Wood, AE | 1 |
| Bouderlique, T; Cai, H; Chang, M; Deneberg, S; Dolinska, M; Ekblom, M; Gao, Y; Hellström-Lindberg, E; Jädersten, M; Johansson, AS; Kondo, M; Le Blanc, K; Lehmann, S; Leonard, E; Li, X; Månsson, A; Medina, JP; Mustjoki, S; Olsson-Strömberg, U; Östman, A; Qian, H; Sandhow, L; Shen, J; Sigvardsson, M; Söderlund, S; Stenke, L; Tobiasson, M; Ungerstedt, J; Xiao, P | 1 |
| Banothu, KK; Gupta, AK; Gupta, P; Haldar, P; Meena, JP | 1 |
| Abd Elkader, AS; Abdel Hammed, MR; Mohamed, NM; Nafady, HA | 1 |
| Goni, D; Jain, A; Jandial, A; Jindal, N; Khadwal, A; Lad, D; Malhotra, P; Nampoothiri, R; Naseem, S; Prakash, G; Singh, C; Varma, N | 1 |
| Abdo, ARN; Bendit, I; Ferreira, APS; Ferreira, MPS; Giorgi, RR; Maciel, FVR; Nardinelli, L; Rego, EM; Rocha, V; Ruiz, ARL; Santos, FM; Seguro, FS | 1 |
| Despas, F; Lapeyre-Mestre, M; Pajiep, M | 1 |
| Abdulrouf, PV; Al-Dewik, NI; Al-Jurf, R; Farrell, T; Ismail, MA; Morsi, H; Nagy, M; Nasrallah, GK; Qoronfleh, MW; Sorio, C; Younes, S; Zayed, H; Ziyada, A | 1 |
| Albano, F; Annunziata, M; Bocchia, M; Breccia, M; Castagnetti, F; Dragani, M; Esposito, MR; Galimberti, S; Gugliotta, G; Iovine, M; Iurlo, A; Latagliata, R; Luciano, L; Martino, B; Palmieri, R; Pregno, P; Rosti, G; Sica, A; Sica, S; Sorà, F; Tiribelli, M | 1 |
| Issa, GC; Jabbour, E; Kantarjian, HM; Lipton, JH; Radich, JP; Sasaki, K; Senapati, J | 1 |
| Bu, X; Ding, R; Feng, L; Li, M; Li, R; Li, Y; Qu, X; Ru, Y; Shen, L; Shen, T; Song, W; Wang, L; Wang, Y; Zhang, J; Zhang, P | 1 |
| Bai, YL; Chen, CY; Chen, SN; Du, X; Feng, R; Gale, RP; Han, YQ; Hu, JD; Huang, J; Huang, XJ; Jia, ZL; Jiang, Q; Jing, Y; Li, F; Li, GH; Li, WM; Liang, R; Lin, LE; Liu, BC; Liu, CS; Liu, XL; Liu, YL; Liu, ZF; Liu, ZG; Luo, JM; Meng, JX; Meng, L; Pan, L; Qiu, HY; Sun, XL; Sun, ZQ; Wang, XD; Weng, JY; Wu, SX; Xiao, Z; Xu, N; Yang, LJ; Yang, S; Yang, W; Yang, YF; Yi, H; Zeng, Y; Zhang, WH; Zhang, X; Zhang, YL; Zhang, YQ; Zhao, YH; Zheng, YJ; Zhou, ZP; Zhu, HL | 1 |
| Březinová, J; Čermáková, K; Klamová, H; Macháčková-Lopotová, T; Mitrovský, O; Myslivcová, D; Obr, A; Ransdorfová, Š; Žáčková, M | 1 |
| Hasegawa, K; Ikezoe, E; Inoue, M; Inoue, Y; Iwahata, T; Nirazuka, A; Osaka, A; Saito, K; Setoguchi, K; Tokumoto, T; Tsujioka, H | 1 |
| Deregowska, A; Lewinska, A; Stoklosa, T; Warzybok, A; Wnuk, M | 1 |
| Ahmad, FJ; Ahmad, S; Gupta, A; Hasan, N; Imran, M; Jain, GK; Kesharwani, P; Nadaf, A; Sahebkar, A | 1 |
| Gayatri, MB; Gundeti, S; Kancha, RK; Patchva, D; Reddy, ABM; Velugonda, N | 1 |
| Chen, C; Gao, FH; Guo, JH; Liu, SL; Liu, Z; Yin, SS; Zhang, C; Zhang, QW | 1 |
| Abebe, M; Abeje, D; Alemayehu, D; Cross, M; Gebremedhin, A; Hailu, S; Howe, R; Jabessa, G; Kelemu, T; Kinde, S; Platzbecker, U; Seifu, D; Sherif, A; Tadesse, F; Tarekegn, A; Tsegaye, A | 1 |
| Alcazer, V; Amé, S; Andreoli, A; Balsat, M; Berger, M; Cayssials, E; Charbonnier, A; Cony-Makhoul, P; Delmer, A; Escoffre-Barbe, M; Etienne, G; Huguet, F; Ianotto, JC; Johnson-Ansah, H; Larosa, F; Legros, L; Meunier, M; Morisset, S; Nicolini, FE; Orvain, C; Rea, D; Roy, L; Tigaud, I | 1 |
| Chai-Adisaksopha, C; Hantrakool, S; Hantrakun, N; Norasetthada, L; Piriyakhuntorn, P; Punnachet, T; Rattanathammethee, T; Rattarittamrong, E; Tantiworawit, A; Towachiraporna, S | 1 |
| Brümmendorf, TH; Crysandt, M | 1 |
| Ross, DM | 4 |
| Chen, B; Guan, J; Ma, J | 1 |
| Barranco-Lampón, G; Córdova, EJ; De la Cruz-Rosas, A; García-Laguna, A; Gómez-Romero, L; Hernández-Zavala, A; Martínez-Castillo, M; Martínez-Tovar, A; Olarte-Carrillo, I; Tovar, H | 1 |
| Fei, J; Hu, H; Huang, G; Li, C; Liu, Y; Nie, H; Su, R; Wang, X; Wen, Z; Yang, J; Yin, Z; Zeng, X | 1 |
| Chen, M; Lin, Y; Liu, L; Lu, X; Ni, J; Yang, H; Zhang, L | 1 |
| Chen, S; Cheng, F; Gale, RP; Guo, H; Li, Q; Li, W; Qu, J; Xiang, H; Zhang, Y | 1 |
| Li, Z; Niu, M; Wu, W; Xu, J; Xu, K; Yin, L; Zhu, F | 1 |
| Li, Y; Liang, Y; Lu, X; Rong, S; Sun, G; Sun, H; Sun, Y; Wang, P; Wang, X; Xie, S; Yan, Y; Yang, X; Yin, B | 1 |
| Abruzzese, E; Annunziata, M; Attolico, I; Binotto, G; Bocchia, M; Bonifacio, M; Breccia, M; Bucelli, C; Capodanno, I; Cavazzini, F; Crescenzi, SL; Crisà, E; Crugnola, M; Dalmazzo, M; Fanin, R; Fava, C; Foà, R; Galimberti, S; Iurlo, A; Latagliata, R; Leporace, AP; Loglisci, G; Lunghi, F; Luzi, D; Maggi, A; Malato, A; Miggiano, MC; Mulas, O; Murgano, P; Pizzuti, M; Rapezzi, D; Russo, S; Saglio, G; Sancetta, R; Scalzulli, E; Scortechini, AR; Sorà, F; Specchia, G; Stagno, F; Tiribelli, M; Vincelli, I | 1 |
| Dai, S; Li, S; Wang, T; Zhong, Y | 1 |
| Czerwińska-Rybak, J; Gil, L; Jarmuż-Szymczak, M; Kanduła, Z; Lewandowski, K; Przybyłowicz-Chalecka, A; Ratajczak, B; Ustaszewski, A | 1 |
| Adattini, JA; Adiwidjaja, J; Gross, AS; McLachlan, AJ | 1 |
| Bozkurt, S; Hekmatshoar, Y; Karabay, AZ; Karadag Gurel, A; Koc, A; Ozkan, T; Rahbar Saadat, Y; Sunguroglu, A | 1 |
| Ansari, S; Verma, M | 1 |
| Chtourou, L; Elloumi, M; Fakhfakh, Y; Frikha, I; Medhaffar, M; Sahnoun, R | 1 |
| Chen, C; Cui, Z; Feng, H; Fu, Y; Gao, Z; Ma, S; Zhang, L; Zhou, M | 1 |
| Erkek, ET; Ipek, Y; Isik, AC; Kul, AN | 1 |
| Gale, RP; Huang, J; Huang, X; Jiang, Q; Liu, B; Qi, F; Zhang, X | 1 |
| Chen, J; Ding, Y; He, Z; Huang, X; Liu, Y; Zheng, H | 1 |
| El-Osta, A; Hung, A; Karagiannis, TC; Khurana, I; Maxwell, SS; Pitsillou, E; Rafehi, H; Tortorella, SM; Ververis, K; Vongsvivut, J; Wall, M; Wood, PA | 1 |
| Brabcova, Z; Copland, M; Dawson, A; de Beauchamp, L; Dunn, K; Gottlieb, E; Ianniciello, A; Kalkman, ER; Khalaf, A; Kwan, R; Michie, AM; Rattigan, KM; Roy, K; Sarnello, D; Scott, MT; Sumpton, D; Tardito, S; Vignir Helgason, G; Zarou, MM | 1 |
| Chen, S; Cheng, Y; Huang, B; Jiang, J; Li, M; Liu, J; Xu, S; Xu, Y; Yang, Y; Yao, F; Zhang, H; Zhong, F | 1 |
| Cantu-Rodriguez, OG; Colunga-Pedraza, PR; Contreras-Arce, A; Dorsey-Trevino, EG; Gomez-Almaguer, D; Gomez-De Leon, A; Gomez-Villarreal, JP; Gonzalez-Cantu, GA; Gutierrez-Aguirre, CH; Jaime-Perez, JC; Mancias-Guerra, MDC; Osorno-Rodriguez, KL; Rios-Rodelo, MR; Tarin-Arzaga, LDC | 1 |
| Bakliwal, A; Bandyopadhyay, A; Chattopadhyay, D; Chetia, R; Dhamija, P; Handu, S; Nath, UK; Palepu, S; Vaniyath, S | 1 |
| Argüello, RJ; Chen, MH; Chen, X; Chimge, NO; Du, J; Gonzalez, PG; Hurwitz, S; Jin, V; Kahn, M; Kim, YM; Nguyen, C; Ogana, H; Ono, M; Teo, JL; Wu, X; Zhao, Y | 1 |
| Branford, S; Dang, P; Hughes, TP; Kok, CH; Saunders, VA; Shanmuganathan, N; White, D; Yeung, D | 1 |
| Atenafu, EG; Bence-Bruckler, I; Busque, L; Delage, R; Forrest, D; Keating, MM; Kim, DDH; Laneuville, P; Leber, B; Liew, E; Lipton, JH; Novitzky-Basso, I; Paulson, K; Perusini, MA; Savoie, L; Stockley, T; Xenocostas, A | 1 |
| Chhabra, R; Singh, P; Verma, M; Yadav, R | 1 |
| Alimirzoyeva, Z; Asadov, C; Bayramov, B; Hasanova, A; Karimova, N; Shirinova, A | 1 |
| Bautista, F; Ducassou, S; Dufour, C; Goto, H; Guinipero, T; Hijiya, N; Izquierdo, M; Kang, HJ; Karakas, Z; Li, S; Maschan, A; Millot, F; Patterson, BC; Rizzari, C; Samis, J; Shimada, H; Sosothikul, D; Titorenko, K; Yoo, KH; Zwaan, CM | 1 |
| Ansari, R; Taghizadeh-Ghehi, M | 1 |
| Haddad, FG; Issa, G; Jabbour, E; Jain, N; Kantarjian, H; Sasaki, K; Short, NJ | 1 |
| Cha, SH; Kim, K; Song, YK | 1 |
| Kitamura, T; Tanaka, Y | 1 |
| Eaves, CJ; Forrest, DL; Grasedieck, S; Jiang, X; Lin, H; Nakamoto, H; Wu, A; Yen, R | 1 |
| Hao, J; Lan, F; Peng, Y; Qiu, Y; Wang, ZJ; Yu, H; Zhang, R | 1 |
| Albayrak, M; Aydın Kaynar, L; Başer Dikyar, AA; Can, F; Çeneli, Ö; Gökçen, S; Karakuş, S; Öcal, R; Özkurt, ZN; Pepeler, S; Savaş, EM; Yağcı, M; Yıldız, A; Yılmaz, S | 1 |
| Bashash, D; Momeny, M; Yousefi, AM; Zehtabcheh, S | 1 |
| Bays, JL; Chen, C; Farrell, A; Jaffe, IZ; Lu, Q; Stepanian, A; Travers, RJ; Wang, Y | 1 |
| Berry, C; Busch, C; Dalby, M; Mulholland, T; Wheadon, H; Zagnoni, M | 1 |
| Bai, YL; Chen, CY; Chen, SN; Du, X; Guo, JX; Han, YQ; Hu, JD; Huang, J; Jiang, Q; Li, F; Li, GH; Li, WM; Liang, R; Lin, H; Lin, LE; Liu, BC; Liu, CS; Liu, XL; Liu, ZF; Liu, ZG; Liu, ZL; Meng, L; Pan, L; Pang, LP; Qiu, HY; Sun, H; Sun, XL; Suo, XH; Tu, CQ; Wang, DY; Wang, XD; Xu, N; Yang, LJ; Yang, W; Yang, YF; Zeng, QS; Zhang, WH; Zhang, XS; Zhang, YL; Zhang, YQ; Zhao, ZY; Zheng, CF; Zheng, YJ; Zhou, L; Zhou, ZP; Zhu, HL | 1 |
| Godínez-Jaimes, F; Martínez-Fonseca, R; Reyes-Carreto, R; Vargas-De-León, C | 1 |
| Abruzzese, E; Annunziata, M; Atelda, R; Binotto, G; Bocchia, M; Bonifacio, M; Breccia, M; Bucelli, C; Calistri, E; Capodanno, I; Castagnetti, F; Cavazzini, F; Cedrone, M; Celesti, F; Crisà, E; Crugnola, M; D'Addosio, A; Falzetti, F; Fava, C; Ferrero, D; Galimberti, S; Giglio, G; Gozzini, A; Gugliotta, G; Isidori, A; Iurlo, A; Latagliata, R; Luciano, L; Mansueto, G; Mauro, E; Montefusco, E; Orlandi, E; Orofino, N; Pregno, P; Rege Cambrin, G; Rosti, G; Russo, S; RussoRossi, A; Sgherza, N; Sorà, F; Stagno, F; Storti, S; Tiribelli, M; Trawinska, MM | 1 |
| Albers, C; Duyster, J; Engelhardt, M; Follo, M; Gorantla, SP; Huber, TB; Illert, AL; Jakob, L; Kreutmair, S; Lippert, LJ; Müller, TA; Müller-Rudorf, A; Yu, C; Yue, Z; Zeiser, R | 1 |
| Bakhshi, S; Pushpam, D | 1 |
| He, ZK; Li, C; Li, L; Liu, Y; Shi, X; Wang, X; Xia, YJ; Xu, Z; Xue, S; Zhang, JX; Zhang, YH | 1 |
| Manley, PW | 1 |
| Ding, Y; Li, Y; Lu, X; Shi, Y; Wang, C; Wei, B; Wu, J | 1 |
| Aoyama, T; Furukawa, T; Shibayama, Y; Sugawara, M; Takekuma, Y | 1 |
| Abdullah, SM; Guru, SA; Mirza, MAB; Rizvi, A; Saxena, A | 1 |
| Yaghmaie, M; Yeung, CC | 1 |
| Gu, Y; Li, K; Zhang, J; Zhou, Y | 1 |
| Dulucq, S; Etienne, G; Groppi, A; Hubert, C; Lichou, F; Longy, M; Mahon, FX; Monnereau, A; Orazio, S; Turcq, B | 1 |
| Abruzzese, E; Bergamaschi, M; Binotto, G; Bonifacio, M; Breccia, M; Caocci, G; Capodanno, I; Cascavilla, N; Castagnetti, F; Cottone, F; Crugnola, M; Efficace, F; Fozza, C; Gozzini, A; Iurlo, A; Martino, B; Patriarca, A; Pregno, P; Rosti, G; Saussele, S; Stagno, F; Tiribelli, M; Vignetti, M | 1 |
| Dong, SH; Shan, B; Zhang, JY; Zhang, XT | 1 |
| Chen, S; Hu, Y; Huang, X; Li, Y; Wu, Y; Yu, X; Zeng, C; Zhang, Y | 1 |
| Harada, T; Hayashi, T; Ikematsu, Y; Kanai, T; Miyazaki, S; Naito, K; Nishiwaki, Y; Ogiku, M; Tamura, H; Tatsuta, K | 1 |
| Abou Dalle, I; Borthakur, G; Burger, J; Cortes, J; Estrov, Z; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Ohanian, M; Ravandi, F; Verstovsek, S | 1 |
| Cole, AL; Dusetzina, SB; Jazowski, SA | 1 |
| Chen, C; Fu, Y; Huang, T; Wang, S; Wang, X; Xu, M; Yin, X; Zhou, M | 1 |
| Belli, C; Bestach, Y; Ferri, C; Larripa, I; Toloza, MJ | 1 |
| Geng, Z; Jiang, L; Li, Q; Liu, W; Wang, H; Xiao, Y; You, Y; Zhou, S; Zhu, X; Zou, P | 1 |
| Akashi, K; Imamura, Y; Ishikawa, J; Kadowaki, N; Kanakura, Y; Kawaguchi, T; Kuroda, J; Matsumura, I; Miyamoto, T; Nagafuji, K; Nakamae, H; Shimose, T; Yamazaki, H | 1 |
| Deininger, MW; O'Hare, T; Pomicter, AD; Yan, D | 1 |
| Alvarado, Y; Anderson, K; Borthakur, G; Bose, P; Burger, J; Cortes, J; Dellasala, S; Estrov, Z; Ferrajoli, A; Jabbour, E; Jain, N; Kantarjian, HM; Naqvi, K; Paul, S; Pemmaraju, N; Skinner, J; Takahashi, K; Thompson, P; Yilmaz, M | 1 |
| Kamachi, K; Kimura, S; Ureshino, H | 1 |
| Chen, M; Diao, Y; Jin, X; Li, N; Wang, L; Zhang, H | 1 |
| Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Kawaguchi, T; Kimura, Y; Kizaki, M; Komatsu, N; Nakazato, T; Sato, E; Sugimoto, KJ; Takaku, T; Tokuhira, M | 3 |
| Raanani, P; Sharf, G | 1 |
| Alimena, G; Breccia, M; Carmosino, I; Cesini, L; Colafigli, G; De Benedittis, D; De Luca, ML; Diverio, D; Foà, R; Latagliata, R; Loglisci, MG; Mancini, M; Mariggiò, E; Massaro, F; Mohamed, S; Molica, M; Rizzo, L; Scalzulli, E; Scamuffa, MC; Vozella, F | 1 |
| Ammar, M; Ben Mahmoud, L; Elloumi, M; Ghozzi, H; Hakim, A; Medhaffar, M; Mseddi, M; Sahnoun, Z; Zeghal, K | 1 |
| Bao, YY; Jiao, WY; Li, T; Liu, YY | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 3 |
| Hou, Y; Huang, XJ; Jiang, Q; Qin, YZ; Yu, L; Zhao, T | 1 |
| Akisawa, T; Hoshiko, T; Kimura, S; Kubota, Y; Tanigawara, K; Watanabe, T; Yano, J | 1 |
| Chroscicki, P; Cysewski, D; Davis, DM; Dudka, W; Klejman, A; Kolba, MD; Kominek, A; Piwocka, K; Ronchi, P; Schwab, Y; Srpan, K; Turos, L; Wlodarczyk, J; Zaręba-Kozioł, M | 1 |
| Abdel-Azim, H; Aljurf, M; Alyea, E; Ancheta, R; Bacher, U; Bajel, A; Beitinjaneh, A; Cahn, JY; Cerny, J; Chaudhri, NA; Daly, A; DeFilipp, Z; Gadalla, S; Gale, RP; Ganguly, S; Gerds, A; Grunwald, MR; Hamadani, M; Hashmi, S; Hildebrandt, GC; Hossain, N; Hsu, JW; Hu, ZH; Inamoto, Y; Juckett, MB; Kalaycio, M; Kamble, R; Kharfan-Dabaja, MA; Lazarus, H; Liesveld, J; Litzow, M; Liu, Y; Nishihori, T; Olsson, R; Popat, U; Ramanathan, M; Reshef, R; Rowe, JM; Saber, W; Savani, BN; Savoie, ML; Schouten, HC; Schultz, KR; Seo, S; Snyder, D; Sobecks, R; Solh, M; Szer, J; Ustun, C; Yared, J | 1 |
| Chaturvedi, A; Thapa, M | 1 |
| Jeyaraman, P; Naithani, R | 1 |
| Ha, D; Iwaisako, K; Jäger, E; Kameoka, Y; Karbach, J; Katayama, N; Kitawaki, T; Maeda, Y; Monma, F; Morikawa, H; Nishikawa, H; Noguchi, S; Ohishi, K; Saito, T; Sakaguchi, S; Sawada, K; Shigeta, N; Shinohara, Y; Sugiyama, D; Takahashi, N; Takeuchi, Y; Tanaka, A | 1 |
| Boknäs, N; Deb, S; Lotfi, K; Ramström, S; Sjöström, C; Tharmakulanathan, A | 1 |
| Alimoghaddam, K; Babakhani, D; Chahardouli, B; Ghahremani, MH; Mohammadi, S; Nekoohesh, L; Nikbakht, M; Rostami, S | 1 |
| Christov, C; Dicato, M; Diederich, M; Gaigneaux, A; Gérard, D; Grandjenette, C; Mazumder, A; Schnekenburger, M | 1 |
| Alfraih, F; Chaudhri, N; El Fakih, R; Jabbour, E; Naqvi, K; Rausch, CR | 1 |
| Aggarwal, A; Bansal, D; Bhansali, A; Khandelwal, N; Sachdeva, N; Varma, N; Walia, R | 1 |
| Instiaty, I; Louisa, M; Nova, R; Priambodo, R; Rinaldi, I; Widyastuti, R | 1 |
| Altamura, H; Braley, J; Branford, S; Carne, L; Dang, P; Grose, R; Hughes, TP; Kok, CH; McLean, J; Pagani, IS; Ross, DM; Rwodzi, Z; Saunders, VA; Shanmuganathan, N; Watts, S; White, DL; Yeung, DT; Yong, ASM | 1 |
| Bayrak, N; Ciftci, HI; Fujita, M; Otsuka, M; Radwan, MO; Tuyun, AF; Yıldırım, H; Yıldız, M | 1 |
| Kim, DDH | 1 |
| Bo, Z; Jiang, Y; Li, S; Song, X; Tong, Y; Wang, C | 1 |
| Cao, D; Chen, S; Fei, J; Gu, C; Huang, G; Liu, Y; Ou, R; Yang, J; Yin, Z; Zhang, Y | 1 |
| Barbuti, AM; Chen, ZS; Ding, K; Gupta, P; Karadkhelkar, N; Pan, J; Yang, DH; Yoganathan, S; Zhang, GN; Zhang, X; Zhou, J | 1 |
| Bence-Bruckler, I; Busque, L; Cote, Y; Hamm, C; Hasegawa, W; Hillis, CM; Jackson Chornenki, NL; Kamel-Reid, S; Leber, B; Lipton, JH; Savoie, L; Turner, AR; Xenocostas, A | 1 |
| Dou, XL; Hou, Y; Huang, XJ; Jiang, Q; Lai, YY; Qin, YZ; Shi, HX; Yu, L | 1 |
| Hong, J; Li, Q; Ni, J; Sun, G; Xia, R; Zeng, Q; Zhang, Z | 1 |
| Choi, SY; Jung, SY; Kee, KM; Kim, DW; Kim, SH; Lee, JI; Noh, H; Shin, H; Yang, SY; Zang, DY | 1 |
| Bernard, PS; Kim, K; McMillin, GA; Schmidt, RL; Tantravahi, S; Walker, BS | 1 |
| Gotoh, A; Moriyama, M; Okabe, S; Tanaka, Y | 1 |
| Chen, L; Chen, Y; Guo, J; Li, W; Meng, L; Wang, H; Xiong, Y; Yin, H | 1 |
| Cao, HX; Huang, YM; Jiang, ZX; Miao, CF; Sang, LN; Sun, L; Zhang, R | 1 |
| BrÜmmendorf, TH; Byrne, J; Clark, RE; Cong, W; Cony-Makhoul, P; Copland, M; Dixon-Hughes, J; Foroni, L; Gallipoli, P; Helgason, GV; Holyoake, TL; Horne, GA; Kelly, C; Koschmieder, S; Latif, AL; McMahon, L; Milojkovic, D; Mukhopadhyay, A; Nicolini, FE; Schafhausen, P; Smith, G; Stobo, J; Thomson, F | 1 |
| Fang, Q; Lu, T; Ma, D; Wang, J; Wei, D; Xiong, J; Yu, K | 1 |
| Jiang, LL; Liu, MH; Liu, XJ; Luo, JM; Ma, Y; Nie, ZY; Yang, L; Yang, Z; Yao, M; Yu, J; Zhang, N; Zhang, XY | 1 |
| Algahtani, FH; Alqahtany, FS | 1 |
| Beckenkamp, A; Beckenkamp, LR; Buffon, A; Pilger, DA; Sévigny, J; Vianna, DRB; Willig, JB; Wink, MR | 1 |
| Butt, E; Ernst, T; Frietsch, JJ; Herrmann, AB; Hochhaus, A; Müller, JP; Müller, ML; Orth, MF; Zernecke, A | 1 |
| Choudhary, S; Malhotra, H; Sharma, R; Singh, J | 1 |
| Beaver, LP; Clair, PM; Deininger, MW; Eiring, AM; Hare, TO; Heaton, WL; Mason, CC; Pomicter, AD; Senina, A; Shacham, S; Than, H; Yan, D | 1 |
| Stirrups, R | 1 |
| Abdullah, M; Al-Dubai, W; Al-Gharasi, L; Al-Ghazaly, J; Noaman, Y; Rosti, G | 1 |
| Bhatia, R; Bhatia, S; Kenzik, KM | 1 |
| Abecasis, M; Du, Z; Hu, R; Liu, C; Wang, C | 1 |
| Ando, K; Hirano, KI; Hozumi, K; Ibrahim, AA; Miyata, T; Muguruma, Y; Naka, K; Vaughan, DE; Yahata, T | 1 |
| Peng, Y; Tan, D; Thomas, AS; Wang, Y; Wei, D | 1 |
| Dou, XL; Hou, Y; Huang, XJ; Jiang, Q; Lai, YY; Qin, YZ; Shi, HX | 1 |
| Cai, HL; He, Q; Jiang, ZP; Shi, XL; Wang, Q; Xiang, DX; Xu, P; Zeng, J; Zhao, XL; Zhong, AN; Zhu, Y | 1 |
| Asanuma, H; Kasahara, H; Kitaoka, S; Morita, S; Okamoto, S; Okayama, M; Oya, M; Shinoda, K; Takahashi, R; Tamaki, S; Yoshida, T | 1 |
| Koesnoe, S; Louisa, M; Putri, A; Rinaldi, I | 1 |
| An, X; Deng, M; Guan, X; Wen, X; Xiao, J; Yu, J | 1 |
| Anczuków-Camarda, O; Cheng, S; Chuah, C; Iqbal, J; Krainer, AR; Lee, KL; Li, H; Li, J; Ong, CCH; Ong, ST; Roca, X; Rozen, SG; Sinnakannu, JR; Tan, SP; Than, H; Yang, H; Yu, M | 1 |
| Camargo, CHF; Germiniani, FMB; Munhoz, RP; Teive, HAG | 1 |
| Bansal, D | 1 |
| Bianchi, S; Biondi, A; Burnelli, R; Foà, R; Giona, F; Ladogana, S; Locatelli, F; Malaspina, F; Moleti, ML; Mura, R; Putti, MC; Rizzo, L; Saglio, G; Testi, AM; Vacca, N | 1 |
| Acikgoz, E; Ateş, H; Baykal-Köse, S; Gönül Geyik, Ö; Özsan, GH; Sezerman, OU; Yavuz, AS; Yüce, Z | 1 |
| Cao, S; Kuang, W; Xiao, FY; Yuan, F; Zhou, FJ; Zhou, G; Zhou, HH | 1 |
| Cai, S; Li, X; Wang, H; Wang, L; You, Y; Zhang, M; Zhong, Z | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Clark, RE; Cortes, JE; Deininger, MW; Guilhot, F; Hehlmann, R; Hjorth-Hansen, H; Hochhaus, A; Hughes, TP; Janssen, JJWM; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Mayer, J; Nicolini, F; Niederwieser, D; Pane, F; Radich, JP; Rea, D; Richter, J; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Schiffer, C; Silver, RT; Soverini, S; Steegmann, JL; Turkina, A; Zaritskey, A | 1 |
| Ebnöther, M; Favre, G; Heim, D | 1 |
| Dou, QP; He, Q; Jiang, L; Lan, X; Liu, J; Rohondia, S; Shi, X; Sun, Y; Wang, J; Wen, C | 1 |
| Abe, A; Hayakawa, F; Ichihara, M; Inoue, C; Kawamoto, Y; Murate, T; Nishizawa, Y; Nozawa, Y; Sobue, S; Suzuki, M | 1 |
| Fang, L; Huang, B; Li, J; Li, SQ; Liao, ZH; Lin, J; Liu, J; Min, QH; Wang, XZ; Wang, Y; Wu, Y; Xu, YM; Yang, WM; Zhang, HB; Zhang, J | 1 |
| Cole, AL; Dusetzina, SB; Elston Lafata, J; Lund, JL; Muluneh, B; Wood, WA | 1 |
| Dou, X; Huang, X; Jiang, Q; Lai, Y; Qin, Y; Shi, H | 1 |
| Chen, PY; Chin, HK; Chuang, CH; Lin, CY; Wu, MJ; Yen, JH | 1 |
| Gust, R; Hohn, V; Obexer, P; Salcher, S; Schoepf, AM; Veider, F | 1 |
| Begley, CE; Chan, W; Krause, TM; Phuar, HL | 1 |
| Chen, WY; Gao, JJ; Wang, MQ; Zhu, XP | 1 |
| Chen, XY; Li, YL; Liang, GH; Lu, ZY; Luo, B; Qu, Q; Tang, JM | 1 |
| Roth, M; Triche, L; Wells, R; Yarbrough, A; Ying, A | 1 |
| Accurso, V; Badalamenti, G; Bronte, E; Di Lisi, D; Macaione, F; Novo, G; Novo, S; Rinaldi, G; Russo, A; Siragusa, S | 1 |
| Bettoni da Cunha-Riehm, C; Hildebrand, V; Metzler, M; Nathrath, M; Suttorp, M | 1 |
| Aggarwal, R; Bansal, D; Jain, R; Malhotra, P; Naseem, S; Sharma, M; Thipparapu, S; Totadri, S; Trehan, A; Varma, N | 1 |
| Friedman, R; G Lindström, HJ | 1 |
| Beyer, AM; Derayunan, A; Durand, MJ; Hader, SN; McIntosh, JJ; Zinkevich, N | 1 |
| Elf, SE | 1 |
| Chakrabarti, SS; Gambhir, IS; Kaur, U; Khare, VR; Singh, A | 1 |
| Aota, Y; Gotoh, A; Honda, T; Okuda, Y; Udagawa, S | 1 |
| Chang, W; Chen, S; Chen, Z; Cheng, H; Gale, RP; Guo, J; Jiang, Q; Li, Q; Li, W; Meng, L; Qin, J; Sheng, L; Wan, C; Wang, D; Yang, Z; You, Y; Yuan, G; Zhang, Y; Zhu, X | 1 |
| Ahamed, M; Bormans, G; Christov, C; Dicato, M; Diederich, M; Gérard, D; Hahn, H; Han, BW; Kim, DW; Lee, JY; Lernoux, M; Losson, H; Mazumder, A; Schnekenburger, M; Vermeulen, K | 1 |
| Austin, G; Clark, RE; Davies, A; Foroni, L; Loaiza, S; Pirmohamed, M; Rodriguez-Vicente, AE | 1 |
| Ali, S; Byrne, J; Campbell, G; Clark, RE; Collington, SJ; Cross, NCP; Dignan, FL; Drummond, M; Fildes, L; Glen, F; Huntly, B; Marshall, S; McMullin, MF; Mead, AJ; Milojkovic, D; Neelakantan, P; Raghavan, M; Ryan, J; Sivakumaran, M; Tighe, J; Wandroo, F; Willis, F | 1 |
| Cho, YU; Choi, EJ; Jang, S; Lee, JH; Lee, MY; Park, CJ; Seo, EJ; Seol, CA; You, E | 1 |
| Abruzzese, E; Andrade-Campos, M; Antolini, L; Assouline, S; Bergamaschi, M; Bonanomi, ML; Crivori, P; Di Bona, E; Diral, E; Elena, C; Fava, C; Fontana, D; Gambacorti-Passerini, C; Gozzini, A; Iurlo, A; Le Coutre, P; Martino, B; Mori, S; Petiti, J; Piazza, R; Pirola, A; Pungolino, E; Stagno, F | 1 |
| Krecak, I; Lucijanic, M | 1 |
| Bergeron, A; Bondeelle, L; Chaumais, MC; Guignabert, C; Humbert, M; Jaïs, X; Montani, D; Rousselot, P; Savale, L; Sitbon, O; Weatherald, J | 1 |
| Cao, WJ; Chang, FF; Guo, JX; Huang, FY; Zhang, FJ | 1 |
| Hasegawa, G; Koda, R; Morita, S; Nagano, O; Seki, Y | 1 |
| Ambrogi, F; Banzi, R; Ferrero, A; Pravettoni, G; Saglio, G; Sant, M; Vener, C | 1 |
| Saroha, M | 1 |
| Diagil, I; Goryainova, N; Melnyk, U; Perekhrestenko, T | 1 |
| Cayuela, JM; Delord, M; Loiseau, C; Rousselot, P; Spentchian, M | 1 |
| Radich, J | 3 |
| Christov, C; Dicato, M; Diederich, M; Gajulapalli, SR; Gérard, D; Hahn, H; Han, BW; Kirsch, G; Lee, JY; Lernoux, M; Losson, H; Mazumder, A; Schnekenburger, M; Seidel, C | 1 |
| Suzuki, K | 1 |
| Buxhofer-Ausch, V; Cejka, D; Enkner, W; Kranewitter, W; Thiem, U; Webersinke, G | 1 |
| Kimura, S; Okamoto, S; Ureshino, H | 1 |
| He, J; Hu, T; Huang, C; Huang, H; Jiang, L; Liao, Y; Liu, J; Liu, Y; Shao, Z; Xia, X; Yu, C | 1 |
| McMillin, GA; Sadler, AJ; Smy, L | 1 |
| Ammar, M; Ben Mahmoud, L; Elloumi, M; Frikha, I; Ghozzi, H; Louati, N; Medhaffar, M; Menif, H; Zeghal, K | 1 |
| Ankathil, R; Azlan, H; Baba, AA; Elias, MH; Sulong, S | 1 |
| Apperley, J; Byrne, J; Copland, M; Cross, NCP; de Lavallade, H; Foroni, L; Goringe, A; Jones, G; Khorashad, J; Mead, AJ; Milojkovic, D; Osborne, W; Plummer, C; Rao, A; Smith, G | 1 |
| Buxhofer-Ausch, V; Greil, R; Heibl, S; Kuehr, T; Lion, T; Melchardt, T; Piringer, G; Schmidt, S; Thaler, J; Webersinke, G; Wolf, D | 1 |
| Bain, BJ; Barreira, R; Fernandes, F; Ramalho, R; Silveira, M | 1 |
| Aroca, C; Ferrer-Marín, F; Martínez-Montesinos, L; Rios, SJ; Teruel-Montoya, R | 1 |
| Fu, L; Liang, H; Liang, X; Liu, J; Liu, Q; Shi, J; Wang, B; Wang, J; Zou, F | 1 |
| Caporale, R; Cheloni, G; Dello Sbarba, P; Gozzini, A; Lombardi, Z; Poteti, M; Rovida, E; Scappini, B; Silvano, A; Tubita, A; Tusa, I | 1 |
| Iriyama, N; Kawaguchi, T; Kirito, K; Kizaki, M; Shimoda, K; Takahashi, N | 1 |
| Asai, H; Azuma, H; Nagaya, K; Nii, M; Nohara, F; Okamoto, T; Terao, R | 1 |
| Liu, L; Tan, L; Xie, Y; Yang, J | 1 |
| Biondi, A; Culic, S; De Bont, E; de Moerloose, B; Guilhot, J; Kalwak, K; Lausen, B; Li, CK; Meyran, D; Millot, F; Petit, A; Sedlacek, P; Suttorp, M | 1 |
| Breccia, M; Colafigli, G; De Luca, G; Di Prima, A; Diverio, D; Efficace, F; Foà, R; Latagliata, R; Martelli, M; Pepe, S; Scalzulli, E | 1 |
| Álvarez, R; Collado-Borrell, R; Escudero-Vilaplana, V; Herranz, A; Sanjurjo, M; Villanueva-Bueno, C | 1 |
| Bai, QX; Chen, SN; Jiang, H; Jiang, Q; Jin, J; Lei, PC; Li, WM; Li, ZY; Lin, H; Lin, LE; Liu, BC; Liu, HL; Lu, ZS; Ma, HX; Meng, L; Shen, XM; Sun, ZM; Yang, GP; You, Y; Zhang, LP; Zhang, LQ; Zhang, X; Zhang, Y; Zhao, XL; Zhao, YH; Zheng, FY; Zhu, HL; Zhu, XF | 1 |
| Escudero-Vilaplana, V; González-Haba, E; Marquinez-Alonso, I; Osorio, S; Rodriguez-Gonzalez, CG; Sanjurjo-Sáez, M | 1 |
| Altuntaş, F; Ata, N; Ayvalı, MO; Başcı, S; Baştürk, A; Berber, İ; Birinci, Ş; Çağlayan, M; Çelik, O; Dal, K; Dal, MS; Doğu, MH; Erkurt, MA; Hacıbekiroğlu, T; Korkmaz, S; Namdaroğlu, S; Turgut, B; Ülgü, MM; Yiğenoğlu, TN | 1 |
| Cherkaoui, S; Dakkoune, M; Hassoune, S; Khoubila, N; Lamchahab, M; Madani, A; Qachouh, M; Quessar, A; Rachid, M; Zoukal, S | 1 |
| Absar, M; Akhtar, T; Aleem, A; Iqbal, Z; Jameel, A; Mahmood, A; Qureshi, K; Rehman, N; Ullah, A | 1 |
| da Silva, MAS; De Paula, EV; De Souza, CA; Delamain, MT; Duarte, GO; Furlin, GCP; Lopes, ABP; Miranda, EC; Pagnano, KBB; Povoa, VMO; Rodrigues, BRV; Vianna, JC | 1 |
| Arous, R; Benchabane, H; Boudiaf, H; Boukhelal, H; Chikhi, L; Ezziane, K; Hakem, S; Himrane, M; Rouis, NO | 1 |
| Bulla, A; Consoli, ML; Conticello, C; DI Raimondo, F; Leotta, S; Markovic, U; Stagno, F; Stella, S; TambÈ, L | 1 |
| Ercaliskan, A; Eskazan, AE; Kabasakal, L; Kucukyurt, S; Yagiz Ozogul, Y | 1 |
| Chaekal, OK; van Besien, K | 1 |
| Cui, J; Gu, J; Hu, Y; Jiang, H; Jiang, M; Jin, J; Li, J; Li, Y; Liu, B; Liu, L; Liu, X; Luo, J; Meng, L; Ouyang, G; Qiao, J; Sun, A; Wang, J; Xie, X; Yang, T; Zhang, L; Zhang, M; Zhang, W; Zhang, X; Zhang, Y; Zhao, C; Zhu, H | 1 |
| Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W | 1 |
| Abed, A; Bekadja, MA; Brahimi, M; Entasoltane, B; Guella, D; Kihel, I; Nachi, M; Yafour, N | 1 |
| Bátorová, A; Mistrík, M; Slezáková, K | 1 |
| Sun, GB; Wang, XY; Wang, YJ; Yan, F | 1 |
| Henk, HJ; Lyman, GH | 1 |
| Baranova, J; Belohlavkova, P; Cicatkova, P; Hornak, T; Klamova, H; Mayer, J; Necasova, T; Prochazkova, J; Semerad, L; Srbova, D; Stejskal, L; Sustkova, Z; Voglova, J; Weinbergerova, B; Zackova, D | 1 |
| Cole, AL; Dusetzina, SB; Leech, AA; Nguyen, JT; Wood, WA | 1 |
| Cao, X; Huang, H; Lei, X; Liu, J; Peng, J; Tang, G; Zhang, Y | 1 |
| Chang, J; He, J; Yuan, R | 1 |
| Dourado, C; Gupta, S; Swaminathan, N | 1 |
| Amrolia, P; Gattens, M; Rao, A; Veys, D; Veys, P; Vora, A | 1 |
| Aksu, S; Aladag, E; Buyukasik, Y; Demiroglu, H; Goker, H; Haznedaroglu, IC; Hekimsoy, V; Karakulak, UN; Kaya, EB; Ozcebe, O; Ozer, N; Sahiner, ML; Sayinalp, N | 1 |
| Daudén, E; García-Diez, A; Llamas-Velasco, M; Ovejero-Merino, E; Requena, L; Steegmann, JL | 1 |
| Almawi, WY; Bahia, W; Ferchichi, S; Mahdhi, A; Radhouani, A; Soltani, I | 1 |
| Breccia, M; Chistolini, A; Di Prima, A; Fiori, L; Scalzulli, E; Serrao, A | 1 |
| Müller, MC | 1 |
| Gutiérrez-Diez, PJ; Russo, J | 1 |
| Liang, HT; Liu, W; Tang, L; You, Y; Zhu, XJ; Zhu, XY; Zou, P | 1 |
| Du, Z; Liu, C; Liu, Z; Wang, C; Xue, H | 1 |
| Assad, D; Foroughmand, AM; Hamid, M; Mohammadi, F; Rostami, G; Shafiei, M | 1 |
| Takaku, T | 1 |
| Sasaki, K | 1 |
| Abdel Ghafar, MT; Eid, MA; Habib, EM; Hassan, AE; Nosiar, NA; Sherief, DE; Taha, AM | 2 |
| Atallah, E; Baim, A; Cortes, J; Deininger, MWN; Flynn, KE; Harrell, J; Helton, B; Horowitz, M; Kota, V; Larson, RA; Lin, L; Mauro, MJ; Moore, JO; Oehler, VG; Pinilla-Ibarz, J; Radich, JP; Ritchie, EK; Schiffer, CA; Shah, NP; Silver, RT; Thompson, JE; Visotcky, A; Wadleigh, M; Weinfurt, KP; Zhang, MJ | 1 |
| Arora, A; Chaudhry, S; Gupta, DK; Jain, A; Khunger, JM; Patarwal, RN; Prasad, P; Saluja, S; Sharma, M; Singh, J | 1 |
| Carrozzo, M; Donnell, CC; Walton, RL | 1 |
| Breccia, M; Colafigli, G; Di Prima, A; Efficace, F; Foà, R; Martelli, M; Scalzulli, E | 1 |
| Bai, J; Chen, X; Jiao, Y; Jing, H; Li, J; Liu, H; Wang, J; Wang, T; Weng, L; Yang, B; Ye, J; Zeng, YX; Zhang, W | 1 |
| Arolla, RG; Bhaduri, U; Gayatri, MB; Kancha, RK; Katika, MR; Madhava Reddy, AB; Malladi, S; Mohan, V; Pattamshetty, P; Satyanarayana Rao, MR; Vudem, DR | 1 |
| Banegas, MP; Barrett, MJ; Enewold, L; Filipski, KK; Freedman, AN; Lam, CK; Mariotto, A; Rivera, DR | 1 |
| Balaskó, M; Erős, A; Farkas, N; Für, G; Hegyi, P; Hegyi, PJ; Hussain, A; Mosdósi, B; Nagy, A; Pammer, J; Simon, M; Szakács, Z; Szujó, S | 1 |
| Bai, KT; Cheng, MX; Dong, L; Li, J; Liu, SD; Sun, YQ; Wang, DP; Wang, ZD; Yu, SR | 1 |
| Couture, G; Gauthier, M; Mouchel, PL; Syrykh, C | 1 |
| Baba, T; Hara, E; Hirao, A; Kawamoto, S; Komatsu, N; Morishita, S; Mukaida, N; Takaku, T; Tanabe, Y | 1 |
| Abdullah, AD; Ankathil, R; Hassan, R; Husin, A; Ismail, SM; Mohd Yunus, N; Sulong, S | 1 |
| Dmytrenko, IV; Dyagil, IS; Fedorenko, VG; Martina, ZV; Minchenko, ZM; Petrusha, OO; Shlyakhtichenko, TY; Sholoiko, VV; Silayev, YO; Stupakova, ZV; Tovstogan, AO | 1 |
| Apperley, JF; Claudiani, S; Dominy, K; Foroni, L; Foskett, P; Hayden, C; J Innes, A; Khan, A; Khorashad, J; Milojkovic, D; Nesr, G; Szydlo, R | 1 |
| Absar, M; Akhtar, T; Akram, AM; Alanazi, N; Aleem, A; Aljarrah, K; Iqbal, J; Iqbal, M; Iqbal, Z; Jameel, A; Karim, S; Khalid, AM; Khalid, M; Mahmood, A; Mirza, Z; Rasool, M; Sabar, MF; Shah, IH | 1 |
| Charfi, M; Elloumi, M; Kallel, F; Kassar, O; Ksouda, K; Maaloul, I | 1 |
| Balaguer, F; Ocaña, T; Olivas, P; Pellisé, M; Tobon, A | 1 |
| Cai, Y; Chen, X; Chen, Y; Guo, Y; Liu, C; Yang, W; Zhang, L; Zhu, X; Zou, Y | 1 |
| Ashok, C; Coumar, MS; Dyavaiah, M; Parcha, PK; Rajasekaran, B; Sarvagalla, S; Sudharshan, SJ | 1 |
| Aimone, P; Bendit, I; Boquimpani, C; Cacciatore, S; Clark, RE; Dubruille, V; Etienne, G; Flinn, IW; Hochhaus, A; Hughes, TP; Issaragrisil, S; Kantarjian, HM; Kim, DW; Kyrcz-Krzemien, S; Larson, RA; le Coutre, P; Medras, E; Pasquini, R; Saglio, G; Titorenko, K; Zanichelli, M | 1 |
| Feng, W; Huang, Z; Wang, X; Wang, Y; Yang, H; Zhang, H | 1 |
| Aghel, N; Hillis, C; Karampatos, S; Leong, D; Pond, G; Rangarajan, S; Seow, H; Siegal, D | 1 |
| Cantonetti, M; Cattel, F; Celeste, MG; Colasanto, I; Costantini, A; de Rosa, C; Di Biagio, K; Federici, F; Franceschini, L; Frazzetto, A; La Barba, G; Lanzillo, R; Luciano, L; Monteverde, M; Musicco, F; Pane, F; Pasquazi, A; Ranucci, E; Rizzo, M; Rossi, C; Santoleri, F; Scaldaferri, M; Scortechini, AR; Torquati, G; Vozza, A | 1 |
| Anandan, S; Balasubramanian, P; Benjamin, ESB; Kausalya, B; Mathews, V; Rajamani, BM; Ravindra, N; Velayudhan, SR; Veldore, V | 1 |
| Alexis, M; Arkam, Y; Berger, M; Berthou, C; Bulabois, CE; Caillot, D; Cambier, N; Cayuela, JM; Chapiro, J; Charbonnier, A; Chomel, JC; Coiteux, V; Cony-Makhoul, P; Deconinck, E; Delmer, A; Delord, M; Dorvaux, V; Dubruille, V; Escoffre Barbe, M; Etienne, G; Fouillard, L; Gardembas, M; Ghomari, K; Glaisner, S; Guerci-Bresler, AP; Guilhot, F; Guilhot, J; Gyan, E; Johnson-Ansah, H; Joly, B; Jourdan, E; Kiladjian, JJ; Lebon, D; Legros, L; Lenain, P; Lhermitte, L; Mahon, FX; Maisonneuve, H; Maloisel, F; Mercier, M; Miclea, JM; Muller, M; Nicolini, FE; Penot, A; Plantier, I; Pollet, B; Preudhomme, C; Rea, D; Rigal-Huguet, F; Rousselot, P; Roy, L; Santagostino, A; Vaida, I; Vekhoff, A; Zerazhi, H | 1 |
| Bartos, O; Brodska, B; Dresler, J; Hrdinova, T; Kabickova, H; Klimentova, J; Krijt, M; Linhartova, J; Machova Polakova, K; Pajer, P; Petrak, J; Polivkova, V; Salovska, B; Toman, O; Vyoral, D; Zivny, J | 1 |
| Bashash, D; Ghaffari, SH; Momeny, M; Safa, M; Salari, S; Yousefi, AM; Zehtabcheh, S | 1 |
| Akdemir, C; Hekmatshoar, Y; Ozcan, M; Ozkan, T; Pamuk, H; Sunguroglu, A; Yagiz, GC; Yaman, G | 1 |
| Abdo, ANR; Bendit, I; Maciel, FVR; Nardinelli, L; Pereira, TDM; Rocha, V; Santos, FM; Seguro, FS | 1 |
| Awasthi, D; Barthwal, MK; Chandra, T; Dikshit, M; Dubey, M; Nagarkoti, S; Singh, AK; Tripathi, AK | 1 |
| Breccia, M; Efficace, F; Scalzulli, E; Sparano, F; Vignetti, M | 1 |
| Fang, Q; Liu, P; Ma, D; Wang, J; Wang, P; Zhou, Z | 1 |
| Beninati, S; Casciano, F; Feriotto, G; Giriolo, R; Khan, MTH; Mischiati, C; Tabolacci, C; Tagliati, F | 1 |
| Frikha, R; Louati, N; Mnif, H; Turki, F | 1 |
| Elloumi, M; Frikha, R; Kamoun, H; Kassar, O; Turki, F | 1 |
| Becker, P; Joubert, AM; Karodia, M; Pool, R; Repsold, L; Tintinger, G | 1 |
| Cao, J; Chen, C; Ge, J; Hu, C; Hu, Z; Li, L; Li, X; Liang, H; Liu, J; Liu, Q; Lu, T; Ren, T; Shen, Y; Wang, A; Wang, W; Xia, R; Zou, F | 1 |
| Han, Y; Ma, Z | 1 |
| Altinok Gunes, B; Hekmatshoar, Y; Karabay, AZ; Karadag Gurel, A; Koc, A; Ozkan, T; Sunguroglu, A | 1 |
| Apperley, JF; Cicconi, S; Clark, RE; Copland, M | 1 |
| Edao, A; Hailemariam, TS; Kinde, S; Mehdi, M; Seifu, D | 1 |
| Akutagawa, J; Braun, BS; Dai, Y; Devidas, M; Loh, ML; Moorman, AV; Mullighan, CG; Nguyen, JV; Roberts, KG; Sali, A; Shah, NP; Smith, CC; Stecula, A; Tran, TH | 1 |
| Bagal, B; Bonda, A; Gokarn, A; Jain, H; Khattry, N; Patkar, N; Punatar, S; Sengar, M; Shetty, D; Subramanian, P; Talker, E; Talker, J | 1 |
| Biswas, N; Paul, T; Roy, R; Sarkar, RD; Sinha, S | 1 |
| Ab Rajab, NS; Abdul Aziz, AA; Ankathil, R; Annuar, AA; Husin, A; Ibrahim, MI; Mohd Yunus, N; Sulong, S | 1 |
| Chamba, C; Hussein, A; Luzzatto, L; Mushi, R; Nasser, A; Schuh, A; Yonazi, M | 1 |
| Brunetti, ND; Casavecchia, G; De Gennaro, L; Di Biase, M; Gravina, M; Magnesa, M; Spinosa, G; Zicchino, S | 1 |
| Dalal, H; Damodar, S; Gowda, DA; H, K; Subramanian, S; V P, S; Vyas, N | 1 |
| Abreu, DC; Anunciação, CE; Barbosa, ADP; Delleon, H; Delmond, KA; Goveia, RM; Mello-Andrade, F; Reis, AADS; Silva, DME; Silveira-Lacerda, E; Tavares, RS; Teixeira, TM | 1 |
| Hijiya, N; Sakamoto, KM; Smith, SM | 1 |
| Morita, K; Sasaki, K | 1 |
| Bohra, GK; Kumar, D; Pandey, H; Purohit, AHL; Saha, S; Sarangi, S | 1 |
| Chen, XJ; Liu, MY; Wang, WZ; Wu, QQ | 1 |
| Li, HL; Lyu, XM; Ye, YF | 1 |
| Kinoshita, E; Kinoshita-Kikuta, E; Koike, T; Yano, M; Yoshimoto, M | 1 |
| Asagiri, T; Kamioka, M; Kojima, K; Togitani, K | 1 |
| Brümmendorf, TH; Chuah, C; Cortes, JE; Do, YR; Koh, LP; Numbenjapon, T; Ohkura, M; Ong, KH; Ono, C; Viqueira, A; Zang, DY | 1 |
| Atenafu, EG; Bence-Bruckler, I; Busque, L; Delage, R; Forrest, D; Kamel-Reid, S; Keating, MM; Kim, DDH; Kim, TS; Laneuville, P; Leber, B; Liew, E; Lipton, JH; Novitzky-Basso, I; Paulson, K; Savoie, L; Stockley, T; Xenocostas, A | 1 |
| Abu Amis, SH; Alauddin, H; Awai, R; Ithnin, A; Jalil, N; Jamali, NS; Raja Sabudin, RZA; Shuib, S; Tumian, NR | 1 |
| Głowacki, S; Skorski, T; Śliwiński, T; Synowiec, E; Szwed, M; Toma, M | 1 |
| Bergsagel, J; Castellino, SM; Effinger, KE; Lewis, RW; Mertens, A; Patterson, B; Sabnis, HS; Sakamoto, KM; Schapira, L; Smith, SM | 1 |
| Buchete, NV; Elber, R; Narayan, B | 1 |
| Jin, Y; Lai, P; Li, S; Liu, C; Nie, D; Zhang, X; Zhou, M | 1 |
| Guo, Q; Li, J; Li, W; Pan, D; Wang, K; Yang, W; Ye, Y; Zeng, Y; Zhao, L | 1 |
| Bonifacio, M; Breccia, M; Caocci, G; Castagnetti, F; Ciccone, G; Gozzini, A; La Barba, G; Luciano, L; Martino, B; Pizzuti, M; Pregno, P; Saglio, G; Scortechini, AR; Specchia, G; Stagno, F; Tiribelli, M | 1 |
| Guo, Y; Guo, Z; Lin, D; Pan, H; Song, T; Uwituze, LB; Wang, H; Wang, Z; Xue, Z; Yin, F; Zhang, H; Zhang, X; Zhang, Z | 1 |
| Ar, MC; Aydın, Y; Başlar, Z; Bayraktar, EA; Bektaş, F; Elverdi, T; Eşkazan, AE; Keskin, D; Öngören, Ş; Özgür Yurttaş, N; Özmen, D; Öztaş, M; Sadri, S; Salihoğlu, A; Soysal, T | 1 |
| Bonnette, UL; Song, T; Wang, P; Zhang, H; Zhang, Z | 1 |
| Echebarrria-Barona, A; Moreno Gamiz, M; Roldán Galiacho, V | 1 |
| Bai, Q; Di, H; Dou, X; Du, X; Jia, Y; Jia, Z; Jiang, Q; Jin, J; Lin, H; Liu, B; Liu, H; Lu, Z; Ma, H; Meng, F; Meng, L; Qian, S; Sun, H; Xu, N; Yang, W; Zhang, L; Zhang, Y; Zhao, X; Zheng, F; Zhou, L; Zhu, X | 1 |
| Cascorbi, I; Dworschak, M; Kaehler, M; Liu, C; Nagel, I; Penas, EMM; Rodin, JP; Ruemenapp, J; Vater, I | 1 |
| Gupta, SK; Kumar, N; Tripathi, AK; Verma, SP | 1 |
| Assad, D; Hamid, M; Jalaeikhoo, H; Mohammadi, F; Rostami, G; Shafiei, M | 1 |
| Kang, KW; Kim, BS; Kim, JH; Lee, BH; Lee, SJ; Park, Y | 1 |
| Dai, H; Feng, W; Liang, Y; Wang, Y; Yuan, Y; Zhu, Y | 1 |
| Liu, Y; Liu, Z; Wang, F; Zhang, Y; Zheng, W; Zhou, B | 1 |
| Hsieh, KP; Huang, RY; Li, PC; Tsai, HJ; Yang, YC; Yang, YH | 1 |
| Cheng, R; Fang, Y; Ge, Y; Huang, Y; Wang, Q; Yan, M | 1 |
| Begna, K; Smith, CJ; Stewart, G | 1 |
| Kimura, S | 6 |
| Cappelleri, JC; Heeg, B; Mamolo, C; Muresan, B; Postma, MJ | 1 |
| De, M; Jethva, DD; Patel, KD; Patel, PS; Rathod, BS | 1 |
| Batorova, A; Harvanova, L; Hatalova, A; Martisova, M; Mistrik, M; Mladosievicova, B; Petrikova, L; Slezakova, K; Sninska, Z | 1 |
| Cao, J; Feng, Y; Jia, Y; Jiang, L; Liu, Y; Wang, X; Wang, Z; Xia, Y | 1 |
| Abubeker, A; Asres, G; Gebremedhin, A; Radich, J; Tadesse, F | 1 |
| Aoki, S; Endo, S; Furuichi, K; Hirao, T; Ito, K; Kikuya, M; Toyooka, N | 1 |
| Catharino, RR; de Oliveira, AN; de Paula, EV; Delafiori, J; Dias-Audibert, FL; Lopes, ABP; Pagnano, KBB; Póvoa, VMO | 1 |
| Aimone, P; Allepuz, A; Bautista, F; Ducassou, S; Dufour, C; Goto, H; Guinipero, T; Hijiya, N; Kang, HJ; Karakas, Z; Maschan, A; Millot, F; Patterson, B; Rizzari, C; Samis, J; Shimada, H; Sosothikul, D; Titorenko, K; Yoo, KH; Zwaan, CM | 1 |
| Aoyama, T; Imai, S; Kashiwagi, H; Kuriyama, H; Sato, Y; Sugawara, M; Takekuma, Y | 1 |
| Chen, Y; Li, Y; Liu, Q; Rao, Q; Wang, JX; Wang, M; Wei, H | 1 |
| Bassotti, G; Del Sordo, R; Lupinacci, G; Tanzi, G; Villanacci, V | 1 |
| Kim, DDH; Lipton, JH; Nee, A | 1 |
| Jeong, JO; Jo, DY; Lee, HJ; Lee, MW; Park, JH; Ryu, H; Song, IC; Sun, BJ; Yeon, SH; Yun, HJ | 1 |
| Akalin, H; Celik, S; Demir, M; Dundar, M; Gokce, N; Karasu, N; Keklik, M; Kulak, H; Yildirim, A | 1 |
| Jiang, Q; Li, WM; Liang, R; Liu, BC; Liu, XL; Meng, L; Wang, HF; Zhang, YL; Zhou, L; Zhu, HL | 1 |
| Ban, H; Hostetler, BJ; McKallip, RJ; Uchakina, ON | 1 |
| Azam, M; Bouso, MF; Cancelas, JA; Gomaa, A; Grimes, HL; Huber, E; Kesarwani, M; Kincaid, Z; Komurov, K; Latif, T; Mulloy, JC; Rohrabaugh, S; Siddiqui, Z; Xu, M | 1 |
| Chandra, D; Chaubey, R; Chikkara, S; Mahapatra, M; Mishra, P; Saxena, R; Sazawal, S; Seth, T; Singh, K | 1 |
| Bogdanovic, A; Colovic, N; Gotic, M; Jovanovic, J; Lekovic, D; Milic, N; Milosevic, V; Zivojinovic, B | 1 |
| Bakhshi, S; Biswas, NR; Gogia, A; Gupta, YK; Harivenkatesh, N; Kabra, M; Kumar, L; Sharma, A; Shastri, SS; Velpandian, T | 1 |
| Brümmendorf, TH; Gjertsen, BT; Hjorth-Hansen, H; Janssen, J; Koskenvesa, P; Kreutzman, A; Lotfi, K; Markevärn, B; Missiry, ME; Mustjoki, S; Olsson-Strömberg, U; Rajala, HLM; Richter, J; Ruusila, A; Stenke, L; Stentoft, J | 1 |
| Fujisawa, S; Ishida, Y; Li, L; Matsue, K; Miyoshi, M; Nakamae, H; Ogura, M; Ohashi, K; Onishi, Y; Takamatsu, Y; Tanimoto, M; Taniwaki, M; Uchida, T; Usuki, K; Utsunomiya, A | 1 |
| James, AR; Joseph, MM; Kusumakumary, P; Manojkumar, TK; Preethi, GU; Priya, R; Raveendran Pillai, K; Shiji, R; Sreelekha, TT; Unnikrishnan, BS | 1 |
| Huang, HM; Lee, YL; Lin, JY; Liou, JP; Yeh, YY | 1 |
| Campiotti, L; Gambacorti-Passerini, C; Grandi, AM; Guasti, L; Piazza, R; Squizzato, A; Suter, MB | 1 |
| Bakhshi, S; Gogia, A; Gupta, YK; Harivenkatesh, N; Kabra, M; Kumar, L; Sharma, A; Shastri, SS; Velpandian, T | 1 |
| Acharya, P; Basnyat, B; Gurung, R; Hayes, B; Karki, S; Kayastha, GK; Kc, RK; Mansfield, A; Poudyal, B; Rajbhandari, P; Ranjitkar, N; Roberts, DJ; Shrestha, R; Thapa, RK; Zimmerman, M | 1 |
| Bober, G; Dudziński, M; Giannopoulos, K; Gil, J; Gniot, M; Góra-Tybor, J; Grzybowska-Izydorczyk, O; Hołojda, J; Mędraś, E; Myśliwiec, K; Niesiobędzka-Krężel, J; Pietkun, I; Sacha, T; Szarejko, M; Wącław, J; Wasilewska, E | 1 |
| Brizard, F; Cayssials, É; Chomel, JC; Sorel, N | 1 |
| Diepstraten, J; Gelderblom, H; Kouwen, S; Posthuma, WF; Swen, JJ; van Lammeren, D; Verboom, MC; Visser, L; Wilms, EB | 1 |
| Brewer, D; Burwick, RM; Druker, BJ; Kuo, K | 1 |
| Busque, L; Guimond, M; Laflamme, P; Leboeuf, DM; Moutuou, MM; Roy, J; Sidi Boumedine, R; Thiant, S | 1 |
| Capitani, S; Celeghini, C; Evangelisti, C; Marisi, G; Martelli, AM; McCubrey, JA; Neri, LM; Simioni, C; Ulivi, P; Ultimo, S; Zauli, G | 1 |
| Din, B; Li, Y; Wang, CL; Yu, L; Zhu, J | 1 |
| Ding, W; Ding, Y; Li, Y; Ma, J; Qian, Z; Shao, J; Wang, Q | 1 |
| Boros, LG; Collins, TQ; D'Agostino, DP; Hitendra, P; Meuillet, EJ; Somlyai, G | 1 |
| Imano, M; Itoh, T; Kino, T; Nakayama, T; Nishida, S; Nishio, K; Sakai, K; Satou, T; Takeda, T; Tsubaki, M | 1 |
| Coha, B; Holik, H; Kovač Peić, A; Novaković, S | 1 |
| Belohlavkova, P; Benes, V; Curik, N; Hercog, R; Jaruskova, M; Klamova, H; Machova Polakova, K; Motlova, E; Pecherkova, P; Polivkova, V; Vrbacky, F | 1 |
| Chen, Y; Fan, G; Jin, M; Kong, D; Qiu, Y; Wang, R; Zhang, L; Zhang, Z; Zhong, Y; Zhou, Q | 1 |
| Huang, Y; Li, C; Peng, Q; Xiao, H; Xin, P; Zheng, Y; Zhu, X | 1 |
| Alessandro, R; Bellavia, D; Calabrese, G; Cirrincione, G; Cristaldi, M; De Leo, G; Diana, P; Fontana, S; Forte, S; Giavaresi, G; Manno, M; Memeo, L; Monteleone, F; Patinella, A; Raccosta, S; Raimondo, S | 1 |
| Fang, Q; Huang, J; Liu, P; Ma, D; Ren, M; Wang, J; Wang, P; Yu, M; Yu, Z; Zhe, N | 1 |
| Chen, J; DU, SH; Jia, PM; Lu, HY; Tong, JH; Wu, YL; Zhou, L | 1 |
| Cheng, YD; Gan, SL; Jiang, ZX; Liu, X; Liu, YF; Ma, J; Sun, H; Xie, XS | 1 |
| Li, YF; Wang, Q | 1 |
| Abruzzese, E; Albano, F; Annunziata, M; Baccarani, M; Bocchia, M; Bochicchio, MT; Bonifacio, M; Breccia, M; Castagnetti, F; Cavazzini, F; Cavo, M; Fava, C; Gherlinzoni, F; Giovanni, M; Gugliotta, G; Iurlo, A; Levato, L; Martino, B; Orlandi, E; Pane, F; Pregno, P; Rossi, G; Rosti, G; Rupoli, S; Saglio, G; Sica, S; Soverini, S; Tiribelli, M; Usala, E; Vigneri, P | 1 |
| Acharya, P; Basnyat, B; Gurung, R; Hayes, B; Karki, S; Kayastha, GK; Kc, RK; Poudyal, B; Rajbhandari, P; Ranjitkar, N; Roberts, DJ; Shrestha, R; Thapa, RK; Zimmerman, M | 1 |
| Akula, S; Duyster, J; Kamasani, S; Kancha, RK; Manga, V; Sivan, SK; Vudem, DR | 1 |
| Chen, Q; Chua, SH; Kok, WL; Lee, SSJ; Ng, SK | 1 |
| Abad-Santos, F; Colom-Fernández, B; Muñoz-Calleja, C; Ruiz-Nuño, A; Steegmann, JL; Wojnicz, A | 1 |
| Kalhagen, L; Leighton, L; McGrath, K; Stein, B | 1 |
| Cayssials, E; Guilhot, F | 1 |
| Antapura, R; Dasappa, L; Jacob, L; Kadabur, L; Kanakasetty, GB; Kuntegowdanahalli, L; Lakkavalli, R; Mallekavu, SB; Thanky, AH | 1 |
| Hunger, SP | 1 |
| Charbonnier, A; Dubruille, V; Dulphy, N; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Henry, G; Huguet, F; Ianotto, JC; Khaznadar, Z; Legros, L; Mahon, FX; Maloisel, F; Moins-Teisserenc, H; Nicolini, F; Rea, D; Rousselot, P; Toubert, A; Villemagne, B | 1 |
| Cheong, SK; Leong, CF; Norziha, ZA; Simbun, A; Tumian, NR; Wong, CL; Yap, E | 1 |
| Fukuda, T; Horikoshi, A; Inokuchi, K; Kouzai, Y; Kumagai, T; Morita, S; Nishiwaki, K; Ohwada, A; Sakamaki, H; Sakamoto, J; Shiseki, M; Takano, H; Takezako, N; Tanaka, J; Yoshida, C | 1 |
| Adusumilli, P; Bala, S; Danthala, M; Digumarti, RR; Gundeti, S; Karnam, AP; Konatam, ML; Kuruva, SP; Maddali, LS; Puligundla, KC | 1 |
| Abruzzese, E; Albano, F; Baccarani, M; Bigazzi, C; Binotto, G; Bonifacio, M; Breccia, M; Caracciolo, C; Castagnetti, F; Cavazzini, F; Cavo, M; D'Adda, M; Foà, R; Gugliotta, G; Intermesoli, T; Iurlo, A; La Barba, G; Levato, L; Martinelli, G; Martino, B; Pane, F; Pregno, P; Rosti, G; Saglio, G; Sorà, F; Soverini, S; Stagno, F; Tiribelli, M | 1 |
| Bi, L; Duan, J; Fan, Z; Pan, L; Qiao, W; Wu, D; Yang, M | 1 |
| Lee, SG; Lipton, JH | 1 |
| Fava, C; Saglio, G | 3 |
| Adeagbo, BA; Bolaji, OO; Bolarinwa, RA; Durosinmi, MA; Ogungbenro, K; Olugbade, TA | 1 |
| Cai, Z; Huang, H; Luo, Y; Shi, J; Tan, Y; Wang, J; Zhao, Y; Zheng, W | 1 |
| Hamid, M; Jalaeikhoo, H; Rostami, G | 1 |
| Du, W; He, YL; Xiao, JH; Zhang, JH; Zhu, R | 1 |
| Fernández, I; Giere, IA; Intile, D; Mela Osorio, MJ; Pavlovsky, C; Pavlovsky, MA | 1 |
| Akram, M; Quraishi, AM; Saeed, S; Tahir, M | 1 |
| Assouline, SE; Azoulay, L; Busque, L; Del Corpo, A; Delage, R; Gratton, MO; Harnois, M; Klil-Drori, AJ; Laneuville, P; Mollica, L; Olney, HJ; Yin, H | 1 |
| Engh, RA; Flå, T; Gruber, FX; Woywod, C | 1 |
| Chen, J; Chen, X; Huang, H; Lan, X; Liu, J; Long, H; Shi, X; Wang, X; Wu, J; Yang, L; Zang, D; Zhang, P; Zhao, C | 1 |
| Hijiya, N; Lee, P; Samis, J; Suttorp, M; Zimmerman, D | 1 |
| Aleshin, S; Chelysheva, E; Chilov, G; Guranda, D; Kazakbaeva, K; Mordanov, S; Oksenjuk, O; Polushkina, E; Shmakov, R; Shokhin, I; Turkina, A; Zeifman, A | 1 |
| Nau, JY | 1 |
| Ćojbašić, I; Mačukanović-Golubović, L; Tijanić, I; Vučić, M | 1 |
| Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hung, MH; Ko, PS; Liu, CJ; Liu, CY; Liu, JH; Liu, YC; Wu, YT; Yu, YB | 1 |
| Gambacorti-Passerini, C; Khandelwal, P; Mologni, L; Piazza, R; Pirola, A | 1 |
| Cornelissen, JJ; Geelen, IGP; Hoogendoorn, M; Janssen, JJWM; Levin, MD; Thielen, N; Visser, O; Westerweel, PE | 1 |
| Bandyopadhyay, S; Cheng, JX; Li, J; Oh, ST; Traer, E; Tyner, JW; Zhou, A | 1 |
| Li, T; Lin, H; Liu, M; Wu, B; Zhong, H | 1 |
| Ghirdaladze, D; Kirtava, T; Vatsadze, T | 1 |
| Al-Kali, A; Begna, K; Elliott, M; Foran, J; Gangat, N; Hogan, W; Hook, C; Leis, J; Litzow, M; Mesa, R; Palmer, J; Pardanani, A; Patnaik, M; Rivera, C; Sproat, L; Tefferi, A; Tibes, R; Wolanskyj-Spinner, A | 1 |
| Huang, XP; Luo, ZB; Ouyang, GF; Xu, N | 1 |
| Chahine, G; Hawi, J; Kerbage, F; Makdissi, J; Massoud, M; Nasr, F; Rached, L; Sakr, R | 1 |
| Hou, XY; Huang, M; Li, JL; Lin, CZ; Qiu, HB; Ruan, HL; Wang, XD; Wu, T; Xin, S; Zhou, ZW; Zhu, X; Zhuang, W | 1 |
| Belsey, SL; Bisquera, A; De Lavallade, H; Flanagan, RJ; Ho, A; Ireland, R; Kizilors, A; Lang, K; Mufti, GJ | 1 |
| Bai, F; Dong, Y; Qin, F; Sun, J; Zhang, XF; Zhao, YH; Zhao, YQ | 1 |
| Chang, X; Chen, X; Cheng, Y; Fang, M; Sun, S; Xiang, Y; Xu, B; Zhou, L | 1 |
| Baerlocher, GM; Balleisen, L; Beelen, DW; Bentz, M; Berdel, WE; Bildat, S; Brossart, P; Brümmendorf, TH; Burchert, A; de Wit, M; Dengler, J; Eckart, MJ; Edinger, M; Fabarius, A; Falge, C; Fuchs, R; Gassmann, W; Geer, T; Goebeler, MC; Gratwohl, A; Haferlach, C; Hahn, M; Hänel, M; Hasford, J; Hebart, H; Hehlmann, R; Heim, D; Hertenstein, B; Ho, A; Hochhaus, A; Hossfeld, DK; Jeromin, S; Kanz, L; Kneba, M; Kohlbrenner, K; Köhne, CA; Kolb, HJ; Krause, S; Kremers, S; Lauseker, M; Lindemann, HW; Link, H; Mayer, J; Müller, L; Müller, MC; Nerl, C; Neubauer, A; Pezzutto, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Rinaldetti, S; Saußele, S; Schäfer, E; Schafhausen, P; Scheid, C; Schenk, M; Schlag, R; Schlegel, F; Schlegelberger, B; Seifarth, W; Spiekermann, K; Spieß, B; Stegelmann, F; Thomalla, J; Trümper, L; Verbeek, W; Voskanyan, A; Waller, CF; Wernli, M | 1 |
| de Paula, EV; de Souza, CA; Delamain, MT; Duarte, GO; Lorand-Metze, I; Miranda, EC; Pagnano, KBB | 1 |
| Abbes, S; Amouri, H; Ben Hadj Othman, H; Ben Hassine, I; Ben Youssef, Y; Farrah, A; Gharbi, H; Ghedira, H; Menif, S; Safra, I; Soltani, I; Teber, M | 1 |
| Nambudiri, VE; Shi, CR | 1 |
| Bhattacharyya, J; Jaganathan, BG; Kumar, A | 1 |
| Abbasi, S; Alrabi, K; Awidi, A; Kheirallah, KA | 1 |
| Bhave, RR; Guzman, ML; He, B; Lentz, SR; Li, F; Ma, X; Tan, K; Xue, HH; Yu, S; Zhao, C | 1 |
| Ar, MC; Aydin, D; Aydin, Y; Aydinli, F; Ayer, M; Baslar, Z; Berk, S; Demirel, N; Elverdi, T; Eskazan, AE; Kantarcioglu, B; Keskin, D; Ongoren, S; Ozbek, U; Ozunal, IE; Sadri, S; Salihoglu, A; Soysal, T; Tuzuner, N; Yalniz, FF; Yokus, O | 1 |
| Acharya, S; Bendit, I; Branford, S; Cervantes, F; Clementino, NCD; Dalal, D; Dorlhiac-Llacer, PE; Glynos, T; Guerci-Bresler, A; Hughes, TP; Kamel-Reid, S; Leber, B; Lipton, JH; Mahon, FX; Pasquini, R; Rea, D; Schwarer, AP; Spector, N | 1 |
| Azma, RZ; Elias, MH; Hamidah, NH; Salwati, S; Sharifah, NA; Tumian, NR; Wong, CL; Yap, E | 1 |
| Eguchi, G; Kanai, Y; Kawaguchi, SI; Konishi, A; Maeda, Y; Okamoto, A; Yamaguchi, T; Yamamoto, K | 1 |
| Leader, A; Raanani, P | 1 |
| Asemissen, AM; Dierlamm, J | 1 |
| Dong, F; Liu, X; Sun, C; Wang, N; Zhang, G; Zhang, X | 1 |
| Baquero, P; Dunn, K; Gottlieb, E; Helgason, GV; Holyoake, TL; Kuntz, EM; Michie, AM; Tardito, S | 1 |
| Nitschmann, S; Saußele, S | 1 |
| Atsuta, Y; Fujimaki, K; Fukuda, T; Gomyo, H; Hatta, Y; Imai, K; Ishikawa, M; Kiguchi, T; Kitamura, K; Kiyoi, H; Kobayashi, S; Kobayashi, Y; Matsumura, I; Minami, Y; Mitsui, H; Miyake, T; Miyamura, K; Miyata, Y; Miyazaki, Y; Naoe, T; Ohishi, K; Ohnishi, K; Ohtake, S; Saburi, Y; Sasaki, O; Suzushima, H; Takada, S; Takahashi, N; Tauchi, T; Togitani, K; Usui, N; Usuki, K | 1 |
| Kahn, M; Massiello, D; Melendez, E; Smbatyan, G; Wu, K; Wu, Y; Zhao, Y | 1 |
| Boehm, JS; Hong, AL; Painter, CA; Sharifnia, T | 1 |
| Asik, A; Avci, CB; Gunduz, C; Kayabasi, C; Okcanoglu, TB; Saydam, G; Susluer, SY; Yelken, BO | 1 |
| Ankathil, R; Baba, AA; Husin, A; Makhtar, SM | 1 |
| Breccia, M; Colafigli, G; Diverio, D; Foà, R; Guarini, A; Latagliata, R; Molica, M; Scalzulli, E | 1 |
| Elsayed, AG; Jamil, MO; Srivastava, R | 1 |
| Bhat, M; Gupta, N; Guru, SA; Masroor, M; Mir, R; Najar, I; Saxena, A; Sumi, M; Zuberi, M | 1 |
| Amarante-Mendes, GP; Calle, Y; Castro, FA; De Carvalho, DD; Hamerschlak, N; Jacysyn, JF; Jones, GE; Pagnano, KB; Pereira, WO; Ribeiro, BF; Sardinha, LR; Zanichelli, MA; Zenteno, ME | 1 |
| Cai, HF; Li, N; Liu, MB; Luo, XF; Weng, LZ; Yang, J; Zhan, FM; Zheng, B | 1 |
| Aguilar, R; Alfaro-Ruiz, L; Arriaga-Pizano, L; Avilés-Vázquez, S; Ayala-Sánchez, M; Chávez-González, A; Hidalgo-Miranda, A; Mayani, H; Moreno-Lorenzana, D; Sandoval-Esquivel, MÁ | 1 |
| Berger, D; Bernthaler, T; Eisenwort, G; Entner, M; Hadzijusufovic, E; Herrmann, H; Hoermann, G; Rülicke, T; Sadovnik, I; Stefanzl, G; Valent, P; Willmann, M | 1 |
| Horiuchi, T; Kato, S; Kawamura, T; Kimura, F; Kobayashi, A; Kobayashi, S; Maekawa, T; Nagao, S; Okada, Y; Saga, R; Sato, K; Tachi, N; Takano, K; Teramoto, M; Watanabe, J; Yamamura, T | 1 |
| Behera, B; Chakrabarti, P; Chakravarty, L; Kundu, N; Maiti, TK; Mukherjee, D; Sarkar, N | 1 |
| Aoki, M; Fukuda, T; Ito, K; Kanda, Y; Matsuda, A; Matsumura, I; Nakamae, H; Nakaseko, C; Ohmine, K; Ono, T; Shibayama, H | 1 |
| Bornhäuser, M; Metzler, M; Millot, F; Schleyer, E; Suttorp, M | 1 |
| Bardy-Bouxin, N; Brümmendorf, TH; Chuah, C; Cortes, JE; Deininger, MW; Dyagil, I; Gambacorti-Passerini, C; Garcia-Gutierrez, V; Glushko, N; Hochhaus, A; Jeynes-Ellis, A; Kim, DW; le Coutre, P; Leip, E; Mauro, MJ; Milojkovic, D; Reilly, L | 1 |
| Cheng, Y; Hao, Y; Hu, C; Jiang, X; Wu, Q; Xu, X; Zhang, A | 1 |
| Aoki, S; Chibana, H; Hirao, T; Ito, K; Kikuya, M; Yamaguchi, M | 1 |
| Gourd, E | 1 |
| Jin, J; Lei, H; Li, X; Liu, M; Luo, H; Wu, Y; Xu, H; Yang, L | 1 |
| Dong, Y; Gao, X; Liu, L; Wei, M; Xu, L; Yang, G; Zhao, Y | 1 |
| Allan, EK; Baquero, P; Calabretta, B; Chan, E; Clark, RE; Druker, BJ; Hair, A; Hamilton, G; Helgason, GV; Herzyk, P; Hewit, K; Holyoake, TL; Hopcroft, LEM; James, D; Maguer-Satta, V; Melo, JV; Mitchell, R; Mitra, S; Mukhopadhyay, A; Nicolini, FE; O'Prey, J; Ryan, KM; Salomoni, P; Shanks, E | 1 |
| Chawla, R; Tripathy, K | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawaguchi, SI; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nagayama, T; Nakano, H; Ochi, SI; Oh, I; Ohmine, K; Sato, K; Shirato, Y; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Chaubey, R; Chauhan, R; Chhikara, S; Dange, P; Deka, R; Mahapatra, M; Ragesh R Nair, R; Saxena, R; Sazawal, S; Singh, K; Veetil, KK | 1 |
| Chen, Y; He, Y; Huang, R; Kang, Q; Li, Y; Liu, H; Tu, S; Wang, L; Wu, A; Yang, J; Zhou, X | 1 |
| Díez, JL; Escudero-Vilaplana, V; García-González, X; Gómez-Centurión, I; González-Arias, E; Osorio, S | 1 |
| Demirkan, TH; Guzelkucuk, Z; Isık, M; Ozcan, AS; Yaralı, N | 1 |
| Chen, QG; Gao, QF; Huang, B; Jiang, YH; Li, J; Li, SQ; Lin, J; Liu, J; Liu, XQ; Min, QH; Sun, F; Wang, XZ; Xu, YM; Yang, WM; Zhang, J; Zhang, L | 1 |
| Hoffman, KR | 1 |
| Jing, Y; Liu, DH; Yang, L | 1 |
| Hirano, M; Imai, Y; Imoto, S; Jimbo, K; Kawamata, T; Miyano, S; Ochi, K; Ogawa, M; Ohno, N; Shimizu, E; Takahashi, N; Tojo, A; Uchimaru, K; Yamaguchi, R; Yokoyama, K; Yokoyama, N | 1 |
| Dogra, S; Handa, S; Khadwal, A; Kumari, S; Lad, D; Malhotra, P; Prakash, G; Suri, V; Varma, S; Vinay, K; Yanamandra, U | 1 |
| Chen, F; Chi, Y; Fan, H; Han, Z; Li, Z; Liu, N; Liu, Y; Ma, F; Song, B; Wei, Y | 1 |
| Felber, E; Koh, HA; Lin, KJ; Rashid, N; Stwalley, B | 1 |
| Inokuchi, K; Komatsu, N; Kumagai, T; Nakayama, K; Ohyashiki, K; Takaku, T; Tauchi, T; Yamaguchi, H; Yokose, N | 1 |
| Capusan, TM; de Argila, D; Herrero-Moyano, M; Martinez-Mera, C; Steegmann Olmedillas, JL; Urquía Renke, A | 1 |
| Du, X; Jin, Y; Li, J; Li, Y; Liu, C; Lu, Y; Nie, D; Pan, J; Zhou, J | 1 |
| Bai, S; Cen, J; Chen, S; Gong, Y; Pan, J; Qiu, H; Shao, H; Wang, Y; Wu, C; Zeng, Z; Zhang, J | 1 |
| Jin, B; Pan, J; Shen, Y; Wang, C | 1 |
| Akashi, K; Hino, M; Hirase, C; Ishikawa, J; Kamimura, T; Kanakura, Y; Kawaguchi, T; Kuroda, J; Matsumura, I; Matsuoka, KI; Miyamoto, T; Nakamae, H; Shibayama, H; Shimose, T | 1 |
| Ali, TFS; Can, M; Ciftci, HI; Fujita, M; Koga, R; Ocak, Z; Otsuka, M; Ozturk, SE; Radwan, MO; Tateishi, H | 1 |
| Berzoti-Coelho, MG; Burin, SM; de Castro, FA; Marsola, APZC; Palma, LC; Simões, BP | 1 |
| Chen, XC; Gu, CH; Li, CX; Wang, P; Wang, T; Wu, DP; Yang, D; Zou, Q | 1 |
| He, B; Huang, J; Liu, X; Lu, Z; Pan, C; Xiao, Y; Xu, N; Zhou, X | 1 |
| Koya, J; Kurokawa, M; Morita, K; Nakamura, F; Toya, T | 1 |
| Bono, S; Dello Sbarba, P; Lulli, M | 1 |
| Di Tullio, F; Mandel, VD; Padalino, C; Pellacani, G; Scotti, R | 1 |
| Benghiat, FS; Dessars, B; El Housni, H; Heimann, P; Heinrichs, A; Peeters, K; Pluymers, W | 1 |
| Angelini, S; Cargnin, S; Ravegnini, G; Soverini, S; Terrazzino, S | 1 |
| Isobe, M; Jimbo, K; Kato, S; Kohara, C; Konuma, T; Mizukami, M; Nagai, E; Ohno, N; Takahashi, S; Tanoue, S; Tojo, A; Watanabe, E | 1 |
| Bavaro, L; Cavo, M; Mancini, M; Martinelli, G; Soverini, S | 1 |
| Sendo, T; Shimada, A; Yagi, K | 1 |
| Acharya, S; Ailawadhi, S; Benyamini, N; Boquimpani, C; Clementino, NCD; De Paz, R; Dengler, J; Fellague-Chebra, R; Hughes, TP; Jin, Y; Kim, DW; Lipton, JH; Mahon, FX; Moiraghi, B; Nicolini, FE; Sacha, T; Shuvaev, V; Takahashi, N; Turkina, AG; Wong, S | 1 |
| Costantini, A; Lasala, R; Logreco, A; Ranucci, E; Santoleri, F | 1 |
| DeAngelo, DJ; Luskin, MR | 1 |
| Einsele, H; Fabarius, A; Falge, C; Hasford, J; Hehlmann, R; Heim, D; Hochhaus, A; Hofmann, WK; Jeromin, S; Kanz, L; Kneba, M; Kohlbrenner, K; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Oppliger Leibundgut, E; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Rinaldetti, S; Saussele, S; Stegelmann, F; Waller, CF | 1 |
| Lejniece, S; Rivkina, A; Udre, I | 1 |
| Ahsan, N; Chorzalska, A; Dubielecka, PM; Gruppuso, PA; Hines, S; Liang, O; Morgan, J; Olszewski, AJ; Rao, RSP; Reagan, JL; Roder, K; Tepper, A; Treaba, DO; Yu, X; Zhang, P; Zhao, TC | 1 |
| Hatta, Y; Iriyama, N; Miura, K; Nakagawa, M; Takahashi, H; Takei, M; Uchino, Y | 1 |
| Anderson, L; Branford, S; D'Rozario, J; Gervasio, O; Hiwase, D; Hughes, T; Irving, I; Levetan, C; Powell, A; Roberts, W; Solterbeck, A; Tan, P; Taper, J; Traficante, R; Wright, M; Yeung, DT | 1 |
| Dasanu, CA; Del Rosario, M; Hwang, A; Iskandar, A | 1 |
| Bertrand, Y; Cardos, RC; Chung, NG; de Martino, ML; De Souza, CA; Fagioli, F; Gore, L; Hijiya, N; Kearns, PR; Lancaster, D; Landman-Parker, J; Place, AE; Rabin, KR; Sacchi, M; Saikia, T; Seo, JJ; Stork, LC; Swanink, R; Zwaan, CM | 1 |
| Angaroni, F; Barcella, M; Barlassina, C; Buklijas, K; Caccia, M; Casalone, R; Conti, A; D'Avila, F; Maserati, E; Michelato, A; Micheloni, G; Millefanti, G; Pirrone, C; Piscitelli, E; Porta, G; Rainero, A; Sirchia, S; Spinelli, O; Tararà, L; Valli, R | 1 |
| Chen, Y; Hong, M; Li, H; Li, J; Lu, L; Qian, S; Qiao, C; Shan, Y; Yang, Z; Zhao, H; Zhu, Y | 1 |
| Breccia, M; Foà, R | 1 |
| Almeida, TP; Azqueta, A; Ferreira, J; Ramos, AA; Rocha, E; Vettorazzi, A | 1 |
| Badowska, W; Ćwiklińska, M; Drabko, K; Janeczko-Czarnecka, M; Januszkiewicz-Lewandowska, D; Karolczyk, G; Karpińska-Derda, I; Kałwak, K; Kołtan, A; Krawczuk-Rybak, M; Musioł, K; Mycko, K; Niedźwiecki, M; Ociepa, T; Pawelec, K; Rybka, B; Ryczan-Krawczyk, R; Ussowicz, M; Zaucha-Prażmo, A | 1 |
| Andraus, W; D'Albuquerque, LC; Lima, FR; Nacif, LS; Pinheiro, RS; Rocha-Santos, V; Waisberg, DR | 1 |
| Venkatesan, P | 1 |
| Peng, X; Yu, H; Zheng, Q | 1 |
| Dai, Q; Ge, YQ | 1 |
| Feng, W; Gao, M; Huang, N; Huang, Z; Liu, L; Luo, Z; Wang, X; Xiao, Q; Zhou, F | 1 |
| Deng, Y; Feng, J; Li, X; Zhang, X | 1 |
| Sreenivasan Tantuan, S; Viljoen, CD | 1 |
| Neill, US | 1 |
| Lambrecht, AM; Larocque, EA; Naganna, N; Opoku-Temeng, C; Sintim, HO | 1 |
| Almeida, AG; Alves, D; David, C; Francisco, ARG; Guerra, L; Pinto, FJ | 1 |
| Hu, Y; Huang, H; Liang, Z; Wang, B; Wang, X; Zhang, H | 1 |
| Honma, Y; Ikejiri, F; Okada, T; Suzumiya, J; Urano, T | 1 |
| Eadie, LN; Hughes, TP; White, DL | 2 |
| Auberger, P; Benhida, R; Bougrin, K; Demange, L; Marzag, H; Robert, G; Tachallait, H; Zerhouni, M | 1 |
| Chen, YJ; Huang, HM; Huang, SY; Liu, YH; Yeh, YY | 1 |
| Hong, M; Li, JY; Li, YR; Lu, L; Pan, LQ; Qian, SX; Qiao, C; Zhu, Y | 1 |
| He, HS; Qi, J; Xu, YH | 1 |
| Dobashi, N; Doki, N; Hatta, Y; Hayakawa, F; Ito, Y; Iwanaga, M; Kanamori, H; Kiyoi, H; Maeda, T; Matsuo, K; Miyazaki, Y; Mizuta, S; Monma, F; Naoe, T; Ohtake, S; Sugiura, I; Takeuchi, J; Ueda, Y; Yoshida, C; Yujiri, T | 1 |
| Cai, H; He, X; Yang, C | 1 |
| Ahlert, H; Babor, F; Bhatia, S; Bopp, B; Borkhardt, A; Diedrich, D; Ernst, T; Frieg, B; Gohlke, H; Grez, M; Groth, G; Hansen, FK; Hauer, J; Hochhaus, A; Jose, J; Kassack, MU; Kögler, G; Krieg, A; Kröger, T; Kunkel, H; Kurz, T; Lang, F; Lüdeke, S; Marquardt, V; Nagel-Steger, L; Oldenburg, M; Opitz, FV; Remke, M; Rodrigues Moita, AJ; Stein, S; Zang, T | 1 |
| Cole, AL; Dusetzina, SB | 1 |
| Bennaceur-Griscelli, A; Bonnet, ML; Cayssials, E; Chomel, JC; Desterke, C; Pagliaro, S; Rahban, H; Sorel, N; Turhan, AG; Voldoire, M | 1 |
| Gover-Proaktor, A; Granot, G; Leader, A; Pasmanik-Chor, M; Pasvolsky, O; Raanani, P; Raz, O; Shapira, S | 1 |
| Cornelissen, JJ; Geelen, IGP; Hoglund, M; Hoogendoorn, M; Janssen, JJWM; Sandin, F; Thielen, N; Visser, O; Westerweel, PE | 1 |
| Breccia, M; Colafigli, G; Fegatelli, DA; Foà, R; Latagliata, R; Massaro, F; Molica, M; Scalzulli, E | 1 |
| Altinok Gunes, B; Bozkurt, S; Hekmatshoar, Y; Karabay, AZ; Karadag, A; Ozkan, T; Sunguroglu, A | 1 |
| Feng, J; Jiang, S; Liang, B; Qian, Y; Shen, Z; Tang, L; Wu, J; Xing, C; Yu, K; Zhuang, Q | 1 |
| Nilsson, A; Salamon, D; Stenke, L; Wallvik, J; Yektaei-Karin, E; Zovko, A | 1 |
| Ribaudo, G; Zagotto, G; Zanforlin, E | 1 |
| Crampe, M; Durney, T; Langabeer, SE | 1 |
| Anne Lin, ZH; Chen, KC; Chen, PH; Chiu, YT; Ho, KH; Lee, YT; Liu, AJ; Shih, CM | 1 |
| Chen, S; Hou, M; Hu, J; Hu, Y; Huang, X; Ji, C; Jin, J; Liu, T; Ma, D; Wang, J; Wang, Y; Zhang, J; Zhou, J | 1 |
| Aleinikova, O; Balduzzi, A; Berthold, F; Borkhardt, A; Claviez, A; de Bont, ESJM; Eggert, A; Glauche, I; Göhring, G; Groll, AH; Groß-Wieltsch, U; Harbott, J; Henze, G; Klein, C; Kreipe, HH; Kremens, B; Krumbholz, M; Kulozik, AE; Lausen, B; Metzler, M; Nowasz, C; Schlegelberger, B; Schrappe, M; Schulze, P; Sedlacek, P; Strauss, G; Sufliarska, S; Suttorp, M; Sykora, KW; Tauer, JT; Thiede, C; von Neuhoff, N | 1 |
| Le, BV; Maifrede, S; Nieborowska-Skorska, M; Piwocka, K; Podszywalow-Bartnicka, P; Skorski, T | 1 |
| Azad, NA; Aziz, SA; Khan, MS; Pandith, AA; Rasool, J; Rasool, R; Shah, ZA | 1 |
| Al-Jamal, HAN; Ismail, I; Johan, MF; Mat Jusoh, SA; Wan Taib, WR | 1 |
| Hamada, T; Hatta, Y; Iriyama, N; Miura, K; Nakagawa, M; Takahashi, H; Takei, M; Uchino, Y | 1 |
| Aktan, F; Altinok Gunes, B; Atalay, A; Buyukbingol, Z; Hekmatshoar, Y; Karabay, AZ; Koc, A; Ozkan, T; Sunguroglu, A | 1 |
| Chang, CS; Cho, SF; Hsiao, HH; Huang, WC; Lin, SF; Liu, TC; Liu, YC; Tsai, YF | 1 |
| Abe, M; Akahane, K; Goi, K; Harama, D; Inukai, T; Kagami, K; Kojika, S; Nakada, S; Oshiro, H; Shinohara, T; Sugihara, E; Sugita, K; Tamai, M; Watanabe, A | 1 |
| Braley, J; Branford, S; Dang, P; Goyne, JM; Hughes, TP; Kommers, IO; Nicola, M; Pagani, IS; Ross, DM; Saunders, VA; White, DL; Yeung, DT | 1 |
| Aggarwal, S; Jauhri, M; Minhas, S; Sankaran, S; Sharma, NR; Shokeen, Y; Taneja, V; Vats, A | 1 |
| Bamodu, OA; Chao, TY; Cheng, WH; Ho, YS; Kuo, KT; Lee, WH; Yeh, CT; Yuan, LP | 1 |
| Bettiol, A; Chinellato, A; Crescioli, G; Gherlinzoni, F; Giusti, P; Lombardi, N; Marconi, E; Vannacci, A; Walley, T | 1 |
| Azad, NA; Jeelani, S; Pandith, AA; Rasool, R; Shah, ZA | 1 |
| Chen, Z; Dong, B; Li, B; Liang, Z; Qu, L; Yang, J; Zheng, L; Zhou, H | 1 |
| Belohlavkova, P; Cetkovsky, P; Faber, E; Klamova, H; Koritakova, E; Malaskova, L; Mayer, J; Prochazkova, J; Racil, Z; Rea, D; Sacha, T; Voglova, J; Wącław, J; Zackova, D; Zak, P | 1 |
| Ji, G; Wang, H; Wang, Z; Wei, S; Xu, Z | 1 |
| Dağlı, M; Keles Oğlu, KS; Koplay, M; Paksoy, Y; Sivri, M | 1 |
| Huang, X; Jiang, Q; Milijkovic, D; Wang, H; Yu, L | 1 |
| Adachi, S; Hamamoto, K; Horibe, K; Hotta, N; Ishii, E; Ito, M; Kurosawa, H; Manabe, A; Mizutani, S; Muramatsu, H; Okada, M; Saito, AM; Shima, H; Shimada, H; Tanizawa, A; Tono, C; Watanabe, A; Yuza, Y | 1 |
| C, SK; Dhangar, S; S, C; Vundinti, BR | 1 |
| Baldow, C; Glauche, I; Kuhn, M; Liebscher, H; Roeder, I; Rothe, T; Roy, A; Schulze, P; Wang, X | 1 |
| Gui, RR; Li, Z; Song, YP; Wei, XD; Yu, FK; Zhang, Y; Zhao, HF; Zhou, J; Zu, YL | 1 |
| Bakhshi, S; Gogia, A; Gupta, YK; Kabra, M; Kumar, L; Natarajan, H; Ranjan Biswas, N; Sharma, A; Velpandian, T | 1 |
| Chen, S; Lai, J; Li, Y; Liu, S; Lu, S; Luo, G; Wang, L; Wu, Y; Yu, X; Yu, Z; Zeng, C | 1 |
| Dong, X; Ji, C; Ji, M; Li, P; Li, W; Lu, F; Ma, D; Pang, Y; Ye, J; Zang, S; Zhang, J | 1 |
| Hu, J; Huang, X; Jiang, Q; Jin, J; Li, J; Liu, T; Meng, F; Shen, Z; Wang, J; Wu, D | 1 |
| Bansal, D; Baruchel, A; Biondi, A; Günes, AM; Hijiya, N; Kalwak, K; Metzler, M; Millot, F; Schrappe, M; Schultz, KR; Sedlacek, P; Shimada, H; Suttorp, M | 1 |
| Benes, V; Botschek, S; Brendel, C; Burchert, A; Cai, D; Calogero, RA; Ernst, T; Fritz, L; Hochhaus, A; Huber, M; Inselmann, S; Liebler, S; Liu, ET; Neubauer, A; Pavlinic, D; Saussele, S; Schütz, C; Wang, Y | 1 |
| Junyavoraluk, A; Owattanapanich, W; Rujirachun, P; Sirinvaravong, S; Suvannarerg, V | 1 |
| Eigendorff, E; Ernst, T; Hochhaus, A | 1 |
| Jandial, A; Kopp, CR; Malhotra, P; Mishra, K; Sandal, R | 1 |
| Bachari, K; Cerella, C; Chateauvieux, S; Dicato, M; Diederich, M; Gaigneaux, A; Hong, CR; Kang, HJ; Kim, DW; Kim, KW; Lee, JY; Lee, Y; Mazumder, A; Orlikova-Boyer, B; Shin, HY; Silva, AMS; Talhi, O | 1 |
| Kato, Y; Kunimasa, K; Sugimoto, Y; Tomida, A | 1 |
| Fu, J; Lin, H; Liu, Y; Wu, B | 1 |
| Cheloni, G; Dello Sbarba, P; Deng, X; DeSouza, NH; Gozzini, A; Gray, NS; Li, S; Poteti, M; Rovida, E; Shan, Y; Tusa, I | 1 |
| Fang, Q; Lu, T; Ma, D; Wang, J; Wang, W; Wei, D; Xiong, J; Yu, K; Zhang, T; Zhang, Z | 1 |
| Bolzacchini, E; Campiotti, L; Grandi, AM; Guasti, L; Maresca, AM; Sutter, MB | 1 |
| Chen, B; Li, X; Lu, T; Ma, D; Wang, J; Wei, D; Xiong, J; Yu, K; Zhang, T | 1 |
| Amata, E; Barbagallo, I; Di Raimondo, F; Dichiara, M; Floresta, G; Intagliata, S; Marrazzo, A; Pittalà, V; Prezzavento, O; Rescifina, A; Romeo, G; Salerno, L; Sorrenti, V; Tibullo, D; Turnaturi, R; Vanella, L | 1 |
| Cho, E; Kim, MH; Sung, Y | 1 |
| Elgehama, A; Li, X; Pang, J; Qiu, H; Shen, Y; Sun, Y; Tian, T; Wang, Y; Wu, X; Xu, Q; Xue, W | 1 |
| Eskazan, AE; Tiribelli, M | 1 |
| Aguiar, KS; Fachi, MM; Fernandez-Llimos, F; Figueiredo, BC; Lenzi, L; Leonart, LP; Pontarolo, R; Tonin, FS | 1 |
| Hu, J; Li, Y; Song, H; Wu, T | 1 |
| Basso, M; Bertoldero, G; Binotto, G; Bonalumi, A; Bonifacio, M; D'Amore, F; Danini, M; De Biasi, E; Fanin, R; Fortuna, S; Frison, L; Griguolo, D; Krampera, M; Marin, L; Miggiano, MC; Minotto, C; Pizzolo, G; Ruggeri, M; Sartori, R; Scaffidi, L; Semenzato, G; Stulle, M; Tinelli, M; Tiribelli, M | 1 |
| Arthur, CK; Braley, J; Branford, S; Dang, P; Filshie, RJ; Grigg, AP; Hughes, TP; Kok, CH; Mills, AK; Pagani, IS; Ross, DM; Saunders, VA; Schwarer, AP; Seymour, JF; Shanmuganathan, N; White, DL; Yeung, DT; Yong, AS | 1 |
| Shu, Y; Xu, X; Yang, W; Zhang, X | 1 |
| Bonecker, S; Carvalho, G; Dobbin, J; Schaffel, R; Zalcberg, I | 1 |
| Rohan, B; Shah, S; Snehal, L; Srinivas, B | 1 |
| Cao, YX; Liao, P; Lu, ZW; Luo, ZY; Wen, F | 1 |
| Crawford, SE; Filipovich, Y; Franco, OE; Hayward, SW; Ishii, K; Katayama, N; Ohishi, K; Sasaki, T; Sugimura, Y; Takahashi, N | 1 |
| Lu, S; Ouyang, W; Wang, Z; Zhao, X | 1 |
| Eldeeb, MA; Esmaili, M; Fahlman, RP; Ragheb, MA | 1 |
| Aguayo-González, Á; Avila-Rojo, JA; Baquerizo-Burgos, JE; Coronel, MFC; Cuevas-Ramos, D; Gomez-Perez, FJ; Gómez-Sámano, MÁ; Gulias-Herrero, A; Molina-Botello, D; Palacios-Báez, L; Villanueva-Martinez, F; Wong-Campoverde, BD; Zentella-Dehesa, A | 1 |
| Blanco, ML; Oñate, G; Pratcorona, M | 1 |
| Andersen, MT; Bjerrum, OW; Fischer-Nielsen, A; Haastrup, EK; Larsen, MT; Lund, KP; Maroun, LL; Pedersen, BW | 1 |
| Cortes, J; Lipton, JH; Rea, D | 1 |
| Carrozzi, G; Cirilli, C; Di Felice, E; Giorgi Rossi, P; Luminari, S; Mangone, L; Roncaglia, F; Venturelli, F | 1 |
| Klamova, H; Koblihova, J; Krutska, M; Machova Polakova, K; Srutova, K | 1 |
| Austin, GM; Bell, J; Carter, A; Christmas, SE; Clark, RE; Foroni, L; Heartin, E; Knight, K; Polydoros, F; Watson, D | 1 |
| Banerjee, A; Biswas, N; Mahato, SK; Paul, T; Reddy, SVB | 1 |
| Heng, W; Huan, C; Jin, L; Na, A; Qiaoxia, Z; Xin, D; Yuming, P | 1 |
| Doki, N; Fujisawa, S; Harada, H; Imajo, K; Inokuchi, K; Kanda, Y; Kawaguchi, A; Kimura, S; Kobayashi, H; Kojima, K; Komukai, S; Kondo, E; Kondo, T; Kosugi, H; Kosugi, N; Kumagai, T; Kuroda, H; Maeda, Y; Morita, S; Nakao, T; Nawa, Y; Nishida, J; Ogasawara, M; Saito, A; Sakamoto, J; Sakura, T; Shikami, M; Tabe, Y; Ueda, Y; Usuki, K; Yoshida, C | 1 |
| Chen, B; Yan, X; Yang, H; Zhang, X | 1 |
| Acar, K; Uz, B | 1 |
| Clark, AJ; Darves-Bornoz, A; Hsu, P; Katzenstein, HM; Mason, EF; Tanaka, ST | 1 |
| Apperley, JF; Claudiani, S | 1 |
| Tsubaki, M | 1 |
| Baerlocher, GM; Balleisen, L; Beelen, DW; Bentz, M; Berdel, WE; Bildat, S; Brossart, P; Brümmendorf, TH; Burchert, A; de Wit, M; Dengler, J; Eckart, MJ; Edinger, M; Fabarius, A; Falge, C; Fuchs, R; Gassmann, W; Geer, T; Goebeler, ME; Haferlach, C; Hahn, M; Hänel, M; Hasford, J; Hebart, H; Hehlmann, R; Heim, D; Hertenstein, B; Ho, A; Hochhaus, A; Hossfeld, DK; Kneba, M; Köhne, CH; Kolb, HJ; Krause, SW; Kremers, S; Lauseker, M; Lindemann, HW; Link, H; Mayer, J; Michel, C; Möhle, R; Müller, L; Nerl, C; Neubauer, A; Pfirrmann, M; Saussele, S; Schäfer, E; Schafhausen, P; Scheid, C; Schenk, M; Schlag, R; Schlegel, F; Schlegelberger, B; Spiekermann, K; Stegelmann, F; Thomalla, J; Trümper, L; Verbeek, W; Waller, CF; Wernli, M; Wündisch, T | 1 |
| Cheng, Y; Hu, C; Jiang, X; Ren, Y; Xu, X; Zhang, A | 1 |
| Bizarro, S; Campilho, F; Campos, A; Cerveira, N; Correia, C; Ferreira, RB; Leite, L; Lisboa, S; Pinho Vaz, C; Santos, R; Teixeira, MR; Torres, L; Vieira, J | 1 |
| Sacha, T; Saglio, G | 1 |
| Eskandari, S; Yazdanparast, R | 1 |
| Hu, S; Medeiros, LJ; Tang, G; Wang, SA; Xie, W; Xu, J | 1 |
| Ahn, JS; Hamad, N; Jung, CW; Kim, DDH; Kim, HJ; Kim, JW; Kim, SH; Kimura, S; Lipton, JH; Moon, JH; Naka, K; Park, EJ; Park, JH; Park, S; Sohn, SK; Won, HH; Woo, YM; Youm, EM | 1 |
| Dmytrenko, IV; Dyagil, IS; Fedorenko, VG; Martina, ZV; Minchenko, ZM; Shlyakhtychenko, TY; Sholoyko, VV; Silayev, YO; Tovstogan, AO | 1 |
| Abdullah, J; Abu Seman, Z; Esa, E; Kamaluddin, NR; Mat Yusoff, Y; Othman, N; Zakaria, Z; Zulkiply, NA | 1 |
| Hantel, A; Larson, RA | 1 |
| Leotta, S; Manzella, L; Massimino, M; Milone, G; Pennisi, MS; Puma, A; Romano, C; Sapienza, G; Scalise, L; Stagno, F; Stella, S; Tirrò, E; Vitale, SR | 1 |
| Fang, Q; He, Z; Lu, T; Ma, D; Wang, J; Wang, P; Wei, D; Yu, K; Yu, Z; Zhang, Y; Zhou, Z | 1 |
| Assouline, SE; Azoulay, L; Busque, L; Gratton, MO; Harnois, M; Klil-Drori, AJ; Yin, H | 1 |
| Angmo, D; Kamble, N; Roop, P; Tomar, AS | 1 |
| Abe, R; Hashida, R; Karigane, D; Kasahara, H; Kato, J; Kikuchi, T; Koda, Y; Matsuki, E; Mori, T; Nakamura, T; Okamoto, S; Sakurai, M; Shimizu, T; Suzuki, S; Toyama, T; Yamane, Y; Yokoyama, Y | 1 |
| Chen, ZP; Li, SD; Ma, J; Wu, RH; Zhang, LQ; Zheng, J | 1 |
| Borlenghi, E; Bottelli, C; Capucci, MA; Cerqui, E; D'Adda, M; Farina, M; Ferrari, S; Gramegna, D; Maifredi, A; Pagani, C; Passi, A; Rossi, G; Ruggeri, G; Schieppati, F; Tucci, A | 1 |
| Natarajan, H | 1 |
| Branford, S; Hiwase, D; Hughes, TP; Shanmuganathan, N | 1 |
| Blanc Mettral, J; Buclin, T; Choong, E; Cruchon, S; Decosterd, LA; Faller, N; Nahimana, A; Schild, L; Sottas, L | 1 |
| Li, YF; Tang, HM | 1 |
| Ghose, S; P, P; Samal, R | 1 |
| Inokuchi, K; Iriyama, N; Kawaguchi, T; Kizaki, M; Kurokawa, M; Matsumura, I; Nakamura, F; Nakaseko, C; Naoe, T; Ohnishi, K; Okamoto, S; Ono, T; Sumi, M; Suzuki, R; Takahashi, N; Usui, N; Yamamoto, K | 1 |
| Guo, L; Miao, W; Wang, Y | 1 |
| Chandrasekhar, C; Kumar, PS; Sarma, PVGK | 1 |
| Bartolomei, MS; Chung, K; Ingles, SA; Krapp, C; Li, K; McGinnis, LK; Nowak, RA; Paulson, RJ; Salem, W | 1 |
| Chollet, C; Dulucq, S; Etienne, G; Hayette, S; Klein, E; Mahon, FX; Morisset, S; Nicolini, FE; Robbesyn, F; Tigaud, I; Turcq, B | 1 |
| Baker, A; Scordino, T; Srinivasan, A | 1 |
| Huang, J; Jin, F; Ouyang, G; Pan, J; Zhang, P | 1 |
| Bombelli, S; Boultwood, J; Branford, S; Citterio, S; Crespiatico, I; D'Aliberti, D; Fontana, D; Gambacorti-Passerini, C; Khandelwal, P; Kim, DW; Magistroni, V; Massimino, L; Mauri, M; Mezzatesta, C; Morotti, A; Nava, M; Parker, W; Perego, R; Piazza, R; Pirola, A; Readelli, S; Rigolio, R; Saglio, G; Schreiber, A; Sharma, N; Viltadi, M; Wang, P; Yeung, D | 1 |
| Abruzzese, E; Annunziata, M; Baccarani, M; Berchialla, P; Bergamaschi, M; Bocchia, M; Breccia, M; Caocci, G; Capodanno, I; Castagnetti, F; Cattaneo, D; Cavazzini, F; Cedrone, M; Cerrano, M; Crugnola, M; Dogliotti, I; Dragani, M; Elena, C; Fava, C; Ferrero, D; Galimberti, S; Gambacorti-Passerini, C; Giai, V; Gozzini, A; Gugliotta, G; Iuliano, F; Iurlo, A; Latagliata, R; Levato, L; Luciano, L; Lunghi, F; Martino, B; Musto, P; Pane, F; Pregno, P; Rapezzi, D; Rege-Cambrin, G; Rosti, G; Russo, S; Saglio, G; Santoro, M; Sgherza, N; Sorà, F; Specchia, G; Stagno, F | 1 |
| Ariano, C; De Vecchis, R | 1 |
| Chou, YJ; Fu, SL; Huang, YL; Leu, CM; Liao, HC; Lin, CC; Lin, CH; Liu, SH; Oswita, A; Sun, CM; Syu, JL; Wang, YL | 1 |
| Ai, T; Horii, T; Kawaguchi, A; Kimura, S; Kitamura, H; Misawa, S; Ohsaka, A; Tabe, Y; Tsuchiya, K; Yuri, M | 1 |
| Borisevich, M; Brons, P; de Bont, ESJM; de Bruijn, CMA; Lausen, B; Millot, F; Suttorp, M | 1 |
| Engidawork, E; Gebremedhin, A; Mulu Fentie, A; Tadesse, F | 1 |
| Fukuda, T; Kasama, T; Miura, O; Suwa, S; Uchida, E; Watanabe, K; Yoshimoto, R | 1 |
| Dong, Q; Ouyang, W; Qin, Q; Xiao, Y; Zhang, Y | 1 |
| Adilgereeva, EP; Chelysheva, EY; Kochergin-Nikitsky, KS; Kutsev, SI; Lavrov, AV; Mordanov, SV; Shukhov, OA; Smirnikhina, SA; Tsaur, GA; Turkina, AG; Yakushina, VD | 1 |
| Ahaneku, H; Boddu, PC; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Jabbour, E; Jain, P; Kadia, TM; Kantarjian, H; Nogueras-González, GM; O'Brien, S; Ravandi, F; Sam, P; Sasaki, K; Verstovsek, S | 1 |
| Kaune, KM; Lueken, N; Zutt, M | 1 |
| Branford, S; Carne, L; Clarson, J; Dang, P; Hughes, TP; Irani, YD; Leclercq, T; McLean, J; Pagani, IS; Reynolds, J; Ritchie, DS; Ross, DM; Saunders, VA; White, DL; Yong, ASM | 1 |
| Chandran, RK; Geetha, N; Krishna, KMNJ; Kumar, RS; Sakthivel, KM; Sreedharan, H | 1 |
| Chen, JL; Chen, K; Feng, R; Guo, G; Huang, S; Liao, Y; Sun, L; Wang, X; Yang, J; Zhang, L | 1 |
| Abreu, LG; da Silva, TA; de Azevedo Branco, LG; Fonseca, FP; Magalhães, GHR; Mesquita, RA; Oliveira, SR; Rocha, AL; Travassos, DV | 1 |
| Chinen, Y; Fujino, T; Horiike, S; Isa, R; Kawaji, Y; Kobayashi, T; Kohno, K; Kuroda, J; Kuwahara-Ota, S; Nakamura, S; Nishiyama, D; Shimura, Y; Tsukamoto, T; Yamaguchi, J | 1 |
| Cong, Y; Li, C; Lin, H; Wang, R; Zhang, C | 1 |
| Brümmendorf, TH; Chuah, C; Cortes, JE; Crescenzo, R; Deininger, MW; Gambacorti-Passerini, C; Garcia-Gutierrez, V; Hochhaus, A; Kim, DW; le Coutre, P; Mamolo, C; Mauro, MJ; Milojkovic, D; Reisman, A | 1 |
| Ghadami, S; Tavallaie, M; Vatanmakanian, M | 1 |
| Bazarbachi, A; El Eit, R; Itani, AR; Jabbour, M; Mahon, FX; Nasr, R; Nassar, F; Rasbieh, N; Santina, A; Zaatari, G | 1 |
| Fava, C; Gale, RP; Saglio, G | 1 |
| Abruzzese, E; Annunziata, M; Baratè, C; Binotto, G; Bonifacio, M; Breccia, M; Caocci, G; Cattaneo, D; De Gregorio, F; Elena, C; Foà, R; Fozza, C; Galimberti, S; Iurlo, A; La Nasa, G; Luciano, L; Martino, B; Molica, M; Mulas, O; Orlandi, EM; Russo Rossi, A; Sgherza, N; Trawinska, MM | 1 |
| Cervera, E; de la Torre-Lujan, AH; Grimaldo, F; Herrera, LA; Leon-Sarmiento, FE; Meneses-García, A; Miranda, D; Prada, D; Rivas, S; Ylescas-Soria, J | 1 |
| Belohlavkova, P; Cmunt, E; Faber, E; Indrak, K; Karas, M; Kristkova, Z; Necasova, T; Papajik, T; Rohon, P; Skoumalova, I; Steinerova, K; Trneny, M; Voglova, J; Vrbacky, F; Zak, P | 1 |
| Cheng, C; Gao, WQ; He, Y; Ji, Z; Li, L; Liu, K; Maguer-Satta, V; Sheng, Y; Voeltzel, T; Wang, J; Wang, X; Xu, W; Zhao, H; Zhu, HH | 1 |
| Accurso, V; Antolino, A; Di Raimondo, F; Forte, S; Impera, S; Malato, A; Mannina, D; Manzella, L; Martino, B; Massimino, M; Mineo, G; Musolino, C; Musso, M; Pennisi, MS; Porretto, F; Russo, S; Siracusa, S; Spitaleri, A; Stagno, F; Stella, S; Tirrò, E; Vigneri, P; Vitale, SR; Zammit, V | 1 |
| Brehm, MA; Green, MR; Hutchinson, L; Li, S; Ma, L; Ou, J; Pak, ML; Shan, Y; St Louis, P; Yu, J; Zhu, LJ | 1 |
| Chen, SH; Chi, WM; Chow, JM; Hsieh, WS; Hsieh, YY; Hsu, KW; Lee, CH; Lin, CY; Shabangu, BM | 1 |
| Alikian, M; Apperley, JF; Bazeos, A; Claudiani, S; Curry, E; Foong, HE; Foroni, L; Gale, RP; Gerrard, G; Khorashad, JS; Loaiza, S; Milojkovic, D; Nikolakopoulou, Z; Nteliopoulos, G; Perrotti, D; Szydlo, R | 1 |
| Jabbour, EJ; Lin, J; Lingohr-Smith, M; Makenbaeva, D; Mendiola, MF | 1 |
| Avetisyan, G; Barragán, E; Cervera, J; Díaz, A; Ibañez, F; Ibáñez, M; Liquori, A; Llop, M; Luna, I; Marco-Ayala, J; Mora, E; Panadero, J; Regadera, A; Sanz, G; Sanz, MA; Senent, L; Such, E; Vicente, A | 1 |
| Ayemou, R; Djoko, S; Emeuraude, N; Kamara, I; Koffi, G; Kouakou, B; Meité, N; Nanho, CD; Sanogo, I; Silué, DA; Sowhe, T; Tolo, A | 1 |
| Ar, MC; Aydin, Y; Baslar, Z; Berk, S; Erdogan Ozunal, I; Eskazan, AE; Keskin, D; Ongoren, S; Ozbek, U; Ozgur Yurttas, N; Sadri, S; Salihoglu, A; Serin, I; Soysal, T | 1 |
| Brandwein, JM; Jiang, X; Meenakshi Sundaram, DN; Remant, KC; Uludağ, H; Valencia-Serna, J | 1 |
| Bavaro, L; Castagnetti, F; Cavo, M; De Santis, S; Gugliotta, G; Mancini, M; Martelli, M; Martinelli, G; Monaldi, C; Rosti, G; Santucci, MA; Soverini, S | 1 |
| de Wijn, AS; Friedman, R; Lindström, HJG | 1 |
| Cai, Z; Hao, T; Lin, Q; Song, Y; Zhang, Y; Zhu, X | 1 |
| Amaral, N; Bonecker, ST; de Souza, PS; Maia, RC; Scheiner, MAM; Thuler, LCS; Vasconcelos, FC; Zalcberg, I | 1 |
| Abruzzese, E; Andreani, G; Cedrone, M; Dragani, M; Elena, C; Fava, C; Ferrero, D; Pregno, P; Rege-Cambrin, G; Saglio, G; Santoro, M | 1 |
| Ammar, W; Beker, RV; Elias, F; Gebran, A; Said, C | 1 |
| Fu, J; Liang, L; Pan, X; Si, R; Sun, Y; Wang, J; Zhang, J; Zhang, Q | 1 |
| Arsov, B; Boban, L; Juginović, A; Mandac Rogulj, I; Matišić, V; Molnar, V; Primorac, D | 1 |
| Goranova-Marinova, VS; Ivanov, HJ; Ivanova, H; Linev, AJ; Stoyanova, VK; Zhelyazkov, IG | 1 |
| Albert, C; Goerlitz, K; Krumbholz, M; Lawlor, J; Metzler, M; Suttorp, M | 1 |
| Apperley, JF; Byrne, J; Clark, RE; Copland, M; de Lavallade, H; Foroni, L; Milojkovic, D; O'Brien, SG; Osborne, W; Pocock, C; Polydoros, F; Read, L; Robinson, L; Rothwell, K | 1 |
| Han, YH; Hong, F; Hu, CY; Li, ZY; Sun, Q; Xu, KL; Yan, ZL; Yu, D; Zeng, LY; Zhang, HX | 1 |
| Wang, PP; Xi, YM; Zhang, J; Zhang, PP | 1 |
| Andrews, CN; Lipton, J | 1 |
| Cortes, JE; Kantarjian, HM; Shih, YT | 1 |
| Apperley, J; Claudiani, S; Khorashad, J; Milojkovic, D; Nesr, G | 1 |
| Gao, S; Han, W; Hu, R; Li, Y; Liu, C | 1 |
| Ćojbašić, I; Ćojbašić, Ž; Mačukanović-Golubović, L; Vučić, M | 1 |
| Cortes, J; Daver, NG; Jabbour, EJ; Kadia, TM; Kamiya-Matsuoka, C; Kantarjian, H; Konopleva, M; Mehta, RS; Naqvi, K; Rafei, H; Sinicrope, KD | 1 |
| De Rosa, V; Del Vecchio, S; Fonti, R; Iommelli, F; Monti, M; Terlizzi, C | 1 |
| Chen, YP; Lv, JL; Yang, Y; Zhang, BS | 1 |
| Eskazan, AE; Soysal, T | 1 |
| Almeida, AM; Alves, R; Freitas-Tavares, P; Gonçalves, AC; Jorge, J; Luís, D; Marques, G; Oliveiros, B; Ribeiro, AB; Sarmento-Ribeiro, AB | 1 |
| Dhangar, S; Shanbhag, V; Shanmukhaiah, C; Vundinti, BR | 1 |
| Bérard, E; Bidet, A; Bréal, C; Déchanet-Merville, J; Dufossée, M; Dulucq, S; Dumas, PY; Etienne, G; Forcade, E; Lafarge, X; Mahon, FX; Milpied, N; Nicolini, F; Pasquet, JM; Réa, D; Turcq, B | 1 |
| Boddu, D; Guruprasad, CS; Nair, M; Rajeswari, B; Seetharam, S; Thankamony, P | 1 |
| Chauhan, R; Harankhedkar, S; Mahapatra, M; Nair, RR; Saxena, R | 1 |
| Bhise, R; Lunge, S | 1 |
| Fukazawa, M; Hatanaka, Y; Iseki, T; Ishizuka, Y; Mimura, N; Mitsukawa, S; Muto, T; Nakaseko, C; Ohwada, C; Oshima-Hasegawa, N; Ozawa, S; Sakaida, E; Takeda, Y; Takeuchi, M; Tsukamoto, S; Yamazaki, M | 1 |
| Bahjat, M; Bende, RJ; Bloedjes, T; de Wilde, G; Eldering, E; Guikema, JEJ; Kersten, MJ; Luijks, DM; Maas, C; van Dam, T; van Noesel, CJM | 1 |
| Abusoglu, G; Abusoglu, S; Bagci, M; Basturk, A; Dagli, M; Onmaz, DE; Tok, O; Unlu, A | 1 |
| Xicoy, B; Zamora, L | 1 |
| Álvarez, É; Díaz, M; Hajos, S; Lompardía, S; Mihalez, C; Papademetrio, D; Pibuel, M; Poodts, D | 1 |
| Bakanay, SM; Dilek, I; Kucuksahin, O; Maral, S | 1 |
| Noronha, S; Sawyer, S | 1 |
| Alimena, G; Baccarani, M; Baratè, C; Bergamaschi, M; Breccia, M; Cottone, F; Dabusti, M; Deliliers, GL; Di Lorenzo, R; Efficace, F; Fava, C; Leoni, P; Levato, L; Luciano, L; Mandelli, F; Martino, B; Rambaldi, A; Rosti, G; Sica, S; Simula, MP; Specchia, G; Stagno, F; Turri, D; Veneri, D; Vignetti, M | 1 |
| Ergene, U; Ozbalci, D | 1 |
| Koutna, I; Mayer, J; Potesil, D; Potesilova, M; Simara, P; Stejskal, S; Tesarova, L; Zdrahal, Z | 1 |
| Huang, XJ; Xu, LP | 1 |
| Aung, T; Beutler, M; Cameron, S; Chapuy, B; Haase, D; Hupfeld, T; Koch, R; Larosee, P; Schrader, V; Truemper, L; Veltkamp, C; Wulf, GG | 1 |
| Alatorre-Ricardo, J; Cantu-Rodriguez, OG; Flores-Jimenez, JA; Garcia-Rodriguez, F; Gomez-Almaguer, D; Gonzalez-Llano, O; Gutierrez-Aguirre, CH; Jaime-Pérez, JC; Mancias-Guerra, C; Martinez-Gonzalez, OL; Ortiz-Galvez, VM; Ortiz-Lopez, R; Salazar-Riojas, R | 1 |
| Boqué, C; Cabezón, M; Feliu, E; Fernández de Sevilla, A; Fernández, C; Grau, J; Marcé, S; Millá, F; Navarro, JT; Ribera, JM; Xicoy, B; Zamora, L | 1 |
| Baran, Y; Camgoz, A; Ceylan, C | 1 |
| Camelo-Santos, J; de Paula Silveira-Lacerda, E; do Prado Barbosa, A; Guillo, LA | 1 |
| Cho, YH; Choi, BR; Jung, W; Kim, DE; Kim, DW; Kim, JE; Kim, KP; Oh, S; Yoon, S | 1 |
| Eissler, CL; Hall, MC; Parker, LL; Yang, TY | 1 |
| Costantini, A; Lasala, R; Rizzo, RC; Santoleri, F; Sorice, P | 1 |
| Antonescu, CR; Jain, S; Martz, J; Mosquera, JM; Popa, EC; Qin, L; Vahdat, LT | 1 |
| Bang, JH; Byeun, JY; Choi, SY; Do, YR; Jang, EJ; Jeon, HR; Jeong, SH; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kim, YK; Koo, DH; Kwak, JY; Lee, SE; Mauro, MJ; Mun, YC; Oh, S; Oh, YJ; Park, JE; Park, JS; Zang, DY | 1 |
| Cahill, MR; Crowley, LC; Elzinga, BM; McKenna, SL; Nyhan, MJ; O'Donovan, TR | 1 |
| Cogle, CR | 1 |
| Arlinghaus, R; Barnett, MJ; Chan, M; Chen, M; DeGeer, D; Eaves, A; Eaves, CJ; Forrest, DL; Gallipoli, P; Holyoake, TL; Jiang, X; Jorgensen, H; Lai, D; Lambie, K; Nakamoto, H; Paul, J; Ringrose, A; Saw, KM; Sloma, I; Stobo, J; Turhan, A; Wang, HM | 1 |
| Deininger, MW; Khorashad, JS; O'Hare, T | 1 |
| Esturo, SV; Moreno, AJ; Pérez, NO; Valls, AT; Viladomiu, Edel A | 1 |
| Buschmann, I; Dombret, H; Dörken, B; Giles, FJ; Grille, P; Haverkamp, W; Kim, TD; Labussière, H; le Coutre, PD; Levato, L; Lindhorst, R; Mirault, T; Nicolini, FE; Rea, D; Rosti, G; Schwarz, M | 1 |
| Giles, FJ; Hochhaus, A; Hong, F; le Coutre, PD; Mauro, MJ; McNeill, C; Ortmann, CE; Saglio, G; Woodman, RC | 1 |
| Gómez Casares, MT; León, LG | 1 |
| Abell, J; Christian, JB; Cullen, MR; Horwitz, RI | 1 |
| Alimena, G; Breccia, M | 15 |
| Berman, E; Chanel, S; Cheng, C; Farooki, A; Fleisher, M; Girotra, M; Heller, G; Maki, R; Shelat, M; Strauss, HW | 1 |
| Chang, CS; Lai, GM; Tsai, CY; Yan, SL | 1 |
| Abdul Wahid, SF; Ankathil, R; Baba, AA; Elias, MH; Hassan, R; Husin, A; Sim, GA; Sulong, S | 1 |
| Bar, M; Radich, J | 1 |
| De Souza, C; Etienne, G; Fan, X; Hochhaus, A; Hoenekopp, A; Hughes, TP; Kalaycio, ME; Kantarjian, HM; Kim, DW; Kurokawa, M; Larson, RA; Rosti, G; Saglio, G; Shou, Y | 1 |
| Fujimaki, K; Ishigatsubo, Y; Miyashita, K | 1 |
| Altamura, HK; Branford, S; Briggs, NE; Field, CR; Georgievski, J; Hertzberg, M; Hughes, TP; Jamison, BA; Phillis, S; Prime, JA; Reynolds, J; Ross, DM; Seymour, JF; Sullivan, B; Yeoman, AL; Yeung, DT | 1 |
| Chen, L; Griffin, JD; Guerin, A; Ionescu-Ittu, R; Luo, J; Macalalad, AR; Wu, EQ | 1 |
| Hirao, A; Matsumoto, A; Naka, K; Nakayama, KI; Onoyama, I; Takeishi, S | 1 |
| Conte, E; Di Raimondo, F; Manzella, L; Stagno, F; Stella, S; Tirrò, E; Vigneri, P | 1 |
| Alimoghaddam, K; Chahardouli, B; Ghavamzade, A; Kazemi, A; Mousavi, SA; Nadali, F; Ostadali, M; Rostami, S; Zaker, F | 1 |
| Aksu, S; Atay, H; Bektas, O; Buyukasik, Y; Eliacik, E; Goker, H; Haznedaroglu, IC; Isik, A; Kelkitli, E; Ozcebe, OI; Sayinalp, N; Turgut, M; Uz, B | 1 |
| Bhatia, R; Bolton-Gillespie, E; Flis, S; Holyoake, TL; Hoser, G; Kerstiens, L; Klein, HU; Koptyra, M; Koschmieder, S; Lange, T; Maier, J; Modi, H; Müller, MC; Nieborowska-Skorska, M; Schemionek, M; Seferynska, I; Skorski, T; Stoklosa, T | 1 |
| Bauer, RC; Duyster, J; Peschel, C; Sänger, J; von Bubnoff, N | 1 |
| Alimoghaddam, K; Ansari, S; Arjmandi Rafsanjani, K; Bahosh, G; Behfar, M; Darbandi, B; Ghavamzadeh, A; Hamidieh, AA; Soroush, A | 1 |
| Irvine, E; Williams, C | 1 |
| Adrian, LT; Agarwal, A; Apgar, J; Deininger, MW; Druker, BJ; Eide, CA; Johnson, KJ; Koop, DR; Latocha, DH; Luo, J; Mackenzie, RJ; Marks, BD; O'Hare, T; Riddle, SM; Tyner, JW; Vogel, KW; You, H; Zabriskie, MS | 1 |
| Alimena, G; Breccia, M; Salaroli, A; Serrao, A; Zacheo, I | 1 |
| Alimena, G; Breccia, M; Salaroli, A; Saracino, R; Serrao, A; Zacheo, I | 1 |
| Chaudhary, SC; Jain, N; Kumar, V; Mishra, S | 1 |
| Cen, JN; Chen, Y; Chen, ZX; Ding, ZX; He, J; Pan, JL; Qiu, QC; Shen, HJ; Yao, L | 1 |
| Adams, E; Chen, H; Van Schepdael, A | 1 |
| Hochhaus, A; Hoser, G; Nieborowska-Skorska, M; Skorski, T; Stoklosa, T | 1 |
| Carrascosa, R; Fraga, J; García Diez, A; Llamas-Velasco, M; Requena, L; Steegmann, JL | 1 |
| Chen, L; Huang, H; Li, JM; Liu, CX; Liu, W; Wei, W; Wu, YL; Yan, H; Zhao, S | 1 |
| Han, SA; Lee, YJ; Moon, JH; Seo, JW; Seo, SK; Shin, HC; Sohn, SK | 1 |
| Chen, CW; Huang, HM; Huang, YW; Lee, YL; Liu, FH | 1 |
| Bell, J; Butt, NM; Clark, RE; De Soysa, L; Francis, S; Kaleel-Rahman, M; Knight, K; Lane, S; Lee, E; Lucas, C; O'Brien, D; Sadik, W; Salim, R; Seale, JR; Wang, L; Watmough, S | 1 |
| Borthakur, G; Cardenas-Turanzas, M; Cortes, J; Jabbour, E; Jain, P; Kantarjian, H; Nazha, A; O'Brien, S; Pierce, S; Quintás-Cardama, A; Ravandi, F; Romo, CG; Verstovsek, S | 1 |
| Bossé, R; Chevet, E; Delom, F; Higa, A; Mahon, FX; Palcy, S; Pasquet, JM; Ségui, B; Taouji, S | 1 |
| Cetkovský, P; Chudej, J; Cmunt, E; Demečková, E; Demitrovičová, L; Dušek, L; Dvořáková, D; Faber, E; Indrák, K; Jarošová, M; Karas, M; Klamová, H; Koza, V; Markuljak, I; Michalová, K; Michalovičová-Sninská, Z; Mikušková, E; Moravcová, J; Mužík, J; Poláková, KM; Ráčil, Z; Sťastná, MM; Steinerová, K; Tóthová, E; Trněný, M; Voglová, J; Záčková, D | 1 |
| Černelč, P; Kralj, E; Kristl, A; Marc, J; Ostanek, B; Pajič, T; Preložnik Zupan, I; Trontelj, J; Žakelj, S | 1 |
| Barisani, A; Dika, E; Fanti, PA; Ismaili, A; Patrizi, A; Vaccari, S | 1 |
| Dogan, NU; Gungor, T; Karsli, F; Sahin, I | 1 |
| Moore, FR; Press, RD; Yang, F | 1 |
| Auberger, P; Cassuto, O; Dufies, M; Jacquel, A; Robert, G | 1 |
| Kataoka, T; Kayukawa, S; Kusumoto, S; Narita, T; Yoshida, T | 1 |
| Alimoghaddam, K; Chahardouli, B; Ghadimi, H; Ghavamzade, A; Mousavi, SA; Nadali, F; Ostadali, M; Rostami, S; Saffari, Z; Zaker, F | 1 |
| Abruzzese, E; Baccarani, M; Bergamaschi, M; Bigazzi, C; Breccia, M; Castagnetti, F; Cesana, BM; De Vivo, A; Fava, C; Gugliotta, G; Iacobucci, I; Intermesoli, T; Malagola, M; Martinelli, G; Martino, B; Pregno, P; Pungolino, E; Rosti, G; Russo, D; Skert, C; Soverini, S; Stagno, F; Testoni, N; Tiribelli, M; Turri, D | 1 |
| Azmy, E; Ebrahim, MA; Elghannam, DM; Hakem, H; Ibrahim, L | 1 |
| Despas, F; Laurent, G; Roche, H | 1 |
| Onoda, M; Shono, K; Togasaki-Yoshimoto, E; Yokota, A | 1 |
| Chen, H; Chen, SS; Chen, YH; Gale, RP; Han, W; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Liu, DH; Liu, KY; Liu, YR; Lv, M; Qin, YZ; Wang, Y; Xu, LP; Zhang, MJ; Zhang, XH; Zhao, XY | 1 |
| Arthur, C; Branford, S; Dang, P; Filshie, RJ; Goyne, JM; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C; White, DL; Yeung, DT | 1 |
| Radich, JP | 3 |
| Al-Barrak, J; Cheung, WY | 1 |
| Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM | 1 |
| Glauche, I; Jung, R; Suttorp, M; Tabea Tauer, J; Ulmer, A | 1 |
| Aotsuka, N; Hata, T; Hatano, Y; Hino, M; Hirasawa, A; Itoh, K; Kashimura, M; Kuroki, J; Masuoka, H; Matsuura, Y; Miura, M; Miyazaki, Y; Mugitani, A; Nakagawa, Y; Nakamae, H; Nakane, T; Niioka, T; Nishiwaki, K; Sano, K; Sawada, K; Shinohara, Y; Takahara, S; Takahashi, N; Wakita, H | 1 |
| Gossart, M; Machaczka, M | 1 |
| Chen, L; Ericson, SG; Goldberg, SL; Guerin, A; Kaminsky, M; Liu, N; Macalalad, AR; Wu, EQ | 1 |
| Baccarani, M; Castagnetti, F; Colita, A; Hellmann, A; Hoffmann, VS; Indrak, K; Lindoerfer, D; Mayer, J; Pfirrmann, M; Prejzner, W; Rosti, G; Steegmann, JL; Turkina, A; Zaritsky, A | 1 |
| Colavita, I; Esposito, N; Nigro, E; Pane, F; Quintarelli, C; Ruoppolo, M; Salvatore, F | 1 |
| Aguzzi, C; Boccadoro, M; Cerrano, M; Crisà, E; Ferrero, D; Pregno, P; Riccomagno, P | 1 |
| Inokuchi, K; Katagiri, S; Kimura, Y; Mizoguchi, I; Mizuguchi, J; Ohyashiki, JH; Ohyashiki, K; Tauchi, T; Yoshimoto, T | 1 |
| Kizaki, M; Nishiyama-Fujita, Y; Sagawa, M; Shimizu, T; Uchida, H | 1 |
| Chakrabarti, P; Ghosh, K; Joshi, D; Vaidya, S; Vundinti, BR | 1 |
| Burger, H; Mathijssen, RH; Sparreboom, A; Wiemer, EA | 1 |
| Borthakur, G; Burton, E; Cortes, J; Eghtedar, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Verstovsek, S | 1 |
| Branford, S; Hughes, TP; Jamison, BA; Parker, WT; Scott, HS; Yeoman, AL; Yeung, DT | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Clark, RE; Cortes, JE; Deininger, MW; Goldman, JM; Guilhot, F; Hehlmann, R; Hjorth-Hansen, H; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Martinelli, G; Mayer, J; Müller, MC; Niederwieser, D; Pane, F; Radich, JP; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Schiffer, C; Silver, R; Simonsson, B; Soverini, S; Steegmann, JL | 1 |
| Mandavilli, A | 1 |
| Sawyers, CL | 8 |
| Fang, BZ; He, GS; Wu, DP; Xie, J; Zhang, X; Zhao, Y | 1 |
| Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Li, JL; Li, LD; Liu, YR; Lu, XJ; Qin, YZ; Zhu, HH | 1 |
| Abdulkadyrov, KM; Bessmel'tsev, SS; Martynkevich, IS; Romanenko, NA; Rugal', VI; Udal'eva, VIu; Zenina, MN | 1 |
| Ge, Z; Hong, M; Li, JY; Pan, LQ; Qian, SX; Song, P; Tian, T; Yu, H; Zhang, SJ; Zhu, Y | 1 |
| Chang, CS; Hsiao, HH; Hsu, JF; Lee, CP; Lin, PM; Lin, SF; Liu, TC; Liu, YC; Yang, MY; Yang, WC | 1 |
| Dai, M; Fan, Z; Feng, R; Huang, F; Jin, H; Liu, Q; Sun, J; Wei, Y; Xiong, Y; Xu, D; Zhang, Y; Zhou, H | 1 |
| Borchmann, P; Engert, A; Monsef, I; Rancea, M; Skoetz, N; Will, A | 1 |
| Pinilla-Ibarz, J; Sweet, K; Zhang, L | 1 |
| Go, SI; Kang, JH; Kang, MH; Kim, HG; Lee, GW; Lee, JH; Lee, WS | 1 |
| Bilban, M; Einwallner, E; Herndlhofer, S; Hoermann, G; Jaeger, E; Mitterbauer-Hohendanner, G; Pernicka, E; Schwarzinger, I; Sillaber, C; Simonitsch-Klupp, I; Steiner, I; Valent, P | 1 |
| Du, Y; Fang, H; Xia, Y; Zhang, J | 1 |
| Apperley, JF | 5 |
| Corbin, AS; Cortes, JE; Deininger, MW; Druker, BJ; Eide, CA; Eiring, AM; Gu, Z; Khorashad, JS; Kraft, IL; Manley, PW; O'Hare, T; Pomicter, AD; Zhang, TY | 1 |
| de Souza, PS; Maia, RC; Moellmann-Coelho, A; Nestal de Moraes, G; Silva, KL; Vasconcelos, Fda C | 1 |
| Branford, S; Carella, AM; Deininger, M; Eiring, A; Goldman, JM; Khorashad, J; Mahon, FX; O'Hare, T; Saglio, G | 1 |
| Baccarani, M; Breccia, M; Castagnetti, F; Cottone, F; Efficace, F; Iurlo, A; Mandelli, F; Rosti, G | 1 |
| Klamová, H | 1 |
| Druker, BJ; Eide, CA; O'Hare, T | 1 |
| Ayoubi, HR; Bazarbachi, AA; Bitar, NM; De Thé, HB; El Eit, RM; Iskandarani, AN; Jabbour, MN; Mahfouz, RA; Mahon, FX; Nasr, RR; Saliba, JL; Zaatari, GS | 1 |
| Chen, L; Guo, A; Liu, J; Marynchenko, M; Sharma, H; Shi, L; Vander Velde, N; Wu, EQ; Yang, H | 1 |
| Saglio, G; Savona, MR | 1 |
| Honda, E; Shibuta, T; Shiotsu, H; Shiratsuchi, M; Tanaka, Y; Umemura, T; Vellasamy, S | 1 |
| Belohlavkova, P; Dyr, J; Klamova, H; Malakova, J; Malaskova, L; Mayer, J; Muzik, J; Polakova, KM; Potesil, D; Racil, Z; Razga, F; Suttnar, J; Voglova, J; Zackova, D; Zdrahal, Z | 1 |
| Blasiak, J; Glowacki, S; Synowiec, E | 1 |
| Boffo, S; Caparrotti, G; Ciarcia, R; d'Angelo, D; Damiano, S; Florio, S; Giordano, A; Montagnaro, S; Morales, F; Pagnini, U; Rizzolio, F; Ruocco, A | 1 |
| Bala, M; Bansal, P; Dahiya, K; Dhankhar, R; Dokwal, S; Ghalaut, PS; Ghalaut, VS; Prakash, G | 1 |
| Li, ZQ; Liu, T; Niu, CC; Pan, J; Si, WK; Wu, WR; Yang, Z; Zhang, XL; Zhao, C | 1 |
| Binotto, G; Bonifacio, M; Branca, A; Calistri, E; Fanin, R; Gherlinzoni, F; Guardalben, E; Maino, E; Marin, L; Pizzolo, G; Sancetta, R; Semenzato, G; Tiribelli, M | 1 |
| Ma, LM; Zhao, J | 1 |
| Chen, S; Chen, Y; Li, B; Li, Y; Liu, S; Lu, Y; Shen, Q; Wu, X; Yang, L; Zhu, K | 1 |
| Chang, NY; Lee, FY; Wang, J; Wen, MC | 1 |
| Bernard, V; Feller, AC; Gebauer, N; Gebauer, W; Merz, H | 1 |
| Pan, J; Shen, Y; Shi, X | 1 |
| Borgo, C; Cesaro, L; Donella-Deana, A; Massimino, ML; Pinna, LA; Ruzzene, M; Salizzato, V | 1 |
| Cao, W; Chen, X; Feng, W; Li, C; Li, Y; Shi, M; Wang, H; Wang, X | 1 |
| Chen, Z; Du, Y; Li, J; Pan, X; Wang, A; Wang, K; Xia, Y; Zhang, J | 1 |
| Abel, G; Baccarani, M; Bombaci, F; Breccia, M; Caocci, G; Cardoni, A; Castagnetti, F; Chie, W; Cocks, K; Efficace, F; Guilhot, F; Mandelli, F; Naeem, A; Nicolatou-Galitis, O; Noens, L; Oerlemans, S; Pallua, S; Rosti, G; Salvucci, M; Saussele, S; Sharf, G; Sprangers, M | 1 |
| Roeker, LE; Wolanskyj, AP | 1 |
| Borthakur, G; Burger, J; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Pierce, S; Quintas-Cardama, A; Ravandi, F; Verstovsek, S; Yilmaz, M | 1 |
| Druker, BJ; Eide, CA; O'Hare, T; Shukron, O; Vainstein, V | 1 |
| Miura, M; Takahashi, N | 1 |
| Deeren, D | 1 |
| Gastl, G; Kastner, U; Lion, T; Mitterbauer-Hohendanner, G; Seger, C; Webersinke, G | 1 |
| Díaz, L; Manrique, G; Moro, MI; Uriarte, R | 1 |
| Huang, HM; Huang, YW; Lee, WH; Tsai, YH | 1 |
| Chirovsky, DR; Davis, CC; Goren, A; Gupta, S; Hirji, I; Moadel, AB; Olavarria, E; Victor, TW | 1 |
| Kimura, S; Kitahara, T; Maekawa, T; Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Leser, U; Leutz, A; Rosenbauer, F; Scheller, M; Schönheit, J; Zimmermann, K | 1 |
| Hou, Z; Liu, T; Zhu, HL | 1 |
| De Micheli, G; Simalatsar, A; You, W | 1 |
| Ayyagari, R; Chen, L; Reichmann, WM; Signorovitch, J; Wu, EQ | 1 |
| Ale, S; Alikian, M; Alonso-Dominguez, J; Apperley, JF; Clark, R; Foroni, L; Gerrard, G; Goldman, JM; Grinfeld, J; Hedgley, C; Marin, D; Milojkovic, D; Nteliopoulos, G; O'Brien, S; Valgañon, M; White, D | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Baccarani, M; Barulli, S; Bocchia, M; Breccia, M; Cancelli, V; Castagnetti, F; Cattina, F; De Vivo, A; Fogli, M; Iacobucci, I; Iurlo, A; Liberati, AM; Lunghi, M; Malagola, M; Mandelli, F; Martinelli, G; Merante, S; Pardini, S; Pica, G; Pierri, I; Pregno, P; Rosti, G; Russo, D; Russo, S; Skert, C; Soverini, S; Stagno, F; Tiribelli, M; Trabacchi, E | 1 |
| Bruzzoni-Giovanelli, H; Calvo, F; Cayuela, JM; Delord, M; Génin, E; Geromin, D; Guilhot, F; Guilhot, J; Loiseau, P; Preudhomme, C; Raffoux, E; Rousselot, P; Sigaux, F | 1 |
| Chang, G; Lin, Y; Ma, L; Pang, T; Wang, J; Zhang, H | 1 |
| Fei, J; Feng, M; Li, Y; Luo, X; Zhang, Y; Zhu, X | 1 |
| Schiffer, CA | 5 |
| Barsan, L; Bumbea, H; Vasile, D; Vladareanu, AM; Voican, I | 1 |
| Abruzzo, L; Borthakur, G; Cortes, J; Faderl, S; Jabbour, E; Jorgensen, JL; Kantarjian, H; Konoplev, S; Luthra, R; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Strati, P; Thomas, D | 1 |
| Chang, CS; Chen, LC; Chen, TC; Huang, YB | 2 |
| Chen, L; Ericson, SG; Gilmore, J; Haislip, S; Hess, T; Jackson, J; Sail, KR; Saleh, MN; Sharpe, J | 1 |
| Audureau, E; Ladner, J; Saba, J; Tavolacci, MP; Tekinturhan, E | 1 |
| Chen, L; Dea, K; Goldberg, SL; Guérin, A; Wu, EQ | 2 |
| Maia, RC; Moellmann-Coelho, A; Nestal de Moraes, G; Vasconcelos, FC | 1 |
| Amariglio, N; Beider, K; Buzaglo, Z; Koren-Michowitz, M; le Coutre, P; Nagler, A; Pessach, I; Ribakovsky, E; Schwarz, M; Shimoni, A | 1 |
| Gerrard, G; Goldman, J; Marco, B; Marin, D; May, P; Milojkovic, D; Neelakantan, P; Paliompeis, C; Reid, A; Rezvani, K | 1 |
| Airiau, K; Augis, V; Belloc, F; Josselin, M; Mahon, FX; Turcq, B | 1 |
| Ali, Z; Aziz, Z; Iqbal, J; Khan, AU | 1 |
| Aaronson, N; Angelucci, E; Baccarani, M; Cottone, F; Efficace, F; Mandelli, F; Molica, S; Rosti, G; Vignetti, M | 1 |
| Ando, T; Kimura, S; Kojima, K | 1 |
| Atanackovic, D; Goekkurt, E; Harbaum, L; Marx, A; Schafhausen, P | 1 |
| Burthem, J; Byers, RJ; Day, PJ; Karimiani, EG; Marriage, F; Merritt, AJ | 1 |
| Blasiak, J; Danisz, K | 1 |
| Binotto, G; Bonifacio, M; Calistri, E; Maino, E; Tiribelli, M | 1 |
| Benchekroun, S; Dehbi, H; Kassogue, Y; Nadifi, S; Quachouh, M; Quessar, A | 2 |
| Baerlocher, GM; Dengler, J; Ehninger, G; Einsele, H; Fabarius, A; Falge, C; Haferlach, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Heimpel, H; Hochhaus, A; Hossfeld, DK; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Nerl, C; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Pletsch, N; Proetel, U; Saußele, S; Schnittger, S; Schreiber, A; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Politi, J; Shah, NP | 1 |
| Arai, H; Handa, T; Iso, H; Mitani, K; Nagasawa, F; Nakamura, Y; Sasaki, K; Takahashi, W; Tokita, K; Tsurumi, S | 1 |
| Crawford, LJ; Irvine, AE; Lu, WH; McCallum, L; Sharpe, DJ; Suresh, S | 1 |
| Akard, LP; Albitar, M; Cortes, JE; Ericson, SG; Goldberg, SL; Radich, JP; Warsi, G; Wetzler, M | 1 |
| Artuso, S; Bucelli, C; Cattaneo, D; Cortelezzi, A; Iurlo, A; Mari, D; Radice, T; Ubertis, A; Zappa, M | 1 |
| Baccarani, M; Boqué, C; Bradley-Garelik, MB; Chuah, C; Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; Kim, DW; Mayer, J; Mohamed, H; Pavlovsky, C; Saglio, G; Shah, NP; Steegmann, JL; Wildgust, M | 1 |
| Oehler, V; Sweet, K | 1 |
| Ahmed, W; Van Etten, RA | 1 |
| Béogo, R; Hien, FM; Ouédraogo, GA; Sawadogo, S; Toguyeni, A | 1 |
| Fraga, J; García Diez, A; Llamas-Velasco, M; Requena, L; Solano-López, GE; Steegmann, JL | 1 |
| Boiso Moreno, S; Carlsson, B; Gréen, H; Jönsson, JI; Skoglund, K; Vikingsson, S | 1 |
| Agape, P; Cayuela, JM; Charbonnier, A; Chomel, JC; Cony-Makhoul, P; Escoffre-Barbe, M; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Mahon, FX; Nicolini, FE; Prost, S; Réa, D; Reiffers, J; Rousselot, P; Roy, L; Spentchian, M; Tulliez, M; Turhan, A; Varet, B | 1 |
| Bai, Y; Lin, Y; Lu, Z; Sun, B; Wang, G; Wang, S | 1 |
| Blennow, K; Guilhot, F; Legros, L; Livesey, FJ; Olsson, B; Smith, J; Strömberg, K; Wilson, DH; Zetterberg, H | 1 |
| Chen, X; Dou, QP; Huang, H; Lan, X; Li, X; Liao, S; Liu, J; Liu, N; Liu, S; Shi, X; Song, W; Wang, S; Wang, X; Xu, L; Zhao, C; Zhou, P | 1 |
| De Souza, CA; Fan, X; Guilhot, F; Hochhaus, A; Hughes, TP; Kalaycio, ME; Kantarjian, HM; Larson, RA; Meier, S; Menssen, HD; Nakaseko, C; Niederwieser, D; Rosti, G; Saglio, G | 1 |
| Ariaudo, A; Calcagno, A; De Francia, S; Di Perri, G; DʼAvolio, A; Fava, C; Piccione, F; Pirro, E; Saglio, G; Simiele, M | 1 |
| Besson, N; Brümmendorf, TH; Cortes, JE; Durrant, S; Gambacorti-Passerini, C; Kantarjian, HM; Kelly, V; Khoury, HJ; Kim, DW; Leip, E; Martinelli, G; Porkka, K; Turnbull, K | 1 |
| Cambrosio, A; Keating, P | 1 |
| Fancher, KM; Green, MR; Newton, MD | 1 |
| Baker, SD; Bruhn, O; Cascorbi, I; Hofmann, U; Hu, S; Kneba, M; Koepsell, H; Nies, AT; Pott, C; Ruth, P; Schaeffeler, E; Schwab, M; Sparreboom, A; van der Kuip, H; Volk, C | 1 |
| Adiko, D; Bureau, C; Dulucq, S; Etienne, G; Etienne, M; Fort, MP; Hayette, S; Lippert, E; Mahon, FX; Marit, G; Morisset, S; Nicolini, FE; Reiffers, J; Schmitt, A; Tigaud, I | 1 |
| Coluccia, AM; Gigli, G; Palamà, IE | 1 |
| Abel, GA; Dusetzina, SB; Huskamp, HA; Keating, NL; Winn, AN | 1 |
| Gellad, WF | 1 |
| Iijima, K; Ishibashi, T; Kiyokawa, N; Kobayashi, K; Mori, T; Okita, H; Osumi, T; Saito, M; Shimizu, T; Tomita, O | 1 |
| Hjorth-Hansen, H; Koskenvesa, P; Kreutzman, A; Lundán, T; Mustjoki, S; Pihlman, M; Porkka, K; Räsänen, A; Remes, K; Rohon, P; Simonsson, B; Vakkila, E; Vakkila, J; Vapaatalo, M | 1 |
| Badrawy, H; Gaber, N; Khalaf, MR; Sayed, D | 1 |
| Imataki, O | 1 |
| Dietz, CT; Erben, P; Hanfstein, B; Hochhaus, A; Hofmann, WK; Kalmanti, L; Mossner, M; Müller, MC; Munjal, U; Nowak, D; Philipp, M; Schwaab, J; Seifarth, W | 1 |
| Agarwal, A; Druker, BJ; Dunlap, J; English, I; Javidi-Sharifi, N; Martinez, J; Traer, E; Tyner, JW; Wong, M | 1 |
| Digumarti, R; Gundeti, S; Jiwtani, S; Kagita, S; Linga, VG; Uppalapati, S | 1 |
| Huang, BT; Tan, Y; Zeng, QC; Zhao, WH | 1 |
| Ding, L; Gao, GL; Liu, QF; Liu, XL; Lu, QS; Sun, J; Wei, YQ; Xiao, YJ; Xu, D; Xu, N; Zhang, Y; Zhou, X | 1 |
| Huang, Q; Li, Y; Wang, XM; Zhang, XY | 1 |
| Marin, D | 4 |
| McCormack, PL; Plosker, GL; Syed, YY | 1 |
| Mauro, MJ | 8 |
| Clark, RE; Davies, A; Giannoudis, A; Harris, RJ; Lucas, CM; Pirmohamed, M | 2 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Liu, DH; Liu, KY; Mo, XD; Wang, Y; Xu, LP; Zhang, XH | 1 |
| Bond, HM; Buffa, P; Consoli, ML; Di Raimondo, F; Manzella, L; Massimino, M; Mesuraca, M; Morrone, G; Pennisi, MS; Romano, C; Sciacca, L; Stagno, F; Stella, S; Tirrò, E; Vigneri, P | 1 |
| Bhargava, S; Kumar, M; Malhotra, B; Malhotra, H; Rathore, OS; Sharma, P | 1 |
| Druker, BJ | 16 |
| Ankathil, R; Azlan, H; Baba, AA; Elias, MH; Fadilah, SA; Padmini, M; Rosline, H; Sim, GA | 1 |
| Lau, A; Seiter, K | 1 |
| Anzalone, CL; Cohen, PR; Cortes, JE; Kurzrock, R | 1 |
| Bazarbachi, A; Bonnet, PA; Deleuze-Masquéfa, C; El Eit, R; Hmadi, R; Iskandarani, A; Mahon, FX; Nasr, R; Saliba, J | 1 |
| Fraga, J; García-Diez, A; Kutzner, H; Llamas-Velasco, M; Requena, L; Steegmann, JL | 1 |
| Bueno, CT; Chiattone, CS; de Castro, FA; de Lima, LT; de Lourdes F Chauffaille, M; Guerra-Shinohara, EM; Hirata, MH; Hirata, RD; Hungria, VT; Luchessi, AD; Vivona, D; Zanichelli, MA | 1 |
| Gambacorti-Passerini, C; Piazza, R; Rusconi, F; Vagge, E | 1 |
| Cao, W; Fu, H; Hu, Y; Huang, H; Liu, L; Luo, Y; Wang, Y; Wu, K; Xiao, H; Xu, Y; Zhang, L; Zhao, Y | 1 |
| Chen, RJ; Chen, YZ; Huang, LS; Liu, Y; Lou, LG; Wu, LX; Wu, Y; Xu, JH; Zheng, ZH | 1 |
| Inokuchi, K; Nakayama, K | 1 |
| Irie, T; Izumiyama, K; Kato, T; Meguro, T; Mori, A; Morioka, M; Musashi, M; Saga, A; Saito, M; Tanaka, M; Tanino, M | 1 |
| Akcay, A; Akici, F; Aydogan, G; Erbey, F; Ozturk, G; Salcioglu, Z; Tugcu, D | 1 |
| Abraham, M; Beider, K; Blaier, O; Darash-Yahana, M; Eizenberg, O; Galun, E; Koren-Michowitz, M; Nagler, A; Peled, A; Wald, H; Wald, O | 1 |
| Anderson, KR; Chambers, CR; Cusano, F; Lam, N; Savoie, ML; Sheikh, N; Yau, PS | 1 |
| Dörken, B; Grille, P; Kaeda, J; le Coutre, P; Manley, PW; Marque, F; Oberender, C; Radimerski, T; Ringel, F; Schwarz, M | 1 |
| Di Stefano, C; Marfe, G | 2 |
| Butow, P; Chee, D; Schofield, P; Seymour, J; Ugalde, A; Wu, S | 1 |
| Ben-Yehuda, D; Cohen, SB; Gatt, ME; Goldschmidt, N; Gural, A; Lavie, D; Levin, M; Libster, D; Ruchlemer, R; Rund, D; Vine, J | 1 |
| Donato, N; Fermeglia, M; Gibbons, DL; Laurini, E; Posocco, P; Pricl, S; Quintás-Cardama, A; Sun, H; Talpaz, M | 1 |
| Close, J; Lottenberg, R; Murphy, M; Rajasekhar, A | 1 |
| Guilhot, F; Guilhot, J; Huault, S; Hueber, AO; Legros, L; Mahon, FX; Preudhomme, C | 1 |
| Cai, Z; Huang, H; Luo, Y; Shi, J; Zhao, Y | 1 |
| de Lemos, ML; Kyritsis, V | 1 |
| Campillo-Recio, D; Cervero-Jimenez, M; Perez-Rodriguez, L; Yebra, E | 1 |
| Brümmendorf, TH; Cortes, JE; Cunningham, M; Guilhot, F; Healey, D; Hochhaus, A; Kantarjian, HM; le Coutre, P; Mohamed, H; Rousselot, P; Saglio, G; Schiffer, CA; Shah, NP | 1 |
| Hochhaus, A | 7 |
| Ankathil, R; Au, A; Aziz Baba, A; Goh, AS; Rosline, H; Teh, A; Wahid Fadilah, SA | 1 |
| Bai, H; Li, S; Qin, Y; Shao, S; Wang, C; Wang, X; Yang, Y; Zhao, C; Zhou, L | 1 |
| Angelini, S; Arici, R; Baratè, C; Bocci, G; Capecchi, M; Cervetti, G; Ciabatti, E; Danesi, R; Di Paolo, A; Fontanelli, G; Galimberti, S; Grassi, S; Guerrini, F; Hrelia, P; Petrini, M; Polillo, M | 1 |
| Bose, CK; Dasgupta, S; Gharami, F; Kanti Ray, U; Mukhopadhyay, A; Mukhopadhyay, S | 1 |
| Atsuta, Y; Fukuda, T; Imai, K; Kanamori, H; Kato, K; Matsuo, K; Miyamura, K; Mizuta, S; Morishima, Y; Nishiwaki, S; Ohashi, K; Onishi, Y; Onizuka, M; Sakamaki, H; Suzuki, R; Takahashi, S; Tanaka, J | 1 |
| Cen, J; Chen, S; He, G; Pan, J; Qiu, H; Sha, X; Sun, A; Wu, D; Xu, Y; Zhang, R; Zhou, M | 1 |
| Davis, A; Gorniak, M; Grigoriadis, G; Ling, VY; Wall, M | 1 |
| Hamad, N; Kamel-Reid, S; Kim, DD; Lee, HG; Lipton, JH | 1 |
| Binda, F; Bucelli, C; Cattaneo, D; Cortelezzi, A; Fermo, E; Gianelli, U; Iurlo, A; Rapezzi, D; Santambrogio, E | 1 |
| Chansung, K; Jootar, S; Kulpeng, W; Sompitak, S; Teerawattananon, Y | 1 |
| Abdul Wahid, SF; Hassan, R; Husin, A; Mohamad Ashari, ZS; Sim, GA; Sulong, S | 1 |
| Cornacchioni, AL; de Souza, C; Hamerschlak, N; Pasquini, R; Spector, N; Steagall, M; Tabak, D | 1 |
| Li, Y; Luo, J; Pan, Y; Shang, Y; Yang, J; Yang, L | 1 |
| Cho, HS; Hyun, MS; Kim, MK; Koh, SA; Lee, HY; Lee, KH | 1 |
| Ar, MC; Aydin, Y; Baslar, Z; Elverdi, T; Eskazan, AE; Ongoren Aydin, S; Ozbek, U; Salihoglu, A; Soysal, T; Tuzuner, N; Yalniz, FF | 1 |
| Fang, Z; Hong, S; Hong, SS; Jung, KH; Kim, J; Kim, SJ; Lee, H; Shin, S; Son, MK; Yan, HH; Yun, SM | 1 |
| Baerlocher, GM; Einsele, H; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Hertenstein, B; Hochhaus, A; Hofmann, WK; Kalmanti, L; Krause, SW; Kremers, S; Lange, E; Lauseker, M; Link, H; Müller, L; Müller, MC; Pfirrman, M; Pletsch, N; Proetel, U; Saußele, S; Schlag, R; Schreiber, A; Wernli, M | 1 |
| Chávez-González, A; Delgado, N; Estrada-González, PK; Flores-Figueroa, E; Gómez-Ceja, L; Mayani, H; Meillón, L; Montesinos, JJ; Sánchez-Nava, E | 1 |
| Ceko, M; le Coutre, P; Lewin, GR; Milenkovic, N; Westermann, J | 1 |
| Adan Gokbulut, A; Baran, Y; Boga, C; Cakmakoglu, B; Cincin, B; Kozanoglu, I; Ozdogu, H; Solmaz, S | 1 |
| Guo, Q; Li, W; Li, X; Li, Z; Miao, H; Zhang, Y; Zhao, L; Zhou, Y | 1 |
| Coleman, M | 1 |
| Chen, S; Rao, Q; Tang, K; Tian, Z; Wang, H; Wang, J; Wang, M; Wei, H; Xing, H; Xiong, Y; Yu, J; Zhang, L | 1 |
| Chandrakala, S; Ghosh, K; Joshi, D; Korgaonkar, S; Vundinti, BR | 1 |
| Abe, T; Fujii, S; Fujita, M; Jomen, W; Kato, J; Kuroda, H; Maeda, M; Matsuno, T; Nojiri, S; Sakurai, T; Sato, M; Yamada, M | 1 |
| Chuah, CT; Huang, W; Lee, KL; Manjeri, A; Ng, KP; Ong, ST; Poellinger, L; Tan, SY | 1 |
| Aguayo, A | 1 |
| Abrams, SI; Banik, D; Griffiths, EA; Nemeth, MJ; Waight, JD | 1 |
| Bu, Q; Cui, L; Ding, K; Du, X; Li, J; Pan, J; Zou, W | 1 |
| Bitar, C; Saba, N | 1 |
| Bao, EN; Liu, Y; Lu, XC; Zhong, WW; Zhu, HL | 1 |
| Digumarti, R; Gundeti, S; Jiwatani, S; Kagita, S; Linga, VG; Nagesh, N; Uppalapati, S | 1 |
| Katagiri, S; Ohyashiki, K; Okabe, S; Tanaka, Y; Tauchi, T | 1 |
| Bilban, M; Blatt, K; Cerny-Reiterer, S; Herndlhofer, S; Herrmann, H; Hoermann, G; Holyoake, TL; Mannhalter, C; Mayerhofer, M; Rülicke, T; Sadovnik, I; Sperr, WR; Stefanzl, G; Streubel, B; Valent, P; Willmann, M | 1 |
| Abkhiz, S; Eishei Oskuei, A; Farrokhpour, M; Makhdoomi, K; Vossoghian, S | 1 |
| Ahn, JY; Jeong, JH; Jeong, JW; Kim, KH; Kim, MJ; Park, J; Park, MJ; Park, PW; Seo, JY; Seo, YH | 1 |
| Abd-Elgalil, AA; Al-Hadiya, BM; Bakheit, AH | 1 |
| Baerlocher, GM; Dengler, J; Dietz, C; Einsele, H; Erben, P; Fabarius, A; Falge, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Kanz, L; Kneba, M; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saussele, S; Schnittger, S; Schubert, J; Shlyakhto, V; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Feng, W; He, D; Huang, Z; Li, Y; Wang, X; Zu, B | 1 |
| Eldeeb, MA; Fahlman, RP | 1 |
| Dilloo, D; Janz, I; Krumbholz, M; Lauten, M; Metzler, M; Moser, O; Suttorp, M; Tauer, JT; Thiede, C | 1 |
| Glauche, I; Jung, R; Suttorp, M; Tauer, JT; Ulmer, A | 1 |
| Dong, Y; Duan, L; Liu, Z; Lu, C; Luo, Y; Niu, T; Wu, X; Xiong, M; Xu, C | 1 |
| Chen, JL; Chen, Q; Chen, R; Chen, Y; Guo, G; Huang, S; Kang, Q; Ouyang, J; Tan, H; Wang, X; Zhang, L; Zhu, X | 1 |
| Baerlocher, GM; Dengler, J; Dietz, C; Einsele, H; Erben, P; Fabarius, A; Falge, C; Haferlach, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Kanz, L; Kneba, M; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saussele, S; Schnittger, S; Schubert, J; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Bouchet, S; Buclin, T; Csajka, C; Decosterd, LA; Gotta, V; Mahon, FX; Molimard, M; Schuld, P; Widmer, N | 1 |
| Altamura, HK; Braley, JA; Branford, S; Donaldson, Z; Fletcher, L; Georgievski, J; Grigg, AP; Hughes, TP; Jamison, BA; Leong, M; Parker, WT; Phillis, S; Purins, L; Roberts, ND; Ross, DM; Seymour, JF; Yeoman, AL; Yeung, DT | 1 |
| Gravitz, L | 1 |
| Bourzac, K | 1 |
| Chen, Z; Cheng, R; Dai, Q; Ge, Y; Xu, X; Yang, B | 1 |
| Blackburn, DF; Dicus, M; Lyons, B; Olson, C; Tran, DA | 1 |
| Coviello, JM; Mendiola, C; Ortega, V; Tonk, VS; Velagaleti, G | 1 |
| Du, Y; Li, NN; Lin, GQ; Lv, FF; Wang, W | 1 |
| Wei, W; Wu, C; Wu, Y; Xu, W; Yan, H; Ye, C; Yu, Q | 1 |
| Brümmendorf, TH; Cortes, JE; Dmoszynska, A; Duvillié, L; Gambacorti-Passerini, C; Gogat Marchant, K; Kantarjian, HM; Khattry, N; Lipton, JH; Pavlov, D; Rossiev, V; Wong, RS | 1 |
| Branford, S; Cervantes, F; Clementino, NC; Collins, L; Dorlhiac Llacer, PE; Hughes, TP; Leber, B; Lipton, JH; Mahon, FX; Pasquini, R; Purkayastha, D; Rea, D; Schwarer, AP; Spector, N; Szczudlo, T | 1 |
| Bukvova, R; Dolezel, P; Kosztyu, P; Mlejnek, P | 1 |
| Abdelaal, M; Abrar, MB; Absi, A; Al-Amri, A; Alsaeed, A; Alshehri, MA; Alsobhi, E; Alzahrani, Z; Bayashoot, S; El-Hemaidi, I; Hashem, H; Merdad, A; Radi, S; Shiekhi, H; Warsi, A | 1 |
| Yahagi, Y | 1 |
| Bhatia, R; Chen, W; Chu, S; Liu, Z; Roth, M; Wang, J; Wang, Z; Wu, X; Yuan, H; Yuan, YC | 1 |
| Al-Jamal, HA; Asan, JM; Hassan, R; Johan, MF; Jusoh, SA; Yong, AC | 1 |
| Fultz, K; Garcia-Gonzalez, P; Levine, PH; Mendizabal, A; Reaman, G; Sadak, KT | 1 |
| Sekine, T; Suzuki, K | 2 |
| Li, JY; Ouyang, Y; Pan, LQ; Qiao, C; Qiu, HX; Wang, JJ; Yang, XC; Zhang, SJ | 1 |
| Akhtari, M; Armitage, JO; Bhatt, VR; Bociek, RG; Dave, BJ; Kessinger, A; Sanger, WG; Sanmann, JN; Yuan, J | 1 |
| Gladstone, DE; Gocke, C; Jones, RJ; Matsui, WH; Smith, BD; Zahurak, M; Zeidner, JF | 1 |
| Usui, N | 4 |
| Chen, C; Huang, T; Jia, J; Li, W; Liu, Z; Sun, J; Wang, J; Yu, Y | 1 |
| Bender, HU; Blau, IW; Burdach, S; Burmeister, T; Hofmann, WK; Kiewe, P; Kolb, HJ; Neumann, M; Notter, M; Pursche, S; Reinwald, M; Schleyer, E; Thiel, E | 1 |
| Chen, L; Guérin, A; Hiscock, R; Ionescu-Ittu, R; Keir, C; Marynchenko, M; Nitulescu, R; Wu, EQ | 1 |
| Hodges, A; Kang, Y; Ong, E; Paternostro, G; Piermarocchi, C; Roberts, W | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; González-Llano, O; Gutiérrez-Aguirre, CH; Jaime-Pérez, JC; Mancias-Guerra, C; Sánchez-Cárdenas, M | 1 |
| Dreger, P; Fruehauf, S; Ho, AD; Jens Zeller, W; Luft, T; Radujkovic, A; Topaly, J | 1 |
| Bera, S; Diamond, AM; Reinke, EN | 1 |
| Antolini, L; Bozzani, S; Di Giacomo, N; Gambacorti Passerini, C; Piazza, R; Viganò, I | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Binotto, G; Breccia, M; Cambrin, GR; Castagnetti, F; Cavalli, L; Cavazzini, F; Cedrone, M; Celesti, F; Crisà, E; D'Addosio, A; Endri, M; Ferrero, D; Giglio, G; Gozzini, A; Isidori, A; Iurlo, A; Latagliata, R; Luciano, L; Molica, M; Montefusco, E; Musto, P; Pregno, P; Rossi, AR; Rosti, G; Russo, S; Sica, S; Sorà, F; Spadea, A; Speccha, G; Stagno, F; Storti, S; Tiribelli, M; Trawinska, MM | 1 |
| Bueno, CT; Chauffaille, Mde L; Chiattone, CS; de Lima, LT; Guerra-Shinohara, EM; Hirata, MH; Hirata, RD; Hungria, VT; Vivona, D; Zanichelli, MA | 1 |
| Bautista, G; Burgaleta, C; Calle, C; Cano, P; Casado Montero, LF; De Paz, R; Duran Nieto, MS; Fernández de la Mata, M; Fernández Valle, Mdel C; Franco Osorio, R; García-Gutiérrez, V; Garrido, PL; Giraldo, P; Hernández-Rivas, JÁ; Jimenez Jambrina, M; Maestro, B; Martinez López, J; Mata Vazquez, MI; Molina Hurtado, JR; Moreno Romero, MV; Muriel, A; Osorio, S; Paz Coll, A; Peñarrubia, MJ; Perez-Encinas, M; Portero, Mde L; Puerta, JM; Ramirez Sanchez, MJ; Requena, MJ; Ruiz Aredondo, J; Sastre, JL; Sola Garcia, R; Steegmann, JL; Suñol, PB; Tallón Pérez, D | 1 |
| Ankathil, R; Au, A; Azlan, H; Baba, AA; Norsa'adah, B | 1 |
| Baccarani, M; Soverini, S | 1 |
| Ea, CK; Lim, YY; Loh, SW; Ng, WL; Yeo, KS | 1 |
| Dreimane, A; Ehrencrona, H; Gedde-Dahl, T; Gjertsen, BT; Hjorth-Hansen, H; Höglund, M; Koskenvesa, P; Lotfi, K; Majeed, W; Markevärn, B; Mustjoki, S; Ohm, L; Olsson-Strömberg, U; Porkka, K; Remes, K; Richter, J; Simonsson, B; Söderlund, S; Stenke, L; Suominen, M | 1 |
| Conticello, SG; Mattiuz, G; Sala, C; Saraconi, G; Severi, F | 1 |
| Al-Allawi, NA; Al-Zebari, SS; Ali, MD; Badi, AI | 1 |
| Hamada, A; Hayashi, M; Kawaguchi, T; Saito, H; Sato, D; Uchida, T; Yamakawa, Y; Yuki, M | 1 |
| Abdelhay, E; Binato, R; Cappelletti, P; Corrêa, S; Du Rocher, B; Ferreira, G; Mencalha, A; Pinto, LF; Soares-Lima, S | 1 |
| Chopra, A; Gogia, A; Jha, A; Kumar, R; Mallik, N | 1 |
| Albright, F; Bauer, H; Brixner, DI; Chen, L; Deininger, MW; Kuo, KL; Raimundo, K; Shami, PJ; Stenehjem, DD | 1 |
| Jackson, RC; Radivoyevitch, T | 2 |
| Sánchez-Guijo, F | 1 |
| Chen, FF; Chen, ZM; Jin, J; Ma, QL; Meng, HT; Mu, QT; Shao, L; Wang, SS; Wang, YG; Xu, WL; Yin, XF | 1 |
| Ahmad, S; Anderson, DJ; Arpin, CC; Baron, R; Deininger, MW; Eiring, AM; Engar, AJ; Gunning, PT; Heaton, WL; Khorashad, JS; Kraft, IL; Mason, CC; Moriggl, R; O'Hare, T; Page, BDG; Pomicter, AD; Resetca, D; Reynolds, KR; Senina, A; Tantravahi, SK; Todic, A; Vellore, NA; Wilson, DJ; Zabriskie, MS; Zhang, TY | 1 |
| Björkholm, M; Carlsson, KS; Dickman, P; Höglund, M; Lundqvist, A; Ohm, L; Persson, U; Stenke, L | 1 |
| Gao, C; Ren, H; Sun, H; Wang, H; Wang, L; Wu, CT; Xiao, F; Xu, J; Yang, Y; Yin, Y | 1 |
| Guo, Q; Hui, H; Li, H; Lu, N; Wang, Q; Wang, X; Yang, H; You, Q; Zhao, K; Zhou, Y; Zhu, Y | 1 |
| Flis, S; Nieborowska-Skorska, M; Skorski, T | 1 |
| Cao, R; Gao, G; Li, L; Liao, L; Liu, X; Meng, F; Xiao, Y; Xu, D; Xu, N; Yin, C; Zhou, X | 1 |
| Diverio, D; Foà, R; Giona, F; Gottardi, E; Laurino, M; Mariani, S; Marzella, D; Moleti, ML; Nanni, M; Piciocchi, A; Rea, M; Saglio, G; Testi, AM | 1 |
| Baruchel, A; Berthou, C; Bertrand, Y; Cayuela, JM; Couillault, G; Galambrun, C; Gandemer, V; Guilhot, J; Lutz, P; Mazingue, F; Mechinaud, F; Millot, F; Petit, A; Reguerre, Y; Schmitt, C; Sirvent, N; Vérité, C; Yakouben, K | 1 |
| Hasford, J; Lauseker, M | 1 |
| Bai, R; Cerny, J; Druker, BJ; Eide, CA; Green, MR; Hutchinson, L; Khoury, HJ; Li, S; Ma, L; Ou, J; Shan, Y; Sheng, Z; Xue, L; Zhu, LJ | 1 |
| Katagiri, S; Mizoguchi, I; Ohtsuki, K; Ohyashiki, JH; Ohyashiki, K; Umezu, T; Yoshimoto, T | 1 |
| Cho, EH; Chung, Y; Eom, HS; Kong, SY; Lee, H; Park, S; Shim, H | 1 |
| Austin, G; Clark, RE; Davies, A; Foroni, L; Giannoudis, A; Holyoake, TL; Kottaridis, PD; Müller, MC; Pirmohamed, M; Wang, L; Zhang, JE | 1 |
| Carter, BZ; Chen, X; Dou, QP; Huang, H; Lan, X; Li, X; Liao, S; Liu, J; Liu, N; Liu, Q; Liu, S; Shi, X; Song, W; Wang, X; Zang, D; Zhao, C | 1 |
| Grebeňová, D; Kuželová, K; Obr, A; Röselová, P | 1 |
| Branford, S; Cortes, J; Gonen, M; Hughes, T; Michor, F; Olshen, A; Quintás-Cardama, A; Tang, M | 1 |
| Chen, B; Chen, C; Chen, Y; Hu, J; Li, J; Liu, T; Qiu, B; Wang, W; Zheng, J; Zheng, Z | 1 |
| Chen, M; Jiang, X; Lin, H; Lorenzi, MV; Rothe, K; Woolfson, A | 1 |
| Geromichalos, GD; Papadopoulos, T; Sahpazidou, D; Sinakos, Z | 1 |
| Angelini, S; Cao, J; Kim, DH; Lipton, JH; Soverini, S; Takahashi, N; Vivona, D; Wu, H; Yu, Q; Zheng, Q | 1 |
| Albers, C; Duyster, J; Illert, AL; Kreutmair, S; Leischner, H; Miething, C; Peschel, C | 1 |
| Alikian, M; Alonso-Dominguez, JM; Apperley, J; Clark, RE; Daghistani, M; Foroni, L; Gerrard, G; Grinfeld, J; Hedgley, C; Marin, D; O'Brien, S; Reid, A | 1 |
| Arici, R; Baratè, C; Carulli, G; Cervetti, G; Di Paolo, A; Ferreri, MI; Fontanelli, G; Galimberti, S; Guerri, V; Guerrini, F; Marini, A; Ottaviano, V; Petrini, M; Polillo, M | 1 |
| Akay, OM; Albayrak, M; Ayyildiz, O; Berber, I; Dal, MS; Dogu, MH; Esen, R; Eser, A; Hacioglu, S; Ilhan, O; Korkmaz, S; Namdaroglu, S; Nizam, I; Pala, C; Sahin, DG; Sencan, M; Tombak, A; Yildirim, R | 1 |
| Chu, A; Kubba, F; Lee, M; Scott, AD | 1 |
| Adams, L; de Boer, B; Harding, DJ; Howman, R; Jeffrey, G; MacQuillan, G; Mitchell, A | 1 |
| Li, XL; Liu, HY; Liu, T; Lü, SJ; Niu, T; Wu, Y; Zheng, SP; Zhu, HL | 1 |
| Ar, MC; Eskazan, AE; Soysal, T | 2 |
| Adiko, D; Bidet, A; Bureau, C; Dulucq, S; Etienne, G; Fort, MP; Hayette, S; Lascaux, A; Lippert, E; Mahon, FX; Nicolini, FE; Reiffers, J; Schmitt, A | 1 |
| Matsumura, I | 3 |
| Takahashi, N | 2 |
| Baerlocher, GM; Benz, R; Buclin, T; Chalandon, Y; Csajka, C; Decosterd, LA; Duchosal, MA; Gotta, V; Gregor, M; Heim, D; Leoncini-Franscini, L; Widmer, N | 1 |
| Ali, MA; Elsalakawy, WA | 1 |
| Granot, G; Hershkovitz-Rokah, O; Modai, S; Pasmanik-Chor, M; Raanani, P; Shomron, N; Shpilberg, O; Toren, A | 2 |
| Lam, YK; Lau, YM; Leung, KH; Lin, SY | 1 |
| Bendit, I; Biasoli, I; Boquimpani, C; Schaffel, R; Spector, N | 1 |
| Koldehoff, M | 1 |
| Chuah, CT; Huang, JW; Ko, TK; Ng, KP; Ong, ST | 1 |
| Alimena, G; Breccia, M; Carmosino, I; Finsinger, P; Latagliata, R; Molica, M; Montagna, C; Romano, A; Salaroli, A; Santopietro, M; Serrao, A; Volpicelli, P; Vozella, F; Zacheo, I | 1 |
| Cao, C; Li, X; Liu, T; Shen, K; Zhang, L; Zhu, H | 1 |
| Hung, A; Karagiannis, TC; Tortorella, SM | 1 |
| Baccarani, M; Benesova, A; de Benedittis, C; Ernst, T; Haferlach, T; Hochhaus, A; Jaruskova, M; Klamova, H; Kohlmann, A; Kulvait, V; Linhartova, J; Machova Polakova, K; Martinelli, G; Soverini, S; Stopka, T | 1 |
| Gambacorti-Passerini, C; Piazza, R | 3 |
| Blatt, K; Cerny-Reiterer, S; Eisenwort, G; Herrmann, H; Holyoake, T; Lion, T; Mayer, J; Ráčil, Z; Sadovnik, I; Valent, P | 1 |
| Gressett Ussery, SM; Heym, KM; Philpot, LM; Trinkman, H | 1 |
| Chen, RA; Hao, MW; Liang, YM; Liu, L; Liu, Q; Xia, DY | 1 |
| Castagnetti, F; Gugliotta, G; Leo, E; Mancini, M; Martinelli, G; Santucci, MA | 1 |
| Abe, S; Abe-Suzuki, S; Hidaka, M; Kitagawa, M; Kurata, M; Murayama, T; Nakagawa, Y; Onishi, I; Yamamoto, K | 1 |
| Erba, HP | 1 |
| Abdelhay, E; Corrêa, S; Du Rocher, B; Mencalha, AL; Salles, D; Santiago, MF | 1 |
| Drabo, YJ; Hien, FM; Ouédraogo, MS; Sawadogo, S | 1 |
| Blalock, SJ; Earnshaw, SR; Fang, G; Happe, LE; Richards, KL; Walko, CM; Ward, MA | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Whiteley, J | 1 |
| Luchinin, AS; Ovsepyan, VA; Zagoskina, TP | 1 |
| Bagg, A; Soderquist, C | 1 |
| He, Y; Li, T; Li, Y; Lin, R; Ren, F; Wang, W; Yang, X; Zhang, J | 1 |
| Barcellos, KS; Bernusso, VA; Duarte, AS; Hansen, MD; Machado-Neto, JA; Olalla Saad, ST; Pericole, FV; Traina, F; Vieira, KP | 1 |
| Jin, XB; Li, L; Lin, XH; Liu, MY; Mao, JW; Pu, QH; Wang, WZ; Wu, LR; Wu, QQ; Zhu, JY | 1 |
| Apperley, JF; Innes, AJ | 1 |
| Baruchel, A; Berthou, C; Bertrand, Y; Chastagner, P; Couillault, G; Galambrun, C; Gandemer, V; Guilhot, J; Khalifeh, T; Leblanc, T; Lutz, P; Mazingue, F; Millot, F; Petit, A; Reguerre, Y; Rialland, F; Vérité, C; Yacouben, K | 1 |
| Henk, HJ; Shapiro, M; Whiteley, J; Woloj, M | 1 |
| Chen, S; Chen, Y; Li, Z; Lin, B; Wu, S; Zheng, C; Zhou, W | 1 |
| Fang, Z; Hong, S; Hong, SS; Jung, KH; Kim, J; Kim, SJ; Lee, H; Lee, S; Lim, JH; Ryu, YL; Son, MK; Suh, JK; Yan, HH | 1 |
| Obut, F; Randall, N; Ustun, C; Valent, P; Young, JA | 1 |
| Abe, A; Kajiguchi, T; Ohno, T; Okuno, S | 1 |
| Fujisawa, S; Hatta, Y; Inokuchi, K; Iwase, O; Kozai, Y; Kumagai, T; Matsuki, E; Oba, K; Ohashi, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Shinagawa, A; Shirasugi, Y; Takeuchi, J; Wakita, H; Yano, S; Yoshida, C | 1 |
| Chen, R; Chen, Y; Fan, Y; Gao, P; Huang, L; Huang, M; Liu, Y; Lou, L; Wu, L; Wu, Y; Xu, J; Yu, J | 1 |
| Bhutra, S; Huang, RS; LaCroix, B; Lenkala, D; Ye, M | 1 |
| Aksu, S; Aydin, C; Buyukasik, Y; Demiroglu, H; Eliacik, E; Goker, H; Haznedaroglu, IC; Isik, A; Ozcebe, O; Sayinalp, N; Uner, A | 1 |
| Arthur, CK; Beresford, J; Braley, J; Branford, S; Filshie, R; Forsyth, CJ; Grigg, AP; Herschtal, A; Hertzberg, M; Hiwase, DK; Hughes, TP; Issa, S; Kornhauser, M; Kwan, YL; Mills, AK; Osborn, MP; Ross, DM; Schwarer, AP; Tam, C; Taper, J; Trotman, J; White, DL; Yeung, DT | 1 |
| Lin, L; Lu, XJ; Song, XB; Wang, J; Ye, YX; Ying, BW; Zhou, J; Zhou, Y; Zhou, YH | 1 |
| Kittai, A; Tabbara, I; Yu, EM | 1 |
| Hong, M; Li, JY; Liu, WX; Pan, LQ; Qian, SX; Qiao, S; Zhu, Y | 1 |
| Alvarez-Calderon, F; DeGregori, J; DeRyckere, D; Gemta, L; Graham, DK; Gregory, MA; Hill, AA; Jordan, CT; Kumar, A; Kumar, V; Pham-Danis, C; Pollyea, DA; Serkova, NJ; Stevens, BM; Wempe, MF; Zaberezhnyy, V | 1 |
| Azam, M; Huber, E; Kesarwani, M; Kincaid, Z | 1 |
| Liu, H; Sun, Z; Tang, B; Wang, L; Yao, W; Zhang, L; Zheng, C; Zhu, X | 1 |
| Bonneau, K; Bowler, AD; Chenchik, A; Deininger, MW; Eiring, AM; Gantz, KC; Heaton, WL; Iovino, AJ; Kauffman, M; Khorashad, JS; Kraft, IL; Mason, CC; O'Hare, T; Pomicter, AD; Redwine, HM; Reynolds, KR; Shacham, S; Tantravahi, SK; Ullman, KS; Yu, F; Zabriskie, MS | 1 |
| Abrantes, AM; Alves, R; Alves, V; Botelho, MF; Carreira, IM; Ferreira-Teixeira, M; Fonseca, AR; Gonçalves, AC; Jorge, L; Lima, J; Matoso, E; Rodrigues-Santos, P; Sarmento-Ribeiro, AB | 1 |
| Bolger, K; Crampe, M; Haslam, K; Kelly, J; Langabeer, SE; McCarron, SL; Morrell, R | 1 |
| Fujii, M; Honma, M; Iizuka, H; Ishida-Yamamoto, A; Iwasaki, T; Kishiyama, K; Takahashi, H; Takahashi, I | 1 |
| Cortes, J; Malhotra, R; Mauro, M; Saglio, G; Steegmann, JL; Ukropec, JA; Wallis, NT | 1 |
| Aujoulat, O; Chantrel, F; Debliquis, A; Eisenmann, JC; Guillon, M; Hinschberger, O; Kenizou, D; Merieau, S; Ojeda-Uribe, M; Veyradier, A | 1 |
| Arock, M; Baumgartner, S; Beham-Schmid, C; Cerny-Reiterer, S; Hartmann, K; Herndlhofer, S; Hoermann, G; Linkesch, W; Mannhalter, C; Müllauer, L; Rabenhorst, A; Sill, H; Sperr, WR; Stefanzl, G; Valent, P | 1 |
| AbdelRahman, IF; El-Haddad, MS; Selim, OM; Shaeer, KZ; Shaeer, OK | 1 |
| Derwich, K; Januszkiewicz-Lewandowska, D; Pieczonka, A; Samborska, M; Skalska-Sadowska, J; Wachowiak, J | 1 |
| Adamaki, M; Athanasiadou, A; Divane, A; Karytianou, A; Moschovi, M; Tourkantoni, N | 1 |
| Benque, D; Chuang, R; Cook, B; Fisher, J; Gottgens, B; Hall, BA; Ishtiaq, S; Koschmieder, S; Piterman, N; Taylor, A; Vardi, M | 1 |
| Ji, C; Li, P; Liu, N; Liu, Q; Ma, D; Sun, X; Zang, S | 1 |
| Bansal, P; Dahiya, K; Dokwal, S; Ghalaut, PS; Ghalaut, R; Ghalaut, VS; Kulshrestha, M; Sharma, TK | 1 |
| Brullo, C; Desogus, A; Musumeci, F; Schenone, S; Tintori, C | 1 |
| Paquin, D; Sacco, D; Shamshoian, J | 1 |
| Burchert, A; Dengler, J; Dietz, CT; Fabarius, A; Falge, C; Hanfstein, B; Hasford, J; Hehlmann, R; Heinrich, L; Hochhaus, A; Kalmanti, L; Kanz, L; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Oppliger-Leibundgut, E; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Rinaldetti, S; Saussele, S; Scheid, C; Spiekermann, K; Stegelmann, F | 1 |
| Brancaccio, M; Camporeale, A; Carrà, G; Crivellaro, S; Cutrin, JC; Di Savino, A; Familiari, U; Ferretti, R; Franco, I; Fusella, F; Gambacorti-Passerini, C; Giugliano, E; Hirsch, E; Miniscalco, B; Morotti, A; Pandolfi, PP; Panuzzo, C; Papotti, M; Piazza, R; Rege-Cambrin, G; Rocca, S; Saglio, G; Silengo, L; Tarone, G; Turco, E | 1 |
| Chae, MJ; Choi, SY; Hwang, HJ; Jang, EJ; Kang, KH; Kim, DW; Kim, SH; Lee, MY; Lee, SE; Oh, YJ; Song, HY; Yoo, HL | 1 |
| Ai, HS; Dong, Z; Guo, M; Hu, KX; Li, BX; Qiao, JH; Sun, QY; Yao, B; Yu, CL; Zhang, ZC | 1 |
| Dai, M; Fan, ZP; Huang, F; Jiang, QL; Li, XF; Liu, QF; Meng, FY; Shen, KF; Sun, J; Wang, HM; Wei, YQ; Xu, D; Yang, M; Zhang, Y; Zhou, HS | 1 |
| Liu, X; Sun, H; Wang, H; Wang, L; Xiao, F; Xu, J; Xu, Q; Xue, S; Yang, Y; Yin, Y; Zhang, Q | 1 |
| Fan, J; Ju, D; Li, Y; Song, P; Sun, Y; Wang, S; Wang, Z; Zeng, X; Zhao, H | 1 |
| Wolf, D | 1 |
| Burchert, A; Eigendorff, E; Hehlmann, R; Hochhaus, A; Hoffmann, J; Inselmann, S; Kostrewa, P; Metzelder, SK; Müller, MC; Neubauer, A; Saussele, S; Schütz, C; Sohlbach, K; Ziermann, J | 1 |
| Pagani, IS; Pirrone, C; Porta, G | 1 |
| Collassanti, MDS; Covas, DT; de Castro, FA; de Oliveira, GLV; de Souza, AM; Ferreira, AF; Hamerschlak, N; Kashima, S; Tognon, R; Zanichelli, MA | 1 |
| Benchekroun, S; Bouchoutrouch, N; Dehbi, H; El Amrani, M; El Hadi, H; Kottwitz, D; Moumen, A; Nadifi, S; Quessar, A; Sefrioui, H | 1 |
| Ellis, M; Mills, AK | 1 |
| Hamid, M; Karimipoor, M; Khani, M; Rostami, G; Yaran, M | 1 |
| Kato, A; Nagata, K; Ohki, M; Takano, H; Wanabe, D | 1 |
| Bautista, G; Burgaleta, C; Calle, C; Casado, LF; de Paz, R; García-Gutiérrez, JV; García-Ormeña, N; Giraldo, P; Hernández-Rivas, JÁ; Maestro, B; Martínez-López, J; Massagué, I; Osorio, S; Palomera, L; Peñarrubia, MJ; Pérez-Encinas, M; Requena, MJ; Steegmann, JL | 1 |
| Kimura, S; Kubota, Y; Tabe, Y; Yokoo, M | 1 |
| Christiansson, L; Hjorth-Hansen, H; Höglund, M; Loskog, A; Mangsbo, S; Markevärn, B; Mustjoki, S; Olsson-Strömberg, U; Richter, J; Söderlund, S; Stenke, L | 1 |
| Akahane, D; Asano, M; Fujimoto, H; Gotoh, M; Ito, Y; Katagiri, S; Kitahara, T; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Saito, Y; Suguro, T; Tanaka, Y; Tauchi, T; Umezu, T; Yoshizawa, S | 1 |
| Baccarani, M; Du, X; Hertle, S; Hou, M; Hu, J; Hu, Y; Huang, H; Huang, X; Jin, J; Li, J; Meng, F; Menssen, HD; Ortmann, CE; Saglio, G; Shen, ZX; Tribouley, C; Wang, J; Yuan, Y; Zhu, H | 1 |
| Cao, L; Fang, Q; Gao, R; Hu, X; Lu, T; Ma, D; Wang, J; Wang, P; Wu, W | 1 |
| Bilko, DI; Diachenko, MV; Dyagil, IS; Gordienko, AI; Perekhrestenko, TP; Sviezhentseva, IO | 1 |
| Ding, X; Huang, L; Li, C; Meng, L; Wang, Y; Xiao, M; Xu, D; Zhang, N; Zhang, P | 1 |
| Kusio-Kobiałka, M | 1 |
| Ambrosetti, A; Binotto, G; Bonifacio, M; Calistri, E; Fanin, R; Maino, E; Medeot, M; Nabergoj, M; Scaffidi, L; Semenzato, G; Tiribelli, M | 1 |
| Conti, RM; Larson, RA; Padula, WV | 1 |
| Ambrosetti, A; Binotto, G; Bonifacio, M; Calistri, E; De Marchi, F; Fanin, R; Frison, L; Krampera, M; Maino, E; Marin, L; Scaffidi, L; Semenzato, G; Tiribelli, M | 1 |
| Dogliotti, I; Fava, C; Morotti, A; Rege-Cambrin, G; Saglio, G | 1 |
| Aljedai, A; Buckle, AM; Hiwarkar, P; Syed, F | 1 |
| Ahn, KS; Jung, SY; Kim, C; Kim, SH; Kim, WS; Lee, JH; Lee, SG; Shim, BS | 1 |
| Chaves, GC; Scopel, CT | 1 |
| Fujisawa, S; Hagihara, M; Ishigatsubo, Y; Ishii, Y; Itabashi, M; Kajiyama, R; Matsumoto, K; Motohashi, K; Numata, A; Yamamoto, W | 1 |
| Boulin, M; Chretien, ML; Lang, AS; Mounier, M; Roques, M | 1 |
| Alimena, G; Breccia, M; Colafigli, G; Molica, M | 1 |
| Choi, CW; Choi, IK; Kim, BS; Kim, HJ; Lee, SR; Park, Y; Sung, HJ; Yhim, HY | 1 |
| Chen, JJ; Lin, DJ; Liu, Q; Long, ZJ; Lu, G; Luo, Y; Tu, XX; Wang, LX; Zheng, FM | 1 |
| Demlová, R; Juřica, J; Turjap, M | 1 |
| Abdel-malek, RR; Edesa, WA | 1 |
| Bailey, BM; Creedon, A; Lyne, A | 1 |
| Biondi, A; Burnelli, R; Consarino, C; Diverio, D; Foà, R; Giona, F; Gottardi, E; Iaria, G; Ladogana, S; Locatelli, F; Menna, G; Messina, C; Micalizzi, C; Moleti, ML; Nanni, M; Pession, A; Piciocchi, A; Putti, MC; Saglio, G; Santoro, N; Tucci, F; Varotto, S | 1 |
| Agrawal, R; Jain, A; Jain, N; Sharma, D | 1 |
| De La Mora-Levy, JG; Hernández-Guerrero, AI; Jáquez-Quintana, JO; Rodríguez-Pendás, F | 1 |
| Cabezón, M; Cortés, M; Feliu, E; Grau, J; Marcé, S; Millá, F; Zamora, L | 1 |
| Bartholomäus, A; Bentz, M; Berdel, WE; Burchert, A; de Wit, M; Eckart, MJ; Fabarius, A; Gassmann, W; Hahn, M; Hanfstein, B; Hasford, J; Hebart, HF; Hehlmann, R; Heim, D; Heymanns, J; Hochhaus, A; Hofmann, WK; Kalmanti, L; Kraemer, D; Krause, SW; Krauss, MP; Lauseker, M; Leibundgut, EO; Müller, MC; Pezzutto, A; Pfirrmann, M; Proetel, U; Saussele, S; Schmidt-Wolf, I; Schmitz, N; Staib, P; Wernli, M; Zettl, F | 1 |
| Digumarti, R; Gundeti, S; Kagita, S; Uppalapati, S | 1 |
| Ahn, S; Cho, SR; Han, JH; Park, JS | 1 |
| Cayuela, JM; Cluzeau, T; Dombret, H; Lippert, E; Maarek, O; Migeon, M; Noguera, ME; Rea, D | 1 |
| Miura, M | 1 |
| Cui, ZG; Li, GL; Shi, X; Wang, YY; Xu, H; Zhao, HG; Zhao, T; Zhou, Y | 1 |
| Ai, HS; Qaio, JH; Zhang, ZC | 1 |
| Aktan, Ç; Baran, Y; Can, BK; Çetintaş, VB; Ceyhan, M; Gökbulut, AA; Günel, NS; Kaymaz, BT; Kıpçak, S; Özel, B; Yandım, MK | 1 |
| Fang, Z; Hong, SS; Jung, KH; Kim, KW; Kim, SJ; Lee, H; Rumman, M; Son, MK; Yan, HH; Yoo, HD | 1 |
| Goto, C; Goto, H; Kasahara, S; Nagaya, K; Osawa, T; Tachi, T; Takahashi, T; Teramachi, H; Umeda, M; Yasuda, M | 1 |
| Gong, Y; Guo, Y; He, G; Li, Y; Lin, J; Shan, Q | 1 |
| Huang, B; Huang, LF; Li, J; Lin, J; Liu, J; Min, QH; Wang, XZ; Wang, Y; Xu, YM; Yang, WM; Zhang, J | 1 |
| Gniot, M; Lewandowski, K; Wasilewska, EM | 1 |
| Jiang, JH; Qian, WB; Xu, WL | 1 |
| Lorand-Metze, I; Metze, K; Rego, MN | 1 |
| Kasahara, K; Kimura, H; Kondo, Y; Nakao, S; Ohata, K; Takato, H; Waseda, Y; Watanabe, S | 1 |
| Ainsworth, P; Carter, R; Dyck, J; Harvey, M; Hillis, C; Leber, B; Lin, HX; Pare, G; Sadikovic, B; Sjaarda, J; Stringer, R | 1 |
| Ganser, A; Manukjan, G; Ripperger, T; Santer, L; Schambach, A; Schlegelberger, B; Steinemann, D; von Neuhoff, N | 1 |
| Fabarius, A; Haaß, W; Haferlach, C; Hehlmann, R; Hofmann, WK; Kleiner, H; Müller, MC; Schlegelberger, B; Seifarth, W; Weiß, C | 1 |
| Abruzzese, E; Albano, F; Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Cavazzini, F; Cavo, M; Gherlinzoni, F; Gugliotta, G; Intermesoli, T; Iurlo, A; Leoni, P; Levato, L; Martinelli, G; Martino, B; Pane, F; Pregno, P; Rossi, G; Rosti, G; Saglio, G; Soverini, S; Stagno, F; Testoni, N; Venturi, C | 1 |
| Hu, J; Huang, X; Jiang, H; Jiang, Q; Wu, D; Xu, L; Zhu, H | 1 |
| Alimena, G; Baccarani, M; Bocchia, M; Bochicchio, MT; Breccia, M; Castagnetti, F; Cavazzini, F; Cavo, M; Cedrone, M; D'Adda, M; Fava, C; Gugliotta, G; Levato, L; Martinelli, G; Martino, B; Pane, F; Rosti, G; Russo Rossi, A; Saglio, G; Salvucci, M; Soverini, S; Stagno, F; Tiribelli, M; Trabacchi, E; Usala, E | 1 |
| Bowles, K; Docherty, SM; Reza, M; Turner, G | 1 |
| Hughes, TP; Watkins, DB; White, DL | 1 |
| Li, YH; Wang, XJ | 1 |
| Filshie, R; Hughes, TP; Nandurkar, H; Ong, J; Yeung, D | 1 |
| Chandrasekaran, A; Dubashi, B; Francis, J; Pradhan, SC; Sundaram, R | 2 |
| Li, Q; Shi, L; Tan, G; Wang, M | 1 |
| Schaffel, R | 1 |
| Albuquerque, DM; Almeida, MH; da Silveira, RA; de Souza, CA; Delamain, MT; Duarte, VO; Lorand-Metze, I; Miranda, EC; Oliveira-Duarte, GB; Pagnano, KB; Ribeiro, BF; Santos, AD; Vergílio, BR | 1 |
| Du, Z; Lyu, Z; Pan, Y; Tian, J; Wen, S; Yan, L | 1 |
| Blaison, D; Brahimi, S; Levasseur, T; Montagnac, R; Schendel, A; Takin, R | 1 |
| Abruzzese, E; Assouline, S; Crivori, P; D'Emilio, A; De Riso, G; Elena, C; Gambacorti-Passerini, C; Giraldo, P; Gozzini, A; Iurlo, A; Kim, DW; le Coutre, P; Lodolo D'Oria, A; Luciani, M; Martino, B; Mezzatesta, C; Mori, S; Petroccione, A; Piazza, R; Pierri, I; Pirola, A; Pungolino, E; Redaelli, S; Stagno, F; Vagge, E | 1 |
| Cen, J; Chen, S; Chen, Y; Gui, X; Guo, L; He, X; Pan, J; Qiu, H; Wu, D; Yue, Y | 1 |
| Berthou, C; Blairvacq, M; Galons, H; Meijer, L; Oumata, N; Troadec, S | 1 |
| Betticher, DC; Cornea, MI; Levrat, E; Pugin, P | 1 |
| Dinan, NM; Golabchifar, AA; Kebriaeezadeh, A; Rezaee, S; Rouini, MR | 1 |
| Herrmann, J; Watson, KE; Yang, EH | 1 |
| Adam, T; Faber, E; Friedecký, D; Hrdá, M; Mičová, K; Široká, J | 1 |
| Azuma, K; Hagihara, K; Horiuchi, M; Imaizumi, J; Itoi, J; Kanashima, H; Nakao, T; Ueda, H; Yamane, T; Yoshida, M | 1 |
| Anderson, DJ; Bowler, AD; Clair, PM; Deininger, MW; Eiring, AM; Gantz, KC; Johnson, K; Khorashad, JS; Kraft, IL; Mason, CC; O'Hare, T; Partlin, MM; Pomicter, AD; Redwine, HM; Reynolds, KR; Yu, F; Zhang, TY | 1 |
| Ingle, AD; Molli, PR; Naik, NR; Pradhan, MB | 1 |
| Borthakur, G; Burger, J; Cortes, JE; Ferrajoli, A; Jabbour, E; Kantarjian, H; Lahoti, A; Nogueras-González, GM; O'Brien, S; Pierce, S; Ravandi, F; Yilmaz, M | 1 |
| Arcadio, V; Cortese, B; D'Amone, S; Gigli, G; Palamà, IE | 1 |
| Bellan, C; Caparrotti, G; Ciarcia, R; Damiano, S; Florio, S; Garofano, T; Giordano, A; Montagnaro, S; Pacilio, C; Pagnini, F; Polito, MS; Puzio, MV | 1 |
| Chen, YH; Jin, XB; Liao, FF; Lin, XH; Liu, MY; Pu, QH; Wang, WZ; Wu, LR; Wu, QQ; Zhu, JY | 1 |
| Abdi, M; Amini, S; Azadi, NA; Ghaderi, B; Salimizand, H | 1 |
| Błasiak, J; Hoser, G; Pawlowska, E; Skorski, T; Synowiec, E; Wojcik, K | 1 |
| Fujii, S; Miura, I; Tanaka, H | 1 |
| Bendit, I; Bengió, RM; Boquimpani, C; Bozzano, AH; Cervera, EE; Chiattone, CS; Clementino, N; Conchon, M; Cortes, J; De Souza, CA; Fogliatto, L; Funke, V; Hamerschlak, N; Hungria, V; Larripa, I; Lopez, JL; Mayta, E; Meillon, LA; Miranda, EC; Moiraghi, EB; Nardinelli, L; Pagnano, KB; Pasquini, R; Pavlovsky, C; Pavlovsky, MA; Silveira, RA; Simões, B; Spector, N; Zalcberg, I | 1 |
| Basu, D; Jacob, SE; Subbiah, A; Verma, SP | 1 |
| Ghosh, K; Shanmukhaiah, C; Vaidya, S; Vundinti, BR | 1 |
| Bao, X; Chen, S; Fu, C; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Alimena, G; Breccia, M; Colafigli, G; De Angelis, F; Diverio, D; Latagliata, R; Mancini, M; Molica, M; Quattrocchi, L | 1 |
| Fei, C; Feng, WL; Huang, ZL; Li, H; Liu, ZL; Wang, L | 1 |
| Allegra, A; Alonci, A; Calapai, G; Gangemi, S; Maisano, V; Mannucci, C; Musolino, C; Russo, S | 1 |
| Angriman, F; Arbelbide, JA; Gimenez Conca, AD; Gutierrez Acevedo, MN; Michelángelo, H; Otero, V; Rossi, MS | 1 |
| Gong, Y; Len, Y; Naren, D; Shi, F; Shi, R; Yan, T; Yang, X | 1 |
| Cesaro, E; Costanzo, P; De Angelis, B; Errichiello, S; Grosso, M; Gullberg, U; Izzo, P; Montano, G; Palladino, C; Pane, F; Quintarelli, C; Sodaro, G; Vidovic, K | 1 |
| Cao, W; Feng, W; Gao, M; Huang, Z; Li, H; Li, Y; Liu, X; Tao, K; Wang, F; Wen, L; Xiao, Q | 1 |
| Antunes, MV; Capra, MZ; Fogliatto, L; Leite, R; Linden, R; Mattevi, VS; Raymundo, S; Reginato, F; Vieira, N; Wagner, SC | 1 |
| Beressi, JP; Castaigne, S; Chomienne, C; Chrétien, S; Leboulch, P; Maneglier, B; Massonnet, G; Ouzegdouh, Y; Prost, S; Raggueneau, V; Relouzat, F; Rousselot, P; Saliba, J; Spentchian, M; Verhoeyen, E | 1 |
| Baratè, C; Barsotti, S; Ciabatti, E; Clermont, PL; Crea, F; Danesi, R; Di Paolo, A; Fontanelli, G; Galimberti, S; Guerrini, F; Helgason, CD; Liu, HH; Morganti, R; Petrini, M; Polillo, M; Ricci, F; Wang, Y | 1 |
| Bhargava, S; Jasuja, S; Kumar, M; Malhotra, B; Malhotra, H; Sharma, P | 1 |
| Bernard, S; Clapp, GD; El Cheikh, R; Labussière-Wallet, H; Lepoutre, T; Levy, D; Nicolini, FE; Ruby, J | 1 |
| Deininger, M; Moslehi, JJ | 1 |
| Baran, Y; Ceylan, C; Elmas, E; Yandim, MK | 1 |
| Altman, JK; Arslan, AD; Beauchamp, EM; Blyth, GT; Curi, DA; Donato, NJ; Giles, FJ; Platanias, LC | 1 |
| Bucelli, C; Cattaneo, D; Consonni, D; Cortelezzi, A; Elena, C; Grancini, V; Iurlo, A; Orlandi, EM; Orofino, N; Orsi, E; Resi, V; Sciumè, M | 1 |
| Akay, OM; Gülbaş, Z; Mutlu, F | 1 |
| Abruzzese, E; Baccarani, M; Bergamaschi, M; Bernardi, S; Bigazzi, C; Bocchia, M; Breccia, M; Cambrin, GR; Cancelli, V; Castagnetti, F; Cesana, BM; D'Emilio, A; De Vivo, A; Fogli, M; Girasoli, M; Intermesoli, T; Lorenzo, RD; Lunghi, M; Malagola, M; Martinelli, G; Martino, B; Nicolini, G; Palma, AD; Pregno, P; Pungolino, E; Rosti, G; Russo, D; Russo, S; Russo-Rossi, A; Santini, V; Skert, C; Soverini, S; Stagno, F; Testoni, N; Tiribelli, M; Turri, D; Usala, E | 1 |
| Huang, R; Kang, Q; Li, Y; Liu, H | 1 |
| Hussain, S; Usman Shaikh, M | 1 |
| Baccarani, M; Castagnetti, F; Cervantes, F; Guilhot, J; Hasford, J; Hehlmann, R; Hoffmann, VS; Ossenkoppele, G; Pfirrmann, M; Saussele, S; Simonsson, B | 1 |
| Cheung, N; Lam, MS | 1 |
| Chen, J; Chen, S; Jin, Z; Lai, J; Li, Y; Lu, Y; Xu, L; Xu, Y; Yang, L; Yu, W; Zha, X; Zhang, Y | 1 |
| Baróti, BÁ; Benedek Lázár, E; Dénes, L; Horváth, A; Pap, Z; Pávai, Z; Szántó, A; Tunyogi, AB | 1 |
| Andreeff, M; Carter, BZ; Champlin, RE; Cortes, J; Kantarjian, HM; Konopleva, M; Mak, DH; Mak, PY; McQueen, T; Ruvolo, VR; Schober, W | 1 |
| Alcalay, M; Andreola, G; Bertolini, F; Calleri, A; Cannella, L; De Molfetta, R; Faretta, M; Gregato, G; Gruszka, AM; Pruneri, G; Rabascio, C; Sammassimo, S | 1 |
| Mukherjee, A; Mukherjee, S; Roy, M; Sarkar, R | 1 |
| DU, X; Han, X; Hou, M; Hu, J; Jiang, Q; Jin, J; Li, Y; Liu, B; Liu, T; Ma, J; Meng, F; Shen, Z; Wu, D; Zhao, D | 1 |
| Arnold, R; Aul, C; Baerlocher, GM; Baurmann, H; Beelen, D; Berger, U; Bormann, M; Bunjes, D; Büsche, G; Döhner, H; Edinger, M; Fabian, M; Falge, C; Fauser, A; Fischer, JT; Ganser, A; Goebeler, ME; Gratwohl, A; Haferlach, C; Hasford, J; Hehlmann, R; Heimpel, H; Hellmann, A; Hertenstein, B; Ho, AD; Hochhaus, A; Hossfeld, DK; Kindler, T; Kolb, HJ; Kröger, N; Kuse, R; Lindemann, HW; Mayer, J; Müller, MC; Nerl, C; Novotny, J; Pfirrmann, M; Pfreundschuh, M; Prümmer, O; Reiter, A; Rosselet, A; Saußele, S; Sayer, HG; Schäfer, E; Schatz, M; Scheid, C; Schenk, M; Schlimok, G; Schmidt-Wolf, I; Schmitz, N; Schnittger, S; Schwerdtfeger, R; Spiekermann, K; Staib, P; Wehmeier, A; Wilhelm, M; Wulf, G; Zander, A | 1 |
| Bělohlávková, P; Radocha, J; Voglová, J; Žák, P | 1 |
| Hoang, U; Khan, U; Mehta, VR; Rachshtut, M | 1 |
| Cheng, J; Durden, DL; Ishii, Y; Massimino, M; Nhiayi, MK; Tse, E; Vigneri, P; Wang, JY | 1 |
| Borthakur, G; Cortes, JE; Daver, N; Jabbour, EJ; Jain, P; Kantarjian, HM; Konopleva, M; O'Brien, SM; Pemmaraju, N; Pierce, SA; Ravandi, F; Sasaki, K; Takahashi, K | 1 |
| Branford, S; Hughes, TP; Tang, C; Vidovic, L; White, DL; Yeung, DT; Yong, AS | 1 |
| Chin, HS; Chuah, CT; Huang, DC; Huang, JW; Khaw, SL; Ko, TK; Ng, KP; Ong, ST | 1 |
| Cho, EH; Jeon, SY; Kim, HS; Kim, JA; Kwak, JY; Lee, B; Lee, NR; Song, EK; Yhim, HY; Yim, CY | 1 |
| Raanani, P | 1 |
| Chen, S; Guo, D; Liu, J; Ma, W; Wu, D; Xiao, L; Xie, J; Xu, H; Yao, H; Zhang, W; Zhang, X; Zhao, Y; Zhou, H; Zhu, L | 1 |
| Bijedic, V; Bovan, NS; Colakovic, F; Eminovic, I; Hasic, A; Kozaric, M; Kurtovic, S; Kurtovic-Kozaric, A; Nefic, H; Radich, JP; Vranic, S | 1 |
| Egan, JM | 1 |
| Balduzzi, A; Faraci, M; Ferretti, M; Giardino, S; Lanino, E; Matthes-Martin, S; Micalizzi, C; Morreale, G | 1 |
| Álvarez, E; Díaz, M; Hajos, SE; Lompardía, SL; Mascaró, M; Papademetrio, DL; Pibuel, M | 1 |
| Chen, Z; Cheng, RB; Ge, YQ; Huang, Z; Yang, B | 1 |
| Akker, M; Cevik, G; Demir, AM; Maden, M; Merev, E; Pamuk, GE; Umit, EG; Uyanik, MS; Uyanik, V | 1 |
| Bonfigli, S; Dore, F; Fozza, C; Longu, F; Pardini, S | 1 |
| Gervasio, FL; Lovera, S; Martinez-Torrecuadrada, JL; Morando, M; Pucheta-Martinez, E; Saladino, G | 1 |
| Akao, Y; Ito, Y; Kumazaki, M; Kuranaga, Y; Minami, Y; Naoe, T; Otsuki, Y; Shinohara, H; Sugito, N; Taniguchi, K; Yamada, N | 1 |
| Ambavane, A; Bolinder, B; Felber, E; Makenbaeva, D; Stillman, I; Whalen, J | 1 |
| Jabbour, E; Yilmaz, M | 1 |
| Bialkowska-Warzecha, J; Blasiak, J; Hoser, G; Pawlowska, E; Skorski, T; Synowiec, E | 1 |
| Ahmed, N; Kaleem, B; Shahab, S; Shamsi, TS | 1 |
| Payandeh, M; Sadeghi, E; Sadeghi, M | 1 |
| Dong, F; Liu, J; Luan, C; Shao, H; Sun, C; Zhang, G; Zhang, X | 2 |
| Li, F; Liu, HJ; Tan, SF; Wang, JL; Wang, JM; Wang, Q; Yang, WY | 1 |
| Bucelli, C; Cannone, M; Cattaneo, D; Guerneri, S; Iurlo, A; Morotti, D; Zappa, M | 1 |
| Au-Yeung, SC; To, KK; Wei, Y | 1 |
| Alimena, G; Breccia, M; Carmosino, I; De Angelis, F; De Luca, ML; Diverio, D; Latagliata, R; Loglisci, MG; Mancini, M; Molica, M; Montagna, C; Nanni, M; Salaroli, A; Serrao, A; Volpicelli, P; Vozella, F | 1 |
| Antunes, MV; Capra, M; Capron, A; Fogliatto, L; Leite, R; Linden, R; Mattevi, VS; Reginato, F; Vieira, N; Wagner, SC; Wallemacq, P | 1 |
| Cho, DJ; Kim, DW; Kim, SH; Lee, JI; Noh, H; Oh, SJ; Park, HL; Park, MS; Zang, DY | 1 |
| Akin Belli, A; Ayer, M; Barut, SG; Dervis, E | 1 |
| Jin, H; Li, Q; Lin, Y; Pang, T; Ren, X; Sun, Q; Wang, C; Wang, J; Xiong, Q; Yang, F | 1 |
| Alattar, ML; Borthakur, G; Cortes, J; Dellasala, S; Jabbour, E; Jain, P; Kantarjian, H; Nogueras Gonzalez, G; O'Brien, S; Pierce, S; Ravandi, F; Sasaki, K; Verstovsek, S; Wierda, W | 1 |
| Aagesen, J; Alsenhed, J; Aluthgedara, W; Bergquist, J; Gréen, H; Hägg, S; Johnsson, A; Lotfi, K; Olsson-Strömberg, U; Peterson, C; Richter, J; Sandstedt, A; Skoglund, K; Söderlund, S; Svedberg, A; Ubhayasekera, SJ; Vikingsson, S | 1 |
| Aquino, X; Ávila, E; Ayala, M; Domínguez, J; Vela, J | 1 |
| Asari, K; Bunte, RM; Casey, PJ; Chuah, C; Ng, BL; Sun, WT; Wang, M; Xiang, W | 1 |
| Ji, C; Ji, M; Li, W; Liu, N; Liu, Q; Liu, Y; Ma, D; Wang, Y; Zang, S | 1 |
| Chen, W; Elgehama, A; Gao, J; Guo, W; Li, J; Mi, S; Pang, J; Shen, Y; Wang, X; Xu, Q; Yu, B | 1 |
| Kurimoto, M; Nagata, A; Noto, S; Sekiguchi, N; Takezako, N | 1 |
| Mihaila, RG | 1 |
| Doki, N; Fujiwara, T; Kakihana, K; Kobayashi, T; Narukawa, K; Ohashi, K; Sakamaki, H | 1 |
| Chen, L; Fernandez, D; Guerin, A; Latremouille-Viau, D; Liu, J; Smith, BD | 1 |
| Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Liu, YR; Qin, YZ; Zhu, HH | 1 |
| Faber, E | 2 |
| Zácková, D | 1 |
| Flamant, M; Gardin, C; Peraldi, MN; Rea, D; Rousselot, P; Serrano, F; Stehlé, T; Vidal-Petiot, E | 1 |
| Acharya, S; Sahoo, SK | 1 |
| Ar, MC; Aydin, Y; Baslar, Z; Buyru, AN; Cengiz, M; Ekizoglu, S; Elverdi, T; Eskazan, AE; Ferhanoglu, B; Gulturk, E; Ongoren Aydin, S; Ozbek, U; Salihoglu, A; Senem Demiroz, A; Soysal, T; Tanrikulu Simsek, E; Tuzuner, N | 1 |
| Bai, C; Chen, Y; Ding, K; Ding, Y; Geng, Y; Li, LY; Liu, JW; Sang, F; Sun, B; Sun, J; Wang, J; Wu, LL; Yang, G; Zhang, Q; Zhang, Z | 1 |
| Huang, HM; Lee, YL; Liu, FH; Wong, SM | 1 |
| Gong, Y; Naren, D; Shi, F; Shi, R; Wang, K; Wu, J; Xu, W; Yan, T; Yang, X | 1 |
| Choi, Y; Kang, JA; Kim, HE; Lee, CR; Park, SG; Yang, T | 1 |
| Bartley, PA; Branford, S; Budgen, B; Hughes, E; Hughes, TP; Latham, S; Morley, AA; Ross, DM; White, D | 1 |
| Clark, RE; Dalal, D; Deng, W; Donohue, B; Dorlhiac-Llacer, PE; Etienne, G; Flinn, IW; Hochhaus, A; Hughes, TP; Issaragrisil, S; Kantarjian, HM; Kim, DW; Larson, RA; le Coutre, PD; Menssen, HD; Nakamae, H; Saglio, G | 1 |
| Baradaran, B; Samadi, N; Shafiei-Irannejad, V; Yousefi, B; Zarghami, N | 1 |
| Ganta, RR; Gundeti, S; Nasaka, S | 1 |
| Borthakur, G; Cortes, J; Dasarathula, J; Dellasala, S; Jabbour, E; Jain, P; Kadia, T; Kantarjian, H; Nogueras Gonzalez, G; O'Brien, S; Pierce, S; Ravandi, F; Sasaki, K; Verstovsek, S; Wierda, W | 1 |
| McDougall, J; Radich, J; Ramsey, SD | 1 |
| Di Raimondo, F; Pennisi, MS; Spitaleri, A; Stagno, F; Stella, S; Vigneri, P | 1 |
| Han, J; Heo, JY; Jang, Y; Jo, YS; Kim, J; Kim, SJ; Ko, BW; Kweon, GR; Lee, MJ; Ryu, MJ; Song, IC | 1 |
| Baerlocher, GM; Brümmendorf, TH; Fabarius, A; Fauser, AA; Flasshove, M; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Hess, U; Hochhaus, A; Hofmann, WK; Hossfeld, DK; Kolb, HJ; Kraus, MP; Krause, SW; Lauseker, M; Mahlberg, R; Miranda, MB; Müller, MC; Neben, K; Nerl, C; Pfirrmann, M; Plöger, C; Proetel, U; Prümmer, O; Rendenbach, B; Saußele, S; Verbeek, W | 1 |
| Choi, CW; Kang, MH; Kim, DS; Na, YJ; Yoon, SY | 1 |
| Arora, R; Iyer, S; Monif, T; Sharma, M | 1 |
| Jiang, H; Jiang, Q; Lai, Y; Qin, Y; Shi, H | 1 |
| Chang, MH; Choi, MY; Choi, SY; Do, YR; Kim, DW; Kim, DY; Kim, H; Kim, HJ; Kim, JA; Kim, SH; Kwak, JY; Kwon, JH; Lee, SE; Lee, WS; Mun, YC; Oh, S; Park, J; Park, JS; Song, HY; Zang, DY | 1 |
| Chen, X; He, W; Huang, X; Lel, W; Qian, W; Wang, L; Ye, X; You, L | 1 |
| Cao, L; Fang, Q; Ma, D; Wang, J; Wang, P; Zhang, Y | 1 |
| Csef, EJ; Hefner, J; Kunzmann, V | 1 |
| Deng, Z; Ding, Y; Li, Y; Lu, X; Wang, Q; Wei, B; Wu, J | 1 |
| Hu, JD; Li, BJ; Lin, MH; Liu, TB; Wang, WF | 1 |
| Aguzzi, C; Boccadoro, M; Cerrano, M; Crisà, E; Ferrero, D; Giai, V | 1 |
| Borgo, C; Cesaro, L; Donella-Deana, A; Pinna, LA; Salizzato, V | 1 |
| Carraro, F; Chiarenza, A; Manetti, F; Naldini, A; Petricci, E; Ruat, M; Taddei, M | 1 |
| Gao, M; Kong, Y; Shi, J; Tao, Y; Wang, H; Wu, X; Xie, B; Xu, H; Yang, G; Zhan, F; Zhang, Y | 1 |
| Aguado, R; Bigas, A; Canelles, M; García-Alegría, E; García-Gutiérrez, L; Lafita-Navarro, MC; León, J; Martín, F; Ruiz-Herguido, C; Sarnataro, K | 1 |
| Apperley, JF; Baccarani, M; Conti, RM; Dusetzina, SB; Eigendorff, E; Guilhot, F; Guilhot, J; Hehlmann, R; Larson, RA; Mahon, FX; Martinelli, G; Mayer, J; Müller, MC; Niederwieser, D; Padula, WV; Saussele, S; Schiffer, CA; Silver, RT; Simonsson, B | 1 |
| Choi, YG; Kim, JA; Lee, J; Nam, YJ; Yim, E | 1 |
| Andrews, LM; Atiq, F; Broers, AE; Doorduijn, JK; Koch, BC; Van Gelder, T; Versmissen, J | 2 |
| Bhattacharya, M; Chakraborty, C; Lee, SS; Patra, BC; Sharma, AR; Sharma, G | 1 |
| Aguiar, JM; Brümmendorf, TH; Cortes, JE; Dimitrov, S; Durand, JB; Fly, KD; Gambacorti-Passerini, C; Jean Khoury, H; Kantarjian, H; Leip, E; Lipton, JH; Matczak, E; Mauro, MJ; Pavlov, D; Shapiro, M | 1 |
| Alfieri, S; Bergamini, C; Bossi, P; Granata, R; Imbimbo, M; Licitra, L; Locati, L; Pala, L | 1 |
| Albano, F; Baccarani, M; Castagnetti, F; Cavo, M; Crugnola, M; De Benedittis, C; Gugliotta, G; Iurlo, A; Klamova, H; Linhartova, J; Mancini, M; Martinelli, G; Papayannidis, C; Polakova, KM; Rosti, G; Russo, D; Salvucci, M; Soverini, S | 1 |
| Alvarado-Moreno, A; Avilés-Vazquez, S; Ayala-Sánchez, M; Chavez-Gonzalez, A; Mayani, H; Moreno-Lorenzana, D; Ortiz-Navarrete, V; Sandoval Esquivel, MA; Torres-Martínez, H | 1 |
| Cortes, JE; Hochhaus, A; le Coutre, P; Mohamed, H; Mustjoki, S; Porkka, K; Saglio, G; Schiffer, CA; Shah, NP | 1 |
| Haider, SI; Jung, C; McHale, CM; Shen, H; Smith, MT; Zhang, L; Zhang, S | 1 |
| Cao, J; Hamad, N; Jung, CW; Kim, DD; Kim, HJ; Lipton, JH; Moon, JH; Sohn, SK; Zheng, Q | 1 |
| Bozkurt, S; Büyükaşık, Y; Eyüpoğlu, D; Güven, D; Haznedaroğlu, İ | 1 |
| Guo, Q; Huang, S; Liu, Y; Lu, L; Wang, S; Xu, X; Yang, L; Zhang, X; Zhao, L | 1 |
| Bee, PC; Gan, GG; Kweh, TY; Ng, RR; Sekaran, V | 1 |
| Ayyoub, M; Kroemer, G; Routy, B; Rusakiewicz, S; Zitvogel, L | 1 |
| Belembaogo, E; Boguikouma, JB; Gaudong Mbethe, GL; Ibaba, J; Magne, C; Mounguengui, D; Moussavou Kombila, JB; Nzenze, JR; Ondounda, M; Yboutsi, L | 1 |
| Amler, L; Deininger, MW; Eiring, AM; Guan, Y; Hampton, G; Lackner, M; Lu, S; O'Hare, T; Wagle, M; Wang, Y; Wongchenko, M; Yan, Y | 1 |
| Cella, D; Cortes, J; Reisman, A; Shapiro, M; Whiteley, J | 1 |
| Ganesan, P; Ganesan, TS; Mani, S; Radhakrishnan, V; Rajaraman, S; Rajendranath, R; Sagar, TG; Unnikrishnan, R; Veeraiah, S; Vidhubala Elangovan, GS | 1 |
| Klamová, H; Kuželová, K; Macháčková-Lopotová, T; Moravcová, J; Ondráčková, Z; Žáčková, M | 1 |
| Chen, X; Gao, X; Li, L; Liu, A; Liu, J; Liu, Y; Wang, J; Xue, Y; Zhang, X; Zhang, Y | 1 |
| Turhan, AG | 2 |
| Andorsky, D; Assouline, S; Baccarani, M; Chuah, C; Clackson, T; Clark, RE; Cortes, JE; Deininger, MW; Etienne, G; Guerci-Bresler, A; Guilhot, F; Haluska, FG; Hochhaus, A; Hughes, T; Kantarjian, HM; le Coutre, P; Lipton, JH; Lustgarten, S; Nicolini, FE; Oehler, V; Rivera, VM; Rosti, G; Shah, NP; Simpson, D; Stenke, L; Talpaz, M | 1 |
| Azuma, K; Fukuoka, Y; Katagiri, S; Kobayashi, C; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Tauchi, T; Umezu, T | 1 |
| Endo, Y; Ishida, M; Mekata, E; Minamiguchi, H; Ohta, H; Shimizu, T; Sonoda, H; Takebayashi, K; Tani, M; Tani, T | 1 |
| Gorkin, L; Kantarjian, H | 1 |
| Shah, BK; Uprety, D | 1 |
| Arceci, RJ; Hijiya, N; Lee, P; Samis, J; Suttorp, M; Zimmerman, D | 1 |
| Göhring, G; Manukjan, G; Ripperger, T; Schambach, A; Schlegelberger, B; Stadler, M; Steinemann, D; Venturini, L | 1 |
| Calleja-Chuclá, T; Fernández-Gabriel, E; García-Queiruga, M; Martín-Herranz, MI; Martínez-López, LM; Seoane-Pillado, T | 1 |
| Angelini, S; Hrelia, P; Ravegnini, G; Sammarini, G | 1 |
| Amitai, I; Leader, A; Raanani, P | 1 |
| Amini, L; Dörken, B; Gresse, M; Kaeda, J; le Coutre, P; Oberender, C; Ringel, F; Schwarz, M | 1 |
| Costantini, A; Di Bartolomeo, P; Di Lorenzo, R; La Barba, G; Lasala, R; Ranucci, E; Santoleri, F; Vetrò, A | 1 |
| Hosono, N; Kimura, S; Maekawa, T; Matsuda, Y; Morinaga, K; Negoro, E; Nishi, R; Ueda, T; Uzui, K; Yamauchi, T; Yoshida, A | 1 |
| Ame, S; Bennaceur-Griscelli, A; Bonnet, ML; Bourhis, JH; Chomel, JC; Guerci-Bresler, A; Legros, L; Marfaing-Koka, A; Rea, D; Rousselot, P; Sloma, I; Sorel, N; Turhan, AG | 1 |
| Cross, NC; Hochhaus, A | 1 |
| Morley, AA | 1 |
| Cortes, JE; Healey, D; Hochhaus, A; Kantarjian, H; Milone, J; Mohamed, H; Rea, D; Rousselot, P; Saglio, G; Schiffer, C; Shah, NP | 1 |
| Chen, X; Chen, Y; Jin, M; Kong, D; Qiu, Y; Wang, R; Zhao, W; Zhong, Y; Zhou, Q | 1 |
| Li, Z; Song, YP; Wang, J; Zhang, Y; Zhou, J; Zu, YL | 1 |
| Cantú-Rodríguez, OG; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Ruiz-Argüelles, GJ | 1 |
| Huang, BT; Li, L; Li, YL; Liu, XL; Xu, LL; Xu, N; Zhang, JF; Zhou, X | 1 |
| Chen, KC; Lin, TY; Liu, AJ; Liu, HJ; Shih, CM; Wang, KL | 1 |
| Basic-Kinda, S; Granic, P; Matic, N; Nemet, D; Ostojic, A; Peric, Z; Radman, I; Roncevic, P; Sertic, D; Serventi-Seiwerth, R; Zadro, R | 1 |
| Fang, L; Li, J; Tu, H; Wan, Q; Wu, Q; Yang, Y; Zhang, X | 1 |
| Abraham, SA; Baquero, P; Carrick, E; Copland, M; Drotar, ME; Dunn, K; Grimmond, SM; Holyoake, TL; Hopcroft, LE; Korfi, K; Nourse, C; Park, LE; Pellicano, F; Pierce, A; Scott, MT; Vetrie, D; Whetton, AD; Williamson, AJ | 1 |
| Abraham, I; Vincelette, ND; Yun, S | 1 |
| Dogné, JM; Douxfils, J; Haguet, H | 1 |
| Du, QF; Li, R; Liu, XL; Xu, N; Zhang, JF | 1 |
| Bengió, R; Ferri, C; Fundia, A; Giere, I; Larripa, I; Moiraghi, B; Pavlovsky, C; Weich, N | 1 |
| Barrett, A; Brandner, S; Evans, IM; Frankel, P; Frolov, A; Li, N; Lockwood, N; Paliashvili, K; Sidlauskas, K; Zachary, IC | 1 |
| Agatheeswaran, S; Chakraborty, S | 1 |
| Han, H; Li, X; Li, Y; Liu, X; Ru, Y; Wang, Q; Yao, L; Ye, M; Zhang, M; Zhong, D | 1 |
| Chen, CW; Chen, TY; Huang, HM; Lee, YL; Liou, JP; Liu, CW; Liu, YH | 1 |
| Crampe, M; Garry, J; Langabeer, SE; Murphy, PT | 1 |
| Dieng, N; Dieye, TN; Diop, S; Faye, BF; Gadji, M; Gueye, YB; Sall, A; Seck, M; Sy, D; Toure, AO; Toure, SA | 1 |
| Arnan, M; Duarte, RF; Muniesa, C; Parody, R; Patino, B; Sánchez-Ortega, I; Servitje, O; Sureda, A | 1 |
| Aumont, C; Bennaceur-Griscelli, A; Feriel, J; Mathy, V; Petit, M; Sloma, I; Turhan, AG; Vatel, O | 1 |
| Ambrifi, M; Bottoni, U; Calvieri, S; Clerico, R; Corsetti, P; Didona, D; Paolino, G | 1 |
| Dang, P; Eadie, LN; Grigg, AP; Hughes, TP; Osborn, MP; Saunders, VA; White, DL; Yeung, DT | 1 |
| Adeagbo, BA; Bolaji, OO; Bolarinwa, RA; Durosinmi, MA; Masimirembwa, C; Olugbade, TA | 1 |
| Fiser, R; Kabickova, T; Linhartova, J; Petrak, J; Polakova, KM; Toman, O; Vit, O; Vyoral, D; Zach, J | 1 |
| Clarkson, B; Dokukin, ME; Guz, NV; Patel, SJ; Sokolov, I | 1 |
| Maschan, A; Miakova, N; Novichkova, G; Persiantseva, M | 1 |
| Ohyashiki, K; Okabe, S; Sakuta, J; Tanaka, Y; Tauchi, T | 1 |
| Angelkovic, R; Cevreska, L; Genadieva-Stavric, S; Pavkovic, M; Popova-Simjanovska, M; Stojanovic, A | 1 |
| Kirken, RA; Oaxaca, DM; Rodriguez, G; Ross, JA; Staniswalis, JG; Yang-Reid, SA | 1 |
| Hino, A; Ishikawa, J; Koike, M; Masaie, H; Minami, R; Tada, Y; Yoshida, H | 1 |
| Duarte, FB; Filho, PA; Filho, TP; Lemes, RP; Moreira-Nunes, CA; Quixada, A | 1 |
| Adam, T; Faber, E; Fikarová, I; Friedecký, D; Gardlo, A; Hrdá, M; Janečková, H; Karlíková, R; Mičová, K; Široká, J; Vrobel, I | 1 |
| Abruzzese, E; Caocci, G; Delogu, G; Fozza, C; Galimberti, S; Galimi, F; Gambacorti Passerini, C; Greco, M; La Nasa, G; Labate, C; Martino, B; Orru, F; Secchi, C; Trawinska, MM | 1 |
| Deininger, MW; Eiring, AM; Gligorich, K; Hein, T; Kelley, TW; Khorashad, JS; Marth, GT; Mason, CC; O'Hare, T; Pomicter, AD; Qiao, Y; Reid, AG; Tantravahi, SK; Yan, D | 1 |
| Bouchet, S; Chaumais, MC; Guignabert, C; Huertas, A; Humbert, M; Jutant, EM; Le Hiress, M; Manéglier, B; Molimard, M; Montani, D; Phan, C; Rousselot, P; Sattler, C; Seferian, A; Simonneau, G; Sitbon, O; Tamura, Y; Thuillet, R; Tu, L | 1 |
| Cugurovic, J; Geissler, J; Narbutas, Š; Padua, R; Remic, M; Sharf, G; Venkatesh, V | 1 |
| Alcazer, V; Cony-Makhoul, P; d'Estaing, SG; Daudin, M; Etienne, G; Fort, MP; Guerci-Bresler, A; Heiblig, M; Huguet, F; Morisset, S; Nicolini, FE; Sobh, M; Soula, V | 1 |
| Basbous, S; Bourmeyster, N; Brizard, F; Gombert, JM; Guilhot, F; Herbelin, A; Levescot, A; Piccirilli, N; Roy, L | 1 |
| Farhadi, E; Rezvani, MR; Safa, M; Zaker, F | 1 |
| Ángeles-Velázquez, JL; Candelaria-Hernández, M; Carrillo-Muñoz, S; Hurtado-Monroy, R; Vargas-Viveros, P | 1 |
| Abruzzese, E; Aprile, L; Baratè, C; Bocchia, M; Bosi, A; Defina, M; Fontanelli, G; Galimberti, S; Gozzetti, A; Gozzini, A; Petrini, M; Puccetti, L; Santilli, F; Scappini, B; Sicuranza, A; Trawinska, MM | 1 |
| Liu, HB; Wang, W; Zhang, M | 1 |
| Ding, Q; Ding, Y; Guo, Q; Li, W; Lu, L; Wang, X; Zhang, X; Zhang, Y; Zhao, L | 1 |
| Huang, XJ; Jiang, Q; Wang, HB; Yu, L | 1 |
| Jiang, Q; Liu, ZC; Zhang, SX | 1 |
| Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Wejaphikul, K; Yansomdet, T | 1 |
| Ergun, T; Eser, A; Kaygusuz Atagunduz, I; Salman, A | 1 |
| Blanco, R; Díaz-Chico, BN; Díaz-Chico, JC; Estévez-Braun, A; Fernández-Pérez, L; Guerra, B; Hueso-Falcón, I; Jiménez-Alonso, S; León, J; Martín-Rodríguez, P; McNaughton-Smith, G; Montero, JC; Pandiella, A; Rodríguez-González, G | 1 |
| Chen, L; Du, X; Jiang, S; Jin, B; Jin, Y; Li, J; Lu, Y; Pan, J; Shen, Y; Yao, Y; Zhu, X | 1 |
| Abruzzese, E; Alimena, G; Annunziata, M; Avanzini, P; Binotto, G; Bocchia, M; Bonifacio, M; Breccia, M; Bucelli, C; Calistri, E; Castagnetti, F; Cattaneo, D; Cavazzini, F; Cedrone, M; Celesti, F; Cortelezzi, A; Cortesi, L; Crugnola, M; D'Addosio, AM; Falzetti, F; Fava, C; Ferrero, D; Galimberti, S; Giglio, G; Gozzini, A; Gugliotta, G; Isidori, A; Iurlo, A; Latagliata, R; Luciano, L; Mannucci, PM; Mansueto, G; Mauro, E; Montefusco, E; Nobili, A; Orlandi, EM; Pregno, P; Rege-Cambrin, G; Rossi, AR; Rosti, G; Russo, S; Saglio, G; Scaffidi, L; Sica, S; Sorà, F; Spadea, A; Stagno, F; Storti, S; Tettamanti, M; Tiribelli, M; Vigneri, P | 1 |
| Cheloni, G; Tanturli, M | 1 |
| Chen, W; Wang, Z | 1 |
| Green, MR; Kelliher, MA; Ma, L; Roderick, J | 1 |
| Agatheeswaran, S; Chakraborty, S; Pattnayak, NC | 1 |
| Feng, W; Gao, M; Hu, J; Huang, N; Huang, Z; Li, H; Luo, Z; Shen, H; Wang, T; Wang, X | 1 |
| Huang, J; Zhao, X | 1 |
| Berdel, WE; Bertrand, J; Ciarimboli, G; Edemir, B; Haferlach, T; Harrach, S; Jeromin, S; Pap, T; Pavenstädt, H; Schlatter, E; Schmidt, E; Schmidt-Lauber, C; Schulze, U | 1 |
| Abbes, S; Bouguerra, G; Douzi, K; Gharbi, H; Hassine, IB; Menif, S; Soltani, I; Teber, M | 1 |
| Cui, L; Du, X; Jin, B; Jin, Y; Li, J; Li, P; Pan, J; Ren, R; Wang, Y; Xu, F; Zhou, J | 1 |
| Deng, XB; Fang, ZG; Lin, DJ; Liu, LL; Liu, Q; Liu, SS; Long, ZJ; Lu, Y; Zou, Y | 1 |
| Ashur-Fabian, O; Elis, A; Ellis, M; Gan, S; Hamburger-Avnery, O; Krashin, E | 1 |
| Albitar, M; Arcila, ME; Berman, E; Hedvat, C; Jhanwar, S; Levine, R; Ma, W; Maloy, M; Wahab, OA | 1 |
| Chiba, S; Hagihara, M; Igarashi, T; Inokuchi, K; Iriyama, N; Kawakami, K; Kouzai, Y; Kumagai, T; Morita, S; Ohyashiki, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Taguchi, J; Takezako, N; Wakita, H; Yano, S; Yoshida, C | 1 |
| Chen, YH; Cheng, L; Jin, XB; Liao, FF; Lin, XH; Liu, MY; Wang, WZ; Wu, QQ; Zhu, JY | 1 |
| Gao, SK; Gui, RR; Li, Z; Song, YP; Zhang, YL; Zhao, HF; Zhou, J; Zu, YL | 1 |
| Liu, BZ; Liu, YL; Shi, LQ; Shi, XJ; Wang, CG; Zeng, L; Zhong, L | 1 |
| Christiansson, L; Hjorth-Hansen, H; Loskog, A; Mustjoki, S; Olsson-Strömberg, U; Persson, I; Richter, J; Simonsson, B; Söderlund, S | 1 |
| Álvarez, É; Díaz, M; Hajos, SE; Lompardía, SL; Papademetrio, DL; Pibuel, M | 1 |
| Chen, ZS; Druker, BJ; Fu, LW; Gupta, P; Kathawala, RJ; Wang, F; Wang, X; Wei, L | 1 |
| Fang, B; Jiang, J; Liu, Y; Wang, P | 1 |
| Kurokawa, M; Morita, K; Nakamura, F; Sakuishi, K; Shimizu, J; Tsuji, S; Yamamoto, T | 1 |
| Gaboriaud-Kolar, N; Gerolymatos, P; Horne, DA; Jove, R; Mikros, E; Myrianthopoulos, V; Nam, S; Skaltsounis, AL; Vougogiannopoulou, K | 1 |
| Huang, XJ; Jiang, H; Jiang, Q; Lai, YY; Liu, YR; Qin, YZ; Shi, HX; Zhao, XS | 1 |
| Dasappa, L; Jacob, LA; Kanakasetty, GB; Kumari, P; Kuntejowdahalli, L; Mallekavu, SB; Thanky, AH | 1 |
| Chen, Y; Jin, M; Kong, D; Qiu, Y; Wang, R; Zhang, L; Zhou, Q | 1 |
| Chen, L; Fangping, C; Huang, J; Qun, H; Wang, L; Xielan, Z; Yajing, X | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Rosti, G | 1 |
| Borthakur, G; Cortes, JE; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; Koller, PB; Nogueras-Gonzalez, GM; O'Brien, SM; Ravandi, F; Verstovsek, S; Wierda, WG | 1 |
| Antolino, A; Baccarani, M; Capodanno, I; Castagnetti, F; Cavazzini, F; Cavo, M; Crugnola, M; De Vivo, A; Di Raimondo, F; Fabbiano, F; Fogli, M; Gugliotta, G; Impera, S; Mannina, D; Marasca, R; Martinelli, G; Mineo, G; Musolino, C; Musso, M; Ragionieri, R; Rizzo, M; Rosti, G; Salvucci, M; Siragusa, S; Soverini, S; Spitaleri, A; Stagno, F; Tomaselli, C; Tosi, P; Trabacchi, E; Vigneri, P; Zironi, A | 1 |
| da Cunha Vasconcelos, F; Maia, RC; Mauricio Scheiner, MA; Mencalha, AL; Moellman-Coelho, A; Renault, IZ; Rumjanek, VM | 1 |
| El-Fattah, MA | 1 |
| Jing, Y; Lu, N; Yang, L; Yu, L | 1 |
| Bao, XB; Li, Z; Qiu, HY; Xue, SL; Zhang, GF; Zhou, M | 1 |
| Dybko, J; Haus, O; Jaźwiec, B; Kaczmar-Dybko, A; Kapelko-Słowik, K; Kuliczkowski, K; Lonc, T; Mędraś, E; Sawicki, M; Urbaniak-Kujda, D; Wróbel, T | 1 |
| Chen, JJ; Hu, Y; Lin, DJ; Liu, LL; Liu, Q; Long, B; Long, ZJ; Lu, G; Luo, Y; Tu, XX; Wang, JD; Wang, LX | 1 |
| Abbes, S; Amouri, H; Ben Hadj Othman, H; Ben Lakhel, R; Benhassine, I; Douzi, K; Farrah, A; Gharbi, H; Menif, S; Soltani, I; Teber, M | 1 |
| Bhat, M; Farooq, S; Gupta, N; Guru, S; Javaid, J; Masroor, M; Mir, R; Najar, IA; Ray, PC; Saxena, A; Yadav, P; Zuberi, M | 1 |
| Calabretta, B; Canonico, PL; Condorelli, F; De Dominici, M; Genazzani, AA; Gnemmi, I; Mariani, SA; Minassi, A; Minieri, V; Riva, B; Salomoni, P | 1 |
| Mahon, FX | 4 |
| Bhattacharyya, S; Chen, L; Fan, L; Guerin, A; Joseph, G; Li, N; Totev, T; Yang, X | 1 |
| Chatelain, C; Dogné, JM; Douxfils, J; Graux, C; Haguet, H; Mullier, F | 1 |
| Chen, M; Jiao, C; Lin, Y; Wang, J; Xiao, Y; Zhang, J; Zhang, Z | 1 |
| Baldow, C; Glauche, I; Hochhaus, A; Müller, MC; Proschmann, R; Roeder, I; Rothe, T; Suttorp, M; Tauer, JT; Thiede, C | 1 |
| Ben-Batalla, I; Bokemeyer, C; Brümmendorf, TH; Carmeliet, P; Clark, RE; Erdmann, R; Ernst, T; Helgason, GV; Hochhaus, A; Holyoake, TL; Jørgensen, H; Koschmieder, S; Loges, S; Mitchell, R; Mitra, S; Pantel, K; Rankin, S; Schafhausen, P; Schultze, A; Vandenberghe, P; Velthaus, JL; von Amsberg, G | 1 |
| Balasubramanian, P; Chopra, A; Kumar, A; Kumar, R; Sharma, A; Singh, IK; Verma, D | 1 |
| Feng, A; Li, M; Li, Q; Liu, Z; Qin, L; Tang, S; Wang, H; Wang, X | 1 |
| Carter, BZ; Chen, J; Chen, X; Huang, H; Lan, X; Liu, J; Long, H; Shi, X; Wang, X; Wu, J; Yang, L; Zang, D; Zhang, P; Zhao, C | 1 |
| Baccarani, M; Martinelli, G; Soverini, S | 1 |
| Björeman, M; Brück, O; Bryceson, YT; Dreimane, A; Ehrencrona, H; Gedde-Dahl, T; Guilhot, J; Hjorth-Hansen, H; Höglund, M; Holm, E; Ilander, M; Kasanen, T; Koskela, S; Koskenvesa, P; Lähteenmäki, H; Lehmann, S; Lotfi, K; Lübking, A; Mahon, FX; Majeed, W; Markevärn, B; Mustjoki, S; Ohm, L; Olsson-Strömberg, U; Porkka, K; Richter, J; Saussele, S; Schlums, H; Själander, A; Söderlund, S; Stenke, L | 1 |
| Cannella, L; Efficace, F | 1 |
| Perrotti, D; Stramucci, L | 1 |
| Chen, S; Dong, C; Liu, C; Miao, M; Sheng, G; Tan, SC; Wu, D; Xiong, T; Zhang, R | 1 |
| Chen, S; Liu, C; Miao, M; Sheng, G; Tan, SC; Wu, D; Xiong, T; Zhang, R | 1 |
| Biondi, A; Burnelli, R; Consarino, C; Cosmi, C; Diverio, D; Foà, R; Giona, F; Iaria, G; Ladogana, S; Leszl, A; Locatelli, F; Menna, G; Micalizzi, C; Moleti, ML; Mura, R; Nanni, M; Putti, MC; Saglio, G; Santopietro, M; Santoro, N; Tucci, F | 1 |
| Cai, X; Cao, P; Chen, J; Guo, C; Sun, X; Yang, J | 1 |
| Angelini, S; Dubashi, B; Jiang, ZP; Sun, L; Takahashi, N; Xu, P; Zhao, XL | 1 |
| Barratt, DT; Cox, HK; Hughes, TP; Menelaou, A; Somogyi, AA; White, DL; Yeung, DT | 1 |
| Jiang, Q; Wang, HB; Yu, L | 1 |
| Huang, J; Liu, H; Qian, W; Wei, J; Xie, W; Ye, X; You, L | 1 |
| Bauwens, D; Beguin, Y; Benghiat, F; Capron, A; Connerotte, T; Delannoy, A; Devos, T; Dubois, C; Efira, A; Graux, C; Kargar-Samani, K; Knoops, L; Montfort, L; Springael, C; Van Obbergh, F; Wallemacq, P | 1 |
| Jin, XS; Jing, Y; Wang, BH; Yang, L; Yu, L | 1 |
| Choi, JR; Kim, Y; Lee, KA; Shin, S; Yu, N | 1 |
| Adelson, D; Banjar, H; Brown, F; Chaudhri, N; Hughes, T; Kroger, T; Leclercq, T; Ranasinghe, D; White, D | 1 |
| Bollinger, MJ; Frei, CR; Jones, X; Koeller, JM; Kreys, ED; Villarreal, SM | 1 |
| Allaoui, M; Elm'hadi, C; Errihani, H; Ichou, M; Khmamouche, MR; Mahtat, E; Messaoudi, N; Oukabli, M; Tanz, R; Toreis, M | 1 |
| Chai, X; Kang, Q; Li, Y; Lu, Y; Wang, J; Xiong, J; Zhao, P | 1 |
| Deniz, R; Eser, A; Firatli Tuglular, T; Gecgel, F; Kara, O; Kaygusuz Atagunduz, I; Ozgumus, T; Sezgin, A; Toptas, T | 1 |
| Nicolini, FE | 1 |
| Baccarani, M; Castagnetti, F; Cervantes, F; Evtimova, D; Gugliotta, G; Hasford, J; Hehlmann, R; Hochhaus, A; Hoffmann, VS; Janssen, J; Pfirrmann, M; Saussele, S | 1 |
| Saydam, G | 1 |
| Brower, V | 1 |
| Heidel, FH; Wolleschak, D | 1 |
| Ahmad, HM; Bakhshi, S; Bhattacharya, A; Gupta, YK; Kumar, L; Muiwo, P; Pandey, RM; Ramachandran, SS; Singh, S | 1 |
| Baccarani, M | 2 |
| Carré, M; Charbonnier, A; Dubruille, V; Etienne, G; Gardembas, M; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Ianotto, JC; Legros, L; Mahon, FX; Nicolini, F; Noel, MP; Rea, D; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Varet, B; Villemagne, B | 1 |
| Ahsan, N; Chorzalska, A; Dubielecka, PM; Gruppuso, PA; Kim, JF; Liang, O; Morgan, J; Olszewski, AJ; Rao, RSP; Roder, K; Tepper, A; Terentyev, D; Treaba, DO; Yu, X; Zhao, TC | 1 |
| Asou, N; Fujioka, I; Fujita, H; Hatta, Y; Iriyama, N; Ishikawa, M; Kawaguchi, T; Kizaki, M; Komatsu, N; Nakazato, T; Sato, E; Sugimoto, KJ; Takaku, T; Tokuhira, M | 1 |
| Bernard, S; Besse, A; Lepoutre, T | 1 |
| Dong, B; Huang, H; Qu, L; Weng, H; Zhao, P; Zhou, H | 1 |
| Auffarth, GU; Kaiser, D; Khoramnia, R; Marx, S; Scheuerle, A; Sel, S; Tandogan, T | 1 |
| Dang, P; Goyne, JM; Hughes, TP; Kok, CH; Leclercq, TM; Lu, L; Saunders, VA; Wang, J; White, DL | 1 |
| Benabbes, M; Meddah, B; Tazi Mezalek, Z | 1 |
| Ansari, M; Kalantary-Khandani, B; Mohajeri, E; Mosavi, N; Pardakhty, A; Safavi, M | 1 |
| Breccia, M; Colafigli, G; Diverio, D; Foà, R; Latagliata, R; Mancini, M; Massaro, F; Molica, M; Quattrocchi, L | 1 |
| Arellano, M; Bodó, I; Chen, Z; El-Rassi, F; Heffner, LT; Hill, B; Jillella, A; Khoury, HJ; Kim, A; Kong, JH; Kota, VK; Langston, AA; Winton, EF | 1 |
| Ding, YH; Li, YF | 1 |
| Gopinath, P; Kamala, LH; Nair, SG; Narayanan, G; Ramachandran, KC; Sreedharan, H; Thambi, SM | 1 |
| Mancini, M | 1 |
| Chen, W; Hui, L; Li, N; Li, Y; Liu, J; Wang, F; Wang, X; Wang, Y; Zhang, L; Zou, Y | 1 |
| Gajendra, S; Gupta, SK; Sachdev, R; Sharma, A; Sharma, R; Sood, N | 1 |
| Baccarani, M; Branford, S; Cervantes, F; Deininger, MW; Druker, BJ; Fujihara, S; Guilhot, F; Hochhaus, A; Hughes, TP; Kantarjian, H; Larson, RA; Menssen, HD; O'Brien, SG; Ortmann, CE; Radich, JP | 1 |
| Baccarani, M; Cortes, J; Deininger, M; Hasford, J; Hehlmann, R; Hoffmann, VS | 1 |
| Borthakur, G; Cortes, J; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Maiti, A; O'Brien, S; Ravandi, F | 1 |
| Hasic, A; Islamagic, E; Kozaric, M; Kurtovic, S; Kurtovic-Kozaric, A; Mehinovic, L; Suljovic Hadzimesic, E | 1 |
| Abbes, S; Amouri, H; Bellaaj, H; Ben Hadj Othman, H; Ben Hassine, I; Farrah, A; Gharbi, H; Lakhal, RB; Menif, S; Romdhane, NB; Soltani, I; Teber, M | 1 |
| Das, L; Gitlin, M; Makenbaeva, D; Siegartel, LR | 1 |
| Bilmes, R; Lin, J; Lingohr-Smith, M; Makenbaeva, D | 1 |
| Arrigoni, E; Baratè, C; Ceccherini, F; Cervetti, G; Ciabatti, E; Cornolti, F; D'Avolio, A; Danesi, R; Di Paolo, A; Domingo, D; Fava, C; Fontanelli, G; Galeotti, L; Galimberti, S; Grassi, S; Guerrini, F; Laurino, M; Petrini, M; Polillo, M; Saglio, G | 1 |
| Jönsson, S; Lorentzon, M; Mellström, D; Ohlsson, C; Olsson, B; Wadenvik, H | 1 |
| Agarwal, A; Corbin, AS; Corless, CL; Deininger, MW; Druker, BJ; Eide, CA; Harlow, A; Heinrich, MC; Mauro, MJ | 1 |
| Gambacorti-Passerini, C | 3 |
| Li, JM; Shen, ZX; Wang, AH; Wang, L; You, JH; Zhou, L | 1 |
| Li, R; Mi, YC; Qian, LS; Qiu, LG; Wang, GR; Wang, XX; Zhao, YZ; Zou, DH | 1 |
| Balabanov, S; Bokemeyer, C; Brümmendorf, TH; Fiedler, W; Gontarewicz, A; Keller, G; Moll, J; Panse, J; Schafhausen, P | 1 |
| Lee, S; Song, S; Westfall, DE; Zhang, L | 1 |
| Duesberg, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Krämer, A; Rebacz, B; Seifarth, W | 1 |
| Alfieri, P; Arcari, A; Ferrari, A; Leonardi, G; Longo, G; Luppi, G; Maffei, R; Marasca, R; Martinelli, S; Piacentini, F; Santachiara, R; Torelli, G; Trabacchi, E; Vallisa, D | 1 |
| Apperley, JF; Bua, M; de Lavallade, H; Goldman, JM; Kaeda, J; Khorashad, JS; Marin, D; Milojkovic, D; Olavarria, E; Reid, AG; Szydlo, R | 2 |
| Bouchet, S; Dulucq, S; Etienne, G; Krajinovic, M; Lippert, E; Mahon, FX; Molimard, M; Reiffers, J; Turcq, B | 1 |
| Ito, Y; Kiguchi, T; Kimura, Y; Miyazawa, K; Ohyashiki, K; Tauchi, T | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Soverini, S | 2 |
| Michor, F | 3 |
| Valent, P | 3 |
| Chang, H; Kamel-Reid, S; Kim, DH; Lipton, JH; Messner, HA; Popradi, G; Sriharsha, L | 1 |
| Amital, H; Khouri, S; Kotliroff, A; Lishner, M | 1 |
| Dang, P; Eadie, L; Frede, A; Hewett, D; Hiwase, DK; Hughes, TP; Kumar, S; Melo, J; Saunders, V; To, LB; White, DL; Zrim, S | 1 |
| Asai, T; Chiba, S; Hangaishi, A; Ichikawa, M; Kumano, K; Kurokawa, M; Nannya, Y; Sato, Y; Takahashi, T; Watanabe, T; Yamamoto, G; Yatomi, Y; Yokota, H | 1 |
| Bonneu, M; Claverol, S; Dupouy, M; Etienne, G; Lagarde, V; Lapaillerie, D; Mahon, FX; Pasquet, JM; Pocaly, M; Turcq, B; Vilain, S | 1 |
| Goldman, JM; Melo, JV | 3 |
| Kim, PS; Lee, PP; Levy, D | 3 |
| Adachi, T; Aikawa, E; Akiyama, M; Kawauchi, K; Motoji, T; Ozaki, K; Yamada, O | 1 |
| Kumlin, M; Lindgren, JA; Ohm, L; Roos, C; Stenke, L; Tornhamre, S; Widell, S | 1 |
| Tuma, RS | 2 |
| Deininger, MW | 6 |
| Blasiak, J; Czechowska, A; Morawiec, Z; Skorski, T; Sliwinski, T; Szemraj, J | 1 |
| Chen, RL; Chien, JH; Lee, CP; Li, CC; Tang, JL | 1 |
| Hughes, TP; Ross, DM | 2 |
| Cantú-Rodríguez, OG; Giralt, S; Gómez-Almaguer, D; Gonzalez-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutierrez-Riveroll, KI; Rangel-Malo, R; Ruiz-Argüelles, GJ; Tarin-Arzaga, LC | 1 |
| Dashti, A; Kawamata, N; Koeffler, HP; Lu, D; Miller, B; Moore, S; Ogawa, S; Schreck, R | 1 |
| Basciani, S; Brama, M; Giona, F; Gnessi, L; Mariani, S | 1 |
| Aribi, A; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Koller, C; Thomas, D | 1 |
| Albajar, M; Delgado, MD; Gómez-Casares, MT; Gutierrez, P; León, J; Richard, C; Rosa-Garrido, M; Steegmann, JL | 1 |
| Cilloni, D; Panuzzo, C; Ulisciani, S; Volpe, G | 1 |
| Abecasis, M; Antin, JH; Arora, M; Bolwell, BJ; Carabasi, MH; Cervantes, F; Champlin, RE; Copelan, E; Gale, RP; George, B; Giralt, SA; Gupta, V; Hale, GA; Halter, J; Horowitz, MM; Ilhan, O; Keating, A; Khoury, HJ; Kukreja, M; Lee, SJ; Liesveld, JL; Litzow, MR; Marks, DI; Maziarz, RT; McCarthy, PL; Olavarria, E; Rizzieri, DA; Schouten, HC; Stadtmauer, EA; Szer, J; Wang, T; Woolfrey, AE; Zander, AR | 1 |
| Chang, Y; Chen, SS; Huang, XJ; Jiang, H; Jiang, Q; Li, JL; Li, LD; Liu, YR; Qin, YZ; Ruan, GR; Zhang, Y; Zhu, HH | 1 |
| de Souza Fernandez, T; Dobbin, J; Ornellas, MH; Otero, L | 1 |
| Ames, PR; Aye, WW; Beatty, C; O'Reilly, D | 1 |
| Egyed, M; Karádi, E; Kollár, B; Matolcsi, A; Rajnics, P | 1 |
| Barbieri, E; Brusa, G; Corrado, P; Mancini, M; Martinelli, G; Petta, S; Santucci, MA | 1 |
| Henley, DC; Hubbard, RA; Laudadio, J; Press, RD; Quigley, NB | 1 |
| Druker, BJ; Fan, HY; Fruehauf, J; Fu, W; Gram, H; Kim, JW; Ko, J; Moore, JC; Ong, ST; Prabhu, S; Trapp, V; Zhang, M | 1 |
| Cuthbert, RJ; Humphreys, MW; Irvine, AE; McMullin, MF; Sheehy, OM | 1 |
| Bello, C; Pinilla-Ibarz, J | 1 |
| Conneally, E; Langabeer, S; McCann, SR; O'Connor, LM | 1 |
| Albitar, M; Cortes, J; Estrov, Z; Giles, F; Hannah, A; Kantarjian, H; Keating, M; O'Brien, S; Tseng, R; Yeh, CH; Zhang, Z | 1 |
| Chi, HS; Cho, YU; Chung, HJ; Kim, KH; Lee, JH; Park, CJ; Seo, EJ | 1 |
| Apperley, JF; Bua, M; Dazzi, F; de Lavallade, H; Foroni, L; Goldman, JM; Kaeda, JS; Khorashad, JS; Klammer, M; Marin, D; Milojkovic, D; Olavarria, E; Pavlu, J; Reid, AG; Rezvani, K | 1 |
| DA, WM; Duan, HF; Gao, CJ; Huang, WR; Li, QF; Wang, H; Wang, LS | 1 |
| Del Cañizo, MC; Garcia, JL; Gutierrez, NC; Hernandez, JM; Lumbreras, E; Miguel, JF; Morais, P; Sanchez-Guijo, FM; Santamaría, C | 1 |
| Goldman, J | 6 |
| Anagnostopoulos, NI; Galanopoulos, A; Georgiakaki, M; Kritikou-Griva, E; Papadhimitriou, SI | 1 |
| Duyster, J; Götze, KS; Kancha, RK; Miething, C; Peschel, C; von Bubnoff, N | 1 |
| Biswas, G; Biswas, S; Chakraborty, S; Kuila, N; Kumari, M; Patnaik, RS; Pattnayak, NC; Sahoo, DP | 1 |
| Austin, GM; Butt, NM; Clark, RE; Dasgupta, R; Galvani, D; Hoyle, CF; Knight, K; Lucas, CM; Seale, JR; Shwe, KH; Wang, L; Watmough, SJ | 1 |
| Brümmendorf, TH; Corm, S; Cortes, J; Coutre, S; Ernst, T; Gambacorti-Passerini, C; Hamerschlak, N; Hochhaus, A; Khoury, HJ; Kim, DW; Martinelli, G; Michallet, M; Radich, JP; Raffoux, E; Rege-Cambrin, G; Ritchie, E; Roy, L; Talpaz, M; Tang, JL; Van Tornout, JM; Zhu, C | 1 |
| Hino, M; Koh, KR; Nakamae, H; Ohsawa, M; Osugi, H; Sakamoto, E; Sawada, T; Wakasa, K; Yamane, T | 1 |
| Kimura, S; Tanaka, R | 1 |
| Joske, DJ | 1 |
| Abou-Mourad, Y; Barnett, MJ; Brinkman, RR; Forrest, DL; Hogge, DE; Lavoie, JC; Nantel, SH; Nevill, TJ; Power, MM; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL; Trainor, S | 1 |
| Choi, MK; Song, IS | 1 |
| Booth, B; Dagher, R; Garnett, C; Harapanhalli, R; Hazarika, M; Jiang, X; Justice, R; Lee, SL; Leighton, JK; Liu, Q; Orr, MS; Pazdur, R; Ramchandani, R; Sridhara, R; Timmer, W | 1 |
| Arthur, C; Branford, S; Catalano, J; Cooney, J; Dunkley, S; Durrant, S; Fay, K; Filshie, R; Grigg, A; Hertzberg, M; Hughes, TP; Januszewicz, H; Joske, D; Koelmeyer, R; Leahy, MF; Lynch, K; Mills, AK; Morton, J; Reynolds, J; Rowlings, P; Schwarer, A; Seymour, JF; Taylor, K; Underhill, C; White, DL | 1 |
| Dhanapala, C; Drummond, M; Holyoake, T; Johnson, PR; Maguire, C; Shepherd, P; White, J | 1 |
| Abdul Mottalib, M; Choudhury, S; Islam, S; Khan, MA; Sultana, TA | 1 |
| Ando, K; Bessho, M; Chiba, S; Dan, K; Higashihara, M; Ikeda, Y; Inokuchi, K; Ito, Y; Kanda, Y; Kimura, Y; Kizaki, M; Kurokawa, M; Ohyashiki, K; Okamoto, S; Oshimi, K; Tauchi, T; Yabe, M; Yokoyama, K | 1 |
| Bhargava, R; Dolai, TK; Mahapatra, M; Mishra, P; Pati, HP; Saxena, R; Seth, T | 1 |
| Albini, A; Ambrosini, C; Fassina, G; Ferrari, N; Frassoni, F; Monteghirfo, S; Pozzi, S; Soverini, S; Stigliani, S; Tosetti, F | 1 |
| Carreras, E; Fernández-Avilés, F; Martínez, C; Mascaró, JM; Moreno-Romero, JA; Rovira, M | 1 |
| Faber, E; Indrak, K; Jarosova, M; Prochazka, M; Rohon, P; Rozmanova, S; Santava, A; Skoumalova, I; Vondrakova, J | 1 |
| Amat, P; Collado, M; Hernández-Boluda, JC; Marugán, I; Roda, D; Tormo, M | 1 |
| Burger, J; Cortes, J; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Reddy, N | 1 |
| Chen, Y; Douglas, L; Hu, Y; Li, S | 1 |
| Li, J; Luo, SK; Su, C; Xu, DR; Zou, WY | 1 |
| Ferreira, AC; Klumb, CE; Kwee, JK; Luque, DG; Maia, RC; Silva, KL; Vasconcelos, FC | 1 |
| Wang, ES; Wetzler, M; Zeidan, A | 1 |
| Cang, S; Liu, D | 1 |
| Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F | 1 |
| Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Kubuki, Y | 1 |
| Hohl, RJ; Holstein, SA; Stokes, JB | 1 |
| Alberti, D; Alimena, G; Baccarani, M; Bassi, S; Bocchia, M; Breccia, M; Castagnetti, F; Ferrara, F; Luatti, S; Martinelli, G; Marzocchi, G; Miglino, M; Palandri, F; Pane, F; Pungolino, E; Rege-Cambrin, G; Rosti, G; Saglio, G; Specchia, G; Testoni, N; Varaldo, R; Zuffa, E | 1 |
| Cho, EH; Kang, SK; Kim, SY | 1 |
| Bewry, NN; Boulware, D; Emmons, MF; Hazlehurst, LA; Nair, RR; Pinilla-Ibarz, J | 1 |
| DeGeer, D; Jiang, X; Kennah, E; Li, XJ; Lin, AE; Ringrose, A; Sheng, G; Turhan, A; Zhao, Y; Zhou, LL | 1 |
| Bajer, J; D'alò, F; De Matteis, S; Leone, G; Sica, S; Sorà, F | 1 |
| Alnadaf, T; Buchdunger, E; Day, E; Jarai, G; Manley, PW; Spiegel, K; Walker, C; Waters, B | 1 |
| Andreeff, M; Jiffar, T; Jurasz, P; Konopleva, M; Kurinna, S; Nica, AF; Radomski, MW; Ruvolo, PP; Tsao, CC; Watt, JC | 1 |
| Einsele, H; Etschmann, B; Gattenlohner, S; Müller-Hermelink, HK; Völker, HU | 1 |
| Hino, M; Inokuchi, K; Isobe, Y; Kizaki, M; Murayama, T; Okamoto, S; Saburi, Y; Shimomura, T; Tanaka, H; Tanimoto, M; Tauchi, T; Tsudo, M | 1 |
| DeVita, VT; Hutchinson, L | 1 |
| Nacinović-Duletić, A | 1 |
| Alvarez, D; Chou, CJ; Druker, BJ; Eide, CA; Gottesfeld, JM; Lefebvre, S; O'Hare, T; Tyner, JW | 1 |
| Assef, Y; Coló, G; Costas, MA; del Mónaco, S; Kotsias, BA; Rubio, F | 1 |
| Dvorak, P; Hruba, M; Subrt, I | 1 |
| Suttorp, M | 1 |
| Bonnotte, B; Cantrell, J; Janikashvili, N; Katsanis, E; LaCasse, CJ; Larmonier, CB; Larmonier, N; Lundeen, T; Situ, E | 1 |
| Cho, SG; Han, K; Jung, CK; Kim, CC; Kim, DW; Kim, M; Kim, Y; Lee, S; Lim, J; Min, WS | 1 |
| Krause, SW; Mackensen, A | 1 |
| Akiyama, H; Jinnai, I; Kimura, Y; Maruta, A; Matsuo, K; Miyawaki, S; Miyazaki, Y; Naoe, T; Narimatsu, H; Nishii, K; Ohno, R; Ohtake, S; Sugiura, I; Takeuchi, J; Takeuchi, M; Ueda, Y; Usui, N; Yagasaki, F; Yanada, M; Yujiri, T | 1 |
| Bhagavathi, S; Borromeo, V; Crisan, D; Desai, H | 1 |
| Huang, HM; Liu, JC | 1 |
| Imataki, O; Ishida, T; Ohnishi, H; Shintani, T; Waki, F | 1 |
| Bright, SA; Brindisi, M; Butini, S; Campiani, G; Greene, LM; Greene, TF; Lawler, M; Meegan, MJ; Williams, DC; Zisterer, DM | 1 |
| Foedermayr, M; Krieger, O; Lutz, D; Zach, O; Zellhofer, B | 1 |
| Deliliers, GL; Ghidoni, R; Onida, F; Radaelli, F; Ricci, C; Saporiti, G; Servida, F; Todoerti, K | 1 |
| Berretta, S; Del Fabro, V; Di Raimondo, F; Massimino, M; Messina, A; Stagno, F; Stella, S; Vigneri, P | 1 |
| Basso, FG; Boer, CC; Cintra, ML; Corrêa, ME; da Silva Santos, P; de Magalhães, MH; de Souza, CA; Torrezan, M | 1 |
| Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Li, JL; Li, LD; Liu, YR; Qin, YZ; Zhang, Y; Zhu, HH | 1 |
| Abe, A; Hayakawa, F; Jamieson, CHM; Katsumi, A; Kitamura, K; Kiyoi, H; Minami, Y; Murata, M; Naoe, T; Nomura, Y; Wang, JYJ | 1 |
| Botta, M; Corradi, V; Mancini, M; Manetti, F; Radi, M; Santucci, MA; Schenone, S | 1 |
| Bruennert, D; Bruns, I; Czibere, A; Gattermann, N; Haas, R; Kronenwett, R; Neumann, F | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Reddy, N; Rios, MB; Shan, J; Verstovsek, S; Wierda, WG | 1 |
| Colombo, D; Finelli, P; Giardino, D; Larizza, L; Malvestiti, F; Perego, D; Rodeschini, O | 1 |
| Balbas, M; Bleickardt, E; Kasap, C; Nicaise, C; Nicoll, JM; Sawyers, CL; Shah, NP; Weier, C | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Cuia, R; Diverio, D; Santopietro, M; Stefanizzi, C | 1 |
| Chuah, C; Melo, JV | 2 |
| Boschelli, F; Gambacorti-Passerini, C; Magistroni, V; Marega, M; Perini, P; Piazza, R; Redaelli, S; Rostagno, R | 1 |
| Yamada, H | 1 |
| Fang, H; Wang, K; Zhang, J | 1 |
| Hrkal, Z; Kuzelová, K | 1 |
| Gora-Tybor, J; Robak, T | 1 |
| Cervantes, F | 1 |
| Colovic, M; Pavlovic, S; Radojkovic, M; Ristic, S | 1 |
| Bendit, I; de Alencar Fischer Chamone, D; de Mello Conchon, MR; Dias, L; Dorlhiac-Llacer, PE; Ferreira, P; Kumeda, C; Lima, W | 1 |
| Cao, L; Chen, H; Jin, J | 1 |
| Conneally, E; Hayat, A; Irvine, S; Langabeer, S; McCann, SR; McMullin, MF | 1 |
| Kim, S; Nojiri, H; Tsuji, T; Uta, S | 1 |
| Bertz, J; Elstner, E; Koeffler, HP; Liu, H; Possinger, K; Wächter, M; Zang, C | 1 |
| Müller, BA | 1 |
| Allan, EK; Hamilton, A; Hatziieremia, S; Holyoake, TL; Jørgensen, HG; Vigneri, P; Zhou, P | 1 |
| Inoue, M; Kawa, K; Kimoto, T | 1 |
| Bagchi, J; Bandyopadhyay, S; Bhattacharjee, S; Biswas, N; Chaudhuri, U; Ganguly, D; Ghosh, M; Mandal, L; Paul, K; Rakshit, S | 1 |
| Alimena, G; Breccia, M; Cannella, L; Federico, V; Frustaci, AM; Grammatico, S; Santopietro, M; Soverini, S; Stefanizzi, C | 1 |
| Crawford, LJ; Irvine, AE; Magill, L; McCallum, L; McMullin, MF; Melo, JV; Ovaa, H; Walker, B; Windrum, P | 1 |
| Airiau, K; Belloc, F; Garcia, M; Guérin, E; Jeanneteau, M; Lippert, E; Mahon, FX; Moreau-Gaudry, F | 1 |
| Celentano, M; Coppola, M; Falcone, U; Ferrara, MG; Guastafierro, S; Sica, A | 1 |
| Bacher, U; Bokemeyer, C; Bruemmendorf, TH; Dierlamm, J; Hochhaus, A; Schafhausen, P; Schnittger, S; Zander, AR | 1 |
| Andersen, BL; Braendstrup, K; Hokland, P; Mikkelsen, LS; Nyvold, CG; Ommen, HB; Ostergaard, M; Stentoft, J | 1 |
| Fermeglia, M; Greco, A; Negri, T; Pavan, GM; Pierotti, MA; Pilotti, S; Pricl, S; Sandri, M; Tamborini, E; Virdis, E | 1 |
| Cortes, JE; Jabbour, E; Kantarjian, HM | 1 |
| Abruzzese, E; Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Iacobucci, I; Luciano, L; Martinelli, G; Martino, B; Palandri, F; Pane, F; Poerio, A; Rege-Cambrin, G; Rosti, G; Saglio, G; Soverini, S; Testoni, N; Tiribelli, M; Varaldo, R | 1 |
| Bengió, R; Bianchini, M; De Brasi, C; Gargallo, P; Gonzalez, M; Larripa, I | 1 |
| Kantarjian, H | 2 |
| Fujiwara, S; Kikuchi, S; Matsuyama, T; Mori, M; Muroi, K; Nagai, T; Oh, I; Oka, S; Ozaki, K; Ozawa, K; Sato, K; Suzuki, T; Toshima, M; Ueda, M | 1 |
| Cho, BS; Chun, H; Goh, HG; Kim, D; Kim, DW; Kim, ND; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH; Yoon, JH | 1 |
| Kang, CD; Kim, HB; Kim, MJ; Kim, SH; Park, SJ | 1 |
| Kovacsovics, T; Meylan, P; Senn, L; Tarr, PE | 1 |
| Baker, KS; Burke, MJ; Luo, X; Trotz, B; Verneris, MR; Wagner, JE; Weisdorf, DJ | 1 |
| Chen, Q; Chen, SJ; Chen, Z; Huang, QH; Liu, P; Lu, J; Mao, JH; Weng, L; Xie, YY; Zhang, QY; Zhang, Y | 1 |
| Hait, WN; Hambley, TW | 1 |
| Alimena, G; Amabile, M; Baccarani, M; Breccia, M; Castagnetti, F; Galieni, P; Iacobucci, I; Iuliano, F; Luatti, S; Martinelli, G; Palandri, F; Pane, F; Rege Cambrin, G; Rosti, G; Saglio, G; Soverini, S; Specchia, G; Stagno, F; Testoni, N | 1 |
| Kumar, L; Meena, R; Singh, N; Velpandian, T | 1 |
| Bakhshi, S; Das, P; Gupta, SD; Kalita, D; Radhakrishnan, S; Singh, S | 1 |
| Bacic, B; Gwanmesia, PM; Ottmann, OG; Romanski, A; Ruthardt, M; Schwarz, K | 1 |
| Bradner, JE | 1 |
| Kiguchi, T; Ohyashiki, K; Tauchi, T | 1 |
| Gastl, G; Haun, M; Hoflehner, E; Kircher, B; Nachbaur, D; Petzer, A; Schumacher, P; Wolf, AM | 1 |
| Cerchione, C; Fabbricini, R; Luciano, L; Pane, F | 1 |
| Arlinghaus, RB; Chakraborty, SN; Hood, J; Kantarjian, H; Perrotti, D; Samanta, AK; Sun, X; Wang, Y | 1 |
| Irvine, DA; Shepherd, JD | 1 |
| Beelen, DW; Ditschkowski, M; Haferlach, C; Schulte, C; Trenschel, R | 1 |
| Hantschel, O; Kuriyan, J; Superti-Furga, G; Winger, JA | 1 |
| Chen, Q; Cheng, C; Jin, Y; Lai, Y; Lu, Z; Pan, J; Shi, X; Zhang, H; Zheng, Q; Zou, W | 1 |
| Daniels, JM; Janssen, JJ; Postmus, PE; van Altena, R; Vonk-Noordegraaf, A | 1 |
| Kami, M; Kobayashi, K; Miyata, S; Narimatsu, H; Takebayashi, C | 1 |
| Cortés, JE; Kantarjian, H; Quintás-Cardama, A | 1 |
| Bixby, DL; Talpaz, M | 1 |
| Angelo, LS; Kohanim, S; Kurzrock, R; Wu, JY; Yang, DJ | 1 |
| Cortes, J; Fava, C; Kantarjian, H; Verma, D | 1 |
| Cheong, JW; Choi, JR; Kim, SJ; Lee, KA; Lee, KW; Park, TS; Song, J; Song, S; Suh, B | 1 |
| Abruzzese, E; Alimena, G; Baccarani, M; Castagnetti, F; Ehrencrona, H; Haznedaroglu, I; Hjorth-Hansen, H; Kairisto, V; Lanng Nielsen, J; Levato, L; Martinelli, G; Nagler, A; Ozbek, U; Palandri, F; Palmieri, F; Pane, F; Porkka, K; Rege-Cambrin, G; Rosti, G; Russo, D; Saglio, G; Simonsson, B; Specchia, G; Testoni, N; Weiss-Bjerrum, O | 1 |
| Borregaard, N; Nielsen, FC | 1 |
| Pubalan, M; Wahiduzzaman, M | 1 |
| Ando, K; Atogami, S; Fukushima, T; Hata, T; Horio, K; Ikeda, S; Imaizumi, Y; Imanishi, D; Inoue, Y; Itonaga, H; Iwanaga, M; Jinnai, I; Joh, T; Kawaguchi, Y; Koida, S; Komoda, M; Kuriyama, K; Matsuo, E; Matsuo, Y; Miyazaki, Y; Moriuchi, Y; Moriwaki, Y; Nagai, K; Nonaka, H; Ogawa, D; Onimaru, Y; Sakai, M; Sawayama, Y; Soda, H; Taguchi, J; Takasaki, Y; Tawara, M; Tominaga, S; Tomonaga, M; Tsuchiya, T; Tsukasaki, K; Tsushima, H; Tsutsumi, C; Yamamura, M; Yamasaki, R; Yoshida, S | 1 |
| Liang, Y; Wei, YL; Xu, L; Xu, XH; Zhao, XY | 1 |
| Goh, HG; Jang, SE; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH | 1 |
| Borthakur, G; Cortes, J; Fava, C; Garcia-Manero, G; Jabbour, E; Jain, N; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Verstovsek, S | 1 |
| Branford, S; Druker, BJ; Foroni, L; Gathmann, I; Goldman, JM; Guilhot, F; Hochhaus, A; Hughes, TP; Larson, RA; Mone, M; Müller, MC; O'Brien, SG; Radich, JP; Rudoltz, M | 1 |
| Gau, JP; Liu, CC; Liu, JH; Tzeng, CH; Wang, WS; Yen, CC | 1 |
| Elmaagacli, AH; Koldehoff, M | 1 |
| Cortes, JE; Kantarjian, H; Pavlovsky, C | 1 |
| Auberger, P; Bénéteau, M; Jacquel, A; Lavallard, VJ; Paul, A; Pradelli, LA; Ricci, JE | 1 |
| Bogdanović, A; Denčić-Fekete, M; Gotić, M; Janković, G; Jovanović, J; Rocchi, M; Storlazzi, CT; Strnad, M; Todorić-Živanović, B; Đorđević, V | 1 |
| de Luis, A; Guerrero, C; Gutierrez-Berzal, J; Gutierrez-Uzquiza, A; Maia, V; Porras, A; Sanz, M | 1 |
| Constantinescu, G; Dobrea, C; Georgescu, D; Gologan, R; Iancu, D; Ostroveanu, D; Popov, V; Vasilache, D | 1 |
| Chen, JY; Hung, WC; Wang, MC | 1 |
| Tyler, T | 1 |
| Cortes, JE; Kantarjian, HM; Quintás-Cardama, A | 2 |
| Hwang, YY; Kwong, YL; So, JC; Tse, E; Wan, TS | 1 |
| Ohyashiki, JH; Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Auberger, P; Cassuto, JP; Colosetti, P; Gamas, P; Grosso, S; Jacquel, A; Mahon, FX; Marchetti, S; Pasquet, JM; Puissant, A | 1 |
| Minami, Y; Stuart, SA; Wang, JY | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H | 4 |
| Chen, X; Feng, Z; Li, H; Liu, H; Meng, Y; Tai, J; Wang, H; Xin, H; Zhang, S; Zhang, Y; Zuo, M | 1 |
| Abraham, I; Albrecht, T; Berneman, Z; De Bock, R; De Geest, S; MacDonald, K; Martiat, P; Mineur, P; Noens, L; Van Eygen, K; van Lierde, MA; Verhoef, G; Zachée, P | 1 |
| Cai, Z; Cao, W; Huang, H; Lai, X; Lin, M; Liu, L; Luo, Y; Shi, J; Tan, Y; Wang, Y; Wu, G; Xie, W; Ye, X; Zhao, Y | 1 |
| Giles, FJ | 4 |
| Bellodi, C; Calabretta, B; Dinsdale, D; Donato, N; Dyer, MJ; Galavotti, S; Hamilton, A; Helgason, GV; Holyoake, T; Hunter, A; Lidonnici, MR; Nicotera, P; Ronchetti, M; Salomoni, P; Selmi, T; Soliera, AR; Tirrò, E; Van Etten, RA; Vigneri, P; Yacobi, R; Young, KW | 1 |
| Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
| Alimena, G; Breccia, M; Cannella, L; Napoleone, L; Santopietro, M; Stefanizzi, C | 1 |
| Ayuk, F; Bacher, U; Brümmendorf, TH; Fiedler, W; Hochhaus, A; Iwanski, GB; Klyuchnikov, E; Kröger, N; Ocheni, S; Schafhausen, P; Schnittger, S; Zabelina, T; Zander, AR | 1 |
| Biswas, G; Chakraborty, S; Dash, N; Kuila, N; Pattnayak, NC; Sahoo, DP | 1 |
| Aisa, Y; Ikeda, Y; Iketani, O; Mori, T; Okamoto, S; Yamazaki, R | 1 |
| Apperley, J; Davis, J; Foroni, L; Gerrard, G; Goldman, J; Greener, L; Khorashad, JS; Loaiza, S; Marin, D; Melo, J; Milojkovic, D; Patel, H; Reid, A; Rezvani, K; Wagner, S; Willimott, S | 1 |
| Takimoto, CH | 1 |
| Berthier, F; Cassuto, JP; Colosetti, P; Dreano, M; Frelin, C; Gonthier, N; Imbert, V; Lounnas, N; Peyron, JF; Rousselot, P; Sirvent, A; Sirvent, N | 1 |
| Minami, Y; Naoe, T | 1 |
| Giles, FJ; Kelly, K; Mahalingam, D; Padmanabhan, S; Swords, R | 1 |
| Balcárková, J; Chroust, K; Faber, E; Holzerová, M; Indrák, K; Jarosová, M; Muzík, J; Rozmanová, S; Urbánková, H; Veselovská, J; Voglová, J | 1 |
| Larson, RA | 2 |
| Mahon, FX; Molimard, M | 1 |
| Boros, LG; Brown, JL; Eckhardt, SG; Klawitter, J; Kominsky, DJ; Melo, JV; Serkova, NJ | 1 |
| Bleickardt, E; Borthakur, G; Chen, TT; Cortes, JE; Kantarjian, HM; Liu, D; O'Brien, S; Quintás-Cardama, A; Ravandi, F | 1 |
| Scuffham, PA; Taylor, MJ | 1 |
| Agirre, X; Arqueros, V; Cervantes, F; Cordeu, L; Fresquet, V; Gárate, L; Heiniger, A; Jiménez-Velasco, A; Martín, V; Martínez-Climent, JA; Prósper, F; Roman-Gomez, J; San José-Eneriz, E; Torres, A | 1 |
| Cortes, JE; Egorin, MJ; Guilhot, F; Mahon, FX; Molimard, M | 1 |
| Berretta, S; Consoli, C; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Messina, A; Messina, L; Stagno, F; Stella, S; Tirrò, E; Vigneri, P | 1 |
| Cortes, J; Kantarjian, H; Mone, M; Silver, RT; Waltzman, R | 1 |
| Cortes, J; Han, X; Kantarjian, H; Quintás-Cardama, A | 1 |
| Kapoor, S | 1 |
| Baietto, L; D'Avolio, A; De Francia, S; De Martino, F; Di Carlo, F; Di Perri, G; Pirro, E; Racca, S; Saglio, G; Siccardi, M; Simiele, M | 1 |
| Lee, SJ; Wang, JY | 1 |
| Aftimos, P; Nasr, F | 1 |
| Clark, RE | 2 |
| Cho, GJ; Choi, YJ; Chung, JS; Kim, SG; Seol, YM; Shin, HJ; Song, MK | 1 |
| Amagasaki, T; Branford, S; Hughes, T; Ishikawa, J; Jinnai, I; Kawaguchi, T; Kobayashi, Y; Maeda, Y; Miyamura, K; Miyazaki, Y; Naoe, T; Natori, H; Nishimura, M; Ohyashiki, K; Okada, M; Okamoto, S; Tanaka, H; Tanii, H; Tojo, A; Urabe, A; Usui, N; Usuki, K | 1 |
| Larson, RA; Mattison, R | 1 |
| Kawakami, T; Kawanabe, T; Soma, Y | 1 |
| Ceglerek, B; Grygalewicz, B; Konopka, L; Krawczyk, P; Pastwińska, A; Pieńkowska-Grela, B; Rygier, J; Seferyńska, I; Sikorska, A; Woroniecka, R | 1 |
| Goh, HG; Jang, SE; Kim, D; Kim, DW; Kim, HJ; Kim, SH; Kim, WS; Kim, YJ; Kweon, IY; Lee, J; Park, SH | 1 |
| Godley, LA | 1 |
| Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Colaci, E; Foà, R; Iori, AP; Latagliata, R; Martinelli, G; Palandri, F; Rosti, G; Torelli, GF; Usai, S; Valle, V | 1 |
| Storey, S | 1 |
| Bienz, N; Dickens, E; Lewis, F | 1 |
| Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J | 1 |
| Abruzzese, E; Apperley, JF; Bullorsky, EO; Cortes, JE; de Souza, CA; Erben, P; Heim, D; Hochhaus, A; Hughes, TP; Khoury, HJ; Kim, DW; Kim, HJ; Larson, RA; Lipton, JH; Roboz, GJ; Rosti, G; Roy, L; Sillaber, C; Stone, RM; Van Tornout, J | 1 |
| Baran, Y; Gucluler, G | 1 |
| Fujiwara, H; Hayama, BY; Iwama, K; Kimura, S; Matsue, K; Matsuo, K; Takeuch, M; Yamakura, M | 1 |
| Cortes, JE; Jabbour, E; Jones, D; Kantarjian, HM; Reddy, NG; Yao, H; Zhang, L; Zhang, WW | 1 |
| Amin, HM; Arlinghaus, RB; Chandra, J; Cortes, JE; Garcia-Manero, G; Gergely, M; Lai, R; Shi, P; Sun, X | 1 |
| Akashi, K; Harada, M; Henzan, H; Miyamoto, T; Nagafuji, K; Nagasaki, Y | 1 |
| Alvarado, Y; Borthakur, G; Burger, J; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Shan, J; Wierda, W | 1 |
| Baccarani, M; Baldazzi, C; Castagnetti, F; Gamberini, C; Luatti, S; Marzocchi, G; Palandri, F; Rosti, G; Stacchini, M; Testoni, N | 1 |
| Borthakur, G; Cortes, J; Jones, D; Kantarjian, HM; Luthra, R; Rios, MB; Verma, D; Verstovsek, S | 1 |
| Cohen, EN; Cortes, J; Ebarb, T; Gao, H; Jain, N; Kantarjian, H; Lee, BN; Li, C; Reuben, JM; Scheinberg, DA | 1 |
| Baccarani, M; Barozzi, P; Forghieri, F; Gnani, A; Iacobucci, I; Luppi, M; Maccaferri, M; Martinelli, G; Martinelli, S; Morselli, M; Potenza, L; Riva, G; Soverini, S; Torelli, G; Volzone, F; Zanetti, E | 1 |
| Jaeger, BA; Lohse, J; Schmid, H; Suttorp, M | 1 |
| Damaj, G; Garidi, R; Marolleau, JP; Parcelier, A; Roszkiewicz, F; Royer, B; Vaida, I | 1 |
| Liang, Y; Wei, YL; Xu, L; Zhao, XY | 1 |
| Ahmad, R; Chaudhary, PD; Tripathi, AK; Tripathi, P; Verma, SK | 1 |
| Jamedhor, M; Reddy, KS; Schwartz, GE | 1 |
| Auberger, P; Barbry, P; Cassuto, JP; Colosetti, P; Deckert, M; Dufies, M; Grosso, S; Jacquel, A; Lebrigand, K; Mari, B; Puissant, A | 1 |
| Borthakur, G; Burger, JA; Cortes, J; Jabbour, E; Jones, D; Kantarjian, HM; Koller, C; O'Brien, S; Tam, C; Wierda, WG | 1 |
| Aceves-Luquero, CI; Agarwal, A; Arias-González, L; Bellón-Echeverria, I; Callejas-Valera, JL; de la Cruz-Morcillo, MA; Deininger, MW; del Peso Ovalle, L; Esparís-Ogando, A; Galán Moya, EM; Gómez, JC; Moreno Gimeno, I; Pandiella, A; Sánchez Prieto, R | 1 |
| Abe, A; Bessyo, M; Ishikawa, M; Jinnai, I; Kato, C; Kyo, T; Miyamura, K; Niwa, T; Ogura, K; Sasaki, H; Yagasaki, F | 1 |
| Haskovec, C; Klamova, H; Otahalova, E; Ullmannova-Benson, V | 1 |
| Hamano, Y; Isobe, Y; Masuda, A; Oshimi, K; Sugimoto, K | 1 |
| Cetkovský, P; Klamová, H; Machová Poláková, K; Marková, M; Moravcová, J; Sisková, M | 1 |
| Ikeda, T; Uchiyama, M | 1 |
| Kamel-Reid, S; Kim, DH; Lipton, JH; Liu, X; Messner, HA; Siminovitch, K; Sriharsha, L; Xu, W | 1 |
| Garber, K | 2 |
| Dorans, K | 1 |
| Ageno, W; Appio, L; Campiotti, L; Solbiati, F; Venco, A | 1 |
| Abruzzese, E; Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Colarossi, S; de Matteis, S; Gnani, A; Gozzini, A; Gugliotta, G; Iacobucci, I; Martinelli, G; Merante, S; Orlandi, E; Palandri, F; Paolini, S; Papayannidis, C; Poerio, A; Rosti, G; Soverini, S | 1 |
| Asenova, S; Ayuk, F; Bacher, U; Brummendorf, TH; Klyuchnikov, E; Kröger, N; Ocheni, S; Osanmaz, O; Schafhausen, P; Zabelina, T; Zander, AR | 1 |
| Chen, SJ; Chen, XQ; Chen, Z; Feng, TT; Hu, Z; Jiang, QL; Liu, DP; Liu, JL; Liu, P; Liu, XL; Liu, Y; Ma, LY; Meng, FY; Pan, XF; Wu, FQ; Zhou, GB | 1 |
| Amabile, M; Baccarani, M; Castagnetti, F; Gugliotta, G; Luatti, S; Martinelli, G; Palandri, F; Poerio, A; Rosti, G; Soverini, S | 1 |
| Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Müller, MC; Niederwieser, D; Pelz-Ackermann, O; Pfirrmann, M; Porkka, K | 1 |
| Burke, MJ; Desai, S; Kadota, R; Willert, J | 1 |
| Cortes, J; Fava, C | 1 |
| Hochhaus, A; Hughes, T | 2 |
| Atallah, E; O'Dwyer, M | 1 |
| Koluman, B; Yağci, M; Yegin, ZA | 1 |
| Bacher, U; Haferlach, C; Haferlach, T; Kern, W; Schnittger, S; Tschulik, C; Weiss, T | 1 |
| Deininger, MW; Laudadio, J; Mauro, MJ; Press, RD; Willis, SG | 1 |
| Dewar, AL; Fitter, S; Hughes, TP; Menicanin, D; To, LB; Vandyke, K; Zannettino, AC | 1 |
| Funke, V; Hamerschlak, N; Neto, BH; Perini, GF; Ruiz, J; Santos, FP | 1 |
| Akagun, T; Cobanoglu, U; Erkut, N; Omay, SB; Ovali, E; Sonmez, M; Topbas, M; Yilmaz, M | 1 |
| Gedde Dahl, T; Gruber, FX; Hjorth-Hansen, H; Hovland, R; Meyer, P; Vefring, HK; Wee, L | 1 |
| Chae, YS; Hwang, YJ; Kang, BW; Kim, JG; Kim, SN; Lee, SJ; Moon, JH; Sohn, SK | 1 |
| Barbieri, E; Corradi, V; Mancini, M; Martinelli, G; Petta, S; Santucci, MA | 1 |
| Druker, B; Gathmann, I; Guilhot, F; Larson, RA; O'Brien, SG; So, C; Waltzman, R | 1 |
| Alacacioglu, I; Bilgir, F; Bilgir, O; Binicier, O; Calan, M; Kebapcilar, L; Oner, P; Payzin, B; Sari, I | 1 |
| Beppu, L; Branford, S; Cortes, J; Erben, P; Gallagher, N; Gottardi, E; Haque, A; Hochhaus, A; Hughes, T; Kim, D; Kim, DW; Martinelli, G; Müller, MC; Radich, J; Saglio, G; Shou, Y; Soverini, S | 1 |
| Cortes, J; Kantarjian, H; Quintás-Cardama, A | 8 |
| Du, Q; Liu, X; Wang, L; Xu, L; Zhang, S; Zheng, W; Zhu, H | 1 |
| Atallah, E; Pearson, L; Vernon, MR | 1 |
| Calandra, G; Dillmann, F; Fruehauf, S; Laufs, S; Sperandio, M; Veldwijk, MR; Wenz, F; Zeller, J | 1 |
| Berendse, HW; Janssen, JJ; Merle, PA; Ossenkoppele, GJ; Schuurhuis, GJ | 1 |
| Brown, JL; Christians, U; Eckhardt, SG; Klawitter, J; Kominsky, DJ; Leibfritz, D; Melo, JV; Serkova, NJ | 1 |
| Cortes, J; Quintás-Cardama, A | 5 |
| Hackanson, B; Lübbert, M; Rückert, A | 1 |
| Emi, N; Handa, K; Hasegawa, A; Inaguma, Y; Maruyama, F; Mizuta, S; Okamoto, M; Tsuzuki, M; Watanabe, M; Yamamoto, Y | 1 |
| Alvares, LA; Azevedo, TC; Beltrão, AC; Bentes, AQ; Bentes, IR; Lemos, JA; Scerni, AC | 1 |
| Beumer, JH; Egorin, MJ; Pavlovsky, C; Pavlovsky, S; Rogel, S; Shah, DD | 1 |
| Melo, JV; Yong, AS | 1 |
| Abakumov, EM; Aseeva, EA; Chelysheva, EIu; Diachenko, LV; Diagileva, OA; Domracheva, EV; Goriacheva, SR; Gusarova, GA; Ivanova, TV; Khoroshko, ND; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Kulikov, SM; Naumova, IN; Semenova, EA; Stakhina, OV; Turkina, AG; Vakhrusheva, MV; Vinogradova, OIu; Vorontsova, AV; Zakharova, AV; Zakharova, ES | 1 |
| Abakumov, EM; Chelysheva, EIu; Domracheva, EV; Goriacheva, SR; Gusarova, GA; Khoroshko, ND; Kuznetsov, SV; Misiurin, AV; Sokolova, MA; Stakhina, OV; Turkina, AG; Vinogradova, OIu; Vorontsova, AV | 1 |
| Campiotti, L; Lo Curto, F; Mattarucchi, E; Pasquali, F; Porta, G; Rambaldi, A; Spinelli, O | 1 |
| Branford, S; Cross, NC; Erben, P; Ernst, T; Hanfstein, B; Hehlmann, R; Hochhaus, A; Müller, MC; Saglio, G; Schenk, T | 1 |
| Clark, RE; Davies, A; Giannoudis, A; Harris, RJ; Hatziieremia, S; Holyoake, TL; Jordanides, NE; Jørgensen, HG; Lucas, CM; Mountford, JC; Pirmohamed, M | 1 |
| Clark, RE; Davies, A; Giannoudis, A; Harris, RJ; Knight, K; Lucas, CM; Wang, L; Watmough, SJ | 1 |
| Kochupillai, V; Kumar, L; Mohanty, S; Sharma, P | 2 |
| Botta, M; Bruno, O; Radi, M; Schenone, S | 1 |
| Basciani, S; Buzzetti, R; Gambacorti-Passerini, C; Gnessi, L; Mariani, S; Sassone, M; Spera, G; Tornaghi, L | 1 |
| Ault, P; Cole, S; Cortés, JE; Kantarjian, H | 1 |
| Fujii, S | 1 |
| Agirre, X; Calasanz, MJ; Cordeu, L; Garate, L; Jiménez-Velasco, A; Martin, V; Prósper, F; Rodríguez-Otero, P; Román-Gómez, J; San José-Enériz, E; Vilas-Zornoza, A | 1 |
| Andreeff, M; Carter, BZ; Chen, W; Cortes, J; Kantarjian, HM; Konopleva, M; Mak, DH; Schober, WD | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garg, RJ; Kantarjian, H; O'Brien, S; Quintás-Cardama, A | 1 |
| Chia, YL; Mahon, FX; Molimard, M; Nedelman, J; Schran, H; Wang, Y | 1 |
| Schatz, DG; Strout, MP | 1 |
| Casellas, R; Duy, C; Feldhahn, N; Groffen, J; Heisterkamp, N; Henke, N; Hoffmann, TK; Hofmann, WK; Iacobucci, I; Jumaa, H; Kim, YM; Klemm, L; Kuchen, S; Li, Z; Lieber, MR; Martinelli, G; Müschen, M; von Levetzow, G | 1 |
| Al-Kali, A; Farooq, S; Tfayli, A | 1 |
| Chen, X; Du, W; He, Y; Hu, Y; Huang, S; Li, X; Liu, J; Xiao, H; Zheng, J | 1 |
| Awidi, A; Mefleh, R; Najib, N; Salem, II; Tarawneh, B | 1 |
| Atzeni, S; Caocci, G; Culurgioni, F; La Nasa, G; Littera, R; Marongiu, F; Orrù, N | 1 |
| Clarkson, B; Drummond, MW; Foo, J; Holyoake, T; Michor, F | 1 |
| Thompson, CB | 1 |
| Goh, HG; Kim, D; Kim, DW; Kim, SH; Kim, WS; Kweon, IY; Lee, J; Park, SH | 1 |
| Chen, F; Hou, M; Ji, C; Li, L; Ma, D; Sun, J; Yan, S; Zhang, M | 1 |
| O'Dwyer, ME | 2 |
| Jalkanen, S; Koskenvesa, P; Lundán, T; Mustjoki, S; Porkka, K; Rapakko, K; Rohon, P | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; Cortés, JE; de Lima, M; Fisher, T; Giralt, S; Hosing, C; Jabbour, E; Kantarjian, H; Kebriaei, P; Popat, U; Qazilbash, M; Rondon, G; Shpall, E | 1 |
| Cortés, JE; Jabbour, E; Kantarjian, H | 1 |
| Bauer, S; Romvari, E | 1 |
| Allen-Bard, S | 1 |
| O'Brien, S | 1 |
| Kantarjian, H; O'Brien, SM; Radich, J | 1 |
| Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; La Rosée, P | 1 |
| Atsuta, Y; Hamamoto, K; Hotta, N; Inoue, M; Ito, M; Kato, K; Kawa, K; Kawase, T; Koike, K; Kojima, S; Kurosawa, H; Morishima, Y; Muramatsu, H; Nagatoshi, Y; Shimada, H; Tanizawa, A; Tono, C; Watanabe, A; Yoshimi, A | 1 |
| Chan, YY; Kwan, TK; Lie, AK; Liu, HS; Ma, ES; Sim, JP; Wan, TS; Yeung, YM; Yip, SF | 1 |
| Bonovolias, ID; Tsiftsoglou, AS | 1 |
| Rumpold, H; Wolf, D | 1 |
| Goldstein, JL | 1 |
| Bayrak, A; Besisik, SK; Cefle, K; Diz-Kucukkaya, R; Nalcaci, M; Ozbek, U; Ozturk, S; Palanduz, S; Pekcelen, Y; Sargin, D; Sirma, S; Ucur, A; Vural, B; Yavuz, S; Yenerel, MN | 1 |
| Jin, Y; Lai, Y; Lu, Z; Pan, J; Qiu, L | 1 |
| Chen, Y; Li, D; Li, S | 1 |
| Bay, JO; Berger, MG; Chaleteix, C; Fleury, J; Gouas, L; Goumy, C; Ledoux-Pilon, A; Richard-Pebrel, C; Tchirkov, A; Tournilhac, O; Vago, P; Véronèse, L | 1 |
| Apperley, JF; Bua, M; de Lavallade, H; Drummond, MW; Foroni, L; Goldman, JM; Holyoake, TL; Khorashad, JS; Marin, D; Milojkovic, D; Nicholson, E; Paliompeis, C; Reid, A; Rezvani, K; Shepherd, P; Szydlo, R | 1 |
| Dvoráková, D; Jurcek, T; Klamová, H; Mayer, J; Moravcová, J; Poláková, KM; Polívková, V; Pospísil, Z; Rulcová, J; Zácková, D | 1 |
| Deininger, MW; Druker, BJ; Harrington, CA; Lange, T; Loriaux, MM; MacPartlin, M; McWeeney, SK; Melo, JV; O'Brien, SG; Pemberton, LC; Pillai, R; Snead, JL; Turpaz, Y; Vartanian, K; Willis, SG; Wilmot, B; Yochum, G | 1 |
| Bouchet, S; Castaigne, S; Devillier, P; Maneglier, B; Molimard, M; Raggueneau, V; Rigaudeau, S; Roth, O; Rousselot, P; Spreux-Varoquaux, O; Therond, P | 1 |
| Amabile, M; Baccarani, M; Bertolini, F; Bianchi, E; Castagnetti, F; Ferrari, S; Fogli, M; Lemoli, RM; Manfredini, R; Marighetti, P; Martin-Padura, I; Martinelli, G; Rabascio, C; Rossi, L; Salati, S; Salvestrini, V; Tafuri, A; Testoni, N; Zini, R | 1 |
| Ozawa, K | 1 |
| Mitani, K; Sasaki, K | 1 |
| Ishizawa, J; Saya, H | 1 |
| Din, BH; Li, YF; Liu, DS; Liu, X; Zhu, JB | 1 |
| Donato, NJ; Fang, D; Giannola, D; Peterson, LF; Sun, H; Talpaz, M | 1 |
| Jung, CW; Kamel-Reid, S; Kim, DH; Kim, S; Lipton, JH; Liu, X; Xu, W | 1 |
| Hamerschlak, N; Kerbauy, FR; Mac-Donald Bley do Nascimento, C; Mauro Kutner, J; Ribeiro, AA; Rodrigues, M; Santos, FP | 1 |
| Apperley, JF; Bertucci, F; Birnbaum, D; Carbuccia, N; Charbonnier, A; de Lavallade, H; Finetti, P; Foroni, L; Khorashad, JS; Mozziconacci, MJ; Vey, N | 1 |
| Branford, S; Hughes, TP; Melo, JV | 1 |
| Chapuy, B; Haase, D; Inagaki, N; Koch, R; Panse, M; Radunski, U; Truemper, L; Wenzel, D; Wulf, GG | 1 |
| Albers, C; Breitenbuecher, F; Brümmendorf, TH; Duyster, J; Fischer, T; Heidel, F; Huber, C; Lipka, D; Markova, B; Melo, JV | 1 |
| Cooper, S; Giles, FJ; Savona, MR | 1 |
| Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Pane, F; Radich, J; Saglio, G; Silver, RT; Simonsson, B | 1 |
| Chang, W; Hu, Z; Huang, M; Ou, D; Zhang, Y; Zhou, J | 1 |
| Dewar, AL; Fitter, S; Hughes, TP; Vandyke, K; Zannettino, AC | 1 |
| Clackson, T; Commodore, L; Dalgarno, DC; Huang, WS; Sawyer, TK; Shakespeare, WC; Wang, Y; Zhou, T; Zhu, X | 1 |
| Arana, M; Beaulieu, N; Bollu, V; Coombs, J; Cortes, J; Feng, W; Guo, A; Johnson, S; Wu, EQ | 1 |
| Negri, T; Perrone, F; Pierotti, MA; Pilotti, S; Pricl, S; Tamborini, E | 1 |
| Matsunaga, T | 1 |
| Chang, S; Dong, JH; Jing, YK; Wang, J; Yin, SL | 1 |
| Auberger, P; Cassuto, JP; Colosetti, P; Puissant, A; Raynaud, S; Robert, G | 1 |
| Balasubramanian, P; Chandy, M; Chendamarai, E; George, B; Markose, P; Mathews, V; Srivastava, A; Srivastava, VM; Velayudhan, SR; Viswabandya, A | 1 |
| Murphy, G; Verma, SM | 1 |
| Apperley, J | 2 |
| Aulitzky, WE; Gutekunst, M; Markwardt, C; Oren, M; Skorta, I; van der Kuip, H | 1 |
| Abu-Amero, KK; Al Mohareb, F; Chaudhri, NA; Khalil, SH | 1 |
| Hu, N; Liu, HW; Meng, WT; Zheng, CX; Zhu, HL | 1 |
| Hu, N; Liu, HW; Liu, T; Meng, WT; Zeng, CX; Zhu, HL | 1 |
| Antoniades, M; Lemesiou, E; Melanthiou, F; Michael, M; Papaminas, N | 1 |
| Hehlmann, R | 3 |
| Cilloni, D; Saglio, G | 2 |
| Goldman, JM | 4 |
| Guilhot, F; Guilhot, J; Roy, L; Saulnier, PJ | 1 |
| Cervantes, F; Hernández-Boluda, JC | 2 |
| Berman, E; Fleisher, M; Gordon, JK; Magid, SK; Maki, RG | 1 |
| Chang, MS; Haferlach, C; Haferlach, T; Hofmann, WK; Kang, S; Kato, M; Kawamata, N; Kim, HS; Koeffler, HP; Kohlmann, A; Meixel, A; Mossner, M; Müschen, M; Nowak, D; Nowak, V; Ogawa, S; Paquette, R; Thoenissen, NH; Thoennissen, NH; Weiss, T | 1 |
| Arnold, R; Beelen, DW; Bunjes, D; Dengler, R; Falge, C; Gratwohl, A; Haferlach, C; Hasford, J; Hehlmann, R; Ho, AD; Hochhaus, A; Holler, E; Kanz, L; Kolb, HJ; Lauseker, M; Leitner, A; Müller, MC; Pfirrmann, M; Pletsch, N; Saussele, S; Schlegelberger, B; Schlimok, G; Schnittger, S; Schwerdtfeger, R; Zander, AR | 1 |
| Ali, R; Budak, F; Karkucak, M; Korkmaz, S; Nazlioglu, HO; Ozcelik, T; Ozkalemkas, F; Ozkocaman, V; Pekgoz, M; Tunali, A; Yakut, T | 1 |
| Lewis, DM | 1 |
| Gordon, RA; Irshad, FA | 1 |
| Cortés, JE | 1 |
| Cortés, JE; Fava, C; Jabbour, E; Kantarjian, H | 1 |
| Dingli, D; Lenaerts, T; Pacheco, JM; Traulsen, A | 1 |
| Bhatia, R; Chen, W; Gao, C; Huang, Q; Wang, Z; Yee, JK; Yuan, H | 1 |
| Bixby, D; Talpaz, M | 2 |
| Branford, S; Hughes, TP | 3 |
| Foryciarz, K; Gniot, M; Hellmann, A; Kobelski, M; Komarnicki, M; Lewandowska, M; Lewandowski, K; Majewski, M; Nowak, G; Prejzner, W; Sacha, T; Scibiorski, C; Siemiatkowski, M; Skotnicki, A; Solarska, I; Warzocha, K; Wasag, B | 1 |
| Gałazka, K; Majewski, M; Rodzaj, M; Zduńczyk, A | 1 |
| Li, S; Peng, C | 1 |
| Barbieri, E; Mancini, M; Martinelli, G; Petta, S; Santucci, MA | 1 |
| Bommer, C; Daniel, P; Dörken, B; Kim, TD; Koca, G; le Coutre, P; Nogai, H; Schwarz, M; Türkmen, S | 1 |
| Beverloo, HB; Cornelissen, JJ; Daenen, SM; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, PJ; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Wijermans, PW; Willemze, R; Wittebol, S | 1 |
| Ravandi, F; Santos, FP | 1 |
| Alimena, G; Breccia, M; Cannella, L; Loglisci, G; Muscaritoli, M; Santopietro, M | 1 |
| Hsiao, HH; Lee, CP; Lin, SF; Liu, YC; Tsai, HJ | 1 |
| Kalesh, KA; Liu, K; Yao, SQ | 1 |
| Hong, FS; Mitchell, CA; Zantomio, D | 1 |
| Baba, N; Fujio, K; Kimura, S; Kohno, M; Kosugi, M; Ozaki, K; Sakamoto, T; Tanimura, S | 1 |
| Azam, M; Clackson, T; Daley, GQ; Dalgarno, D; Einhorn, W; Huang, WS; Powers, JT; Sawyer, TK; Shakespeare, WC; Zhu, X | 1 |
| Ahn, KS; Kim, BK; Kim, KI; Oh, JM; Park, J; Shin, WG; Won, NH; Yoon, SS | 1 |
| Attar, EC; DeAngelo, DJ | 1 |
| Albajar, M; Blanco, R; Caraballo, JM; Delgado, MD; Ferrandiz, N; Gomez-Casares, MT; Leon, J; Lopez-Jorge, CE | 1 |
| Bee, PC; Gan, GG; Latiff, NA; Menaka, N; Nadarajan, VS | 1 |
| Biedrzycki, B; Chia, C; Garrett-Mayer, E; Gocke, C; Harding, TC; Hege, K; Jones, R; Kasamon, YL; Kowalski, J; Levitsky, HI; Miller, CB; Murphy, K; Qin, L; Smith, BD; Tsai, HL; Tu, GH | 1 |
| Gotlib, J; Pardanani, A; Tefferi, A | 1 |
| Gréen, H; Lotfi, K; Mirghani, RA; Rommel, F; Skoglund, K | 1 |
| Digumarti, R; Gundeti, S; Jacob, RT; Mallavarapu, KM; Rajappa, S; Roshnipaul, T | 1 |
| Thachil, J | 1 |
| Hughes, T; Osborn, M | 1 |
| Clark, RE; Giannoudis, A; Harris, RJ; Knight, K; Lucas, CM; Watmough, SJ | 1 |
| Hochhaus, A; La Rosée, P | 3 |
| Adrián, FJ; Azam, M; Bursulaya, B; Choi, Y; Cowan-Jacob, SW; Daley, GQ; Deng, X; Dierks, C; Ding, Q; Engen, JR; Fendrich, G; Gray, NS; Grzesiek, S; Guo, GR; Iacob, RE; Jahnke, W; Li, AG; Liu, G; Liu, Y; Manley, PW; Okram, B; Powers, J; Sim, T; Strauss, A; Sun, F; Tuntland, T; Vajpai, N; Warmuth, M; Wojciechowski, A; Zhang, J | 1 |
| Waller, CF | 1 |
| Engel, JM; Onitilo, AA | 1 |
| Alacacioglu, I; Bilgir, F; Bilgir, O; Karaca, B; Kebapcilar, L; Oner, P; Sarì, I | 1 |
| Egorin, MJ; Mauro, MJ; Trent, JC | 1 |
| Auberger, P; Cassuto, JP; Fenouille, N; Luciano, F; Puissant, A; Raynaud, S; Robert, G | 1 |
| Hasegawa, M; Ishikawa, O; Kuraishi, N; Nagai, Y | 1 |
| Aizawa, Y; Furukawa, T; Fuse, I; Kaji, M; Masuko, M; Nakamura, T; Narita, M; Saitoh, A; Takahashi, M; Toba, K; Tochiki, N; Watanabe, N; Yamahira, A | 1 |
| Campione, E; Chimenti, S; Di Marcantonio, D; Diluvio, L; Francesconi, A; Orlandi, A; Paternò, EJ; Terrinoni, A | 1 |
| Craddock, C; Farndon, P; Griffiths, M; Li-Wan-Po, A | 1 |
| DU, QF; Liu, XL; Meng, FY; Zhang, S | 1 |
| Aleem, A | 1 |
| Cortes, J; Hochhaus, A; Kantarjian, HM; La Rosée, P | 1 |
| Redner, RL | 1 |
| Liu, X; Lu, X; Song, X; Wang, J; Wang, L; Ye, Y; Ying, B; Zhang, L; Zhou, Y | 1 |
| Basu, S; Biswas, G; Das, T | 1 |
| Hirao, A; Hoshii, T; Kondo, Y; Motoyama, N; Muraguchi, T; Naka, K; Nakao, S; Ooshio, T; Tadokoro, Y | 1 |
| Ruiz-Argüelles, GJ | 2 |
| Miao, HW; Ni, J; Wang, L; Wu, LL; Xia, RX; Yang, MZ; Zeng, QS | 1 |
| Qian, LS; Qiu, LG; Wang, GR; Wang, JX; Wang, Y; Wang, YY; Yi, SH; Yu, Z; Zhao, YZ; Zhou, KS | 1 |
| Chen, FY; Chen, XQ; Guo, T; Hou, M; Hu, JD; Hu, Y; Huang, HH; Huang, XJ; Ji, CY; Jiang, B; Jiao, L; Li, Y; Liu, T; Liu, TB; Lü, XY; Meng, FY; Qiu, LG; Ren, HY; Song, XM; Sun, AN; Wang, JM; Wang, JX; Wang, SJ; Wu, DP; Xu, D; Yu, L; Zhu, HL | 1 |
| Deng, D; Lai, Y; Li, Q; Liang, Y; Liu, R; Luo, J; Ma, J; Peng, Z; Schwarzenberger, P; Shi, L; Yang, J; Zhou, J; Zhou, Y | 1 |
| Ashihara, E; Fujiyama, Y; Imoto, M; Kawatani, M; Kimura, S; Kuroda, J; Maekawa, T; Nagao, R; Nakahata, T; Osada, H; Takeuchi, M; Tanaka, R; Tsuruo, T; Umezawa, K; Yasui, E; Yokota, A | 1 |
| Bostel, T; Burchert, A; Erben, P; Hehlmann, R; Hochhaus, A; Kostrewa, P; Liebler, S; Müller, MC; Neubauer, A | 1 |
| Grünebach, F; Hilpert, J; Krusch, M; Placke, T; Salih, HR; Salih, J; Steinle, A | 1 |
| Cerny-Reiterer, S; Ferenc, V; Gleixner, KV; Gruze, A; Hadzijusufovic, E; Mayerhofer, M; Meyer, RA; Peter, B; Pickl, WF; Sillaber, C; Valent, P | 1 |
| Range, U; Schlegelberger, B; Suttorp, M; Tauer, JT; Thiede, C; von Neuhoff, N | 1 |
| Bogdanovic, A; Dyagil, I; Fong, D; Gastl, G; Gercheva, L; Goranov, S; Griniute, R; Griskevicius, L; Kwakkelstein, M; Lejniece, S; Lion, T; Masliak, Z; Oucheva, R; Petzer, AL; Peytchev, D; Rancati, F; Stojanovic, A; Tzvetkov, N; Ulmer, H; Wolf, D | 1 |
| Wodarz, D | 3 |
| Engler, JR; Frede, A; Hughes, TP; Saunders, VA; White, DL; Zannettino, AC | 1 |
| Eadie, L; Hughes, TP; White, DL | 1 |
| Baratè, C; Buda, G; Cannizzo, E; Carulli, G; Cervetti, G; Galimberti, S; Marini, A; Ottaviano, V; Petrini, M | 1 |
| Cui, J; Jin, Y; Li, S; Lin, Y; Lu, Z; Pan, J; Pang, J; Shi, X; Xu, F | 1 |
| Cahill, MR; Crampe, M; Haslam, K; Kelly, J; Langabeer, SE | 1 |
| Li, QF; Liu, XY; Ma, XN; Wang, H; Wang, LS; Wu, CT; Xiao, FJ; Yan, J; Yang, YF; Zhang, QW | 1 |
| Dingli, D; Pacheco, JM; Traulsen, A | 1 |
| Caccamo, N; D'Asaro, M; Di Liberto, D; Di Raimondo, F; Dieli, F; Fourniè, JJ; Guggino, G; La Mendola, C; Meraviglia, S; Messina, A; Orlando, V; Salerno, A; Spina, M; Stassi, G; Todaro, M; Vigneri, P | 1 |
| Apperley, J; Bonnet, D; Dazzi, F; Gomes, AR; Ho, KK; Lam, EW; Lymperi, S; Marin, D; Tisato, V; Vianello, F; Villanova, F | 1 |
| Ahn, JS; Chung, J; Hyun, MS; Joo, YD; Jung, CW; Kim, BK; Kim, CS; Kim, DY; Kim, HJ; Kim, I; Kim, MK; Kim, SH; Kim, SJ; Koh, Y; Lee, JH; Lee, KH; Park, E; Park, S; Shin, HJ; Sohn, SK; Song, HS; Yoon, SS | 1 |
| Akiyama, H; Fukuda, S; Kobayashi, T; Nagata, Y; Ohashi, K; Sakamaki, H; Yamashita, T | 1 |
| Jamal, Y; Usmani, SZ; Yunus, SA | 1 |
| Dilea, C; Laneuville, P; Manley, PW; Mestan, J; Woodman, RC; Yin, OQ | 1 |
| Chen, Y; Hu, J; Li, JM; Shen, ZX; Wang, AH; Wang, L; Wang, YY; Xu, ZZ; Yao, Y; Zhang, L; Zhou, L | 1 |
| Li, JY; Miao, KR; Ni, LN; Qian, SX; Qiao, C; Qiu, HR; Zhang, SJ | 1 |
| Bright, SA; Campiani, G; Deininger, MW; Lawler, M; Williams, DC; Zisterer, DM | 1 |
| Duyster, J; von Bubnoff, N | 1 |
| Condorelli, F; Genazzani, AA | 1 |
| Bui, TV; Carroll, M; Gruber, JJ; Lum, JJ; Mancuso, A; Melo, JV; Perl, AE; Sanchez, PV; Sayed, N; Swider, CR; Thompson, CB; Tong, X; Tuttle, SW; Zhao, F | 1 |
| Al-Seraihy, A; Al-Shehri, A; Belgaumi, AF; Owaidah, TM | 1 |
| Blomen, VA; Brummelkamp, TR; Camargo, FD; Carette, JE; Gokhale, S; Jaenisch, R; Pruszak, J; Varadarajan, M; Wernig, M | 1 |
| Kashimura, M; Ohyashiki, K | 1 |
| Cobaleda, C; Flores, T; González-Herrero, I; Jiménez, R; Orfao, A; Sánchez-García, I; Vicente-Dueñas, C | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Martinelli, G; Palandri, F; Rosti, G | 1 |
| Hu, J; Li, JM; Shen, ZX; Wang, AH; Wang, L; You, JH; Zhou, L | 1 |
| Karsono, B; Mulansari, NA; Prayogo, N; Rajabto, W; Reksodiputro, AH; Rinaldi, I; Syafei, S | 1 |
| Agirre, X; Albero, MP; Andreu, EJ; Franch, L; Ivorra, C; Pérez-Roger, I; Poch, E; Prosper, F; Vaquer, JM; Villanueva, JJ | 1 |
| Alimena, G; Breccia, M; Cannella, L; Del Fabro, V; Di Raimondo, F; Latagliata, R; Stagno, F; Vigneri, P | 1 |
| Baran, Y; Bassoy, EY; Oztekin, C | 1 |
| Baxendale, IR; Hopkin, MD; Ley, SV | 1 |
| Cortes, J; Hochhaus, A; Kantarjian, H; Kimura, S; le Coutre, P; Nagler, A; Ottmann, O; Pinilla-Ibarz, J | 1 |
| Antolino, A; Consoli, C; Consoli, ML; Cupri, A; Del Fabro, V; Di Raimondo, F; Massimino, M; Stagno, F; Stella, S; Tambè, L; Vigneri, P | 1 |
| Ananthakrishnan, AN; Atallah, E; Bell, K; Bilgi, N | 1 |
| Aprile, L; Bocchia, M; Chitarrelli, I; Defina, M; Gozzetti, A; Ippoliti, M; Lauria, F; Rondoni, M | 1 |
| Morioka, M; Saito, M | 1 |
| Alimena, G; Bocchia, M; Breccia, M; Cannella, L; Defina, M; Ippoliti, M; Lauria, F; Loglisci, G; Santopietro, M | 1 |
| Gondo, H; Ide, M; Kimura, S; Kuwahara, N; Matsuishi, E | 1 |
| Chen, R; Li, D; Mu, S; Xiao, W | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carmosino, I; Loglisci, G; Santopietro, M; Stagno, F | 1 |
| Ahmad, R; Singh, R; Singh, RK; Singh, S; Tripathi, AK; Tripathi, P | 1 |
| Kata, D; Kyrcz-Krzemień, S; Mrówka-Kata, K; Najda, J; Pajak, J; Seweryn, M | 1 |
| Golub, T | 1 |
| Arslan, M; Erkut, M; Erkut, N; Ersoz, S; Sonmez, M | 1 |
| Druker, B | 2 |
| Auberger, P; Cassuto, JP; Dufies, M; Puissant, A; Raynaud, S | 1 |
| Chen, S; Li, Y; Wang, L; Yang, L; Zha, X; Zhu, K | 1 |
| Apperley, JF; Bazeos, A; Bua, M; de Lavallade, H; Desai, R; Eliasson, L; Foroni, L; Goldman, J; Guallar, C; Khorashad, JS; Kozlowski, K; Latham, V; Mahon, FX; Marin, D; Milojkovic, D; Molimard, M; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Kochkareva, IuB; Kostina, IE; Stakhina, OV; Turkina, AG | 1 |
| Barbieri, E; Iacobucci, I; Mancini, M; Petta, S; Salvestrini, V; Santucci, MA | 1 |
| Cingolani, R; Coluccia, AM; de Luca, E; Di Renzo, N; Gambacorti-Passerini, C; Gigli, G; Leporatti, S; Maffia, M; Palamà, IE; Rinaldi, R | 1 |
| Borojevic, R; Costa, ES; Dutra, FF; Freitas, MS; Guerra, MC; Maia, SF; Oliveira, GA; Otazu, IB; Silva, JL; Tabernero, MD | 1 |
| Deininger, M | 3 |
| Chen, R; Huang, S; Li, G; Liang, Y; Liu, L; Liu, Q; Wu, Y; Yin, D | 1 |
| Ketterling, RP; Knudson, RA; Lasho, TL; Levitt, R; Tefferi, A | 1 |
| Akbulak, R; Atanackovic, D; Bartels, BM; Bartels, K; Bokemeyer, C; Brümmendorf, TH; Cao, Y; Gontarewicz, A; Gordic, M; Hildebrandt, Y; Kobold, S; Kröger, N; Lajmi, N; Luetkens, T; Meyer, S; Schafhausen, P; Stasche, T; Uhlich, F | 1 |
| Al-Ahmari, A; Al-Mahr, M; Al-Seraihy, A; Al-Shehri, A; Ayas, M; Belgaumi, AF; El-Solh, H | 1 |
| Ekblom, M; Juvonen, V; Kairisto, V; Kreutzman, A; Mustjoki, S; Porkka, K; Seggewiss, R; Stenke, L | 1 |
| Kami, M; Kodama, Y | 1 |
| Catanzano, F; Colavita, I; Esposito, N; Martinelli, R; Melo, JV; Pane, F; Ruoppolo, M; Salvatore, F | 1 |
| Arai, A; Kurosu, T; Miura, O; Murakami, N; Oshikawa, G | 1 |
| Goozner, M | 1 |
| Schiffer, CA; Zonder, JA | 2 |
| Oehler, VG; Radich, JP | 2 |
| Antin, JH; Cutler, C | 1 |
| Ohno, R | 3 |
| Skorski, T | 1 |
| Alvarado, Y; Cortes, J; Giles, FJ; Swords, R | 1 |
| Agrawal, M; Cortes, J; Garg, RJ; Quintás-Cardama, A | 1 |
| Helgason, GV; Holyoake, TL; Young, GA | 1 |
| Cilloni, D; Fava, M; Gottardi, E; Saglio, G; Ulisciani, S | 1 |
| Buresova, L; Cetkovsky, P; Faber, E; Klamova, H; Mayer, J; Racil, Z; Razga, F; Voglova, J; Zackova, D | 1 |
| Abe, D; Fujisawa, S; Hoshino, T; Kanamori, H; Kanda, Y; Maruta, A; Nakaseko, C; Nakasone, H; Okamoto, S; Sakura, T; Takahashi, S; Takasaki, H; Usuki, K; Yano, S; Yokota, A | 1 |
| Brezinova, J; Cetkovsky, P; Cmunt, E; Dvorakova, D; Faber, E; Indrak, K; Jarosova, M; Klamova, H; Machova-Polakova, K; Markova, M; Mayer, J; Michalova, K; Moravcova, J; Novakova, L; Oltova, A; Voglova, J; Zackova, D | 1 |
| Chun, JM; Hwang, YJ; Jin, R; Kim, JY; Kim, SG; Won, DI | 1 |
| Dastugue, N; Eclache, V; Etienne, G; Fort, MP; Gachard, N; Gervais, C; Girault, S; Huguet, F; Laibe, S; Legros, L; Lippert, E; Mahon, FX; Mozziconacci, MJ; Tigaud, I | 1 |
| Adam, T; Divoká, M; Faber, E; Friedecký, D; Indrák, K; Jarosová, M; Katrincsáková, B; Micová, K; Rozmanová, S | 1 |
| Ahn, KS; Kim, BK; Kim, KI; Koh, Y; Lee, DS; Oh, JM; Park, J; Won, NH; Yoon, SS | 1 |
| Boschelli, F; Gambacorti-Passerini, C; Perini, P; Pirola, A; Redaelli, S; Viltadi, M | 1 |
| Apperley, JF; Bazeos, A; de Lavallade, H; Foroni, L; Garland, P; Gerrard, G; Goldman, JM; Khorashad, JS; Marin, D; May, PC; Milojkovic, D; Reid, AG; Rezvani, K | 1 |
| Botta, M; Crespan, E; Maga, G; Radi, M; Schenone, S; Zanoli, S | 1 |
| Klein, S; Levitzki, A | 2 |
| Eapen, M | 1 |
| Pene-Dumitrescu, T; Smithgall, TE | 1 |
| Coetzee, MJ; Gartrell, K; Louw, VJ; Viljoen, CD | 1 |
| Bonnet, ML; Chomel, JC; Flamant, S; Guilhot, F; Guilhot, J; Holst, J; Rasko, JE; Ritchie, W; Turhan, AG | 1 |
| Apperley, JF; Cross, NC; Melo, JV; Score, J; Sobrinho-Simões, M; Wilczek, V | 1 |
| Fitter, S; Hughes, TP; Schultz, CG; Vandyke, K; White, D; Zannettino, AC | 1 |
| Azzena, A; Baccarani, M; Baldazzi, C; Castagnetti, F; Cavazzini, F; Cianciulli, AM; Cipriani, R; Dalsass, A; Donti, E; Gamberini, C; Giannini, B; Giugliano, E; Gozzetti, A; Grimoldi, MG; Luatti, S; Marzocchi, G; Ronconi, S; Rosti, G; Santoro, A; Spedicato, F; Stacchini, M; Testoni, N; Tonelli, M; Valenti, AM; Zaccaria, A; Zanatta, L | 1 |
| Donti, E; Falchi, L; Fava, C; Giugliano, E; Gubbiotti, M; Liberati, AM; Luzi, D; Rege-Cambrin, G; Schippa, M | 1 |
| Bhatia, R; Chu, S; Ho, Y; Holyoake, T; Huettner, CS; Li, M; Shiang, KD; Shultz, L; Snyder, DS; Strauss, AC; Zhang, B | 1 |
| Alcalá, M; Barrios, M; Heiniger, AI; Jiménez-Velasco, A | 1 |
| Cao, Q; Chen, C; Jin, Y; Li, J; Lu, Z; Pan, J | 1 |
| Barr, RD | 1 |
| Bartley, PA; Branford, S; Budgen, B; Hughes, TP; Latham, S; Martin-Harris, MH; Morley, AA; Ross, DM; Wilczek, V | 1 |
| Fang, B; Han, Q; Li, N; Song, Y; Zhao, RC | 1 |
| Borthakur, G; Cortes, J; Estrov, Z; Garcia-Manero, G; Kantarjian, H; Koller, C; O'Brien, S; Shan, J; Verma, D | 1 |
| Albano, F; Anelli, L; Casieri, P; Coccaro, N; Liso, V; Rocchi, M; Rossi, AR; Specchia, G; Vicari, L; Zagaria, A | 1 |
| Saglio, G | 1 |
| Baccarani, M; Saglio, G | 1 |
| Bumm, T; Dao, KH; Deininger, MW; Druker, BJ; Hantschel, O; Kaupe, I; Lange, T; Press, RD; Sherbenou, DW; Superti-Furga, G; Turaga, LP; Willis, S | 1 |
| Friedhuber, A; Grigg, A; Ng, AP; Servadei, P; Tuckfield, A | 1 |
| Focosi, D; Kast, RE | 1 |
| Etienne, G; Milpied, B; Nicolini, FE; Réa, D; Rigal-Huguet, F; Tulliez, M | 1 |
| Dosne Pasqualini, C | 1 |
| Deininger, MW; Traer, E | 1 |
| Cortés, JE; Fullmer, A; Jabbour, E; Kantarjian, H | 1 |
| Kim, PS; Lee, PP; Levy, D; Paquin, D | 1 |
| Jamieson, CH; Rice, KN | 1 |
| An, X; Ashby, CR; Chen, ZS; Ding, PR; Sun, Y; Tiwari, AK | 1 |
| Berghoff, AT; English, JC | 1 |
| Bittencourt, H; Castro, LC; Clementino, NC; Freitas, IF; Macedo, AV; Mendes, CU; Oliveira, FB; Rego, EM; Resende, C; Vieira, AK | 1 |
| Goto, H; Hara, Y; Kamura, Y; Mugishima, H; Oikawa, A; Shichino, H | 1 |
| Ashihara, E; Kimura, S; Lyons, JF; Maekawa, T; Nagao, R; Ottmann, OG; Reule, M; Smyth, T; Squires, MS; Takeuchi, M; Tanaka, R; Thompson, NT; Yamauchi, T; Yao, H; Yokota, A | 1 |
| Baccarani, M; Dreyling, M | 1 |
| Kimura, F; Kobayashi, A; Kobayashi, S; Nakamura, Y; Osawa, Y; Sato, K | 1 |
| Breeden, M; Cortes, J; Galbincea, J; Jabbour, E; Jones, D; Luthra, R; Reddy, N; Yin, CC | 1 |
| Hamada, Y; Ito, I; Ito, Y; Maruyama, S; Masuda, T; Matsuo, S; Mizuno, M; Ozaki, T; Sato, W; Tatematsu, M; Yasuda, Y; Yuzawa, Y | 1 |
| Borthakur, G; Champlin, R; Cortes, J; De Lima, M; Giralt, S; Jones, D; Kantarjian, HM; Rondon, G; Velev, N | 1 |
| Bradley-Garelik, MB; Cortes, J; Dombret, H; Erben, P; Goh, YT; Hochhaus, A; Maloisel, F; Masszi, T; Paquette, R; Pasquini, R; Saglio, G; Zhu, C | 1 |
| Press, RD | 2 |
| Duyster, J; Goldschmidt, N; Koren-Michowitz, M; le Coutre, P; Nagler, A; Panayiotidis, P; Prejzner, W; Rowe, JM; Scheid, C; Schwarz, M | 1 |
| Brinkman, RR; Eaves, A; Eaves, C; Forrest, D; Guilhot, J; Holyoake, T; Jiang, X; Jorgensen, H; Lambie, K; Lehn, P; Nicolini, F; Pang, E; Ringrose, A; Saw, KM; Smith, C; Turhan, A; Vukovic, R; Yip, C; Yu, M | 1 |
| Buresova, L; Cetkovsky, P; Dvorakova, D; Jurcek, T; Mayer, J; Racil, Z; Razga, F; Timilsina, S; Zackova, D | 1 |
| Graves, LM; Lawrence, DS; Martin, TD; Toutchkine, A; Wang, Q; Zimmerman, EI | 1 |
| Kilara, N; Manjunath, R; Mysorekar, V; Subramanian, M | 1 |
| Bernheim, A | 1 |
| Boehm, A; Dieckmann, K; Fischer, G; Greinix, HT; Haas, OA; Hinterberger, W; Kalhs, P; Lechner, K; Mitterbauer, G; Mitterbauer, M; Pernicka, E; Rabitsch, W; Rosenmayr, A; Schwarzinger, I; Sperr, WR; Valent, P; Walcherberger, B; Wöhrer, S; Worel, N | 1 |
| Chabane, K; Charbonnier, A; Guerci, A; Hayette, S; Legros, L; Magaud, JP; Maloisel, F; Michallet, M; Nicolini, FE; Paillet, C; Pivot, C; Prébet, T; Rigal-Huguet, F; Rousselot, P; Tulliez, M | 1 |
| Baldini, L; F, FG; Ferrario, A; Goldaniga, M; Olivero, B; Radaelli, F; Rossi, F | 1 |
| Alpermann, T; Bacher, U; Dicker, F; Haferlach, C; Haferlach, T; Kern, W; Schnittger, S | 1 |
| Alvarez-Calderon, F; Degregori, J; Druker, BJ; Eide, CA; Gregory, MA; Neviani, P; O'Hare, T; Perrotti, D; Phang, TL; Williams, RT; Zaberezhnyy, V | 1 |
| Novelli, EM; Redner, RL | 1 |
| Bardsley, WG; Barrera, I; Burguillo, FJ; Martin, J | 1 |
| Chatelut, E; Dehours, E; Fourcade, O; Huguet, F; Recher, C; Riu, B; Valle, B | 1 |
| Hosen, N; Kawakami, M; Kawase, I; Morita, S; Murao, A; Nakajima, H; Narita, M; Nishida, S; Oji, Y; Oka, Y; Sakamoto, J; Shirakata, T; Sugiyama, H; Takahashi, K; Takahashi, M; Tanaka, T; Tsuboi, A | 1 |
| Engler, JR; Frede, A; Hughes, TP; Saunders, V; White, DL; Zannettino, A | 1 |
| Aïnseba, B; Benosman, C | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Chen, C; Chen, ZC; Li, QB; Wang, HX; Wu, YL; You, Y; Zou, P | 1 |
| Anthony, N; Shanks, J; Terebelo, H | 1 |
| Bashir, Q; Champlin, RE; Cortes, JE; De Lima, MJ; Garcia-Manero, G; Giralt, SA; Hosing, C; Jones, D; Kantarjian, H; McMannis, JD; O'Brien, SM; Qazilbash, M; Shpall, E; Wei, W | 1 |
| Mustjoki, S; Porkka, K; Rohon, P | 1 |
| Ayala-Sanchez, M; Bendit, I; Best-Aguilera, C; Cortes, J; De Souza, C; Enrico, A; Hamerschlak, N; Meillon, L; Pagnano, K; Pasquini, R | 1 |
| Harlan, LC; Hromas, RA; Libby, EN; Nelson, HE; Stevens, JL; Wiggins, CL; Willman, CL | 1 |
| Asaka, M; Darmanin, S; Kondo, T; Mizutani, T; Ohba, Y; Tanaka, S; Tobiume, M; Tsuda, M | 1 |
| Chabane, K; Cony-Makhoul, P; Hayette, S; Magaud, JP; Maguer-Satta, V; Michallat, E; Michallet, M; Nicolini, FE; Salesse, S | 1 |
| Branford, S; Druker, BJ; Foroni, L; Goldman, JM; Guilhot, F; Hochhaus, A; Hughes, TP; Kaeda, JS; Larson, RA; Modur, V; Mone, M; Müller, MC; O'Brien, SG; Radich, JP; Rudoltz, MS; Wehrle, E | 1 |
| Hibbard, M; Rowe, L; Salama, M; Shetty, S; Toydemir, R | 1 |
| Joseph, A; Kingham, BF; Martin, SE; Sausen, M | 1 |
| Kubota, Y; Waki, M | 1 |
| Corm, S; Dauphin, V; Etienne, G; Figeac, M; Grardel, N; Guilhot, F; Idziorek, T; Joha, S; Laï, JL; Leprêtre, F; Lippert, E; Maguer-Satta, V; Nibourel, O; Nicolini, FE; Preudhomme, C; Quesnel, B; Roche-Lestienne, C; Roumier, C | 1 |
| Smith, BD; Stein, B | 1 |
| Arafat, E; Awidi, A; Ayed, AO; Bishtawi, M; Bsoul, N; Dweiri, M; Magablah, A; Marie, L; Mefleh, R; Ramahi, M | 1 |
| Chen, H; Chen, YH; Han, W; Huang, XJ; Liu, DH; Liu, KY; Liu, YR; Wang, Y; Xu, LP | 1 |
| Barbosa, MM; Bittencourt, HN; Boersma, E; Clementino, NC; Geleijnse, ML; Marcolino, MS; Nunes, Mdo C; Ribeiro, AL; Silva, MH | 1 |
| Imai, T; Machida, T; Shima, Y; Uemura, Y | 1 |
| Chen, S; Huang, X; Jiang, B; Jiang, H; Jiang, Q; Lai, Y; Li, J; Li, L; Liu, Y; Qin, Y | 1 |
| Beaufils, N; Bennour, A; Gabert, J; Meddeb, B; Saad, A; Sennana, H | 1 |
| Fu, L; Lou, L; Luo, H; Quan, H; Xie, C; Xu, Y | 1 |
| Apperley, J; Babb, A; Bua, M; Foroni, L; Goldman, J; Ibrahim, A; Kuwabara, A; Marin, D; Milojkovic, D; Reid, A; Rezvani, K | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carmosino, I; De Cuia, R; Diverio, D; Frustaci, A; Latagliata, R; Loglisci, G; Mancini, M; Santopietro, M; Stefanizzi, C; Volpicelli, P; Vozella, F | 1 |
| Adam, T; Faber, E; Friedecký, D; Mičová, K; Polýnková, A | 1 |
| Chen, Y | 1 |
| Clark, RE; Craddock, C; Dyer, MJ; Eaves, CJ; Foroni, L; Forrest, D; Gerrard, G; Grant, H; Griffiths, M; Irving, JA; Jiang, X; Karran, L; Khorashad, JS; O'Brien, S; Page, K; Stebbing, J; Wang, L; Wang, M; Woolfson, A | 1 |
| Al-Shehri, A; Belgaumi, AF | 1 |
| Arthur, C; Bartley, PA; Branford, S; Dang, P; Field, C; Filshie, RJ; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C | 1 |
| Dang, P; Engler, J; Hughes, TP; Saunders, VA; White, DL | 1 |
| Chen, M; Li, J; Luo, SK; Su, C; Xu, DR; Zou, WY | 1 |
| Cowan-Jacob, SW; Gallagher, N; Kaufman, S; Manley, PW; Mestan, J; Stiefl, N; Wartmann, M; Wiesmann, M; Woodman, R | 1 |
| Birge, RB; Matsuda, M; Tunceroglu, A | 1 |
| Levy, D; Tomasetti, C | 1 |
| Grebeňová, D; Halada, P; Hrkal, Z; Kuželová, K; Pavlásková, K; Pluskalová, M | 1 |
| Botta, M; Corradi, V; Mancini, M; Manetti, F; Petta, S; Santucci, MA | 1 |
| Apperley, JF; Bua, M; Dazzi, F; de Lavallade, H; Foroni, L; Goldman, JM; Ibrahim, AR; Khorashad, JS; Marin, D; Milojkovic, D; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Abdelhay, E; Amarante-Mendes, GP; Binato, R; Bueno-Da-Silva, AE; Castro, FA; Colassanti, MD; De Carvalho, DD; Jacysyn, JF; Leroy, JM; Pereira, WO; Proto-Siqueira, R; Zago, MA; Zanichelli, MA | 1 |
| Fujishima, N; Hirokawa, M; Kameoka, Y; Kitabayashi, A; Saitoh, H; Sawada, K; Tagawa, H; Takahashi, K; Takahashi, N; Yoshioka, T | 1 |
| Rao, DN; Rao, DR; Sailaja, K; Surekha, D; Vishnupriya, S | 1 |
| Bakhshi, S; Gupta, R; Kumar, L; Kumar, R; Medhi, K; Raina, V; Sharma, A | 1 |
| Barbosa, MM; Boersma, E; Clementino, NC; Geleijnse, ML; Marcolino, MS; Nunes, Mdo C; Ribeiro, AL; Silva, MH | 1 |
| Deininger, M; Hochhaus, A; Jabbour, E | 1 |
| Cortes, J | 5 |
| Deininger, MW; La Rosée, P | 1 |
| Andreeff, M; Carter, BZ; Cortes, J; Mak, DH | 1 |
| Breccia, M | 1 |
| Hackanson, B; Waller, CF | 1 |
| Cortes, J; Mauro, MJ; Pinilla-Ibarz, J | 1 |
| Arnold, R; Braun, D; Dörken, B; Grille, P; Kim, TD; le Coutre, P; Nogai, H; Plöckinger, U; Schwarz, M; Schweizer, U; Westermann, J | 1 |
| Hassan, AQ; Sharma, SV; Warmuth, M | 1 |
| Alimena, G; Breccia, M; Capria, S; Foà, R; Iori, AP; Meloni, G | 1 |
| A, J; Cao, B; Hong, M; Huang, Q; Li, J; Li, M; Liu, L; Lu, H; Ni, L; Qian, S; Shi, J; Wang, G; Wu, H; Yan, B; Zha, W; Zhang, S | 1 |
| Dong, X; Jiang, X; Wang, Y; Xiong, L; Yuan, B; Zhang, J | 1 |
| Ashizawa, M; Kako, S; Kanda, Y; Kikuchi, M; Kimura, S; Nakasone, H; Nishida, J; Okuda, S; Oshima, K; Sakamoto, K; Sato, M; Terasako, K; Wada, H; Watanabe, T; Yamazaki, R | 1 |
| Bencivenga, D; Borriello, A; Caldarelli, I; Cucciolla, V; Danise, P; Della Ragione, F; Oliva, A; Perrotta, S; Ronzoni, L; Usala, E | 1 |
| Spataro, V | 1 |
| Byeun, JY; Jung, CW; Kamel-Reid, S; Kim, DH; Kim, HJ; Kim, YK; Kong, JH; Lipton, JH; Liu, X; Xu, W | 1 |
| Kizaki, M | 2 |
| Abe, A; Kajiguchi, T; Kiyoi, H; Minami, Y; Naoe, T; Ohno, T | 1 |
| Charbonnier, A; Etienne, G; Guerci, A; Guilhot, F; Guilhot, J; Huguet, F; Legros, L; Mahon, FX; Nicolini, F; Réa, D; Reiffers, J; Rousselot, P; Varet, B | 1 |
| Medeot, M; Tiribelli, M | 1 |
| Aberg, E; Duyster, J; Engh, RA; Gorantla, SP; Oliveira, TM; Peschel, C; Thöne, S; von Bubnoff, N | 1 |
| Alimena, G; Breccia, M; Diverio, D; Federico, V; Grammatico, S; Latagliata, R; Loglisci, G; Mancini, M; Orlandi, SM; Salaroli, A; Santopietro, M | 1 |
| Clark, RE; Estabragh, ZR; Hart, G; Knight, K; Lane, S; Vinjamuri, S; Watmough, SJ | 1 |
| Salie, R; Silver, RT | 1 |
| Alessandro, R; Arlinghaus, R; Corrado, C; Flugy, AM; Fontana, S; Iovino, F; Kohn, EC; Leo, GD; Marfia, A; Raimondo, S; Santoro, A; Stassi, G | 1 |
| Barbieri, E; Botta, M; Corradi, V; Mancini, M; Manetti, F; Petta, S; Santucci, MA | 1 |
| Arnould, C; Bravo, S; Chiesa, J; Donadio, D; Exbrayat, C; Gaillard, JB; Jourdan, E; Lavabre-Bertrand, T; Reboul, D | 1 |
| Cojbasić, I; Macukanović-Golubović, L | 2 |
| Hochhaus, A; Leitner, AA; Müller, MC | 1 |
| Annunziata, M; Breccia, M; Camera, A; Cavazzini, F; Gozzini, A; Isidori, A; Montefusco, E; Morra, E; Piccaluga, PP; Pregno, P; Santini, V; Specchia, G; Stagno, F; Usala, E; Visani, G | 1 |
| Barbetti, V; Dello Sbarba, P; Di Gesualdo, F; Giuntoli, S; Rovida, E; Tanturli, M | 1 |
| Cortes, J; Fullmer, A; Jabbour, E; Kantarjian, H | 1 |
| de la Peña Moral, JM; Martínez Pascual, C; Miras López, M; Valdés Mas, M | 1 |
| Alimena, G; Breccia, M; Efficace, F | 1 |
| Mustjoki, S; Porkka, K; Simonsson, B | 1 |
| Schmidt, S; Wolf, D | 1 |
| Dörken, B; Kim, TD; le Coutre, P | 1 |
| Gratwohl, A; Heim, D | 1 |
| Alkhatib, MA | 1 |
| Beris, P; Clark, RE; Giles, FJ; le Coutre, P; Mahon, FX; Rosti, G; Saglio, G; Steegmann, JL; Valent, P | 1 |
| Carew, JS; Ecsedy, J; Giles, FJ; Kelly, KR; Mahalingam, D; Medina, E; Nawrocki, ST; Padmanabhan, S | 1 |
| Barber, N; Clifford, S; Eliasson, L; Marin, D | 1 |
| Auberger, P; Cassuto, JP; Deckert, M; Dufies, M; Fenouille, N; Jacquel, A; Mahon, FX; Ohanna, M; Pasquet, JM; Puissant, A; Raynaud, S; Robert, G; Tartare-Deckert, S | 1 |
| Baran, Y; Cakir, Z; Ozturk, E; Topcu, Z; Zencir, S | 1 |
| Etienne, G; Huguet, F | 1 |
| Liu, D; Rafiyath, S; Wei, G | 1 |
| Azuma, T; Fujiwara, H; Suemori, K; Watanabe, S; Yasukawa, M | 1 |
| Kobayashi, Y | 1 |
| Clackson, T; Commodore, L; Dalgarno, DC; Huang, WS; Keats, J; Rivera, VM; Shakespeare, WC; Thomas, M; Wang, Y; Xu, Q; Zhou, T; Zhu, X | 1 |
| Kim, TD; le Coutre, P | 1 |
| Cosset, E; Dumontet, C; Hamdan, G; Hayette, S; Jeanpierre, S; Maguer-Satta, V; Mahon, FX; Nicolini, FE; Puisieux, A; Sagorny, K; Voeltzel, T | 1 |
| Crowley, LC; Elzinga, BM; McKenna, SL; O'Sullivan, GC | 1 |
| Daniel, PT; Dörken, B; Grille, P; Kaeda, J; Kim, TD; Kreuzer, KA; Le Coutre, P; Movassaghi, K; Schwarz, M | 1 |
| Artz, AS; Liu, H | 1 |
| Ernst, T; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; Leitner, A; Lorentz, C; Müller, MC; Schenk, T; Schwindel, U | 1 |
| George, S; Trent, JC | 1 |
| Berthou, C; Castaigne, S; Cayuela, JM; Cony-Makhoul, P; Deau, B; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Hayette, S; Huguet, F; Legros, L; Mahon, FX; Michallet, M; Nicolini, FE; Pautas, C; Réa, D; Rousselot, P; Weiss, IR | 1 |
| Dan, K; Hino, M; Ikeda, Y; Inokuchi, K; Isobe, Y; Kizaki, M; Murayama, T; Ohyashiki, K; Okamoto, S; Oshimi, K; Saburi, Y; Shimomura, T; Tanaka, H; Tanimoto, M; Tauchi, T; Tsudo, M | 1 |
| Chung, J; Chung, YJ; Joo, YD; Jung, SH; Kim, BK; Kim, DY; Kim, HJ; Kim, I; Kim, SH; Kim, SJ; Koh, Y; Park, E; Park, S; Park, SH; Shin, HJ; Shin, SH; Sohn, SK; Song, HS; Yoon, SS | 1 |
| Cortés, JE; Holyoake, T; Kantarjian, H; Ranganathan, A; Saglio, G | 1 |
| Carroll, M; Perl, A | 1 |
| Agarwal, A; Corbin, AS; Cortes, J; Deininger, MW; Druker, BJ; Loriaux, M | 1 |
| Han, K; Kim, M; Kim, Y; Lee, SA; Lim, J | 1 |
| Burger, H; Eechoute, K; Franke, RM; Loos, WJ; Mathijssen, RH; Schiavon, G; Sparreboom, A; Verweij, J; Wiemer, EA | 1 |
| White, DL; Yeung, DT | 1 |
| Liang, MY; Wang, DP; Wang, SM; Zhang, XH | 1 |
| Bumbea, H; Coliţa, A; Coriu, D; Ilea, A; Radesi, S; Tălmaci, R; Vasile, D; Vlădăreanu, AM; Voican, I | 1 |
| Chu, IW; Cornelissen, JJ; Deenik, W; Janssen, JJ; Ossenkoppele, GJ; Sonneveld, P; Valk, PJ; van der Heiden, IP; van der Holt, B; van Schaik, RH | 1 |
| Abdel-Wahab, O; Imada, K; Jhanwar, SC; Levine, RL; Nimer, SD; Perna, F | 1 |
| Li, QF; Wang, H; Wang, LS; Wu, CT; Xiao, FJ; Yan, J; Yang, YF; Zhang, K | 1 |
| Hamšíková, E; Humlová, Z; Janatková, I; Klamová, H; Králíková, P; Malíčková, K; Roth, Z; Sterzl, I; Vonka, V | 1 |
| Barbagallo, I; Chiarenza, A; Conticello, C; Del Fabro, V; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Parrinello, N; Romano, A; Stagno, F; Tibullo, D | 1 |
| Chen, Y; Li, D; Li, S; Peng, C | 2 |
| Tefferi, A | 1 |
| Hamada, A; Kawaguchi, T; Mitsuya, H; Nakashima, R; Nambu, T; Saito, H; Yuki, M | 1 |
| Alfonso, G; Alú, MF; Belli, C; Bianchini, M; Larripa, I | 1 |
| Demirhan, E; Hayes, M; Jin, Y; Kim, DW; Park, S; Schran, H; Tan, EY; Wang, Y | 1 |
| Cortes, J; Hochhaus, A; Hughes, T; Kantarjian, H | 1 |
| Cerny-Reiterer, S; Dworzak, M; Eckelhart, E; Egger, G; Fajmann, S; Gleixner, KV; Herrmann, H; Hoermann, G; Hölbl, A; Kollmann, K; Mayerhofer, M; Moriggl, R; Sexl, V; Sillaber, C; Valent, P; Warsch, W | 1 |
| Cross, NC; Ernst, T; Hochhaus, A; La Rosée, P; Müller, MC | 1 |
| Gedde-Dahl, T; Goll, R; Gruber, FX; Hjorth-Hansen, H; Knuutila, S; Lundán, T; Mikkola, I; Porkka, K; Rekvig, OP; Remes, K; Silye, A | 1 |
| Chang, JG; Chang, WH; Chen, TY; Lee, CC; Lin, YH; Liu, TC; Yang, WK | 1 |
| Dolezel, P; Faber, E; Kosztyu, P; Mlejnek, P | 1 |
| Hehlmann, R; Jung-Munkwitz, S; Saussele, S | 1 |
| Doisaki, S; Hama, A; Kato, K; Kojima, S; Matsumoto, K; Muramatsu, H; Nishio, N; Sakaguchi, H; Shimada, A; Takahashi, Y; Yagasaki, H | 1 |
| Dolezel, P; Mlejnek, P; Novak, O | 1 |
| Aoyama, Y; Emi, N; Fujita, H; Kanamori, H; Kaya, H; Kimura, F; Kitamura, K; Miyawaki, S; Naoe, T; Ohnishi, K; Ohno, R; Ohtake, S; Ono, T; Sugiura, I; Tadokoro, K; Tamaki, S; Usuki, K; Yamaguchi, T | 1 |
| Bartholomeusz, G; Bornmann, WG; Donato, NJ; Fang, D; Kapuria, V; Peterson, LF; Sun, H; Talpaz, M | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Okimoto, RA; Van Etten, RA | 1 |
| Burchert, A; Neubauer, A | 1 |
| Fujisaki, T; Moriyama, Y; Muta, T; Sawada, Y; Seike, Y; Tokuyama, T; Ueda, Y | 1 |
| Adachi, Y; Aoki, G; Fujikawa, K; Imamura, Y; Inaguma, Y; Kasai, M; Kashiwagi, H; Katayama, T; Kizaki, M; Matsumura, I; Nagai, T; Nannya, Y; Niimi, H; Okabe, M; Okada, M; Saburi, Y; Sakamoto, E; Takeuchi, M; Tanimoto, K; Yagi, T | 1 |
| Baute, RG; Cabeza, AH; Cabrera, OM; Díaz, RM; Estrada, EE; Facundo, JC; Martínez, EE; Morán, VP; Núñez, AA; Otero, AG; Padrón, CH; Ramírez, PH; Sánchez, KL; Uría, JC; Virgil, AM | 1 |
| Chakupurakal, G; Etti, RJ; Murray, JA | 1 |
| Ashihara, E; Kimura, S; Maekawa, T; Ohyashiki, K; Okabe, S; Tauchi, T | 1 |
| Fujimori, Y; Ikegame, K; Kaida, K; Ogawa, H; Okada, M; Satake, A; Soma, T; Tamaki, H; Taniguchi, K; Yoshihara, S | 1 |
| Deininger, M; Diamond, AM; Gann, PH; Molokie, R; Terry, EN | 1 |
| Abe, T; Aizawa, Y; Fujiwara, M; Furukawa, T; Higuchi, W; Isahai, N; Kishi, K; Kobayashi, M; Koike, T; Koyama, S; Kuroha, T; Maruyama, S; Masuko, M; Nagai, K; Narita, M; Nikkuni, K; Nomoto, N; Seki, Y; Shibata, A; Takahashi, H; Takahashi, M; Takai, K; Toba, K | 1 |
| Hobernicht, SL; Hunger, SP; Schweiger, B; Wang, M; Zeitler, P | 1 |
| Deininger, M; Mitchell, B | 1 |
| Diamond, JM; Melo, JV | 1 |
| Drexler, HG; Eberth, S; Quentmeier, H; Romani, J; Zaborski, M | 1 |
| Akkerhuis, KM; Boersma, E; Clementino, NCD; Macedo, AV; Marcolino, MS; Marx-Neto, AD; Ribeiro, AL; Silva, MHCR; van Gelder, T | 1 |
| Hamada, A; Hirayama, C; Kawaguchi, T; Nakashima, R; Saito, H; Yamakawa, Y; Yuki, M | 1 |
| Anand, MS; Juneja, SS; Varma, N; Varma, S | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Propris, MS; Diverio, D; Federico, V; Loglisci, G; Nanni, M; Petrucci, L; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Ando, K; Hayama, N; Kojima, M; Komatsu, M; Kumaki, N; Morita, F; Ogawa, Y; Ogiya, D; Ohmachi, K; Tazume, K; Tsuboi, K | 1 |
| Quintás-Cardama, A; Santos, FP | 1 |
| Christerson, L; Halbritter, S; Mattsson, U; Mörner Serikoff, E; Warfvinge, G | 1 |
| Bouvresse, S; Clérici, T; de Masson, A; Mahé, E; Saïag, P | 1 |
| Li, C; Meng, L; Wang, G; Zhao, D | 1 |
| Argentou, N; Braimi, M; Germenis, AE; Gramoustianou, ES; Karanikas, V; Mandala, E; Matsouka, P; Ritis, K; Speletas, M | 1 |
| Apperley, JF; Bazeos, A; Bua, M; Eliasson, L; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Khorashad, JS; Kozlowski, K; Mahon, FX; Marin, D; Milojkovic, D; Molimard, M; Paliompeis, C; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Cai, Z; Han, X; He, J; Huang, H; Li, L; Lin, M; Luo, Y; Shi, J; Tan, Y; Xie, W; Ye, X; Zhao, Y; Zheng, Y | 1 |
| Akiyama, M; Furukawa, T; Kawauchi, K; Machida, M; Matsuoka, R; Mitsuishi, T; Motoji, T; Ozaki, K; Wang, YH; Yamada, H; Yamada, O | 1 |
| Harnicar, S | 1 |
| Branford, S; Prime, J | 1 |
| Feng, SZ; Han, MZ; He, Y; Huang, Y; Jiang, EL; Ma, QL; Song, AX; Wang, M; Wei, JL; Yan, ZS; Yang, DL; Zhai, WH; Zhang, RL | 1 |
| Deville, L; Hillion, J; Nguyen, E; Pendino, F; Samy, M; Ségal-Bendirdjian, E | 1 |
| Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M | 1 |
| Basu, S; Luong, P; Man, YK; Melo, JV; Nteliopoulos, G; Sears, D; Yuan, M | 1 |
| Arellano, M; Bernal-Mizrachi, L; Heffner, L; Khoury, HJ; Langston, A; Lima, L; Mann, KP; McLemore, M; Saxe, D; Tighiouart, M; Winton, E | 1 |
| Bosi, A; Buchi, F; Ferrari, G; Gozzini, A; Pastorelli, R; Santini, V; Sassolini, F; Spinelli, E; Tombaccini, D | 1 |
| Huh, J; Jung, CW; Kim, DH; Kim, HJ; Kim, JW; Kim, SH; Kim, YK; Lee, JE; Moon, JH; Nam, GH; Shin, MG; Sohn, SK; Suh, JS | 1 |
| Ang, CH; Bee, PC; Gan, GG; Liang, KL; Nadarajan, VS; Phan, CL; Zakaria, Z | 1 |
| Abruzzese, E; Amadori, S; Birge, RB; de Fabritis, P; Di Stefano, C; Gambacorti-Passerini, C; Gambacurta, A; Marfe, G; Martini, V; Mologni, L; Ottone, T; Sinibaldi-Salimei, P | 1 |
| Fujisawa, S; Hirano, I; Nagata, Y; Nakamura, S; Ohnishi, K; Shibata, K; Shigeno, K; Takemura, T; Tan, L; Yokota, D | 1 |
| Dan, K; Hamada, Y; Nakamura, K; Tajika, K | 1 |
| Hashidate, H; Nikkuni, K; Shibuya, H; Takai, K; Ushiki, T | 1 |
| Baran, Y; Can, G; Ekiz, HA | 1 |
| Guimarães, JE; Helena Vasconcelos, M; Lima, RT; Seca, H | 1 |
| Griffiths, EA; Vigil, CE; Wang, ES; Wetzler, M | 1 |
| Abruzzese, E; Antolini, L; Assouline, S; D'Emilio, A; Deininger, M; Della Casa, CM; Durosinmi, MA; Fava, C; Gambacorti-Passerini, C; Giraldo, P; Guilhot, F; Hurtado-Monroy, R; Jang, E; Kim, DW; le Coutre, P; Leeksma, O; Mahon, FX; Martino, B; Morra, E; Nagler, A; Pane, F; Piccin, A; Pogliani, EM; Puttini, M; Reiffers, J; Santini, V; Stagno, F; Valsecchi, MG | 1 |
| Smith, BD | 1 |
| Balleisen, L; Gratwohl, A; Haferlach, C; Hänel, M; Hasford, J; Hehlmann, R; Hochhaus, A; Hossfeld, DK; Jung-Munkwitz, S; Krause, SW; Lauseker, M; Leitner, A; Müller, MC; Nerl, C; Pfirrmann, M; Pletsch, N; Pralle, H; Proetel, U; Saussele, S; Schlegelberger, B | 1 |
| Zimmermann, J | 1 |
| DU, QF; Liu, XL; Ouyang, Z; Wang, S; Wang, Y; Xu, N; Yang, J | 1 |
| Ang, CH; Bee, PC; Nadarajan, VS; Syed-Sultan, MK | 1 |
| Amabile, M; Baccarani, M; Baldazzi, C; Bonaldi, L; Castagnetti, F; Cianciulli, AM; Discepoli, G; Giacobbi, F; Giudici, G; Giussani, U; Gugliotta, G; Luatti, S; Martinelli, G; Marzocchi, G; Montaldi, A; Palandri, F; Pane, F; Rosti, G; Saglio, G; Santoro, A; Sessarego, M; Specchia, G; Stacchini, M; Testoni, N; Valori, L | 1 |
| Silver, RT | 2 |
| Acosta, JC; Albajar, M; Bermúdez, A; Delgado, MD; Donato, N; Gómez-Casares, MT; León, J; Llorca, J; Mauleon, I; Vaqué, JP | 1 |
| Ben Youssef, Y; Bennour, A; Elloumi, M; Harrabi, I; Khelif, A; Laatiri, MA; Meddeb, B; Ouahchi, I; Saad, A; Sennana, H; Zaier, M | 1 |
| Alimena, G; Breccia, M; Cannella, L; De Cuia, R; Federico, V; Loglisci, G; Loglisci, MG; Mancini, M; Nanni, M; Salaroli, A; Santopietro, M; Serrao, A | 1 |
| Alonzo, TA; Arceci, RJ; Bernstein, ML; Champagne, MA; Chang, M; Chen, H; Cooley, LD; French, ME; Fu, CH; Gerbing, RB; Heerema, NA; Oehler, V; Smith, FO; Wood, C | 1 |
| Cheong, JW; Jung, CW; Kim, DH; Kim, HJ; Kim, IH; Kim, JS; Kim, SN; Kim, YK; Min, YH; Moon, JH; Park, SY; Sohn, SK; Yoon, SS | 1 |
| Attkisson, E; Dai, Y; Grant, S; Jordan, N; Kolluri, N; Kramer, L; Muschen, M; Nguyen, N; Nguyen, T | 1 |
| Baig, MA; Dutcher, JP; Lee, SH; Paietta, E; Racevskis, J; Wiernik, PH | 1 |
| Craddock, C; Novitzky-Basso, I | 1 |
| Castagnetti, F; Dingli, D; Lenaerts, T; Pacheco, JM; Rosti, G; Traulsen, A | 1 |
| Persano Adorno, D; Pizzolato, N; Spagnolo, B; Valenti, D | 1 |
| Bachmeyer, C; Garandeau, E; Lecomte, I; Lionnet, F; Stankovic Stojanovic, K; Thiolière, B | 1 |
| Rudzki, J; Wolf, D | 1 |
| Arellano, M; Assouline, S; Bernal-Mizrachi, L; Cortes, J; Khoury, HJ; Lima, LM; McLemore, M; Nault, S; Sampat, K; Saxe, D; Tighiouart, M; Winton, E | 1 |
| Adrian, LT; Anderson, DJ; Deininger, MW; Druker, BJ; Eide, CA; Flynn, DL; Mac Partlin, M; O'Hare, T; Petillo, PA; Smith, BD; Tyner, JW; Wise, SC | 1 |
| Branford, S; Cortes, JE; Jabbour, E; Jones, D; Kantarjian, HM; Saglio, G | 1 |
| Bassi, S; Cinieri, S; Cocorocchio, E; Colpi, GM; Peccatori, FA; Shash, E | 1 |
| Drummond, M; Gallipoli, P; Holyoake, T; Irvine, D; Shepherd, P | 1 |
| Klumb, CE; Maia, RC; Moellmann-Coelho, A; Silva, KL; Silva, LF; Souza, PS; Vasconcelos, FC | 1 |
| Apohan, E; Baran, Y; El-Shewy, HM; Fernandes, D; Gault, CR; Mahajan, S; Marcucci, G; Meyers-Needham, M; Oaks, J; Obeid, LM; Ogretmen, B; Perrotti, D; Ponnusamy, S; Saddoughi, SA; Salas, A; Santhanam, R; Selvam, SP; Senkal, CE; Sentelle, RD; Smith, C; Stuart, R | 1 |
| Akinci, S; Atalay, HV; Basturk, A; Dilek, I; Hacibekiroglu, T | 1 |
| Catellani, S; Gobbi, M; Pierri, I; Poggi, A; Zocchi, MR | 1 |
| Chudej, J; Cmunt, E; Demečková, E; Demitrovičová, L; Dušek, L; Faber, E; Indrák, K; Jarošová, M; Koza, V; Kozák, T; Markuljak, I; Mužík, J; Tóthová, E; Voglová, J | 1 |
| Chandra, HS; Heisterkamp, NC; Hungerford, A; Morrissette, JJ; Nowell, PC; Rowley, JD; Testa, JR | 1 |
| Baccarani, M; Guilhot, F; Guilhot, J; Hasford, J; Hehlmann, R; Hoffmann, V; Lindoerfer, D; Ossenkoppele, G; Pfirrmann, M; Porkka, K; Rosti, G; Saussele, S; Simonsson, B | 1 |
| Aichberger, KJ; Herndlhofer, S; Mitterbauer-Hohendanner, G; Schernthaner, GH; Schillinger, M; Sillaber, C; Valent, P | 1 |
| Balabanov, S; Barett, C; Bokemeyer, C; Bosotti, R; Braig, M; Brümmendorf, TH; Gontarewicz, A; Holyoake, TL; Jost, E; Keller, G; Moll, J; Raddrizzani, L; Rohe, I | 1 |
| Bao, Y; Duan, Y; Kong, J; Liu, Z; Ma, X; Shan, B; Wang, Y; Wu, X | 1 |
| Hu, R; Jin, W; Li, H; Li, Q; Lin, Y; Lu, Y; Ma, L; Pang, T; Wang, J; Wang, L | 1 |
| Andersson, T; Björkholm, M; Derolf, A; Dickman, PW; Eloranta, S; Höglund, M; Hultcrantz, M; Kristinsson, SY; Landgren, O; Ohm, L; Richter, J; Sjöberg, J | 1 |
| Kiarie, GW; Othieno-Abinya, NA; Riyat, MS | 1 |
| Hamamoto, K; Horibe, K; Hotta, N; Ito, M; Kato, K; Kurosawa, H; Muramatsu, H; Shima, H; Shimada, H; Tanizawa, A; Tokuyama, M; Tono, C; Tsurusawa, M; Watanabe, A | 1 |
| Ando, K; Fujisawa, S; Iida, S; Ishizawa, K; Kobayashi, Y; Miyawaki, S; Motoji, T; Nagai, T; Ohno, R; Okada, M; Sakamaki, H; Seriu, T; Taniwaki, M; Uoshima, N; Usui, N; Yamamoto, K | 1 |
| Block, AW; Vigil, C; Wetzler, M | 1 |
| Letendre, L; Tefferi, A | 1 |
| Claiborn, K | 1 |
| Baccarani, M; Iacobucci, I; Martinelli, G; Rosti, G; Soverini, S | 2 |
| Hamada, A; Kai, H; Kawaguchi, T; Saito, H; Shuto, T; Uchida, T; Yamakawa, Y; Yuki, M | 1 |
| Gilbert, M; Klieb, HB; Sade, S; Wong, M | 1 |
| Baniahmad, A; Eberhart, M; Hentschel, J; Hipler, C; Loncarevic, IF; Rubio, I; Schiefner, J; Schubert, K; von Eggeling, F; Wittig, U | 1 |
| Hino, M; Koh, KR; Nakamae, H; Nakane, T; Nakao, T; Terada, Y; Yamane, T; Yoshida, N | 1 |
| Branford, S; Cortes, J; Field, C; Gonen, M; Hughes, TP; Kantarjian, H; Michor, F; Quintas-Cardama, A; Tang, M | 1 |
| Aranguren, PN; Bengió, R; Fernandez, I; García, J; Giere, I; Labanca, V; Lastiri, F; Lombardi, V; Magariños, AE; Martinez, L; Milone, J; Moiraghi, B; Murro, H; Pavlovsky, C; Pavlovsky, MA; Pavlovsky, S; Reinoso, FG; Uriarte, R | 1 |
| Bengió, RM; Bianchini, M; Bullorsky, E; Lanari, E; Larripa, I; Milone, J; Moiraghi, B; Murro, H; Riva, ME; Tezanos Pinto, Md; Ventriglia, V | 1 |
| Dinis, J; Fernandes, AR; Gromicho, M; Laires, A; Magalhães, M; Rodrigues, AS; Rueff, J; Tavares, P | 1 |
| Beel, K; Brümmendorf, TH; Carmeliet, G; Carmeliet, P; Cauwenberghs, S; Clark, RE; Cools, J; De Keersmaecker, K; De Mol, M; Dewerchin, M; Dias, S; Fragoso, R; Fraisl, P; Hochhaus, A; Holyoake, T; Jonckx, B; Karin, M; Kharabi Masouleh, B; Kleppe, M; Loges, S; Maes, C; Rafii, S; Schenk, T; Schmidt, T; Tjwa, M; Vandenberghe, P; Verfaillie, C; Vinckier, S | 1 |
| Hiwase, DK; White, DL; Yeung, DT | 1 |
| Baruchel, A; Bernard, F; Berthou, C; Bertrand, Y; Bordigoni, P; Cayuela, JM; Couillault, G; Edan, C; Galambrun, C; Guilhot, F; Guilhot, J; Leblanc, T; Lutz, P; Mazingue, F; Méchinaud, F; Millot, F; Petit, A; Reguerre, Y; Vérité, C; Yacouben, K | 1 |
| Guo, L; He, L; Li, J; Xu, G; Yu, S | 1 |
| Almqvist, A; Bjerrum, OW; Björeman, M; Ehrencrona, H; Flogegård, M; Gedde-Dahl, T; Gruber, F; Hjorth-Hansen, H; Kairisto, V; Koskenvesa, P; Lindblom, A; Malm, C; Markevärn, B; Mustjoki, S; Myhr-Eriksson, K; Nagler, A; Nielsen, JL; Ohm, L; Olsson, K; Porkka, K; Räsänen, A; Remes, K; Sandin, F; Simonsson, B; Sinisalo, M; Själander, A; Stentoft, J; Strömberg, U | 1 |
| Dasgupta, Y; Glodkowska-Mrowka, E; Koptyra, M; Nacheva, EP; Skorski, T; Stoklosa, T; Virgili, A | 1 |
| Helgason, GV; Holyoake, TL; Karvela, M | 2 |
| Abdool, A; Bruey, JM; Yeh, CH | 1 |
| Ohnishi, K | 7 |
| Oyashiki, K; Tauchi, T | 1 |
| Ajimura, TO; Borges, KB; de Castro, FA; de Gaitani, CM; Ferreira, AF | 1 |
| Yano, S | 1 |
| Elliott, M; Holyoake, T; Iqbal, Z; Jørgensen, H; Watson, DG | 1 |
| Green, MR; Ma, L; Sheng, Z; Sun, JE; Zhu, LJ | 1 |
| Judson, I; Thanopoulou, E | 1 |
| Feng, S; Kohn, PH; Lu, CM; Qi, Z; Yu, J; Zhou, L | 1 |
| Hughes, TP; Moore, S; Parker, WT; Prime, JA; Schafranek, L; Tang, C; Watkins, DB; White, DL | 1 |
| Cortes, J; Gibbons, DL; Kantarjian, H; Pricl, S; Quintás-Cardama, A | 1 |
| De Souza, C; Gallagher, N; Jootar, S; le Coutre, P; Nicolini, FE; Powell, BL; Shen, ZX; Szczudlo, T; Turkina, A; Zheng, M | 1 |
| Chollet, C; Costaglioli, P; Dupouy, M; Etienne, G; Garbay, B; Lagarde, V; Mahon, FX; Pasquet, JM; Reiffers, J; Turcq, B | 1 |
| Fujiwara, M; Goto, H; Goya, T; Ishii, H; Koide, T; Nakajima, A; Nakamoto, K; Oka, T; Saraya, T; Shibata, H | 1 |
| Buda-Okreglak, EM; Cordaro, DV | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Garcia-Manero, G; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J | 1 |
| Alimena, G; Baccarani, M; Baratè, C; Bergamaschi, M; Breccia, M; Cottone, F; Dabusti, M; Deliliers, GL; Di Raimondo, F; Efficace, F; Fioritoni, G; Leoni, P; Levato, L; Luciano, L; Mandelli, F; Martino, B; Rambaldi, A; Rossi, AR; Rosti, G; Sica, S; Simula, MP; Turri, D; Ulisciani, S; Veneri, D; Vignetti, M | 1 |
| Leof, EB; Torres, VE | 1 |
| Chung, W; Cortes, JE; Estecio, MR; Gharibyan, V; He, R; Issa, JP; Jelinek, J; Kantarjian, HM; Kondo, K; Liang, S; Lu, Y; Zhang, N | 1 |
| Arqueros, V; Martín-Palanco, V; Martínez, F; Román-Gómez, J; Torres, A | 1 |
| Alvira, D; Bhatt, L; Cotter, TG; Landry, WD; Naughton, R; Tedesco, S | 1 |
| Helgason, GV; Holyoake, TL; Karvela, M; Mukhopadhyay, A | 1 |
| Aloyz, R; Johnston, JB; Kumar, R; Yoon, JY | 1 |
| Berthon, C; Dauphin, V; Dezitter, X; Hétuin, D; Idziorek, T; Joha, S; Mahon, FX; Nugues, AL; Preudhomme, C; Quesnel, B; Roche-Lestienne, C | 1 |
| Dubey, KD; Ojha, RP | 1 |
| Abruzzese, E; Dombret, H; Dörken, B; Herndlhofer, S; Le Coutre, P; Rea, D; Trawinska, MM; Valent, P | 1 |
| Guo, Y; Munoz, J | 1 |
| Ghosh, K; Vaidya, S; Vundinti, BR | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Ferrajoli, A; Kantarjian, H; McConkey, D; O'Brien, S; Santos, FP; Wright, J | 1 |
| Engh, RA; Ernst, T; Gruber, FX; Hochhaus, A; Lange, T; Maier, J; Mikkola, I; Porkka, K | 1 |
| Branford, S; Buonomo, T; Colavita, I; Del Vecchio, L; Esposito, N; Hughes, TP; Kalebic, T; Luciano, L; Martinelli, G; Martinelli, R; Melo, JV; Pane, F; Peluso, AL; Picardi, M; Quintarelli, C; Radich, JP; Ruoppolo, M; Russo, D; Saglio, G; Sica, AR; White, D | 1 |
| Baker, DP; Bhattacharya, S; Carroll, M; Fuchs, SY; Tzimas, C; Zheng, H | 1 |
| Besson, C; Darné, C; Delomas, T | 1 |
| Baran, Y; Bielawski, J; Gunduz, U; Ogretmen, B | 1 |
| Dahiya, K; Dhankhar, R; Ghalaut, PS; Ghalaut, VS; Saharan, R; Sangwan, L | 1 |
| Ahmad, S; Alsuliman, A; Apperley, JF; Bua, M; Clark, R; Cooper, N; Davis, J; de Lavallade, H; Foroni, L; Gabriel, IH; Goldman, JM; Hedgley, C; Khoder, A; Khorashad, JS; Marin, D; Milojkovic, D; O'Brien, S; Rezvani, K; Sergeant, R; Stringaris, K | 1 |
| Chen, X; Yang, W; Zhu, X | 1 |
| Balwierz, W; Cwynar, D; Czekalska, S; Florek, I; Foryciarz, K; Sacha, T; Skotnicki, AB; Wator, G; Zawada, M | 1 |
| Blakesley, RE; De Souza, C; Flinn, IW; Gallagher, NJ; Goh, YT; Hochhaus, A; Hoenekopp, A; Hughes, TP; Kantarjian, HM; Larson, RA; Nakamae, H; Rosti, G; Saglio, G; Stenke, L | 1 |
| Davies, J | 1 |
| Li, QF; Wang, H; Wang, LS; Wu, CT; Xiao, FJ; Yan, J; Yang, YF | 1 |
| Apperley, JF; Byrne, J; Clark, RE; Goldman, J; Holyoake, TL; Ibrahim, AR; Marin, D; Milojkovic, D; Shepherd, P; Szydlo, R | 1 |
| Abbas, R; Arkin, S; Besson, N; Brümmendorf, TH; Cortes, JE; Gambacorti-Passerini, C; Kantarjian, HM; Khoury, HJ; Kim, DW; Leip, E; Pasquini, R; Shen, ZX; Turkina, AG; Volkert, A; Wang, J | 1 |
| Bagadi, S; Das, B; Pany, A; Saikia, T | 1 |
| Huang, Q; Huang, S; Li, X; Yang, Y | 1 |
| Behulova, R; Bujalkova, MG; Hojsikova, I; Lukackova, R; Mistrik, M; Repiska, V; Strhakova, L | 1 |
| Gastl, G; Geissler, K; Greil, R; Hantschel, O; Lang, A; Linkesch, W; Lion, T; Petzer, AL; Pittermann, E; Pleyer, L; Thaler, J; Valent, P; Wolf, D | 1 |
| Bottino, D; Branford, S; Goldman, JM; Hochhaus, A; Hughes, TP; Kaeda, J; Modur, V; Radich, JP; Stein, AM | 1 |
| Altvater, B; Berdel, WE; Chen, CI; Gerss, J; Juergens, H; Kerstiens, L; Koschmieder, S; Lee, PP; Maecker, HT; Pscherer, S; Rossig, C; Schemionek, M | 1 |
| Ashihara, E; Hayashi, Y; Hirai, H; Kimura, S; Maekawa, T; Nagao, R; Padia, J; Strand, K; Strovel, JW; Takeuchi, M; Tanaka, R; Yao, H | 1 |
| Adrian, LT; Agarwal, A; Corbin, AS; Deininger, MW; Druker, BJ; Eide, CA; O'Hare, T; Press, RD; Rivera, VM; Toplin, J; Wong, S; Yang, F; You, H; Zabriskie, MS | 1 |
| Chan, KW; Lockhart, S; McDonald, L; Rytting, M | 1 |
| Agarwal, A; Braig, M; Cerchietti, L; Druker, BJ; Hatzi, K; Herzog, S; Hochhaus, A; Hofmann, WK; Hurtz, C; Jumaa, H; Kim, YM; Melnick, AM; Müller, MC; Müschen, M; Park, E; Ramezani-Rad, P; Shah, NP; Ye, BH | 1 |
| Armbrust, T; Binder, L; Brandhorst, G; Braulke, F; Cameron, S; Haase, D; Hafke, A; Oellerich, M; Ramadori, G; Streit, F; Walson, P | 1 |
| Kapadia, RK; Steeves, JH | 1 |
| Bhatia, R; Chakraborty, S; Chu, S; Huang, Q; Lin, A; McDonald, T; Snyder, DS | 1 |
| Chen, JY; Hsu, MC; Hung, WC; Wang, MC; Yang, KT | 1 |
| Caparrotti, G; Ciarcia, R; Conti, D; d'Angelo, D; Florio, S; Galdiero, M; Giordano, A; Iovane, V; Pacilio, C; Pagnini, D; Tomei, V; Vitiello, MT | 1 |
| Bandyopadhyay, S; Biswas, N; Chakraborty, JB; Chaudhuri, J; Chaudhuri, U; Choudhury Mukherjee, I; Chowdhury, AA; Ganguly, D; Jaisankar, P; Joshi, K; Konar, A; Mahato, SK; Mandal, L; Manna, A; Pal, BC; Pal, C; Paul, K; Rakshit, S; Roy, S; Shinde, V; Vinayagam, J | 1 |
| Shah, NP; Smith, CC | 2 |
| Cedars, MI; Druker, BJ; Egorin, MJ; Mauro, MJ; Oktay, K; Rosen, MP; Zamah, AM | 1 |
| Bassan, R; Bussini, A; Castagnetti, F; Gnani, A; Intermesoli, T; Rosti, G; Soverini, S; Spinelli, O | 1 |
| Mehta, R; Sayar, H; Sharfuddin, AA; Taber, TE | 1 |
| Tojo, A | 1 |
| Roychowdhury, S; Talpaz, M | 1 |
| Allegra, A; Alonci, A; Bellomo, G; Campo, S; Cannavò, A; Centorrino, R; D'Angelo, A; Musolino, C; Penna, G; Russo, S | 1 |
| Arora, M; Cortes, J; Gale, RP; George, B; Giralt, SA; Goldman, JM; Gupta, V; Halter, J; Horowitz, MM; Keating, A; Khoury, HJ; Kukreja, M; Lee, SJ; Marks, DI; Maziarz, RT; McCarthy, PL; Rizzieri, DA; Szer, J; Wang, T; Woolfrey, A | 1 |
| Angelopoulou, MK; Bartzi, V; Bitsani, A; Boutsikas, G; Dimou, M; Efthymiou, A; Georgiou, G; Kyrtsonis, MC; Panayiotidis, P; Pessach, I; Plata, E; Tofas, P; Vardounioti, I; Vassilakopoulos, TP | 1 |
| Cetkovský, P; Dušek, L; Janoušová, E; Klamová, H; Mayer, J; Mužík, J; Pavlík, T; Pospíšil, Z; Ráčil, Z; Trněný, M; Záčková, D | 1 |
| Branford, S; Ho, M; Hughes, TP; Irwin, DL; Lawrence, RM; Parker, WT; Scott, HS | 1 |
| Beug, H; Cerny-Reiterer, S; Gish, GD; Grebien, F; Hantschel, O; Kaupe, I; Koide, A; Koide, S; Kovacic, B; Pawson, T; Superti-Furga, G; Valent, P; Wojcik, J; Wyrzucki, AM | 1 |
| Ankathil, R; Gan, SH; Tan, KL | 1 |
| Cao, R; He, H; Huang, KK; Jiang, XJ; Liao, LB; Lin, R; Meng, FY; Wang, Q; Wu, FQ; Xu, D; Yang, M; Yi, ZS; Yin, CX; Zheng, ZX; Zhou, HS | 1 |
| Andreeff, M; Cortes, J; Ichikawa, N; Iwabuchi, K; Jin, L; Konopleva, M; Miida, T; Tabe, Y; Wang, RY | 1 |
| Dorlhiac-Llacer, PE; Gallagher, NJ; Jootar, S; Masszi, T; Nicolini, FE; Powell, BL; Shen, Z; Szczudlo, T; Turkina, A; Zheng, M | 1 |
| Andreeff, M; Carter, BZ; Cortes, J; Kantarjian, H; Konopleva, M; Mak, DH; Schober, WD; Wang, RY | 1 |
| Cornelison, AM; Cortes, J; Jabbour, E; Kantarjian, H | 1 |
| Ariaudo, A; Baietto, L; Cusato, J; D'Avolio, A; De Francia, S; Di Carlo, F; Di Perri, G; Fava, C; Saglio, G; Simiele, M | 1 |
| Besson, N; Cella, D; Kelly, V; Kim, DW; Masszi, T; Trask, PC | 1 |
| Akagi, T; Kaimori, M; Kubo, K; Mariya, Y; Ogura, K; Oshikiri, T; Sakamoto, Y; Sasaki, S; Segawa, M; Teshiromori, R | 1 |
| Andrikovics, H; Fekete, S; Kalmár, L; Masszi, T; Meggyesi, N; Tordai, A | 1 |
| Ahmadzadeh, A; Charoosaei, R; Haybar, H; Jalaeikhoo, H; Keyhani, M; Toogeh, G; Valizadeh, A; Yadollahzadeh, M | 1 |
| Jiang, QL; Meng, FY; Shu, LL; Yang, M | 1 |
| Jönsson, S; Olsson, B; Söderberg, J; Wadenvik, H | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H; Parikh, SA | 1 |
| DeAngelo, DJ | 1 |
| Jain, N; van Besien, K | 1 |
| Chosa, N; Fukudome, T; Hisakata, T; Horikawa, N; Ito, M; Kanda, Y; Kawano, N; Kugimiya, H; Okuda, S; Sakurai, R; Ueda, A; Yamashita, K; Yoshida, S | 1 |
| Levi, MM | 1 |
| Janssen, JJ; Ossenkoppele, GJ; Schuurhuis, GJ; Thielen, N | 1 |
| Arnan, M; Duarte, RF; Manresa, F; Ortí, G; Peralta, T; Sánchez-Ortega, I; Servitje, O | 1 |
| Apperley, JF; Baccarani, M; Blakesley, R; Cortes, J; Gallagher, NJ; Giles, FJ; Hochhaus, A; Kantarjian, HM; le Coutre, PD; Ossenkoppele, GJ; Shou, Y | 1 |
| Katagiri, S; Kyo, T; Maeda, Y; Matsumura, I; Ohyashiki, JH; Ohyashiki, K; Tauchi, T | 1 |
| Krusch, M; Salih, HR | 1 |
| Erben, P; Hanfstein, B; Härtel, N; Hochhaus, A; Klag, T; La Rosée, P; Mueller, MC; Schenk, T | 1 |
| Dai, M; Meng, FY; Wei, YQ; Xu, D; Zhong, JS; Zhou, HS | 1 |
| Bendit, I; de Barros Ferreira, P; Dorlhiac-Llacer, PE; Martins, TF; Nardinelli, L; Sanabani, SS; Seguro, F; Serpa, M | 1 |
| Auberger, P; Cassuto, JP; Cluzeau, T; Dufies, M; Fenouille, N; Jacquel, A; Legros, L; Luciano, F; Puissant, A; Raynaud, S; Robert, G | 1 |
| Aluigi, M; Barbieri, E; Castagnetti, F; Leo, E; Mancini, M; Marcozzi, C; Santucci, MA | 1 |
| Bhatia, R; Chen, WY; Roth, M; Wang, Z; Yuan, H; Zhang, H | 1 |
| Agarwal, JP; Banavali, S; Budrukkar, A; Chatturvedi, P; D'Cruz, A; Laskar, SG; Murthy, V; Muttagi, S; Shahid, T | 1 |
| Bueno, CT; Chiattone, CS; Guerra-Shinohara, EM; Hirata, MH; Hirata, RD; Lima, LT; Luchessi, AD; Vivona, D; Zanichelli, MA | 1 |
| Auberger, P; Belhacene, N; Cassuto, JP; Cluzeau, T; Dufies, M; Jacquel, A; Luciano, F; Raynaud, S; Robert, G | 1 |
| Kalaycio, M; Tiu, R | 1 |
| Chai, JH; Chng, WJ; Li, B; Tan, WH; Wang, X; Zhang, Y | 1 |
| Higa, B; Thakral, B; Velankar, MM; Venkataraman, G | 1 |
| Cornelissen, JJ; Deenik, W; Janssen, JJ; Kelder, A; Ossenkoppele, GJ; Pouwels, W; Schuurhuis, GJ; Smolders, KG; van Kuijk, BJ | 1 |
| Baccarani, M; Blakesley, RE; Gallagher, NJ; Giles, FJ; Gillis, K; Goldberg, SL; Hochhaus, A; Kantarjian, HM; Larson, RA; le Coutre, PD; Mahon, FX; Ottmann, OG | 1 |
| Du, Y; Guo, D; Huang, S; Li, H; Liang, K; Zheng, F | 1 |
| Cziraky, M; Davis, C; Hamdan, M; Hirji, I; Oliveria, SA; Yood, MU | 1 |
| Aoki, J; Hirashima, Y; Kakihana, K; Kobayashi, T; Ohashi, K; Sakamaki, H | 1 |
| Druker, BJ; Eide, CA; Hayward, R; Heidorn, S; Marais, R; Niculescu-Duvaz, I; O'Hare, T; Packer, LM; Rana, S; Rebocho, A; Springer, C; Zabriskie, MS | 1 |
| Amariglio, N; Hardan, I; Koren-Michowitz, M; Nagler, A; Shimoni, A; Stanevsky, A; Tohami, T; Trakhtenbrot, L; Volchek, Y | 1 |
| Giannopoulos, K; Kosior, K; Lewandowska-Grygiel, M | 1 |
| Apperley, JF; Bua, M; Foroni, L; Gerrard, G; Goldman, J; Ibrahim, AR; Marin, D; Milojkovic, D; Reid, A; Rezvani, K; Szydlo, R | 1 |
| Balci, TB; Karakus, S; Ozdogu, H; Sahin, FI | 1 |
| Chen, MC; Chen, SH; Chong, PN; Yang, SH; Yao, TK | 1 |
| Calabretta, B; Salomoni, P | 1 |
| Alessandro, R; De Leo, G; Flugy, A; Garfield, SH; Kohn, EC; Mineo, M; Taverna, S | 1 |
| Baccarani, M; Castagnetti, F; Gugliotta, G; Palandri, F; Rosti, G | 1 |
| Bhatia, R; Chen, W; Horne, D; Li, L; Modi, H; Wang, Z; Yuan, H; Zhang, H | 1 |
| Blaeser, BF; Boyle, N; Dehni, WJ; Kabani, SP; Li, CC; Malik, SM; Toner, M; Woo, SB | 1 |
| Branford, S; Ho, M; Hughes, TP; Parker, WT; Scott, HS | 1 |
| Andolina, JR; Corey, SJ; Neudorf, SM | 1 |
| Hagihara, K; Hayashi, Y; Hino, M; Hirose, A; Katayama, T; Koh, H; Nakamae, H; Nakamae, M; Nakane, T; Nakao, Y; Terada, Y | 1 |
| Borroni, G; Brazzelli, V; Fiandrino, G; Lucioni, M; Manna, G; Moggio, E; Muzio, F; Orlandi, E; Vassallo, C | 1 |
| Chen, C; Hou, M; Ji, CY; Liu, CF; Song, Q; Wang, LQ; Wang, W; Xu, CG | 1 |
| Chen, BB; He, HS; Su, GP | 1 |
| Ensom, MH; Mabasa, VH; Teng, JF | 1 |
| Balabanov, S; Brümmendorf, TH; Lutz, D; Traulsen, A; Werner, B | 1 |
| Charles, KS; Leelah, N; Oluwabusi, TA; Ramon, L; Seemungal, T | 1 |
| Horne, HL; Maung, Z; Reddy, H | 1 |
| Cariou, ME; Cayuela, JM; Coude, MM; Dombret, H; Luycx, O; Maarek, O; Rea, D | 1 |
| Guilhot, F; Roy, L; Tomowiak, C | 1 |
| Borthakur, G; Champlin, R; Cortes, J; Faderl, S; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; O'Brien, S; Quintas-Cardama, A; Ravandi, F; Rios, MB; Shan, J; Talpaz, M | 1 |
| Adam, T; Divoká, M; Faber, E; Friedecký, D; Indrák, K; Jarošová, M; Mičová, K; Rožmanová, S | 1 |
| Dvorakova, D; Jurcek, T; Koutna, I; Mayer, J; Peterkova, M; Potesilova, M; Racil, Z; Razga, F; Simara, P; Stejskal, S | 1 |
| Airiau, K; Belloc, F; Jeanneteau, M; Josselin, M; Mahon, FX; Turcq, B | 1 |
| Bruhn, O; Cascorbi, I; Diewock, T; Haenisch, S; Laechelt, S; Turrini, E | 1 |
| Achari, C; Aparna, A; Arunasree, KM; Bharat Reddy, D; Chandramohan Reddy, T; Gupta, G; Lakshmipathi, V; Reddanna, P; Reddy, GV; Subramanyam, A | 1 |
| Balasubramanian, P; Branford, S; Chandy, M; Chendamarai, E; Fletcher, L; George, B; Markose, P; Mathews, V; Srivastava, A | 1 |
| Al-Ali, HK; Bach, E; Cross, M; Jilo, A; Lange, T; Niederwieser, D; Tschiedel, S; Vucinic, V; Wang, SY | 1 |
| Bee, PC; Chin, E; Gan, GG; Haris, AR; Tai, YT; Veera, SN | 1 |
| Erba, HP; Pham, DC; Tai, S; Vu, H; Zaiden, R | 1 |
| Doi, Y; Fukushima, T; Hata, T; Imaizumi, Y; Imanishi, D; Itonaga, H; Kamihira, S; Kawaguchi, Y; Matsuo, E; Miyazaki, Y; Mori, S; Tomonaga, M; Tsushima, H | 1 |
| Coluccia, AM; De Leo, S; de Luca, E; De Matteis, S; Di Renzo, N; Dini, L; Maffia, M; Palamà, I; Passerini, CG; Reddiconto, G; Toto, C | 1 |
| Amat, JC; Ballester, C; Bauça, JM; Besalduch, J; Bex, T; Gutiérrez, A; Marcús, TF; Martinez-Serra, J; Navarro-Palou, M; Novo, A; Ros, T; SanFelix, S; Santos, C; Soverini, S; Vidal, C | 1 |
| Cortes, J; Jabbour, E; Kantarjian, H; O'Brien, S; Pemmaraju, N; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S; Wierda, W | 1 |
| Dörken, B; Fateh-Moghadam, S; Giles, FJ; Grille, P; Haverkamp, W; Kim, TD; Köhncke, C; le Coutre, P; Levitin, M; Schwarz, M | 1 |
| Dreosti, L; Jogessar, V; Louw, VJ; Moodley, D; Novitzky, N; Patel, M; Ruff, P; Schmidt, A; Willem, P | 1 |
| Anagnostopoulos, A; Athanasiadou, A; Batsis, I; Gaitatzi, M; Papaioannou, G; Touloumenidou, T; Voutiadou, G | 1 |
| Abbott, BL | 1 |
| Cortes, J; Fava, C; Kantarjian, H | 1 |
| Eckelhart, E; Grebien, F; Hantschel, O; Kaupe, I; Sexl, V; Superti-Furga, G; Wagner, KU; Warsch, W | 1 |
| Ji, JM; Ji, O; Jiang, PJ; Shen, Q; Wu, Y; Yu, H; Zhang, YC; Zhu, GR | 1 |
| Amet, Y; Berthou, C; Dalbies, F; Eveillard, JR; Grall, P; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Erben, P; Härtel, N; Hochhaus, A; Klag, T; La Rosée, P; Schenk, T; Schnetzke, U; Schwaab, J | 1 |
| Auewarakul, CU; Thongnoppakhun, W; Wongboonma, W | 1 |
| Baccarani, M; Cortes, J; Druker, BJ; Gathmann, I; Granvil, C; Guilhot, F; Hayes, M; Hughes, TP; Wang, Y | 1 |
| Gallipoli, P; Holyoake, T; Jørgensen, H; Lyons, J; Shah, M | 1 |
| Besen, A; Disel, U; Duman, BB; Gurkan, E; Paydas, S | 1 |
| Fang, BZ; Xie, J; Zhang, X | 1 |
| Bhatia, R; Chen, W; Ho, Y; Holyoake, TL; Li, L; McDonald, T; Wang, L; Wang, Z | 1 |
| Juan, WC; Ong, ST | 1 |
| Fujisawa, S; Imai, K; Kiyoi, H; Maeda, Y; Miyamura, K; Miyazaki, Y; Mori, N; Nagai, T; Nakaseko, C; Naoe, T; Ohnishi, K; Ohtake, S; Takeuchi, J; Tauchi, T; Usui, N; Yagasaki, F; Yamazaki, H | 1 |
| Abed El Baky, M; Bartholomew, C; Holyoake, TL; Jørgensen, HG; Melo, JV; Roy, P; Roy, S; Strathdee, G | 1 |
| Fukushima, N; Ichinohe, T; Kimura, S | 1 |
| Blasdel, C; Boston, BA; Druker, B; Nguyen, T; Rastogi, MV; Stork, L | 1 |
| Ghosh, K; Idicula-Thomas, S; Sonawani, A; Vaidya, S; Vundinti, BR | 1 |
| Bhatia, R; Chen, W; Cheng, X; Eisenbrand, G; Jove, R; Konig, H; Merz, KH; Nam, S; Park, S; Scuto, A; Yang, F; Yoo, HS | 1 |
| Bao, RF; Cao, Y; Duan, LN; Lu, CR; Luo, Y; Wang, Z; Xue, M; Yan, S; Zhang, YJ; Zhu, F | 1 |
| Abáigar, M; Benito, R; Cañizo, MC; Delgado, M; García, JL; Gutiérrez, NC; Lumbreras, E; Rivas, JM; Robledo, C; Rodríguez-Vicente, AE | 1 |
| Cao, L; Kang, R; Tang, D; Vernon, P; Yang, L; Yu, Y; Zhao, M; Zhu, S | 1 |
| Eckardt, L; Millot, F; Suttorp, M; Tauer, JT | 1 |
| Chao, KS; Chen, YJ; Hou, MH; Jhih Cai, C; Liao, HF; Su, YC; Zheng, ZY | 1 |
| Cho, EH; Jeon, SY; Kim, HS; Kim, JA; Kwak, JY; Lee, NR; Shin, S; Song, EK; Yhim, HY; Yim, CY | 1 |
| Goulden, S; Stevens, A; Sutcliffe, F | 1 |
| Holmes, D | 1 |
| Jönsson, S; Mellström, D; Olsson, B; Standal, T; Wadenvik, H | 1 |
| Ahn, KW; Akpek, G; Aljurf, M; Artz, A; Cahn, JY; Cairo, M; Chen, YB; Cooper, B; de Lima, M; Deol, A; Giralt, S; Gupta, V; Khoury, HJ; Kohrt, H; Lazarus, HM; Lewis, I; Olsson, R; Pedersen, TL; Pidala, J; Pulsipher, M; Savani, BN; Seftel, M; Socié, G; Tallman, M; Ustun, C; Vij, R; Vindeløv, L; Warlick, E; Weisdorf, D | 1 |
| Bhatia, R; Chen, WY; Roth, M; Stark, JM; Wang, Z; Yuan, H | 1 |
| Foo, J; Gönen, M; Guilhot, J; Mahon, FX; Michor, F; Tang, M | 1 |
| Field, EA; Rajlawat, BP; Steele, JC; Triantafyllou, A | 1 |
| Candelaria, M; Cervera, E; Cortes, J; Dueñas-González, A; Gonzalez-Fierro, A; Gordillo-Bastidas, D; Labardini, J; López-Navarro, O; Taja-Chayeb, L | 1 |
| Pfirrmann, M; Saussele, S | 1 |
| Abe, A; Hiraga, J; Inagaki, Y; Kitamura, K; Minami, M; Minami, Y; Miyamura, K; Mizuno, S; Naoe, T; Sawa, M; Ymamoto, K | 1 |
| Bang, JH; Branford, S; Choi, SY; Hughes, TP; Kim, DW; Park, JE; Prime, JA; Ross, DM; Yeung, DT | 1 |
| Wise, J | 1 |
| Brunstein, C; Cayci, Z; Rogosheske, J; Shune, L; Ustun, C | 1 |
| Baerlocher, GM; Branford, S; Dengler, J; Einsele, H; Erben, P; Fabarius, A; Falge, C; Göhring, G; Haferlach, C; Hänel, M; Hanfstein, B; Hasford, J; Hehlmann, R; Hochhaus, A; Hofmann, WK; Hughes, TP; Kanz, L; Kneba, M; Kolb, HJ; Krause, SW; Lauseker, M; Müller, MC; Neubauer, A; Pfirrmann, M; Pfreundschuh, M; Proetel, U; Saußele, S; Schnittger, S; Schubert, J; Spiekermann, K; Stegelmann, F; Waller, CF | 1 |
| Ayres, ML; Chen, LS; Gandhi, V; Keating, MJ; Nowak, BJ; Pillai, RN; Shpall, EJ; Thomas, MW | 1 |
| Atallah, E; Haddad, RY; Torgerson, SR | 1 |
| Hayashi, T; Igarashi, T; Ikeda, H; Ishida, T; Shinomura, Y; Takahashi, T; Yasui, H | 1 |
| Bergeron, A; Bergot, E; Bourdin, A; Bouvaist, H; Canuet, M; Girerd, B; Guignabert, C; Günther, S; Humbert, M; Jaïs, X; Macro, M; Montani, D; Natali, D; O'Callaghan, DS; Perros, F; Pison, C; Poubeau, P; Savale, L; Simonneau, G; Sitbon, O; Tubert-Bitter, P; Zalcman, G | 1 |
| Candrilli, SD; Iyer, S; Kaye, JA; Mitra, D; Trask, PC | 1 |
| Damnhouri, G; Elhefni, AM; Mabed, M | 1 |
| Auberger, P; Ben Sahra, I; Cassuto, JP; Chéli, Y; Cluzeau, T; Deckert, M; Dufies, M; Fenouille, N; Jacquel, A; Legros, L; Luciano, F; Mahon, FX; Pasquet, JM; Puissant, A; Raynaud, S; Robert, G; Tichet, M | 1 |
| Chen, W; Dowell, J; Tirado, CA; Wakim, JJ | 1 |
| Dai, M; Meng, FY; Xu, D; Zhong, JS; Zhou, HS | 2 |
| Dinis, J; Gromicho, M; Laires, A; Martins, C; Rendeiro, P; Rodrigues, A; Rueff, J; Silva, V; Tavares, P; Torres, F | 1 |
| Armstrong, SA; Bullinger, L; Feng, Z; Heidel, FH; Kalaitzidis, D; Lane, SW; Neff, TA; Stein, L; Wang, Z | 1 |
| Carrasco-Daza, D; de Ocariz, MS; Durán-McKinster, C; García-Romero, MT; Orozco-Covarrubias, L; Palacios-López, C; Ruiz-Maldonado, R | 1 |
| Borsky, M; Dvorakova, D; Jeziskova, I; Jurcek, T; Mayer, J; Racil, Z; Razga, F; Zackova, D | 1 |
| Boxer, SG; Levinson, NM | 1 |
| Koskela, H; Koskenvesa, P; Mustjoki, S; Porkka, K | 1 |
| Jootar, S | 1 |
| Bhatia, R; Hair, A; Ho, YW; Holyoake, TL; Huang, Q; Huettner, C; Lee, SU; Lin, A; Maeda, T; Zhang, B | 1 |
| Hatanaka, N; Kami, M; Kishi, Y; Kodama, Y; Kusumi, E; Matsui, A; Matsumura, T; Morozumi, R; Murashige, N; Takita, M; Tanaka, Y | 1 |
| D'Andrea, RJ; Frede, A; Groot-Obbink, K; Hughes, TP; Kok, CH; Osborn, M; Saunders, VA; Somogyi, AA; Wang, J; White, DL | 1 |
| Baccarani, M; Breccia, M; Caocci, G; Cardoni, A; Chie, W; Cocks, K; Efficace, F; Kossak-Roth, U; Mandelli, F; Naeem, A; Nicolatou-Galitis, O; Saussele, S; Sprangers, M; Vignetti, M | 1 |
| Giles, F; Gjertsen, B; Labar, B; Mahon, FX; Rosti, G; Swords, R; Turkina, A | 1 |
| Hoyle, M; Liu, Z; Moxham, T; Pitt, M; Rogers, G; Stein, K; Thompson Coon, J | 1 |
| Bryant, J; Clegg, A; Colquitt, JL; Cooper, K; Frampton, GK; Loveman, E | 1 |
| Huang, LS; Tong, JF; Xu, XH; Yang, J; Yu, T; Yuan, XG; Zhao, XY | 1 |
| Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Qin, YZ; Shi, HX | 1 |
| Shen, ZX; Zhou, L | 1 |
| Diwu, L; Dong, T; Huang, J; Huang, Q; Kuang, P; Liu, T; Lu, X; Meng, W; Wang, Y; Xiang, B; Yang, S; Ye, Y | 1 |
| Barra, A; Basbous, S; Giraud, C; Gombert, JM; Guilhot, F; Herbelin, A; Jacomet, F; Levescot, A; Robin, A; Rossignol, A; Roy, L; Turhan, AG | 1 |
| Abraham, LJ; Appaji, L; Arunakumari, BS; Bhise, R; Govindbabu, K; Lakshmaiah, KC; Lokanatha, D; Purohit, S; Suresh, TM | 1 |
| Cervantes, F; le Coutre, P; Porkka, K; Saglio, G; Steegmann, JL | 1 |
| Cao, L; Kang, R; Lotze, M; Tang, D; Yang, L; Yu, Y | 1 |
| Abe, A; Cragg, MS; Hind, CK; Kiyoi, H; Minami, Y; Naoe, T; Shimada, K; Tomita, A | 1 |
| Baer, MR; Gojo, I; Rapoport, AP; Rassool, FV; Robert, C; Tobin, LA; Tomkinson, AE | 1 |
| Arvidsson, I; Barbany, G; Hast, R; Ohm, L; Stenke, L | 1 |
| Klemm, J; Mehr, SR | 1 |
| Chantry, A; Smith, PG; Tanaka, H | 1 |
| Hautaniemi, S; Heckman, CA; Jalkanen, SE; Lahesmaa-Korpinen, AM; Mustjoki, S; Porkka, K; Rantanen, V | 1 |
| Divoka, M; Faber, E; Friedecky, D; Indrak, K; Jarosova, M; Rohon, P; Rozmanova, S | 1 |
| Chen, S; He, H; Shen, Y; Zhu, Y | 1 |
| Chen, Y; Guo, Z; Li, D; Li, S; Peng, C; Shan, Y; Zhang, H | 1 |
| Austin, G; Clark, RE; Giannoudis, A; Wang, L | 1 |
| Chen, ZC; Hu, HH; Li, WM; Wang, HX; Xiao, Y; You, Y; Zhong, ZD; Zhu, XJ; Zou, P | 1 |
| Blakesley, RE; Clark, RE; Etienne, G; Flinn, IW; Gallagher, NJ; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Kurokawa, M; Larson, RA; Moiraghi, B; Saglio, G; Yu, R | 1 |
| Bhatt, VR; Gupta, S; Varma, S | 1 |
| Kuo, CC; Lee, CM; Lin, LC; Wang, LS; Wu, AT; Wu, CH; Yang, WC; Yeh, CT; Yen, GC | 1 |
| Alvarez, S; Blanco, R; Bretones, G; Caraballo, JM; Cigudosa, JC; Delgado, MD; Ferrándiz, N; García-Alegria, E; Gómez-Casares, MT; León, J; López-Jorge, CE; Martín-Perez, J; Sánchez-Bailón, P; Vaqué, JP | 1 |
| Catalano, A; Chong, L; Iland, H; Khoo, TL; Supple, S; Yeoh, SC; Yeung, S | 1 |
| Chen, SS; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Liu, YR; Qin, YZ | 1 |
| Chen, L; Griffin, JD; Guérin, A; Ponce de Leon, D; Wu, EQ | 1 |
| Bazarbachi, A; Nasr, R | 1 |
| Baran, Y; Cakir, Z; Can, G; Gunduz, U; Kartal, M | 1 |
| Abdelhay, E; Cecchini, R; Lemos, G; Panis, C; Pizzatti, L; Rocha, M; Souza, GH | 1 |
| Alimena, G; Breccia, M; Finsinger, P; Latagliata, R; Loglisci, G; Mancini, M; Salaroli, A; Serrao, A; Zacheo, I | 1 |
| Hao, SG; Liang, H; Ma, LY; Tao, R; Yan, JS; Yang, H | 1 |
| Du, X; Huang, XJ; Jin, J; Meng, FY; Shen, ZX; Zeng, QS; Zhou, L | 1 |
| Fang, BJ; Gui, RR; Zhang, YL | 1 |
| Wu, SH; Xu, J; Zheng, CP | 1 |
| Caruso, M; de Campos-Lima, PO; Ghani, K; Naud, JS | 1 |
| Chan, M; Choong, A; Chu, S; Chuah, C; Goh, YT; Hwang, W; Koh, M; Lim, TJ; Linn, YC; Loh, Y; Ng, HJ; Niam, M; Suck, G; Yong, HX | 1 |
| Dziadosz, M; Fischer, T; Heidel, F; Kindler, T; Koschmieder, S; Lipka, DB; Melo, JV; Müller-Tidow, C; Schemionek, M; Schnöder, T; Wagner, MC | 1 |
| Cao, R; Chen, W; Feng, R; Liu, Q; Meng, F; Wei, Y; Yin, C; Zhang, X | 1 |
| Fava, C; Rege-Cambrin, G; Saglio, G | 1 |
| Chen, R; Huang, S; Liang, Y; Liu, L; Wang, M; Wang, S; Wu, Y; Xiao, F; Zhang, B; Zhang, J | 1 |
| Dingermann, T; Marschalek, R; Zündorf, I | 1 |
| Airley, R | 1 |
| Auberger, P; Aumann, K; Braun, S; Brummer, T; Daly, RJ; Halbach, S; Laßmann, S; Pahl, HL; Penninger, JM; Schramek, D; Schwemmers, S; Waller, CF; Werner, M; Wöhrle, FU; Zeiser, R | 1 |
| Fabarius, A; Giehl, M; Haaß, W; Hofmann, WK; Nittka, S; Schrotz-King, P; Seifarth, W; Stehle, M | 1 |
| Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Cottone, F; Efficace, F; Gherlinzoni, F; Iurlo, A; Mandelli, F; Pardini, S; Rossi, AR; Rosti, G; Salvucci, M; Tiribelli, M; Vignetti, M | 1 |
| Angelini, S; Baccarani, M; Barnett, M; Cantelli-Forti, G; Cilloni, D; Hrelia, P; Hughes, TP; Iacobucci, I; Kim, DW; Martinelli, G; Pane, F; Perini, G; Radich, J; Ravegnini, G; Saglio, G; Soverini, S; Thornquist, M; Turrini, E; White, DL; Woodman, R | 1 |
| Alessandro, R; Corrado, C; De Leo, G; Flugy, AM; Guggino, G; Karmali, R; Raimondo, S; Taverna, S | 1 |
| Cui, GH; Gowrea, B; Hu, Y; Li, M; Wang, YD; Xia, J | 1 |
| Chen, WW; Meng, FY; Wang, ZX; Yin, CX; Zhong, JS | 1 |
| Agarwal, A; Deininger, MW; Druker, BJ; Fleischman, AG; Loriaux, M; Luty, S; MacKenzie, R; Petersen, CL; Woltjer, RL | 1 |
| Gong, Y; Guo, Y; Lin, J; Shan, Q; Yang, X; Zhou, R | 1 |
| Auberger, P; Brisson, A; Djavaheri-Mergny, M; Drullion, C; Gioia, R; Lagarde, V; Mahon, FX; Pasquet, JM; Priault, M; Tan, S; Trégoat, C | 1 |
| Alonso, A; Brusic, V; Cai, A; DeLuca, DS; Hammond, NN; Keskin, DB; Nardi, V; Neuberg, D; Sidney, J; Stone, RM; Wu, CJ; Zhang, GL; Zhang, W | 1 |
| Ghosh, B; Goel, N; Pangtey, B; Raina, UK; Thakar, M | 1 |
| Ansah, AJ; Bamdad, M; Berger, J; Berger, MG; Boiret-Dupré, N; Bourgne, C; Cahn, JY; Gagnieu, MC; Guerci, A; Guyotat, D; Hermet, E; Janel, A; Libert, F; Makhoul, PC; Pereira, B; Pereira, S; Pigeon, P; Rapatel, C; Trouillier, S | 1 |
| Giraudier, S; Huguet, F; Legros, L; Mahon, FX; Nicolini, FE; Rousselot, P; Tulliez, M | 1 |
| Alpár, D; de Jong, D; Kajtár, B; Kereskai, L; Pajor, L; Savola, S; Szuhai, K; Yigittop, H | 1 |
| Bueso-Ramos, CE; Cortes, JE; Hoehn, D; Kantarjian, HM; Medeiros, LJ; Wang, X | 1 |
| Abraham, I; MacDonald, K | 1 |
| Jabbour, E; Mathisen, MS; O'Brien, S | 1 |
| Constance, JE; Lim, CS; Matissek, KJ; Mossalam, M; Woessner, DW | 1 |
| Abboud, MR; Fahed, Z; Farhat, FS; Kassem, N; Mahfouz, RA; Nasr, F; Otrock, ZK; Ziade, A | 1 |
| Huang, XJ; Jiang, B; Jiang, Q; Lai, YY; Liu, YR; Qin, YZ; Zhao, XY | 1 |
| Hanumanthu, PL; Keechilat, P; Koyakutty, M; Malarvizhi, GL; Menon, D; Menon, K; Mony, U; Nair, S; Prabhu, R; Retnakumari, AP; Sidharthan, N; Thampi, MV | 1 |
| Chihara, D; Ito, H; Katanoda, K; Matsuda, T; Matsuo, K; Saika, K; Shibata, A; Sobue, T | 1 |
| Bernardo, PS; Maia, RC; Reis, FR | 1 |
| Anderson, KI; Bleijerveld, OB; Corradini, E; Heck, AJ; Kolch, W; Müller, PJ; Preisinger, C; Scholten, A; Schwarz, JP | 1 |
| De Vellis, A; Foà, R; Giona, F; Gnessi, L; Mariani, S; Marzella, D; Moleti, ML; Rea, M; Testi, AM | 1 |
| Berthou, C; Bornand, A; Cony-Makhoul, P; Guilhot, F; Guilhot, J; Mahon, FX; Nicolini, F; Réa, D; Reiffers, J; Rousselot, P; Saint-Jean, O | 1 |
| Shere, Y; Vigneswaran, N; Yu, YH | 1 |
| Bi, C; Cheong, LL; Chng, WJ; Chong, PS; Liu, SC; Mahara, S; Ong, KO; Zeng, Q; Zhou, J | 1 |
| Bianchino, G; D'Arena, G; D'Auria, F; Deaglio, S; Del Vecchio, L; Gemei, M; Grieco, V; Guariglia, R; Luciano, L; Mansueto, G; Martorelli, MC; Musto, P; Pietrantuono, G; Statuto, T; Villani, O | 1 |
| Ababneh, N; Abbasi, S; Awidi, A; Bsoul, N; Magablah, A; Marei, L; Mefleh, R | 1 |
| Bennett, KL; Bilban, M; Breitwieser, FP; Carlson, SM; Colinge, J; Gleixner, KV; Grebien, F; Gridling, M; Müller, AC; Rix, U; Superti-Furga, G; Valent, P; White, FM; Winter, GE | 1 |
| Bowles, DW; Green, K; Thienelt, CD | 1 |
| Cano-Abad, MF; Moreno, JM; Ruiz-Nuño, A; Steegman, JL; Wojnicz, A | 1 |
| Dan, K; Inokuchi, K; Tamai, H; Yamaguchi, H | 1 |
| Baccarani, M; Giles, FJ; Kantarjian, HM; le Coutre, PD; Ottmann, OG; Sallas, WM; Woodman, RC; Yin, OQ | 1 |
| Bai, LY; Chang, CH; Chen, CC; Chen, TY; Hsiao, PC; Kuo, CY; Kuo, MC; Lai, CL; Lan, YJ; Lin, TH; Lin, TL; Shih, LY; Wang, MC; Yang, Y | 1 |
| Capra, ME; Fogliatto, LM; Koshiyama, DB; Oliveira, CA; Paskulin, GA; Rosa, RF; Vanelli, T; Zen, PR | 1 |
| Chen, T; Fang, Y; Gan, X; Gan, Y; Gu, Y; Huang, L; Huang, W; Li, H; Lou, G; Meng, Z; Tang, J; Wang, K; Xu, G; Xu, R; Xu, X; Zhang, X; Zheng, S; Zhou, H | 1 |
| Huh, JY; Kang, MS; Kim, M; Kim, TY; Kim, Y; Lee, DS; Min, HJ; Oh, B | 1 |
| Chamnanchanunt, S; Iam-arunthai, K; Nakhakes, C; Suwanban, T; Thungthong, P | 1 |
| Ding, K; Leng, F; Li, Y; Long, H; Lu, X; Luo, J; Pan, X; Ren, X; Shen, M; Tu, Z; Wen, D; Zhang, F; Zhang, Z | 1 |
| Barbagallo, I; Di Raimondo, F; Giallongo, C; La Cava, P; Li Volti, G; Palumbo, GA; Parrinello, N; Stagno, F; Tibullo, D; Vanella, L | 1 |
| Glodkowska-Mrowka, E; Koromilas, AE; Kusio-Kobialka, M; Leszak, G; Peidis, P; Piwocka, K; Podszywalow-Bartnicka, P; Seferynska, I; Stoklosa, T; Wolanin, K | 1 |
| Brümmendorf, TH; Keller-V Amsberg, G | 1 |
| Branford, S; Haque, A; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Martinelli, G; Müller, MC; Radich, JP; Saglio, G; Shou, Y; Soverini, S; Woodman, RC | 1 |
| Ambrosino, B; Belanger, C; Bouchet, S; Lassalle, R; Mahon, FX; Molimard, M; Moore, N; Poulette, S; Schuld, P; Titier, K | 1 |
| Katagiri, S; Ohyashiki, JH; Ohyashiki, K; Umezu, T | 1 |
| Bang, SM; Cheong, JW; Chung, JS; Eom, KS; Hyun, MS; Jo, DY; Joo, YD; Jung, CW; Kim, BS; Kim, CS; Kim, DH; Kim, H; Kim, HJ; Kim, I; Kim, MK; Kim, YK; Lee, HG; Lee, HW; Lim, M; Min, YH; Moon, JH; Oh, SJ; Park, EK; Park, J; Park, JS; Park, MR; Park, SY; Ryoo, HM; Seong, SJ; Sohn, SK; Won, JH; Yoon, SS; Yoon, YR; Zang, DY | 1 |
| Chen, T; Gan, YC; Gu, Y; Tang, JF; Xie, YY; Xu, F; Xu, GB; Xu, RZ; Xu, XH; Zhao, XY; Zhou, H | 1 |
| Chen, L; Ericson, SG; Guérin, A; Jabbour, E; Wu, EQ; Xie, J; Yu, AP | 1 |
| Chi, HS; Cho, YU; Jang, S; Kwon, MR; Park, CJ; Park, SH | 1 |
| Hirase, C; Matsumura, I | 1 |
| Anderson, R; Ciani, O; Cooper, C; Crathorne, L; Garside, R; Hoyle, M; Jones-Hughes, T; Osipenko, L; Pavey, T; Rudin, C; Ukoumunne, O; Venkatachalam, M | 1 |
| Gu, HL; Qin, ZH; Wang, J | 1 |
| Drew, J; Fitter, S; Fukumoto, S; Hughes, TP; Schultz, CG; Sims, NA; Vandyke, K; Yeung, DT; Zannettino, AC | 1 |
| Amala, K; Bhujanga Rao, AK; Gondi, CS; Gorantla, B; Rao, JS | 1 |
| Shim, HS; Woo, SH | 1 |
| Eadie, LN; Hiwase, DK; Hughes, TP; Saunders, VA; White, DL | 1 |
| Baccarani, M; Bhalla, KN; Cortes, J; Gattermann, N; Giles, F; Hochhaus, A; Hughes, TP; Jabbour, E; Kantarjian, HM; Kim, DW; Larson, RA; le Coutre, PD; Martinelli, G; Ottmann, OG; Pinilla-Ibarz, J; Radich, JP; Reynolds, J; Saglio, G; Woodman, RC | 1 |
| Glauche, I; Hehlmann, R; Hochhaus, A; Horn, M; Loeffler, M; Müller, MC; Roeder, I | 1 |
| Shah, NP | 4 |
| Goldman, JM; Marin, D | 2 |
| Jacobsen, PB; Jim, HS; Komrokji, R; Lancet, J; Lee, MR; Phillips, KM; Pinilla-Ibarz, J; Small, BJ; Sokol, L; Sotomayor, E; Sweet, K; Tinsley, S | 1 |
| Bolt, DM; Mandal, R; Shah, BK | 1 |
| Arellano, C; Chatelut, E; Gandia, P; Huguet, F; Lafont, T; Malard, L | 1 |
| Jaeger, BA; Kuhlisch, E; Roth, HJ; Suttorp, M; Tauer, JT; Ulmer, A | 1 |
| Lee, J; Shen, P; Wu, X; Zhang, G; Zhang, X | 1 |
| Kurzrock, R; Westin, JR | 1 |
| Alimena, G; Barulli, S; Breccia, M; Carmosino, I; Diverio, D; Federico, V; Finsinger, P; Isidori, A; Latagliata, R; Loglisci, G; Mancini, M; Nanni, M; Santopietro, M; Visani, G; Volpicelli, P; Vozella, F | 1 |
| Chim, CS; Dou, L; Fu, H; Gao, L; Gao, X; Jing, Y; Li, J; Li, Y; Luo, X; Wang, L; Wang, W; Xu, C; Yu, L; Zheng, X | 1 |
| Adrian, LT; Alikian, M; Anderson, DJ; Deininger, MW; Druker, BJ; Eide, CA; Eiring, AM; Estrada, JC; Foroni, L; Gu, Z; Kelley, TW; Khorashad, JS; Kraft, IL; Lange, T; Marin, D; Mason, CC; O'Hare, T; Pomicter, AD; Reid, AG; Soverini, S; Szankasi, P; Zabriskie, MS | 1 |
| Austin, G; Clark, RE; Davies, A; Foroni, L; Giannoudis, A; Holyoake, TL; Jorgensen, AL; Kottaridis, PD; Liloglou, T; Müller, MC; Pirmohamed, M; Pushpakom, S; Wang, L; Xinarianos, G; Zhang, JE | 1 |
| Dinis, J; Fernandes, AR; Gromicho, M; Laires, A; Magalhães, M; Rendeiro, P; Rueff, J; Sebastião Rodrigues, A; Tavares, P; Torres, F | 1 |
| Ding, W; Li, ZQ; Niu, CC; Pan, J; Si, WK; Wu, WR; Yang, Z; Yang, ZD; Zhang, XL; Zhao, C | 1 |
| Kurosu, T; Miura, O; Nagao, T; Oshikawa, G; Wu, N | 1 |
| Branford, S | 1 |
| Auberger, P; Cassuto, JP; Cassuto, O; Dubois, A; Dufies, M; Ginet, C; Hamouda, A; Jacquel, A; Karsenti, JM; Legros, L; Lenain, P; Luciano, F; Puissant, A; Robert, G | 1 |
| Aduwa, E; Apperley, JF; Foroni, L; Goldman, J; Marin, D; Milojkovic, D; Reid, A; Szydlo, R | 1 |
| Baxendale, IR; Deadman, BJ; Hopkin, MD; Ley, SV | 1 |
| Belhadj, S; Ben Abdelghani, K; Chekili, S; El Menaa, M; Laatar, A; Souabni, L; Zakraoui, L | 1 |
| Kravchenko, SK; Moiseyeva, TN; Sharkunov, NN; Vinogradova, OY; Zybunova, EE | 1 |
| Liu, J; Zhao, XL | 1 |
| Chan, JY; Chowbay, B; Heng, CC; Lin, K; Singh, O | 1 |
| Gencer, EB; Hantschel, O; Kuzyk, O; Lamontanara, AJ | 1 |
| Browett, P; Gamble, G; Grey, A; Horne, A; O'Sullivan, S; Porteous, F; Wattie, D | 1 |
| Alimena, G; Breccia, M; Diverio, D; Latagliata, R; Loglisci, G; Mancini, M; Salaroli, A; Serrao, A | 1 |
| Bektas, O; Bozkurt, S; Buyukasik, Y; Goker, H; Inanc, A; Kansu, E; Uz, B | 1 |
| Dolgin, E | 1 |
| Chi, HS; Cho, YU; Im, HJ; Jang, S; Park, CJ; Park, SH | 1 |
| Chen, S; Engen, JR; Iacob, RE; Panjarian, S; Smithgall, TE | 1 |
| Jiang, W; Lin, YL; Meng, Y; Roux, B | 1 |
| Hu, YX; Huang, H; Lai, XY; Liu, LZ; Luo, Y; Tan, YM; Wu, KN; Zhao, YM | 1 |
| Bansal, D; Bhansali, A; Marwaha, RK; Narayanan, KR; Sachdeva, N; Varma, N; Walia, R | 1 |
| Bellisola, G; Cinque, G; Gambacorti Passerini, C; Moratti, E; Redaelli, S; Silvestri, G; Sorio, C; Vezzalini, M; Wehbe, K | 1 |
| Balabanov, S; Barett, C; Bokemeyer, C; Braig, M; Brümmendorf, TH; Keller, G; Pospisil, H; Scharf, C; Schuppert, A; Venz, S; Walther, R; Wilhelm, T | 1 |
| Barbany, G; Dybedal, I; Ehrencrona, H; Fioretos, T; Gedde-Dahl, T; Gjertsen, BT; Hernesniemi, S; Hjorth-Hansen, H; Hovland, R; Josefsen, D; Koskenvesa, P; Markevärn, B; Mustjoki, S; Olofsson, T; Olsson-Strömberg, U; Porkka, K; Rapakko, K; Richter, J; Simonsson, B; Stenke, L; Thunberg, S | 1 |
| Cui, GH; Hu, Y; Li, M; Wang, YD; Xia, J; You, Y | 1 |
| Kim, DH; Kim, JI; Kim, WS; Kim, YC; Lee, JE; Lee, MJ; Park, SG; Song, MR | 1 |
| Bhatia, R; Chamberlin, AR; Chen, CF; Chen, PL; Goldblatt, E; Hu, CM; Konig, H; Lee, WH; Li, G; Lin, X; Qiu, XL; Wu, G; Zhou, L; Zhu, J | 1 |
| Chen, Y; Green, MR; Li, S; Ma, L; Peng, C; Rosmarin, AG; Wang, J; Yang, ZF; Zhang, H | 1 |
| Himanshu, D; Jain, N; Jha, P; Singh, AK | 1 |
| Bubenheim, M; Daouphars, M; Jardin, F; Lenain, P; Ouvry, M; Rouvet, J; Varin, R | 1 |
| de Almeida, MH; de Souza, CA; Lorand-Metze, I; Pagnano, KB; Vigorito, AC | 1 |
| Hu, JD; Huang, XJ; Jin, J; Li, JY; Liu, T; Meng, FY; Shen, ZX; Wang, JM; Wang, JX; Wu, DP | 1 |
| Di Cristina, A; Dieli, F; Ferro, A; Grimaudo, S; Meli, M; Pipitone, MR; Romagnoli, R; Simoni, D; Tolomeo, M | 1 |
| Simoneau, CA | 1 |
| Cetkovsky, P; Cmunt, E; Dusek, L; Dvorakova, D; Jurcek, T; Klamova, H; Machova Polakova, K; Mayer, J; Muzik, J; Racil, Z; Razga, F; Zackova, D | 1 |
| Barbagallo, I; Chiarenza, A; Consoli, C; Cupri, A; Di Raimondo, F; Giallongo, C; La Cava, P; Palumbo, GA; Parrinello, N; Stagno, F; Tibullo, D | 1 |
| Jabbour, EJ; Quintás-Cardama, A | 1 |
| Bouchet, S; Dulucq, S; Lagarde, V; Mahon, FX; Molimard, M; Pasquet, JM | 1 |
| Bedewy, AM; El-Maghraby, SM | 1 |
| Baran, Y; Bozkurt, S; Kansu, E; Özkan, T; Özmen, F; Sunguroğlu, A | 1 |
| Augé, S; Casetti, L; Chomel, JC; Dusanter-Fourt, I; Lauret, E; Martin-Lannerée, S; Najjar, I; Plo, I; Roy, L; Turhan, AG | 1 |
| Lim, D; Muir, J | 2 |
| Albitar, M; Andreeff, M; Beran, M; Capdeville, R; Cortes, JE; Faderl, S; Freireich, EJ; Garcia-Manero, G; Giles, FJ; Hayes, K; Issa, JP; Kantarjian, HM; Keating, M; Koller, C; Kornblau, SM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Smith, TL; Talpaz, M; Thomas, DA | 1 |
| Arlinghaus, R; Atallah, E; Fernandes-Reese, S; Guo, JQ; Kantarjian, H; O'brien, S; Rios, MB; Talpaz, M | 1 |
| Buchdunger, E; Capdeville, R; Matter, A; Zimmermann, J | 1 |
| Baker, DE | 1 |
| Facon, T; Fenaux, P; Grardel-Duflos, N; Laï, JL; Philippe, N; Preudhomme, C; Roche-Lestienne, C; Soenen-Cornu, V | 1 |
| Daley, GQ; Hoover, RR; Mahon, FX; Melo, JV | 1 |
| Druker, BJ; Johnson, K; La Rosée, P; O'Dwyer, ME | 1 |
| Blay, JY; Ray-Coquard, I | 1 |
| Brasher, BB; Gorre, ME; Nicoll, J; Roumiantsev, S; Sawyers, CL; Shah, NP; Van Etten, RA | 1 |
| Cony-Makhoul, P; Etienne, G; Mahon, FX | 1 |
| Beran, M; Dong, L; Kantarjian, HM; Keating, MJ; Onida, F; Scappini, B; Verstovsek, S | 1 |
| Arlinghaus, R; Champlin, R; Cortes, JE; De Lima, M; Faderl, S; Garcia-Manero, G; Giles, FJ; Giralt, SA; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, DA | 1 |
| Balleisen, S; Capdeville, R; Druker, BJ; Kurilik, G; Magenis, E; Mauro, MJ; Mori, M; O'Dwyer, ME; Olson, S | 1 |
| Clark, RE; Ferguson, JE; Pearson, K; Pillitteri, L; Wang, L | 1 |
| Barbany, G; Höglund, M; Simonsson, B | 1 |
| Klejman, A; Morrione, A; Rushen, L; Skorski, T; Slupianek, A | 1 |
| Druker, BJ; O'Dwyer, ME | 4 |
| Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Kreil, S; Kuhn, C; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Schoch, C; Weisser, A | 1 |
| Shannon, KM | 1 |
| Gorre, ME; Kuriyan, J; Nagar, B; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP | 1 |
| Ahmadi, MA; Butler, CE; Esmaeli, B; Kantarjian, HM; Kim, SK; Prieto, VG; Talpaz, M | 1 |
| Apperley, JF; Armstrong, L; Bua, M; Goldman, JM; Marin, D; Marktel, S; Olavarria, E | 1 |
| Lim, DS; Muir, J | 1 |
| Dimopoulou, M; Konstantopoulos, K; Kourelis, C; Meletis, J; Papadogianni, A | 1 |
| Dent, P; Grant, S; Krystal, G; Yu, C | 1 |
| Cáceres, W; Corujo, Y | 1 |
| Baiocchi, OC; Bordin, JO; Chauffaille, ML; Hungria, VT; Pelloso, LA; Yamamoto, M | 1 |
| Chiosis, G; Ellwood-Yen, K; Gorre, ME; Rosen, N; Sawyers, CL | 1 |
| Barton, JC; Jones, SC; Lamberth, WC; Reymann, MT; Scott, VC | 1 |
| Siddall, R | 1 |
| Ebihara, Y; Ito, Y; Kimura, Y; Kuriyama, Y; Miyazawa, H; Nakajima, A; Ohyashiki, K; Serizawa, H; Tauchi, T | 1 |
| Fruehauf, S; Topaly, J; Zeller, WJ | 2 |
| Barthe, C; Chollet, C; Cony-Makhoul, P; Gharbi, MJ; Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Reiffers, J | 1 |
| O'Brien, SG; Rule, SA | 1 |
| Alomar, A; Puig, L; Sureda, A; Vidal, D | 1 |
| Kantarijian, H; Talpaz, M; Tsao, AS | 1 |
| Au, WY; Chan, EC; Kwong, YL; Liang, R; Lie, AK; Ma, SK; Wan, TS | 1 |
| Ades, L; Bergeron, A; Bergot, E; Calvo, F; Devergie, A; Espérou, H; Gluckman, E; Ribaud, P; Rousselot, P; Socié, G; Tazi, A; Vilela, G | 1 |
| Bali, P; Bhalla, K; Burnette, PK; Huang, M; Jove, R; Loughran, T; Nimmanapalli, R; O'Bryan, E; Tepperberg, J | 1 |
| Kmietowicz, Z | 1 |
| Pindolia, VK; Zarowitz, BJ | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D | 1 |
| Arlinghaus, R; Bochinski, K; Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, HM; Letvak, L; O'Brien, S; Rios, MB; Talpaz, M; Thomas, D | 1 |
| Berg, T; Brendel, C; Burchert, A; Cai, D; Denecke, B; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Lahaye, T; Müller, MC; Neubauer, A; Odyvanova, L; Schmidt, M; Wittig, B; Wölfl, S | 1 |
| Hochhaus, A; Lahaye, T; Müller, MC | 1 |
| Berger, U; Corbin, AS; Cross, NC; Druker, BJ; Gschaidmeier, H; Hanfstein, B; Hehlmann, R; Hochhaus, A; Kreil, S; La Rosée, P; Lahaye, T; Müller, MC; Schoch, C | 1 |
| Cohen, MH; Moses, ML; Pazdur, R | 1 |
| Al-Ali, HK; Deininger, MW; Günther, C; Köhler, T; Krahl, R; Lange, T; Leiblein, S; Musiol, S; Niederwieser, D; van Hoomissen, I | 1 |
| Bhalla, K; Nimmanapalli, R | 2 |
| Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Friedrich, T; Hennig, E; Krahl, R; Krohn, K; Leiblein, S; Müller, C; Niederwieser, D; Schmidt, E; Shepherd, P | 1 |
| Ito, Y; Nakajima, A; Ohyashiki, K; Shimamoto, T; Sshida, G; Sumi, M; Tauchi, T | 1 |
| Beran, M; Divoky, V; Gatto, S; Kantarjian, HM; Onida, F; Ricci, C; Scappini, B; Verstovsek, S | 1 |
| Bhutani, M; Raina, V; Sharma, A; Vora, A | 1 |
| Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Schwarz, M | 1 |
| Adams, R; Albritton, K; Coffin, C; Goldsby, R; Pulsipher, M; Wagner, L | 1 |
| Losonczy, H; Molnár, L | 1 |
| Cortes, J; Druker, BJ; O'Brien, SG; Radich, J | 1 |
| Bhalla, K; Fuino, L; Nimmanapalli, R; Richon, V; Stobaugh, C | 1 |
| Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Tipping, AJ; Zafirides, G | 1 |
| Endo, H; Kikuchi, S; Kirito, K; Komatsu, N; Liu, Q; Miyazawa, K; Mori, M; Nagai, T; Ozawa, K; Tauchi, T; Uchida, M; Watanabe, T | 1 |
| Akiyama, T; Fujimi, A; Kato, J; Kikuchi, T; Kogawa, K; Kura, T; Maeda, T; Matsunaga, T; Niitsu, Y; Sato, T; Seki, R; Takahari, D; Takemoto, N; Tanaka, I; Terui, T | 1 |
| Hirose, Y; Ito, M; Iwai, M; Kiyoi, H; Naoe, T; Yokozawa, T | 1 |
| Hentrich, M; Ledderose, G; Salat, C; Stoetzer, OJ | 1 |
| Hentrich, M; Salat, C; Stoetzer, OJ | 1 |
| Balabanov, S; Bartolovic, K; Berger, U; Bokemeyer, C; Brümmendorf, TH; Dietz, K; Ersöz, I; Gschaidmeier, H; Hartmann, U; Hehlmann, R; Hochhaus, A; Kanz, L; Kreil, S; Lahaye, T; Lansdorp, PM; Paschka, P; Wahl, A | 1 |
| Consoli, C; Consoli, U; Giustolisi, R; Guido, G; Milone, G; Palumbo, GA | 1 |
| Buchdunger, E; Dumont, D; Ebos, JM; Kerbel, RS; Master, Z; Melo, JV; Tran, J | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; La Rosée, P; Stoffregen, EP | 1 |
| Goi, K; Inukai, T; Kagami, K; Kayagaki, N; Koyama-Okazaki, T; Nakazawa, S; Nemoto, A; Okumura, K; Sato, H; Sugita, K; Suzuki, T; Takahashi, K; Uno, K; Yagita, H; Yamaguchi, N | 1 |
| Mehdi, SA; Potti, A; Ramar, K | 1 |
| Agis, H; Geissler, K; Sagaster, V | 1 |
| Arlinghaus, R; Donato, NJ; Gallick, G; Lin, H; Stapley, J; Talpaz, M; Wu, JY | 1 |
| Goldberg, SL; Hsu, JW; Madan, RA; Pecora, AL; Rowley, SD; Tantravahi, R | 1 |
| Capriotti, T | 1 |
| Berger, U; Engelich, G; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Reiter, A | 1 |
| Buchdunger, E; O'Reilly, T; Wood, J | 1 |
| Capdeville, R; Dimitrijevic, S; Silberman, S | 1 |
| Conneally, E; Gately, K; Lawler, M; McCann, SR | 1 |
| Clark, RE; Lin, K; Salim, R; Wang, L | 1 |
| Arlinghaus, R; Cortes, J; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D | 1 |
| Campbell, LJ; Januszewicz, EH; Patsouris, C; Rayeroux, KC; Somana, K; Szer, J | 1 |
| Baron, F; Beguin, Y; Fillet, G; Frère, P; Herens, C | 1 |
| Cortes, JE; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, DA; Wierda, W | 1 |
| Gotoh, A; Ito, Y; Katagiri, T; Kawakubo, K; Kawanishi, Y; Kimura, Y; Kuriyama, Y; Miyazawa, K; Nishimaki, J; Ohyashiki, K; Sashida, G; Shimamoto, T; Shoji, N; Suzuki, A; Tauchi, T | 1 |
| Galietta, A; Gambacorti-Passerini, CB; Gunby, RH; Piazza, R; Rostagno, R; Scapozza, L | 1 |
| Arber, DA; Bhatia, R; Forman, SJ; Gray, R; Holtz, M; Niu, N; Sawyers, CL; Slovak, ML; Snyder, DS | 1 |
| Alberti, D; Bungaro, S; Corneo, G; D'Incalci, M; Frapolli, R; Gambacorti-Passerini, C; Pioltelli, P; Pogliani, E; Rossi, F; Russo, D; Tornaghi, L; Verga, M; Zucchetti, M | 1 |
| Camós, M; Cervantes, F; del Campo, R; García-Conde, J; Hernández-Boluda, JC; Martínez-Climent, JA; Montserrat, E; Odriozola, J; Villalón, L | 1 |
| Bachot, N; Bastuji-Garin, S; Berthaud, P; Giraudier, S; Revuz, J; Tulliez, M; Valeyrie, L; Wechsler, J | 1 |
| Brodsky, AL | 1 |
| Salesse, S; Verfaillie, CM | 1 |
| Granzelius, A; Lindgren, JA; Näsman-Glaser, B; Roos, C; Sjölinder, M; Stenke, L; Tornhamre, S; Widell, S | 1 |
| Avigdor, A; Ben-Bassat, I; Hardan, I; Kröger, N; Nagler, A; Rowe, JM; Shimoni, A; Yeshurun, M; Zander, AR | 1 |
| Boeckx, N; Decorte, R; Hagemeijer, A; Ronsyn, E; Vandenberghe, P; Verhoef, G | 1 |
| Berger, U; Haferlach, T; Hehlmann, R; Hiddemann, W; Hochhaus, A; Kern, W; Schnittger, S; Schoch, C | 1 |
| Demuynck, H; Hagemeijer, A; Martiat, P; Meeus, P; Michaux, L; Wouters, E | 1 |
| Egorin, M; Ilaria, RL; Richardson, JA; Wolff, NC | 1 |
| Apperley, JF; Bua, M; Foot, N; Goldman, JM; Marin, D; Marktel, S | 1 |
| Bernu S, T; Besalduch, J; Guti Rrez, A; Parody, R | 1 |
| Belloc, F; Chollet, C; Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Moreau-Gaudry, F; Reiffers, J | 1 |
| Alyea, EP; Capdeville, R; Chillemi, A; DeAngelo, D; Galinsky, I; Hochberg, EP; McLaughlin, S; Neuberg, D; Ritz, J; Soiffer, RJ; Stone, RM; Wu, CJ | 1 |
| Liu, NS; O'Brien, S | 1 |
| Christoforidis, JB; D'Amico, DJ; DeAngelo, DJ | 1 |
| Kondo, M; Toga, W; Tokoro, A | 1 |
| Chuah, CT; Goh, YT; Hwang, WY; Koh, LP; Linn, YC; Ng, HJ; Tan, CH; Tan, PH | 1 |
| Arthur, C; Branford, S; Grigg, A; Herrmann, R; Hughes, T; Joske, D; Lynch, K; Parkinson, I; Rudzki, Z; Seymour, JF; Szer, J; Taylor, K; Walsh, S | 1 |
| Cortes, JE; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Kontoyiannis, D; Mattiuzzi, GN; Raad, I; Reuben, J; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S | 1 |
| Dalziel, K; Garside, R; Round, A; Royle, P; Stein, K | 1 |
| May, TS | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Freireich, EJ; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Rios, MB; Talpaz, M; Thomas, D; Verstovsek, S | 1 |
| Mackinnon, S; Peggs, K | 1 |
| Campbell, L; Grigg, A; Hoyt, R; Juneja, S; Lynch, K; McNamara, C; Roberts, A; Szer, J | 1 |
| Braziel, RM; Druker, BJ; Gatter, KM; Lawce, H; Loriaux, M; Magenis, RE; Mauro, MJ; Maziarz, RT; O'Dwyer, ME; Olson, SB | 1 |
| Chee, YL; Culligan, DJ; Holyoake, TL; Stevenson, D; Vickers, MA | 1 |
| Baron, F; Beguin, Y; Fillet, G; Hafraoui, K; Humblet-Baron, S | 1 |
| Clark, RE; Ferguson, JE; Pearson, K; Wang, L | 1 |
| Calvo, F; Giraudier, S; Larghero, J; Raffoux, E; Rousselot, P; Rybojad, M; Tulliez, M | 1 |
| O'Dwyer, M | 2 |
| Alberti, D; Baccarani, M; Bassi, S; Bonifazi, F; de Vivo, A; Fincato, G; Martinelli, G; Rosti, G; Saglio, G; Trabacchi, E | 1 |
| Apperley, JF; Bua, M; Dazzi, F; De Melo, VA; Foot, N; Goldman, JM; Karadimitris, A; Kotzampaltiris, P; Marin, D; Marktel, S; Olavarria, E; Rahemtulla, A; Szydlo, R | 1 |
| Azam, M; Daley, GQ; Latek, RR | 1 |
| Audring, H; Baskaynak, G; Dörken, B; Kreuzer, KA; le Coutre, P; Riess, H; Schwarz, M; Zuber, J | 1 |
| Abgrall, JF; Berthou, C; Braekeleer, MD; Bris, MJ; Calvez, GL; Herry, A; Marion, V; Morel, F | 1 |
| Deininger, MW; Druker, BJ; Ford, JM; O'Brien, SG | 1 |
| Fujisawa, S; Kobayashi, M; Yano, K | 1 |
| Holyoake, TL; Jørgensen, HG; Paterson, SC; Smith, KD | 1 |
| Hehlmann, R; Larson, R; Schiffer, CA | 1 |
| Ashihara, E; Fuchida, SI; Fujita, N; Inaba, T; Nakagawa, M; Ochiai, N; Okano, A; Shimazaki, C; Uchida, R | 1 |
| Ebnöther, M; Gratwohl, A; Heim, D; Linn, M; Meyer-Monard, S; Tichelli, A; Tsakiris, D | 1 |
| Sausville, EA | 4 |
| Caligiuri, MA; Marcucci, G; Perrotti, D | 1 |
| Mohamed, AN; Pemberton, P; Schiffer, CA; Zonder, J | 1 |
| Rák, K | 1 |
| Feller, SM; Tuchscherer, G; Voss, J | 1 |
| Bornhäuser, M; Griesinger, F; Gschaidmeier, H; Hochhaus, A; Hoelzer, D; Ottmann, OG; Pfeifer, H; Scheuring, U; Schleyer, E; Thiede, C; Wassmann, B | 1 |
| Dörken, B; Hochhaus, A; Kreuzer, KA; Landt, O; Le Coutre, P; Na, IK; Schultheis, K; Schwarz, M | 1 |
| Deacon, A; Ho, AY; Mufti, GJ; Osborne, G | 1 |
| Bornhäuser, M; Ehninger, G; Illmer, T; Schaich, M; Schäkel, K | 1 |
| Cortes, J; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Kornblau, S; O'Brien, S; Rios, MB; Talpaz, M; Verstovsek, S; White, K; Wierda, W | 1 |
| Fruehauf, S; Gschaidmeier, H; Ho, AD; Hochhaus, A; Paschka, P; Schad, M; Topaly, J; Zeller, WJ | 1 |
| Kim, DH; Kim, JG; Lee, KB; Sohn, SK | 1 |
| Emi, N; Hirai, H; Jin-nai, I; Kagami, Y; Kaneta, Y; Katagiri, T; Nakamura, Y; Ohnishi, K; Ohno, R; Taguchi, H; Tomida, A; Tsunoda, T; Tsuruo, T; Ueda, T | 1 |
| Albertini, A; Capucci, M; Cariani, E; Micheletti, M; Rossi, G; Spalenza, F; Zanella, I | 1 |
| Komatsu, N; Mano, H; Miyoshi, T; Muroi, K; Nagai, T; Ohmine, K; Ozawa, K; Takaku, F; Tarumoto, T | 1 |
| Brandwein, J; Gupta, V; Kamel-Reid, S; Lipton, JH; Messner, HA; Minden, MD | 1 |
| Bown, N; Brizard, A; Byrne, J; Clark, RE; Cuthbert, G; Deininger, MW; Franke, C; Freeman-Edward, J; Green, AR; Guilhot, F; Hennig, E; Huntly, BJ; Nacheva, EP; Niederwieser, D; Reid, AG; Vassiliou, G | 1 |
| Aulitzky, WE; Duyster, J; Knabbe, C; Miething, C; van der Kuip, H; Vornlocher, HP; Wohlbold, L | 1 |
| Branford, S; Goh, KY; Grigg, A; Hoyt, R; Hughes, TP; Hui, CH; Kwan, YL; Ma, DD; Rudzki, B; Seymour, JF; To, LB; Trickett, A; Walsh, S; White, D | 1 |
| Duyster, J; Peschel, C; von Bubnoff, N | 1 |
| Cony-Makhoul, P; James, C; Mahon, FX; Marit, G; Trouette, H | 1 |
| Fruehauf, S; Laufs, S; Melo, JV; Schad, M; Topaly, J; Zeller, WJ | 1 |
| Druker, BJ; Kantarjian, HM; Kurzrock, R; Talpaz, M | 1 |
| Deininger, MW; Friedrich, T; Rumpel, M | 1 |
| Enjo, F; Kimura, S; Kobayashi, Y; Kuroda, J; Maekawa, T; Ottmann, OG; Segawa, H; Tokuda, H; Ueda, T; Urasaki, Y; Yoshikawa, T | 1 |
| Breitenbuecher, F; Carius, B; Fischer, T; Gschaidmeier, H; Huber, C; Kasper, S; Kindler, T; Stevens, T | 1 |
| Carella, AM | 3 |
| Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Salvado, A; Talpaz, M; Thomas, D | 1 |
| Darré, S; Facon, T; Laï, JL; Preudhomme, C; Roche-Lestienne, C | 1 |
| Hingorani, SR; Tuveson, DA | 1 |
| Capdeville, R; Silberman, S | 1 |
| Glendenning, GA; Hahn, EA | 1 |
| Deininger, MW; O'Brien, SG | 1 |
| Nakamura, Y; Ohno, R | 1 |
| Baccarani, M; Martinelli, G; Rosti, G; Testoni, N | 1 |
| Branford, S; Hughes, T | 3 |
| Melo, JV; Tipping, AJ | 1 |
| Preudhomme, C; Roche-Lestienne, C | 1 |
| Apperley, JF; Goldman, JM; Marin, D; Olavarria, E | 2 |
| Berthaud, P; Berthou, C; Buzyn, A; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Najman, A; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M | 1 |
| Naoe, J | 1 |
| Konishi, I; Yamaguchi, M | 1 |
| Giamelli, J; Jayabose, S; Sandoval, C | 1 |
| Bross, P; Chen, G; Cohen, M; Gobburu, J; Johnson, JR; Pazdur, R; Rahman, A; Rothmann, M; Staten, A; Zajicek, A | 1 |
| Brandt, H; Mohamed, AN; Pemberton, P; Schiffer, CA; Zonder, JA | 1 |
| Balabanov, S; Bartolovic, K; Berger, U; Berner, B; Bokemeyer, C; Brummendorf, TH; Dietz, K; Ersoz, I; Gschaidmeier, H; Hartmann, U; Hehlmann, R; Hochhaus, A; Kanz, L; Kreil, S; Lahaye, T; Lansdorp, PM; Paschka, P; Wolke, H | 1 |
| Cambiaghi, N; Cavagnini, F; Corneo, G; Gambacorti-Passerini, C; Gnessi, L; Mariani, L; Pecori-Giraldi, F; Pogliani, E; Rossi, P; Tornaghi, L | 1 |
| Abe, T; Aizawa, Y; Furukawa, T; Liu, A; Narita, M; Nikkuni, K; Sato, N; Takahashi, M; Toba, K; Yagisawa, K | 1 |
| Ono, R | 1 |
| Nielsen, JL | 1 |
| Druker, BJ; Frater, JL; Hrisinko, MA; Peterson, LC; Resta, D; Riley, MB; Tallman, MS; Variakojis, D | 1 |
| Furukawa, H; Hada, S; Hishita, T; Mizumoto, T; Ohno, T; Tabata, S; Tomo, K | 1 |
| Ahlgren, T; Barbouti, A; Fioretos, T; Höglund, M; Johansson, B; Lassen, C; Mitelman, F; Turesson, I | 1 |
| Akiyama, S; Aoki, S; Che, XF; Furukawa, T; Haraguchi, M; Kobayashi, M; Mukai, M; Ren, XQ; Sugimoto, Y; Sumizawa, T; Takamatsu, H | 1 |
| Champagne, M; Davies, SM; Lipton, JM; Perentesis, JP; Smith, FO; Thornley, I | 1 |
| Hibi, S; Imashuku, S; Kano, G; Kuriyama, K; Morimoto, A; Todo, S | 1 |
| Creamer, D; du Vivier, AW; Milojkovic, D; Mufti, GJ; Salisbury, JR; Short, K | 1 |
| Chung, NG; Hwang, JY; Kim, CC; Kim, DW; Kim, YJ; Kim, YL; Lee, S | 1 |
| Aláez, C; Arranz, E; de la Cámara, R; Fernández-Rañada, JM; Granda, A; Moreno, G; Muñoz, C; Osorio, S; Reino, FG; Salvanés, FR; Steegmann, JL | 1 |
| Bossone, G; Della Longa, G; Di Cocco, B; Salesi, N | 1 |
| Bányai, A; Barta, A; Dolgos, J; Gopcsa, L; Halm, G; Pálóczi, K | 1 |
| Chen, SS; Jiang, B; Jiang, H; Jiang, Q; Lu, DP | 1 |
| Liu, WH; Makrigiorgos, GM | 1 |
| Okamoto, S | 1 |
| Apperley, J; Goldman, J; Kanfer, E; Marin, D; Olavarria, E | 1 |
| Augustson, B; Basu, S; Craddock, C | 1 |
| Cervantes, F; Drummond, M; Goldman, J; Kaeda, J; Lin, F; O'Brien, S | 1 |
| Deininger, MW; Druker, BJ | 2 |
| Apperley, JF; Goldman, JM; Gordon, MY; Kaeda, J; Marin, D; Marley, SB; Szydlo, R | 1 |
| Baskaynak, G; Ehninger, G; Gschaidmeier, H; Holdhoff, M; Huhn, D; Kreuzer, KA; Le Coutre, P; Lupberger, J; Na, IK; Platzbecker, U; Prejzner, W; Schmidt, CA; Schwarz, M | 1 |
| Asai, O; Dobashi, N; Kobayashi, M; Okawa, Y; Saito, T; Sugiyama, K; Takahara, S; Takei, Y; Uno, S; Usui, N; Yano, S | 1 |
| Apperley, JF; Bua, M; Crawley, C; Foot, N; Franceschino, A; Goldman, JM; Lennard, A; Marin, D; Marktel, S; Na Nakorn, T; Nathan, I; Neylon, A; O'Brien, SG; Olavarria, E; Szydlo, RM | 1 |
| Ding, J; Guo, XN | 1 |
| Conrad, D; Dent, P; Grant, S; Rahmani, M; Subler, M; Yu, C | 1 |
| Fukuhara, T; Maekawa, I; Miyake, T; Onozawa, M; Takahata, M; Yamamoto, Y | 1 |
| Druker, BJ; Mauro, MJ; O'Dwyer, ME | 3 |
| Chadburn, A; Feldman, E; Najfeld, V; Roboz, G; Schuster, M; Silver, RT | 1 |
| Friedrich, MJ | 2 |
| Groot, MT; Huijgens, PC; Kramer, MH; Ossenkoppele, GJ; Uyl-de Groot, CA; van den Boom, G | 1 |
| Ahn, YS; Donna, E; Rosado, MF | 1 |
| Botey, A; Cervantes, F; Pou, M; Saurina, A; Saval, N; Solé, M; Vera, M | 1 |
| Chen, S; Huang, X; Jiang, B; Jiang, H; Jiang, Q; Lu, D; Lu, Y | 1 |
| Albitar, M; Beran, M; Cortes, JE; Faderl, S; Feldman, EJ; Giles, FJ; Kantarjian, HM; Larson, RA; Mamus, SW; O'Brien, SM; Roboz, GJ; Talpaz, M; Verstovsek, S | 1 |
| Czekalska, S; Czopek, J; Hanfstein, B; Hochhaus, A; Jakóbczyk, M; Müller, MC; Rudzki, Z; Sacha, T; Salamanchuk, Z; Skotnicki, AB; Wolska-Smoleń, T | 1 |
| Horikoshi, A; Sawada, S; Takei, K | 1 |
| Ikeda, Y; Miyazaki, K; Mori, T; Naito, K; Okamoto, S; Tsukada, Y | 1 |
| Ault, P; Kaled, S; Rios, MB | 1 |
| Corbin, AS; Deininger, MW; Druker, BJ; Johnson, K; La Rosée, P; Mauro, MM; Melo, JV; Moseson, EM; Stoffregen, EP; Willis, S | 1 |
| Berthaud, P; Berthou, C; Buzyn, A; Cheron, N; Facon, T; Gardembas, M; Guilhot, F; Guilhot, J; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Rigal-Huguet, F; Rousselot, P; Tulliez, M; Vigier, M | 1 |
| Brezinschek, R; Linkesch, W; Neumeister, P; Sill, H; Staber, PB | 1 |
| Ohyashiki, K; Tauchi, T | 3 |
| Urabe, A | 2 |
| Antin, JH | 1 |
| Atadja, P; Bali, P; Bhalla, K; Fuino, L; Gasparetto, M; Glozak, M; Jove, R; Moscinski, L; Nimmanapalli, R; Smith, C; Tao, J; Wu, J | 1 |
| Mauro, MJ; Maziarz, RT | 2 |
| Andreeff, M; Cortes, J; Faderl, S; Freireich, E; Garcia-Manero, G; Giles, F; Kantarjian, HM; Kornblau, S; Mallard, S; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; White, K | 1 |
| Apperley, JF; Bua, M; Foot, N; Goldman, JM; Kanfer, E; Klein, JP; Marin, D; Marktel, S; Olavarria, E; Shepherd, P; Szydlo, R | 1 |
| Bohr, VA; Cheng, WH; Fields, KM; Kufe, D; Opresko, PL; Ren, J; von Kobbe, C | 1 |
| Armstrong, F; Brousset, P; Dastugue, N; Delsol, G; Laurent, G; Trempat, P; Villalva, C | 1 |
| Bocchia, M; Crupi, R; Gentili, S; Gozzetti, A; Lauria, F; Raspadori, D; Tozzuoli, D | 1 |
| Dan, K; Inami, M; Inokuchi, K; Nakayama, K; Shimada, T; Tamura, H | 1 |
| Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; König, H; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Petzold, A; Schoch, C; Weisser, A | 1 |
| Bai, RY; Duyster, J; Grundler, R; Hoepfl, J; Miething, C; Mugler, C; Peschel, C | 1 |
| Bandini, G; Byrne, J; Clark, RE; Deininger, M; Fischer, T; Lipton, J; Michallet, M; Niederwieser, D; Olavarria, E; Ottmann, OG; Siegert, W; Ullmann, A; Vitek, A; Wassmann, B | 1 |
| Bacigalupo, A | 1 |
| Blaise, D; Caillères, S; Lafage-Pochitaloff, M; Maurice, C; Mozziconacci, MJ; Sainty, D; Vey, N | 1 |
| Beth Rios, M; Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Shan, J; Talpaz, M; Wierda, W | 1 |
| Agis, H; Geissler, K; Mannhalter, C; Mayerhofer, M; Sagaster, V; Sillaber, C; Sperr, WR; Valent, P | 1 |
| Font de Mora, J; Garcia, JL; Gutierrez, NC; Hernandez, JM; Queizan, JA; San Miguel, JF | 1 |
| Byrne, J; Cuthbert, RJ; Humphreys, M; McMullin, MF; O'Dwyer, ME; Russell, NH | 1 |
| Lou, FD; Lu, XC | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S | 1 |
| Cotter, TG; Keeshan, K; McKenna, SL | 1 |
| Blasdel, C; Druker, BJ; Farnsworth, M; Hsieh, YC; Kurilik, G; Mauro, MJ; Mori, M; O'Dwyer, ME | 1 |
| Binckebanck, A; Gschaidmeier, H; Hoelzer, D; Käbisch, A; Leimer, L; Lübbert, M; Ottmann, OG; Pfeifer, H; Scheuring, U; Wassmann, B | 1 |
| Deininger, MW; Hennig, E; Leiblein, S; Niederwieser, D; Reinhold, U | 1 |
| Cherrier-De Wilde, S; Delannoy, A; Hagemeijer, A; Rack, K; Vannuffel, P | 1 |
| Arechiga, AF; Ly, C; Melo, JV; Ong, ST; Walsh, CM | 1 |
| Arthur, C; Bradstock, K; Branford, S; Browett, P; Durrant, S; Gathmann, I; Grigg, A; Harper, A; Hughes, TP; Joske, D; Lynch, K; Ma, D; Rudzki, Z; Schwarer, AP; Seymour, JF; Taylor, K | 1 |
| Aulitzky, W; Berger, U; Berndt, A; Deininger, MW; Fischer, T; Freund, M; Fruehauf, S; Gattermann, N; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; Hossfeld, DK; König, H; Krause, SW; Kreil, S; Lahaye, T; le Coutre, P; Merx, K; Müller, MC; Nerl, C; Neubauer, A; Ottmann, OG; Paschka, P; Sayer, HG; Schneller, F; Waller, C | 1 |
| Fischer, T; Friedrich-Freksa, A; Gschaidmeier, H; Hess, G; Huber, C; Kolbe, K; Meyer, RG; Ullmann, AJ | 1 |
| Hoyer, J; Ketterling, RP; Mesa, RA; Steensma, DP | 1 |
| Löwenberg, B | 1 |
| Bolton, AE; Branford, S; Gathmann, I; Goldman, JM; Hensley, ML; Hochhaus, A; Hughes, TP; Kaeda, J; Radich, JP; Rudzki, Z; van Hoomissen, IC | 1 |
| Deininger, MW; Lange, T; Niederwieser, DW | 1 |
| Drummond, MW; Holyoake, TL | 2 |
| Andreeff, M; Beran, M; Champlin, R; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, S; Kantarjian, H; Keating, MJ; Kornblau, SM; Letvak, L; O'Brien, S; Pierce, S; Salvado, A; Talpaz, M; Thomas, DA; Verstovsek, S | 1 |
| Alvarez-Larrán, A; Camós, M; Cervantes, F; Conde, E; García-Conde, J; Hernández-Boluda, JC; López-Jiménez, J; Odriozola, J; Osorio, S; Steegmann, JL; Villalón, L | 1 |
| Bornmann, WG; Clarkson, B; Duyster, J; Li, W; Miller, WT; Peschel, C; Sänger, J; Veach, DR; von Bubnoff, N | 1 |
| Arnold, R; Baskaynak, G; Dörken, B; Genvresse, I; Kreuzer, KA; le Coutre, P; Lupberger, J; Mapara, M; Massenkeil, G; Zschieschang, P | 1 |
| Korycka, A; Robak, T | 1 |
| Bloomfield, K; Braunschweig, I; Chadburn, A; Darji, J; Gotlib, V; Patel, A | 1 |
| Aljurf, M; Banka, N; Hamadah, I | 1 |
| Alimena, G; Breccia, M; Carmosino, I; Latagliata, R; Mandelli, F | 1 |
| Atta, J; Binckebanck, A; Brück, P; Ehninger, G; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Leimer, L; Lipp, T; Ottmann, OG; Perz, J; Pfeifer, H; Rieder, H; Scheuring, UJ; Schoch, C; Schwerdtfeger, R; Stelljes, M; Wassmann, B | 1 |
| Sawyers, CL; Shah, NP | 2 |
| Hankins, RW; Ihara, A; Maehiro, S; Miyachi, K; Miyashita, H; Murai, R | 1 |
| Chida, S; Endo, M; Hosokawa, T; Nakatuji, Y; Sugawara, W | 1 |
| Baron, F; Bours, V; Croisiau, C; Herens, C; Tassin, F | 1 |
| Binckebanck, A; Brück, P; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Komor, M; Leimer, L; Lübbert, M; Ottmann, OG; Pfeifer, H; Scheuring, U; Schleyer, E; Wassmann, B; Wolff, T | 1 |
| Cortes, J; Garcia-Manero, G; Giles, F; Hayes, K; Kantarjian, H; Medina, J; O'Brien, S; Rios, MB; Talpaz, M | 1 |
| Deininger, MW; Goldman, JM; Melo, JV; Tipping, AJ | 1 |
| Jin Huh, H; Lee, M; Myong Seong, C; Soon Chung, W; Won Huh, J | 1 |
| Auberger, P; Belhacene, N; Herrant, M; Hofman, P; Jacquel, A; Legros, L; Luciano, F; Pages, G | 1 |
| Baba, Y; Bakalova, R; Ishikawa, M; Ohba, H; Shinohara, Y; Zhelev, Z | 1 |
| Bastie, JN; Berthaud, P; Calvo, F; Chomienne, C; Degos, L; Larghero, J; Leguay, T; Madelaine-Chambrin, I; Mahon, FX; Marolleau, JP; Mourah, S; Raffoux, E; Rousselot, P; Taksin, AL | 1 |
| Kuenen, BC; Pinedo, HM | 1 |
| Carrasco, M; Conde, E; de Miguel, M; Díaz-Mediavilla, J; Martínez, JA; Sanz, MA; Sierra, J; Sureda, A | 1 |
| Matsouka, P; Monastirli, A; Pasmatzi, E; Tsambaos, D | 1 |
| Beck, J; Bond, E; Capdeville, R; Dutreix, C; Fischer, T; Huber, C; Mehring, G; Meinhardt, P; Milosavljev, S; O'Brien, SG; Peng, B | 1 |
| Alimena, G; Breccia, M; De Felice, L; Ferranti, G; Gallucci, C; Mancini, M; Mandelli, F | 1 |
| Cashen, A; DiPersio, JF; Khoury, H | 1 |
| Abruzzese, E; Amadori, S; Anemona, L; Campione, E; Cantonetti, M; Del Principe, MI; Masi, M; Morino, L; Orlandi, A; Orlandi, G; Tendas, A | 1 |
| Byrne, JL; Clark, RE; Drummond, MW; Holyoake, TL; Lennard, A; Marin, D | 1 |
| Bekkenk, MW; Jansen, PM; Meijer, CJ; Middeldorp, JM; Stevens, SJ; Vermeer, MH; Willemze, R | 1 |
| Huang, F; Liu, XL; Meng, FY; Song, LL; Xu, B; Zhang, Y; Zheng, WY | 1 |
| Hwang, JY; Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Kim, YL; Lee, JW; Lee, S; Min, WS; Park, YH | 1 |
| Apperley, JF; Hughes, TP; Melo, JV | 1 |
| Cortes, J; Kantarjian, H; O'Brien, S; Talpaz, M; Tsao, AS | 1 |
| Nakajima, M; Toga, W | 1 |
| Griffin, JD; Weisberg, E | 2 |
| Alberti, D; Amabile, M; Baccarani, M; Bassi, S; Bonifazi, F; Cambrin, GR; Cilloni, D; De Vivo, A; Giannini, B; Gottardi, E; Izzo, B; Luatti, S; Martinelli, G; Pane, F; Rosti, G; Saglio, G; Salvatore, F; Soverini, S; Testoni, N; Trabacchi, E | 1 |
| Adachi, S; Imai, T; Kroemer, G; Nakahata, T; Okada, M; Toyokuni, SY; Ueno, M; Watanabe, K; Zervos, AS | 1 |
| Binckebanck, A; Gökbuget, N; Gschaidmeier, H; Hoelzer, D; Ottmann, OG; Reutzel, R; Scheuring, UJ; Wassmann, B | 1 |
| Lewalle, P; Martiat, P | 1 |
| Ajima, A; Hasegawa, Y; Kojima, H; Nagasawa, T; Takayama, N | 1 |
| Fukutsuka, K; Hayashi, T; Kishimori, C; Miyanishi, S; Okumura, A; Umeki, K | 1 |
| Baccarani, M; Benvenuti, M; Brusa, G; Mancini, M; Martinelli, G; Mazzacurati, L; Pattacini, L; Santucci, MA | 1 |
| Feek, U; Groneberg, DA; Moll, R; Staats, P; Vogelmeier, C; Wagner, U | 1 |
| Burchert, A; Cai, D; Duyster, J; Eilers, M; Hochhaus, A; Hofbauer, LC; Müller, R; Neubauer, A; Ritter, M; Samuelsson, MK; Schmidt, M; Slater, EP | 1 |
| Baskaynak, G; Bonin, Mv; Bornhäuser, M; Dörken, B; Ehninger, G; Jenke, A; Kreuzer, KA; le Coutre, P; Leopold, T; Ottmann, O; Pursche, S; Schleyer, E | 1 |
| Aswald, JM; Aswald, S; Lipton, JH; Messner, HA | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Keating, M; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S; Wierda, W | 1 |
| Kolb, EA; Ladanyi, M; Pan, Q; Steinherz, PG | 1 |
| Deininger, M; Druker, BJ; La Rosée, P; Shen, L; Stoffregen, EP | 1 |
| Bornhauser, M; Ehninger, G; Freiberg-Richter, J; Jenke, A; Mohr, B; Radke, J; Schleyer, E; Schuler, US | 1 |
| Azam, M; Daley, GQ; Nardi, V | 1 |
| Chrobák, L; Voglová, J | 1 |
| Liu, QF; Liu, XL; Meng, FY; Song, LL; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhou, SY | 1 |
| Cheong, JW; Hahn, JS; Jeung, HK; Kim, JS; Ko, YW; Lee, ST; Maeng, H; Min, YH | 1 |
| Baskaynak, G; Dörken, B; Klühs, C; Kreuzer, KA; le Coutre, P; Movassaghi, K | 1 |
| Agirre, X; Andreu, EJ; Calasanz, MJ; Fernández-Luna, JL; Fontalba, A; Larráyoz, MJ; Montiel, C; Odero, MD; Prósper, F | 1 |
| Chao, TC; Chen, PM; Chiou, TJ; Hsiao, LT; Lee, MY; Lin, JT; Yang, MH | 1 |
| Bekele, BN; Cortes, JE; Faderl, S; Giles, F; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Sneed, TB; Talpaz, M; Wierda, W; Zhou, X | 1 |
| Au, WY; Ho, WK; Hon, C; Kwok, AK; Lie, AK; Ng, WM; Shek, TW | 1 |
| Maness, LJ; McSweeney, PA | 1 |
| Blaise, D; Damaj, G; Gaugler, B; Isnardon, D; Jourdan, E; Mami, NB; Mohty, M; Olive, D; Vey, N | 1 |
| Chung, NG; Hwang, JY; Kim, CC; Kim, DW; Kim, YJ; Kim, YL; Lee, S; Min, CK | 1 |
| Li, JE; Sun, GL; Wu, WL; Wu, YL | 1 |
| Bergemann, T; Ehninger, G; Freiberg-Richter, J; Illmer, T; Oelschlägel, U; Platzbecker, U; Pursche, S; Schaich, M; Schleyer, E; von Bonin, M | 1 |
| Engels, K; Griesshammer, M; Klose, J; Kriener, S; Kvasnicka, HM; Schmitt-Graeff, A; Staib, P; Thiele, J | 1 |
| Bocchia, M; Crupi, R; Fanelli, A; Gentili, S; Gozzetti, A; Lauria, F; Mazzotta, S; Raspadori, D; Tozzuoli, D | 1 |
| Carter, C; Cullen, MJ; Dickinson, H; Owen, RG; Richards, SJ; Swirsky, DM | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Kornblau, S; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S; Wierda, W | 1 |
| Capdeville, R; Dressman, M; Gathmann, I; McLean, LA; Polymeropoulos, MH | 1 |
| Berger, U; Hehlmann, R | 1 |
| Cortes, J; Kantarjian, H | 5 |
| Griffin, JD; Ikeda, Y; Kizaki, M; Miyakawa, Y; Sawafuji, K; Weisberg, E | 1 |
| Aggarwal, BB; Albitar, M; Arlinghaus, R; Donato, NJ; Hayes, K; Kantarjian, H; Lin, H; Shishodia, S; Shishodin, S; Stapley, J; Talpaz, M; Wu, JY | 1 |
| Al-Ali, HK; Deininger, MW; Druker, BJ; Heinrich, MC; Krahl, R; Lange, T; Mueller, M; Müller, C; Niederwieser, D | 1 |
| Bell, C; Botteman, M; Casagrande, J; Laskin, B; Pashos, C; Redaelli, A; Stephens, J | 1 |
| Al-Ali, HK; Bumm, T; Deininger, MW; Köhler, T; Kovacs, I; Krahl, R; Krug, D; Lange, T; Niederwieser, D; Otto, S | 1 |
| Cohen, SR; McMahon, R; Slovak, ML; Snyder, DS | 1 |
| Arora, B; Kochupillai, V; Kumar, L; Sharma, A; Wadhwa, J | 1 |
| Giakoumi, X; Mantzouranis, M; Pangalis, GA; Vassilakopoulos, TP; Viniou, NA | 1 |
| Angioï, K; Champigneulle, J; George, JL; Guerci, A; Maalouf, T | 1 |
| Bainbridge, TM; Deininger, MW; Druker, BJ; Heinrich, MC; McGreevey, L; Willis, S | 1 |
| Auberger, P; Bourcier, C; Cassuto, JP; Jacquel, A; Legros, L; Mahon, FX; Pagès, G | 1 |
| Borg, C; Maruyama, K; Taïeb, J; Terme, M; Zitvogel, L | 1 |
| Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Ottmann, OG; Sato, K; Segawa, H; Yuasa, T | 1 |
| Capdeville, R; Druker, BJ; Ford, J; Hayes, M; Lloyd, P; Peng, B; Racine-Poon, A; Resta, D; Rosamilia, M; Sawyers, CL; Talpaz, M | 1 |
| Benowitz, S | 1 |
| Tauchi, T | 1 |
| Delgado, MD; Gómez-Casares, MT; Lemes, A; León, J; Molero, T; Vaqué, JP | 1 |
| Hino, N; Myojo, T | 1 |
| Beran, M; Cortes, J; Freireich, EJ; Giles, FJ; Golemovic, M; Gourdeau, H; Kantarjian, H; Orsolic, N; Verstovsek, S | 1 |
| Engels, K; Kriener, S; Kvasnicka, HM; Schmitt-Graeff, A; Staib, P; Thiele, J | 1 |
| Hochhaus, A; Janssen, JJ; Ossenkoppele, GJ; Schuurhuis, GJ; van Oostveen, JW; Waisfisz, Q | 1 |
| Atherton, MG; Butt, NM; Clark, RE; Wang, L | 1 |
| Chrobák, L | 1 |
| Azzarà, A; Cervetti, G; Fazzi, R; Galimberti, S; Papineschi, F; Petrini, M; Simi, P | 1 |
| Anagnostopoulos, A; Asteriou, O; Athanasiadou, A; Fassas, A; Saloum, R; Stavroyianni, N | 1 |
| Witte, ON; Wong, S | 1 |
| Cowan-Jacob, SW; Fabbro, D; Fendrich, G; Furet, P; Griffin, JD; Guez, V; Liebetanz, J; Manley, PW; Mestan, J | 1 |
| Butler, WF; Chachisvilis, M; Chung, TD; Esener, SC; Forster, AH; Hall, JM; Kariv, I; Kibar, O; Lykstad, K; Marchand, PJ; Mercer, EM; Pestana, LM; Sur, S; Tu, E; Wang, MM; Yang, R; Zhang, H | 1 |
| Crossman, LC; O'Brien, S | 1 |
| Van Etten, RA | 1 |
| Baxter, J; Baylor, E; Bennett, JM; Cromwell, B; Cross, N; Felgar, R; Goldberg, J; Horan, J; Wittman, B | 1 |
| Apperley, JF; Avery, S; Brito Babapulle, F; Goldman, JM; Kaeda, J; Marin, D; Nadal, E; Olavarria, E; Vulliamy, T | 1 |
| Dai, Y; Dent, P; Grant, S; Pei, XY; Rahmani, M | 1 |
| Andreeff, M; Beran, M; Divoky, V; Dong, L; Gatto, S; Hayes, K; Kantarjian, HM; Onida, F; Ricci, C; Scappini, B; Verstovsek, S; Wierda, WG | 1 |
| Taéron, C | 1 |
| Fukuhara, S; Ishii, K; Nomura, S; Yamamoto, Y | 1 |
| Baccarani, M; Barbieri, E; Benvenuti, M; Brusa, G; Greenberger, JS; Mancini, M; Martinelli, G; Mazzacurati, L; Pattacini, L; Santucci, MA | 1 |
| Komatsu, N; Kondo, T; Mitsugi, K; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Nakano, S; Ohmine, K; Ozawa, K; Tarumoto, T | 1 |
| Mitani, K | 1 |
| Ueda, T | 1 |
| Freeman, A; Neumann, Y; Rechavi, G; Toren, A; Waldman, D; Weintraub, M | 1 |
| Gumerlock, PH; Hatcher, S; Larkin, E; Richman, C; Rodler, E; Unger, K; Welborn, J; Wun, T | 1 |
| Fish, EN; Katsoulidis, E; Lal, L; Li, Y; Majchrzak, B; Parmar, S; Platanias, LC; Ravandi, F; Sassano, A; Tallman, MS; Verma, A | 1 |
| Adil, SN; Arain, S; Kakepoto, GN; Khurshid, M; Sajid, R; Usman, M | 1 |
| Ascani, S; Bonomini, S; Caramatti, C; Colla, S; Craviotto, L; Crugnola, M; De Celis, I; Giuliani, N; Hojden, M; Morandi, F; Rizzoli, V; Sabbatini, E; Sammarelli, G | 1 |
| Cortes, JE; El-Zimaity, MM; Ferrajoli, A; Garcia-Manero, G; Giles, F; Glassman, AB; Hayes, K; Kantarjian, H; Nebiyou Bekele, B; O'Brien, S; Rios, MB; Talpaz, M; Thomas, D; Verstovsek, S; Zhou, X | 1 |
| Feng, H; Graner, MW; Katsanis, E; Li, G; Zeng, Y | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Letvak, L; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; Verstovsek, S | 1 |
| Bhatia, R; Chu, S; Gupta, M; Holtz, M | 1 |
| Capdeville, R; Dressman, MA; Gathmann, I; Hensley, M; Malinowski, R; McLean, LA; Polymeropoulos, MH | 1 |
| Alimena, G; Breccia, M; Mancini, F; Mecarocci, S; Nanni, M; Russo, E | 1 |
| Angstreich, GR; Jones, RJ; Smith, BD | 1 |
| Arakawa, A; Kami, M; Kato, D; Kishi, Y; Kusumi, E; Miyakoshi, S; Morinaga, S; Murashige, N; Muto, Y; Taniguchi, S; Ueyama, J; Yuji, K | 1 |
| Berthou, C; Bourquard, P; Braekeleer, MD; Guilbert-Douet, N; Le Bris, MJ; Morel, F; Morice, P | 1 |
| Du, QF; Liu, QF; Liu, XL; Meng, FY; Song, LL; Xu, B; Zhang, S; Zheng, WY; Zhou, SY | 1 |
| Buchdunger, E; Fabbro, D; Hallek, M; Hu, Y; Li, S; Liu, Y; Pelletier, S; Van Etten, RA; Warmuth, M | 1 |
| Jones, RJ; Matsui, WH; Smith, BD | 1 |
| Bhatia, R; Holtz, MS | 1 |
| Bujassoum, S; Lipton, JH; Rifkind, J | 1 |
| Amabile, M; Baccarani, M; Bianchini, M; Martinelli, G; Pane, F; Poerio, A; Rosti, G; Saglio, G; Soverini, S | 1 |
| Aulitzky, WE; Duyster, J; Miething, C; Moehring, A; van der Kuip, H; Wohlbold, L | 1 |
| Faber, E; Jarosová, M; Klamová, H; Michalová, K; Moravcová, J; Rabasová, J; Voglová, J; Zmeková, V | 1 |
| Ault, P; Cortes, J; Giles, F; Kantarjian, H; Rios, MB; Welch, MA | 1 |
| Bonnie, G; Cortes, J; Faderl, S; Garcia-Manero, G; Kantarjian, H; Medina, J; Rios, A; Tsimberidou, AM | 1 |
| Grossman, WJ; Wilson, DB | 1 |
| Aichberger, KJ; Bilban, M; Florian, S; Fritsch, G; Krauth, MT; Marculescu, R; Mayerhofer, M; Printz, D; Selzer, E; Sillaber, C; Sperr, WR; Valent, P; Wagner, O | 1 |
| Dahl, TG; Ghanima, W; Kahrs, J; Tjonnfjord, GE | 1 |
| Braun, H; Franke, A; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M; Pelz, AF; Wieacker, P | 1 |
| Isshiki, I; Okamoto, S; Yamaguchi, K | 1 |
| Gordon, MY; Lewis, JL; Marley, SB; Rudd, CE; Schneider, H | 1 |
| Asano, S; Bai, Y; Chen, M; Harata, M; Iseki, T; Izawa, K; Kobayashi, S; Maruyama, K; Nagamura, F; Nakazawa, S; Ooi, J; Soda, Y; Sugita, K; Takahashi, S; Takahashi, TA; Takizawa, T; Tani, K; Tojo, A; Tomonari, A; Tsuji, T; Uchimaru, K | 1 |
| Cortes, J; Giles, F; Kantarjian, H; O'Brien, S; Quintas, A; Rios, MB; Shan, J; Talpaz, M | 1 |
| Goh, AS; Lee, TC; Leong, KW | 1 |
| Croom, KF; Curran, MP; Goa, KL | 1 |
| Stone, RM | 1 |
| Guilhot, F | 2 |
| Dávid, M; Kovács, G; Losonczy, H; Méhes, G; Molnár, L; Nagy, A; Szomor, A | 1 |
| Hochhaus, A; Merx, K; Paschka, P | 1 |
| Chen, SS; Jiang, B; Jiang, H; Jiang, Q; Lu, DP; Lu, Y; Shi, HL | 1 |
| Atadja, P; Boehrer, S; Brieger, A; Chow, KU; Hoelzer, D; Kim, SZ; Mitrou, PS; Nowak, D; Ruthardt, M; Schaaf, S; Weidmann, E | 1 |
| Auger, N; Bastie, JN; Castaigne, S; Charrin, C; Dastugue, N; Eclache, V; Flandrin, G; Gervais, C; Giraudier, S; Imbert, M; Lafage-Pochitaloff, M; Laurent, G; Leonard, C; Lessard, M; Leymarie, V; Maarek, O; Maloisel, F; Mossafa, H; Mozziconacci, MJ; Mugneret, F; N'Guyen Khac, F; Nicolini, F; Recher, C; Rousselot, P; Roussi, J; Roux, GL; Salles, B; Talmant, P; Terre, C; Van den Akker, J; Vernant, JP; Vey, N; Vigier, M; Viguié, F; Yacouben, Y | 1 |
| Barnes, DJ; Melo, J | 1 |
| Arteaga, CL; Baselga, J | 1 |
| Cortes, JE; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, HM; Luthra, R; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Thomas, D; Verstovsek, S | 1 |
| Baluch, S; Barnes, DJ; Bornmann, WG; Clarkson, BM; Goldman, JM; Mahon, FX; Melo, JV; Tipping, AJ; Veach, DR | 1 |
| Nadal, E; Olavarria, E | 1 |
| Brûmmendorf, T; Drummond, M; Holyoake, T; Lennard, A | 1 |
| Higashi, T; Iwashige, A; Kato, C; Machida, S; Mizobe, T; Morimoto, H; Ogawa, R; Tanaka, Y; Toda, Y; Tsukada, J | 1 |
| Hirai, H; Honda, H; Inaba, T; Inukai, T; Kuribara, R; Matsui, H; Nakazawa, S; Ozawa, K; Shinjyo, T; Sugita, K | 1 |
| Hall, AG; Irving, JA; Lennard, AL; Lin, F; Minto, L; O'Brien, S | 1 |
| Ganesan, TS; Madhusudan, S | 1 |
| Borthakur, G; Cortes, JE | 1 |
| Melo, JV; Yoshida, C | 1 |
| Bueso-Ramos, CE; Cortes, J; Giles, F; Kantarjian, H; Medeiros, LJ; O'Brien, S; Rios, MB; Talpaz, M | 1 |
| Dalziel, K; Garside, R; Price, A; Round, A; Stein, K | 1 |
| Knight, GW; McLellan, D | 1 |
| Goldman, JM; Mughal, TI | 4 |
| Abdullah, OM; Bohacek, RS; Clackson, T; Dalgarno, D; Deininger, MW; Druker, BJ; Keats, JA; Metcalf, CA; Moseson, EM; O'Hare, T; Pollock, R; Rivera, VM; Sawyer, TK; Shakespeare, WC; Stoffregen, EP; Sundaramoorthi, R; Tang, H; Wang, Y | 1 |
| Arthur, C; Bradstock, K; Branford, S; Browett, P; Catalano, J; Durrant, S; Filshie, R; Grigg, A; Herrmann, R; Hughes, T; Joske, D; Leahy, MF; Lynch, K; Parkinson, I; Rudzki, Z; Schwarer, AP; Seymour, JF; Taylor, K | 1 |
| Travis, J | 1 |
| Chen, P; Lee, FY; Norris, D; Sawyers, CL; Shah, NP; Tran, C | 1 |
| Alimena, G; Breccia, M; D'Elia, GM; De Cuia, MR; Francesca, B; Mandelli, F | 1 |
| Crossman, LC; O'Brien, SG | 1 |
| Alvarez, RH; Cortes, JE; Giles, F; Kantarjian, HM; O'Brien, SM; Talpaz, M | 1 |
| Bilgrami, S; Kapur, D; Smaradottir, A | 1 |
| Doval, DC; Pavithran, K | 1 |
| Kawai, Y; Ueda, T | 1 |
| Hwang, JY; Kim, DW; Kim, HJ; Kim, YJ; Kim, YL; Lee, JJ; Lee, S | 1 |
| Asaka, M; Ehira, N; Imamura, M; Kanamori, H; Kawamura, T; Masauzi, N; Miura, T; Obara, S; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Sato, Y; Tanizawa, Y; Yujiri, T | 1 |
| Alyea, EP; Antin, JH; DeAngelo, DJ; Galinsky, I; Hochberg, EP; Lee, S; Longtine, J; Parekkedon, B; Ritz, J; Soiffer, RJ; Stone, RM | 1 |
| Clarke, MF | 1 |
| Ailles, LE; Dylla, SJ; Gotlib, J; Jamieson, CH; Jones, C; Keating, A; Li, K; Manz, MG; Muijtjens, M; Sawyers, CL; Weissman, IL; Zehnder, JL | 1 |
| Chen, SS; Jiang, B; Jiang, H; Jiang, Q; Lu, DP; Lu, Y | 2 |
| Alberti, D; Amabile, M; Baccarani, M; Bassi, S; Bonifazi, F; Castagnetti, F; Cilloni, D; de Vivo, A; Fincato, G; Giugliano, E; Izzo, B; Luatti, S; Martinelli, G; Messa, E; Pane, F; Poerio, A; Rosti, G; Russo, D; Saglio, G; Soverini, S; Testoni, N; Trabacchi, E | 1 |
| Murdur, G | 1 |
| Fujiwara, T; Harigae, H; Ishizawa, K; Kameoka, J; Miyamura, K; Sasaki, T; Tomiya, Y; Yamada, M; Yokoyama, H | 1 |
| Alberti, D; Arruga, F; Baccarani, M; Carturan, S; Cilloni, D; Defilippi, I; Fava, M; Giugliano, E; Gottardi, E; Messa, E; Messa, F; Morotti, A; Rege-Cambrin, G; Saglio, G | 1 |
| Calistri, E; Damiani, D; Fanin, R; Geromin, A; Marin, L; Tiribelli, M | 1 |
| Nguyen, PL; Wahner, AE; Xu, Y | 1 |
| Kreuzer, KA; le Coutre, P | 1 |
| Chen, GQ; Chen, SJ; Chen, Z; Du, YZ; Sun, GL; Sun, HP; Wang, KK; Wu, YL; Yin, T; Zhang, J | 1 |
| Boissel, N; Cayuela, JM; Charron, D; Degos, L; Dombret, H; Maarek, O; Raffoux, E; Rea, D; Rousselot, P; Toubert, A | 1 |
| Bhatia, R; Chu, S; Forman, SJ; Sawyers, CL; Shah, NP; Snyder, DS; Xu, H | 1 |
| Amariglio, N; Ashur-Fabian, O; Ben-Bassat, I; Brok-Simoni, F; Gan, S; Itskovich, S; Mark, Z; Nagler, A; Raanani, P; Rechavi, G; Trakhtenbrot, L | 1 |
| Bruzzone, R; Frassoni, F; Fugazza, G; Gatti, AM; Gobbi, M; Grasso, R; Miglino, M; Quintino, S; Sessarego, M | 1 |
| Cho, B; Chung, NG; Chung, YJ; Goh, HG; Han, CW; Jin, JY; Kim, CC; Kim, DW; Kim, HJ; Kim, HK; Kim, JA; Kim, JW; Kim, SH; Kim, TG; Kim, YJ; Kim, YL; Lee, JW; Lee, S; Min, CK; Min, WS; Oh, IH | 1 |
| Agis, H; Geissler, K; Haas, OA; Kalhs, P; Keil, F; Krauth, MT; Lechner, K; Mannhalter, C; Pirc-Danoewinata, H; Sperr, WR; Valent, P | 1 |
| Clark, RE; Heartin, E; Walkinshaw, S | 1 |
| Rytting, ME; Wierda, WG | 1 |
| Griesshammer, M; Kvasnicka, HM; Ollig, E; Schmitt-Graeff, A; Staib, P; Thiele, J; Varus, E | 1 |
| Al-Beirouti, B; Keating, A; Lipton, JH; McCrae, J; Messner, HA; Rifkind, J; Song, KW; Yee, K | 1 |
| Engels, K; Griesshammer, M; Hansmann, ML; Kriener, S; Kvasnicka, HM; Ottmann, OG; Schmitt-Graeff, A; Staib, P; Thiele, J; Waller, CF | 1 |
| Curtin, PT; Druker, BJ; Leis, JF; Maziarz, RT; Primack, SL; Schubach, SE | 1 |
| Fujimoto, M; Fukumot, T; Kuwajima, M; Mano, S; Matsuhashi, Y; Nagai, M; Tamura, T; Tasaka, T | 1 |
| Cortes, J; Kantarjian, H; O'Brien, S | 1 |
| Bonnet, ML; Brizard, A; Guilhot, F; Guillier, M; Sorel, N; Turhan, AG | 1 |
| Han, H; Han, JY; Kim, HJ; Kim, JS; Kim, SH; Kwon, HC; Lee, YH; Roh, MS; Seo, SY | 1 |
| Pulsipher, MA | 1 |
| Goh, HG; Kim, CC; Kim, DW; Kim, HJ; Kim, SH; Kim, TG; Kim, YJ; Kim, YL; Lee, JW; Lee, JY; Lee, S; Min, CK; Min, WS | 1 |
| Etoh, T; Hiroyama, T; Ikuta, T; Kurita, R; Maeda, T; Muta, H; Mutoh, T; Nakajima, Y; Nakayama, M; Nakazaki, Y; Nishimura, J; Shimizu, K; Shiratsuchi, M; Somada, S; Tani, K; Yasuda, M | 1 |
| Nelson, L | 1 |
| Gastl, G; Hiddemann, W | 1 |
| Berger, U; Hehlmann, R; Hochhaus, A | 1 |
| Aulitzky, WE; Bornmann, WG; Clarkson, B; Duyster, J; Peschel, C; Sänger, J; Seipel, P; van der Kuip, H; Veach, DR; von Bubnoff, N | 1 |
| Harrison, SJ; Holyoake, TL; Johnson, PR | 1 |
| Fibach, E; Goldberg, Z; Haupt, Y; Krichevsky, S; Levav, Y | 1 |
| Belloc, F; Chollet, C; Desplat, V; Lagarde, V; Leguay, T; Mahon, FX; Pasquet, JM; Praloran, V | 1 |
| Arock, M; Bonnemye, P; Hamouda, NB; Kuen, RL; Leriche, L; Merle-Beral, H; N'Guyen Khac, F; Piffaut, MC; Ribadeau Dumas, A; Tricottet, V | 1 |
| Anderson, N; Eckhardt, SG; Gottschalk, S; Hainz, C; Serkova, NJ | 1 |
| Babendreier, E; Chauhan, D; Chu, SC; Gramlich, JL; Griffin, JD; Kim, JH; Podar, K; Pride, YB; Salgia, R; Sattler, M | 1 |
| Allen, AS; Anstrom, KJ; Glendenning, GA; Reed, SD; Schulman, KA | 1 |
| Anstrom, KJ; Glendenning, GA; Ludmer, JA; Reed, SD; Schulman, KA | 1 |
| Hou, J; Zhou, X | 1 |
| Andreoni, F; Galietta, A; Gambacorti-Passerini, C; Gasser, M; Magistroni, V; Piazza, RG; Scapozza, L | 1 |
| Fujimi, A; Hirayama, Y; Matsunaga, T; Murase, K; Niitsu, Y; Takeuchi, N; Takimoto, R; Terui, T | 1 |
| Ikeda, T; Kimura, F; Kobayashi, A; Kobayashi, S; Motoyoshi, K; Ogura, K; Sato, K; Torikai, H | 1 |
| Kawano-Yamamoto, C; Kikuchi, S; Komatsu, N; Miyazato, A; Mori, M; Muroi, K; Nagai, T; Ozawa, K; Takahashi, S; Takatoku, M | 1 |
| Savage, DG; Zipin, D | 1 |
| Annavarapu, S; Atadja, P; Bali, P; Bhalla, K; Fiskus, W; George, P; Guo, F; Moscinski, L; Scuto, A; Sigua, C; Sondarva, G | 1 |
| Boucher, A; El Jastimi, S; Rocca, P; Scoazec, JY; Trépo, C; Troncy, J; Vial, T; Zoulim, F | 1 |
| Elrick, LJ; Holyoake, TL; Jorgensen, HG; Mountford, JC | 1 |
| Klamová, H; Klener, P | 1 |
| Berthaud, P; Brun-Strang, C; Guilhot, F; Michallet, M; Rousselot, P; Sambuc, R; Tardieu, S | 1 |
| Alimena, G; Breccia, M; Cimino, G; De Propris, MS; Diverio, D; Mancini, M; Mandelli, F; Nanni, M; Pane, F | 1 |
| Ikeda, Y; Iwata, S; Kizaki, M; Kuribara, A; Miyakawa, Y; Morimoto, C; Shimizu, T; Tiganis, T | 1 |
| Alimena, G; Aversa, Z; Breccia, M; Mandelli, F; Muscaritoli, M | 1 |
| von Mehren, M | 1 |
| Gambacorti-Passerini, C; Piazza, R; Pilotti, S; Pogliani, E; Tornaghi, L | 1 |
| Asaka, M; Dazai, M; Hashino, S; Imamura, M; Izumiyama, K; Kobayashi, S; Kondo, T; Morita, R; Onozawa, M; Ota, S; Sogabe, S | 1 |
| Klepfish, A; Patchenko, P; Rachmilewitz, EA; Rothman, R; Trakhtenbrot, L | 1 |
| Belloc, F; Boyer, C; Desplat, V; Lagarde, V; Mahon, FX; Melo, JV; Praloran, V; Reiffers, J | 1 |
| O'Brien, S; Tefferi, A; Valent, P | 1 |
| Arima, N; Arimura, K; Ayukawa, T; Kukita, T; Kuroki, T; Matsushita, K; Ohtsubo, H; Tei, C | 1 |
| Anderlini, P; Champlin, RE; Giralt, S; Hicks, K; Ippoliti, C; Sheth, S | 1 |
| Bekele, BN; Cortes, J; Garcia-Manero, G; Glassman, A; Hayes, K; Kantarjian, H; O'Brien, S; Quintas-Cardama, A; Rios, MB; Talpaz, M; Verstovsek, S; Zhou, X | 1 |
| Ekeland-Sjöberg, K; Gustavsson, B; Hardling, M; Palmqvist, L; Ricksten, A; Stockelberg, D; Swolin, B; Wadenvik, H; Wei, Y | 1 |
| Mahon, FX; Preudhomme, C; Roche-Lestienne, C | 1 |
| Peggs, K | 1 |
| Cai, CC; Hong, WD; Li, J; Li, QH; Li, XH; Luo, SK; Peng, AH; Tan, EX; Tong, XZ; Zhang, GC; Zheng, D | 1 |
| Sawamura, D; Shimizu, H; Yanagi, T | 1 |
| Dib, EG; Ifthikharuddin, JJ; Partilo, SR; Scott, GA | 1 |
| Iijima, K; Iki, S; Urabe, A; Usuki, K | 1 |
| Popat, U; Rice, L | 1 |
| Alimena, G; Breccia, M; D'Andrea, M; D'Elia, GM; Latagliata, R | 1 |
| Mizutani, S; Nagasawa, M | 1 |
| Buchdunger, E; Deininger, M; Druker, BJ | 1 |
| Bork, S; Brors, B; Eils, R; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Kliszewski, S; Kronenwett, R; Neumann, F; Roes, N; Royer-Pokora, B; Schimkus, N; Steidl, U; Teutsch, N | 1 |
| Bacher, U; Berger, U; Haferlach, T; Hehlmann, R; Hiddemann, W; Hochhaus, A; Schoch, C | 1 |
| Aichberger, KJ; Akgul, C; Derdak, S; Florian, S; Krauth, MT; Mayerhofer, M; Monia, BP; Moriggl, R; Pickl, WF; Selzer, E; Sillaber, C; Skvara, H; Sonneck, K; Valent, P; Wacheck, V | 1 |
| Cao, YX; Feng, Q; Liu, XP; Shang, ZC; Sun, BZ; Wang, W; Yao, LB | 1 |
| Gordois, A; Scuffham, P; Ward, S; Warren, E | 1 |
| Darré, S; Facon, T; Guilhot, J; Laï, JL; Preudhomme, C; Roche-Lestienne, C | 1 |
| Cilloni, D; Giugliano, E; Mattioli, G; Messa, E; Morotti, A; Rege-Cambrin, G; Saglio, G; Volpe, G | 1 |
| Alimena, G; Breccia, M; Carmosino, I; Latagliata, R; Morano, SG; Russo, E | 1 |
| Babu, KG; Bapsy, PP; George, J; Singhal, N | 1 |
| Bornmann, WG; Clarkson, B; Ilaria, RL; Tong, WP; Veach, DR; Wolff, NC | 1 |
| Alimena, G; Antonio, C; Antonio, S; Biondo, F; Breccia, M; Carmosino, I; Chiara, S; Chistolini, A; De Cuia, R; Eleonora, R; Enrico, M; Fiammetta, N; Francesca, B; Franco, M; Giacomo, MS; Giuliana, A; Ida, C; Latagliata, R; Mancini, M; Mandelli, F; Marco, M; Massimo, B; Montefusco, E; Morano, GS; Natalino, F; Roberto, L; Rosa, de C; Russo, E; Sarlo, C; Spadea, A | 1 |
| Dörken, B; Kreuzer, KA; le Coutre, P; Lupberger, J; Na, IK | 1 |
| Cohen, MH; Johnson, JR; Pazdur, R | 1 |
| Güran, S; Tunca, Y | 1 |
| Baker, SJ; Cosenza, SC; Gumireddy, K; John, P; Kang, AD; Reddy, EP; Reddy, MV; Robell, KA | 1 |
| Czepulkowski, B; Jan-Mohamed, R; Kaczmarski, R; Pavlu, J | 1 |
| Balwierz, W; Klekawka, T; Niezgoda, A; Pawińska, K; Skoczeń, S; Strojny, W | 1 |
| Adigüzel, C; Bayik, M; Bizargity, P; Eksioglu-Demiralp, E; Ozilhan, G | 1 |
| Copland, M; Fraser, AR; Harrison, SJ; Holyoake, TL | 1 |
| Andreasson, C; Apperley, JF; Bua, M; Dazzi, F; Fleming, A; Goldman, JM; Howard, J; Kaeda, J; Kanfer, E; Marin, D; Olavarria, E; Rahemtulla, A; Saunders, S; Szydlo, R | 1 |
| Andersen, MK; Brondum-Nielsen, K; Dufva, IH; Johnsen, HE; Karle, H; Madsen, HO | 1 |
| Doggrell, SA | 2 |
| Deininger, MW; Druker, BJ; O'Hare, T; Walters, DK | 1 |
| Azam, M; Breitenstein, W; Brüggen, J; Callahan, L; Catley, L; Cavazza, C; Cowan-Jacob, SW; Daley, GQ; Fabbro, D; Fendrich, G; Gilliland, DG; Griffin, JD; Hall-Meyers, E; Huntly, B; Kung, AL; Manley, PW; Mestan, J; Mohammed, A; Neuberg, D; Ray, A; Weisberg, E; Wright, RD | 1 |
| Borisch, B; Cogliatti, SB; Dirnhofer, S; Ebnoether, M; Gratwohl, A; Hawle, H; Hess, U; Korte, W; Lugli, A; Mach-Pascual, S; Passweg, J; Tichelli, A; Tinguely, M; Von Juergensonn, S | 1 |
| Cools, J; De Keersmaecker, K; Graux, C; Hagemeijer, A; Maertens, J; Marynen, P; Mentens, N; Odero, MD; Somers, R; Vandenberghe, P; Wlodarska, I | 1 |
| Ren, R | 1 |
| Kakihana, K; Kurosu, T; Miura, O; Murakami, N; Yamamoto, M | 1 |
| Campbell, PJ; Curtin, NJ; Green, AR | 1 |
| Baldwin, SA; Barnes, K; Bentley, J; Daley, GQ; McIntosh, E; Whetton, AD | 1 |
| Benová, B; Fricová, M; Kafková, A; Kirschnerová, G; Tóthová, A; Tóthová, E | 1 |
| Franceschini, R; Garuti, A; Gobbi, M; Zoppi, F | 1 |
| Berger, U; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Riehm, B; Schoch, C; Schwindel, U | 1 |
| Deininger, MW; Holyoake, TL | 1 |
| Randolph, TR | 1 |
| Huang, XJ; Jiang, B; Jiang, H; Liu, DH; Lu, DP; Qiu, JY; Shi, HX | 1 |
| Cortes, J; Dewald, GW; Kantarjian, HM; Litzow, ML; Mauro, MJ; Talpaz, M; Tefferi, A | 1 |
| Bonora, E; Franchini, M; Veneri, D | 1 |
| Ahmad, K | 1 |
| Couzin, J | 1 |
| Udvardy, M | 1 |
| Ayirookuzhi, SJ; Ma, L; Mills, G; Ramshesh, P | 1 |
| Bullorsky, E; Ricchione, D; Saxton, R; Schamun, A; Stemmelin, G | 1 |
| Aichberger, KJ; Deininger, M; Derdak, S; Druker, BJ; Esterbauer, H; Florian, S; Griffin, JD; Hauswirth, AW; Krauth, MT; Marosi, C; Mayerhofer, M; Pickl, WF; Sillaber, C; Sperr, WR; Valent, P; Wagner, O; Weisberg, E | 1 |
| Andreasson, C; Apperley, JF; Bua, M; Goldman, JM; Kaeda, JS; Marin, D; Olavarria, E; Saunders, SM | 1 |
| DellaValla, J; Martin, SE | 1 |
| Eklund, EA; Fish, EN; Kambhampati, S; Katsoulidis, E; Majchrzak, B; Parmar, S; Platanias, LC; Sassano, A; Smith, J; Tallman, MS; Uddin, S | 1 |
| Jones, RL; Judson, IR | 1 |
| Berthebaud, M; Buet, D; Foudi, A; Geay, JF; Jarrier, P; Louache, F; Turhan, AG; Vainchenker, W; Zhang, Y | 1 |
| Azzarone, B; Bourhis, JH; Caignard, A; Cebo, C; Chelbi-Alix, M; Chouaib, S; Da Rocha, S; Jalil, A; Turhan, AG; Voutsadakis, IA | 1 |
| Duch-Samper, A; Hurtado-Sarrió, M; Martínez-Dominguez, JA; Menezo-Rozalén, JL; Senent-Peris, ML; Taboada-Esteve, J | 1 |
| Ashraf, H | 1 |
| Decoteau, J; Hirokawa, M; Ichinohasama, R; Kawabata, Y; Kitabayashi, A; Kobayashi, Y; Kume, M; Miura, AB; Miura, I; Nishijima, H; Ohtsubo, K; Otane, W; Sawada, K; Takahashi, K; Takahashi, N; Yoshioka, T | 1 |
| Bessho, M; Ito, K; Jinnai, I; Suzuki, T; Tominaga, K | 1 |
| Bhatia, R; Forman, SJ; Holtz, MS | 1 |
| Basara, N; Binckebanck, A; Bornhaüser, M; Brück, P; Bug, G; Bunjes, D; Gschaidmeier, H; Hoelzer, D; Ledderose, G; Mahlberg, R; Ottmann, OG; Perz, J; Pfeifer, H; Scheuring, UJ; Schwerdtfeger, R; Stadler, M; Stelljes, M; Wassmann, B | 1 |
| Crossman, LC; Deininger, MW; Druker, BJ; Harrington, CA; Hehlmann, R; Hochhaus, A; Hsieh, YC; Krohn, K; Lange, T; Mori, M; Niederwieser, DW; Paschka, P | 1 |
| Baccarani, M; Cilloni, D; Martinelli, G; Rosti, G; Soverini, S | 1 |
| Alonso, E; Boqué, C; Domingo, A; Espinet, B; Oliveira, AC; Solé, F | 1 |
| Bartlett, HM; Costakos, D; Mandava, N | 1 |
| Albero, MP; Andreu, EJ; Arbona, C; Ivorra, C; Lledó, E; Martínez-Climent, JA; Montiel-Duarte, C; Pérez-Calvo, J; Pérez-Roger, I; Poch, E; Prósper, F; Rifón, J | 1 |
| Bradbury, J | 1 |
| Blasiak, J; Czechowska, A; Drzewoski, J; Poplawski, T | 1 |
| Engels, K; Fokkema, S; Griesshammer, M; Hansmann, ML; Keller, C; Kriener, S; Kvasnicka, HM; Ollig, ES; Ottmann, OG; Schmitt-Graeff, A; Staib, P; Thiele, J; Waller, CF | 1 |
| Ballard, EE; Skrepnek, GH | 1 |
| Aksu, S; Beyazit, Y; Goker, H; Haznedaroglu, IC; Kekilli, M; Kilickap, S | 1 |
| Phatak, PD; Rajda, J | 1 |
| Chen, SJ; Chen, Z; Gu, BW; Jiang, CL; Li, JM; Shen, ZX; Sun, HP; Wang, AH; Xing, W; Zhao, RH; Zhu, YM | 1 |
| Al-Ali, HK; Bumm, T; Deininger, MW; Franke, C; Grommisch, L; Krahl, R; Lange, T; Mueller, M; Musiol, S; Niederwieser, D; Otto, S | 1 |
| Hasford, J; Hochhaus, A; Pfirrmann, M | 1 |
| Chng, WJ; Tan, LH | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, H; Luthra, R; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S | 1 |
| AlKindi, S; Dennison, D; Pathare, A | 1 |
| Haskovec, C; Klamová, H; Moravcová, J; Polák, J; Rulcová, J; Zemanová, Z | 1 |
| Cortes, J; Garcia-Manero, G; Gharibyan, V; Issa, JP; Jelinek, J; Kantarjian, HM; Morris, G; Talpaz, M; Verstovsek, S | 1 |
| Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
| Dalziel, K; Garside, R; Round, A; Stein, K | 1 |
| Büsche, G; Gadzicki, D; Just, M; Kreipe, H; Schlegelberger, B; Steinemann, D; von Neuhoff, N; Wilkens, L | 1 |
| Fruehauf, S; Jauch, A; Laufs, S; Melo, JV; Radujkovic, A; Schad, M; Schultheis, BS; Topaly, J; Veldwijk, MR; Zeller, WJ | 1 |
| Hirase, C; Kanamaru, A; Maeda, Y; Matsuda, M; Miyatake, J; Morita, Y; Shimada, T; Tanaka, M; Tatsumi, Y | 1 |
| Crossman, L; Deininger, MW; Demehri, S; Druker, BJ; Kovacs, I; Lange, T; McWeeney, S; Niederwieser, D; Otto, S; Park, B; Stoffregen, EP; Willis, SG | 1 |
| Dewar, AL; Hughes, TP; Lyons, AB; Zannettino, AC | 1 |
| Masszi, T | 1 |
| Lovas, N; Poros, A | 1 |
| Eckhardt, S | 1 |
| Bonin, M; Bornhäuser, M; Ehninger, G; Freiberg-Richter, J; Illmer, T; Jenke, A; Pursche, S; Schleyer, E | 1 |
| Dann, EJ; Eytan, GD; Regev, R; Yeheskely-Hayon, D | 1 |
| Cowan-Jacob, SW; Deininger, MW; Druker, BJ; Heinrich, MC; Jia, T; Lee, FY; Manley, PW; Mestan, J; O'Hare, T; Stoffregen, EP; Walters, DK | 1 |
| Apperley, JF; Mahon, FX; Melo, JV; Schultheis, B; Szydlo, R | 1 |
| Ozdemirli, M; Tutuncuoglu, SO; Yanovich, S | 1 |
| Chang, Y; Chen, SS; Fu, JY; Jiang, B; Jiang, H; Jiang, Q; Li, JL; Liu, YR; Lu, DP; Qin, YZ; Qiu, JY; Ruan, GR; Wang, H | 1 |
| Chen, SS; Jiang, B; Jiang, H; Jiang, Q; Lu, DP; Lu, Y; Qiu, JY | 1 |
| Agirre, X; Andreu, EJ; Beltrán de Heredia, JM; Calasanz, MJ; Jiménez-Velasco, A; Lahortiga, I; Larráyoz, MJ; Márquez, J; Odero, MD; Prósper, F; Román-Gómez, J; Vázquez, I | 1 |
| Branford, S; Grigg, A; Hughes, T; Lyons, AB; Saunders, V; To, LB; White, D | 1 |
| Bona, RD; Chakravarthi, P; Fang, M; Gaffney, J; Glynn, L; Hegde, U; Kulko, JM; Laska, EJ; Li, Z; Liu, B; Ménoret, A; Moyo, V; Qiao, Y; Runowicz, CD; Srivastava, PK; Tannenbaum, SH | 1 |
| Gastl, G; Gruenewald, K; Gunsilius, E; Rumpold, H; Wolf, AM; Wolf, D | 1 |
| Gordon, MY; Marley, SB | 1 |
| Desplat, V; Lagarde, V; Leguay, T; Mahon, FX; Marit, G; Reiffers, J | 1 |
| Ali, R; Gülten, T; Kimya, Y; Köksal, N; Ozan, U; Ozçelik, T; Ozkalemkaş, F; Ozkocaman, V; Tunali, A; Yakut, T | 1 |
| Komarova, NL; Wodarz, D | 2 |
| Amare-Kadam, P; Baisane, C; Bakshi, A; Deshmukh, C; Parikh, P; Saikia, T | 1 |
| Bakshi, A; Biswas, G; Deshmukh, C; Parikh, PM; Prasad, N; Sastry, PS | 1 |
| Biondi, A; Colnaghi, F; Dassi, M; Elli, E; Fumagalli, M; Gambacorti-Passerini, C; Giudici, G; Parma, M; Perseghin, P; Pioltelli, P; Pogliani, EM; Ponchio, L; Tornaghi, L | 1 |
| Gilliland, DG; Huntly, BJ | 1 |
| Branford, S; Hughes, TP; Iwasa, Y; Michor, F; Nowak, MA; Sawyers, CL; Shah, NP | 1 |
| Raghunadharao, D; Rajappa, S; Rao, IS; Surath, A; Uppin, SG | 1 |
| Bernasconi, P; Boni, M; Calatroni, S; Lazzarino, M; Merante, S; Orlandi, E | 1 |
| Apperley, JF; Bacigalupo, A; Brune, M; Crawley, C; Gratwohl, A; Juliusson, G; Komarnicki, M; Lalancette, M; Lange, A; Mayer, J; Nagler, A; Niederwieser, D; Passweg, J; Rambaldi, A; Ringden, O; Sierra, J; Szydlo, R; Vitek, A; Zander, A | 1 |
| Alland, L; Arlinghaus, RB; Beran, M; Cortes, J; Dugan, M; Giles, F; Golemovic, M; Griffin, JD; Kantarjian, H; Manley, PW; Manshouri, T; Mestan, J; Sun, T; Verstovsek, S | 1 |
| Sorrentino, BP; Zhou, S; Zong, Y | 1 |
| Bohlander, SK; Griesinger, F; Haase, D; Hennig, H; Hillmer, F; Pies, A; Podleschny, M; Steffens, R; Wörmann, B | 1 |
| Balon, J; Giebel, S; Gooley, TA; Hellmann, A; Hołowiecki, J; Kałwak, K; Kruzel, T; Prejzner, W; Szatkowski, D; Wojnar, J; Zaucha, JM | 1 |
| Guilhot, F; Guilhot, J; Larchée, R; Martineau, G; Roy, L | 1 |
| Caplan, SN; Fetni, R; Johnson, NA | 1 |
| Eisendle, K; Gastl, G; Kircher-Eibl, B; Wolf, D | 1 |
| Kumar, L; Kumari, M; Lokeshwar, N | 1 |
| Bueso-Ramos, CE; Cortes, J; Giles, F; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M | 1 |
| Aleem, A; Siddiqui, N | 1 |
| Dong, Q; Gan, X; Lu, Q; Wu, D; Xu, R; Xu, X; Yu, XF; Yu, Y; Zhao, X | 1 |
| Meng, FY | 1 |
| Chen, RA; Hao, MW; He, H; Jiang, SS; Liang, YM; Liu, L; Liu, Q; Wang, LH; Zhang, JL | 1 |
| Clark, RE; Crossman, LC; Deininger, MW; Druker, BJ; Pirmohamed, M; Wang, L | 1 |
| Baille, ML; Hayette, S; Magaud, JP; Michallet, M; Nicolini, FE | 1 |
| Angstreich, GR; Barber, J; Griffin, CA; Hawkins, AL; Huff, CA; Jones, RJ; Matsui, W; Smith, BD; Vala, MS | 1 |
| Chiusolo, P; De Matteis, S; De Vita, S; Fiorini, A; Laurenti, L; Leone, G; Reddiconto, G; Sica, S | 1 |
| Crescenzi, B; Gorello, P; Gottardi, E; La Starza, R; Martelli, MF; Mecucci, C; Roti, G | 1 |
| Fermeglia, M; Ferrone, M; Pricl, S; Tamborini, E | 1 |
| Hiraoka, A | 1 |
| Ashihara, E; Fujiyama, Y; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; Ottmann, OG; Sato, K; Segawa, H; Yokota, A; Yuasa, T | 1 |
| Bakshi, A; Biswas, G; Menon, H; Parikh, PM; Prabhash, K; Prasad, N; Sastry, PS | 1 |
| Gray, A; Hamzah, HG; Irvine, A; Peter Downes, C; Pierce, A; Spooncer, E; Stewart, WA; Whetton, AD | 1 |
| Cailleres, S; David, M; Lafage-Pochitaloff, M; Mozziconacci, MJ; Popovici, C; Sainty, D | 1 |
| Agis, H; Horny, HP; Sotlar, K; Valent, P | 1 |
| Arana-Trejo, RM; Ayala-Sánchez, M; Chávez-González, A; Mayani, H; Ruiz-Sánchez, E; Sánchez-Valle, E; Vela-Ojeda, J | 1 |
| Abakumov, EM; Chelysheva, EIu; Diachenko, LV; Domracheva, EV; Druzhkova, GA; Ivanova, TV; Khoroshko, ND; Kolosheĭnova, TI; Kolosova, LIu; Kovaleva, LG; Kruglov, SS; Kurova, ES; Loriia, SS; Nemchenko, IS; Sysoeva, EP; Triputen', NZ; Turkina, AG; Vinogradova, OIu; Zakharova, AV; Zakharova, ES; Zhuravlev, VS; Zingerman, BV | 1 |
| Cassuto, JP; Legros, L; Ortonne, JP | 1 |
| Andreoni, F; Bungaro, S; Colnaghi, F; Corneo, G; Franceschino, A; Gambacorti-Passerini, C; Magistroni, V; Piazza, RG; Pogliani, EM; Tornaghi, L; Varella-Garcia, M | 1 |
| Clément, JF; Contentin, N; Courville, P; Jardin, F; Laquerriere, A; Lehembre, S; Lenain, P; Lenormand, B; Pouplin, S; Tilly, H | 1 |
| Burchert, A; Cai, D; Duyster, J; Hochhaus, A; Müller-Brüsselbach, S; Neubauer, A; Ottmann, OG; Paschka, P; von Bubnoff, N; Wang, Y | 1 |
| Corbin, AS; Crossman, LC; Deininger, MW; Druker, BJ; Heinrich, MC; Lange, T; Middleton, PG; O'Brien, SG; O'Hare, T; Stoffregen, EP; Willis, SG | 1 |
| Cortes, JE; Donato, NJ; Gao, H; Kantarjian, HM; Lee, BN; Reuben, JM; Talpaz, M | 1 |
| Biggio, V; Corm, S; Facon, T; Laï, JL; Nicolini, FE; Philippe, N; Preudhomme, C; Roche-Lestienne, C; Yakoub-Agha, I | 1 |
| Luppi, M; Marasca, R; Martinelli, S; Potenza, L; Riva, G; Torelli, G | 1 |
| Cervetti, G; Fazzi, R; Galimberti, S; Guerrini, F; Pacini, S; Petrini, M; Simi, P; Testi, R | 1 |
| Kim, S; Kim, Y; Lee, D; Oh, C; Park, J; Yoon, SS | 1 |
| Baccarani, M; Rosti, G | 1 |
| Barnes, DJ; Chuah, C; Corbin, A; Deininger, MW; Druker, BJ; Kwok, M; Melo, JV | 1 |
| Goss, VL; Melnick, M; Norris, B; Popova, L; Smith, BL; Wetzel, R | 1 |
| Agirre, X; Barrios, M; Castillejo, JA; Cervantes, F; Colomer, D; Garate, L; Heiniger, A; Jimenez-Velasco, A; Navarro, G; Prosper, F; Roman-Gomez, J; Sanchez, J; Torres, A | 1 |
| Cowan-Jacob, SW; Manley, PW; Mestan, J | 1 |
| Fay, M; Goldman, J; Murphy, PT; O'Donnell, R; Quinn, J; Swords, R | 1 |
| Baccarani, M; Martinelli, G; Rosti, G; Soverini, S | 1 |
| Azzara', A; Carulli, G; Fazzi, R; Galimberti, S; Orciuolo, E; Petrini, M; Testi, C | 1 |
| Hiddemann, W; Kolb, HJ; Schmid, C; Schoch, C; Weisser, M | 1 |
| Dalod, M; Vivier, E; Walzer, T; Zitvogel, L | 1 |
| McGlave, P | 1 |
| Abruzzo, L; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, H; O'Brien, S; Rios, MB; Verstovsek, S | 1 |
| Barrett, AJ; Childs, RW; Dorrance, C; Espinoza-Delgado, I; Igarashi, T; Lundqvist, A; Rezvani, K; Savani, BN; Srinivasan, R; Takahashi, Y | 1 |
| Deininger, MW; Druker, BJ; Heinrich, MC; O'Hare, T; Sherbenou, DW; Stoffregen, EP; Walters, DK | 1 |
| Barnes, DJ; Goldman, JM; Melo, JV; Palaiologou, D; Panousopoulou, E; Pattacini, L; Schultheis, B; Wong, A; Yong, AS | 1 |
| Barrett, AJ; Childs, R; Hensel, N; Kurlander, R; Montero, A; Savani, BN | 1 |
| Sattler, M; Walz, C | 1 |
| Allan, EK; Elliott, MA; Harrison, S; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
| Jinnai, I | 4 |
| Bui-Thi, MH; Callet-Bauchu, E; Cayuela, JM; Chabane, K; Espinouse, D; Hayette, S; Magaud, JP; Nicolini, F; Ollagnier, C; Raffoux, E; Rousselot, P; Tigaud, I | 1 |
| Anonli, A; Gedde-Dahl, T; Gruber, FX; Hjort-Hansen, H; Lamark, T; Olsen, M; Skogen, B; Sovershaev, MA | 1 |
| Barbagallo, T; Bellani, E; Borroni, G; Brazzelli, V; Orlandi, E; Passamonti, F; Prestinari, F; Roveda, E; Vassallo, C | 1 |
| Barbieri, E; Brusa, G; Calabrò, A; Campanini, F; Mancini, M; Santucci, MA; Zuffa, E | 1 |
| Aichberger, KJ; Deininger, M; Derdak, S; Druker, BJ; Esterbauer, H; Kondo, R; Krauth, MT; Mayerhofer, M; Pickl, WF; Selzer, E; Sillaber, C; Valent, P; Vales, A | 1 |
| Bornhäuser, M; Bunjes, D; Fischer, T; Gschaidmeier, H; Haus, U; Hess, G; Hochhaus, A; Huber, C; Kindler, T; Kobbe, G; Ledderose, G; Schwerdtfeger, R; Siegert, W; Ullmann, AJ; Wassmann, B | 1 |
| D'Antonio, J | 1 |
| Aksu, S; Cetiner, D; Goker, H; Haznedaroglu, IC; Koca, E; Ozcebe, OI; Turgan, C | 1 |
| de-Souza, C; García-Ruiz-Esparza, MA; Giralt, S; Gómez-Almaguer, D; Gutiérrez-Aguirre, CH; Karduss, A; Manzano, C; Miranda, E; Morales-Toquero, A; Ruiz-Argüelles, GJ; Sumoza, A; Vela-Ojeda, J | 1 |
| Cavenagh, J; Clark, RE; Cummins, M; Cwynarski, K; Dazzi, F; Holyoake, TL; Marks, DI; Marktel, S; Milligan, D; Parker, A; Russell, NH | 1 |
| Aloisi, A; Bruzzi, P; Di Gregorio, S; Gambacorti-Passerini, C; Giustolisi, R; Guglielmo, P; Mannino, F; Messina, A; Saglio, G; Sormani, MP; Stagno, F; Venuta, S; Vigneri, P | 1 |
| Andreeff, M; Beran, M; Cabreira-Hansen, M; Carter, BZ; Chen, W; Mak, DH; McQueen, T; Schober, WD | 1 |
| Champlin, RE; Kantarjian, H | 1 |
| Hughes, TP; Hui, CH | 1 |
| Alimena, G; Breccia, M; Muscaritoli, M | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Clapisson, G; Hayette, S; Michallet, M; Nicolini, FE; Philip, I; Prebet, T; Tigaud, I | 1 |
| Paterson, S; Smith, KD | 1 |
| Bergmann, JF; Bouscary, D; Ferrand, H; Mouly, S; Tamburini, J | 1 |
| Berger, M; Couderc, JL; Goumy, C; Périssel, B; Regnier, A; Tchirkov, A; Uhrhammer, N; Verrelle, P | 1 |
| Arruga, F; Baccarani, M; Bracco, E; Carturan, S; Cilloni, D; Defilippi, I; Giugliano, E; Martinelli, G; Messa, E; Messa, F; Morotti, A; Pautasso, M; Rosso, V; Saglio, G; Sen, A | 1 |
| Battmer, K; Chaturvedi, A; Dallmann, I; Eder, M; Ganser, A; Scherr, M; Schultheis, B | 1 |
| Abruzzese, E; Bocchia, M; Forconi, F; Gozzetti, A; Ippoliti, M; Lauria, F; Pirrotta, MT; Raspadori, D; Tozzi, M; Trawinska, MM | 1 |
| Desplat, V; Leguay, T; Mahon, FX; Marit, G | 1 |
| Blaser, BW; Bloomfield, CD; Bruner-Klisovic, R; Caligiuri, MA; Chang, JS; Galietta, A; Liu, S; Mao, H; Marcucci, G; Neviani, P; Notari, M; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Uttam, A; Valtieri, M | 1 |
| Decosterd, LA; Duchosal, MA; Gambillara, E; Kovacsovics, T; Laffitte, E; Panizzon, RG; Widmer, N | 1 |
| Choudhary, DR; Choudhry, VP; Kumar, R; Mahapatra, M; Mishra, P | 1 |
| Hatfield, A; Owen, S; Pilot, PR; Sablinska, K | 1 |
| Hyodo, H; Ito, T; Katayama, Y; Kimura, A; Miyoshi, N; Niimi, H; Tanaka, H | 1 |
| Ikuta, K; Inamura, J; Jimbo, J; Kohgo, Y; Miyokawa, N; Sato, K; Shindo, M; Tokusashi, Y; Torimoto, Y | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Ilaria, RL | 1 |
| Cortes, JE; Giles, FJ; Kantarjian, HM | 1 |
| Houtenbos, I; Janssen, JJ; Ossenkoppele, GJ; Snoijs, NC; van de Loosdrecht, AA; Westers, TM | 1 |
| Gotoh, A; Itoh, Y; Kimura, Y; Miyazawa, K; Ohyashiki, JH; Ohyashiki, K; Sashida, G; Shoji, N; Sumi, M; Tauchi, T | 1 |
| Berman, E; Bhalla, K; Copelan, EA; Devetten, MP; Emanuel, PD; Erba, HP; Greenberg, PL; Moore, JO; O'Brien, S; Przepiorka, D; Radich, JP; Schilder, RJ; Shami, P; Smith, BD; Snyder, DS; Soiffer, RJ; Tallman, MS; Talpaz, M; Wetzler, M | 1 |
| Deininger, MW; Lange, T; Park, B; Willis, SG | 1 |
| Goldman, J; Gordon, M | 1 |
| Ikeda, K; Kai, T; Kimura, H; Maruyama, Y; Nakamura, A; Noji, H; Ogawa, K; Ohira, H; Sato, Y; Shiga, Y; Takahashi, A; Takeyama, K | 1 |
| Baer, MR; Dunford, LM; Lawrence, W; McCarthy, PL; Ramanarayanan, J; Sait, SN | 1 |
| Kim, JY; Kim, S; Kim, Y; Lee, D; Oh, JK; Park, J; Yoon, SS | 1 |
| Bernheim, A; Bories, D; Bourhis, JH; Brouzes, C; Clausse, B; Danglot, G; Fauvet, D; Leon, B; Lozach, F; Ossard-Receveur, A; Turhan, AG | 1 |
| Békassy, AN; De Bont, ES; Gadner, H; Gschaidmeier, H; Guilhot, F; Guilhot, J; Leblanc, T; Millot, F; Nelken, B; Stary, J; Sufliarska, S; Suttorp, M | 1 |
| Borthakur, G; Cortes, J; Daley, G; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Sugrue, M; Talpaz, M | 1 |
| Hasford, J; Pfirrmann, M | 1 |
| Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR | 1 |
| Corbin, AS; Druker, BJ; O'Hare, T | 1 |
| Iwasa, Y | 1 |
| Frazão Rosa, Fde O; Maria Morselli, F; Ommati, LV; Rodrigues Oliveira, JS; Rosário Cavalheiro, Rde C; Vicari, P | 1 |
| Gherlinzoni, F; Gottardi, M; Manzato, E | 1 |
| Błasiak, J; Majsterek, I; Pytel, D | 1 |
| Chung, JH; Ha, E; Jung, KH; Kim, BS; Park, HJ; Park, YH; Yim, SV; Yoon, SH | 1 |
| Blasiak, J; Kowalski, M; Majsterek, I; Poplawski, T; Pytel, D; Skorski, T; Sliwinski, T; Slupianek, A | 1 |
| Dumur, CI; Ferreira-Gonzalez, A; Fossey, SC; Garrett, CT; Vnencak-Jones, CL | 1 |
| Abdelali, J; Bourhis, JH; Caignard, A; Caillat-Zucman, S; Cebo, C; Chouaib, S; Da Rocha, S; Turhan, AG; Wittnebel, S | 1 |
| Fang, BJ; Song, YP; Wei, XD; Zheng, S | 2 |
| Amabile, M; Baccarani, M; Castagnetti, F; Cilloni, D; Frassoni, F; Iacobucci, I; Martinelli, G; Merante, S; Pane, F; Rosti, G; Saglio, G; Soverini, S; Specchia, G; Testoni, N; Zaccaria, A | 1 |
| Elstner, E; Fenner, MH; Koeffler, HP; Liu, D; Liu, H; Possinger, K; Zang, C | 1 |
| Chang, Y; Chen, SS; Fu, JY; Huang, XJ; Jiang, Q; Li, JL; Li, LD; Liu, YR; Lu, Y; Qin, YZ; Qiu, JY; Ruan, GR; Zhu, HH | 1 |
| Binder, T; Esterbauer, H; Florian, S; Haas, OA; Müllauer, L; Sillaber, C; Sperr, WR; Valent, P | 1 |
| Miki, Y; Nagasaki, K; Shimoji, T | 1 |
| Adrián, FJ; Ding, Q; Ding, S; Fabbro, D; Gray, NS; Hur, W; Liu, Y; Manley, P; Mestan, J; Sim, T; Sloan, C; Velentza, A; Zhang, G | 1 |
| Abruzzese, E; Alimena, G; Amabile, M; Baccarani, M; Cilloni, D; Gobbi, M; Iacobucci, I; Iuliano, F; Martinelli, G; Martino, B; Montefusco, E; Ottaviani, E; Pane, F; Poerio, A; Rosti, G; Russo, D; Saglio, G; Soverini, S; Terragna, C; Testoni, N | 1 |
| Hochhaus, A; Schmitt-Graeff, A | 1 |
| Biggs, WH; Chao, LH; Kuriyan, J; Lockhart, DJ; Milanov, ZV; Patel, HK; Sawyers, CL; Seeliger, M; Shah, NP; Treiber, DK; Young, MA; Zarrinkar, PP | 1 |
| Allan, EK; Copland, M; Eaves, A; Eaves, C; Holyoake, TL; Jiang, X; Jørgensen, HG | 1 |
| Hampton, T | 1 |
| Andersson, BS; Champlin, RE; de Lima, M; Decker, WK; Eaves, AC; Eaves, C; Jones, R; Lee, MS; Li, S; McMannis, JD; Ng, J; Niu, T; Robinson, SN; Shpall, EJ; Xing, D; Yang, H; Yao, X | 1 |
| Choufi, B; Dombret, H; Dupriez, B; Huguet, F; Legros, L; Maury, S; Ojeda-Uribe, M; Pigneux, A; Raffoux, E; Rea, D; Recher, C; Reman, O; Rousselot, P; Royer, B; Stéphane, D; Thomas, X; Turlure, P; Vigier, M | 1 |
| Akioka, T; Hanafusa, T; Hara, S; Nakayama, S; Oka, S; Tsuji, M; Yamano, T; Yokote, T | 1 |
| Akiyama, T; Fujimi, A; Kida, M; Kuroda, H; Matsunaga, T; Niitsu, Y; Sato, T; Shimizu, K; Shirao, S; Tanaka, I; Watanabe, H | 1 |
| Higashi, T; Kubota, A; Matsuura, A; Mizobe, T; Morimoto, H; Mouri, F; Ohta, T; Sugito, M; Tanaka, Y; Tsukada, J | 1 |
| Arruga, F; Baraban, D; Bracco, E; Carturan, S; Catalano, R; Chiarenza, A; Cilloni, D; Defilippi, I; Gottardi, E; Guerrasio, A; Messa, F; Morotti, A; Pautasso, M; Pilatrino, C; Rosso, V; Saglio, G; Taulli, R | 1 |
| Ault, P; Beran, M; Cortes, J; Faderl, S; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Talpaz, M | 1 |
| Bando, M; Ohno, S; Sugiyama, Y; Yamasawa, H | 1 |
| Deininger, MW; Mauro, MJ | 1 |
| Chollet, C; Colombat, M; Fort, MP; Mahon, FX; Marit, G; Praloran, V; Preudhomme, C; Reiffers, J; Roche, C | 1 |
| Clark, RE; Knight, K; Lucas, C; Wang, L | 1 |
| Cortes, JE; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S | 1 |
| Deininger, MW; Druker, BJ; Love, Z; Mauro, MJ; Mongoue-Tchokote, S; Mori, M; Press, RD; Tran, T; Tronnes, AA; Yang, R | 1 |
| Al-Jabary, T; Anand, M; Apperley, JF; Goldman, JM; Iqbal, A; Kaeda, J; Khorashad, JS; Margerison, S; Marin, D; Melo, JV; Saunders, S | 1 |
| Allan, EK; Baird, JW; Barow, M; Copland, M; Elrick, LJ; Hamilton, A; Holyoake, TL; Jordanides, N; Mountford, JC | 1 |
| Dua, HS; Masood, I; Negi, A | 1 |
| Azevedo, TC; Beltrão, AC; Bentes, AQ; Bentes, IR; de Lemos, JA; de Oliveira, CM; Maradei-Pereira, LM; Scerni, AC | 1 |
| Dai, H; Druker, B; Friend, S; Linsley, PS; Mao, M; Oehler, V; Radich, JP; Sawyers, C; Schelter, J; Shah, N; Stock, W; Willman, CL | 1 |
| Branford, S; Hughes, TP; Moore, S; Ross, DM | 1 |
| Scheinfeld, N; Schienfeld, N | 1 |
| Hong-eng, S; Limsuwan, A; Pakakasama, S; Rochanawutanon, M | 1 |
| Bagot, C; Cross, TJ; Gillett, D; Portmann, B; Wendon, J | 1 |
| Bernardini, K; Buratti, T; Lanthaler, AJ; Mitterer, M | 1 |
| Buxhofer-Ausch, V; Hinterberger, W; Hinterberger-Fischer, M | 1 |
| Cotter, TG; Hickey, FB | 1 |
| Comb, MJ; Goss, VL; Lee, KA; MacNeill, J; Moritz, A; Nardone, J; Polakiewicz, RD; Rush, J; Spek, EJ | 1 |
| Boultwood, J; Campbell, LJ; Eagleton, H; Fidler, C; Gal, S; Kusec, R; Littlewood, TJ; Peniket, A; Wainscoat, JS | 1 |
| Chang, Y; Chen, SS; Fu, JY; Li, JL; Liu, YR; Ma, X; Qin, YZ; Ruan, GR; Wang, YZ | 1 |
| Fricker, J | 2 |
| Christen, S; Friess, D; Gratwohl, A; Heim, D; Meyer-Monard, S; Passweg, JR; Stüssi, G; Tichelli, A | 1 |
| Arai, Y; Mitani, K; Tadokoro, J; Takahashi, W; Takeuchi, K; Yamagata, T | 1 |
| Atadja, P; Balasis, M; Bali, P; Bhalla, K; Boyapalle, S; Fiskus, W; Giles, F; Kumaraswamy, S; Manley, PW; Pranpat, M; Rocha, K; Wu, J | 1 |
| Anavim, A; Dennehey, CF; Kong, KM; Moore, JC; Tiong Ong, S | 1 |
| Dai, CW; Li, RJ; Liu, DS; Zhang, GS | 1 |
| Karp, JE; Smith, BD | 1 |
| Copland, M; Elrick, L; Hamilton, A; Holyoake, T; Jørgensen, H; Melo, JV; Myssina, S | 1 |
| Connor, RF; Hurd, D; Koty, P; Molnár, I; Pettenati, MJ | 1 |
| Boissel, N; Brun, M; Cayuela, JM; Charron, D; Dombret, H; Dulphy, N; Le Bouteiller, P; Mahon, FX; Rea, D; Rousselot, P; Steinle, A; Tamouza, R; Tieng, V; Toubert, A | 1 |
| Cambareri, AC; Dang, P; Engler, J; Hughes, TP; Manley, PW; Quinn, SR; Saunders, VA; White, DL; Zannettino, AC | 1 |
| Kudoh, S; Ohnishi, K; Ohno, R; Sakai, F | 1 |
| Casado, LF; Fernández-Ruiz, E; Granda, A; Lombardía, L; Martínez, J; Martínez, P; Odriozola, J; Piris, MA; Pollán, M; Steegmann, JL; Tracey, L; Villalón, L; Villuendas, R | 1 |
| Andersson, BS; Champlin, R; Cortes, J; de Lima, M; Giles, F; Giralt, S; Jabbour, E; Jones, D; Jones, R; Kantarjian, HM | 1 |
| Baron, F; Beguin, Y; Castermans, E; Di Stefano, I; Giet, O; Gothot, A; Greimers, R; Meuris, N; Pirson, L | 1 |
| Duyster, J; Manley, PW; Mestan, J; Peschel, C; Sanger, J; von Bubnoff, N | 1 |
| Roussel, MF; Sherr, CJ; Williams, RT | 1 |
| Kolb, HJ; Ledderose, G; Schnittger, S; Schoch, C; Tischer, J; Weisser, M | 1 |
| Goh, HG; Hwang, JY; Kang, HY; Kim, DW; Kim, M; Kim, SH | 1 |
| Holyoake, TL; Jordanides, NE; Jorgensen, HG; Mountford, JC | 1 |
| Druker, BJ; Guerci-Bresler, A; Guilhot, F; Guilhot, J; Krahnke, T; Larson, RA; Massimini, G; O'Brien, S; Roy, L; So, C | 1 |
| Alimena, G; Biondo, F; Breccia, M; Diverio, D; Frustaci, A; Gentilini, F; Nanni, M; Pane, F; Russo, E | 1 |
| Cole, PA; Karplus, M; Koldobskiy, M; Kuchment, O; Kuriyan, J; Levinson, NM; Shen, K; Young, MA | 1 |
| Bories, D; Cayuela, JM; Corm, S; Facon, T; Giraudier, S; Guilhot, F; Hayette, S; Lê, QH; Leguay, T; Mahon, FX; Michallet, M; Nicolini, FE; Preudhomme, C; Roche-Lestienne, C; Rousselot, P; Roy, L; Sorel, N; Tulliez, M | 1 |
| Huff, CA; Jones, RJ; Matsui, WH; Smith, BD | 1 |
| Alli, N; Artuz, F; Erbasi, S; Han, O; Lenk, N; Oztas, P; Polat, M | 1 |
| Azam, M; Daley, GQ | 1 |
| Bertin, D; Crescenzio, N; Doria, A; Ricotti, E; Saglio, G; Timeus, F; Tovo, PA | 1 |
| Calabretta, B; Cattelani, S; Donato, NJ; Ferrari-Amorotti, G; Guerzoni, C; Iotti, G; Keeshan, K; Zattoni, M | 1 |
| Ikeda, A; Moore, TB; Sakamoto, KM; Shankar, DB; Tamanoi, F; Watanabe, M | 1 |
| Golovleva, I; Lazarevic, V; Nygren, I; Wahlin, A | 1 |
| Kansu, E; Koc, Y; Ozdemir, E | 1 |
| Cabello, P; Cesar, JM; Ferro, T; Navarro, JL | 1 |
| Litzow, MR | 1 |
| Agis, H; Doninger, B; Drach, J; Jaeger, E; Marosi, C; Oehler, L; Schwarzinger, I; Sillaber, C; Valent, P | 1 |
| Berman, E; Chanel, S; Fleisher, M; Heller, G; Maki, RG; Nicolaides, M; Sauter, NP; Scheu, K; Wilson, BA | 1 |
| Heim, D | 1 |
| Deguchi, N; Kawamura, T; Kitamura, R; Matsue, H; Shibagaki, N; Shimada, S; Shimizu, A; Yanagi, M | 1 |
| Calbecka, M; Hellmann, A; Prejzner, W; Wyrowinska, E; Zaucha, JM | 1 |
| O'Brien, SG; Reilly, JT; Simpson, E | 1 |
| Amabile, M; Baccarani, M; Bassan, R; Bassi, S; Breccia, M; Cilloni, D; Frassoni, F; Iacobucci, I; Izzo, B; Lauria, F; Martinelli, G; Merante, S; Montefusco, E; Pane, F; Paolini, S; Poerio, A; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 1 |
| Appelbaum, F; Apperley, J; Baccarani, M; Cervantes, F; Cortes, J; Deininger, M; Goldman, J; Gratwohl, A; Guilhot, F; Hehlmann, R; Hochhaus, A; Horowitz, M; Hughes, T; Kantarjian, H; Larson, R; Niederwieser, D; Saglio, G; Silver, R; Simonsson, B | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, HM; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Talpaz, M | 1 |
| Barbetti, V; Cipolleschi, MG; Dello Sbarba, P; Giuntoli, S; Olivotto, M; Rovida, E | 1 |
| Brors, B; Fabarius, A; Frank, O; Gretz, N; Haak, M; Hehlmann, R; Hochhaus, A; Li, L; Merk, S; Müller, MC; Schwindel, U; Seifarth, W; Zheng, C | 1 |
| Chen, Y; Lai, YR; Lu, YY; Luo, J; Peng, ZG; Song, SJ | 2 |
| Divoký, V; Faber, E; Indrák, K; Jarosová, M; Nausová, J; Priwitzerová, M | 1 |
| Levitzki, A; Mishani, E | 1 |
| Cortes, J; Kantarjian, HM | 1 |
| Blackwood-Chirchir, MA; Bleickardt, E; Chen, TT; Cortes, J; Decillis, AP; Donato, N; Huang, F; Iyer, V; Kantarjian, H; Nicaise, C; Nicoll, J; O'Brien, S; Paquette, R; Sawyers, CL; Shah, NP; Talpaz, M | 1 |
| Albitar, M; Alland, L; Bhalla, K; Bochinski, K; Cortes, J; Dugan, M; Giles, F; Griffin, JD; Hochhaus, A; Hoelzer, D; Kantarjian, H; Manley, P; Mietlowski, W; O'Brien, S; Ottmann, OG; Rae, P; Tanaka, C; Wassmann, B; Wunderle, L | 1 |
| Pu, Q | 1 |
| Akdag, I; Ali, R; Ozan, U; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V; Tunali, A | 1 |
| Batár, P; László, R; Telek, B; Udvardy, M | 1 |
| Majhail, NS; Schiffer, CA; Weisdorf, DJ | 1 |
| Franceschino, A; Gambacorti Passerini, C; Piazza, R; Pogliani, E; Tornaghi, L | 1 |
| Boccadoro, M; Campa, E; Dellacasa, C; Fava, C; Ferrero, D; Fumagalli, M; Mattioli, G; Perfetti, P; Pogliani, EM; Rege-Cambrin, G | 1 |
| Naithani, R; Panigrahi, I | 1 |
| Huang, M; Liu, WL; Ran, D; Sun, HY; Zhang, YC; Zhou, JF | 1 |
| Jootar, S; Lassarat, S | 1 |
| Beumer, JH; Egorin, MJ; Lagattuta, TF; Natale, JJ; Raptis, A | 1 |
| Abruzzo, LV; Cortes, J; Garcia-Manero, G; Kantarjian, H; Kovitz, C | 1 |
| Asaka, M; Hashino, S; Imamura, M; Kondo, K; Matsuno, K; Mori, A; Musashi, M; Onozawa, M; Ota, S; Tanaka, J; Toubai, T; Toyoshima, N | 1 |
| Dömötör, M; Egyed, M; Gasztonyi, Z; Iványi, JL; Jaksó, P; Kajtár, B; Kereskai, L; Losonczy, H; Méhes, G; Pajor, L; Tóth, A; Tóth, P | 1 |
| Calabrese, G; Di Gianfilippo, R; Di Lorenzo, R; Fantasia, D; Palka, G; Stuppia, L | 1 |
| Arlinghaus, RB; Kantarjian, H; Lin, H; Samanta, AK; Sun, T | 1 |
| Basic, I; Chandra, J; Giles, F; Golemovic, M; Kantarjian, H; Manshouri, T; Orsolic, N; Quintás-Cardama, A; Scappini, B; Verstovsek, S | 1 |
| Assouline, S; Benemacher, V; Gambacorti-Passerini, C | 1 |
| Cesarman, E; Chen, Q; Knowles, DM; Lee, JW; Wang, YL | 1 |
| Cortes, JE; Quintás-Cardama, A | 1 |
| Bachmann, M; Bornhäuser, M; Mohr, B; Platzbecker, U; Rieber, EP; Schäkel, K; Schmitz, M; Temme, A; Wehner, R; Wendisch, M | 1 |
| Kalaycio, M; Suppiah, R | 1 |
| Divoký, V; Egorin, MJ; Faber, E; Holzerová, M; Indrák, K; Jarosová, M; Maresová, I; Nausová, J; Rozmanová, S | 1 |
| Biollaz, J; Buclin, T; Csajka, C; Decosterd, LA; Duchosal, MA; Eap, CB; Henry, H; Leyvraz, S; Rochat, B; Rosselet, A; Widmer, N | 1 |
| Amiel, A; Fejgin, M; Gaber, E; Josef, G; Leopold, L; Lishner, M; Yukla, M | 1 |
| Bekele, N; Cortes, J; Garcia-Manero, G; Giles, F; Jabbour, E; Jones, D; Kantarjian, H; Luthra, R; O'Brien, S; Rios, MB; Talpaz, M; Verstovsek, S; Zhou, X | 1 |
| Chung, YJ; Ha, SA; Kang, HM; Kim, DW; Kim, HK; Kim, JH; Kim, JW; Kim, S; Kim, TM; Lee, YJ; Namkoong, H; Shin, SM | 1 |
| Clarkson, B; Hajivandi, M; Liang, X; Pope, RM; Resh, MD; Veach, D; Wisniewski, D | 1 |
| Grigg, A; Hughes, T | 1 |
| Augustson, B; Cannell, P; Joske, D; Willson, A | 1 |
| Apperley, JF; Khorashad, JS; Marin, D; Olavarria, E; Perz, JB | 1 |
| Alimena, G; Biondo, F; Breccia, M; Carmosino, I; Diverio, D; Latagliata, R; Mancini, M; Mandelli, F; Nanni, M; Russo, E | 1 |
| Bumm, T; Corbin, AS; Deininger, MW; Druker, BJ; Goss, VL; Griswold, IJ; Johnson, K; Lee, KA; MacPartlin, M; Moseson, EM; O'Hare, T; Polakiewicz, RD; Smith, C; Stoffregen, EP; Wood, LJ | 1 |
| Wang, JY | 1 |
| Cogoi, S; Rapozzi, V; Xodo, LE | 1 |
| Mann, DL | 1 |
| Ali, R; Ozcelik, T; Ozkalemkas, F; Ozkan, A; Ozkocaman, V | 1 |
| Aleskog, A; Barbany, G; Bengtsson, M; Björnberg, A; Höglund, M; Larsson, R; Lindhagen, E; Olsson-Strömberg, U; Simonsson, B | 1 |
| Moosavi, MA; Yazdanparast, R | 1 |
| Fujii, S; Fujimoto, K; Hidaka, M; Kadowaki, N; Kawano, F; Konishi, N; Makita, N; Shimizu, K; Taniguchi, M; Uchiyama, T | 1 |
| Ahn, JS; Jung, CW; Kang, WK; Kim, HJ; Kim, K; Kim, WS; Ko, YH; Park, K | 1 |
| Ballerini, F; Canepa, L; Clavio, M; Colombo, N; Fugazza, G; Garuti, A; Gobbi, M; Grasso, R; Ibatici, A; Miglino, M; Pierri, I; Sessarego, M; Varaldo, R | 1 |
| Conneally, E; Langabeer, S; Lynch, M; McCann, S; McMenamin, ME; Piccin, A | 1 |
| Chen, CK; Ikeda, Y; Mori, T; Okamoto, S; Saito, H; Sakamoto, M; Shibata, R; Tada, S; Yamazaki, R | 1 |
| Chomel, JC; Guilhot, F; Martineau, G; Roy, L; Sorel, N; Turhan, AG | 1 |
| Frangoul, H; Loken, MR; Manes, B; Vnencak-Jones, CL; Woods-Swafford, W | 1 |
| Albitar, M; Bhalla, K; Giles, F; Gorre, M; Jilani, I; Kantarjian, H; Ma, W; Ottmann, O | 1 |
| Inokuchi, K | 1 |
| Fruehauf, JP; Halbur, L; Ong, ST; Prabhu, S; Saadat, D; Zhang, M | 1 |
| Cornetta, K; Cripe, LD; Fausel, C; Nelson, RP; Ramanuja, S; Ward, KE | 1 |
| Banerjee, D; Banerjee, S; Chandra, S; Sengupta, A | 1 |
| Ashihara, E; Deguchi, Y; Hatake, K; Inui, K; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; Masuda, S; Ruthardt, M; Sato, K; Terui, Y; Ueda, T; Urasaki, Y; Yokota, A | 1 |
| Bassetti, A; Bianchi, E; Donti, E; Giannini, B; Liberati, AM; Prontera, P; Saglio, G; Valenti, A; Venti, G; Zaccaria, A | 1 |
| Chu, SC; Li, CC; Tang, JL | 1 |
| Barnett, MJ; Bruyère, H; Forrest, DL; Hogge, DE; Horsman, DE; Lavoie, JC; Lin, Y; Nantel, SH; Nevill, TJ; Pantzar, T; Shepherd, JD; Smith, CA; Song, KW; Sutherland, HJ; Toze, CL | 1 |
| Kapelushnik, J; Manor, E; Moser, AM; Narkis, G | 1 |
| Estrov, Z; Kurzrock, R; Li, L; Talpaz, M | 1 |
| Andreeff, M; Carter, BZ; Dean, NM; Koller, E; Konopleva, M; Mak, DH; Schober, WD; Shi, Y; Wang, RY | 1 |
| Abruzzese, E; Amadori, S; Artico, M; Catalano, G; Cirilli, R; Ciriolo, MR; Di Stefano, C; Filomeni, G; La Regina, G; La Torre, F; Lavecchia, A; Marfè, G; Morgante, E; Morgante, M; Novellino, E; Russo, MA; Silvestri, R; Sinibaldi Salimei, P | 1 |
| Blanchet, O; Cayuela, JM; Gardembas, M; Gluckman, E; Huguet, F; Legros, L; Maarek, O; Mahon, FX; Marit, G; Rea, D; Reiffers, J; Rousselot, P | 1 |
| Baccarani, M; Cilloni, D; Iacobucci, I; Martinelli, G; Pane, F; Saglio, G; Soverini, S | 1 |
| Cortes, J; Giles, F; Jones, D; Kantarjian, H; Nicaise, C; O'Brien, S; Quintas-Cardama, A; Talpaz, M | 1 |
| Bouillet, P; Cragg, MS; Druker, BJ; Huang, DC; Kelly, PN; Kimura, S; Kuroda, J; Ottmann, OG; Puthalakath, H; Roberts, AW; Strasser, A; Villunger, A | 1 |
| Kaufmann, SH | 1 |
| Hardling, M; Hezaveh, R; Olsson, B; Ricksten, A; Stockelberg, D; Wadenvik, H; Wei, Y | 1 |
| Gruber, FX; Hjorth-Hansen, H; Johansen, T; Mikkola, I; Stenke, L | 1 |
| Bunjes, D; Chen, B; Chen, J; Döhner, H; Greiner, J; Guillaume, P; Ringhoffer, M; Rojewski, M; Schmitt, A; Schmitt, M; von Harsdorf, S | 1 |
| Hoyer, R; Krook, J; LeMarbre, G; Schinstock, C; Tefferi, A | 1 |
| Góra-Tybor, J; Grzybowska-Izydorczyk, O; Robak, T | 1 |
| Glauche, I; Hochhaus, A; Horn, M; Loeffler, M; Mueller, MC; Roeder, I | 1 |
| Kumar, R; Pati, HP; Pillai, LS; Saxena, R; Srinivas, U | 1 |
| Alimena, G; Breccia, M; De Propris, MS; Frustaci, A; Russo, E | 1 |
| Balasis, M; Bali, P; Bhalla, K; Estrella, V; Fiskus, W; Herger, B; Kumaraswamy, S; Lee, F; Pranpat, M; Rao, R; Richon, V; Rocha, K | 1 |
| Anand, M; Apperley, JF; Goldman, JM; Kaeda, JS; Khorashad, J; Marin, D | 1 |
| Ardito, F; Chiusolo, P; De Matteis, S; Di Mario, A; Laurenti, L; Leone, G; Maiuro, G; Sica, S; Sorà, F | 1 |
| Abbott, LH; Michor, F | 1 |
| Besson, C; Buffet, C; Dhalluin-Venier, V; Dimet, S; Tchernia, G; Thirot-Bibault, A | 1 |
| Asahina, A; Fujimoto, M; Ihn, H; Kuwano, Y; Tamaki, K; Watanabe, R | 1 |
| Auberger, P; Belhacene, N; Breittmayer, JP; Colosetti, P; Grosso, S; Jacquel, A; Marchetti, S; Puissant, A | 1 |
| Igarashi, K; Ikebe, D; Kobayashi, M; Kono, K; Melo, JV; Muto, A; Ono, A; Sun, J; Tashiro, S; Ueda, K | 1 |
| Burkhardt, R; Lange, T; Niederwieser, D; Pelz-Ackermann, O | 1 |
| Alonso, V; García, L; Jordá, E; Martín, JM; Monteagudo, C; Villalón, G | 1 |
| Appelbaum, FR; Bhatia, R; Chu, S; Cummings, CC; Forman, SJ; Gooley, T; Johnston, L; Lin, A; Negrin, RS; Oehler, VG; Radich, JP; Snyder, DS | 1 |
| Jin, J; Tong, XM; Zheng, SE | 1 |
| Horiike, S; Misawa, S; Taniwaki, M; Ueda, K; Zen, K | 1 |
| Brdicka, R; Bruchova, H; Merkerova, M | 1 |
| Duffy, TM; Hu, Y; Lee, FY; Li, S; Swerdlow, S; Weinmann, R | 1 |
| Azhipa, O; Friedman, TM; Goldberg, SL; Hsu, JW; Korngold, R; Pecora, AL; Preti, RA; Rowley, SD; Tkachuk, Y; Zilberberg, J | 1 |
| Bonham, L; de Vries, P; Deininger, MW; Demehri, S; Druker, BJ; Härtel, N; Hollenback, D; Jia, T; La Rosée, P; Melo, JV; Singer, JW | 1 |
| Barett, C; Brendel, C; Burchert, A; Cai, D; Erben, P; Hochhaus, A; Manley, PW; Neubauer, A; Wang, Y | 1 |
| Beránek, M; Chrobák, L; Maisnar, V; Voglová, J | 1 |
| Büyükasik, Y; Cetiner, D; Goker, H; Haznedaroglu, IC; Koca, E; Ozcebe, O; Sayinalp, N; Sevimli, F | 1 |
| Jin, L; Kato, A; Tabe, Y | 1 |
| Bertz, J; Elstner, E; Eucker, J; Koeffler, HP; Liu, H; Possinger, K; Waechter, M; Zang, C | 1 |
| Lipton, JH; Medeiros, BC | 1 |
| Hullberg, S; Ricksten, A; Stockelberg, D; Wadenvik, H; Wei, Y | 1 |
| Burger, JA; Bürkle, A; Finke, J; Schmitt-Gräff, A; Seiler, L | 1 |
| Chen, R; Gandhi, V; Plunkett, W | 1 |
| Appelbaum, FR; Carpenter, PA; Flowers, ME; Gooley, TA; Martin, PJ; Radich, JP; Sanders, JE; Snyder, DS | 1 |
| Jin, J; Li, Y; Meng, HT; Qian, WB; Yang, CM | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Countouriotis, AM; Druker, BJ; Ezzeddine, R; Facon, T; Goldberg, SL; Hochhaus, A; Hughes, TP; Kantarjian, HM; Lipton, JH; Muller, MC; Niederwieser, D; Shah, NP; Silver, RT; Stone, RM | 1 |
| Harigae, H; Ishikawa, I; Ishizawa, K; Kameoka, J; Kato, C; Miyamura, K; Sasaki, T; Sugawara, T; Tomiya, Y; Yamada, M | 1 |
| Chen, SS | 1 |
| Agis, H; Baccarani, M; Cervantes, F; Cornelissen, JJ; Deininger, MW; Druker, BJ; Fischer, T; Gabrilove, JL; Gathmann, I; Gattermann, N; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Hughes, T; Kantarjian, H; Larson, RA; Letvak, L; Nielsen, JL; O'Brien, SG; Powell, BL; Radich, JP; Reiffers, J; Rousselot, P; Saglio, G; Shepherd, J; Silver, RT; Simonsson, B; So, C; Stone, RM; Taylor, K; Verhoef, G | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Ladie, N; Murgo, A; O'Brien, S; Quintás-Cardama, A; Verstovsek, S | 1 |
| Albarello, A; Aquino, S; Clavio, M; Colombo, N; Garuti, A; Gobbi, M; Grasso, R; Miglino, M; Sessarego, M; Varaldo, R | 1 |
| Nichols, G; Ritchie, E | 1 |
| Handa, H; Irisawa, H; Iriuchishima, H; Karasawa, M; Matsushima, T; Murakami, H; Nojima, Y; Saitoh, T; Tsukamoto, N; Yamane, A | 1 |
| Hashiguchi, M; Imamura, R; Nagata, S; Ogata, H; Okamura, T; Oku, E; Osaki, K; Otsubo, K; Sata, M; Seki, R; Takata, Y; Yakushiji, K; Yoshimoto, K | 1 |
| Barnes, DJ; Melo, JV | 1 |
| Cortes, J; Giles, F; Kantarjian, HM; O'Brien, S; Talpaz, M | 1 |
| Borras-Blasco, J; Conesa, V; Matarredona, J; Miralles, J; Pascual, JC | 1 |
| Agarwal, P; Apperley, J; Baccarani, M; Branford, S; Cortes, J; Coutre, S; Erben, P; Gollerkeri, A; Guilhot, F; Hamerschlak, N; Hochhaus, A; Kim, DW; Ottmann, O; Ritchie, E; Rousselot, P; Saglio, G; Shah, N | 1 |
| Chang, CS; Chang, JG; Hsiao, HH; Lin, SF; Liu, TC; Liu, YC; Tsai, HJ; Tseng, SB; Yang, MY | 1 |
| Kanagalingam, D; Koh, LP | 1 |
| Abruzzese, E; Amabile, M; Baccarani, M; Caracciolo, C; Castagnetti, F; Ciccone, F; Colarossi, S; di Lorenzo, R; Gnani, A; Iacobucci, I; Izzo, B; Martinelli, G; Orlandi, E; Pane, F; Poerio, A; Radaelli, F; Rosti, G; Saglio, G; Soverini, S; Tiribelli, M | 1 |
| Begaud, B; Bernard, MA; Ducint, D; Etienne, G; Lassalle, R; Mahon, FX; Marit, G; Molimard, M; Moore, N; Picard, S; Reiffers, J; Teilhet, E; Titier, K | 1 |
| Higuchi, M; Nishinaka, H; Yamano, Y | 1 |
| Bartholomeusz, GA; Donato, NJ; Estrov, Z; Kapuria, V; Kong, LY; Priebe, W; Talpaz, M; Wang, S; Wu, J | 1 |
| Bosi, A; Buchi, F; Ferrari, G; Gozzini, A; Pastorelli, R; Santini, V; Spinelli, E | 1 |
| Corneo, G; Franceschino, A; Gambacorti, C; Gambacorti-Passerini, C; Piazza, R; Pogliani, E; Tornaghi, L | 1 |
| Hatfield, A; Owen, S; Pilot, PR | 1 |
| Atallah, E; Cortes, J; Kantarjian, H | 1 |
| Baccarani, M; Martinelli, G; Rosti, G | 1 |
| Chabane, K; Hayette, S; Magaud, JP; Michallet, M; Nicolini, FE; Tigaud, I | 1 |
| Amabile, M; Angelucci, E; Baccarani, M; Bandini, G; Benedetti, F; Fanin, R; Martinelli, G; Palandri, F; Rosti, G; Tiribelli, M; Usala, E | 1 |
| Allan, EK; Holyoake, TL; Jordanides, NE; Jørgensen, HG; Mountford, JC | 1 |
| Beacci, D; Chase, A; Cools, J; Crescenzi, B; Cross, NC; Gallì, A; Jones, AV; Martelli, MF; Marynen, P; Mecucci, C; Rosti, V; Specchia, G; Starza, RL; Vandenberghe, P | 1 |
| Dent, P; Grant, S; Harada, H; Nguyen, TK; Rahmani, M | 1 |
| Han, MK; Horowitz, JC; Moore, BB; Thannickal, VJ; Vittal, R; Zhang, H | 1 |
| Bejarano, PA; Jeffers, LJ; Martinez, EJ; Mindikoglu, AL; Regev, A; Schiff, ER | 1 |
| Bunjes, D; Döhner, H; Döhner, K; Greiner, J; Harsdorf, Sv; Marx, M; Ringhoffer, M; Schmitt, M; Stilgenbauer, S; Wiesneth, M; Zenz, T | 1 |
| Caliskan, Y; Cin, N; Gurses, N; Kalayoglu-Besisik, S; Nalcaci, M; Ozbek, U; Ozturk, GB; Sargin, D | 1 |
| Bae, JH; Chung, BS; Ju, DS; Kang, CD; Kim, DW; Kim, MJ; Kim, SH; Lee, HS; Lee, MK; Song, HS | 1 |
| Alimena, G; Amabile, M; Baccarani, M; Bassi, S; Castagnetti, F; Cilloni, D; Iacobucci, I; Iuliano, F; Latagliata, R; Martinelli, G; Palandri, F; Pane, F; Poerio, A; Rege Cambrin, G; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 1 |
| Chen, XG; Liu, H | 1 |
| Czyz, M; Jakubowska, J | 2 |
| Deininger, MW; Druker, BJ; Harrell, P; Heinrich, MC; Humayun, A; Mauro, M; McGreevey, LS; Press, RD; Sherbenou, DW; Wong, MJ; Yang, R | 1 |
| Atallah, E; Cortes, J | 1 |
| Agarwal, P; Amadori, S; Apperley, J; Baccarani, M; Branford, S; Bullorsky, EO; de Souza, CA; Gollerkeri, A; Guilhot, F; Heim, D; Hochhaus, A; Kim, DW; Larson, RA; Lipton, JH; Muller, MC; Roboz, GJ; Talpaz, M | 1 |
| Belyaeva, I; Merkin, V; Rabizadeh, E; Shaklai, M; Zimra, Y | 1 |
| Austin, DJ; Deisseroth, A; Kufe, D; Lerma, EI; Melo, JV; Nguyen, VA; Tipping, A; Wang, T | 1 |
| Fenk, R; Germing, U; Haas, R; Hildebrandt, B; Neumann, F; Poelitz, A; Royer-Pokora, B | 1 |
| Bhatia, R; Forman, SJ; Holtz, M | 1 |
| McKeage, K; Moen, MD; Plosker, GL; Siddiqui, MA | 1 |
| D'Incalci, M; Franceschino, A; Gambacorti-Passerini, CB; Marangon, E; Pogliani, EM; Tornaghi, L; Zucchetti, M | 1 |
| Kumar, R; Mahapatra, M; Mishra, P | 1 |
| Alvarez, RH; Cortes, JE; Kantarjian, H | 1 |
| Erben, P; Ernst, T; Hochhaus, A; Mueller, MC | 1 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S | 1 |
| Agirre, X; Castillejo, JA; Cervantes, F; Cordeu, L; Garate, L; Heiniger, A; Jimenez-Velasco, A; Navarro, G; Prosper, F; Roman-Gomez, J; San Jose-Eneriz, E; Torres, A | 1 |
| Albitar, M; Cortes, J; Giles, F; Gorre, M; Jilani, I; Kantarjian, H; Keating, M; Ma, W; O'Brien, S; Tseng, R | 1 |
| Hayashi, Y | 1 |
| Maekawa, T | 1 |
| Dan, K; Inami, M; Inokuchi, K; Kosaka, F; Mitamura, Y; Okabe, M; Yamaguchi, H | 1 |
| Hoshino, T; Isoda, A; Mitsui, T; Nakahashi, H; Yoshida, Y | 1 |
| Chun, K; Kamel-Reid, S; Lipton, J; Medeiros, BC | 1 |
| Baran, Y; Bielawski, J; Gunduz, U; Obeid, LM; Ogretmen, B; Salas, A; Senkal, CE | 1 |
| Abou Ayache, R; Bridoux, F; Dreyfus, B; Guilhot, F; Milin, S; Thierry, A; Touchard, G | 1 |
| Bocchia, M; Calabrese, S; Crupi, R; Gozzetti, A; Lauria, F; Pirrotta, MT; Raspadori, D | 1 |
| Barbagallo, T; Borroni, G; Brazzelli, V; Locatelli, F; Orlandi, E; Passamonti, F; Prestinari, F; Rona, C; Villani, S; Zecca, M | 1 |
| Baldomero, H; Frauendorfer, K; Gratwohl, A; Gratwohl, M; Schwendener, A; Urbano-Ispizua, A | 1 |
| Gajewski, JL; Robinson, P | 1 |
| Akram, M; Aziz, Z; Iqbal, J; Saeed, S | 1 |
| Cortes, J; Giles, F; Kantarjian, HM; Quintás-Cardama, A | 1 |
| Benati, D; Bustos, VH; Coluccia, AM; Duñach, M; Gambacorti-Passerini, C; Mologni, L; Pinna, LA; Redaelli, S; Vacca, A | 1 |
| Altintas, A; Ayyildiz, O; Cil, T; Kaplan, MA; Kilinc, I | 1 |
| Ando, K; Atogami, S; Fukushima, T; Hata, T; Honda, M; Ikeda, S; Imaizumi, Y; Imanishi, D; Inoue, Y; Iwanaga, M; Jinnai, I; Joh, T; Kawaguchi, Y; Kawasaki, C; Kuriyama, K; Matsuo, E; Matsuo, Y; Miyazaki, Y; Momita, S; Moriuchi, Y; Nagai, K; Nonaka, H; Ogawa, D; Onimaru, Y; Sakai, M; Sawayama, Y; Soda, H; Taguchi, J; Takasaki, Y; Tawara, M; Tomonaga, M; Tsuchiya, T; Tsukasaki, K; Tsushima, H; Tsutsumi, C; Yamamura, M; Yamasaki, R; Yoshida, S; Yoshida, Y | 1 |
| Akahane, D; Honda, S; Ishii, Y; Nunoda, K; Ohyashiki, K; Okabe, S; Takaku, T; Tauchi, T | 1 |
| Lipton, J; Ostro, D | 1 |
| Cortes, J; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Ravandi, F; Thomas, D; Wierda, W | 1 |
| Haferlach, C; Kolb, HJ; Schleuning, M; Schwerdtfeger, R; Weisser, M | 1 |
| Baccarani, M; Cortes, J; Guilhot, F; Hochhaus, A; Kantarjian, HM; Lokey, L | 1 |
| Baccarani, M; Castagnetti, F; Colarossi, S; Gnani, A; Martinelli, G; Paolini, S; Rondoni, M; Rosti, G; Soverini, S | 1 |
| Eaves, A; Eaves, C; Gasparetto, M; Jiang, X; Smith, C; Turhan, A; Zhao, Y | 1 |
| Baccarani, M; Bosi, C; Castagnetti, F; Cilloni, D; Colarossi, S; Giannoulia, P; Gnani, A; Iacobucci, I; Luatti, S; Martinelli, G; Marzocchi, G; Palandri, F; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G; Saglio, G; Soverini, S; Testoni, N | 1 |
| Balleisen, L; Buss, EC; Emmerich, B; Fischer, T; Fruehauf, S; Hehlmann, R; Ho, AD; Hochhaus, A; Müller, MC; Ottmann, OG; Schuld, P; Topaly, J | 1 |
| Borthakur, G; Cortes, J; Faderl, S; Giles, F; Kantarjian, H; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S | 1 |
| Chantry, A; Frost, V; Melo, JV; Møller, GM | 1 |
| Brothman, AR; Chen, Z; Gaffney, MR; Nibley, WE; Rowe, LR | 1 |
| Arévalo, M; Cañizares, C; Leone, PE; Paz-Y-Miño, C; Sánchez, ME | 1 |
| Di Mario, A; Garzia, M; La Rocca, LM; Rumi, C; Sica, S; Sora, F; Teofili, L; Voso, MT; Zini, G | 1 |
| Bakhshi, S; Singh, N | 1 |
| Brero, S; Duyster, J; Geigl, J; Grundler, R; Hoepfl, J; Miething, C; Mugler, C; Ottmann, O; Peschel, C; Speicher, MR | 1 |
| Al Sobhi, E; Zahrani, Z; Zevallos, E; Zuraiki, A | 1 |
| Heaney, NB; Holyoake, TL | 2 |
| Apperley, JF; Elderfield, K; Elliot, V; Horncastle, D; Howard, J; Lampert, IA; Marin, D; Naresh, KN | 1 |
| Akhtar, MS; Carpenter, MW; Egorin, MJ; Lagattuta, TF; Russell, MA | 1 |
| Cortes, J; Giles, F; Jabbour, E; Kantarjian, H; O'Brien, S; Rios, MB | 1 |
| Guilhot, F; Guilhot, J; Martineua, G; Millot, F; Roy, L | 1 |
| Eaves, A; Eaves, C; Jiang, X; Smith, C | 1 |
| Giralt, S | 1 |
| Deininger, MW; Eide, CA; O'Hare, T | 3 |
| Alimena, G; Breccia, M; Carmosino, I; Gentilini, F; Latagliata, R; Muscaritoli, M; Rossi Fanelli, F | 1 |
| Cao, G; Fang, B; Han, Z; Li, D; Lin, Q; Liu, X; Nie, N; Shi, Y; Song, Y; Sun, J; Tian, G; Wei, X; Yang, R; Zhao, RC; Zhu, X | 1 |
| Bunjes, D; Chen, B; Chen, J; Schmitt, A; Schmitt, M | 1 |
| Dwyer, JP; Fogo, AB; Koury, MJ; Stone, WJ; Sumner, EL; Wang, Y; Yates, KM; Zent, R | 1 |
| Baer, MR; Barcos, M; Coignet, LJ; Nganga, A; Pawarode, A; Sait, SN | 1 |
| Azzarà, A; Buda, G; Cannizzo, E; Carulli, G; Cervetti, G; Galimberti, S; Orciuolo, E; Petrini, M | 1 |
| Appio, L; Campiotti, L; Codari, R; Maria Grandi, A; Solbiati, F; Ultori, C; Venco, A | 1 |
| Barbu, V; Carbonne, B; Garderet, L; Gorin, NC; Santacruz, R; van den Akker, J | 1 |
| Alimena, G; Breccia, M; Gentilini, F | 1 |
| Hayden, J; Ho, AY; Lim, Z; Mufti, GJ; Ramasamy, K | 1 |
| Anupama, G; Attili, VS; Bapsy, PP; Govind Babu, K | 1 |
| Aguilon, P; Charbonnier, A; Gisserot, O; Mozziconacci, MJ; Olschwang, S; Popovici, C; Rémy, V | 1 |
| Andreasson, C; Apperley, JF; Chuah, C; Goldman, JM; Kaeda, J; Marin, D; Pavlu, J | 1 |
| Buclin, T; Decosterd, LA; Fayet, A; Rumpold, H; Untergasser, G; Widmer, N | 1 |
| Cortes, JE; Giles, FJ; Jabbour, E; Kantarjian, HM; O'Brien, S | 1 |
| Cannell, E | 1 |
| Ito, T; Kimura, A; Tanaka, H | 1 |
| Ault, P | 1 |
| Apperley, JF; Chaidos, A; Kanfer, E | 1 |
| Dazzi, F; Fozza, C | 1 |
| Bock, O; Buesche, G; Flasshove, M; Henneke, F; Hussein, K; Kreipe, HH; Seegers, A | 1 |
| Duyster, J; Haferlach, C; Hochhaus, A; Menzel, H; Peschel, C; von Bubnoff, N | 1 |
| Konopka, L; Kos, K; Majewski, M; Pastwińska, A; Pienkowska-Grela, B; Solarska, I; Woroniecka, R | 1 |
| Asmus, C; Iqbal, MA; Lee, A; Li, L; Liesveld, JL; O'Malley, J; Siebert, S; Szych, CM; Wang, N | 1 |
| Grewal, SS; Richardson, MW | 1 |
| Cowan-Jacob, SW; Griffin, JD; Hochhaus, A; Manley, PW; Weisberg, E | 1 |
| Arora, M; Giralt, SA; Goldman, JM; Horowitz, MM; Lee, SJ; Maziarz, RT; McCarthy, PL; Sobocinski, KA | 1 |
| Azzarà, A; Buda, G; Carulli, G; Cervetti, G; Galimberti, S; Orciuolo, E; Pelosini, M; Petrini, M | 1 |
| Holler, E; Krause, SW | 1 |
| Battmer, K; Chaturvedi, A; Eder, M; Ganser, A; Schaefer, D; Scherr, M | 1 |
| Rodrigues, MS; Sattler, M | 1 |
| Eaves, A; Eaves, C; Jiang, X; Saw, KM | 1 |
| Ashihara, E; Maekawa, T | 1 |
| Isshiki, I | 1 |
| Yagasaki, F | 1 |
| Cheung, K; Kamel-Reid, S; Lipton, JH; Ostro, D | 1 |
| Donti, E; Gozzetti, A; Ronconi, S; Spedicato, F; Valenti, AM; Zaccaria, A | 1 |
| Yang, DG | 1 |
| Balleine, RL; Clarke, CL; Collins, M; Delforce, SE; Gurney, H; Hoskins, JM; Lynch, K; Mann, GJ; McLachlan, AJ; Rivory, LP; Schran, H; Wilcken, N; Wong, M | 1 |
| Browning, J; Chan, CY; Hsu, S; Martinelli, PT; Smith-Zagone, MJ | 1 |
| Andreeff, M; Ashihara, E; Kamitsuji, Y; Kawata, E; Kimura, S; Kuroda, J; Maekawa, T; O'Reilly, LA; Strasser, A; Tabe, Y; Takeuchi, M; Tanaka, R; Taniwaki, M; Yokota, A | 1 |
| Danbara, M; Higashihara, M; Horie, R; Kanda, Y; Kon, S; Maruta, A; Miyazaki, K; Ohsaka, M; Suzuki, Y; Togano, T; Watanabe, T | 1 |
| Ambudkar, SV; Bates, SE; Boudriot, U; Brendel, C; Burchert, A; Dohse, M; Neubauer, A; Robey, RW; Scharenberg, C; Shukla, S; Wang, Y; Wennemuth, G | 1 |
| Baladi, JF; Cortes, J; Darkow, T; Feng, W; Goldberg, GA; Hatfield, A; Henk, HJ; Thomas, SK | 1 |
| Fujimori, Y; Hara, H; Hirota, S; Ishikawa, H; Itsukuma, T; Kai, S; Misawa, M; Nakagawa, K; Sugihara, A; Terada, N | 1 |
| Adám, E; Andrikovics, H; Barta, A; Bors, A; Kajtár, B; Kozma, A; Nahajevszky, S; Poros, A; Szilvási, A; Tordai, A | 1 |
| Jin, J; Qian, WB; Tong, XM; Xue, YQ; Zheng, SE | 1 |
| Azam, M; Cortes, J; Daley, GQ; Nardi, V; Raz, T | 1 |
| Belloc, F; Cazalis, L; Jeanneteau, M; Lacombe, F; Mahon, FX; Moreau-Gaudry, F; Praloran, V; Uhalde, M | 1 |
| Cassuto, JP; Chabane, K; Hayette, S; Legros, L; Magaud, JP; Michallet, M; Nicolini, FE; Raynaud, S | 1 |
| Belaud-Rotureau, MA; Bouabdallah, K; Fitoussi, O; Foucaud, C; Leguay, T; Marit, G; Milpied, N; Parrens, M; Pigneux, A; Tabrizi, R | 1 |
| Brauer, KM; Bringmann, A; Brossart, P; Grünebach, F; Kanz, L; von Schwarzenberg, K; Werth, D | 1 |
| Hartmann, I; Hennig, K; Liehr, T; Loncarevic, IF; Michel, S; Rosenhahn, J; Schiefner, J; Schubert, K; von Eggeling, F; Weise, A | 1 |
| Erben, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Lahaye, T; Müller, MC; Seifarth, W | 1 |
| Härtel, N; Hehlmann, R; Hochhaus, A; Konig, H; La Rosée, P; Lorentz, C; Melo, JV; Schatz, M; Schultheis, B | 1 |
| Adams, J; Burthem, J; Lucas, GS; Mottram, R; Rees-Unwin, K; Spooncer, E; Whetton, AD | 1 |
| Ezra, E; Georgalas, I; Pavesio, C | 1 |
| Colomer, D; Espinet, B; Feliu, E; Granada, I; Grau, J; Juncà, J; Millá, F; Navarro, JT; Oriol, A; Ribera, JM | 1 |
| Aksenova, EV; Chelysheva, EIu; Domracheva, EV; Khoroshko, ND; Misiurin, AV; Turkina, AG; Zakharova, AV | 1 |
| Knuutila, S; Lundán, T; Mustjoki, S; Porkka, K | 1 |
| Bae, JH; Chung, BS; Kang, CD; Kim, DW; Kim, MJ; Kim, SH; Lee, HS; Lee, MK; Lee, SM | 1 |
| Curvo, RP; Moellmann-Coelho, A; Moreira, MA; Pires, V; Scholl, V; Zalcberg, IR | 1 |
| Agarwal, MB | 1 |
| Gupta, A; Prasad, K | 1 |
| Adil, SN; Kakepoto, GN; Khurshid, M; Syed, NN; Usman, M | 1 |
| Carella, AM; Lerma, E | 1 |
| Dent, P; Grant, S; Nguyen, TK; Rahmani, M | 1 |
| Duan, HF; Huang, WR; Li, QF; Wang, H; Wang, LS; Wu, CT | 1 |
| Lenhart, S; Moore, H; Nanda, S | 1 |
| Arthur, C; Branford, S; Filshie, R; Hughes, T; Koelmeyer, R; Lynch, K; Milner, A; Moreton, S; Schwarer, A; Taylor, K | 1 |
| Cho, BS; Eom, KS; Kim, CC; Kim, HJ; Lee, JW; Lee, S; Min, WS | 1 |
| Beelen, DW; Elmaagacli, AH; Koldehoff, M; Steckel, NK | 1 |
| Broxmeyer, HE; Gotoh, A; Nakajima, A; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Sashida, G; Tauchi, T | 1 |
| Cross, NC; Erben, P; Hensel, M; Ho, AD; Hochhaus, A; Jones, AV; Krämer, A; Kruth, J; Müller, M; Reiter, A | 1 |
| Bergstrom, LK; Cameron, JD; Erickson, LA; Grimm, TE; Larson, JS | 1 |
| Cortes, J; Daley, GQ; Ferrajoli, A; Jabbour, E; Kantarjian, H; Koller, C; O'Brien, S; Statkevich, P; Verstovsek, S; Zhu, Y | 1 |
| Bee, PC; Gan, GG; Haris, AR; Teh, A | 1 |
| Abruzzo, LV; Cortes, J; Garcia-Manero, G; Jabbour, E; Kantarjian, HM; O'Brien, S; Rios, MB; Shan, J; Verstovsek, S | 1 |
| Araki, H; Araki, N; Fujimi, A; Hirayama, Y; Kato, J; Kogawa, K; Matsunaga, T; Murase, K; Niitsu, Y; Takahira, N; Takimoto, R; Terui, T | 1 |
| Boddy, AV; Dutreix, C; Garner, C; Griffin, MJ; Kendrick, J; Mistry, P; Newell, DR; O'Brien, SG; Sludden, J | 1 |
| Clark, RE; Knight, K; Rojas, JM; Wang, L | 1 |
| Bhatia, R; Chu, S; Li, L; Singh, H | 1 |
| Chen, X; Chen, Z; He, Y; Huang, S; Li, H; Li, X; Liu, J; Yang, J; Zheng, J | 1 |
| Anderson, B; Barcos, M; Kakati, S; Wetzler, M; Zeidan, A | 1 |
| Raaijmakers, MH | 1 |
| Glauche, I; Roeder, I | 1 |
| Baccarani, M; Hehlmann, R; Hochhaus, A | 1 |
| Hunter, T | 1 |
| Druker, BJ; Sherbenou, DW | 1 |
| Arai, A; Miyamura, K; Motomura, S; Usui, N; Yokoyama, M | 1 |
| Cao, X; Church, G; Cortes, J; Daley, GQ; Deininger, MW; Nardi, V; Raz, T; Stone, RM; Wu, CJ; Zhu, J | 1 |
| Nishida, T | 1 |
| Hrkal, Z; Pilcova, H; Pluskalova, M; Smetana, K | 1 |
| Abruzzese, E; Amabile, M; Bocchia, M; Calabrese, S; Crupi, R; Defina, M; Gozzetti, A; Ippoliti, M; Lauria, F; Martinelli, G; Pirrotta, MT; Tozzuoli, D; Trawinska, MM | 1 |
| Alimena, G; Breccia, M; Carmosino, I; De Angelis, B; Diverio, D; Izzo, B; Latagliata, R; Luciano, L; Mancini, M; Mandelli, F; Nanni, M; Pane, F; Picardi, M; Quarantelli, F; Rotoli, B | 1 |
| Oestreicher, P | 2 |
| Chae, YS; Cho, YY; Hong, SP; Kim, JG; Kim, SO; Lee, KS; Moon, JH; Sohn, SK | 1 |
| Branford, S; Hughes, TP; Nicoll, JM; Paquette, RL; Sawyers, CL; Shah, NP; Skaggs, BJ | 1 |
| Blasdel, C; Deininger, MW; Druker, BJ; Egorin, MJ; Lagattuta, TF | 1 |
| Alimena, G; Bhalla, K; Bhatia, R; Cervantes, F; Gattermann, N; Giles, F; Haque, A; Hochhaus, A; Kantarjian, HM; le Coutre, P; Litzow, M; Nicolini, FE; O'Brien, SG; Ossenkoppele, GJ; Palandri, F; Resta, DJ; Shou, Y; Weitzman, A | 1 |
| Blaser, BW; Bloomfield, CD; Byrd, JC; Caligiuri, MA; Chen, CS; Cortes, J; Druker, BJ; Eiring, AM; Gambacorti-Passerini, C; Liu, S; Marcucci, G; Muthusamy, N; Neviani, P; Notari, M; Oaks, JJ; Perrotti, D; Roy, DC; Santhanam, R; Trotta, R; Verrills, NM | 1 |
| Luo, Y; Pan, J; Shi, JM | 1 |
| Bennett, KL; Colinge, J; Dürnberger, G; Fernbach, NV; Hantschel, O; Kaupe, I; Köcher, T; Planyavsky, M; Remsing Rix, LL; Rix, U; Superti-Furga, G; Valent, P | 1 |
| Chen, GQ; Wang, LS; Wu, YL; Yu, Y | 1 |
| Chodorowski, Z; Hellmann, A; Prejzner, W; Sein Anand, J | 1 |
| Agis, H; Aichberger, KJ; Esterbauer, H; Haas, OA; Herndlhofer, S; Jäger, U; Knöbl, P; Rabitsch, W; Schwarzinger, I; Sillaber, C; Sperr, WR; Thalhammer, R; Valent, P | 1 |
| Fioretos, T; Gullberg, U; Lassen, C; Olofsson, T; Richter, J; Svensson, E; Vidovic, K | 1 |
| Dang, P; Engler, J; Hughes, T; Lynch, K; Manley, PW; Saunders, VA; Venables, A; White, DL; Zannettino, A; Zrim, S | 1 |
| Borthakur, G; Bruzzi, J; Cortes, J; Kantarjian, H; Munden, R; O'brien, S; Quintás-Cardama, A | 1 |
| Ahn, KS; Bae, E; Kim, BK; Kim, BS; Kim, Y; Kim, YJ; Lee, D; Lee, YY; Park, J; Rhee, JY; Yoon, SS | 1 |
| Bachy, E; Bories, D; Corm, S; Guilhot, F; Hayette, S; Kiladjian, JJ; Lê, QH; Legros, L; Mahon, FX; Maloisel, F; Michallet, M; Nicolini, FE; Preudhomme, C; Roche-Lestienne, C; Tulliez, M | 1 |
| Barbu, V; Bories, D; Coppo, P; Gorin, NC; Portnoï, MF; Van Den Akker, J | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Montefusco, E; Pacilli, M | 1 |
| Agis, H; Esterbauer, H; Geissler, K; Haas, OA; Herndlhofer, S; Jäger, U; Mannhalter, C; Pirc-Danoewinata, H; Semper, H; Sillaber, C; Sperr, WR; Valent, P | 1 |
| Al Bahar, S; Pandita, R; Prakash, A; Ramamoorthy, SK; Ramaswamy, NV | 1 |
| Bock, O; Buesche, G; Frye, B; Gadzicki, D; Ganser, A; Hecker, H; Kreipe, H; Schlegelberger, B; von Neuhoff, N | 1 |
| Becze, E | 1 |
| Alimena, G; Breccia, M; Cannella, L; Finolezzi, E; Frustaci, A; Levi, A; Martelli, M; Russo, E; Stefanizzi, C | 1 |
| Cortes, J; Ebarb, T; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Thomas, D | 1 |
| Baran, Y; Gunduz, U; Ural, AU | 1 |
| Bechthold, K; El-Kholy, I; Hess, G; Huber, C; Meyer, RG; Schuch, B | 1 |
| Apperley, JF; Arrazi, JM; Avery, S; Byrne, JL; Craddock, CF; Goldman, JM; Griffiths, MJ; Lennard, AL; O'Shea, D; Olavarria, E; Pallan, L; Perz, JB; Piper, KP; Siddique, S | 1 |
| Inoue, H; Jinnouchi, S; Kukita, T; Matsumoto, T; Nakajo, M; Otsuka, M; Tanabe, H; Tateno, R | 1 |
| Antolino, A; Berretta, S; Di Raimondo, F; Giustolisi, R; Massimino, M; Messina, A; Stagno, F; Stella, S; Vigneri, P | 1 |
| Bhargav, R; Kumar, R; Mahapatra, M; Mishra, P | 1 |
| Alimena, G; Breccia, M; Cannella, L; Nanni, M; Stefanizzi, C | 1 |
| Kikuchi, S; Kirito, K; Komatsu, N; Kunitama, M; Nagai, T; Ozawa, K | 1 |
| Albitar, M; Bhalla, K; Cortes, J; Giles, FJ; Gorre, M; Jilani, I; Kantarjian, H; Ottmann, O | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Levi, A; Stefanizzi, C | 1 |
| Arthur, C; Filshie, R; Grigg, A; Hughes, T; Leahy, MF; Lynch, K; Saunders, V; To, LB; White, D | 1 |
| Bhatia, K; Doval, DC; Talwar, V | 1 |
| Huh, CH; Park, KC; Woo, SM; Youn, SW | 1 |
| Burthem, J; Griffiths, SD; Holyoake, TL; Lucas, GS; Melo, JV; Unwin, RD; Whetton, AD | 1 |
| Baccarani, M; Martinelli, G; Paolini, S; Piccaluga, PP; Rondoni, M; Rosti, G | 1 |
| Klonizakis, F; Paletas, K; Sarigianni, M; Tsapas, A; Vlachaki, E | 1 |
| Alessandro, R; Colomba, P; Corrado, C; De Leo, G; Flugy, AM; Fontana, S; Giordano, M; Kohn, EC; Santoro, A | 1 |
| Gollard, R; Trent, J; Wierda, W | 1 |
| Dewald, GW; Ketterling, RP; Knudson, RA; Landstrom, AP; Tefferi, A | 1 |
| Digumarti, R; Paul, TR; Rajappa, S; Varadpande, L | 1 |
| Chen, X; Fu, J; Li, H; Li, J; Li, Y; Liu, H; Liu, Y; Meng, Y | 1 |
| Chelysheva, EIu; Danil'cheva, ES; Ermakova, TA; Misiurin, AV; Sokolova, MA; Turkina, AG; Zakharova, AV | 1 |
| Berets, O; Bladé, JS; Defuentes, G | 1 |
| Ashihara, E; Kimura, S; Maekawa, T | 1 |
| Nagai, T | 1 |
| Deininger, MW; Druker, BJ; Galderisi, C; Mauro, MJ; Press, RD; Rempfer, C; Willis, SG; Yang, R | 1 |
| Holyoake, TL; Jørgensen, HG | 1 |
| Bednarek, A; Czyz, M; Jakubowska, J; Stasiak, M; Szulawska, A | 1 |
| Bagg, A; Ou, J; Vergilio, JA | 1 |
| Forster, K; Hallek, M; Krause, G; Mitina, O; Obermeier, A; Simon, N; Warmuth, M | 1 |
| Hayette, S; Labussière, H; Michallet, M; Nicolini, FE; Tigaud, I | 1 |
| Fausel, C | 2 |
| Frame, D | 3 |
| Bruguera, M; Fuster, F; Granell, M; Medina, L; Vallansot, R | 1 |
| Jagani, Z; Khosravi-Far, R; Singh, A | 1 |
| Anand, M; Apperley, JF; Babb, A; de Lavallade, H; De Melo, V; Ghorashian, S; Goldman, JM; Kaeda, JS; Khorashad, JS; Marin, D; Mehta, P; Milojkovic, D; Olavarria, E; Reid, AG | 1 |
| Iseki, T; Nagamura-Inoue, T; Nakayama, S; Ohno, N; Ooi, J; Takahashi, S; Tojo, A; Uchimaru, K; Yokoyama, K | 1 |
| Dempke, W; Linke, R | 1 |
| Fu, YB; Li, CY; Li, L; Meng, FY; Song, LL; Sun, QX; Yi, ZS | 1 |
| Aichberger, KJ; Derdak, S; Esterbauer, H; Gleixner, KV; Greish, K; Hoermann, G; Jaeger, E; Maeda, H; Mayerhofer, J; Mayerhofer, M; Nakamura, H; Ott, RG; Pickl, WF; Samorapoompichit, P; Schwarzinger, I; Sexl, V; Sillaber, C; Valent, P | 1 |
| Fukuhara, T; Hashino, S; Imamura, M; Kasai, M; Koda, K; Koizumi, K; Kurosawa, M; Masauji, N; Nishimura, S; Sugita, J; Tanaka, J; Torimoto, E | 1 |
| Chang, HJ; Cho, MS; Choi, MY; Kong, JH; Kwon, JM; Lee, KE; Lee, SM; Lee, SN; Mun, YC; Nam, E; Nam, SH; Seong, CM; Yoo, SH | 1 |
| Abdulhaq, H; Jalil, A; Lister, J; Makary, A; Rossetti, J; Shadduck, RK; Talreja, N | 1 |
| Dewar, AL; Fitter, S; Hughes, TP; Kostakis, P; Lynch, K; Roberts, MM; To, LB; Vernon-Roberts, B; Zannettino, AC | 1 |
| Apperley, J; Milojkovic, D | 1 |
| Arthur, C; Branford, S; Grigg, A; Hughes, T; Lynch, K; Rudzki, Z; Seymour, JF | 1 |
| Bhatia, R; Holyoake, TL; Konig, H | 1 |
| Fausel, C; Frame, D; Sessions, J | 1 |
| Choi, CW; Choi, IK; Kim, BS; Kim, JS; Kim, SJ; Kim, YH; Oh, SC; Park, KH; Park, SJ; Seo, HY; Seo, JH; Shin, SW; Sung, HJ | 1 |
| Gordon, MY; Greener, L; Marley, SB; Patel, H | 1 |
| Alimena, G; Breccia, M; Cannella, L; Carmosino, I; Frustaci, A; Gentilini, F; Latagliata, R | 1 |
| Kujawski, L; Talpaz, M | 1 |
| Balat, O; Demirhan, O; Kuçukosmanoglu, E; Okan, V; Pehlivan, M; Pehlivan, S; Yilmaz, M | 1 |
| Dobrovic, A; Kovalenko, S; McBean, M; Ritchie, DS; Seymour, JF; Westerman, DA | 1 |
| Beth Rios, M; Cortes, J; Faderl, S; Garcia-Manero, G; Huang, X; Kantarjian, H; O'Brien, S; Ravandi-Kashani, F; Shan, J; Verstovsek, S | 1 |
| Arancibia, AM; Bendit, I; Epelman, S | 1 |
| Albitar, M; Bhalla, K; Cortes, J; Faraji, H; Giles, F; Gorre, M; Jilani, I; Kantarjian, H; O'Brien, S; Ottmann, O | 1 |
| Allan, EK; Copland, M; Hamilton, A; Holyoake, TL; Lee, FY; Pellicano, F; Richmond, L; Weinmann, R | 1 |
| Steinberg, M | 1 |
| Cacchione, R; Gadano, AC; Mandó, OG; Marciano, S; Ridruejo, E; Villamil, AG | 1 |
| Abruzzese, E; Amabile, M; Baccarani, M; Breccia, M; Castagnetti, F; Cilloni, D; De Vivo, A; Iacobucci, I; Liberati, AM; Martinelli, G; Martino, B; Palandri, F; Pane, F; Poerio, A; Rosti, G; Saglio, G; Soverini, S; Specchia, G; Testoni, N | 1 |
| Akin, C; Arthur, DC; Cools, J; Kocabas, C; Lahortiga, I; Lessin, LS; Maric, I; Marynen, P; Mentens, N; Metcalfe, DD; Noel, P; Robyn, J; Wilson, TM; Wlodarska, I | 1 |
| Beverloo, HB; Cornelissen, JJ; Deenik, W; Ferrant, A; Janssen, JJ; Kersten, MJ; Kluin-Nelemans, HC; Löwenberg, B; Ossenkoppele, GJ; Schattenberg, AV; Smit, WM; Sonneveld, P; Valk, P; van der Holt, B; van Marwijk Kooy, M; Verdonck, LF; Verhoef, GE; Westveer, PH; Wijermans, PW; Willemze, R; Wittebol, S | 1 |
| Amin, HM; Arlinghaus, RB; Ban, K; Bar-Eli, M; Chandra, J; Gao, Y; Howard, A; Leng, X; Lin, Q; Miller, C; Munsell, M | 1 |
| Andersson, A; Fioretos, T; Gullberg, U; Håkansson, P; Lassen, C; Nilsson, B | 1 |
| Kantarjian, H; Tefferi, A | 1 |
| Alanoğlu, G; Coşkun, HS; Göksu, SS; Sahin, M | 1 |
| Busuttil, DP | 1 |
| Hirano, I; Nakamura, S; Ohnishi, K; Okinaka, K; Ono, T; Shigeno, K; Shinjo, K; Sugimoto, Y | 1 |
| Ashihara, E; Deguchi, Y; Fujiyama, Y; Hodohara, K; Kimura, S; Maekawa, T; Niwa, T | 1 |
| Artoni, A; Colombi, M; Deliliers, GL; Iurlo, A; Radaelli, F; Reda, G; Ripamonti, F; Vener, C | 1 |
| Asada, N; Asakura, H; Koseki, M; Matsue, K; Takeuchi, M; Uryu, H | 1 |
| Argon, D; Buyukbayrak, EE; Ergen, B; Kars, B; Karsidag, YK; Turan, C | 1 |
| Andreeff, M; Calvert, L; Jin, L; Kantarjian, H; Kimura, S; Konoplev, S; Konopleva, M; Leysath, CE; Lu, H; Ohsaka, A; Rios, MB; Tabe, Y; Xu, Y | 1 |
| Li, S | 1 |
| Hammond, JM; Marshall, HM | 1 |
| Coppo, P; Fouqueray, B; François, H; Hayman, JP; Mougenot, B; Ronco, P | 1 |
| Anupama, G; Attili, VS; Bapsy, PP; Lokanatha, D | 1 |
| Erben, P; Ernst, T; Hehlmann, R; Hochhaus, A; Hoffmann, J; Kreil, S; La Rosée, P; Müller, MC; Paschka, P; Schenk, T | 1 |
| Bornmann, W; Donato, NJ; Kong, L; Lu, H; Meng, F; Peng, Z; Talpaz, M; Wu, J | 1 |
| Dobrovolna, M; Formankova, R; Ivaskova, E; Keslova, P; Kobylka, P; Krol, L; Michalova, K; Moravcova, J; Navratilova, J; Sedlacek, P; Stary, J; Vavra, V; Zemanova, Z | 1 |
| Auberger, P; Belhacene, N; Cassuto, JP; Colosetti, P; Grosso, S; Jacquel, A; Puissant, A | 1 |
| Baccarani, M; Pane, F; Saglio, G | 1 |
| Assouline, S; Benemacher, V; Franceschino, A; Gambacorti-Passerini, C; Tornaghi, L | 1 |
| DeCoteau, JF; Geyer, CR; Lakshmikuttyamma, A; Pastural, E; Sawada, K; Sheridan, DP; Takahashi, N | 1 |
| Balabanov, S; Benten, D; Bokemeyer, C; Brümmendorf, TH; Colombo, R; Fiedler, W; Gontarewicz, A; Graziano, A; Keller, G; Moll, J; Pesenti, E | 1 |
| Bhatia, R; Forman, SJ; Holtz, M; Holyoake, TL; Konig, H; Manley, P; Modi, H | 1 |
| Croisy, M; Favaudon, V; Giocanti, N; Hennequin, C; Huguet, F; Touboul, E | 1 |
| Cambier, N; Cazaentre, T; Cossement, C; Giraudier, S; Grardel, N; Laï, JL; Preudhomme, C; Renneville, A; Rose, C; Soenen, V | 1 |
| Fu, Z; Jin, Z; Miao, M; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D | 1 |
| Kruglov, SS; Mechetner, EB; Rybalkina, EY; Stavrovskaya, AA; Stromskaya, TP; Turkina, AG; Zabotina, TN | 1 |
| Al Bahar, S; Ramesh, P; Zámecníkova, A | 2 |
| Artz, A; Chuang, K; Godley, L; Gordon, MK; Karrison, T; Kebriaei, P; Larson, RA; McDonnell, D; Michaelis, L; Odenike, O; Rich, E; Sher, D; Stock, W; Thirman, MJ; van Besien, K; Wickrema, A; Zhang, Y | 1 |
| Ghosh, A | 1 |
| Maziarz, RT | 1 |
| Erben, P; Ernst, T; Hehlmann, R; Hochhaus, A; Hoffmann, J; Müller, MC | 1 |
| Apperley, J; Chaidos, A; Dannie, E; Davis, J; Gabriel, I; Goldman, J; Marin, D; Sorouri, J | 1 |
| Barbina, G; Candoni, A; Colatutto, A; Damiani, D; Fanin, R; Marin, L; Medeot, M; Qualizza, U; Sala, P; Tiribelli, M; Toffoletti, E; Tonutti, E | 1 |
| Ahmed, MS; Cheng, YC; Davis, NB; King, DM; Kroft, SH | 1 |
| Kawakami, Y; Kimura, H; Nakamura, K; Nishibu, A; Yamamoto, T; Yanagihori, H | 1 |
| Liu, XL; Zhang, S; Zhu, HQ | 1 |
| Apperley, JF; Ault, P; Cortes, J; Hatfield, A; Kantarjian, H; Pilot, R; Pye, SM; Rosti, G | 1 |
| Christopoulos, C; Dimakopoulou, V; Rotas, E | 1 |
| Chen, CI; Lee, PP; Maecker, HT | 1 |
| Chen, ZM; Jin, J; Lou, JY; Wang, HP; Xu, H; Yu, YB | 1 |
| Gurney, H; Klumpen, HJ; Liddle, C | 1 |
| Kimura, S; Maekawa, T; Morinaga, K; Ueda, T; Yamauchi, T | 1 |
| Capdeville, R; Ford, JM; Gathmann, I; Hatfield, A; Krahnke, T; Van Hoomissen, I | 1 |
| Bumm, T; Deininger, MW; Druker, BJ; Hantschel, O; Kaupe, I; Press, RD; Sherbenou, DW; Superti-Furga, G; Turaga, L; Willis, S | 1 |
| Cortes, J; Kantarjian, H; Kebriaei, P; O'Brien, S; Ravandi, F; Thomas, D; Vega-Ruiz, A | 1 |
| Chow, WC; Chuah, TH; Lui, HF; Tan, HH; Thia, TJ | 1 |
| Binckebanck, A; Debatin, J; Dugan, M; Erben, P; Ernst, T; Härtel, N; Hehlmann, R; Hochhaus, A; Holm-Eriksen, S; Konig, H; La Rosée, P; Mueller, MC; Ottmann, OG; Shou, Y; Wunderle, L | 1 |
| Amabile, M; Baccarani, M; Breccia, M; Castagnetti, F; Iacobucci, I; Intermesoli, T; Iuliano, F; Martinelli, G; Miglino, M; Palandri, F; Pane, F; Poerio, A; Rege-Cambrin, G; Rosti, G; Saglio, G; Testoni, N; Tiribelli, M | 1 |
| Gafter-Gvili, A; Okon, E; Pazgal, I; Raanani, P; Ram, R; Shpilberg, O | 1 |
| Futami, M; Hatano, T; Kobayashi, S; Miyagishi, M; Soda, Y; Tojo, A | 1 |
| Crosta, L; Di Cristina, A; Dusonchet, L; Gebbia, N; Grimaudo, S; Invidiata, FP; Meli, M; Pipitone, RM; Simoni, D; Titone, L; Tolomeo, M | 1 |
| Fojo, T | 1 |
| Copland, M; Crawley, C; Godden, J; Heaney, NB; Holyoake, TL; McQuaker, IG; Parker, AN; Shepherd, P; Smith, GM; Stewart, K | 1 |
| Dutreix, C; Leroy, E; Riviere, GJ; Schran, H; Sethuraman, V; Shen, ZX; Wang, Y; Yin, OQ; Yin, Q; Zhou, L | 1 |
| Mcpherson, T; Sherman, V; Turner, R | 1 |
| Savona, M; Talpaz, M | 1 |
| Arlinghaus, RB; Carew, J; Giles, FJ; Huang, P; Keating, MJ; Lu, W; Trachootham, D; Zhang, H | 1 |
| Barrett, JS; Bernstein, M; Blaney, SM; Bond, M; Champagne, M; Fossler, MJ; Jayaraman, B; Menon-Andersen, D; Mondick, JT; Thompson, PA | 1 |
| Hantschel, O; Rix, U; Superti-Furga, G | 1 |
| Barra, A; Gombert, JM; Guilhot, F; Guilhot, J; Roy, L; Saulnier, PJ; Turhan, A | 1 |
| Bosa, M; Cilloni, D; Rege-Cambrin, G; Saglio, G; Ulisciani, S | 1 |
| Clark, RE; Davies, A; Giannoudis, A; Pirmohamed, M | 1 |
| Berthou, C; Bourmeyster, N; Chomel, JC; Dalbiès, F; Guilhot, F; Saulnier, PJ; Thuran, A | 1 |
| Barnes, DJ; Bonhoure, E; Cuvillier, O; Kohama, T; Lauret, A; Malavaud, B; Martin, C; Melo, JV | 1 |
| Apperley, JF; Baccarani, M; Cervantes, F; Corm, S; Countouriotis, AM; Deininger, M; Dombret, H; Ezzeddine, R; Goldberg, SL; Hochhaus, A; Hughes, T; Kantarjian, HM; Larson, RA; Lipton, JH; Müller, MC; Niederwieser, D; Roy, L; Shah, NP; Silver, RT; Stone, RM | 1 |
| Fandi, A; Lee, F; Voi, M | 1 |
| Borthakur, G; Breeden, M; Cortes, J; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, H; O'Brien, S; Ravandi, F | 1 |
| Andrieux, J; Corm, S; Eclache, V; Laï, JL; Maareck, O; Perot, C; Portnoi, MF; Richebourg, S; Roche-Lestienne, C; Soenen, V; Terré, C; Van den Akker, J; Viguié, F | 1 |
| Ghosh, K; Jijina, F; Madkaikar, M; Meera, V; Shrikande, M | 1 |
| Avalos, JC; Foncuberta, MC; Tartas, NE | 1 |
| Dora, JM; Fogliatto, LM; Leie, MA; Maia, AL; Netto, B; Silla, L; Torres, F | 1 |
| Battmer, K; Breyer, B; Eder, M; Kardinal, C; Koch, A; Mancini, A; Scherr, M; Tamura, T | 1 |
| Barańska, M; Gniot, M; Iwoła, M; Komarnicki, M; Lewandowska, M; Lewandowski, K | 1 |
| DiPersio, JF; Ramirez, P | 1 |
| Bruennert, D; Fenk, R; Gattermann, N; Haas, R; Koch, A; Kronenwett, R; Markett, J; Neumann, F; Pooten, M; Royer-Pokora, B; Schimkus, N; Wulfert, M | 1 |
| Cortes, J; Jain, N; Kantarjian, H; Verma, D | 1 |
| Bloomfield, CD; Donohue, KA; Feldman, EJ; Hurd, DD; Larson, RA; Odenike, OM; Stone, RM; Westerfelt, P; Wetzler, M | 1 |
| Alobeid, B; Bhagat, G; Fisher, JG; Flamm, MJ; Murty, VV; Schlaberg, R | 1 |
| Chao, K; Kyathari, S; Liu, D; Seiter, K | 1 |
| White, DL | 1 |
| Alimena, G; Breccia, M; Cannella, L; Frustaci, A; Stefanizzi, C | 1 |
| Contentin, N; Courville, P; Duval-Modeste, AB; Goldman, J; Joly, P; Lambert, A; Musette, P | 1 |
| Junaid, A; Khan, KA; Mukhtar, K; Siddiqui, NS; Siddiqui, S | 1 |
| Bajel, A; Bassili, S; Seymour, JF | 1 |
| Krause, DS; Van Etten, RA | 1 |
| Katayama, Y; Matsui, T; Minagawa, K; Nishikawa, S; Shimoyama, M; Yakushijin, K; Yamamoto, K | 1 |
| Biollaz, J; Buclin, T; Csajka, C; Debiec-Rychter, M; Decosterd, LA; Duchosal, MA; Leyvraz, S; Rosselet, A; Widmer, N | 1 |
| Chen, LJ; Han, BH; Lu, RZ; Ma, J; Qiu, L; Wang, XD; Zhan, ZM; Zhang, BL | 1 |
| Andreeff, M; Beran, M; Dunner, K; Kantarjian, H; Kondo, S; Konopleva, M; Korchin, B; Kurinna, S; Ruvolo, P; Samudio, I | 1 |
| Borthakur, G; Cortes, J; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Shan, J; Tam, CS | 1 |
| Barbosa, MM; Bittencourt, HN; Clementino, NC; Marcolino, MS; Nunes, Mdo C; Ribeiro, AL; Xavier, VF | 1 |
| DU, QF; Gong, JM; Liu, XL; Liu, Z; Ouyang, LY; Ouyang, Z; Song, LL; Zhang, S; Zhu, HQ | 1 |
| Chen, S; Dai, Y; Dent, P; Grant, S; Nguyen, TK; Pei, XY; Venditti, CA | 1 |
| Buchdunger, E; Druker, BJ; Fanning, S; Lydon, NB; Ohno, S; Segal, GM; Tamura, S; Zimmermann, J | 1 |
| Deininger, MW; Goldman, JM; Lydon, N; Melo, JV | 1 |
| Aulitzky, WE; Buchdunger, E; Fischer, T; Huber, C; Jonuleit, T; Peschel, C; Schwab, R; van der Kuip, H | 1 |
| Arlinghaus, RB; Beran, M; Cao, X; Estrov, Z; Jeha, S; Jin, G; Kantarjian, H; Lydon, NB; O'Brien, S; Talpaz, M | 1 |
| Deininger, MW; Goldman, JM; Gora-Tybor, J; Melo, JV | 1 |
| Buchdunger, E; Cleris, L; Formelli, F; Gambacorti-Passerini, C; Giardini, R; le Coutre, P; Marchesi, E; Mologni, L | 1 |
| Dan, S; Naito, M; Tsuruo, T | 1 |
| Buchdunger, E; Fruehauf, S; Ho, AD; Kasper, B; Schiedlmeier, B; Zeller, WJ | 1 |
| Algate, PA; Byrne, CH; Griffin, JD; Rohrschneider, LR; Sattler, M; Shrikhande, G; Verma, S; Winkler, T | 1 |
| Druker, BJ; Lydon, NB | 1 |
| Aulitzky, WE; Duyster, J; Götz, A; Hallek, M; Jonuleit, T; Michels, H; Oetzel, C; van der Kuip, H | 1 |
| Marx, J | 2 |
| Barni, R; Brueggen, J; Cabrita, G; Cleris, L; Corneo, G; Cozens, R; D'Incalci, M; Formelli, F; Gambacorti-Passerini, C; Gianazza, E; le Coutre, P; Pioltelli, P; Pogliani, E; Rossi, F; Zucchetti, M | 1 |
| Kalb, C | 1 |
| Druker, BJ; Mauro, MJ | 3 |
| Melo, J | 1 |
| Vigneri, P; Wang, JY | 1 |
| Lichtman, MA | 1 |
| Akutsu, M; Furukawa, Y; Honma, Y; Kano, Y; Mano, H; Sato, Y; Tsunoda, S | 1 |
| Brunstein, CG; Mcglave, PB | 1 |
| Rutherford, A | 1 |
| Buchdunger, E; Capdeville, R; Druker, BJ; Ford, JM; Kantarjian, H; Lydon, NB; Ohno-Jones, S; Peng, B; Resta, DJ; Sawyers, CL; Talpaz, M | 1 |
| Capdeville, R; Druker, BJ; Ford, JM; Kantarjian, H; Reese, SF; Resta, DJ; Sawyers, CL; Talpaz, M | 1 |
| Barni, R; Corneo, GM; Gambacorti-Passerini, C; Marchesi, E; Pioltelli, P; Pogliani, E; Rossi, F; Verga, M | 1 |
| de Boer, J | 1 |
| Holyoake, DT | 1 |
| Griffin, JD; Sattler, M | 1 |
| Jahagirdar, BN; Miller, JS; Shet, A; Verfaillie, CM | 1 |
| Sobel, RK | 1 |
| Nakajima, A; Ohyashiki, K; Tauchi, T | 1 |
| Ellwood, K; Gorre, ME; Hsu, N; Mohammed, M; Paquette, R; Rao, PN; Sawyers, CL | 1 |
| Chabner, BA | 1 |
| Schwetz, BA | 1 |
| Arnold, K | 1 |
| McCormick, F | 1 |
| Ahmed, S; Bassilian, S; Boren, J; Boros, LG; Cascante, M; Centelles, JJ; Comín-Anduix, B; Lee, WN; Lim, S; Marin, S | 1 |
| Etienne, G; Mahon, FX | 1 |
| Cheson, BD; Gravell, AE; Murgo, A; Wood, KF | 1 |
| Martindale, D | 1 |
| Witte, O | 1 |
| Talpaz, M | 1 |
| Brouard, M; Saurat, JH | 1 |
| Brouard, MC; Mach-Pascual, S; Prins, C; Saurat, JH | 1 |
| Buchdunger, E; Druker, BJ; Matter, A | 1 |
| Barthe, C; Cony-Makhoul, P; Mahon, JR; Melo, JV | 1 |
| Druker, BJ; Goldman, JM | 1 |
| Berger, U; Corbin, A; Corneo, G; Cross, NC; D'Incalci, M; Druker, BJ; Gambacorti- Passerini, C; Hehlmann, R; Hochhaus, A; Kreil, S; La Rosée, P; Lahaye, T; Linkesch, W | 1 |
| Birgens, H; Dufva, IH | 1 |
| Judson, I; van Oosterom, A; Verweij, J | 1 |
| Neylon, A; O'Brien, S | 1 |
| Davidson, RJ; Eades, A; Goldman, JM; Gordon, MY; Lewis, JL; Marley, SB; Nguyen, DX; Parker, S | 1 |
| Aulitzky, WE; Goetz, AW; Maya, R; Oren, M; van der Kuip, H | 1 |
| Jeanteur, P | 1 |
| Ilaria, RL; Wolff, NC | 1 |
| Dimitrijevic, S; Joensuu, H | 1 |
| Najfeld, V; Silver, RT; Sirulink, A | 1 |
| Banerji, L; Deininger, MW; Goldman, JM; Köhler, T; Lam, EW; Mahon, FX; Melo, JV; Parada, Y; Peters, G; Vieira, SA | 1 |
| Jarvis, B; Lyseng-Williamson, K | 1 |
| Barbour, V | 1 |
| Kalaycio, ME | 1 |
| Baccarani, M; Capdeville, R; Druker, BJ; Ford, JM; Goldman, JM; Sawyers, CL | 1 |
| Goldman, JM; Lagarde, V; Mahon, FX; Melo, JV; Tipping, AJ | 1 |
| Griffin, J | 1 |
| Kantarjian, HM; Talpaz, M | 1 |
| O'Brien, SG | 1 |
| Edwards, J; Rajaratnam, G | 1 |
| Calabretta, B; Caligiuri, MA; Campbell, K; Cesi, V; Condorelli, F; Gambacorti-Passerini, C; Guerzoni, C; Iervolino, A; Perrotti, D; Santilli, G; Trotta, R | 1 |
| Alcorn, MJ; Allan, E; Graham, SM; Holyoake, TL; Jørgensen, HG; Pearson, C; Richmond, L | 1 |
| Apfelbeck, U; Beham-Schmid, C; Haas, OA; Höfler, G; Linkesch, W; Sill, H; Tsybrovsky, O | 1 |
| Asano, S | 1 |
| Druker, BJ; Heinrich, MC; Mauro, MJ; O'Dwyer, M | 1 |
| Chandra, J; Griffin, JD; Hallgren, CG; Kaufmann, SH; Kottke, TJ; Litzow, MR; Mow, BM; Narayanan, VL; Sausville, EA; Svingen, PA; Tefferi, A; Weisberg, E | 1 |
| Allan, EK; Carr, CE; Elliott, MA; Holyoake, TL; Jørgensen, HG; Smith, KD | 1 |
| Morris, RH | 1 |
| Hiddemann, W; Schleuning, M | 1 |
| Olavarria, E | 1 |
| Ben-Bassat, I; Goldman, JM; Raanani, P | 1 |
| Cornelissen, JJ; Löwenberg, B; Ossenkoppele, GJ; Shamelian, SO; Somers, JA | 1 |
| Deininger, M; Niederwieser, D | 1 |
| Buchdunger, E | 1 |
| Fischer, T | 1 |
| Berger, U; Hehlmann, R; Hochhaus, A; Kreil, S; Lahaye, T; Reiter, A | 1 |
| Davidson, RJ; Goldman, JM; Gordon, MY; Marley, SB | 1 |
| Casadevall, N; Delmer, A; Legrand, O; Marie, JP; Rio, B; Ugo, V | 1 |
| Mayer, J | 1 |
| Griffin, JD | 1 |
| de Vos, S; Elashoff, D; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Koeffler, HP; Ottmann, OG | 1 |
| Duyster, J; Peschel, C; Schneller, F; von Bubnoff, N | 1 |
| Carapeti-Marootian, M; Goldman, JM; Hochhaus, A; Melo, JV; Schultheis, B; Weisser, A | 1 |
| de Vos, S; Gschaidmeier, H; Hoelzer, D; Hofmann, WK; Jones, LC; Koeffler, HP; Lemp, NA; Ottmann, OG | 1 |
| Baccarani, M; Brown, R; Capdeville, R; Cony-Makhoul, P; Druker, B; Facon, T; Fischer, T; Gambacorti-Passerini, C; Goldman, J; Gratwohl, A; Guilhot, F; Hochhaus, A; Kantarjian, H; Lazzarino, M; Loughran, T; Mandelli, F; Miller, C; Morra, E; Niederwieser, D; O'Brien, SG; Ottmann, O; Resta, D; Russell, N; Russo, D; Saglio, G; Sawyers, C; Schiffer, C; Schuster, M; Stone, R; Tallman, M; Talpaz, M; Zoellner, U | 1 |
| Antman, KH; Savage, DG | 1 |
| Azzi, A; Burton, C; Kerridge, I | 1 |
| Baccarani, M; Capdeville, R; Deininger, MW; Druker, BJ; Fernandes-Reese, S; Fischer, T; Gambacorti-Passerini, C; Gathmann, I; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Kantarjian, HM; Lennard, AL; Mahon, FX; Ottmann, OG; Sawyers, CL; Schiffer, CA; Silver, RT; Stone, R; Talpaz, M; Tura, S | 1 |
| Apperley, JF; Boecklin, F; Chase, A; Dhar, S; Goldman, JM; Hasserjian, RP; Henry, K; Lampert, I; Olavarria, E; Parker, S; Zaiac, M | 1 |
| Sausville, EA; Thambi, P | 1 |
| Eldor, A; Nadav, L | 1 |
| Habeck, M | 1 |
| Atichartakarn, V; Kitiyakara, C | 1 |
| Blagosklonny, MV | 1 |
| Arthur, C; Branford, S; Grigg, A; Herrmann, R; Hughes, TP; Lynch, KP; Rudzki, Z; Taylor, K; Walsh, S | 1 |
| Klingemann, HG | 1 |
| Ben-Am, M; Capdeville, R; Chapuis, B; Coutre, S; Deininger, MW; Druker, BJ; Feldman, E; Fischer, T; Gambacorti-Passerini, CB; Gathmann, I; Goldman, JM; Gratwohl, A; Guilhot, F; Hochhaus, A; Larson, RA; Mandelli, F; Miller, CB; Morra, E; O'Brien, SG; Ottmann, OG; Paquette, RL; Peschel, C; Reiffers, JJ; Russell, NH; Saven, A; Sawyers, CL; Schiffer, CA; Shea, TC; Stone, RM; Talpaz, M; Tura, S | 1 |
| Albitar, M; Cortes, J; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; O'Brien, S; Resta, D; Rios, MB; Shan, J; Talpaz, M; Thomas, DA | 1 |
| Bhatia, R; Forman, SJ; Holtz, MS; Sawyers, CL; Slovak, ML; Zhang, F | 1 |
| Apperley, JF; Craddock, C; Dazzi, F; Goldman, JM; Marin, D; Marktel, S; Olavarria, E | 1 |
| Joel, SP; Liu, WM; Stimson, LA | 1 |
| Fruehauf, S; Ho, AD; Topaly, J; Zeller, WJ | 1 |
| Brooksbank, C | 1 |
| Benson, K; Chen, G; Cohen, MH; Duan, J; Gobburu, J; Johnson, JR; Kim, SK; Leighton, J; Pazdur, R; Rahman, A; Rothmann, M; Staten, AM; U, KM; Williams, G; Wood, R | 1 |
| Bhalla, KN; Druker, BJ; La Rosée, P; Nimmanapalli, R; O'Dwyer, ME | 1 |
| Chen, PM; Chiou, TJ; Chung, HM; Fan, FS; Hsiao, LT; Lin, JT; Liu, JH; Wang, WS; Yen, CC | 1 |
| Duba, HC; Gastl, G; Grünewald, K; Gunsilius, E; Hayes, M; Petzer, AL; Poewe, W; Schneller, F; Stockhammer, G | 1 |
| Anastasiadou, E; Borrow, J; Dash, AB; Druker, B; Gilliland, DG; Housman, D; Kutok, JL; Li, S; Lindahl, K; Tomasson, MH; Van Etten, RA; Williams, IR | 1 |
| Belloc, F; Berthaud, P; Cony Makhoul, P; Lacombe, F; Lagarde, V; Mahon, FX; Melo, JV; Reiffers, J; Tabrizi, R | 1 |
| Gorre, ME; Sawyers, CL | 1 |
| Ohnisi, K | 1 |
| Buhl, L; Ebnöether, M; Ford, J; Gratwohl, A; Stentoft, J | 1 |
| Bakalova, R; Ohba, H; Zhelev, Z | 1 |
| Mayor, S | 1 |
| Kantarjian, H; Kurzrock, R; Talpaz, M | 1 |
| Stephenson, J | 1 |
| Apperley, J; Clark, R; Goldman, J; Green, T; Holyoake, T; O'Brien, S; Shepherd, P | 1 |
| Buchdunger, E; Corbin, AS; Druker, BJ; Pascal, F | 1 |
| Hasselbalch, HC | 1 |
| Braziel, RM; Druker, BJ; Launder, TM; Magenis, RE; Mauro, MJ; O'Dwyer, ME; Olson, SB; Paquette, RL; Sawyers, CL | 1 |
| Druker, BJ; La Rosée, P; O'Dwyer, ME | 1 |
| Beck, J; Beltrami, G; Carella, A; Corsetti, MT; Fischer, T; Gschaidmeier, H; Hehlmann, R; Hess, GR; Hochhaus, A; Huber, C; Kreil, S; Meinhardt, P; Reifenrath, C; Schuch, B | 1 |
| Andersen, MK; Brøndum-Nielsen, K; Dufva, IH; Kjeldsen, L; Pedersen-Bjergaard, J | 1 |
| Boros, LG; Cascante, M; Lee, WN | 1 |
| Bron, D; Lewalle, P; Martiat, P; Meuleman, N; Verhest, A | 1 |
733 review(s) available for imatinib mesylate and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs.
Topics: Antineoplastic Agents; Drugs, Generic; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2021 |
How I treat chronic-phase chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors | 2022 |
Research Status, Synthesis and Clinical Application of Recently Marketed and Clinical BCR-ABL Inhibitors.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Tyrosine | 2022 |
External evaluation of population pharmacokinetic models of imatinib in adults diagnosed with chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Bayes Theorem; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological | 2022 |
Impact of imatinib treatment on renal function in chronic myeloid leukaemia patients.
Topics: Chronic Disease; Humans; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2022 |
Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Cardiotoxicity; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2021 |
Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors | 2022 |
Prevalence of Anemia among Chronic Myeloid Leukemia Patients Treated with Imatinib: A Evidence-based Meta-analysis.
Topics: Anemia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prevalence; Protein Kinase Inhibitors; Pyrimidines | 2023 |
Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review.
Topics: Asian People; Humans; Imatinib Mesylate; Language; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2022 |
The progress of small-molecules and degraders against BCR-ABL for the treatment of CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
Alterations in cellular metabolisms after Imatinib therapy: a review.
Topics: Amino Acids; Apoptosis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Glucose; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nucleotides; Protein Kinase Inhibitors | 2022 |
Management of Myeloproliferative Neoplasms in the Molecular Era: From Research to Practice.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Janus Kinase Inhibitors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Primary Myelofibrosis; Protein Kinase Inhibitors | 2022 |
A rare cause of persistent leukocytosis with massive splenomegaly: Myeloid neoplasm with BCR-PDGFRA rearrangement-Case report and literature review.
Topics: Adult; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Myeloproliferative Disorders; Splenomegaly | 2022 |
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.
Topics: Antineoplastic Agents; COVID-19; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pandemics; Protein Kinase Inhibitors | 2022 |
Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity.
Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors | 2022 |
Management of Chronic Myeloid Leukemia in Children and Young Adults.
Topics: Adolescent; Child; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Young Adult | 2022 |
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA.
Topics: Antineoplastic Agents; Drugs, Generic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Marketing; Protein Kinase Inhibitors | 2022 |
A Systematic Literature Review of the Economic Evaluations of Treatments for Patients with Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality-Adjusted Life Years; State Medicine | 2022 |
A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life; Recurrence | 2023 |
Prostate cancer, chronic myelogenous leukemia and multiple myeloma in a single patient: a case report and review of the literature.
Topics: Aged, 80 and over; Humans; Imatinib Mesylate; Iran; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Multiple Myeloma; Prostatic Neoplasms; Protein Kinase Inhibitors | 2023 |
Family Planning and Pregnancy in Patients with Chronic Myeloid Leukemia.
Topics: Dasatinib; Family Planning Services; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Semen | 2023 |
What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes | 2023 |
Effect of Imatinib Mesylate on Growth in Pediatric Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Topics: Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies | 2023 |
Drug-drug interactions of protein kinase inhibitors in chronic myeloid leukaemia patients: A study using the French health insurance database.
Topics: Antineoplastic Agents; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Insurance, Health; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Management of chronic myeloid leukaemia: current treatment options, challenges, and future strategies.
Topics: Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2023 |
Management of chronic myeloid leukemia in 2023 - common ground and common sense.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2023 |
Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies.
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230
Topics: Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Philadelphia Chromosome | 2023 |
Rash with different types of BCR-ABL inhibitors in chronic myelogenous leukemia: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Exanthema; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2023 |
Control of Ph
Topics: Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Comparison of cutaneous adverse events between second-generation tyrosine kinase inhibitors and imatinib for chronic myeloid leukemia: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Dasatinib; Exanthema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pruritus; Pyrimidines; Tyrosine Kinase Inhibitors | 2023 |
Paediatric chronic myeloid leukaemia: Is it really a different disease?
Topics: Antineoplastic Agents; Child; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pediatrics; Pyrimidines; Thiazoles | 2019 |
Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review.
Topics: Antineoplastic Agents; Calreticulin; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein-Tyrosine Kinases; Thrombocythemia, Essential | 2020 |
The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients.
Topics: Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; STAT5 Transcription Factor; Tumor Suppressor Proteins | 2019 |
Chronic Myeloid Leukemia in Children: Challenges and Opportunities : Based on 7th Dr. I. C. Verma Excellence Award for Young Pediatricians Delivered as Oration on 29th Sept. 2019.
Topics: Adolescent; Adult; Awards and Prizes; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pediatricians; Protein Kinase Inhibitors | 2020 |
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Decision-Making; Consensus Development Conferences as Topic; Dasatinib; Disease Management; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Expectancy; Monitoring, Physiologic; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Survival Analysis | 2020 |
[Chronic myeloid leukemia - update 2020].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Pyrimidines | 2019 |
Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2020 |
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.
Topics: Adult; Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase | 2020 |
A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia.
Topics: Adolescent; Adult; Allografts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Child, Preschool; Dasatinib; Drug Resistance, Neoplasm; Female; Hematology; Humans; Imatinib Mesylate; Imidazoles; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nitriles; Pyridazines; Pyrimidines; Quinolines; Societies, Medical; United Kingdom | 2020 |
JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
Topics: Cytarabine; Dasatinib; Drug Monitoring; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2020 |
Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
Topics: Binding Sites; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyridines; Pyrroles | 2021 |
[Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors | 2020 |
The blue palate-A case series of imatinib-related oral pigmentation and literature review.
Topics: Antineoplastic Agents; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pigmentation | 2021 |
Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Meta-Analysis as Topic; Musculoskeletal Pain; Observational Studies as Topic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; RNA, Messenger; RNA, Neoplasm; Substance Withdrawal Syndrome; Withholding Treatment | 2020 |
Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review.
Topics: Abnormalities, Multiple; Aniline Compounds; Antineoplastic Agents; Child; Dasatinib; Fathers; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nitriles; Paternal Exposure; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Pyrimidines; Quinolines | 2020 |
Topics: ATP Binding Cassette Transporter, Subfamily B; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymorphism, Single Nucleotide | 2022 |
Chronic Myelogenous Leukemia in Childhood.
Topics: Adolescent; Antineoplastic Agents; Child; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2021 |
Current status and novel strategy of CML.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Artificial Intelligence; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Stem Cell Transplantation; Transplantation, Homologous | 2021 |
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aniline Compounds; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Dasatinib; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Oncogene Proteins v-abl; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyridazines; Pyrimidines; Quinolines; Risk; Young Adult | 2021 |
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis.
Topics: Aged; Antineoplastic Agents; Drug Substitution; Feasibility Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2017 |
Treatment and molecular monitoring update in chronic myeloid leukemia management.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Monitoring, Physiologic; Mutation; Protein Kinase Inhibitors; Protein Kinases | 2017 |
Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.
Topics: Atorvastatin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Metformin; Phenformin | 2017 |
[Research Progress of Homoharringtonine Effect on IM-resistant Chronic Myelogenous Leukemia -Review].
Topics: Antineoplastic Agents, Phytogenic; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2017 |
The use of Imatinib resistance mutation analysis to direct therapy in Philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukaemia patients failing Imatinib treatment, in Patan Hospital, Nepal.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Protein-Tyrosine Kinases; Retrospective Studies | 2017 |
Chronic Myeloid Leukemia: Immunobiology and Novel Immunotherapeutic Approaches.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Signal Transduction | 2017 |
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Emerging Opportunities for Target Discovery in Rare Cancers.
Topics: CRISPR-Cas Systems; Drug Discovery; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Precision Medicine; RNA Interference; Small Molecule Libraries | 2017 |
Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.
Topics: Drug Administration Schedule; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Remission Induction | 2017 |
Pharmacology and pharmacokinetics of imatinib in pediatric patients.
Topics: Adolescent; Animals; Antineoplastic Agents; Child; Drug Monitoring; Food-Drug Interactions; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Protein Kinase Inhibitors | 2018 |
Philadelphia chromosome-negative acute promyelocytic leukemia manifesting after long-term imatinib treatment for chronic myeloid leukemia: a case report and literature review.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome | 2018 |
Imatinib-induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature.
Topics: Antineoplastic Agents; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Mucosa; Nails; Skin | 2018 |
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis.
Topics: Antineoplastic Agents; Asian People; Cytochrome P-450 CYP3A; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Polymorphism, Single Nucleotide | 2018 |
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.
Topics: Animals; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction | 2018 |
How to treat chronic myeloid leukemia (CML) in older adults.
Topics: Aged; Aniline Compounds; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Randomized Controlled Trials as Topic | 2018 |
Current Information and Recommendations on the Discontinuation of TKI Inhibitors in Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome | 2018 |
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
Topics: Abdominal Pain; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Imatinib Mesylate; Immunosuppression Therapy; Jaundice; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Liver Transplantation; Nausea; Protein Kinase Inhibitors; Time Factors; Treatment Outcome | 2018 |
A Chemical Approach to Overcome Tyrosine Kinase Inhibitors Resistance: Learning from Chronic Myeloid Leukemia.
Topics: Allosteric Regulation; Carboxylic Ester Hydrolases; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines | 2019 |
Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients.
Topics: Antineoplastic Agents; Child; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors | 2018 |
Leukemic arthritis and severe hypercalcemia in a man with chronic myeloid leukemia: a case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Arthritis; Blast Crisis; Humans; Hypercalcemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2018 |
Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
Topics: Cost-Benefit Analysis; Dasatinib; Developed Countries; Female; Humans; Imatinib Mesylate; Income; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Quality-Adjusted Life Years | 2018 |
Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors | 2018 |
Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Molecular Targeted Therapy; Monte Carlo Method; Multicenter Studies as Topic; Neoplasm Proteins; Network Meta-Analysis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Regulating Apoptosis by Degradation: The N-End Rule-Mediated Regulation of Apoptotic Proteolytic Fragments in Mammalian Cells.
Topics: Animals; Apoptosis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Peptides; Proteolysis | 2018 |
Treatment-free remission with first- and second-generation tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dasatinib; Disease Management; Drug Administration Schedule; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2019 |
Leukostasis retinopathy: An uncommon visual threatening complication of chronic myeloid leukemia with severe hyperleukocytosis - A case report and review of the literature.
Topics: Antineoplastic Agents; Blindness; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Leukostasis; Male; Retinal Diseases; Tomography, Optical Coherence; Visual Acuity; Young Adult | 2018 |
The argument for using imatinib in CML.
Topics: Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Quality of Life | 2018 |
[MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Topics: Antineoplastic Agents; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2018 |
Nilotinib in the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2019 |
Uncontrolled neovascular glaucoma - an alarming manifestation of chronic myeloid leukemia on imatinib therapy - a case report and review of literature.
Topics: Antineoplastic Agents; Glaucoma, Neovascular; Gonioscopy; Humans; Imatinib Mesylate; Intraocular Pressure; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Trabeculectomy; Visual Acuity | 2019 |
[Research Progress of C-Myc in Chronic Myelogenous Leukemia --Review].
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Proto-Oncogene Proteins c-myc | 2019 |
Association of oral mucosa hyperpigmentation with imatinib mesylate use: a cross-sectional study and a systematic literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brazil; Cross-Sectional Studies; Female; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Mucosa; Young Adult | 2019 |
Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein Kinases | 2019 |
Mutations Associated with Imatinib Mesylate Resistance - Review.
Topics: Amino Acid Substitution; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Point Mutation; Protein Domains; Protein Kinase Inhibitors | 2018 |
Occurrence and current management of side effects in chronic myeloid leukemia patients treated frontline with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Neoadjuvant Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2013 |
Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2013 |
Management options for refractory chronic myeloid leukemia: considerations for the elderly.
Topics: Age Factors; Aged; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Anticancer drug adherence].
Topics: Administration, Oral; Age Factors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Medication Adherence; Neoplasms; Physician's Role; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Risk Factors; Socioeconomic Factors | 2013 |
Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2013 |
Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Piperazines; Pyrimidines | 2013 |
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Treatment Outcome | 2013 |
Biomarkers for determining the prognosis in chronic myelogenous leukemia.
Topics: Animals; Benzamides; Biomarkers, Tumor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2013 |
[Tyrosine kinase inhibitors - major change in the prognosis of chronic myeloid leukaemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2013 |
Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2013 |
[Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients].
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
[Current diagnostic requirements in chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Guideline Adherence; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction; Thiazoles; Treatment Outcome | 2013 |
Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Ever-advancing chronic myeloid leukemia treatment.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2014 |
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when is this a safe option to consider?
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2013 |
Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.
Topics: Australia; Benzamides; Clinical Trials as Topic; Disease-Free Survival; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2013 |
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant | 2016 |
Patient with chronic myeloid leukemia in complete cytogenetic response: what does it mean, and what does one do next?
Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Asthenia; Benzamides; Bone Marrow Examination; Cytogenetic Analysis; Drug Administration Schedule; Drug Substitution; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Phenotype; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome | 2014 |
Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Topics: Aniline Compounds; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Treatment Outcome | 2014 |
Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Treatment Outcome | 2014 |
Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines | 2014 |
[Chronic myeloid leukemia: up-to-date management].
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Discovery; Drug Monitoring; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Molecular Targeted Therapy; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2014 |
Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2014 |
Bypass mechanisms of resistance to tyrosine kinase inhibition in chronic myelogenous leukaemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazepines | 2014 |
Chronic myeloid leukemia as a secondary malignancy after diffuse large B-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Chemoradiotherapy; Cyclophosphamide; Doxorubicin; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Piperazines; Positron-Emission Tomography; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vincristine; Whole Body Imaging | 2014 |
[Polycythemia vera developed after a major molecular response to imatinib mesylate treatment in a patient with chronic myelogenous leukemia].
Topics: Aged; Benzamides; Fusion Proteins, bcr-abl; Hematocrit; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Mutation; Phlebotomy; Piperazines; Polycythemia Vera; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction | 2014 |
Imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Chemistry, Pharmaceutical; Drug Resistance, Neoplasm; Drug Stability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Pyrimidines | 2014 |
ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Asian People; ATP Binding Cassette Transporter, Subfamily B; Child; Child, Preschool; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2015 |
[Treatment of chronic myeloid leukemia in chronic phase].
Topics: Allografts; Benzamides; Busulfan; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Translocation, Genetic | 2014 |
[Management of advanced stage chronic myeloid leukemia].
Topics: Allografts; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease Progression; Drug Design; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Staging; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2014 |
The implication of cancer progenitor cells and the role of epigenetics in the development of novel therapeutic strategies for chronic myeloid leukemia.
Topics: Animals; Benzamides; Epigenesis, Genetic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2015 |
How I treat newly diagnosed chronic myeloid leukemia in 2015.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2015 |
DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dipeptidyl Peptidase 4; Early Detection of Cancer; Forecasting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction | 2015 |
Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Transplantation, Homologous; Treatment Outcome | 2014 |
Chronic myeloid leukaemia.
Topics: Adult; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2015 |
Priapism as a result of chronic myeloid leukemia: case report, pathology, and review of the literature.
Topics: Antineoplastic Agents; Benzamides; Cryopreservation; Endothelium, Vascular; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Penile Prosthesis; Piperazines; Priapism; Pyrimidines; Semen Preservation; Treatment Outcome; Young Adult | 2015 |
Bcr-Abl tyrosine kinase inhibitors: a patent review.
Topics: Animals; Antineoplastic Agents; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patents as Topic; Protein Kinase Inhibitors | 2015 |
Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU.
Topics: Animals; Antineoplastic Agents; Benzamides; Cost Savings; Drug Costs; Drugs, Generic; European Union; Fusion Proteins, bcr-abl; Health Impact Assessment; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Molecular Targeted Therapy; Patents as Topic; Piperazines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; United States | 2015 |
Update on emerging treatments for chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Drug Approval; Drug Design; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life; Survival | 2015 |
[Potential clinical benefit of therapeutic drug monitoring of imatinib in oncology].
Topics: Benzamides; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2015 |
Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines | 2015 |
OCT1 and imatinib transport in CML: is it clinically relevant?
Topics: Animals; Biological Transport; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Prognosis; Protein Kinase Inhibitors | 2015 |
Chronic Myeloid Leukemia Monitoring after Imatinib Failure: Still More Questions than Answers.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Treatment Failure | 2015 |
[Development of Ph negative acute myeloid leukemia in a patient with minor-BCR/ABL positive chronic myeloid leukemia achieving a partial cytogenetic response during tyrosine kinase inhibitor treatment].
Topics: Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2015 |
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Cardiovascular System; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Hypertension; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Nitriles; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines | 2015 |
New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2016 |
Tyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous Leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quinolines; Treatment Outcome | 2015 |
Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Topics: Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Prognosis; Protein Kinase Inhibitors | 2015 |
Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia.
Topics: Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; China; Drug Resistance, Neoplasm; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Polymorphism, Genetic | 2015 |
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation | 2015 |
Peroxisome Proliferator-Activated Receptor Ligands and Their Role in Chronic Myeloid Leukemia: Therapeutic Strategies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; Peroxisome Proliferator-Activated Receptors | 2016 |
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Time Factors | 2016 |
MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia.
Topics: Animals; Cell Survival; Chromosome Mapping; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; MicroRNAs; Mitogen-Activated Protein Kinases; Neoplasms; Rats; Signal Transduction | 2016 |
Immunological off-target effects of imatinib.
Topics: Antigens, Neoplasm; Antineoplastic Agents; B7 Antigens; Drug Approval; Forecasting; Gastrointestinal Stromal Tumors; Hematopoiesis; Humans; Imatinib Mesylate; Immune Tolerance; Immunity, Cellular; Immunologic Surveillance; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Chaperones; Molecular Targeted Therapy; Natural Cytotoxicity Triggering Receptor 3; Protein-Tyrosine Kinases; T-Lymphocytes; Tumor Escape; Vascular Endothelial Growth Factor A | 2016 |
Pyomyositis at the surgical site in a patient with chronic myeloid leukemia: a case report and literature review.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Staging; Prognosis; Pyomyositis | 2016 |
Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
Topics: Adrenal Glands; Aniline Compounds; Antineoplastic Agents; Bone Remodeling; Child; Dasatinib; Endocrine System; Endocrine System Diseases; Fusion Proteins, bcr-abl; Glucose Metabolism Disorders; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Thyroid Gland | 2016 |
Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
Topics: Antineoplastic Agents; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors | 2016 |
The treatment of CML at an environment with limited resources.
Topics: Antineoplastic Agents; Health Resources; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2016 |
Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis.
Topics: Antineoplastic Agents; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Odds Ratio; Protein Kinase Inhibitors; Publication Bias; Treatment Outcome | 2016 |
Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quinolines; Remission Induction; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Discontinuation of TKI therapy and 'functional' cure for CML.
Topics: Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors | 2016 |
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Vascular Diseases | 2017 |
The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.
Topics: Cost of Illness; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life; Survival Rate | 2016 |
Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.
Topics: Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 2; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Polymorphism, Single Nucleotide; Predictive Value of Tests; Treatment Outcome | 2017 |
[Progress of Researches on Prediction of Tyrosine Kinase Inhibitor Efficacy for Treatment of Chronic Myelocid Leukemia -Review].
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2017 |
Isodicentric Philadelphia Chromosome: A Rare Chromosomal Aberration in Imatinib-Resistant Chronic Myelogenous Leukemia Patients - Case Report with Review of the Literature.
Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome | 2016 |
Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2017 |
The value of open access and a patient centric approach to oral oncolytic utilization in the treatment of Chronic Myelogenous Leukemia: A U.S. perspective.
Topics: Access to Information; Administration, Oral; Antineoplastic Agents; Drug Costs; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient-Centered Care; Protein Kinase Inhibitors; Survival | 2017 |
Imatinib mesylate for the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Treatment Outcome | 2008 |
Mathematical models of cancer stem cells.
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Mutation; Neoplastic Stem Cells; Patient Selection; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors | 2008 |
Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2008 |
BCR-ABL in chronic myelogenous leukemia--how does it work?
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Nilotinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Chemical; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Imatinib resistance in CML.
Topics: Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Modern approaches to treating chronic myelogenous leukemia.
Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Signal Transduction; Stem Cell Transplantation; Treatment Outcome | 2008 |
Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines | 2008 |
Chronic myeloid leukaemia: the evolution of gene-targeted therapy.
Topics: Antineoplastic Agents; Australia; Benzamides; Drug Approval; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United States | 2008 |
Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences.
Topics: Animals; Benzamides; Cisplatin; Humans; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metformin; Organic Cation Transport Proteins; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Substrate Specificity | 2008 |
P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2008 |
[Management of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Clinical Trials as Topic; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Living Donors; Male; Monitoring, Physiologic; Piperazines; Pyrimidines; Recurrence; Transplantation, Homologous | 2008 |
Translation of the Philadelphia chromosome into therapy for CML.
Topics: Benzamides; Biomedical Research; Drug Delivery Systems; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Milestones and monitoring in patients with CML treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Staging; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Spleen; Treatment Failure; Treatment Outcome | 2008 |
Novel agents in CML therapy: tyrosine kinase inhibitors and beyond.
Topics: Aniline Compounds; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Harringtonines; Histone Deacetylase Inhibitors; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2008 |
[Current state and the future of molecular target drugs: lessons learned from the success of imatinib].
Topics: Antineoplastic Agents; Benzamides; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Targeting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2008 |
Transcriptome and proteome analyses of drug interactions with natural products.
Topics: Animals; Arsenic Trioxide; Arsenicals; Benzamides; Drug Discovery; Drug Synergism; Gene Expression Profiling; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Proteome; Pyrimidines; Tretinoin | 2008 |
Rho-signaling pathways in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Drug Delivery Systems; Fusion Proteins, bcr-abl; Guanine Nucleotide Exchange Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; rho GTP-Binding Proteins; rho-Associated Kinases; Signal Transduction; src Homology Domains | 2008 |
Targeted drugs in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; src-Family Kinases; Thiazoles | 2008 |
[Chronic myeloid leukemia 2008].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2008 |
Imatinib and its successors--how modern chemistry has changed drug development.
Topics: Animals; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Discovery; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2009 |
Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
Topics: Adult; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors | 2009 |
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Treatment Failure | 2009 |
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Efficacy of various doses and schedules of second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review.
Topics: Administration, Oral; Administration, Topical; Adult; Benzamides; Clobetasol; Drug Administration Schedule; Foot; Glucocorticoids; Hand; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Mouth Mucosa; Nails; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Skin; Treatment Outcome | 2008 |
Resistance to imatinib in chronic myeloid leukemia and therapeutic approaches to circumvent the problem.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2009 |
First-line therapy for chronic myeloid leukemia: Past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Topics: Benzamides; Bone and Bones; Glucose; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Metabolism; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Tailoring tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Treatment selection after imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Utilization; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Genetic; Practice Guidelines as Topic; Pyrimidines; Stem Cell Transplantation; Thiazoles; Treatment Failure | 2009 |
Maximum tolerated dose: clinical endpoint for a bygone era?
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Health Planning Guidelines; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maximum Tolerated Dose; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Treatment Outcome | 2009 |
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Topics: Benzamides; Cell Proliferation; Cytotoxicity, Immunologic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Serositis; Thiazoles; Treatment Outcome | 2009 |
Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Costs and Cost Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles; Treatment Outcome | 2009 |
Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Interactions; Humans; Imatinib Mesylate; Intestinal Absorption; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Orosomucoid; Piperazines; Protein Binding; Pyrimidines; Treatment Failure | 2009 |
Isolated CNS lymphoid blast crisis in a patient with imatinib-resistant chronic myelogenous leukemia: case report and review of the literature.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2009 |
Appropriate sequencing of tyrosine kinase inhibitors in chronic myelogenous leukemia: when to change? A perspective in 2009.
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.
Topics: Animals; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Response dynamics in chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Tyrosine kinase inhibitors and solid tumours: case report and review of the literature.
Topics: Administration, Oral; Benzamides; Carcinoma; Dasatinib; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate.
Topics: Benzamides; Central Nervous System; Central Nervous System Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Meningitis, Bacterial; Middle Aged; Piperazines; Pyrimidines | 2009 |
[Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients].
Topics: Aniline Compounds; Antineoplastic Agents; Aurora Kinases; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2009 |
Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review.
Topics: Antineoplastic Agents; Benzamides; Hepatitis B, Chronic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Transplantation; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Severity of Illness Index | 2009 |
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome | 2009 |
In vitro anti-leukaemia activity of pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Thiazepines | 2010 |
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML).
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Cytarabine; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukocytosis; Male; Monosomy; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic | 2009 |
The impact of gene profiling in chronic myeloid leukaemia.
Topics: Benzamides; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines | 2009 |
Harmonization of molecular monitoring of CML therapy in Europe.
Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Europe; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
New insights into small-molecule inhibitors of Bcr-Abl.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2011 |
Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines | 2009 |
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; Benzamides; Clinical Trials as Topic; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Chronic myelogenous leukemia. Clinical practice guidelines in oncology.
Topics: Benzamides; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Homologous | 2003 |
How to monitor patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2003 |
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
Topics: Adult; Aged; Benzamides; Cell Transformation, Neoplastic; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome | 2009 |
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Feeding; Drug Delivery Systems; Drug Interactions; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines | 2009 |
[History, current status, and future prospects in clinical study of myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Design; Drug Therapy, Combination; Gene Targeting; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Precision Medicine; Pyrimidines; Remission Induction; Risk; Tretinoin | 2009 |
[Molecular pathogenesis of chronic myeloid leukemia].
Topics: Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Gene Silencing; Gene Targeting; Genes, Tumor Suppressor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2009 |
[Current clinical trials using new targeted therapies for myeloid leukemia and the research trends].
Topics: Animals; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplastic Stem Cells; Piperazines; Pyrimidines; Translational Research, Biomedical; Tretinoin | 2009 |
Overcoming resistance in chronic myelogenous leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction | 2009 |
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Europe; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Transplantation, Homologous; Treatment Failure; Treatment Outcome | 2009 |
Dysregulation of bone remodeling by imatinib mesylate.
Topics: Benzamides; Bone Remodeling; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Osteoclasts; Osteolysis; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Targeted therapies: the rare cancer paradigm.
Topics: Antineoplastic Protocols; Benzamides; Cancer Vaccines; Colorectal Neoplasms; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nervous System Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Reference Standards; Signal Transduction | 2010 |
[Clinical progress in chronic myelogenous leukemia].
Topics: Benzamides; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dasatinib; Drug Discovery; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisolone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
Issues of imatinib and pregnancy outcome.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Animal; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Risk Factors; Teratogens | 2009 |
CML: a model for targeted therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Treatment strategies for CML.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
Interferon in chronic myeloid leukaemia: past and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Prognostic factors in chronic myeloid leukaemia.
Topics: Benzamides; Biomarkers; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Piperazines; Prognosis; Pyrimidines; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Pharmacologic monitoring and determinants of intracytoplasmic drug levels.
Topics: Benzamides; Cytoplasm; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
CML in pregnancy and childhood.
Topics: Abnormalities, Drug-Induced; Adult; Age Factors; Benzamides; Child; Female; Fetal Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Maternal-Fetal Exchange; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Treatment Outcome; Young Adult | 2009 |
Standard management of patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance.
Topics: Antineoplastic Agents; Benzamides; Biological Transport; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Signal Transduction; Structure-Activity Relationship | 2009 |
Initial treatment for patients with CML.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cytostatic Agents; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Patient Selection; Piperazines; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Hematologic; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Transplantation, Homologous | 2009 |
Monitoring disease response to tyrosine kinase inhibitor therapy in CML.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Examination; Computer Systems; DNA Mutational Analysis; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Neoplasm Proteins; Patient Compliance; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm | 2009 |
Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Comorbidity; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Mutation; Piperazines; Prognosis; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2010 |
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.
Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Causality; Decision Trees; Diagnosis, Differential; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Mastocytosis; mRNA Cleavage and Polyadenylation Factors; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor | 2010 |
Managing imatinib resistance in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Molecular pathogenesis of tyrosine kinase resistance in chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Evolution, Molecular; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2010 |
Imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Review: Imatinib plasma trough levels in the management of CML: Ready for prime time?
Topics: Benzamides; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
Lichenoid drug eruption with palmoplantar hyperkeratosis due to imatinib mesylate: a case report and a review of the literature.
Topics: Administration, Topical; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Imatinib Mesylate; Keratoderma, Palmoplantar; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Skin; Treatment Outcome | 2010 |
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Why doesn't imatinib cure chronic myeloid leukemia?
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
[Overview of chronic myelogenous leukemia and its current diagnosis and treatment patterns in 15 hospitals in China.].
Topics: Benzamides; China; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Chronic myelogenous leukemia: treatment and monitoring.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prevalence; Pyrimidines; Risk Assessment; Risk Factors; Stem Cell Transplantation; Survival Analysis; Survival Rate; Treatment Outcome | 2010 |
Dasatinib: is it all in the dose?
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Uncommon case of chronic myeloid leukemia with multiple myeloma.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Female; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Piperazines; Pyrimidines | 2010 |
Testicular cancer developed in a chronic myeloid leukemia patient with a continued complete cytogenetic and molecular response to imatinib. A case report and review of the literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Testicular Neoplasms; Young Adult | 2010 |
[Economic burden for patients with chronic myelogenous leukemia--healthcare economics and medical governance of cancer].
Topics: Antineoplastic Agents; Benzamides; Drug Costs; Humans; Imatinib Mesylate; Internet; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Update on practical aspects of the treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Combined Modality Therapy; Dasatinib; Drug Eruptions; Drug Interactions; Edema; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Thiazoles | 2006 |
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Sensitivity and Specificity | 2006 |
The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Living Donors; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Siblings; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia with imatinib in combination with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Doxorubicin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Multicenter Studies as Topic; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Rate; Vincristine | 2006 |
Genomic instability: The cause and effect of BCR/ABL tyrosine kinase.
Topics: Apoptosis; Benzamides; Cell Differentiation; Disease Progression; DNA Repair; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species | 2007 |
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Topics: Animals; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mice; Multicenter Studies as Topic; Mutation; Piperazines; Protein Isoforms; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thiazoles | 2007 |
Immunotherapeutic strategies in chronic myeloid leukemia.
Topics: Antigens, Neoplasm; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Clonal Anergy; Dendritic Cells; Epitopes; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloblastin; Neoplasm Proteins; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocyte Subsets; Vaccination; Vaccines, Subunit; WT1 Proteins | 2007 |
Tyrosine kinase inhibitors: the first decade.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Treatment Outcome | 2010 |
Targeting chronic myeloid leukemia stem cells.
Topics: Animals; Antigens, CD34; Benzamides; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2010 |
Signal transduction therapy of cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Neoplasms; Piperazines; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2010 |
Imatinib mesylate in children and adolescents with cancer.
Topics: Adolescent; Benzamides; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2010 |
First-line therapy for chronic myeloid leukemia: new horizons and an update.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
Improving imatinib delivery to central nervous system.
Topics: Animals; Benzamides; Blood-Brain Barrier; Central Nervous System; Drug Delivery Systems; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methamphetamine; Piperazines; Pyrimidines | 2010 |
How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Molecular pathways to CML stem cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2010 |
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
Topics: Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger | 2010 |
Standard treatment of Ph+ CML in 2010: how, when and where not to use what BCR/ABL1 kinase inhibitor?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Cytogenomics of cancers: from chromosome to sequence.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Chromosome Aberrations; Chromosomes; Cytogenetics; Disease Progression; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines | 2010 |
Optimal control for resistance and suboptimal response in CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines | 2010 |
The significance of early, major and stable molecular responses in chronic myeloid leukemia in the imatinib era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction; RNA, Messenger; Survival Rate; Transcription, Genetic; Treatment Outcome | 2011 |
Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Topics: Aged; Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Comorbidity; Dasatinib; Disease Management; Drug Administration Schedule; Drug Eruptions; Humans; Hypercholesterolemia; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Pericardial Effusion; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Thiazoles; Treatment Outcome | 2010 |
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma; Cell Line; Disease Progression; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Melanoma; Piperazines; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Pyrimidines; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Transcription Factors; Tumor Cells, Cultured; Up-Regulation | 2011 |
Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Towards a cure for chronic myeloid leukemia: are we there yet?
Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2010 |
Current status of imatinib as frontline therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines | 2010 |
Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Practical considerations for monitoring patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2010 |
Resistance to imatinib: mutations and beyond.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Stem cell transplant for chronic myeloid leukemia in the imatinib era.
Topics: Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome | 2010 |
The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2010 |
Third-generation tyrosine kinase inhibitors and beyond.
Topics: Benzamides; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2010 |
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Thiazoles | 2011 |
Allosteric inhibition of BCR-ABL.
Topics: Allosteric Regulation; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
[Management of chronic myeloid leukemia by imatinib].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2010 |
Current treatment concepts of CML.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2010 |
Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Pyrimidines | 2011 |
Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2009 |
Role of gene-expression profiling in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Piperazines; Prognosis; Pyrimidines | 2009 |
Role of allogeneic transplantation in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Risk Factors; Transplantation, Homologous | 2008 |
Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Duplication; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Organic Cation Transporter 1; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2011 |
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
Topics: Antibodies, Monoclonal; Antigens, CD20; Benzamides; Biomarkers; Drugs, Investigational; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
The expanding role of nilotinib in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
The role of imatinib plasma level testing in gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Pharmacogenetics; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia.
Topics: Benzamides; Clinical Trials as Topic; Congresses as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Drug transporters and imatinib treatment: implications for clinical practice.
Topics: Benzamides; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Transport Proteins; Piperazines; Pyrimidines | 2011 |
Molecular and cellular bases of chronic myeloid leukemia.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Benzamides; Disease Models, Animal; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyrimidines | 2010 |
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Topics: Benzamides; Chromosome Aberrations; DNA Mismatch Repair; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy | 2011 |
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2011 |
Treatment of chronic myeloid leukemia when imatinib fails.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Mutation; Piperazines; Pyrimidines; Treatment Failure | 2011 |
Mutational analysis in chronic myeloid leukemia: when and what to do?
Topics: Benzamides; DNA Mutational Analysis; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2011 |
Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Clinical Trials as Topic; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
[Chronic myeloid leukemia. Diagnostics, therapy and future strategy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles | 2011 |
Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk | 2011 |
Mechanisms of resistance to BCR-ABL kinase inhibitors.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
New drugs for chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thiazoles | 2011 |
Bilateral masculine mastoplasia associated with imatinib mesylate: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Benzamides; Gynecomastia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2011 |
Pharmacotherapy for chronic myelogenous leukemia: a case-based approach.
Topics: Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Chronic myelogenous leukemia: monitoring response to therapy.
Topics: Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine | 2011 |
Interpretation of cytogenetic and molecular results in patients treated for CML.
Topics: Benzamides; Cytogenetics; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Algorithms; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retreatment | 2011 |
Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications.
Topics: Antineoplastic Agents; Benzamides; Cytogenetics; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Probability; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Oral melanosis after tyrosine kinase inhibition with Imatinib for chronic myelogenous leukemia: report of a case and review of the literature.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanins; Melanosis; Mouth Diseases; Palate, Hard; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transport Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Topics: Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Publication Bias; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Models, Biological; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; ras Proteins; Signal Transduction; STAT Transcription Factors | 2011 |
The safety profile of imatinib in CML and GIST: long-term considerations.
Topics: Animals; Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Time Factors | 2012 |
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2012 |
[A case of imatinib mesylate-induced pneumonitis based on the detection of epithelioid granulomas by video-assisted thoracoscopic surgery biopsy in a patient with chronic myeloid leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy; Granuloma; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pneumonia; Pyrimidines; Thoracic Surgery, Video-Assisted | 2011 |
Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2011 |
[TKI therapy for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2011 |
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
Topics: Antineoplastic Agents; Benzamides; Cerebrovascular Disorders; Clinical Trials as Topic; Comorbidity; Contraindications; Diabetes Mellitus; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2012 |
[Chronic myeloid leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction | 2011 |
[Current status and future perspective in imatinib therapy against CML].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2011 |
Managing resistance in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
[Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML].
Topics: Antineoplastic Agents; Benzamides; Caspase 3; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Thrombocytopenia; Thrombopoiesis | 2011 |
Chronic myeloid leukemia: mechanisms of resistance and treatment.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2011 |
Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2011 |
New insights into the pathogenesis of chronic myeloid leukaemia: towards a path to cure.
Topics: Benzamides; Disease Progression; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2011 |
Effects of BCR-ABL inhibitors on anti-tumor immunity.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles | 2011 |
Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Tyrosine kinase inhibitor therapy for chronic myeloid leukemia: approach to patients with treatment-naive or refractory chronic-phase disease.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2011 |
Tyrosine kinase inhibitors in hematological malignancies.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2011 |
Suppression of autophagy by BCR/ABL.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzamides; Chloroquine; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2012 |
[Initial therapy of imatinib mesylate for extramedullary T lymphoblastic crisis of chronic myeloid leukemia: a case report and review of the literature].
Topics: Adult; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2011 |
The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2012 |
Current treatment strategies in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Clinical Trials as Topic; Cytogenetics; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2012 |
Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2011 |
Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials, Phase III as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Molecular resistance: an early indicator for treatment change?
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2012 |
Secondary malignancy after imatinib therapy: eight cases and review of the literature.
Topics: Adult; Aged; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2012 |
The role of protein phosphorylation in therapy resistance and disease progression in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Autophagy; Benzamides; Blast Crisis; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphoprotein Phosphatases; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Signal Transduction; src-Family Kinases | 2012 |
Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Disease Management; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cells; Piperazines; Pluripotent Stem Cells; Protein Kinase Inhibitors; Pyrimidines; Therapies, Investigational; Treatment Outcome | 2012 |
[Myeloproliferative neoplasms (including chronic myeloid leukemia)].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Receptor, Platelet-Derived Growth Factor alpha; Thiazoles | 2012 |
Second-generation tyrosine kinase inhibitors as first-line treatment strategy in newly diagnosed chronic phase chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles; Treatment Outcome | 2012 |
Management of chronic myeloid leukemia in childhood.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease Management; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Clinical trials in chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2012 |
Chronic myelogenous leukemia for primary care physicians.
Topics: Benzamides; Biopsy, Fine-Needle; Bone Marrow; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Philadelphia Chromosome; Piperazines; Platelet Count; Pregnancy; Pregnancy Complications, Neoplastic; Primary Health Care; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2012 |
Bosutinib for the treatment of chronic myeloid leukemia in chronic phase.
Topics: Aniline Compounds; Animals; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Treatment Failure | 2012 |
[Current therapy of chronic myeloid leukemia].
Topics: Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Research Design; Thiazoles; Treatment Outcome | 2012 |
Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Benzamides; Blast Crisis; Clinical Trials as Topic; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Models, Economic; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Thiazoles | 2012 |
Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia: a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Benzamides; Confidence Intervals; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance; Drug Therapy, Combination; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Thiazoles; Treatment Outcome; United Kingdom | 2012 |
[Progress in the study of plasma-drug concentration of imatinib for treatment of chronic myeloid leukemia].
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2012 |
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Diarrhea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Thrombocytopenia; Time Factors | 2012 |
Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges.
Topics: Benzamides; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2012 |
[Chronic myeloid leukemia: "archetype" of the impact of targeted therapies].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2012 |
Chronic myeloid leukemia: state of the art in 2012.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Leukemia: A highly malignant disease].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Disease Models, Animal; History, 19th Century; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Tretinoin | 2012 |
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.
Topics: Benzamides; Clinical Trials as Topic; DNA Mutational Analysis; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2012 |
[Standard therapy for chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Drug Discovery; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines | 2012 |
[Chronic myelogenous leukemia: management of treatment-related adverse events].
Topics: Benzamides; Drug Administration Schedule; Drug Monitoring; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Thiazoles; Treatment Outcome | 2012 |
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Biological Availability; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Pharmacovigilance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Therapeutic Equivalency; Treatment Outcome | 2012 |
Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Risk Assessment; Thiazoles | 2012 |
It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2012 |
Monitoring after successful therapy for chronic myeloid leukemia.
Topics: Benzamides; Cell Line, Tumor; Cytogenetics; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Medication Adherence; Neoplasms; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Nitriles; Piperazines; Pyrimidines; Quinolines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2012 |
Is going for cure in chronic myeloid leukemia possible and justifiable?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Multicenter Studies as Topic; Neoplastic Stem Cells; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Thiazoles | 2013 |
Mechanisms of resistance to BCR-ABL and other kinase inhibitors.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines | 2013 |
Structure and dynamic regulation of Abl kinases.
Topics: Benzamides; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Models, Chemical; Molecular Conformation; Mutation; Myristic Acid; Piperazines; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Mas; Pyrimidines; src Homology Domains | 2013 |
Twin pregnancy and childbirth after reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation combined with imatinib mesylate for chronic myeloid leukaemia: case report and literature review.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Female; Fertility; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Parturition; Piperazines; Pregnancy; Pregnancy Outcome; Pregnancy, Twin; Pyrimidines; Transplantation Conditioning | 2012 |
[Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy in patients with chronic myeloid leukemia: two cases report and literatures review].
Topics: Adult; Benzamides; Hepatitis B; Hepatitis B virus; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Virus Activation | 2012 |
Treating chronic myeloid leukemia: improving management through understanding of the patient experience.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Style; Patient Compliance; Patient Education as Topic; Piperazines; Pyrimidines; Quality of Life; Thiazoles | 2013 |
Management of the new patient with CML in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.
Topics: Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug.
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2002 |
Imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2002 |
The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Evaluation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Resistance in the land of molecular cancer therapeutics.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2002 |
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Topics: Benzamides; Disease Progression; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2002 |
Signal transduction inhibitors (STI571): molecularly targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Diarrhea; Edema; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2002 |
Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2002 |
STI-571 in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2002 |
Imatinib mesylate, the first molecularly targeted gene suppressor.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Neoplasm; Food-Drug Interactions; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Education as Topic; Piperazines; Pyrimidines; Sarcoma; Stromal Cells | 2002 |
Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Topics: Adenosine Triphosphate; Benzamides; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2002 |
Chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Survival Analysis | 2002 |
[Chronic myeloid leukemia--treatment].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Risk Factors; Stem Cell Transplantation | 2002 |
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
Topics: Antineoplastic Agents; Benzamides; Down-Regulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation | 2003 |
Gleevec: zeroing in on cancer.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2002 |
[Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Aberrations; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2002 |
Pharmacology of imatinib (STI571).
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Connective Tissue; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells | 2002 |
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2002 |
Imatinib: the first 3 years.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Survival Analysis | 2002 |
Imatinib alone and in combination for chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Management decisions in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Decision Making; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
Topics: Acute Disease; Animals; Antineoplastic Agents; Benzamides; Chronic Disease; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2003 |
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Topics: Antineoplastic Agents; Benzamides; Biological Availability; Clinical Trials as Topic; Half-Life; Humans; Imatinib Mesylate; Intestinal Absorption; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Pyrimidines | 2002 |
[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy].
Topics: Animals; Apoptosis; Benzamides; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; United Kingdom | 2002 |
[How I treat...chronic myeloid leukemia].
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Topics: Antineoplastic Agents; Arthralgia; Benzamides; Bone Marrow; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Edema; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Cell Growth Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Muscle Cramp; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vomiting | 2003 |
Is there a cloud in the silver lining for imatinib?
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Amplification; Genes, MDR; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Orosomucoid; Piperazines; Pyrimidines | 2003 |
Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1).
Topics: Antineoplastic Agents; Benzamides; Biomarkers; Biomarkers, Tumor; Blast Crisis; Bone Marrow Examination; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Life Tables; Neoplasm Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis | 2003 |
Understanding the molecular basis of imatinib mesylate therapy in chronic myelogenous leukemia and the related mechanisms of resistance. Commentary re: A. N. Mohamed et al., The effect of imatinib mesylate on patients with Philadelphia chromosome-positive
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
[Current therapy of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Enzyme Inhibitors; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Stem Cell Transplantation | 2003 |
High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Design; Enzyme Inhibitors; Fatty Acids, Unsaturated; Forecasting; Fusion Proteins, bcr-abl; GRB2 Adaptor Protein; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macromolecular Substances; Mice; Neoplasm Proteins; Peptide Fragments; Phosphatidylinositol 3-Kinases; Piperazines; Protein Binding; Proteins; Pyrimidines; ras Proteins; Signal Transduction; Son of Sevenless Proteins; src Homology Domains; Structure-Activity Relationship; Transcription Factors | 2003 |
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Topics: Animals; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Genes, abl; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Animal; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2003 |
Current CML therapy: progress and dilemma.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation | 2003 |
Targeting oncogene dependence and resistance.
Topics: Alleles; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasms; Oncogenes; Piperazines; Pyrimidines | 2003 |
Chronic myeloid leukemia in the imatinib era.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2003 |
Imatinib: a targeted clinical drug development.
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Treatment Outcome | 2003 |
Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy.
Topics: Benzamides; Biomarkers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; RNA, Messenger; WT1 Proteins | 2003 |
Cytogenetic studies in patients on imatinib.
Topics: Benzamides; Clone Cells; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines | 2003 |
The cytogenetic response as a surrogate marker of survival.
Topics: Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Remission Induction; Survival Analysis | 2003 |
Molecular monitoring of chronic myeloid leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines | 2003 |
Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction | 2003 |
Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.
Topics: Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oncogene Proteins v-abl; Piperazines; Pyrimidines | 2003 |
Clinical decisions for chronic myeloid leukemia in the imatinib era.
Topics: Benzamides; Decision Making; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Piperazines; Pyrimidines | 2003 |
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Protocols; Clinical Trials as Topic; Cytarabine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
[Pathophysiology and treatment of acute myeloid leukemia].
Topics: Animals; Antineoplastic Agents; Benzamides; fms-Like Tyrosine Kinase 3; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Tretinoin | 2003 |
[Molecular targeting therapy for chronic myelogenous leukemia].
Topics: Animals; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fusion Proteins, bcr-abl; Gene Targeting; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
[A new drug in the therapy of chronic myeloid leukemia: ST1571].
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
[Evidence-based therapy for chronic leukemia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Transplantation, Homologous; Vidarabine | 2003 |
Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cells; Transplantation, Homologous | 2003 |
[Gleevec: an novel inhibitor of bcr-abl tyrosine kinase].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.
Topics: Benzamides; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence | 2003 |
Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylate.
Topics: Benzamides; Blast Crisis; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transplantation, Homologous; Treatment Outcome | 2003 |
STI571 as a targeted therapy for CML.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Management of molecular-targeted therapy for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Survival Analysis | 2003 |
[Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
[Imatinib].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2003 |
Transplantation for chronic myelogenous leukemia: yes, no, maybe so. . . An Oregon perspective.
Topics: Algorithms; Benzamides; Disease Management; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Examination; Clinical Trials as Topic; Cytarabine; Diagnosis, Differential; Drug Resistance; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Risk Factors; Sirolimus; Stem Cell Transplantation; Time Factors | 2003 |
Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2003 |
Chronic myeloid leukemia--advances in biology and new approaches to treatment.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction; Stem Cell Transplantation; Transcription, Genetic | 2003 |
Eosinophilic variant of chronic myeloid leukemia with vascular complications.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Benzamides; Bone Marrow; Diagnostic Errors; Eosinophilia; Fingers; Gangrene; Humans; Imatinib Mesylate; Leg; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pain; Piperazines; Pyrimidines; Radiography; Vasculitis; Vitamins | 2003 |
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Topics: Amino Acid Sequence; Animals; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Piperazines; Pyrimidines | 2003 |
Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.
Topics: Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2003 |
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2004 |
Chronic myeloid leukemia.
Topics: Benzamides; Drug Delivery Systems; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2003 |
Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Resistance to imatinib (Glivec): update on clinical mechanisms.
Topics: Administration, Oral; Benzamides; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
[Chronic myeloid leukemia in 2003].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines | 2003 |
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
Topics: Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Survival Rate; Treatment Outcome | 2003 |
Mechanisms and implications of imatinib resistance mutations in BCR-ABL.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2004 |
Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Treatment options for newly diagnosed patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Marrow Transplantation; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome | 2004 |
Cancer treatment with kinase inhibitors: what have we learnt from imatinib?
Topics: Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Chronic myeloid leukemia-still a few questions.
Topics: Benzamides; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; HSP70 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2004 |
Clinical and epidemiologic burden of chronic myelogenous leukemia.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2004 |
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides | 2004 |
[Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2004 |
The BCR-ABL story: bench to bedside and back.
Topics: Animals; Antineoplastic Agents; Benzamides; Cytogenetics; Drug Design; Genes, abl; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2004 |
Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Clinical results with imatinib in chronic myeloid leukaemia.
Topics: Benzamides; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2004 |
Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era.
Topics: Benzamides; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction | 2004 |
Molecular mechanisms of resistance of leukemia to imatinib mesylate.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Heterogeneity; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2004 |
[Molecular target therapy for hematologic malignancy].
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gene Targeting; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tretinoin | 2004 |
[Recent progress in diagnosis of and therapy for patients with leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Monitoring; Fusion Proteins, bcr-abl; Gene Targeting; Genes, Wilms Tumor; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplasm, Residual; Oncogene Proteins, Fusion; Pharmacogenetics; Piperazines; Pyrimidines; Recombinant Fusion Proteins; Therapeutic Equivalency; Tretinoin | 2004 |
Blastic mantle cell lymphoma developing concurrently in a patient with chronic myelogenous leukemia and a review of the literature.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Mantle-Cell; Male; Philadelphia Chromosome; Piperazines; Pyrimidines | 2004 |
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Burkitt Lymphoma; Cytarabine; Daunorubicin; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Remission Induction | 2004 |
Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Decision Making; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Transplantation, Homologous; Treatment Outcome | 2004 |
Cancer stem cells: are we missing the target?
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Neoplastic Stem Cells; Piperazines; Pyrimidines; Survival | 2004 |
Effect of imatinib mesylate on chronic myelogenous leukemia hematopoietic progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cells | 2004 |
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stromal Cells | 2004 |
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Spotlight on imatinib mesylate in chronic myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Optimizing treatment of chronic myeloid leukemia: a rational approach.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2004 |
Indications for imatinib mesylate therapy and clinical management.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chemical and Drug Induced Liver Injury; Drug Eruptions; Edema; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Muscle Cramp; Piperazines; Pyrimidines | 2004 |
Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Treatment Outcome | 2004 |
Switching off oncogenic signals in chronic myeloid leukaemia.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Binding Sites; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oncogenes; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; ras Proteins; RNA Interference; Signal Transduction; TOR Serine-Threonine Kinases | 2004 |
Imatinib mesylate (Gleevec/Glivec) a molecular-targeted therapy for chronic myeloid leukaemia and other malignancies.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Pilot Projects; Piperazines; Prognosis; Pyrimidines | 2004 |
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytogenetics; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2004 |
Tyrosine kinase inhibitors in cancer therapy.
Topics: Benzamides; Clinical Trials as Topic; Forecasting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cytarabine; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Stem Cell Transplantation | 2004 |
Imatinib mesylate in combination with other chemotherapeutic agents for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Signal Transduction; Survival Analysis | 2004 |
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2004 |
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2004 |
Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2004 |
Chronic myeloid leukemia: current status and controversies.
Topics: Benzamides; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation | 2004 |
Natural history and staging of chronic myelogenous leukemia.
Topics: Benzamides; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2004 |
Imatinib therapy in chronic myeloid leukemia.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Piperazines; Prognosis; Pyrimidines; Remission Induction; Treatment Outcome | 2004 |
Investigational strategies in chronic myelogenous leukemia.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Cancer Vaccines; DNA Methylation; Enzyme Inhibitors; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Research; Treatment Outcome | 2004 |
Clinical resistance to imatinib: mechanisms and implications.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2004 |
[Imatinib therapy for patients with chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2004 |
Imatinib as a paradigm of targeted therapies.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Neoplasm Proteins; Neoplasms; Oncogenes; Patient Selection; Piperazines; Protein Conformation; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Effects of the tyrosine kinase inhibitor imatinib mesylate (STI571) on bone marrow features in patients with chronic myelogenous leukemia.
Topics: Apoptosis; Benzamides; Bone Marrow; Cell Proliferation; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microcirculation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stromal Cells | 2004 |
Treatment of CML in pediatric patients: should imatinib mesylate (STI-571, Gleevec) or allogeneic hematopoietic cell transplant be front-line therapy?
Topics: Antineoplastic Agents; Benzamides; Child; Clinical Trials as Topic; Decision Making; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous | 2004 |
[Therapy of chronic myelogenous leukemia in 2004].
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction | 2004 |
[Resistance mechanism of ST1571 and its prevention research--review].
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2004 |
Punish the parent not the progeny.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2005 |
[Imatinib--a new perspective in the treatment of tumors].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Chronic myelogenous leukemia and myeloproliferative disease.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Piperazines; Primary Myelofibrosis; Pyrimidines | 2004 |
[Origin of resistance to Imatinib mesylate: lessons learned from this experience].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2004 |
Imatinib mesylate--gold standards and silver linings.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Mas; Pyrimidines | 2004 |
Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; WT1 Proteins | 2005 |
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2005 |
Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia.
Topics: Benzamides; Biomarkers, Tumor; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytoplasm; Disease Progression; Drug Design; Drug Industry; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2004 |
Chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation | 2004 |
[Perspectives in the use of imatinib in the treatment of childhood cancers].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Child; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Male; Neuroblastoma; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
[Chronic myelogenous leukaemia: recent progress in biology and therapeutic strategies].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Forecasting; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation | 2005 |
Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Dendritic Cells; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cells; T-Lymphocytes, Cytotoxic | 2005 |
BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2005 |
AMN107: tightening the grip of imatinib.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Chemical; Mutation; Piperazines; Pyrimidines; Recurrence | 2005 |
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Oncogene Proteins v-abl; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines | 2005 |
Can we afford to let sleeping dogs lie?
Topics: Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Pyrimidines | 2005 |
Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins | 2005 |
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cytarabine; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Treatment Outcome | 2005 |
[Chronic myeloid leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diagnosis, Differential; Enzyme Activation; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2005 |
[Imatinib therapy for patients with chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2005 |
The development and application of imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chronic Disease; Dermatofibrosarcoma; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
[Stem cell transplantation in the imatinib era].
Topics: Algorithms; Antineoplastic Agents; Benzamides; Decision Making; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Transplantation, Homologous | 2005 |
[The role of imatinib in the treatment of acute lymphoid leukemias].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Neoplasm, Residual; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2005 |
[Clinical studies with imatinib in 2004].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dermatofibrosarcoma; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2005 |
Chronic myeloid leukaemia: stem cell derived but progenitor cell driven.
Topics: Benzamides; Cell Proliferation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Translocation, Genetic | 2005 |
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Janus Kinase 2; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcr; Pyrimidines; Translocation, Genetic | 2005 |
Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.
Topics: Antineoplastic Agents; Benzamides; Cancer Vaccines; Cytokines; Dendritic Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Myeloid Cells; Piperazines; Pyrimidines; T-Lymphocytes | 2005 |
Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
Topics: Animals; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2005 |
[Treatment outcome of hematopoietic stem cell transplantation for chronic myelogenous leukemia].
Topics: Benzamides; Graft vs Leukemia Effect; Health Facilities; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Piperazines; Pyrimidines; Survival Rate; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2005 |
Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo?
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Skin Pigmentation; Vitiligo | 2005 |
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Models, Genetic; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2006 |
New targeted approaches in chronic myeloid leukemia.
Topics: Benzamides; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis | 2005 |
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Dual tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases | 2005 |
Natural killer cell-dendritic cell crosstalk in the initiation of immune responses.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Benzamides; Cell Communication; Clinical Trials as Topic; Cytokines; Dendritic Cells; Drug Evaluation, Preclinical; Gastrointestinal Stromal Tumors; Herpesviridae Infections; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Immunologic; Signal Transduction | 2005 |
Allogeneic transplantation for chronic myelogenous leukemia.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Transfusion; Piperazines; Pyrimidines; Transplantation, Homologous | 2005 |
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
[Treatment of chronic myelogenous leukemia by using imatinib].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2005 |
Chronic myelogenous leukemia.
Topics: Age Distribution; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Stem Cell Transplantation; Thiazoles; Translocation, Genetic | 2005 |
Strategies for the treatment of imatinib-resistant chronic myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Resistance to imatinib: mechanisms and management.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
Topics: Benzamides; Cell Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Targeted CML therapy: controlling drug resistance, seeking cure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[Cancer initiation as mini-evolution].
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Chromosomal Instability; Computational Biology; Epithelial Cells; Evolution, Molecular; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Mutation; Neoplasms; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2005 |
[Tyrosine kinases. New target of anticancer therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Breast Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphatic Metastasis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, ErbB-2; Trastuzumab | 2005 |
[Gene expression profiling for prediction of response to chemotherapy].
Topics: Antineoplastic Agents; Benzamides; Breast Neoplasms; Drug Screening Assays, Antitumor; Esophageal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Targeting; Genome, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines | 2006 |
Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Biomarkers; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2006 |
[EBM in the treatment of CML].
Topics: Algorithms; Antineoplastic Agents; Benzamides; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation | 2005 |
Overcoming drug resistance in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Farnesyltranstransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Animal; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases | 2006 |
Chronic myeloid leukemia in 2006: a perspective.
Topics: Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2006 |
A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases.
Topics: Animals; Benzamides; Dermatofibrosarcoma; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin Diseases; Skin Neoplasms | 2006 |
Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2006 |
Strategies to eliminate cancer stem cells: clinical implications.
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2006 |
Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Molecular targets and the treatment of myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Promyelocytic, Acute; Piperazines; Pyrimidines; ras Proteins; Receptor Protein-Tyrosine Kinases; Translocation, Genetic; Tretinoin | 2006 |
Imatinib resistance: obstacles and opportunities.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
[Tyrosine kinase inhibitors for the treatment of CML].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase II as Topic; Cytarabine; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors | 2006 |
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Combined Modality Therapy; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Recombinant Proteins; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure | 2006 |
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
Tyrphostins and other tyrosine kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Graft Occlusion, Vascular; Humans; Imatinib Mesylate; Janus Kinase 2; Janus Kinase 3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tyrphostins | 2006 |
New strategies in chronic myeloid leukemia.
Topics: Angiogenesis Inhibitors; Azacitidine; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Decitabine; Drug Resistance, Neoplasm; Farnesyl-Diphosphate Farnesyltransferase; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2006 |
Imatinib mesylate: A designer drug.
Topics: Benzamides; Eosinophilia; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Risk Factors | 2006 |
[Cytogenetic and molecular monitoring of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic; Treatment Outcome | 2006 |
Chronic myeloid leukemia: diagnosis and treatment.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2006 |
[Chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Therapy, Combination; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines | 2006 |
Treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Benzamides; Combined Modality Therapy; Drug Resistance; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.
Topics: Adult; Benzamides; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2006 |
Chronic myelogenous leukemia: from molecular biology to clinical aspects and novel targeted therapies.
Topics: Animals; Benzamides; Disease Models, Animal; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Piperazines; Pyrimidines | 2006 |
Resistance to imatinib mesylate in chronic myeloid leukaemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines | 2007 |
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Topics: Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Guidelines as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Mutation; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2006 |
[Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia].
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Mathematical models of targeted cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Growth Factor; Treatment Outcome | 2006 |
[Molecular monitoring: an essential component of the treatment for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2006 |
Defining and managing imatinib resistance.
Topics: Benzamides; Disease Management; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines | 2006 |
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2006 |
Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia.
Topics: Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Fluoresceins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cells; Succinimides | 2006 |
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; src-Family Kinases | 2006 |
Pregnancies in patients with chronic myeloid leukemia in the era of imatinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Live Birth; Piperazines; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Complications, Neoplastic; Pyrimidines | 2006 |
3. Imatinib therapy in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
[STI571: a summary of targeted therapy].
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drug Therapy, Combination; Drug Tolerance; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction | 2006 |
[Novel inhibitors of Bcr-Abl].
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Panobinostat; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyridones; Pyrimidines; Thiazoles | 2006 |
Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Benzamides; Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines | 2007 |
Imatinib: a review of its use in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
The biology of chronic myelogenous leukemia: implications for imatinib therapy.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2007 |
Resistance to targeted therapy in chronic myelogenous leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2007 |
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Topics: Adaptor Proteins, Signal Transducing; Aniline Compounds; Benzamides; Cancer Vaccines; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
[Molecular targeting therapy for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Important therapeutic targets in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction | 2007 |
What is new in chronic myeloid leukaemia?
Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Hepatomegaly; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Splenomegaly; Thiazoles | 2007 |
Optimizing therapy of chronic myeloid leukemia.
Topics: Benzamides; Clinical Trials as Topic; Disease-Free Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Stem Cell Transplantation; Transplantation, Homologous | 2007 |
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Topics: Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2007 |
Immunotherapy in chronic myelogenous leukemia.
Topics: Benzamides; Clinical Trials as Topic; Heat-Shock Proteins; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; T-Lymphocytes, Cytotoxic; Transplantation, Homologous | 2007 |
The challenges of targeting chronic myeloid leukemia stem cells.
Topics: ATP-Binding Cassette Transporters; Benzamides; Cell Differentiation; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Pyrimidines | 2007 |
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2007 |
Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date.
Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous | 2007 |
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Signal Transduction | 2007 |
Targeted cancer therapy: promise and reality.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Drug Screening Assays, Antitumor; ErbB Receptors; Forecasting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplasm Proteins; Neoplasms; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2007 |
Current and emerging treatment options in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Therapeutic targets in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Overview of second-generation tyrosine kinase inhibitors for patients with imatinib-resistant chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Dasatinib; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nurse's Role; Nursing Assessment; Oncology Nursing; Philadelphia Chromosome; Piperazines; Practice Guidelines as Topic; Primary Health Care; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Thiazoles; Treatment Outcome | 2007 |
Risk assessment in haemotopoietic stem cell transplantation: disease and disease stage.
Topics: Acute Disease; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Pyrimidines; Recurrence; Risk Assessment; Survival Analysis; Transplantation, Homologous | 2007 |
Disease relapse after haematopoietic stem cell transplantation: risk factors and treatment.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Piperazines; Pyrimidines; Risk Factors; Secondary Prevention; Transplantation, Homologous | 2007 |
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Models, Molecular; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Signal Transduction | 2007 |
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
[Overcoming imatinib resistance].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
[Adverse effects of imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
[The management of chronic phase CML].
Topics: Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
[Treatment of chronic myelogenous leukemia with imatinib: current and future therapeutic strategies].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
[Experimental advance of targeted medicines for chronic myeloid leukemia--review].
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines | 2007 |
[Early blastic transformation within a year of imatinib treatment in 2 cases of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Male; Monitoring, Physiologic; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction | 2007 |
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis | 2007 |
How I treat chronic myeloid leukemia in the imatinib era.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
[Novel anti-CML agents beyond imatinib].
Topics: Adenosine Triphosphate; Aniline Compounds; Antineoplastic Agents; Benzamides; Benzene Derivatives; Binding Sites; Binding, Competitive; Dasatinib; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Thiazoles | 2007 |
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Adult; Benzamides; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
ATP-binding-cassette transporters in hematopoietic stem cells and their utility as therapeutical targets in acute and chronic myeloid leukemia.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Benzamides; Cell Differentiation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Models, Biological; Phenotype; Piperazines; Protein Binding; Pyrimidines | 2007 |
Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia--insights from mathematical model analyses.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2008 |
Chronic myeloid leukaemia.
Topics: Benzamides; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Survival Rate | 2007 |
Treatment for chronic myelogenous leukemia: the long road to imatinib.
Topics: Animals; Benzamides; DNA, Recombinant; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Sequence Analysis, DNA | 2007 |
Applying the discovery of the Philadelphia chromosome.
Topics: Benzamides; Biomarkers, Tumor; Clinical Trials as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Leukemia, an effective model for chemical biology and target therapy.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Dasatinib; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Oxides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tretinoin | 2007 |
The future is now for the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Drug Monitoring; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Piperazines; Pyrimidines | 2007 |
What's blasting off in CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Monitoring; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Philadelphia Chromosome; Piperazines; Pyrimidines; Risk Factors; Thiazoles | 2007 |
Imatinib mesylate in the treatment of hematologic malignancies.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Interactions; Drug Resistance; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Treatment Outcome | 2007 |
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
[Trends in molecular targeting therapeutics for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
Characterization of cancer stem cells in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2007 |
Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease Progression; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
[Treatment of chronic myeloid leukemia in 2007].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines | 2007 |
Targeted chronic myeloid leukemia therapy: seeking a cure.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
New strategies in controlling drug resistance.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines | 2007 |
[Imatinib-induced toxic hepatitis: description of two cases and review of the literature].
Topics: Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stomach Neoplasms; Time Factors | 2007 |
FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.
Topics: Apoptosis; Benzamides; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines; Signal Transduction | 2008 |
Nilotinib therapy in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Controlled Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Management of imatinib-resistant CML patients.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Germany; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrimidines | 2007 |
Medical management of CML.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
State-of-the-art in the treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cells; Transplantation, Homologous | 2008 |
Part II: management of resistance to imatinib in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Drugs, Investigational; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Failure; Treatment Outcome | 2007 |
New strategies in controlling drug resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
[An advance in the treatment of CML].
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
Topics: Benzamides; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Contraindications; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Chemical; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcr; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Thiazoles | 2007 |
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Signal Transduction; src-Family Kinases | 2008 |
Treatment options in imatinib-resistant chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2008 |
Monitoring treatment of chronic myeloid leukemia.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Piperazines; Point Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Retrospective Studies | 2008 |
Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
Topics: Aged; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
[Research advance on molecular genetics of CML blast crisis].
Topics: Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Translocation, Genetic | 2008 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
Getting to the stem of chronic myeloid leukaemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Suppressor Proteins | 2008 |
First-Line management of CML: a state of the art review.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transplantation, Homologous | 2008 |
Resistance and relapse with imatinib in CML: causes and consequences.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Immunotherapeutic approaches in chronic myelogenous leukemia.
Topics: Benzamides; Humans; Imatinib Mesylate; Immunotherapy; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Vaccines | 2008 |
New therapeutic approaches and prognostic factors in chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines | 2008 |
Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia.
Topics: Benzamides; Biomarkers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Prognosis; Pyrimidines | 2008 |
Overcoming kinase resistance in chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
[Treatment of hematologic neoplasms during pregnancy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Lymphoma, Non-Hodgkin; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Radiotherapy; Rituximab | 2007 |
Therapy options in imatinib failures.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2008 |
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha.
Topics: Aged; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction | 2008 |
Management of patients with resistant or refractory chronic myelogenous leukemia.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Treatment Outcome | 2008 |
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Clinical Trials as Topic; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Genes, abl; Harringtonines; Homoharringtonine; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Tumor Cells, Cultured | 2008 |
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Drug Design; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines | 2000 |
Trial of IFN or STI571 before proceeding to allografting for CML?
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Risk Factors; Survival Analysis; Transplantation, Homologous | 2000 |
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Models, Animal; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2000 |
Chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines | 2001 |
The biology and treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Survival Analysis | 2001 |
Chronic myeloid leukaemia. STI 571 magnifies the therapeutic dilemma.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Recurrence; Signal Transduction | 2001 |
STI571: a gene product-targeted therapy for leukemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.
Topics: Animals; Apoptosis; Benzamides; Cell Adhesion; Cell Cycle; Cell Line, Transformed; Clinical Trials as Topic; Cytoskeleton; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Growth Substances; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Models, Animal; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Stem Cells; Telomere | 2001 |
Mechanisms of transformation by the BCR/ABL oncogene.
Topics: Benzamides; Cell Transformation, Neoplastic; Cytoskeleton; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Oncogene Proteins, Fusion; Philadelphia Chromosome; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Protein Structure, Tertiary; Protein Transport; Pyrimidines; Reactive Oxygen Species; Signal Transduction | 2001 |
Novel therapies for chronic myelogenous leukemia.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Cancer Vaccines; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Genes, myb; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Models, Biological; Multicenter Studies as Topic; Neoplasm Proteins; Oligonucleotides, Antisense; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Tetrahydrofolate Dehydrogenase | 2001 |
Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good?
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
STI571: targeting BCR-ABL as therapy for CML.
Topics: Animals; Antineoplastic Agents; Benzamides; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2001 |
Chronic myelogenous leukaemia--new therapeutic principles.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2001 |
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Transplantation; Cancer Vaccines; Cell Adhesion; Drug Resistance, Neoplasm; Enzyme Inhibitors; Forecasting; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotides, Antisense; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2001 |
Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2001 |
The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology.
Topics: Animals; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation; Stem Cells | 2001 |
Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction | 2001 |
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence | 2001 |
Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction | 2001 |
Implications of imatinib mesylate for hematopoietic stem cell transplantation.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2001 |
Bcr-Abl inhibition as a modality of CML therapeutics.
Topics: Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Division; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Tumor Cells, Cultured | 2001 |
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Forecasting; Gene Targeting; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2001 |
STI571: a magic bullet?
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
[Chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Survival Rate | 2001 |
[Chronic myeloid leukemia and tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cytogenetics; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2001 |
STI-571: current status and future prospects.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence | 2001 |
Chronic myelogenous leukemia: the news you have and haven't heard.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Clinical Trials as Topic; Diagnosis, Differential; Enzyme Inhibitors; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2001 |
Chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Treatment Outcome | 2001 |
The biology of signal transduction inhibition: basic science to novel therapies.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2001 |
Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Signal transduction inhibition: changing paradigms in cancer care.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orphan Drug Production; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2001 |
[Treatment of chronic myelogenous leukemia with tyrosine kinase inhibitor].
Topics: Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
STI571: a paradigm of new agents for cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Design; Drug Evaluation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2002 |
[New molecular therapy options in hematology and oncology, exemplified by STI571].
Topics: Benzamides; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Administration Schedule; Enzyme Inhibitors; Germany; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2001 |
[Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)].
Topics: Animals; Benzamides; Blast Crisis; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Recent advancements in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Activation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
[Update on malignant hemopathies].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotoxins; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Lymphoma; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Tretinoin | 2002 |
Imatinib mesylate--a new oral targeted therapy.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance; Gastrointestinal Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Sarcoma | 2002 |
[Selective tyrosine kinase inhibitor imatinib (STI571) in haematological and oncological disease].
Topics: Adult; Antineoplastic Agents; Benzamides; Carcinoma, Small Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytogenetics; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Male; Mastocytosis; Multicenter Studies as Topic; Mutation; Neoplasms; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Time Factors | 2002 |
STI571 (imatinib mesylate): the tale of a targeted therapy.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
[Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy].
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction | 2002 |
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Disease Models, Animal; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity | 2000 |
STI571 (Gleevec) as a paradigm for cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.
Topics: Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
The promise of gene expression analysis in hematopoetic malignancies.
Topics: Animals; Benzamides; DNA Fingerprinting; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Myelodysplastic Syndromes; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines | 2002 |
Multifaceted approach to the treatment of bcr-abl-positive leukemias.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Treatment Outcome | 2002 |
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Enzyme Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
[Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Chronic myelogenous leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
[STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Drug Interactions; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2002 |
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Perspectives on the development of a molecularly targeted agent.
Topics: Animals; Antineoplastic Agents; Benzamides; Binding Sites; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Monitoring; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2002 |
358 trial(s) available for imatinib mesylate and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow‑up of the Japanese subgroup of the randomized ENESTnd trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Blast Crisis; Disease Progression; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2022 |
Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; Drug Tapering; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Philadelphia Chromosome; Prognosis; Pyrimidines; Quinolines; Retrospective Studies; Young Adult | 2021 |
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2022 |
A predictive scoring system for therapy-failure in persons with chronic myeloid leukemia receiving initial imatinib therapy.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Progression-Free Survival; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Remission Induction; Stromal Interaction Molecule 2; Treatment Outcome | 2022 |
Predictive scoring systems for molecular responses in persons with chronic phase chronic myeloid leukemia receiving initial imatinib therapy.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers.
Topics: Area Under Curve; China; Cross-Over Studies; Drugs, Generic; Healthy Volunteers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Therapeutic Equivalency | 2022 |
Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
Topics: Antineoplastic Agents; Follow-Up Studies; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase | 2022 |
Dynamic changes in the levels of sCD62L and SPARC in chronic myeloid leukaemia patients during imatinib treatment.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Osteonectin; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Tumor Microenvironment | 2022 |
Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML.
Topics: Aged; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
Safety and efficacy of Vitamin D
Topics: Cholecalciferol; Dietary Supplements; Female; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy | 2023 |
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Survival Rate; Time Factors | 2019 |
Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy.
Topics: Aged; Antineoplastic Agents; Case-Control Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life | 2020 |
Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Topics: Adult; Aged; Consolidation Chemotherapy; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Recurrence; Remission Induction; Substance Withdrawal Syndrome; Withholding Treatment | 2019 |
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Bridged Bicyclo Compounds, Heterocyclic; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Protein Kinase Inhibitors; Sulfonamides; Treatment Outcome | 2020 |
A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Effects of Trough Concentration and Solute Carrier Polymorphisms on Imatinib Efficacy in Chinese Patients with Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Proteins; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2020 |
Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Socioeconomic Factors | 2020 |
Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment.
Topics: Adolescent; Antineoplastic Agents; Chickenpox Vaccine; Child; Female; Humans; Imatinib Mesylate; Immunologic Memory; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Measles-Mumps-Rubella Vaccine; Seroconversion; Treatment Outcome; Vaccination; Vaccines, Attenuated | 2020 |
Imatinib-Induced Hypogammaglobulinemia in Children and Adolescents with Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Agammaglobulinemia; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2020 |
Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Diarrhea; Female; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Minisatellite Repeats; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Serotonin Plasma Membrane Transport Proteins; Young Adult | 2020 |
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Retreatment; Treatment Failure; Treatment Outcome | 2020 |
Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI-PIO) in chronic myeloid leukemia with deep molecular response.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pioglitazone; Survival Rate | 2020 |
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
Topics: Adult; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prospective Studies; Protein Kinase Inhibitors | 2021 |
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Pyrimidines; Survival Rate | 2021 |
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polyethylene Glycols; Prognosis; Prospective Studies; Recombinant Proteins; Survival Rate; Young Adult | 2021 |
MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Pilot Projects; Prospective Studies; Recurrence; Time Factors | 2021 |
Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Asia; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinolines; Treatment Outcome; Young Adult | 2021 |
Optimal duration of imatinib treatment/deep molecular response for treatment-free remission after imatinib discontinuation from a Canadian tyrosine kinase inhibitor discontinuation trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canada; Child; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Survival Rate | 2021 |
Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Metabolic Diseases; Metabolome; Middle Aged; Non-Randomized Controlled Trials as Topic; Pioglitazone; Prognosis; Prospective Studies; Retrospective Studies; Withholding Treatment; Young Adult | 2021 |
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Topics: Child; Growth Disorders; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines | 2021 |
Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report.
Topics: Adult; Aged; Asian People; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Survival Rate | 2017 |
A multicenter prospective study on efficacy and safety of imatinib generics: A report from Polish Adult Leukemia Group imatinib generics registry.
Topics: Adult; Aged; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Poland | 2017 |
Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study.
Topics: Cell Count; Disease-Free Survival; Humans; Imatinib Mesylate; Interferon-gamma; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Receptors, Natural Killer Cell; Recurrence | 2017 |
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Topics: Adult; Aged; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2017 |
Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Child; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Protein Kinase Inhibitors; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients.
Topics: Disease-Free Survival; Exome; Female; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Survival Rate | 2017 |
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Survival Analysis; Young Adult | 2017 |
Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.
Topics: Antineoplastic Agents; Cross-Over Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines | 2017 |
Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.
Topics: Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Prospective Studies; Remission Induction; Treatment Outcome | 2018 |
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Phenotype; Philadelphia Chromosome; Protein Kinase Inhibitors; Quinolines; Time Factors; Treatment Outcome; Young Adult | 2018 |
Bosutinib more effective than imatinib in CML.
Topics: Aniline Compounds; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Molecular Targeted Therapy; Nitriles; Prognosis; Protein Kinase Inhibitors; Quinolines; Survival Rate | 2017 |
Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Dasatinib; Databases, Factual; Delivery of Health Care, Integrated; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Registries; Retrospective Studies; United States; Young Adult | 2018 |
Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Topics: Adult; Aged; Antineoplastic Agents; Cardiovascular Diseases; Drug Substitution; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pyrimidines; Safety; Time Factors; Treatment Outcome; Young Adult | 2018 |
Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular responses on the international scale in a EUTOS-certified lab.
Topics: Adult; Antineoplastic Agents; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Internationality; Laboratories; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Remission Induction; Risk Factors; RNA, Messenger; Treatment Outcome; Withholding Treatment | 2018 |
Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Topics: Adult; Aged; Aged, 80 and over; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2018 |
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Machine Learning; Male; Middle Aged; Models, Theoretical; Progression-Free Survival; Remission Induction; Treatment Failure; Young Adult | 2018 |
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2018 |
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prospective Studies; Treatment Outcome | 2018 |
Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
Topics: Adolescent; Antineoplastic Agents; Biomarkers; Bone Marrow; Child; Child, Preschool; Combined Modality Therapy; Disease Progression; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Grading; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Treatment Failure; Treatment Outcome | 2018 |
Pattern of Use and Long-Term Safety of Tyrosine Kinase Inhibitors: A Decade of Real-World Management of Chronic Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Exanthema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pain; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Time Factors; Young Adult | 2018 |
Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study.
Topics: Adult; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Prospective Studies; Pyrimidines; Quality of Life; Survival Analysis; Treatment Outcome | 2018 |
Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Topics: Adolescent; Adult; Child; Child, Preschool; Dasatinib; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies | 2018 |
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.
Topics: Adult; Aged; Aged, 80 and over; Drugs, Generic; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Time Factors | 2018 |
The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
Topics: Antineoplastic Agents; Dasatinib; Drug Administration Schedule; Drug Substitution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Protein Kinase Inhibitors; Pyrimidines | 2019 |
Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; Withholding Treatment | 2019 |
Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.
Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Withholding Treatment | 2019 |
Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Anemia; Female; Follow-Up Studies; Hemoglobins; Humans; Imatinib Mesylate; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Time Factors | 2019 |
Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Registries; Retrospective Studies; Survival Rate | 2019 |
Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian's with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Ethiopia; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Prevalence; Prospective Studies; Socioeconomic Factors; Surveys and Questionnaires | 2019 |
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
Topics: Adult; Antineoplastic Agents; Cardiovascular Diseases; Dasatinib; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Thrombosis; Treatment Outcome | 2019 |
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia.
Topics: Aged; Female; Humans; Imatinib Mesylate; Immunologic Factors; Lenalidomide; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Middle Aged; Treatment Outcome | 2019 |
Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.
Topics: Aged; Chronic Disease; Databases, Factual; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Smoking; Survival Rate | 2019 |
Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Aniline Compounds; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Nitriles; Patient Reported Outcome Measures; Quality of Life; Quinolines; Surveys and Questionnaires | 2019 |
De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Topics: Adult; Aged; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Recurrence; Treatment Outcome | 2019 |
Comparison of the Efficacy of Nilotinib and Imatinib in the Treatment of Chronic Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Agents; China; Female; Humans; Imatinib Mesylate; Interleukin-6; Interleukin-8; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Orosomucoid; Pyrimidines; Treatment Outcome; Young Adult | 2019 |
Effect of imatinib on growth in children with chronic myeloid leukemia.
Topics: Adolescent; Adolescent Development; Body Height; Child; Child Development; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2019 |
Tyrosinekinase inhibition facilitates cooperation of transcription factor SALL4 and ABC transporter A3 towards intrinsic CML cell drug resistance.
Topics: Animals; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription Factors | 2013 |
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2013 |
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Thiazoles | 2013 |
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.
Topics: Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Health Policy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome | 2013 |
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Treatment Outcome; Withholding Treatment | 2013 |
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult | 2013 |
TK inhibitor treatment disrupts growth hormone axis: clinical observations in children with CML and experimental data from a juvenile animal model.
Topics: Adolescent; Animals; Animals, Newborn; Antineoplastic Agents; Benzamides; Body Height; Bone Development; Child; Disease Models, Animal; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Wistar | 2013 |
A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Imatinib Mesylate; Internationality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2013 |
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Piperazines; Polymerase Chain Reaction; Pyrimidines; Retrospective Studies; Survival Rate | 2013 |
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thiazoles | 2013 |
High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cohort Studies; DNA, Neoplasm; Female; Genotype; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Retrospective Studies; Treatment Outcome | 2013 |
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Cytogenetic Analysis; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Time Factors; Treatment Outcome | 2014 |
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2014 |
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Down-Regulation; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome | 2014 |
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Withholding Treatment; Young Adult | 2014 |
Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Cohort Studies; Cross-Sectional Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prospective Studies; Pyrimidines; Quality of Life; Risk Factors; Transplantation, Homologous | 2014 |
Interferon decreases VEGF levels in patients with chronic myeloid leukemia treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Vascular Endothelial Growth Factor A | 2014 |
Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Topics: Adolescent; Adult; Benzamides; Child; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Young Adult | 2014 |
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Time; Treatment Outcome | 2014 |
Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Chemical and Drug Induced Liver Injury; Child; Drug Resistance, Neoplasm; Female; Genotype; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
Older patients with chronic myeloid leukemia (≥65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Topics: Adolescent; Adult; Aged; Benzamides; Child; Child, Preschool; Chromosome Deletion; Chromosomes, Artificial, Bacterial; Chromosomes, Human, Pair 9; Down-Regulation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2014 |
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Glucuronidase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Pyrimidines; Risk; Sensitivity and Specificity; Treatment Outcome; Young Adult | 2014 |
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alternative Splicing; Antineoplastic Agents; Benzamides; Blood Platelets; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; Phenotype; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger; Survival Analysis; Treatment Outcome | 2014 |
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.
Topics: Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Time Factors | 2014 |
Effect of interaction of glutathione S-transferases (T1 and M1) on the hematologic and cytogenetic responses in chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Glutathione Transferase; Heterozygote; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Pyrimidines; Young Adult | 2014 |
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Alanine Transaminase; Aniline Compounds; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Diarrhea; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Myalgia; Nitriles; Pain; Piperazines; Pyrimidines; Quinolines; Vomiting | 2014 |
Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Drug Substitution; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors | 2014 |
Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Synergism; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Young Adult | 2014 |
Efficacy and pharmacologic data of second-generation tyrosine kinase inhibitor nilotinib in BCR-ABL-positive leukemia patients with central nervous system relapse after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Benzamides; Central Nervous System; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2014 |
Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Health Status; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Quality of Life; Treatment Outcome | 2014 |
First-line treatment of 102 chronic myeloid leukemia patients with imatinib: a long-term single institution analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate | 2014 |
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk; Survival Analysis; Thiazoles | 2015 |
Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.
Topics: Adolescent; Benzamides; Child; Child, Preschool; Cytogenetic Analysis; Disease-Free Survival; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2014 |
Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precision Medicine; Prospective Studies; Pyrimidines; Treatment Outcome | 2014 |
Human organic cation transporter 1 protein levels of granulocytes can optimize imatinib therapy in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Flow Cytometry; Gene Expression Regulation, Leukemic; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Organic Cation Transporter 1; Philadelphia Chromosome; Piperazines; Pyrimidines | 2015 |
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic p
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Treatment Outcome; Young Adult | 2014 |
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; China; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2015 |
Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
Topics: Adult; Aged; Apoptosis; Benzamides; Cation Transport Proteins; Drug Resistance, Neoplasm; Enzyme Induction; Female; Gene Expression Regulation, Leukemic; Heme Oxygenase-1; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Neoplasm Proteins; NF-E2-Related Factor 2; Oxidative Stress; Piperazines; Protein Kinase C beta; Protein Kinase Inhibitors; Pyrimidines; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers | 2015 |
Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Stem Cell Transplantation; Survival Rate | 2015 |
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Comorbidity; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
[Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure].
Topics: Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins; Retrospective Studies; Treatment Failure; Treatment Outcome | 2015 |
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Retreatment; Time Factors; Treatment Outcome; Young Adult | 2015 |
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
Topics: Adult; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Survival Rate | 2015 |
Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Organic Cation Transporter 1; Pharmacogenetics; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; RNA, Messenger; RNA, Neoplasm; Treatment Failure | 2015 |
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study.
Topics: Adult; Age Factors; Aged; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Cross-Over Studies; Female; Gastrointestinal Absorption; Healthy Volunteers; Humans; Imatinib Mesylate; Iran; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Plasma; Therapeutic Equivalency; Tissue Distribution; Young Adult | 2016 |
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pilot Projects; Remission Induction | 2015 |
[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Cytogenetics; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors; Remission Induction; Thrombocytopenia; Treatment Outcome | 2015 |
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Family; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Remission Induction; Risk; Survival Analysis; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2016 |
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Genotype; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Receptors, KIR2DL5; Treatment Outcome | 2015 |
Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Body Weight; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrazines; Treatment Outcome; Young Adult | 2016 |
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Topics: Blood Glucose; Cholesterol; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Pyrimidines; Risk Assessment; Treatment Outcome | 2016 |
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Time Factors | 2016 |
Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV.
Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Incidence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Sex Factors | 2016 |
A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Tablets; Therapeutic Equivalency | 2016 |
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aniline Compounds; Cardiotoxicity; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinolines; Retrospective Studies; Risk Factors; Vascular Diseases; Young Adult | 2016 |
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pyridazines; Treatment Outcome | 2016 |
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Topics: Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Pancytopenia; Patient Safety; Pleural Effusion; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Dasatinib; E-Selectin; Female; Genetic Predisposition to Disease; Hemodynamics; Humans; Hypertension, Pulmonary; Hypoxia; Imatinib Mesylate; Intercellular Adhesion Molecule-1; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Male; Middle Aged; Mitochondria; Rats; Reactive Oxygen Species; Vascular Cell Adhesion Molecule-1 | 2016 |
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors | 2016 |
The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index; Survival Rate; Young Adult | 2016 |
Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gene Expression; Germany; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; RNA, Messenger; Treatment Outcome | 2017 |
Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia.
Topics: Case-Control Studies; Cytokines; Dasatinib; Disease-Free Survival; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Lymphocyte Subsets; Protein Kinase Inhibitors; Pyrimidines; Withholding Treatment | 2017 |
Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2018 |
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Young Adult | 2017 |
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Cytarabine; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Intention to Treat Analysis; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Young Adult | 2017 |
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Staging; Retreatment; Treatment Outcome; Young Adult | 2017 |
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2008 |
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors | 2008 |
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Young Adult | 2008 |
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2008 |
Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2008 |
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2009 |
Effective use of imatinib-mesylate in the treatment of relapsed chronic myeloid leukemia after allogeneic transplantation.
Topics: Adolescent; Adult; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult | 2009 |
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Time Factors | 2009 |
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Prospective Studies; Pyrimidines; Risk Factors; Treatment Outcome | 2009 |
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dose-Response Relationship, Drug; Europe; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase
Topics: Adolescent; Adult; Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure; Young Adult | 2009 |
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Topics: Benzamides; Disease Progression; Follow-Up Studies; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2009 |
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Treatment Outcome | 2009 |
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome; Young Adult | 2009 |
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Topics: Adult; Benzamides; Cancer Vaccines; CD4 Lymphocyte Count; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; T-Lymphocyte Subsets; Vaccines, Subunit; Vaccines, Synthetic | 2009 |
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2009 |
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Cytarabine; Diarrhea; Drug Administration Schedule; Edema; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Muscle Cramp; Nausea; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Australia; Benzamides; Drug Resistance, Neoplasm; Europe; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Korea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Treatment Outcome; United States | 2009 |
[Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Time Factors; Young Adult | 2009 |
Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
Topics: Adolescent; Adult; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pharmacogenetics; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger; Treatment Outcome; Young Adult | 2010 |
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Thiazoles; Young Adult | 2009 |
Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous | 2010 |
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2010 |
K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
Topics: Adult; Aged; Aminoquinolines; Benzamides; Cancer Vaccines; Female; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Imiquimod; Immunotherapy; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Piperazines; Pyrimidines; Tumor Burden | 2010 |
Targeted agents for chronic myelogenous leukemia: will that be the end of allogeneic bone marrow transplantation for that disease?
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Disease Progression; Disease-Free Survival; Drug Therapy; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Myeloblastin; Piperazines; Pyrimidines; Recombinant Proteins; Secondary Prevention; Survival Analysis; T-Lymphocytes, Cytotoxic | 2010 |
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Internationality; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Remission Induction; Young Adult | 2010 |
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blast Crisis; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Survival Rate | 2010 |
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Topics: Adolescent; Adult; Aged; Benzamides; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?
Topics: Absorptiometry, Photon; Adiponectin; Adiposity; Analysis of Variance; Benzamides; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imatinib Mesylate; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2010 |
Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Failure; Treatment Outcome; Young Adult | 2010 |
Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2010 |
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Polyethylene Glycols; Pyrimidines; Recombinant Proteins; Remission Induction | 2011 |
Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; China; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2010 |
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Genes, abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2010 |
Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Thiazoles; Treatment Outcome | 2010 |
Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Female; Follow-Up Studies; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; India; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome; Young Adult | 2010 |
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; France; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Long-term follow-up of patients with Philadelphia chromosome-positive chronic myeloid leukemia after stem cell mobilization under imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Time Factors; Young Adult | 2011 |
The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Exanthema; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Proliferation; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Cuba; Cytogenetic Analysis; Female; Genetic Markers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Pyrimidines; Survival Analysis; Young Adult | 2011 |
Clinical value of assessing the response to imatinib monitored by interphase FISH and RQ-PCR for BCR-ABL in peripheral blood for long-term survival of chronic phase CML patients: results of the Niigata CML-multi-institutional co-operative clinical study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Neutrophils; Piperazines; Polymerase Chain Reaction; Pyrimidines; Survival Rate; Time Factors | 2011 |
Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Cells; Bone Marrow Cells; Disease Progression; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Peptide Fragments; Piperazines; Protein Isoforms; Pyrimidines; Survivin; T-Lymphocytes, Cytotoxic; Treatment Outcome; Young Adult | 2011 |
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Odds Ratio; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Time Factors; Treatment Outcome | 2011 |
Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chi-Square Distribution; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Germany; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Young Adult | 2011 |
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction; Survival Rate | 2011 |
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Topics: Adult; Aged; Benzamides; Blood Glucose; Cohort Studies; Constriction, Pathologic; Drug Resistance, Neoplasm; Fasting; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Argentina; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome; Uruguay; Young Adult | 2011 |
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; France; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prospective Studies; Pyrimidines; Survival Analysis | 2011 |
Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers; Drug Dosage Calculations; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polyethylene Glycols; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins; Remission Induction; Risk Factors; Treatment Outcome | 2011 |
Analysis of imatinib in bone marrow and plasma samples of chronic myeloid leukaemia patients using solid phase extraction LC-ESI-MS.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Chromatography, Liquid; Drug Stability; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Spectrometry, Mass, Electrospray Ionization | 2011 |
Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Compassionate Use Trials; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2012 |
Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Curcuma; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitric Oxide; Piperazines; Plant Extracts; Powders; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Topics: Administration, Oral; Antineoplastic Agents; Australia; Benzamides; Brazil; Disease-Free Survival; Drug Administration Schedule; Europe; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Singapore; Survival Rate; Time Factors; Treatment Outcome; United States | 2011 |
Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed.
Topics: Adolescent; Antiviral Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Infant; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate | 2011 |
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Pyrimidines; Quinolines; Treatment Outcome; Young Adult | 2011 |
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission.
Topics: Acute-Phase Proteins; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leptin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipocalin-2; Lipocalins; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Remission Induction | 2012 |
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis.
Topics: Adolescent; Adult; Aged; Benzamides; Child; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Siblings; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2012 |
Expanding Nilotinib Access in Clinical Trials (ENACT), an open-label multicenter study of oral nilotinib in adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase or blast crisis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Compassionate Use Trials; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Pyrimidines; Quality of Life; Quinolines; Young Adult | 2012 |
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Chronic Disease; Dasatinib; Drug Resistance; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Salvage Therapy; Sclerosis; Skin Diseases; Thiazoles; Transplantation, Homologous | 2012 |
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Treatment with interferon alpha prior to discontinuation of imatinib in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Benzamides; Demography; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Withholding Treatment | 2012 |
Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chemokines; Cytokines; Dasatinib; Female; Humans; Imatinib Mesylate; Immunophenotyping; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2012 |
[Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2011 |
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Probability; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2012 |
Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Remodeling; Fanconi Syndrome; Female; Humans; Hyperparathyroidism, Secondary; Hypophosphatemia; Imatinib Mesylate; Kidney Tubules, Proximal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Biological; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Renal Aminoacidurias | 2012 |
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial.
Topics: Adolescent; Adult; Aged; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Tissue Distribution; Treatment Outcome; Young Adult | 2012 |
Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Body Height; Body Mass Index; Child; Female; Growth Disorders; Humans; Imatinib Mesylate; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retrospective Studies; Thyroid Hormones; Time Factors | 2012 |
Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Benzamides; Biomarkers; Bone Density; Calcium; Collagen Type I; Female; Humans; Hyperparathyroidism, Secondary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnesium; Male; Menopause; Middle Aged; Osteocalcin; Parathyroid Hormone; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Smoking | 2012 |
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Remission Induction; Survival Rate; Young Adult | 2012 |
Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2012 |
Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; China; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Genetic Markers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
Topics: Benzamides; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
[A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α].
Topics: Adult; Aged; Benzamides; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission.
Topics: Adult; Benzamides; CD3 Complex; CD56 Antigen; Cytokine-Induced Killer Cells; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines | 2012 |
Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prospective Studies; Pyrimidines; Survival Rate; Time Factors | 2013 |
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biological Availability; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Biological; Piperazines; Pyrimidines; Young Adult | 2013 |
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.
Topics: Absorptiometry, Photon; Adult; Aged; Antineoplastic Agents; Benzamides; Bone and Bones; Bone Density; Bone Remodeling; Female; Femur Neck; Forearm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lumbar Vertebrae; Male; Middle Aged; Organ Specificity; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.
Topics: Adolescent; Benzamides; Biomarkers, Tumor; Bone and Bones; Calcifediol; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Osteocalcin; Piperazines; Pyrimidines; Reference Values | 2012 |
Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Pilot Projects; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2013 |
[Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib].
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Topics: Benzamides; Chronic Disease; Cytogenetic Analysis; Enzyme Inhibitors; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Failure; Treatment Outcome | 2002 |
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Survival Analysis; Transplantation, Homologous | 2002 |
Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2002 |
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Treatment Outcome | 2003 |
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; RNA, Neoplasm | 2003 |
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; DNA Mutational Analysis; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Recurrence, Local; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2002 |
High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Blast Crisis; Chemokines, CC; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Count; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Remission Induction; RNA, Messenger; Stem Cell Transplantation; Transplantation, Homologous; Tumor Cells, Cultured | 2003 |
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Topics: Age Factors; Age of Onset; Antineoplastic Agents; Benzamides; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Patient Selection; Piperazines; Prognosis; Pyrimidines; Splenomegaly; Survival Analysis; Time Factors | 2003 |
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzamides; Blast Crisis; Cell Division; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Orosomucoid; Piperazines; Protein Binding; Pyrimidines; Thymidine; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Failure; Treatment Outcome | 2003 |
Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Survival Rate; Time Factors; Transplantation, Homologous; Treatment Outcome | 2003 |
Imatinib mesylate induces durable complete remission of advanced CML persisting after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Piperazines; Pyrimidines; Remission Induction; Transplantation, Homologous | 2003 |
Morphological effects of imatinib mesylate (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Count; Cytogenetic Analysis; Drug Resistance; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Reticulin; Thrombocytopenia; Treatment Outcome | 2003 |
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Polyethylene Glycols; Pyrimidines; Recombinant Proteins; Risk Assessment; Treatment Outcome | 2003 |
Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
Topics: Adolescent; Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Cytogenetic Analysis; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines | 2003 |
The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Risk Factors; Survival Analysis; Treatment Outcome | 2003 |
Quality of life on imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Quality of Life; Treatment Outcome | 2003 |
Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Cytogenetic Analysis; Disease Progression; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Capsules; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Sex Factors | 2003 |
Normalization of previously shortened telomere length under treatment with imatinib argues against a preexisting telomere length deficit in normal hematopoietic stem cells from patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Benzamides; Female; Granulocytes; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Telomerase; Telomere | 2003 |
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Cytogenetic Analysis; Drug Resistance; Fibrosis; Fusion Proteins, bcr-abl; Histiocytes; Humans; Hyperplasia; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Megakaryocytes; Piperazines; Pyrimidines; Reticulin; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.
Topics: Adolescent; Adult; Agammaglobulinemia; Aged; Antineoplastic Agents; Autoimmunity; Benzamides; Drug Resistance; Drug Tolerance; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoglobulins; Immunophenotyping; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2003 |
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytosine; Dioxolanes; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy | 2003 |
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Safety; Thrombocytopenia | 2003 |
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Drug Administration Schedule; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2003 |
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa.
Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Pyrimidines; Survival Analysis; Treatment Failure; Treatment Outcome | 2003 |
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2003 |
Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.
Topics: Adult; Aged; Benzamides; Blood Cell Count; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Immunosuppressive Agents; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Probability; Prognosis; Pyrimidines; Recurrence; Treatment Failure | 2004 |
Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; Treatment Outcome | 2003 |
FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Metaphase; Middle Aged; Neutrophils; Piperazines; Pyrimidines; Translocation, Genetic | 2003 |
Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Bone Marrow; Cross-Over Studies; Cytarabine; Cytogenetics; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases; Piperazines; Prognosis; Protein Structure, Tertiary; Pyrimidines; Treatment Outcome | 2003 |
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cross-Over Studies; Cytarabine; Cytogenetics; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Recurrence; Risk Factors; RNA, Messenger; Treatment Outcome | 2003 |
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2003 |
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Survival Analysis; Time Factors; Transplantation, Homologous; Vincristine | 2004 |
Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benzamides; Disease-Free Survival; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Spain; Treatment Outcome | 2003 |
Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Pyrimidines; Recurrence; Remission Induction; Survival Analysis | 2004 |
Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Disease-Free Survival; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
Topics: Administration, Oral; Adult; Area Under Curve; Benzamides; Drug Interactions; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Simvastatin | 2003 |
Cytogenetic clonal evolution alone in CML relapse post-transplantation does not adversely affect response to imatinib mesylate treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Combined Modality Therapy; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2004 |
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Bone Marrow Cells; Follow-Up Studies; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2004 |
A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chrom
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction | 2003 |
Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recombinant Proteins | 2004 |
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Neutropenia; Piperazines; Platelet Count; Pyrimidines; Risk Factors; Thrombocytopenia; Treatment Outcome | 2004 |
Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
Topics: Acute Disease; Adolescent; Adult; Benzamides; Combined Modality Therapy; Disease Progression; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prospective Studies; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Transplantation, Homologous | 2004 |
Pharmacogenomic analysis of cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; RNA, Neoplasm; Treatment Outcome | 2004 |
[Imatinib-New, molecular therapeutic possibility in chronic myeloid leukemia. The IRIS Study].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2004 |
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Exanthema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pigmentation Disorders; Piperazines; Pyrimidines | 2004 |
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Topics: Administration, Oral; Adult; Aged; Benzamides; Biological Availability; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrimidines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2004 |
[Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Quality of Life; Treatment Outcome | 2004 |
[Bone marrow morphologic features in patients treated with imatinib for Philadelphia chromosome positive chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow Cells; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2004 |
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Pyrimidines; Treatment Outcome | 2004 |
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recombinant Proteins | 2004 |
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Topics: Adult; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Predictive Value of Tests; Probability; Prognosis; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Salvage Therapy | 2004 |
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2005 |
Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment.
Topics: Age Factors; Aged; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2005 |
U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Blast Crisis; Dose-Response Relationship, Drug; Drug Approval; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2005 |
Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Monitoring, Physiologic; Neutrophils; Piperazines; Pyrimidines | 2005 |
Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Recurrence; Treatment Outcome | 2005 |
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chromosome Aberrations; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2005 |
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Combination of imatinib mesylate with autologous leukocyte-derived heat shock protein and chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cancer Vaccines; Cytotoxicity, Immunologic; Feasibility Studies; Female; Heat-Shock Proteins; Humans; Imatinib Mesylate; Interferon-gamma; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; Piperazines; Pyrimidines; T-Lymphocytes; Treatment Outcome | 2005 |
Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
Topics: Adolescent; Adult; Aged; Benzamides; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2005 |
Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bilirubin; Blood Platelets; Creatinine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Male; Middle Aged; Neutrophils; Piperazines; Pyrimidines; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous | 2005 |
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Topics: Adult; Antineoplastic Agents; Benzamides; Feasibility Studies; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maximum Tolerated Dose; Piperazines; Polymerase Chain Reaction; Prospective Studies; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome | 2005 |
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Chronic Disease; Drug Administration Schedule; Europe; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Stem Cell Transplantation; Survival Rate; Treatment Outcome | 2006 |
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Farnesyltranstransferase; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Piperidines; Pyridines; Pyrimidines | 2006 |
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction | 2006 |
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines; Remission Induction; RNA, Messenger; Time Factors | 2006 |
In vivo effects of imatinib mesylate on human haematopoietic progenitor cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brain Neoplasms; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2006 |
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Endpoint Determination; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2006 |
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Survival Rate | 2006 |
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neutropenia; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Jejunostomy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Short Bowel Syndrome | 2006 |
Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
Topics: Adult; Aged; Aneuploidy; Antineoplastic Agents; Benzamides; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2006 |
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Withholding Treatment | 2007 |
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Dasatinib; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Staging; Piperazines; Prognosis; Protein Kinases; Protein Structure, Tertiary; Pyrimidines; Treatment Outcome | 2006 |
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Drug Administration Schedule; Drug Tolerance; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines | 2007 |
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Thiazoles; Treatment Failure | 2007 |
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Care Planning; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Treatment Outcome | 2006 |
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Benzamides; Blast Crisis; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure; Treatment Outcome | 2007 |
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
Topics: Administration, Oral; Adult; Aged; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recovery of Function; src-Family Kinases; Thiazoles | 2007 |
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Failure | 2007 |
BCR-ABL mutant kinetics in CML patients treated with dasatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.
Topics: Antigens, CD34; Apoptosis; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Tumor Stem Cell Assay | 2007 |
MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.
Topics: Benzamides; Butadienes; Dasatinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2007 |
Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse.
Topics: Adult; Benzamides; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Depletion; Male; Middle Aged; Neoplasm, Residual; Pilot Projects; Piperazines; Pyrimidines; Recurrence; Risk; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2007 |
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2007 |
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Cytogenetic Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Creatine Kinase; Cytogenetic Analysis; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2007 |
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Topics: Adolescent; Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Codon; Dasatinib; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Structure-Activity Relationship; Thiazoles | 2007 |
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Etoposide; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2007 |
Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tetradecanoylphorbol Acetate; Treatment Outcome | 2007 |
Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Density Conservation Agents; Cytogenetic Analysis; Diphosphonates; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; ras Proteins; Remission Induction; Signal Transduction; Zoledronic Acid | 2007 |
Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cohort Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metabolic Clearance Rate; Middle Aged; Organic Anion Transporters; Phenotype; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
Topics: Adult; Aged; Benzamides; Chromosome Aberrations; Clone Cells; Dasatinib; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Salvage Therapy; Thiazoles | 2007 |
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Patient Dropouts; Piperazines; Prospective Studies; Pyrimidines; Time Factors; Transcription, Genetic; Treatment Outcome | 2007 |
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Vomiting | 2007 |
Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study.
Topics: Adult; Antineoplastic Agents; Benzamides; Cancer Vaccines; CD4-Positive T-Lymphocytes; Dendritic Cells; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peptides; Piperazines; Pyrimidines; T-Lymphocytes | 2007 |
Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome | 2008 |
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chronic Disease; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2007 |
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.
Topics: Adult; Benzamides; Cohort Studies; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Organic Cation Transporter 1; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Risk Factors; Time Factors | 2007 |
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Drug Administration Schedule; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pleural Effusion; Pyrimidines; Radiography; Risk Factors; Thiazoles; Treatment Failure | 2007 |
Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Bone Marrow; Disease Progression; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Primary Myelofibrosis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Salvage Therapy | 2007 |
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrimidines; Quinolones | 2007 |
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Middle Aged; Piperazines; Pyrimidines; Secondary Prevention; Transplantation, Homologous; Treatment Outcome | 2007 |
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Failure | 2008 |
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict se
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; RNA, Messenger; Sensitivity and Specificity | 2007 |
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Communicable Diseases; Cytarabine; Cytogenetic Analysis; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Tests; Humans; Imatinib Mesylate; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mortality; Piperazines; Pyrimidines | 2008 |
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Cytogenetics; Disease-Free Survival; Follow-Up Studies; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Pyrimidines; Time Factors; Treatment Outcome | 2008 |
Complete molecular responses are achieved after reduced intensity stem cell transplantation and donor lymphocyte infusion in chronic myeloid leukemia.
Topics: Adult; Benzamides; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Length of Stay; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Virus Activation | 2008 |
Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Topics: Administration, Oral; Adolescent; Aging; Antineoplastic Agents; Benzamides; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Biological; Multivariate Analysis; Piperazines; Pyrimidines; Young Adult | 2009 |
Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thyroid Diseases; Thyroidectomy | 2008 |
Therapy adapted to molecular response in patients with chronic myelogenous leukaemia in first chronic phase: results of the Duesseldorf study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Cell Count; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; RNA, Messenger; Treatment Outcome | 2008 |
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Feasibility Studies; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Thionucleotides; Treatment Failure | 2008 |
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Analysis; Thiazoles; Treatment Failure | 2008 |
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2001 |
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Cell Count; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction | 2001 |
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction | 2001 |
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Topics: Administration, Oral; Analysis of Variance; Antineoplastic Agents; Benzamides; Blood Cell Count; Cytogenetics; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Regression Analysis | 2002 |
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Blood Cells; Bone Marrow; Cytogenetic Analysis; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome | 2002 |
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Cell Count; Cell Differentiation; Cytogenetic Analysis; Fibrosis; Hematopoiesis; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Necrosis; Piperazines; Pyrimidines | 2002 |
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytogenetic Analysis; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome | 2002 |
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blood Cell Count; Cytarabine; Cytogenetic Analysis; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome | 2002 |
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Cell Count; Combined Modality Therapy; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transplantation, Autologous; Treatment Outcome | 2002 |
3511 other study(ies) available for imatinib mesylate and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Discovery of pyrrole derivatives for the treatment of glioblastoma and chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Female; Glioblastoma; Heterocyclic Compounds; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methane; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Polymerization; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2021 |
Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of 5 Tyrosine Kinase Inhibitors and 2 Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2022 |
Management of chronic myeloid leukemia presenting with isolated thrombocytosis and complex Philadelphia chromosome: A case report.
Topics: Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Thrombocytosis; Young Adult | 2021 |
Quality of Life Improvements in Patients With Chronic Myeloid Leukemia After Stopping Long-Term Therapy: Who Can Benefit the Most?
Topics: Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Quality of Life | 2022 |
Association of creatine kinase elevation with clinical outcomes in chronic myeloid leukemia: a retrospective cohort study.
Topics: Creatine Kinase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
[What is the best treatment for chronic-phase CML?]
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2021 |
Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study.
Topics: Aged; Aged, 80 and over; Dasatinib; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2021 |
Focal segmental glomerulosclerosis and concurrent glomerular microangiopathy after long-term imatinib administration.
Topics: Aged; Endothelial Cells; Female; Glomerulosclerosis, Focal Segmental; Humans; Imatinib Mesylate; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proteinuria | 2022 |
Regulation of miR-126 and miR-122 Expression and Response of Imatinib Treatment on Its Expression in Chronic Myeloid Leukemia Patients.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2021 |
Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia.
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
New insight into the catalytic -dependent and -independent roles of METTL3 in sustaining aberrant translation in chronic myeloid leukemia.
Topics: Adenosine; Catalysis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methyltransferases; Models, Biological; Protein Biosynthesis; Proto-Oncogene Proteins c-myc; RNA-Binding Proteins; RNA, Messenger; Up-Regulation | 2021 |
Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.
Topics: Antigens, CD34; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phosphate-Binding Proteins; Poly(ADP-ribose) Polymerases; Pore Forming Cytotoxic Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyroptosis; Small Molecule Libraries; Thiophenes | 2021 |
Proteomics analysis reveals the correlation of programmed ROS-autophagy loop and dysregulated G1/S checkpoint with imatinib resistance in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proteomics; Reactive Oxygen Species | 2022 |
Massive retinal infiltrates as the presenting sign of chronic myeloid leukemia: Clinical and imaging features of leukemic retinopathy.
Topics: Animals; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Retina; Retinal Diseases; Retinal Hemorrhage; Vision Disorders | 2023 |
Outcomes and toxicity of allogeneic hematopoietic cell transplantation in chronic myeloid leukemia patients previously treated with second-generation tyrosine kinase inhibitors: a prospective non-interventional study from the Chronic Malignancy Working Pa
Topics: Dasatinib; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prospective Studies; Protein Kinase Inhibitors | 2022 |
Investigation on the interaction behavior of afatinib, dasatinib, and imatinib docked to the BCR-ABL protein.
Topics: Afatinib; Antineoplastic Agents; Catalytic Domain; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methionine; Molecular Docking Simulation; Mutation; Quantum Theory; Sulfur | 2021 |
Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Disease Models, Animal; Disease Progression; DNA Breaks, Double-Stranded; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Gene Ontology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Mice, Inbred C57BL; MicroRNAs; RNA, Messenger; Up-Regulation | 2021 |
CML Chapter.
Topics: Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life | 2021 |
MiR-125a-3p and MiR-320b Differentially Expressed in Patients with Chronic Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Imatinib Mesylate.
Topics: Adult; Antineoplastic Agents; Computational Biology; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Protein Interaction Maps; Up-Regulation | 2021 |
Concurrence of imatinib-induced massive pleural/pericardial effusion and Campylobacter bacteremia in an adolescent with chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Bacteremia; Campylobacter; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pericardial Effusion | 2022 |
Aplastic anemia secondary to tyrosine kinase inhibitor therapy in a patient with chronic myeloid leukemia.
Topics: Adult; Anemia, Aplastic; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Naphthoquinones; Protein Kinase Inhibitors; Signal Transduction; STAT5 Transcription Factor | 2021 |
Combination therapy using TGF-β1 and STI-571 can induce apoptosis in BCR-ABL oncogene-expressing cells.
Topics: Apoptosis; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Transforming Growth Factor beta1 | 2021 |
CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome.
Topics: Adolescent; ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Biomarkers, Tumor; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2021 |
No margin for non-adherence: Probabilistic kaplan-meier modeling of imatinib non-adherence and treatment response in CML (ADAGIO study).
Topics: Antineoplastic Agents; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Models, Statistical; Prospective Studies; Risk Factors; Treatment Outcome | 2021 |
Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia.
Topics: Aged; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Protein Kinase Inhibitors | 2021 |
Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance.
Topics: Cell Line; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HEK293 Cells; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors | 2021 |
Imatinib can act as an Allosteric Activator of Abl Kinase.
Topics: Allosteric Regulation; Allosteric Site; Antineoplastic Agents; Catalytic Domain; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Protein Kinase Inhibitors | 2022 |
Vitreous hemorrhage: A rare ophthalmic adverse effect due to imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Drug-Related Side Effects and Adverse Reactions; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Vitreous Hemorrhage | 2022 |
Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.
Topics: Adult; Antineoplastic Agents; Bayes Theorem; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines; United States | 2022 |
Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; RNA, Circular; Signal Transduction | 2021 |
Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors.
Topics: Cell Proliferation; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Genetic Therapy; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase 14; Protein Kinase Inhibitors | 2021 |
Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Simvastatin; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
Antimetabolic cooperativity with the clinically approved l-asparaginase and tyrosine kinase inhibitors to eradicate CML stem cells.
Topics: Animals; Apoptosis; Asparaginase; Asparagine; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2022 |
[Transcriptome Analysis of Chronic Myelogenous Leukemia Cell Line with Imatinib Resistance].
Topics: Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2021 |
[Clinical Effect of Tyrosine Kinase Inhibitors in the Treatment of P230 Chronic Myeloid Leukemia].
Topics: Adult; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Young Adult | 2021 |
Expression dynamics of the immune mediators ARG1, TBET, CIITA, IL10 and TGFB1 in chronic myeloid leukaemia patients during the first year of imatinib therapy.
Topics: Adult; Antineoplastic Agents; Arginase; Biomarkers, Pharmacological; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Immunologic Factors; Interleukin-10; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nuclear Proteins; Protein Kinase Inhibitors; Trans-Activators; Transcriptome; Transforming Growth Factor beta1 | 2022 |
Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2022 |
Anticancer Activity and Molecular Mechanism of
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Momordica; Myeloid Cell Leukemia Sequence 1 Protein; Plant Extracts; Xenograft Model Antitumor Assays | 2022 |
Large-scale topological disruption of chromosome territories 9 and 22 is associated with nonresponse to treatment in CML.
Topics: Chromosomes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2022 |
DIA-Based Proteomics Identifies IDH2 as a Targetable Regulator of Acquired Drug Resistance in Chronic Myeloid Leukemia.
Topics: Doxorubicin; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proteomics | 2022 |
Chronic Myeloid Leukemia in a Patient with Previous Idiopathic Thrombocytopenic Purpura: How to Manage Imatinib Together with Eltrombopag.
Topics: Benzoates; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Purpura, Thrombocytopenic, Idiopathic; Pyrazoles | 2021 |
A bis-pyridinium fullerene derivative induces apoptosis through the generation of ROS in BCR-ABL-positive leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Fullerenes; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reactive Oxygen Species | 2022 |
Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Smad4 Protein | 2022 |
CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Daunorubicin; Drug Synergism; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; NADPH Oxidase 4; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Sp1 Transcription Factor; Sulfonamides | 2022 |
The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib.
Topics: Apoptosis; Cannabidiol; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; TRPV Cation Channels | 2022 |
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Real-Time Polymerase Chain Reaction; Technology | 2022 |
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Topics: Dasatinib; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myocardial Infarction; Protein Kinase Inhibitors | 2022 |
Indication-Specific Generic Uptake of Imatinib Demonstrates the Impact of Skinny Labeling.
Topics: Adult; Aged; Cross-Sectional Studies; Drugs, Generic; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medicare; United States | 2022 |
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors.
Topics: Animals; Antineoplastic Agents; Chronic Disease; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immune Checkpoint Inhibitors; Interleukin-1 Receptor-Associated Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Mice; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors | 2022 |
Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia.
Topics: Adult; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; RNA, Antisense; RNA, Neoplasm | 2022 |
Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate.
Topics: Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged | 2023 |
Assessment of Imatinib as a Primary Treatment of Chronic Myeloid Leukemia in Chronic Phase: a Cohort Study.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome | 2023 |
HucMSC exosomes promoted imatinib-induced apoptosis in K562-R cells via a miR-145a-5p/USP6/GLS1 axis.
Topics: Adult; Apoptosis; Child; Drug Resistance, Neoplasm; Exosomes; Glutaminase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Ubiquitin Thiolesterase | 2022 |
Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Kenya; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2022 |
Waking up CML leukemia stem cells for the kill.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Stem Cells | 2022 |
Impact of metformin on tyrosine kinase inhibitor response in chronic myeloid leukemia.
Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Metformin; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Discovery of Anticancer Hybrid Molecules by Supervised Machine Learning Models and
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Supervised Machine Learning | 2022 |
Ex vivo platelet morphology assessment of chronic myeloid leukemia patients before and after Imatinib treatment.
Topics: Antineoplastic Agents; Blood Platelets; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2022 |
Patient characteristics and management practices in chronic myeloid leukemia in Turkey: reflections from an expert meeting.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life; Turkey | 2022 |
Paradoxical Pandora's box of pigmentary side effects by imatinib mesylate in case of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2022 |
Impact of Variants in the
Topics: Benzamides; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Hydroxymethyl and Formyl Transferases; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multienzyme Complexes; Nucleotide Deaminases; Piperazines; Pyrimidines; Transcription Factors; Translocation, Genetic | 2022 |
Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls.
Topics: Antineoplastic Agents; Echocardiography; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nigeria; Protein Kinase Inhibitors | 2022 |
FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
Topics: Animals; Apoptosis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; NF-kappa B; Protein Kinase Inhibitors; Proteins | 2022 |
Asymptomatic chronic-phase chronic myeloid leukemia BCR-ABL. (+) without splenomegaly: A case report.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Splenomegaly | 2022 |
TRIB2 regulates the expression of miR‑33a‑5p through the ERK/c‑Fos pathway to affect the imatinib resistance of chronic myeloid leukemia cells.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; MicroRNAs; Signal Transduction | 2022 |
MiR-199a-3p Overexpression Suppressed Cell Proliferation and Sensitized Chronic Myeloid Leukaemia Cells to Imatinib by Inhibiting mTOR Signalling.
Topics: Apoptosis; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases; MicroRNAs; Protein-Tyrosine Kinases; TOR Serine-Threonine Kinases | 2022 |
Pediatric Chronic Myelogenous Leukemia in T-lineage Blast Crisis: A Reminder in Relevance.
Topics: Blast Crisis; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 2022 |
Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB.
Topics: alpha-Crystallin B Chain; Aminopyridines; Apoptosis; Benzamides; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2022 |
Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines | 2022 |
Hsa-miR-181a-5p, hsa-miR-182-5p, and hsa-miR-26a-5p as potential biomarkers for BCR-ABL1 among adult chronic myeloid leukemia treated with tyrosine kinase inhibitors at the molecular response.
Topics: Adult; Biomarkers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Protein Kinase Inhibitors | 2022 |
LncRNA CCAT2 expression at diagnosis predicts imatinib response in chronic phase chronic myeloid leukemia patients.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Leukocytes, Mononuclear; RNA, Long Noncoding | 2022 |
Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
Topics: Apoptosis; Cell Cycle; Chronic Disease; Cytokines; Disease Progression; DNA; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Surveys and Questionnaires; Tumor Suppressor Protein p14ARF | 2022 |
Skin and soft tissue infections in adolescent chronic myeloid leukemia under dasatinib treatment.
Topics: Adolescent; Adult; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Soft Tissue Infections | 2022 |
The association between FOXO3a rs4946936 gene polymorphism and the levels of FOXO3a among chronic granulocytic leukemia patients treated with imatinib mesylate.
Topics: Cross-Sectional Studies; Forkhead Box Protein O3; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2021 |
[Prevalence of Adverse Effects of Tyrosine Kinase Inhibitors Used in Management of Chronic Myeloid Leukemia at Sidi Bel-Abbès University Hospital Center].
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Hospitals, University; Humans; Iatrogenic Disease; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Prevalence; Protein Kinase Inhibitors; Protein Kinases; Retrospective Studies | 2022 |
In silico design and computational evaluation of novel 2-arylaminopyrimidine-based compounds as potential multi-targeted protein kinase inhibitors: application for the native and mutant (T315I) Bcr-Abl tyrosine kinase.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Catalytic Domain; Computer Simulation; Drug Design; Fusion Proteins, bcr-abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; Machine Learning; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Protein Kinase Inhibitors; Pyrimidines | 2023 |
Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China.
Topics: China; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Topics: Adolescent; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies; Young Adult | 2022 |
Long-term outcomes of patients with Chronic Myeloid Leukemia who commenced treatment with imatinib: a 20-year single-centre experience.
Topics: Antineoplastic Agents; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate.
Topics: Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Female; Hand Strength; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nutritional Status; Piperazines; Pyrimidines | 2022 |
Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
Topics: Antineoplastic Agents; Cell Line; CRISPR-Associated Protein 9; CRISPR-Cas Systems; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nucleotides; Oligodeoxyribonucleotides; Philadelphia Chromosome; Poly (ADP-Ribose) Polymerase-1; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; RNA, Guide, Kinetoplastida | 2022 |
Co-variates associated with outcomes of tyrosine kinase-inhibitor therapy in persons with chronic myeloid leukaemia initially presenting in accelerated phase.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome | 2022 |
Anti-Cancer Role of Dendrosomal Nano Solanine in Chronic Myelogenous Leukemia Cell Line through Attenuation of PI3K/AKT/mTOR Signaling Pathway and Inhibition of hTERT Expression.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Messenger; Signal Transduction; Solanine; TOR Serine-Threonine Kinases | 2023 |
Predictive Factors for Molecular Response in Chronic Myeloid Leukemia: Reduction Ratio and Halving Time of
Topics: Chronic Disease; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia.
Topics: Chronic Disease; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Protein Kinase Inhibitors | 2022 |
Outcome prediction of chronic myeloid leukemia (CML) in children.
Topics: Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2022 |
Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib.
Topics: Activins; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Apoptosis; Cell Differentiation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Lectins, C-Type; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metallothionein; p38 Mitogen-Activated Protein Kinases | 2022 |
Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Polymorphism, Single Nucleotide | 2022 |
Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pain; Quality of Life | 2022 |
Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Real-Time Polymerase Chain Reaction | 2022 |
[Dose optimization: an individualized treatment strategy for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2022 |
Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type-B receptor 4.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Ephrins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Piperidines; Quinazolines | 2022 |
Targeting UPR signaling pathway by dasatinib as a promising therapeutic approach in chronic myeloid leukemia.
Topics: Antineoplastic Agents; CCAAT-Enhancer-Binding Proteins; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction; Ubiquitin-Protein Ligases; Unfolded Protein Response | 2022 |
Genome‑wide expression and methylation analyses reveal aberrant cell adhesion signaling in tyrosine kinase inhibitor‑resistant CML cells.
Topics: Cell Adhesion; Drug Resistance, Neoplasm; Fibronectins; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methylation; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction | 2022 |
The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia.
Topics: Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; S-Phase Kinase-Associated Proteins | 2022 |
Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2022 |
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
Topics: Adult; Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Recurrence | 2022 |
Peptide-based targeted cancer therapeutics: Design, synthesis and biological evaluation.
Topics: Antineoplastic Agents; Glioblastoma; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peptides; Protein Kinase Inhibitors; Tyrosine | 2022 |
Itrifal-e-Aftimoon potentiates imatinib-induced anti-leukemic effect by influencing FAK/STAT/Akt/ERK signalling pathways against chronic myeloid leukaemia in vitro.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-akt | 2022 |
A Ten-Year Experience of Treating Chronic Myeloid Leukemia in Rural Rwanda: Outcomes and Insights for a Changing Landscape.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Retrospective Studies; Rwanda; Young Adult | 2022 |
Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Topics: Antineoplastic Agents; Dasatinib; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Pleural Effusion; Prospective Studies; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia.
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Recurrence; Remission Induction; Treatment Outcome | 2022 |
Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Doxorubicin; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Ketoconazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2022 |
Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission.
Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission Induction | 2022 |
Prevalence of therapeutic drug monitoring and adherence to imatinib in chronic myeloid leukemia in Japan.
Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Gout Suppressants; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Piperazines; Prevalence; Protein Kinase Inhibitors; Pyrimidines | 2022 |
Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia.
Topics: Aldosterone; Angiotensins; Antihypertensive Agents; Enzyme Inhibitors; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Renin; Retrospective Studies | 2022 |
Novel pyrazolo[3,4-d]pyrimidines as dual Src/Bcr-Abl kinase inhibitors: Synthesis and biological evaluation for chronic myeloid leukemia treatment.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors.
Topics: Antigens, CD34; Apoptosis; Cell Line, Tumor; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Stem Cells; Up-Regulation | 2022 |
The mRNA Expression of
Topics: Adult; Antineoplastic Agents; Apoptosis; Case-Control Studies; Child; Humans; Imatinib Mesylate; Iran; Janus Kinase 3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; RNA, Messenger; Sequestosome-1 Protein | 2023 |
Impact of emerging ACA on survival in chronic myeloid leukemia (CML).
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2022 |
Real-world therapeutic response and tyrosine kinase inhibitor discontinuation in chronic phase-chronic myeloid leukemia: data from the French observatory.
Topics: Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
circCRKL, a circRNA derived from CRKL, regulates BCR-ABL via sponging miR-877-5p to promote chronic myeloid leukemia cell proliferation.
Topics: Animals; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; MicroRNAs; RNA, Circular; RNA, Small Interfering | 2022 |
KIF23 promotes autophagy-induced imatinib resistance in chronic myeloid leukaemia through activating Wnt/β-catenin pathway.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; Wnt Signaling Pathway | 2022 |
Gene Expression Landscape of Chronic Myeloid Leukemia K562 Cells Overexpressing the Tumor Suppressor Gene PTPRG.
Topics: Drug Resistance, Neoplasm; Gene Expression; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoric Monoester Hydrolases; Protein Kinase Inhibitors; Receptor-Like Protein Tyrosine Phosphatases, Class 5; Transcription Factors | 2022 |
A Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Assay Identifies Nilotinib as an Inhibitor of Inflammation in Acute Myeloid Leukemia.
Topics: Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Protein Kinase Inhibitors; Proteome; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2022 |
Real-world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience.
Topics: Australia; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.
Topics: Cohort Studies; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Prospective Studies | 2022 |
Targeting MDC1 promotes apoptosis and sensitizes Imatinib resistance in CML cells by mainly disrupting non-homologous end-joining repair.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Cycle Proteins; DNA Repair; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2022 |
Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; China; Diarrhea; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines | 2022 |
Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.
Topics: Adult; Aged; Boron Compounds; Bortezomib; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Glycine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors | 2022 |
Design, semi-synthesis and examination of new gypsogenin derivatives against leukemia via Abl tyrosine kinase inhibition and apoptosis induction.
Topics: Apoptosis; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2022 |
The Application of Virtual Therapeutic Drug Monitoring to Assess the Pharmacokinetics of Imatinib in a Chinese Cancer Population Group.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Monitoring; East Asian People; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Population Groups; Pyrimidines | 2023 |
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the "GRUPPO TRIVENETO LMC".
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Remission Induction | 2023 |
Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biological Products; Cell Line, Tumor; Cell Proliferation; Deubiquitinating Enzymes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Proteasome Endopeptidase Complex; Ubiquitin Thiolesterase | 2023 |
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies; Tyrosine Kinase Inhibitors | 2023 |
Volumetric dried blood microsampling for monitoring imatinib mesylate therapy: Method development and clinical application in patients with chronic myeloid leukemia.
Topics: Adult; Child; Chromatography, Liquid; Chronic Disease; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2023 |
[The Evolution of the Treatment of Chronic Myelogenous Leukemia].
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors | 2022 |
EVI1 upregulates PTGS1 (COX1) and decreases the action of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia cells.
Topics: Apoptosis; Cyclooxygenase 1; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
ACSL1 promotes imatinib-induced chronic myeloid leukemia cell senescence by regulating SIRT1/p53/p21 pathway.
Topics: Apoptosis; Cellular Senescence; Coenzyme A; Coenzyme A Ligases; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligases; Protein Kinase Inhibitors; Sirtuin 1; Tumor Suppressor Protein p53 | 2022 |
Adverse Reaction Profiles Related to Gastrointestinal Bleeding Events Associated with BCR-ABL Tyrosine Kinase Inhibitors.
Topics: Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines | 2022 |
Higher neutrophil counts are associated with successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
Topics: Aged; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neutrophils; Protein Kinase Inhibitors; Retrospective Studies | 2022 |
Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Protein Kinase Inhibitors; Rituximab; Treatment Outcome | 2023 |
Long-Term Molecular Remission after Treatment with Imatinib in a Chronic Myeloid Leukemia Patient with Extreme Thrombocytosis Harboring Rare e14a3 (b3a3) BCR::ABL1 Transcript: A Case Report.
Topics: Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission Induction; Thrombocytosis | 2022 |
Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course.
Topics: Adolescent; Adult; Anemia; Antineoplastic Agents; Child; Hemoglobins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prevalence; Prognosis; Protein Kinase Inhibitors | 2023 |
Improvement of immune thrombocytopenia with imatinib therapy following chronic myeloid leukemia.
Topics: Adrenal Cortex Hormones; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prednisolone; Protein Kinase Inhibitors; Purpura, Thrombocytopenic, Idiopathic; Thrombocytopenia | 2023 |
Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Topics: Cell Line; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets | 2023 |
Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.
Topics: Ado-Trastuzumab Emtansine; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastectomy; Maytansine; Receptor, ErbB-2; Trastuzumab | 2022 |
Cytogenetical and hematological analysis of chronic myelogenous leukemia patients with a novel case 52XX, t (1;9;22) (q23.3; q34; q11.2), +6, +8, i(9) (q10;q10), +18,+19,+21+der22 t(9;22)(q34;q11).
Topics: Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Translocation, Genetic | 2022 |
A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia.
Topics: Chronic Disease; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Switzerland | 2022 |
Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells.
Topics: Animals; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Mice; Protein Kinase Inhibitors; Signal Transduction; STAT5 Transcription Factor | 2022 |
Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Treatment Outcome | 2023 |
Reply to "Plasma imatinib trough levels for predicting efficacy and toxicity in patients with chronic myeloid leukemia in chronic phase: Still a matter of debate!"
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2023 |
A Central Contribution of TG2 Activity to the Antiproliferative and Pro-Apoptotic Effects of Caffeic Acid in K562 Cells of Human Chronic Myeloid Leukemia.
Topics: Apoptosis; Caffeic Acids; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2022 |
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: COVID-19; COVID-19 Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tyrosine Kinase Inhibitors | 2023 |
miR-495-3p sensitizes BCR-ABL1-expressing leukemic cells to tyrosine kinase inhibitors by targeting multidrug resistance 1 gene in T315I mutated cells.
Topics: Adenosine Triphosphate; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy.
Topics: Adult; Antineoplastic Agents; Dasatinib; Financial Stress; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life; Retrospective Studies | 2023 |
Attenuated Dose Dasatinib in Newly Diagnosed Chronic Myeloid Leukemia Chronic Phase Patients in India.
Topics: Adult; Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Cost-effectiveness analysis of dasatinib versus imatinib in pediatric philadelphia chromosome-positive acute lymphoblastic leukemia patients in China.
Topics: Child; China; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years | 2022 |
Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating DNA damage repair dependent on ATM-γH2AX-MDC1.
Topics: Animals; Cell Proliferation; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Sincalide | 2022 |
Inequality in Drug Utilization among Chronic Myeloid Leukaemia Patients in Malaysia: A Cost-Utility Analysis.
Topics: Antineoplastic Agents; Chronic Disease; Cost-Benefit Analysis; Dasatinib; Drug Utilization; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Protein Kinase Inhibitors; Pyrimidines; Quality of Life | 2022 |
Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2023 |
A Study to Explore the Role of IDH1 (R132) Mutation on Imatinib Toxicity and Effect of ABCG2/OCT1 Expression on N-Desmethyl Imatinib Plasma Level in Egyptian Chronic Myeloid Leukemia Patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Egypt; Humans; Imatinib Mesylate; Isocitrate Dehydrogenase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Prospective Studies; Tandem Mass Spectrometry | 2023 |
Focal Segmental Sclerosis Associated with the Novel Multi-tyrosine Kinase Inhibitor Ponatinib.
Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Sclerosis; Tyrosine Kinase Inhibitors | 2023 |
Insights into dasatinib use and outcomes in real-world patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors | 2023 |
Impact of Tyrosine Kinase Inhibitors Applied for First-Line Chronic Myeloid Leukemia Treatment on Platelet Function in Whole Blood of Healthy Volunteers In Vitro.
Topics: Adenosine Triphosphate; Adult; Arachidonic Acid; Dasatinib; Healthy Volunteers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Tyrosine Kinase Inhibitors | 2023 |
Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia.
Topics: Blood Glucose; Cardiovascular Diseases; Fluorodeoxyglucose F18; Glucose; Glycogen; Humans; Hyperglycemia; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pyrimidines; Tyrosine Kinase Inhibitors | 2023 |
Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cytogenetic Analysis; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Polymorphism, Single Nucleotide; Smoking; Treatment Outcome | 2023 |
Is it time to reconsider molecular response milestones in chronic myeloid leukemia?
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Protein Kinase Inhibitors | 2023 |
[Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Topics: Aged; Aged, 80 and over; East Asian People; Female; Humans; Imatinib Mesylate; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Tyrosine Kinase Inhibitors | 2022 |
Children with chronic myeloid leukaemia treated with front-line imatinib have a slower molecular response and comparable survival compared with adults: a multicenter experience in Taiwan.
Topics: Adult; Antineoplastic Agents; Child; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Taiwan; Treatment Outcome | 2023 |
Myricetin is effective and selective in inhibiting imatinib-resistant chronic myeloid leukemia stem and differentiated cells through targeting eIF4E.
Topics: Animals; Apoptosis; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-4E; Flavonoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice | 2023 |
[Effect of Cyr61 on Imatinib Resistance in Chronic Myeloid Leukemia and Its Mechanism].
Topics: Animals; Apoptosis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Signal Transduction | 2023 |
[Study on the Relationship between Integrin 2A and Drug Resistance in Chronic Myeloid Leukemia].
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Signal Transduction | 2023 |
Late appearance of JAK2 mutated polycythaemia vera in a patient with typical chronic myeloid leukaemia on imatinib: Speculations about role of therapeutic pressure and of secondary genetic events.
Topics: Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Polycythemia Vera | 2023 |
Concomitant Venetoclax and Imatinib for Comanaging Chronic Lymphocytic Leukemia and Chronic Myeloid Leukemia: A Case Report.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2023 |
Connexin 43-modified bone marrow stromal cells reverse the imatinib resistance of K562 cells via Ca 2+ -dependent gap junction intercellular communication.
Topics: Animals; Apoptosis; Bone Marrow Cells; Calcium; Cell Communication; Connexin 43; Gap Junctions; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; Mice; Tumor Microenvironment | 2023 |
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN.
Topics: Animals; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Tetraspanins | 2023 |
A single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia.
Topics: Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors | 2023 |
Effect of Imatinib treatment on renal anaemia in chronic myeloid leukemia patients.
Topics: Anemia; Antineoplastic Agents; Hemoglobins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Renal Insufficiency, Chronic | 2023 |
Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia.
Topics: Female; Humans; Imatinib Mesylate; Intracranial Hemorrhages; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Thrombocytopenia; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention.
Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Philadelphia Chromosome; Protein Kinase Inhibitors | 2023 |
Imatinib blocks tyrosine phosphorylation of Smad4 and restores TGF-β growth-suppressive signaling in BCR-ABL1-positive leukemia.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Smad4 Protein; Transforming Growth Factor beta; Tyrosine | 2023 |
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2023 |
The Impact of Improved Treatments on Survival of Adult U.S. Leukemia Patients: 1990-2018.
Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Registries | 2023 |
Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option.
Topics: Animals; Bone Marrow; Chemokines, CXC; Cytokines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Protein Kinase Inhibitors; Signal Transduction | 2023 |
Kinetic of liver enzymes and serum electrolytes in HCV, HBV, and HIV negative chronic phase chronic myeloid leukemia patients treated with imatinib or nilotinib.
Topics: Adult; Calcium; Fusion Proteins, bcr-abl; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2023 |
Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study.
Topics: Drugs, Generic; Feasibility Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission Induction; Treatment Outcome | 2023 |
Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Prospective Studies; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials.
Topics: Aged; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2023 |
BCR-ABL triggers a glucose-dependent survival program during leukemogenesis through the suppression of TXNIP.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinogenesis; Carrier Proteins; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Knockout; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thioredoxins | 2023 |
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2023 |
Inhibition of casein kinase 2 induces cell death in tyrosine kinase inhibitor resistant chronic myelogenous leukemia cells.
Topics: Apoptosis; Casein Kinase II; Cell Death; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Tyrosine Kinase Inhibitors | 2023 |
A Case Report of Successful Kidney Transplantation in a Patient With Chronic Myelogenous Leukemia (CML) Who Has Been in Remission for 15 Years on Imatinib.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Remission Induction; Renal Insufficiency, Chronic; Treatment Outcome | 2023 |
Telomere loss is accompanied by decreased pool of shelterin proteins TRF2 and RAP1, elevated levels of TERRA and enhanced glycolysis in imatinib-resistant CML cells.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shelterin Complex; Telomere; Telomere-Binding Proteins; Telomeric Repeat Binding Protein 2 | 2023 |
Metformin exerts antileukemic effects by modulating lactate metabolism and overcomes imatinib resistance in chronic myelogenous leukemia.
Topics: Adenosine Triphosphate; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Glucose; Humans; Imatinib Mesylate; Lactic Acid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Metformin | 2023 |
Isoalantolactone mediates the degradation of BCR-ABL protein in imatinib-resistant CML cells by down-regulating survivin.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; RNA, Messenger; Survivin; Ubiquitins | 2023 |
Estimating prognostic relevant cutoff values for a multiplex PCR detecting BCR::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiplex Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Resource-Limited Settings; Tyrosine Kinase Inhibitors | 2023 |
First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.
Topics: Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Long-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients.
Topics: Adult; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
[Current management and new treatment strategies of chronic myeloid leukemia].
Topics: Comorbidity; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life | 2023 |
Single cells tell multiple tales in CML.
Topics: Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2023 |
Genetic alterations in the BCR-ABL1 fusion gene related to imatinib resistance in chronic myeloid leukemia.
Topics: Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nucleotides; Protein Kinase Inhibitors | 2023 |
System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
Topics: Animals; Berberine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Stem Cells | 2023 |
Cost-effectiveness analysis of imatinib versus dasatinib in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia when combined with conventional chemotherapy in China.
Topics: Child; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines | 2023 |
SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia.
Topics: Aged; COVID-19; Fatigue; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; SARS-CoV-2 | 2023 |
Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; STAT3 Transcription Factor; STAT5 Transcription Factor | 2023 |
NDRG3 regulates imatinib resistance by promoting β‑catenin accumulation in the nucleus in chronic myelogenous leukemia.
Topics: beta Catenin; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2023 |
Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML.
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies; Tyrosine Kinase Inhibitors | 2023 |
The presence of additional cytogenetic aberrations in chronic myeloid leukemia cells at the time of diagnosis or their appearance on tyrosine kinase inhibitor therapy predicts the imatinib treatment failure.
Topics: Chromosome Aberrations; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Treatment Failure; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.
Topics: Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2023 |
Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.
Topics: Apoptosis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenotype; Protein Kinase Inhibitors | 2023 |
Imatinib mesylate-induced acute hepatotoxicity.
Topics: Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
Topics: Apoptosis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Demethylases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Transcription Factors | 2023 |
Tyrosine Kinase Inhibitor Therapies in Chronic Myeloid Leukemia: Effects on Clinical Characteristics and Triglyceride-to-High Density Lipoprotein Cholesterol Ratio.
Topics: Cholesterol, HDL; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tyrosine Kinase Inhibitors | 2023 |
External validation of the predictive scoring systems for molecular responses in chronic myeloid leukaemia receiving initial imatinib-therapy.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid | 2023 |
Therapeutic Drug Monitoring of Imatinib and N-Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC-MS/MS in a Cohort Study.
Topics: Adolescent; Antineoplastic Agents; Chromatography, Liquid; Cohort Studies; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Tandem Mass Spectrometry | 2023 |
Characterization of K562 cells: uncovering novel chromosomes, assessing transferrin receptor expression, and probing pharmacological therapies.
Topics: Apoptosis; Chromosomes; Doxorubicin; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Deacetylases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesylates; Pyrimidines; Receptors, Transferrin; Transferrin | 2023 |
Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells.
Topics: Acclimatization; Biological Assay; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyruvic Acid | 2023 |
Bioinformatic analysis of the expression profile and identification of RhoGDI2 as a biomarker in imatinib-resistant K562 cells.
Topics: Biomarkers; Computational Biology; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Protein Kinase Inhibitors; rho Guanine Nucleotide Dissociation Inhibitor beta; rho-Specific Guanine Nucleotide Dissociation Inhibitors | 2023 |
Long-Term Efficacy of High-Dose Imatinib in Hispanic Patients Without Access to Second-Generation Tyrosine Kinase Inhibitors Treated in LATAM Centers.
Topics: Drug Substitution; Hispanic or Latino; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Retrospective Studies; Tyrosine Kinase Inhibitors | 2023 |
A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Topics: beta Catenin; Chromatin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reactive Oxygen Species; Recurrence | 2024 |
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib.
Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Splenomegaly | 2023 |
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Analysis of the Inhibitory Effect of hsa-miR-145-5p and hsa-miR-203a-5p on Imatinib-Resistant K562 Cells by GC/MS Metabolomics Method.
Topics: Gas Chromatography-Mass Spectrometry; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2023 |
Association of
Topics: Azerbaijan; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymorphism, Single Nucleotide; Treatment Outcome | 2023 |
The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
Topics: Antineoplastic Agents; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines | 2023 |
Comment on "Effect of imatinib treatment on renal anemia in chronic myeloid leukemia patients".
Topics: Anemia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2023 |
Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy-The Surveillance, Epidemiology, and End Results database, 2000-2019.
Topics: Aged; Humans; Imatinib Mesylate; Income; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; United States | 2023 |
[Novel therapeutic strategy for targeting chronic myeloid leukemia stem cells via IRAK1/4 inhibition].
Topics: Apoptosis; B7-H1 Antigen; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-1 Receptor-Associated Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; NF-kappa B; Protein Kinase Inhibitors; Stem Cells | 2023 |
Identification of multivariable microRNA and clinical biomarker panels to predict imatinib response in chronic myeloid leukemia at diagnosis.
Topics: Biomarkers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Protein Kinase Inhibitors | 2023 |
circ_SIRT1 upregulates ATG12 to facilitate Imatinib resistance in CML through interacting with EIF4A3.
Topics: Antineoplastic Agents; Apoptosis; Autophagy-Related Protein 12; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-4A; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Sirtuin 1 | 2024 |
Long-term Results of Imatinib Discontinuation in Patients with Chronic-phase Chronic Myeloid Leukemia: A National Multicenter Prospective Study
Topics: Adult; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Recurrence; Treatment Outcome | 2023 |
C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2023 |
Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Dasatinib; Endothelial Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Thrombosis; Tyrosine Kinase Inhibitors | 2023 |
Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Topics: Apoptosis; Bone Marrow; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2023 |
[To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome | 2023 |
Bayesian analysis of the effect of exosomes in a mouse xenograft model of chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Bayes Theorem; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Female; Heterografts; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Rats | 2023 |
Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia.
Topics: Animals; Autophagy; Beclin-1; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation | 2020 |
[Expression Levels of JARID1B, Hes1 and MMP-9 Genes in CML Patients Treated with Imatinib Mesylate].
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Jumonji Domain-Containing Histone Demethylases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Matrix Metalloproteinase 9; Nuclear Proteins; Repressor Proteins; Transcription Factor HES-1 | 2019 |
Investigations into the Potential Role of Metabolites on the Anti-Leukemic Activity of Imatinib, Nilotinib and Midostaurin.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Staurosporine | 2019 |
Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX.
Topics: Apoptosis; Down-Regulation; Gene Expression Regulation, Leukemic; Homoharringtonine; Humans; Imatinib Mesylate; K562 Cells; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins | 2019 |
Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines | 2019 |
microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blast Crisis; Case-Control Studies; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Prognosis; Survival Rate | 2019 |
Chronic myeloid leukaemia in a patient with psoriasis following bimolane treatment.
Topics: Antineoplastic Agents; Dermatologic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Psoriasis; Razoxane | 2020 |
Novel analytical methods to interpret large sequencing data from small sample sizes.
Topics: Adult; Aged; Aged, 80 and over; Alleles; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Glucuronosyltransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Nuclear Proteins; Pharmacogenomic Variants; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 22; Sample Size; Transcription Factors; UDP-Glucuronosyltransferase 1A9; Young Adult | 2019 |
MicroRNA-577 promotes the sensitivity of chronic myeloid leukemia cells to imatinib by targeting NUP160.
Topics: Antineoplastic Agents; Cells, Cultured; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Nuclear Pore Complex Proteins | 2019 |
TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
Topics: Antineoplastic Agents; Apoptosis; Cells, Cultured; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Messenger; T-Cell Acute Lymphocytic Leukemia Protein 1 | 2019 |
[Postoperative Adjuvant Chemotherapy for Descending Colon Cancer Treated with Imatinib for Chronic Myeloid Leukemia].
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colon, Descending; Colonic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Treatment Outcome | 2019 |
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States.
Topics: Adult; Aged; Antineoplastic Agents; Child; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Therapeutic Equivalency; Treatment Outcome; United States; Young Adult | 2019 |
Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Topics: Adult; Cohort Studies; Databases, Factual; Drug Costs; Drugs, Generic; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors | 2019 |
Tyrosine Kinase Inhibitors in the Clinical Setting: A Conundrum of Choices.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2020 |
miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Topics: 3' Untranslated Regions; Aminopyridines; Base Sequence; Benzamides; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oncogenes; Protein Biosynthesis | 2019 |
The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interleukin-6; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Tumor Necrosis Factor-alpha | 2019 |
The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Topics: Bone Marrow Cells; Dasatinib; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mitochondria; Neoplasm Proteins; Neoplastic Stem Cells; Oxidative Phosphorylation; Primary Cell Culture; Proteomics | 2019 |
ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Polymerase Chain Reaction | 2019 |
Japan's high-cost medical expense benefit system could be an obstacle to promoting generic imatinib.
Topics: Costs and Cost Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2019 |
Imatinib mesylate inhibits proliferation and promotes apoptosis of chronic myeloid leukemia cells via STAT3 pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; STAT3 Transcription Factor | 2023 |
Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Clonal Evolution; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2019 |
Interview with a Patients' Advocate.
Topics: Disease Management; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Advocacy; Physician-Patient Relations | 2020 |
Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
Topics: Age Factors; Aged; Aged, 80 and over; Anemia; Erythrocyte Transfusion; Erythropoietin; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2019 |
Relationship of oxidative stress in the resistance to imatinib in Tunisian patients with chronic myeloid leukemia: A retrospective study.
Topics: Adult; Advanced Oxidation Protein Products; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Case-Control Studies; Drug Resistance, Neoplasm; Enzymes; Female; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Treatment Outcome; Tunisia | 2020 |
MiRNA-409-5p dysregulation promotes imatinib resistance and disease progression in children with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Child; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Tumor Cells, Cultured | 2019 |
Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Cells, Cultured; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
[Efficacy, safety and health-related life quality of chronic myeloid leukemia during the chronic period switching from branded Gleevec or Tasigna to generic imatinib].
Topics: Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Quality of Life; Treatment Outcome | 2019 |
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA; Fusion Proteins, bcr-abl; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotides, Antisense; Protein Kinase Inhibitors; RNA, Messenger | 2020 |
Tunneling nanotube-mediated intercellular vesicle and protein transfer in the stroma-provided imatinib resistance in chronic myeloid leukemia cells.
Topics: Biological Transport; Cell Communication; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microscopy, Electron; Mitochondria; Nanotubes; Stromal Cells | 2019 |
Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study.
Topics: Adult; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2020 |
Imatinib-induced melanonychia in a patient of chronic myeloid leukaemia: rarely reported side effect.
Topics: Adult; Antineoplastic Agents; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nail Diseases; Pigmentation Disorders | 2020 |
Discontinuation of Imatinib in a Child With Chronic Myeloid Leukemia.
Topics: Adolescent; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2020 |
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.
Topics: Animals; Apoptosis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunity; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Mice, Inbred BALB C; Mice, SCID; Mice, Transgenic; Protein Kinase Inhibitors; Receptors, Antigen, T-Cell; T-Lymphocytes, Regulatory; Treatment Outcome | 2020 |
Varying effects of tyrosine kinase inhibitors on platelet function-A need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications?
Topics: Adult; Aniline Compounds; Blood Platelets; Dasatinib; Dose-Response Relationship, Drug; Female; Flow Cytometry; Healthy Volunteers; Hemorrhage; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nitriles; Platelet Activation; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; Thrombin; Thromboembolism; Young Adult | 2020 |
Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Iran; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Young Adult | 2020 |
Human telomerase reverse transcriptase depletion potentiates the growth-inhibitory activity of imatinib in chronic myeloid leukemia stem cells.
Topics: Aldehyde Dehydrogenase 1 Family; Apoptosis; Carcinogenesis; Cell Lineage; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Protein Kinase Inhibitors; Telomerase | 2020 |
Complexity of chronic-phase CML management after failing a second-generation TKI.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Salvage Therapy | 2020 |
Acquired neuro-secretory defect in growth hormone secretion due to Imatinib mesylate and the efficacy of growth hormone therapy in children with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2020 |
Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Case-Control Studies; Female; Follow-Up Studies; Genotype; Humans; Imatinib Mesylate; Indonesia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Polymorphism, Single Nucleotide; Prognosis | 2019 |
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.
Topics: Adult; Aged; Aged, 80 and over; Cell Lineage; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Male; Middle Aged; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Remission Induction | 2020 |
A novel series of chlorinated plastoquinone analogs: Design, synthesis, and evaluation of anticancer activity.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; DNA Cleavage; Drug Screening Assays, Antitumor; Halogenation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Plastoquinone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Structure-Activity Relationship | 2020 |
Are we ready to use precision medicine in chronic myeloid leukemia practice?
Topics: Epigenesis, Genetic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precision Medicine; Protein Kinase Inhibitors | 2019 |
Homoharringtonine promotes BCR‑ABL degradation through the p62‑mediated autophagy pathway.
Topics: Antineoplastic Agents, Phytogenic; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Homoharringtonine; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proteolysis; RNA-Binding Proteins; Signal Transduction | 2020 |
The role of phosphorylation of MLF2 at serine 24 in BCR-ABL leukemogenesis.
Topics: Animals; Apoptosis; Carcinogenesis; Cell Proliferation; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Nuclear Proteins; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; RNA, Small Interfering; Serine; Xenograft Model Antitumor Assays | 2020 |
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia.
Topics: Biological Availability; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Intracellular Space; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Octamer Transcription Factor-1; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2020 |
[Comparison of the efficacy and safety of Chinese generic imatinib and branded imatinib in patients with chronic myeloid leukemia in consideration of demographic characteristics].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Demography; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Primary Myelofibrosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2020 |
Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Body Weight; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Precision Medicine; Safety; Thrombocytopenia; Time Factors; Treatment Outcome; Young Adult | 2020 |
Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cost-Benefit Analysis; Cytogenetic Analysis; Drug Monitoring; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Pharmacogenomic Testing; Quality-Adjusted Life Years; Survival Analysis | 2019 |
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Philadelphia Chromosome; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines | 2020 |
Feasibility Study of Switching to Nilotinib After First-line Imatinib in the Chronic Phase of Chronic Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Feasibility Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies | 2020 |
Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy by sponging miR-34a-5p in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein-1 Homolog; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2020 |
Betulinic acid restores imatinib sensitivity in BCR-ABL1 kinase-independent, imatinib-resistant chronic myeloid leukemia by increasing HDAC3 ubiquitination and degradation.
Topics: Adult; Apoptosis; Betulinic Acid; Bone Marrow Cells; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Histone Deacetylases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pentacyclic Triterpenes; Signal Transduction; Triterpenes; Ubiquitination; Young Adult | 2020 |
De-regulated STAT5A/miR-202-5p/USP15/Caspase-6 regulatory axis suppresses CML cell apoptosis and contributes to Imatinib resistance.
Topics: Antineoplastic Agents; Apoptosis; Case-Control Studies; Caspase 6; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Signal Transduction; STAT5 Transcription Factor; Tumor Suppressor Proteins; Ubiquitin-Specific Proteases | 2020 |
Evaluation and characterisation of Chronic myeloid leukemia and various treatments in Saudi Arabia: A retrospective study.
Topics: Abdominal Pain; Adult; Age Factors; Female; Hepatomegaly; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Retrospective Studies; Saudi Arabia; Sex Factors; Splenomegaly; Young Adult | 2020 |
Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrophosphatases | 2020 |
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Cell Adhesion; Cell Death; Cell Degranulation; Cell Movement; Cell Proliferation; Cell Survival; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Imatinib Mesylate; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; LIM Domain Proteins; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Transcription, Genetic; Treatment Outcome | 2020 |
Clinical & Lab Marker Predicting Early Molecular Response Inpatient of CML Chronic Phase Treated With Imatinib.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Inpatients; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Treatment Outcome | 2020 |
Coordinated inhibition of nuclear export and Bcr-Abl1 selectively targets chronic myeloid leukemia stem cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydrazines; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Dasatinib versus imatinib for childhood acute lymphocytic leukaemia.
Topics: Child; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2020 |
Outcome of Imatinib Treatment in Yemeni Patients With Chronic Myeloid Leukemia and the Influence of Nonadherence to Treatment and Duration of Previous Hydroxyurea Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Progression-Free Survival; Treatment Outcome; Yemen; Young Adult | 2020 |
Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
Topics: Adolescent; Adult; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medicaid; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; United States; Young Adult | 2020 |
Targeting of plasminogen activator inhibitor-1 activity promotes elimination of chronic myeloid leukemia stem cells.
Topics: Animals; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Plasminogen Activator Inhibitor 1; Protein Kinase Inhibitors; Serpin E2 | 2021 |
An Aggressive Approach Toward a Case of Refractory Ulcerative Colitis With Uncertain Etiology in the Context of Chronic Myeloid Leukemia.
Topics: Aged; Colitis, Ulcerative; Colonoscopy; Dasatinib; Fatal Outcome; Fecal Microbiota Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2020 |
[Fertility and disease outcomes in patients with chronic myeloid leukemia].
Topics: Adult; Dasatinib; Female; Fertility; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pregnancy; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report.
Topics: Dasatinib; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors | 2020 |
Clinical efficacy and safety of imatinib treatment in children and adolescents with chronic myeloid leukemia: A single-center experience in China.
Topics: Adolescent; Antineoplastic Agents; Child; China; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Retrospective Studies; Treatment Outcome | 2020 |
SRSF1 mediates cytokine-induced impaired imatinib sensitivity in chronic myeloid leukemia.
Topics: Biomarkers, Tumor; Bone Marrow; Cytokines; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Prognosis; Protein Kinase Inhibitors; Serine-Arginine Splicing Factors; Tumor Cells, Cultured | 2020 |
Blepharospasm and periorbital edema after imatinib mesylate: improvement with botulinum toxin.
Topics: Aged; Antineoplastic Agents; Blepharospasm; Botulinum Toxins; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Orbital Diseases; Treatment Outcome | 2020 |
Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia.
Topics: Adolescent; Antineoplastic Agents; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Treatment Outcome | 2020 |
Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells.
Topics: 3T3 Cells; Animals; Antigens, CD; Cadherins; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Oligonucleotide Array Sequence Analysis; Protein Domains; Protein Kinase Inhibitors | 2020 |
The potentiation of menadione on imatinib by downregulation of ABCB1 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Vitamin K 3 | 2020 |
Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report.
Topics: Adolescent; Anemia, Hemolytic, Autoimmune; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Splenectomy | 2020 |
Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and -resistant chronic myeloid leukaemia cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Diterpenes; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Mitosis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cyclin D2; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leupeptins; Macrocyclic Compounds; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; Proteolysis; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridazines; Pyrroles; Signal Transduction; Wortmannin | 2020 |
Correction of Bcl-x splicing improves responses to imatinib in chronic myeloid leukaemia cells and mouse models.
Topics: Animals; bcl-X Protein; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Morpholinos; Neoplasms, Experimental; RNA Splicing; Xenograft Model Antitumor Assays | 2020 |
Comparative Safety and Health Care Expenditures Among Patients With Chronic Myeloid Leukemia Initiating First-Line Imatinib, Dasatinib, or Nilotinib.
Topics: Aged; Dasatinib; Health Expenditures; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medicare; Protein Kinase Inhibitors; Pyrimidines; United States | 2020 |
Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?
Topics: Cytogenetic Analysis; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase | 2020 |
Nobiletin Promotes Megakaryocytic Differentiation through the MAPK/ERK-Dependent EGR1 Expression and Exerts Anti-Leukemic Effects in Human Chronic Myeloid Leukemia (CML) K562 Cells.
Topics: Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Differentiation; Cell Nucleus; Cell Proliferation; Early Growth Response Protein 1; Flavones; Gene Expression Regulation, Leukemic; Gene Ontology; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Megakaryocytes; RNA, Messenger; Up-Regulation | 2020 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Synthesis and Characterization of Telmisartan-Derived Cell Death Modulators to Circumvent Imatinib Resistance in Chronic Myeloid Leukemia.
Topics: Animals; Carbazoles; Cell Death; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Topics: Adolescent; Adult; Antineoplastic Agents; Dasatinib; Female; Health Care Costs; Humans; Imatinib Mesylate; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Patient Acceptance of Health Care; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Young Adult | 2020 |
[Relationship between PANTR1 and Imatinib Resistance of Chronic Myeloid Leukemia Cell Line K562 and Its Related Mechanisms].
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2020 |
MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Molecular Targeted Therapy; Proto-Oncogene Proteins c-bcl-2; Up-Regulation | 2020 |
Sustained molecular response following a failed attempt of tyrosine kinase inhibitor discontinuation & the effects on growth in a child with chronic myeloid leukemia: not always a short story.
Topics: Child Development; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome; Withholding Treatment | 2020 |
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
Topics: Aged; Coronary Artery Disease; Dasatinib; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pulse Wave Analysis; Pyridazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2020 |
The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Cell Line, Tumor; Computer Simulation; Dasatinib; Drug Discovery; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Niacinamide; Pyrazoles | 2020 |
Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic.
Topics: Antineoplastic Agents; Antiviral Agents; COVID-19; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pandemics; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2020 |
BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
Topics: Adult; Aged; Antineoplastic Agents; Arterioles; Cardiotonic Agents; Catalase; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Hydrogen Peroxide; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Microvessels; Middle Aged; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Polyethylene Glycols; Protein Kinase Inhibitors; Pyrimidines; Vasodilation | 2020 |
"All Our Wisdom is Stored in the Trees" - Degrading BCR-ABL with
Topics: Antineoplastic Agents; Benzamides; Berberine; Berberis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Trees; Ubiquitin-Protein Ligases | 2020 |
Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.
Topics: Aged; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors | 2020 |
[Delivery of a Healthy Newborn by the Partner of a Patient with CML Undergoing Treatment with Nilotinib].
Topics: Dasatinib; Female; Humans; Imatinib Mesylate; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Retrospective Studies | 2020 |
COVID-19 in persons with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Betacoronavirus; Child; China; Coronavirus Infections; COVID-19; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pandemics; Pneumonia, Viral; Prevalence; Protein Kinase Inhibitors; Risk Factors; SARS-CoV-2; Surveys and Questionnaires | 2020 |
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Topics: Acetylation; Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Beclin-1; Binding Sites; Cell Cycle Checkpoints; Computer Simulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imatinib Mesylate; Isoenzymes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Signal Transduction | 2020 |
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Topics: Adult; Disease Management; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; United Kingdom | 2021 |
Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Child; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Programmed Cell Death 1 Receptor; Young Adult | 2020 |
Increased tumor burden in patients with chronic myeloid leukemia after 36 months of imatinib discontinuation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Survival Rate; Tumor Burden; Withholding Treatment; Young Adult | 2020 |
Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors.
Topics: Age Factors; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Female; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Withholding Treatment | 2020 |
[MiR-124-3p Enhances the Sansitivity of Chronic Myelogenous Leukemia Cell K562-R to Imatinib by Targeting ABCA2].
Topics: Animals; Apoptosis; ATP-Binding Cassette Transporters; Cell Proliferation; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; MicroRNAs | 2020 |
Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Substitution; Endothelium, Vascular; Humans; Hydroxyurea; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome | 2020 |
Cutaneous adverse reaction to imatinib in a case of childhood chronic myeloid leukemia.
Topics: Antineoplastic Agents; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prognosis; Skin Diseases | 2020 |
Expression of Ki-67 and CD34 on blood and bone marrow cells of CML patients with different response to imatinib and nilotinib therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Bone Marrow Cells; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Ki-67 Antigen; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2020 |
Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Recurrence; Treatment Outcome | 2020 |
Molecular testing of chronic myeloid leukaemia in low resource areas.
Topics: Antineoplastic Agents; Developing Countries; Dried Blood Spot Testing; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Real-Time Polymerase Chain Reaction; Treatment Outcome | 2021 |
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase 6; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Tumor Stem Cell Assay; Ubiquitination; Xenograft Model Antitumor Assays | 2020 |
[Progress of MM/CML treatment and medical economics].
Topics: Antineoplastic Agents; Economics, Medical; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiple Myeloma; Protein Kinase Inhibitors | 2020 |
Successful kidney transplantation in a patient with pre-existing chronic myeloid leukemia treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2021 |
J-SKI will be able to elucidate whether the renal function recover or not after discontinuation of tyrosine kinase inhibitors.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Female; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multicenter Studies as Topic; Observational Studies as Topic; Protein Kinase Inhibitors; Recovery of Function; Withholding Treatment | 2020 |
Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; S-Phase Kinase-Associated Proteins; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Evaluation of Imatinib Concentrations in Samples Submitted for BCR-ABL1 or Imatinib Testing-Evidence to Support Therapeutic Drug Monitoring for Dose Optimization?
Topics: Aged; Antineoplastic Agents; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies | 2020 |
Overexpression of P-glycoprotein and resistance to Imatinib in chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Case-Control Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Topics: Adult; Biomarkers, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Homeodomain Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Transcription Factors | 2018 |
Large granular lymphocytosis induced by dasatinib.
Topics: Aged; Antineoplastic Agents; Cell Nucleus; Cytoplasmic Granules; Dasatinib; Drug Substitution; Female; Humans; Imatinib Mesylate; Immunophenotyping; Killer Cells, Natural; Leukemia, Large Granular Lymphocytic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes | 2021 |
Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia.
Topics: Adult; Blastocyst; Cryopreservation; Embryo Transfer; Female; Fertilization in Vitro; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infertility, Female; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ovulation Induction; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2020 |
An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nanoparticles; Protein Kinase Inhibitors | 2020 |
In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Pyridazines | 2020 |
Breastfeeding in a patient with chronic myeloid leukemia during tyrosine kinase inhibitor therapy.
Topics: Adult; Antineoplastic Agents; Breast Feeding; Female; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Japan; Lactation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors | 2021 |
[Curative Efficacy of First Generation TKI in the Treatment of CML-CP Combined with vPh and Analysis of Its Genetic Characteristics].
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2020 |
Lymphoblastic predominance of blastic phase in children with chronic myeloid leukaemia treated with imatinib: A report from the I-CML-Ped Study.
Topics: Adolescent; Blast Crisis; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male | 2020 |
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up.
Topics: Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
Acute pancreatitis in a patient treated with imatinib and gefitinib.
Topics: Antineoplastic Agents; Drug Interactions; Female; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pancreatitis; Protein Kinase Inhibitors | 2021 |
[Effect of imatinib on the height of children with chronic myeloid leukemia in the chronic phase].
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; China; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Time Factors; Treatment Outcome; Young Adult | 2020 |
Evaluation of the use, effectiveness and safety of tyrosine kinase inhibitors in chronic myelogenous leukaemia in a general university hospital.
Topics: Adult; Aged; Aged, 80 and over; Female; Hospitals, University; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2020 |
Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Imatinib Mesylate; Length of Stay; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome and Process Assessment, Health Care; Pandemics; Pneumonia, Viral; Protein Kinase Inhibitors; Respiration, Artificial; Retrospective Studies; SARS-CoV-2; Severity of Illness Index; Turkey | 2020 |
[Imatinib in the treatment of chronic myeloid leukemia in Morocco].
Topics: Adult; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morocco; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Outcome | 2020 |
Long term outcome of chronic myeloid leukemia patients treated with imatinib: Report from a developing country.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Developing Countries; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pakistan; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2020 |
Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
Topics: Adolescent; Algeria; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Central Nervous System; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Recurrence | 2020 |
Second-line Dasatinib Therapy Improved Compliance and Deep Molecular Responses in Imatinib-intolerant Chronic Myeloid Leukemia Patients.
Topics: Aged; Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Grading; Patient Compliance; Protein Kinase Inhibitors; Retreatment; Treatment Outcome | 2020 |
Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor.
Topics: Bone Marrow; Chemoradiotherapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radioisotopes; Sunitinib | 2020 |
Allogeneic transplant for CML in chronic phase after failure of imatinib. Not needed or needlessly neglected?
Topics: Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Transplantation, Homologous | 2020 |
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.
Topics: Aminopyridines; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Piperazines; Pyrimidines; Treatment Outcome | 2021 |
Secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Pyrimidines; Remission Induction; Transplantation, Autologous | 2020 |
Impact of the Major BCR-ABL1 Transcript Type on Clinical and Biological Parameters and Molecular Response in Patients With Chronic Myeloid Leukemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Real-Time Polymerase Chain Reaction | 2022 |
Contemporary treatment methods of adult patients with BCR/ABL1 positive chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2020 |
Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Topics: Allosteric Regulation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Emodin; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Secondary; STAT5 Transcription Factor | 2020 |
Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia.
Topics: Antineoplastic Agents; Costs and Cost Analysis; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2020 |
Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice.
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2021 |
Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Dasatinib; Decision Support Techniques; Drug Costs; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein-Tyrosine Kinases; Pyrimidines; Quality-Adjusted Life Years | 2020 |
The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Decision Support Techniques; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Progression-Free Survival; Protein Kinase Inhibitors; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Young Adult | 2020 |
Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Twist-Related Protein 1 | 2020 |
Case Report: IgG multiple myeloma and chronic myeloid leukemia in a single patient.
Topics: Bortezomib; Dexamethasone; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Thalidomide | 2020 |
The Role of Blood and Marrow Transplantation in Treating Pediatric Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors.
Topics: Bone Marrow; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2021 |
Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Cardiotoxicity; Cross-Sectional Studies; Dasatinib; Early Diagnosis; Echocardiography, Four-Dimensional; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Systole; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2021 |
Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: General description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment's prognosti
Topics: Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors | 2020 |
Comprehensive in-silico analysis of damage associated SNPs in hOCT1 affecting Imatinib response in chronic myeloid leukemia.
Topics: Amino Acid Substitution; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Dynamics Simulation; Octamer Transcription Factor-1; Polymorphism, Single Nucleotide | 2021 |
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors.
Topics: Administration, Oral; Adult; Aged; Aniline Compounds; Anticoagulants; Cohort Studies; Female; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Retrospective Studies; Venous Thromboembolism | 2020 |
New Drug for Chronic Myeloid Leukemia Might Stimulate the Market.
Topics: Aminopyridines; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2021 |
Design of personalized cancer treatments by use of optimal control problems: The case of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Computer Simulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2020 |
AICAR and Decitabine Enhance the Sensitivity of K562 Cells to Imatinib by Promoting Mitochondrial Activity.
Topics: Aminoimidazole Carboxamide; Apoptosis; Cell Line, Tumor; Cell Proliferation; Decitabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Protein Kinase Inhibitors; Ribonucleotides | 2020 |
Clinical features and prognosis of duplex primary malignant neoplasms involving chronic myeloid leukemia.
Topics: Age Factors; Anticarcinogenic Agents; Breast Neoplasms; China; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Multiple Primary; Prognosis; Retrospective Studies; Risk Factors; Sex Factors; Survival Analysis; Time Factors | 2020 |
Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Case-Control Studies; Drug Resistance, Neoplasm; Female; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Risk Factors; Smoking; Treatment Failure | 2021 |
[Chronic myeloid leukemia: update on treatment and survival prediction].
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Survival | 2020 |
Circulating miR-146a expression predicts early treatment response to imatinib in adult chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Case-Control Studies; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Prognosis | 2021 |
Prospective evaluation of variables affecting platelet function in patients with newly diagnosed chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Blood Platelets; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Platelet Aggregation; Platelet Count; Platelet Function Tests; Prospective Studies; Young Adult | 2020 |
Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia.
Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Neoplastic Stem Cells; Protein Kinase Inhibitors; RNA-Seq; Single-Cell Analysis; Transcriptome | 2020 |
Analysis of cellular models of clonal evolution reveals co-evolution of imatinib and HSP90 inhibitor resistances.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromosome Aberrations; Clonal Evolution; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Transcriptome | 2021 |
Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
Topics: Aged; Dasatinib; Female; Health Expenditures; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medicare; Protein Kinase Inhibitors; Pyrimidines; Registries; SEER Program; United States | 2020 |
[Inhibitory Effects of Agaricus Blazei Murrill (FA-2-b-β) on Proliferation of Chronic Myeloid Leukemia Cells in vivo and Its Mechanism].
Topics: Agaricus; Animals; Apoptosis; Cell Proliferation; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice | 2020 |
Chronic myeloid leukemia revealed through focal bone lesions responding to imatinib: The bee's knees.
Topics: Animals; Antineoplastic Agents; Bees; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2021 |
Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis.
Topics: Animals; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Mice | 2020 |
Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
Topics: Antineoplastic Agents; Cytogenetic Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction | 2020 |
CHRONIC MYELOID LEUKEMIA COURSE IN PERSONS EXPOSED TO IONIZING RADIATION AS A RESULT OF THE CHORNOBYL ACCIDENT.
Topics: Aged; Air Pollutants, Radioactive; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Chernobyl Nuclear Accident; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Emergency Responders; Female; Food Contamination, Radioactive; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Radiation Exposure; Radiation Injuries; Radiation, Ionizing; Soil Pollutants, Radioactive; Survival Analysis; Translocation, Genetic; Ukraine | 2020 |
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Comorbidity; Dasatinib; Drug Tapering; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Remission Induction; Retrospective Studies; Safety; Treatment Outcome | 2021 |
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Topics: Adult; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Molecular; Mutation; Prognosis; Protein Conformation; Protein Kinase Inhibitors | 2020 |
Hypersensitivity pneumonitis related to imatinib mesylate therapy in a patient with chronic myeloid leukemia.
Topics: Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Male; Middle Aged; Prednisolone | 2021 |
Imatinib: a new chemopreventive option in adenomatous polyposis?
Topics: Adenomatous Polyposis Coli; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2020 |
Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
Topics: Abnormal Karyotype; Adolescent; Anorexia; Antineoplastic Agents; Child; Child, Preschool; China; Drug Evaluation; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Growth Disorders; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Musculoskeletal Diseases; Progression-Free Survival; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Treatment Outcome | 2021 |
Repositioning antispasmodic drug Papaverine for the treatment of chronic myeloid leukemia.
Topics: Allosteric Site; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Cell Line, Tumor; Drug Repositioning; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Molecular Dynamics Simulation; Papaverine; Parasympatholytics; RAW 264.7 Cells; Reactive Oxygen Species; Signal Transduction | 2021 |
Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2020 |
TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Topics: Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; beta Catenin; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multidrug Resistance-Associated Protein 2; RNA-Seq; T Cell Transcription Factor 1; Wnt Signaling Pathway | 2021 |
Tyrosine kinase inhibitors in chronic myeloid leukaemia and emergent cardiovascular disease.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Ontario; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors | 2021 |
Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2021 |
Topics: Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors | 2021 |
Exosomes released by imatinib‑resistant K562 cells contain specific membrane markers, IFITM3, CD146 and CD36 and increase the survival of imatinib‑sensitive cells in the presence of imatinib.
Topics: Apoptosis; CD146 Antigen; CD36 Antigens; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exosomes; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Protein Kinase Inhibitors; RNA-Binding Proteins | 2021 |
Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Panobinostat; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-myc | 2021 |
Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; bcl-2-Associated X Protein; Catechols; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multidrug Resistance-Associated Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2 | 2021 |
Expression of inducible NOS is indispensable for the antiproliferative and proapoptotic effect of imatinib in BCR-ABL positive cells.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitric Oxide Synthase Type II; Protein Kinase Inhibitors; Young Adult | 2021 |
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Topics: Adult; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Quality of Life; Surveys and Questionnaires | 2021 |
PKC-β/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Arachidonate 5-Lipoxygenase; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Phosphorylation; Protein Kinase C beta; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Survival Analysis; Up-Regulation; Young Adult | 2021 |
Caffeic Acid Enhances the Anti-Leukemic Effect of Imatinib on Chronic Myeloid Leukemia Cells and Triggers Apoptosis in Cells Sensitive and Resistant to Imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caffeic Acids; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Synergism; Forkhead Transcription Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondrial Membranes | 2021 |
Co-existence of
Topics: Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Protein Kinase Inhibitors | 2021 |
Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Apoptosis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Platelet Activation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Young Adult | 2021 |
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Fusion; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
LncRNA highly upregulated in liver cancer regulates imatinib resistance in chronic myeloid leukemia via the miR-150-5p/MCL1 axis.
Topics: Case-Control Studies; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; RNA, Long Noncoding; Signal Transduction; Up-Regulation | 2021 |
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Topics: Antineoplastic Agents; Apoptosis; Azithromycin; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2021 |
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.
Topics: Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; United Kingdom | 2021 |
BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Developing Countries; Female; Fusion Proteins, bcr-abl; Health Services Accessibility; Humans; Hydroxyurea; Imatinib Mesylate; L-Lactate Dehydrogenase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Uric Acid; Young Adult | 2021 |
The
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor beta; Trans-Activators | 2021 |
Evaluation of cytogenetic response in CML patients with variant Philadelphia translocation.
Topics: Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Translocation, Genetic | 2022 |
H
Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Down-Regulation; Humans; Hydrogen Peroxide; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-akt; X-Linked Inhibitor of Apoptosis Protein | 2021 |
Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Fas Ligand Protein; Female; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Malaysia; Male; Middle Aged; Polymorphism, Genetic; Promoter Regions, Genetic; Retrospective Studies; Young Adult | 2021 |
Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Phosphorylation; PPAR gamma; STAT5 Transcription Factor; Telmisartan; Transcriptional Activation; Tumor Suppressor Proteins | 2021 |
Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Tanzania; Treatment Outcome; Young Adult | 2021 |
Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cardiovascular Diseases; Dasatinib; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prospective Studies; Protein Kinase Inhibitors | 2022 |
Exovesicular-Shh confers Imatinib resistance by upregulating Bcl2 expression in chronic myeloid leukemia with variant chromosomes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Thiazoles; Up-Regulation; Veratrum Alkaloids | 2021 |
Influence of genetic polymorphisms in glutathione-S-transferases gene in response to imatinib among Brazilian patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Brazil; Female; Genetic Predisposition to Disease; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymorphism, Genetic; Young Adult | 2021 |
Is Priapism a Common Presentation of Chronic Myeloid Leukemia in an Adolescent Patient?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Priapism | 2021 |
[Effect of Etoposide on Elimination of Chronic Myeloid Leukemia Stem Cells by Imatinib in Vivo].
Topics: Animals; Drug Resistance, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Stem Cells | 2021 |
[Therapeutic Effect of Imatinib Made in Real World to Newly Diagnosed Chronic Myeloid Leukemia].
Topics: Antineoplastic Agents; Benzamides; China; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2021 |
An assay of human tyrosine protein kinase ABL activity using an
Topics: Escherichia coli; Escherichia coli Proteins; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phosphorylation; Pyrimidines | 2021 |
[Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
Topics: Adult; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors | 2021 |
How much imatinib is enough?
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2021 |
H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.
Topics: Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrimidines | 2021 |
Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells.
Topics: Animals; Antineoplastic Agents; Catalase; Cell Line, Tumor; DNA Damage; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Glutathione; Glutathione Peroxidase; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mice; Oxidative Stress | 2021 |
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Topics: Absorptiometry, Photon; Adolescent; Age Determination by Skeleton; Cancer Survivors; Child; Dasatinib; Echocardiography; Electrocardiography; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Molecular Targeted Therapy; Philadelphia Chromosome; Population Surveillance; Protein Kinase Inhibitors; Retrospective Studies; Thyrotropin | 2021 |
Computer Simulations of the Dissociation Mechanism of Gleevec from Abl Kinase with Milestoning.
Topics: Computer Simulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Conformation | 2021 |
Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Primary Cell Culture; Quinazolines; SOXD Transcription Factors; Xenograft Model Antitumor Assays | 2021 |
AKR1C3 decreased CML sensitivity to Imatinib in bone marrow microenvironment via dysregulation of miR-379-5p.
Topics: Aldo-Keto Reductase Family 1 Member C3; Animals; Apoptosis; Bone Marrow; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; MicroRNAs; Tumor Microenvironment | 2021 |
Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Prognosis; Prospective Studies; Pyrimidines; Retrospective Studies; Severity of Illness Index; Survival Rate | 2021 |
Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; HSP70 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Prognosis; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Small Molecule Libraries; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome; Turkey | 2021 |
Screening and identification of key genes in imatinib-resistant chronic myelogenous leukemia cells: a bioinformatics study.
Topics: Antineoplastic Agents; Computational Biology; Databases, Genetic; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Ontology; Gene Regulatory Networks; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Interaction Maps | 2021 |
Aggregates of Pseudogaucher Cells in a Pediatric Patient With Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Bone Marrow; Cell Aggregation; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2021 |
Adolescents experienced more treatment failure than children with chronic myeloid leukemia receiving imatinib as frontline therapy: a retrospective multicenter study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2021 |
ZFP36L1 plays an ambiguous role in the regulation of cell expansion and negatively regulates CDKN1A in chronic myeloid leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Butyrate Response Factor 1; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2021 |
Case reports of chronic myeloid leukemia and tuberculosis: Is imatinib the link between the two?
Topics: Adult; Antineoplastic Agents, Immunological; Causality; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mycobacterium tuberculosis; Pleural Effusion; Protein Kinase Inhibitors; Treatment Outcome; Tuberculosis, Central Nervous System; Tuberculosis, Pleural | 2021 |
Association of SLC22A1,SLCO1B3 Drug Transporter Polymorphisms and Smoking with Disease Risk and Cytogenetic Response to Imatinib in Patients with Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Catecholamine Plasma Membrane Transport Proteins; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Polymorphism, Single Nucleotide; Smoking; Solute Carrier Organic Anion Transporter Family Member 1B3; Treatment Outcome | 2021 |
CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Interleukin-8; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Interleukin-8B; Triazoles; Young Adult | 2021 |
Targeting FEN1 Suppresses the Proliferation of Chronic Myeloid Leukemia Cells Through Regulating Alternative End-Joining Pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cells, Cultured; DNA End-Joining Repair; DNA Ligase ATP; Drug Resistance, Neoplasm; Flap Endonucleases; HEK293 Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proliferating Cell Nuclear Antigen; THP-1 Cells | 2021 |
Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HSC70 Heat-Shock Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction | 2021 |
Cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors in Taiwan: a nationwide population-based study.
Topics: Cardiovascular Diseases; Cohort Studies; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies; Taiwan | 2022 |
Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
Topics: Animals; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Eukaryotic Initiation Factor-4E; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phenanthrenes; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
44-Year-Old Man With Fatigue, Weight Loss, and Leukocytosis.
Topics: Adult; Basophils; Diagnosis, Differential; Exercise Tolerance; Fatigue; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytosis; Male; Protein Kinase Inhibitors; Treatment Outcome; Weight Loss | 2021 |
[Chronic myeloid leukemia: aiming for treatment free remission].
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome | 2021 |
Cost-Effectiveness of Bosutinib for the Treatment of Adult Patients with Chronic Phase Chronic Myeloid Leukemia in the Second-Line Setting.
Topics: Adult; Aniline Compounds; Cost-Benefit Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinolines | 2021 |
Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2022 |
Cardiovascular events and atherogenic lipid profile in chronic myeloid leukemia patients treated with nilotinib versus imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Cardiovascular Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipids; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Young Adult | 2021 |
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
Topics: Adult; Drug Resistance, Neoplasm; Ethiopia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2021 |
Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Aniline Compounds; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Glucose; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinolines; Rhodanine; Thiazolidines | 2021 |
cAMP Signaling Pathway Prevents Dasatinib-Induced Vascular Hyperpermeability.
Topics: Aniline Compounds; Antigens, CD; Cadherins; Capillary Permeability; Cell Culture Techniques; Cyclic AMP; Dasatinib; Endothelial Cells; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Permeability; Pleural Effusion; Protein Kinase Inhibitors; Quinolines; Signal Transduction | 2021 |
MiR-150 Expression in Chronic Myeloid Leukemia: Relation to Imatinib Response.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2022 |
[Distribution of ETV6-ABL Fusion Gene in Hematopoietic Cell Populations of Myeloproliferative Neoplasm].
Topics: Adult; Fusion Proteins, bcr-abl; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myeloproliferative Disorders | 2021 |
Imatinib and Dasatinib-induced Ulcerative Colitis: Case Report.
Topics: Colitis, Ulcerative; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines | 2022 |
Early prediction of stable MR
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2022 |
Pulmonary hypertension in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Echocardiography; Female; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Young Adult | 2021 |
Health-related quality of life using EQ-5D among chronic myeloid leukaemia patients in health centres in Klang Valley, Malaysia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Health Status; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Surveys and Questionnaires; Young Adult | 2021 |
Detection of mutations in CML patients resistant to tyrosine kinase inhibitor: imatinib mesylate therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Young Adult | 2021 |
[Treatment status of tyrosine kinase inhibitors in Chinese patients with chronic myeloid leukemia in 2020].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Cross-Sectional Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Young Adult | 2021 |
Treatment of Hematological Malignancies with Glycyrrhizic Acid.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Glycyrrhizic Acid; Hematologic Neoplasms; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Lymphoma; Mice; Neoplasm Transplantation; Reactive Oxygen Species | 2017 |
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Topics: Adult; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Flow Cytometry; Gene Expression Profiling; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Knockout; Mice, Transgenic; Middle Aged; Neoplasm Transplantation; Neoplasm, Residual; Neoplasms, Experimental; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Real-Time Polymerase Chain Reaction; Tumor Stem Cell Assay | 2017 |
Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: A report of three cases from India.
Topics: Adult; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Transcription, Genetic; Treatment Outcome | 2017 |
Predictive parameters for imatinib failure in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Comorbidity; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Treatment Failure; Treatment Outcome; Young Adult | 2017 |
Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Young Adult | 2017 |
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.
Topics: Adult; Aniline Compounds; B-Lymphocytes; Bone Marrow Cells; Dasatinib; Female; Humans; Imatinib Mesylate; Immunity, Humoral; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Treatment Outcome | 2017 |
Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; DNA Topoisomerases; Drug Resistance, Neoplasm; ErbB Receptors; Glucans; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nanoconjugates; Protein-Tyrosine Kinases; Recombinant Fusion Proteins | 2017 |
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Cells, Cultured; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Tubulin; Tubulin Modulators | 2017 |
Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
Topics: Adult; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Cytochrome P-450 CYP3A; Cytogenetics; Female; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Recurrence; Young Adult | 2017 |
Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medically Underserved Area; Middle Aged; Nepal; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2017 |
Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP2C8; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies | 2017 |
Maternal, Fetal, and Neonatal Imatinib Levels With Treatment of Chronic Myeloid Leukemia in Pregnancy.
Topics: Adult; Antineoplastic Agents; Diagnosis, Differential; Female; Fetus; Gestational Age; Humans; Imatinib Mesylate; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Prenatal Diagnosis | 2017 |
Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Line, Tumor; Humans; Imatinib Mesylate; Interleukin-7; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphopenia; Mice; Phosphorylation; Receptors, Antigen, T-Cell; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoenzymes; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Thiazoles; Triazines | 2017 |
Continuing Imatinib Treatment for Chronic Myeloid Leukemia Patients Who Had Serious Adverse Events at the Onset of Therapy.
Topics: Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2017 |
Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-6; RNA Interference; Signal Transduction; Tumor Suppressor Protein p53; Young Adult | 2017 |
Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Neuroendocrine tumor of cecum in patient treated with imatinib mesylate for blastic phase of chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Ascites; Cecal Neoplasms; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Neuroendocrine Tumors | 2017 |
Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Female; Genotype; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linkage Disequilibrium; Male; Mutation Rate; Organic Cation Transport Proteins; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Sequence Analysis, DNA; Solute Carrier Family 22 Member 5; Symporters; Treatment Outcome | 2017 |
Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Caspase 9; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Phosphatidylinositol 3-Kinases; Phosphorylation; Porifera; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Triterpenes; Tumor Suppressor Proteins | 2017 |
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2017 |
Interleukin 3- receptor targeted exosomes inhibit
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Carriers; Exosomes; HEK293 Cells; Heterografts; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Receptors, Interleukin-3; Treatment Outcome | 2017 |
Overexpression of heme oxygenase-1 in bone marrow stromal cells promotes microenvironment-mediated imatinib resistance in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cellular Microenvironment; Chemokine CXCL12; Chromones; Cytoprotection; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Recurrence; Signal Transduction; Solubility; Stromal Cells; Survival Analysis; Up-Regulation; Young Adult | 2017 |
[Effects of Quercetin on Chronic Myeloid Leukemia Cell Line Resistant to Imatinib and Its Mechanism].
Topics: Antioxidants; Apoptosis; Benzamides; Cell Line; DNA Damage; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 4; Piperazines; Pyrimidines; Quercetin | 2017 |
[Clinical Analysis for 42 Imatinib-resistant Patients with Chronic Myelogenous Leukemia].
Topics: Antineoplastic Agents; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors | 2017 |
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Transcription, Genetic; Treatment Outcome; Young Adult | 2017 |
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Topics: Axitinib; Computational Biology; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl | 2017 |
A case series of imatinib-induced generalized hypopigmentation and progression of existing acquired dermal melanocytosis.
Topics: Aged; Antineoplastic Agents; Disease Progression; Female; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Skin | 2017 |
Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
Topics: Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Solid Phase Extraction; Tandem Mass Spectrometry | 2017 |
Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
Topics: Aged; Antineoplastic Agents; Dasatinib; Eosinophilia; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2017 |
Can the Use of Bone Marrow Parameters Improve the Efficacy of Risk Prediction Scores in Chronic Myeloid Leukemia in Imatinib Era?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2017 |
CML in blast crisis: more common than we think?
Topics: Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2017 |
MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
Topics: Adult; BRCA1 Protein; Case-Control Studies; Computer Simulation; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Fanconi Anemia; Fusion Proteins, bcr-abl; Gene Expression Regulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Middle Aged | 2017 |
Generic Imatinib in Chronic Myeloid Leukemia: Survival of the Cheapest.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Secondary breast carcinoma after completely remitted chronic myeloid leukemia following targeted tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mammography; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Sentinel Lymph Node Biopsy; Ultrasonography, Doppler, Color | 2017 |
Everything old is new again: the case for imatinib as frontline therapy in 2017.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2017 |
The biology of CML supports second-generation TKIs as frontline treatment.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2017 |
Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.
Topics: Adolescent; Adult; Antineoplastic Agents; Black People; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Biological; Nigeria; Reproducibility of Results; Young Adult | 2017 |
Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Breakpoints; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymorphism, Genetic; Recurrence; RNA, Messenger | 2017 |
Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells.
Topics: Apoptosis; Benzamides; Cell Cycle Proteins; Cell Division; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Piperazines; Pyrimidines; Signal Transduction | 2017 |
[Chronic myelogenous leukemia: monitoring and predictors of a favorable response to treatment with imatinib].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Predictive Value of Tests; Survival Analysis; Young Adult | 2017 |
Philadelphia Chromosome Positive de novo Acute Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Daunorubicin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Rare Diseases; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2016 |
Early switch to second-line tyrosine kinase inhibitor in chronic myeloid leukemia patients failing to achieve early molecular response.
Topics: Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Dosage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Registries | 2017 |
Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.
Topics: Algorithms; Antineoplastic Agents; Cell Proliferation; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Pyrimidines | 2017 |
Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bortezomib; Caspases; Cell Line, Tumor; Cell Proliferation; Deubiquitinating Enzymes; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Mice; Mice, Nude; Organoplatinum Compounds; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyridines; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
The complexity of growth failure in children receiving tyrosine kinase inhibitor therapy for chronic myelogenous leukemia.
Topics: Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein-Tyrosine Kinases | 2017 |
Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.
Topics: Adult; Female; Fetus; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maternal-Fetal Exchange; Perfusion; Placenta; Pregnancy; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Tissue Distribution | 2018 |
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polyethylene Glycols; Recombinant Proteins; Treatment Outcome | 2017 |
Analyses of Treatment Outcome According to Age in Patients With Chronic Myeloid Leukemia Receiving Front-line Imatinib Therapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Moderate anemia at diagnosis is an independent prognostic marker of the EUTOS, Sokal, and Hasford scores for survival and treatment response in chronic-phase, chronic myeloid leukemia patients with frontline imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; World Health Organization | 2017 |
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Topics: Acetamides; Acetates; Animals; Apoptosis; Cell Proliferation; Cholesterol; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Esterification; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Mutation; Protein Kinase Inhibitors; Sulfonamides; Sulfonic Acids; Xenograft Model Antitumor Assays | 2017 |
An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.
Topics: Antineoplastic Agents; China; Chronic Disease; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Models, Economic; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Treatment Outcome | 2017 |
CHRONIC MYELOID LEUKEMIA EXPECTED RELAPSE'S CLINICAL-LABORATORY INDEXES.
Topics: Anemia; Antineoplastic Agents; Blood Platelets; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Prognosis; Recurrence; Retrospective Studies; Risk | 2017 |
Current treatment preferences in chronic myeloid leukemia: The Mayo Clinic Physicians' survey.
Topics: Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Physicians; Protein Kinase Inhibitors; Pyrimidines; Surveys and Questionnaires | 2017 |
Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection.
Topics: China; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Tuberculosis | 2017 |
Analysis of Survival of Patients with Chronic Myeloid Leukemia Treated with Imatinib in the Last 15 Years in Lebanon.
Topics: Adult; Antineoplastic Agents; Cytogenetic Analysis; Dasatinib; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Lebanon; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Salvage Therapy; Survival Rate | 2017 |
Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1.
Topics: Alleles; ATP Binding Cassette Transporter, Subfamily B; ErbB Receptors; Eye Diseases; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Polymorphism, Single Nucleotide; Solute Carrier Family 22 Member 5 | 2018 |
Women Administered Standard Dose Imatinib for Chronic Myeloid Leukemia Have Higher Dose-Adjusted Plasma Imatinib and Norimatinib Concentrations Than Men.
Topics: Adult; Aged; Cohort Studies; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Plasma; Young Adult | 2017 |
Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments.
Topics: Cluster Analysis; Gene Expression Regulation, Leukemic; Gene Ontology; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Time Factors | 2017 |
Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase.
Topics: Antineoplastic Agents; Fertility; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2017 |
Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genotype; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; RNA, Messenger; Treatment Outcome; Tunisia; Young Adult | 2017 |
Imatinib-induced psoriasiform eruption in a patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Drug Eruptions; Female; Hand Dermatoses; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Protein Kinase Inhibitors; Scalp Dermatoses; Skin Diseases, Papulosquamous | 2018 |
Adhesion to stromal cells mediates imatinib resistance in chronic myeloid leukemia through ERK and BMP signaling pathways.
Topics: Bone Morphogenetic Proteins; Cell Adhesion; Cell Communication; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Signal Transduction; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment | 2017 |
Generic Imatinib Therapy Among Jordanians: An Observational Assessment of Efficacy and Safety in Routine Clinical Practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drugs, Generic; Eye Diseases; Female; Humans; Imatinib Mesylate; Jordan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Practice Patterns, Physicians'; Prospective Studies; Treatment Outcome; Young Adult | 2017 |
Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1.
Topics: Alprostadil; Animals; beta Catenin; Cell Line, Tumor; Cell Self Renewal; Drug Synergism; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Misoprostol; Neoplastic Stem Cells; Proto-Oncogene Proteins c-fos; Receptors, Prostaglandin E, EP4 Subtype; Transcription Factor AP-1; Transcription, Genetic; Xenograft Model Antitumor Assays | 2017 |
Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drugs, Generic; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult | 2017 |
Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
Topics: Adult; Aged; Antineoplastic Agents; Developing Countries; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Improved Drug Adherence in Patients with Chronic Myeloid Leukemia in the Chronic Phase by Switching to Second-Generation Tyrosine Kinase Inhibitors.
Topics: Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2017 |
Switching-On Adherence in Chronic Myeloid Leukemia.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Protein Kinase Inhibitors | 2017 |
The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
Topics: Adult; Antineoplastic Agents; Blast Crisis; Bone Marrow; Chromosomes, Human, Pair 8; Genes, myc; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Isochromosomes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Protein Kinase Inhibitors | 2017 |
Aberrantly expressed transcription factors C/EBP and SOX4 have positive effects in the development of chronic myeloid leukemia.
Topics: Age Factors; Antineoplastic Agents; Case-Control Studies; CCAAT-Enhancer-Binding Protein-alpha; Down-Regulation; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; RNA, Messenger; Sex Factors; SOXC Transcription Factors | 2017 |
Targeting mitochondrial oxidative phosphorylation eradicates therapy-resistant chronic myeloid leukemia stem cells.
Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cell Survival; Chromatography, Liquid; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Metabolomics; Mice; Mice, Inbred NOD; Minocycline; Mitochondria; Neoplastic Stem Cells; Oxidative Phosphorylation; Phenformin; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Tigecycline; Tumor Cells, Cultured; Tumor Stem Cell Assay; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
[Treatment of chronic myeloid leukemia with imatinib : IRIS study].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2017 |
Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.
Topics: Antigens, CD; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Catenins; Cell Line, Tumor; CREB-Binding Protein; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Neoplastic Stem Cells; Phenotype; Pyrimidinones; Tumor Stem Cell Assay | 2018 |
Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Topics: Apoptosis; Autophagy; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Neoplastic Stem Cells; Protein Kinase Inhibitors; Pyridazines; Signal Transduction; Tumor Cells, Cultured | 2017 |
Association of GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms with clinical response to imatinib mesylate treatment among Malaysian chronic myeloid leukaemia patients.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Female; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Odds Ratio; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Timing and deepness of response to tyrosine kinase inhibitors as a measure of potential treatment discontinuation in chronic myeloid leukemia patients managed in the real-life.
Topics: Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2017 |
PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Topics: Adult; Antineoplastic Agents; Case-Control Studies; Female; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Receptor, Platelet-Derived Growth Factor alpha; Risk Factors; Thrombocytopenia | 2017 |
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinogenesis; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Promoter Regions, Genetic; Protein Kinase Inhibitors; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Wiskott-Aldrich Syndrome Protein | 2017 |
Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
Topics: Antineoplastic Agents; China; Cost-Benefit Analysis; Dasatinib; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Treatment Outcome | 2018 |
Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Computational Biology; Databases, Genetic; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Ion Channels; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Receptors, G-Protein-Coupled; Receptors, Peptide; Transcriptome; Tumor Cells, Cultured | 2017 |
Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph
Topics: Adamantane; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Coculture Techniques; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Synergism; Fibroblasts; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Pyrrolidines; Tumor Cells, Cultured; Vildagliptin; Xenograft Model Antitumor Assays | 2018 |
Sudden blast phase in chronic myeloid leukemia developed during nilotinib therapy after major molecular response was achieved.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Substitution; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2018 |
Membrane perturbation through novel cell-penetrating peptides influences intracellular accumulation of imatinib mesylate in CML cells.
Topics: Cell Membrane; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Diffusion; Humans; Imatinib Mesylate; Intracellular Space; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Fluidity; Membrane Microdomains | 2018 |
Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Young Adult | 2018 |
Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Topics: DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, abl; Histones; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-mdm2; Reactive Oxygen Species; Signal Transduction; STAT5 Transcription Factor; Tumor Suppressor p53-Binding Protein 1; Tumor Suppressor Protein p53 | 2018 |
Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.
Topics: AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction | 2018 |
Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.
Topics: Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Thiazoles | 2018 |
Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Pyrazoles; Pyrimidines; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2018 |
Semi‑random mutagenesis profile of BCR‑ABL during imatinib resistance acquirement in K562 cells.
Topics: Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutagenesis; Mutation; Signal Transduction | 2017 |
Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Panuveitis simulating ocular Behçet's in cases of chronic myelogenous leukaemia in remission.
Topics: Adult; Antineoplastic Agents; Behcet Syndrome; Diagnosis, Differential; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Oral Ulcer; Panuveitis; Retinal Detachment; Steroids | 2017 |
Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Topics: Aniline Compounds; Dasatinib; Drug Substitution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Time Factors; Treatment Outcome | 2018 |
Reversal of Glanzmann thrombasthenia platelet phenotype after imatinib treatment in a pediatric chronic myeloid leukemia patient.
Topics: Antineoplastic Agents; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Thrombasthenia | 2018 |
EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2018 |
Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.
Topics: Aged, 80 and over; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Phenytoin; Protein Kinase Inhibitors | 2019 |
Imatinib-related interstitial lung disease.
Topics: Adolescent; Echocardiography; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male | 2018 |
Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Exosomes; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Protein Kinase Inhibitors | 2018 |
How Does One Decide Which Tyrosine Kinase Inhibitor To Use for the Initial Treatment of Chronic-Phase Chronic Myeloid Leukemia?
Topics: Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2017 |
[Analysis of Efficacy and Related Factors of Acquired Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with TKI].
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2017 |
Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Neoplasms; Central Nervous System Neoplasms; Dasatinib; Drug Administration Schedule; Drug Substitution; Fatal Outcome; Female; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyridazines; Pyrimidines; Recurrence | 2018 |
Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Cross-Sectional Studies; Drug Eruptions; Edema; Eye Diseases; Female; Humans; Hyperpigmentation; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Mouth Diseases; Mouth Mucosa; Nail Diseases; Sex Factors; Skin Diseases, Vesiculobullous; Time Factors; Young Adult | 2018 |
Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.
Topics: Apoptosis; Caspases; Cell Survival; Exosomes; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; Signal Transduction | 2018 |
Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; RNA, Messenger; Translocation, Genetic; Treatment Outcome; Young Adult | 2018 |
Imatinib-induced pseudoporphyria.
Topics: Antineoplastic Agents; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Porphyrias; Skin | 2018 |
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclopentanes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplastic Stem Cells; Point Mutation; Pyrimidines; Ubiquitin-Activating Enzymes | 2018 |
The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
Topics: Adolescent; Antineoplastic Agents; Child; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prognosis; Retrospective Studies; Time Factors | 2018 |
Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Topics: Animals; Anthelmintics; Apoptosis; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Nude; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niclosamide; Protein Kinase Inhibitors; Signal Transduction; Sp1 Transcription Factor; Survival Analysis; Transcription, Genetic; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2018 |
The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Caryophyllaceae; Cell Survival; Cells, Cultured; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Saponins; Signal Transduction; Triterpenes | 2018 |
Expression of Hippo signaling pathway and Aurora kinase genes in chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aurora Kinase A; Aurora Kinase B; Biomarkers, Tumor; Case-Control Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Hippo Signaling Pathway; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction; Young Adult | 2018 |
[Correlation of Serum Concentration of Nilotinib with Clinical Efficacy in Patients with Chronic Myeloid Leukemia].
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Treatment Outcome | 2018 |
Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
Topics: Adult; Apoptosis; Cell Cycle Checkpoints; Cell Hypoxia; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nuclear Proteins; Tumor Microenvironment; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; Vitamin K 3 | 2018 |
Imatinib-mesylate enhances the maintenance of chronic myeloid leukemia stem cell potential in the absence of glucose.
Topics: Biomarkers, Tumor; Cell Proliferation; Cell Survival; Fusion Proteins, bcr-abl; Glucose; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nanog Homeobox Protein; Neoplastic Stem Cells; SOXB1 Transcription Factors; Tumor Stem Cell Assay | 2018 |
Monocyte subsets and their phenotypes during treatment with BCR-ABL1 tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monocytes; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Receptors, Chemokine; Scavenger Receptors, Class A | 2018 |
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Humans; Imatinib Mesylate; Janus Kinase 3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperidines; Pyrimidines; Pyrroles; Signal Transduction | 2018 |
Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrimidines; Young Adult | 2019 |
Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drugs, Generic; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Latvia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2017 |
Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Models, Biological; NF-kappa B; Phosphopeptides; Proteomics; Proto-Oncogene Proteins; Signal Transduction; src-Family Kinases | 2018 |
Enhanced perforin expression associated with dasatinib therapy in natural killer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Interferon-gamma; Interleukin-2; Janus Kinase 1; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Perforin; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor | 2018 |
Cystic acne due to imatinib therapy for chronic myelocytic leukemia.
Topics: Acne Vulgaris; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2019 |
gDNA qPCR is statistically more reliable than mRNA analysis in detecting leukemic cells to monitor CML.
Topics: Aged; DNA; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; Young Adult | 2018 |
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphofructokinase-2; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Trans-Activators; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Cytotoxic activity of fucoxanthin, alone and in combination with the cancer drugs imatinib and doxorubicin, in CML cell lines.
Topics: Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; Doxorubicin; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Xanthophylls | 2018 |
Imatinib in the treatment of chronic myeloid leukemia in children and adolescents is effective and well tolerated: Report of the Polish Pediatric Study Group for the Treatment of Leukemias and Lymphomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Poland; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Dasatinib in paediatric chronic myeloid leukaemias.
Topics: Child; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2018 |
Local Anesthetic Drug Inhibits Growth and Survival in Chronic Myeloid Leukemia Through Suppressing PI3K/Akt/mTOR.
Topics: Amides; Anesthetics, Local; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dasatinib; G2 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Ropivacaine; Signal Transduction; Stem Cells; TOR Serine-Threonine Kinases | 2018 |
[Inhibitory effect and mechanism of platycodin D combined with imatinib on K562/R].
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Saponins; Signal Transduction; Triterpenes | 2018 |
Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Editing; Genetic Vectors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Recombinational DNA Repair; Sequence Analysis, DNA; Xenograft Model Antitumor Assays; Zinc Finger Nucleases | 2018 |
Overexpression of
Topics: Adult; Apoptosis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Hexokinase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Protein Kinase Inhibitors | 2018 |
Imatinib Affects the Expression of SLC22A1 in a Non-Linear Concentration-Dependent Manner Within 24 Hours.
Topics: Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Time Factors | 2018 |
A conversation with Charles Sawyers.
Topics: Animals; Dasatinib; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Portraits as Topic; Prostatic Neoplasms, Castration-Resistant | 2018 |
Alkynylnicotinamide-Based Compounds as ABL1 Inhibitors with Potent Activities against Drug-Resistant CML Harboring ABL1(T315I) Mutant Kinase.
Topics: Alkynes; Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Isoquinolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Docking Simulation; Naphthyridines; Niacinamide; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Quinazolines | 2018 |
Cardiotoxicity in Hematological Diseases: Are the Tyrosine Kinase Inhibitors Imatinib and Nilotinib Safe?
Topics: Aged; Antineoplastic Agents; Cardiotoxicity; Echocardiography; Female; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Portugal; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Time Factors; Treatment Outcome | 2018 |
The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
Cotylenin A and tyrosine kinase inhibitors synergistically inhibit the growth of chronic myeloid leukemia cells.
Topics: Aged; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Diterpenes; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc | 2018 |
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Prazosin; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger | 2018 |
Modular synthesis of new C-aryl-nucleosides and their anti-CML activity.
Topics: Antineoplastic Agents; Catalysis; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesylates; Microtubule-Associated Proteins; Nucleosides | 2018 |
CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Topics: Antigens, CD; Antigens, CD34; Antigens, Differentiation, T-Lymphocyte; Apoptosis; CD24 Antigen; Cell Line, Tumor; Erythroid Cells; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Lectins, C-Type; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Phosphorylation; Phosphoserine; Promoter Regions, Genetic; Signal Transduction | 2018 |
[Mean Corpuscular Volume Can Be A Predictor for Therapeutic Response of Patients with Chronic Myeloid Leukemia].
Topics: Antineoplastic Agents; Erythrocyte Indices; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2018 |
[Imatinib as Second-Line Treatment Drug for CML Patients Intolerant to Nilotinib].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2018 |
The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis.
Topics: Age Factors; Blast Crisis; Cost-Benefit Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Socioeconomic Factors | 2018 |
Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Remission Induction; Survival Analysis; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Sesquiterpenes; Signal Transduction; STAT5 Transcription Factor | 2018 |
Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.
Topics: Animals; Antineoplastic Agents; Binding Sites; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heat-Shock Response; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Molecular Conformation; Molecular Structure; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Protein Multimerization; Spectrum Analysis; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2018 |
Generic Price Competition For Specialty Drugs: Too Little, Too Late?
Topics: Antineoplastic Agents; Cost Savings; Dasatinib; Databases, Factual; Drug Costs; Drugs, Generic; Economic Competition; Female; Humans; Imatinib Mesylate; Insurance, Pharmaceutical Services; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Marketing; Outpatients; Retrospective Studies; United States | 2018 |
Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cell Line, Tumor; Cohort Studies; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Random Allocation; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Transcriptome | 2018 |
Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Culture Techniques; Cell Survival; Dasatinib; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neovascularization, Physiologic; Nitriles; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinolines; RNA-Seq; Signal Transduction; Toxicity Tests; Transcription, Genetic | 2019 |
Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Young Adult | 2018 |
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biotransformation; Cardiovascular Diseases; Creatinine; Dasatinib; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Kidney Tubules; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myocardial Ischemia; Protein Kinase Inhibitors; Pyrimidines; Renal Insufficiency, Chronic; Retrospective Studies; Young Adult | 2018 |
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Biological Transport; Carrier Proteins; Caspases; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Neoplasm Proteins; Point Mutation; Protein Kinase Inhibitors | 2018 |
Down-regulation of CD19 expression inhibits proliferation, adhesion, migration and invasion and promotes apoptosis and the efficacy of chemotherapeutic agents and imatinib in SUP-B15 cells.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD19; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction | 2018 |
Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
Topics: Acetates; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclopropanes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukotriene Antagonists; Protein Kinase Inhibitors; Quinolines; Receptors, Leukotriene; Signal Transduction; Sulfides | 2018 |
The impact of sample processing delay on deep molecular responses in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Real-Time Polymerase Chain Reaction; Specimen Handling | 2019 |
microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2 signaling-mediated protective autophagy in imatinib-resistant chronic myeloid leukemia cells.
Topics: 3' Untranslated Regions; Apoptosis; Autophagy; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Signal Transduction; Treatment Outcome; Wnt2 Protein | 2018 |
Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Survival Analysis; Transcription, Genetic; Treatment Outcome; Young Adult | 2018 |
PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Line, Tumor; Coculture Techniques; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Phthalazines; Poly (ADP-Ribose) Polymerase-1; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib.\
A First of Its Kind Study on CML Patients of Kashmir
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Child; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2018 |
Re-Expression of Bone Marrow Proteoglycan-2 by 5-Azacytidine is associated with STAT3 Inactivation and Sensitivity\
Response to Imatinib in Resistant CML Cells
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Azacitidine; Bone Marrow; Cell Proliferation; Drug Resistance, Neoplasm; Eosinophil Major Basic Protein; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proteoglycans; STAT3 Transcription Factor; Tumor Cells, Cultured | 2018 |
Thrombopoietin Levels During Tyrosine Kinase Inhibitor Therapy for Chronic Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cohort Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Platelet Count; Protein Kinase Inhibitors; Thrombopoietin | 2018 |
Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Topics: beta Catenin; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Transcription Factor RelA; Transcription Factors | 2018 |
Side effects and medication adherence of tyrosine kinase inhibitors for patients with chronic myeloid leukemia in Taiwan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Protein-Tyrosine Kinases; Retrospective Studies; Sex Factors; Socioeconomic Factors; Taiwan; Young Adult | 2018 |
T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system.
Topics: Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Homologous Recombination; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Schiff Bases | 2018 |
Topics: Adolescent; Adult; Aged; Aged, 80 and over; DNA, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Protein Kinase Inhibitors; Young Adult | 2018 |
Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.
Topics: Adult; Antigens, Surface; Antineoplastic Agents; Carbonic Anhydrases; Drug Resistance, Neoplasm; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Transport Proteins; Middle Aged; Milk Proteins; Mutation; Prognosis; Protein Kinase Inhibitors | 2018 |
HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1.
Topics: Animals; Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; MicroRNAs; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines | 2018 |
Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm, Residual; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2018 |
Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Interleukin-6; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Phenanthrenes; Phosphorylation; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor; STAT5 Transcription Factor | 2018 |
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.
Topics: Anthropometry; Antineoplastic Agents; Dasatinib; Glucose Intolerance; Humans; Hyperinsulinism; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines | 2018 |
Inhibition of ER stress-related IRE1α/CREB/NLRP1 pathway promotes the apoptosis of human chronic myelogenous leukemia cell.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Down-Regulation; Endoplasmic Reticulum Stress; Endoribonucleases; Humans; Imatinib Mesylate; Inflammasomes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NLR Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Signal Transduction; Up-Regulation | 2018 |
An atypical isolated CNS blast crisis in chronic myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Blast Crisis; Brain; Central Nervous System Diseases; Cytarabine; Glucocorticoids; Humans; Image Enhancement; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Maintenance Chemotherapy; Male; Methotrexate; Neuroimaging; Spinal Cord; Treatment Outcome | 2018 |
Imatinib resistance due to a novel and rare class of mutation at position S348 (1043nt C→A) of Bcr/Abl gene in a chronic myeloid leukemia patient.
Topics: Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Point Mutation | 2018 |
Quantitative prediction of long-term molecular response in TKI-treated CML - Lessons from an imatinib versus dasatinib comparison.
Topics: Biomarkers, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplastic Stem Cells; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Treatment Outcome | 2018 |
[Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia].
Topics: Adult; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Treatment Outcome; Young Adult | 2019 |
The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells.
Topics: Cell Proliferation; Cell Survival; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-myc; PTB-Associated Splicing Factor; RNA, Long Noncoding; Sequence Analysis, RNA | 2018 |
Novel AF1q/MLLT11 favorably affects imatinib resistance and cell survival in chronic myeloid leukemia.
Topics: Antigens, CD34; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Hyaluronan Receptors; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins | 2018 |
Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Topics: Adult; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Regression Analysis; Treatment Outcome | 2019 |
Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.
Topics: Animals; Antiviral Agents; CD8-Positive T-Lymphocytes; Dendritic Cells; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immune System; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; T-Lymphocytes | 2018 |
[Chronic Myelogenous Leukemia].
Topics: Aniline Compounds; Antineoplastic Agents; Blast Crisis; Cytogenetic Analysis; Dasatinib; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Complications, Neoplastic; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines | 2018 |
Myasthenia gravis unmasked by imatinib.
Topics: Adult; Blepharoptosis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myasthenia Gravis; Neostigmine; Prednisolone; Pyridostigmine Bromide | 2019 |
Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: Involvement of ER stress and DAMP release.
Topics: Alarmins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum Stress; Homoharringtonine; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Mice; Phagocytosis; Xenograft Model Antitumor Assays; Zebrafish | 2018 |
BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562 cells.
Topics: Activating Transcription Factor 4; Apoptosis; Dasatinib; eIF-2 Kinase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Signal Transduction; Stress, Physiological | 2018 |
Targeting the Extracellular Signal-Regulated Kinase 5 Pathway to Suppress Human Chronic Myeloid Leukemia Stem Cells.
Topics: Adult; Aged; Animals; Antigens, CD34; Benzodiazepinones; Cell Count; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice, Inbred C57BL; Middle Aged; Mitogen-Activated Protein Kinase 7; Molecular Targeted Therapy; Neoplastic Stem Cells; Oxygen; Protein Kinase Inhibitors; Tumor Stem Cell Assay | 2018 |
Synergistic activity of imatinib and AR-42 against chronic myeloid leukemia cells mainly through HDAC1 inhibition.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Drug Combinations; Drug Synergism; Gene Expression Regulation, Enzymologic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenylbutyrates; Tumor Cells, Cultured | 2018 |
Vitamin D and tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrazoles; Pyrimidines; Vitamin D | 2018 |
Heme oxygenase-1 reduces the sensitivity to imatinib through nonselective activation of histone deacetylases in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Histone Deacetylases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction; Young Adult | 2019 |
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heme Oxygenase-1; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation | 2018 |
Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate.
Topics: Adult; Dermal Fillers; Esthetics; Female; Humans; Hyaluronic Acid; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nose | 2019 |
Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Topics: Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2018 |
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/β-catenin signaling.
Topics: Anisomycin; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Wnt Signaling Pathway | 2018 |
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Long-Term Care; Male; Middle Aged; Protein Kinase Inhibitors; Remission Induction; RNA, Messenger; Treatment Outcome | 2018 |
Recurrent chronic myeloid leukemia with t (9;22;16) (q34; q11; p13) treated by nilotinib: A case report.
Topics: Antineoplastic Agents; Chromosomes, Human, 16-18; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Neoplasm Recurrence, Local; Philadelphia Chromosome; Pyrimidines; Translocation, Genetic | 2018 |
Early molecular response ≤1% has strong prognostic impact for CML patients that switch to second-line therapy with BCR-ABL1 ≤10% and no major molecular response.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Drug Substitution; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Survival Analysis; Young Adult | 2019 |
Results of Outcome of Two Pregnancies with Imatinib.
Topics: Adult; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Twin; Premature Birth; Protein Kinase Inhibitors | 2018 |
LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia.
Topics: Base Sequence; CCAAT-Enhancer-Binding Proteins; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; RNA, Long Noncoding; Up-Regulation | 2018 |
Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.
Topics: Aged; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Kallikreins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Receptors, Androgen; RNA, Messenger | 2019 |
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report.
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Monoclonal Gammopathy of Undetermined Significance; Mutation; Positive Regulatory Domain I-Binding Factor 1; Prednisolone; Prevalence; Thalidomide; Treatment Outcome | 2018 |
Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor.
Topics: Adult; Antineoplastic Agents; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Fasting; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Acquisition of Inv(16)(p13q22) in a blast crisis of chronic myeloid leukemia: case report.
Topics: Abnormal Karyotype; Adult; Antineoplastic Agents; Blast Crisis; Chromosome Inversion; Chromosomes, Human, Pair 16; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Translocation, Genetic; Trisomy | 2019 |
Apheresis principles in a patient with chronic myeloid leukemia during pregnancy: challenges in cell separation and assessing transcript levels.
Topics: Adult; Blood Component Removal; Cell Separation; Female; Gestational Age; Humans; Imatinib Mesylate; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy | 2019 |
The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.
Topics: Age Factors; Aged; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors | 2018 |
AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amplified Fragment Length Polymorphism Analysis; Antineoplastic Agents; Base Sequence; Case-Control Studies; Cohort Studies; Computational Biology; Computer Simulation; DNA Fingerprinting; DNA, Neoplasm; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Repetitive Sequences, Nucleic Acid; Sequence Analysis, DNA; Young Adult | 2018 |
Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Eugenol; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reactive Oxygen Species; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2019 |
MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Repressor Proteins | 2018 |
A chronic myeloid leukemia case with a variant translocation t(11;22) (q23;q11.2): masked Philadelphia or simple variant translocation?
Topics: Adult; Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Translocation, Genetic | 2018 |
Case 3: Priapism in a 13-year-old Boy.
Topics: Adolescent; Antineoplastic Agents; Blood Cell Count; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukostasis; Male; Priapism | 2018 |
MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Prognosis; STAT5 Transcription Factor; Tumor Cells, Cultured; Young Adult | 2019 |
Ponatinib induces a sustained deep molecular response in a chronic myeloid leukaemia patient with an early relapse with a T315I mutation following allogeneic hematopoietic stem cell transplantation: a case report.
Topics: Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pyridazines; Recurrence | 2018 |
Overexpression of Hes1 is involved in sensitization of K562 cells to Imatinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Forkhead Box Protein O1; Forkhead Box Protein O3; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Naphthoquinones; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Transcription Factor HES-1 | 2019 |
Myeloproliferative neoplasm with ABL1/ETV6 rearrangement mimics chronic myeloid leukemia and responds to tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Chromosome Aberrations; Dasatinib; ETS Translocation Variant 6 Protein; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-ets; Repressor Proteins | 2018 |
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell Survival; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Oxo-Acid-Lyases; Prognosis; Protein Kinase Inhibitors; Survival Rate; Tumor Cells, Cultured; Young Adult | 2019 |
CASE OF DEVELOPMENT OF NON-HODGKIN'S MALIGNANT LYMPHOMA ON THE BACKGROUND OF CHRONIC MYELOID LEUKEMIA IN A PATIENT WHO SUFFERED OF THE CHORNOBYL ACCIDENT.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chernobyl Nuclear Accident; Cyclophosphamide; Doxorubicin; Environmental Exposure; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell; Middle Aged; Prednisone; Radiation Exposure; Radiation, Ionizing; Treatment Outcome; Ukraine; Vincristine | 2018 |
Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Mutation; Prevalence; Protein Kinase Inhibitors; Young Adult | 2018 |
Imatinib is still recommended for frontline therapy for CML.
Topics: Clinical Trials as Topic; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Progression-Free Survival; Protein Kinase Inhibitors; Survival Rate; Treatment Outcome | 2018 |
B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2
Topics: DNA Mutational Analysis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Recurrence; Remission Induction; Transplantation, Autologous | 2019 |
Low-dose staurosporine selectively reverses BCR-ABL-independent IM resistance through PKC-α-mediated G2/M phase arrest in chronic myeloid leukaemia.
Topics: Animals; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; G2 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; M Phase Cell Cycle Checkpoints; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase C-alpha; Staurosporine; Xenograft Model Antitumor Assays | 2018 |
Persistence with generic imatinib for chronic myeloid leukemia: a matched cohort study.
Topics: Antineoplastic Agents; Case-Control Studies; Drugs, Generic; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate | 2019 |
[A retrospective analysis of the efficacy and safety of imatinib in children with chronic myeloid leukemia during chronic phase].
Topics: Antineoplastic Agents; Child; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Retrospective Studies; Treatment Outcome | 2019 |
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2019 |
Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?
Topics: Biomarkers; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase | 2019 |
Plasma imatinib trough level measurements is still appropriate to predict therapeutic responses in patients with chronic myeloid leukemia.
Topics: Biomarkers; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase | 2019 |
Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Primary Myelofibrosis; Protein Kinase Inhibitors | 2019 |
Imatinib Uptake into Cells is Not Mediated by Organic Cation Transporters OCT1, OCT2, or OCT3, But is Influenced by Extracellular pH.
Topics: Animals; Extracellular Space; HEK293 Cells; Humans; Hydrogen-Ion Concentration; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Oocytes; Organic Cation Transport Proteins; Organic Cation Transporter 2; Protein Kinase Inhibitors; Xenopus laevis | 2019 |
Chronic myeloid leukaemia in pregnancy: call for guidelines.
Topics: Adult; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome | 2019 |
Imatinib-Induced Changes in Protein Expression and ATP-Binding Affinities of Kinases in Chronic Myelocytic Leukemia Cells.
Topics: Adenosine Triphosphate; DNA Damage; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Binding; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Proto-Oncogene Proteins c-abl | 2019 |
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Dynamics Simulation; Mutation; Protein Conformation; Protein Domains; Protein Kinase Inhibitors; Structure-Activity Relationship | 2019 |
Imatinib treatments have long-term impact on placentation and embryo survival.
Topics: Animals; Antineoplastic Agents; Embryo Implantation; Embryo, Mammalian; Female; Gastrointestinal Stromal Tumors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Animal; Placentation; Pregnancy | 2019 |
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.
Topics: Adult; Aged; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2019 |
Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up.
Topics: Adolescent; Antineoplastic Agents; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha | 2019 |
Imatinib-induced irreversible interstitial lung disease: A case report.
Topics: Glucocorticoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Lung Diseases, Interstitial; Male; Middle Aged; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Tomography, X-Ray Computed | 2019 |
Topics: Blast Crisis; Cell Differentiation; Disease Progression; Drug Resistance, Neoplasm; Exome Sequencing; Female; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Mutation; Protein Kinase Inhibitors; Sequence Analysis, DNA; Ubiquitin-Conjugating Enzymes | 2019 |
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.
Topics: Adult; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Safety-Based Drug Withdrawals; Treatment Outcome | 2019 |
Network meta-analysis: a new analysis tool of the experimental evidence.
Topics: Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Dabigatran; Dasatinib; Data Interpretation, Statistical; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Network Meta-Analysis; Pyrimidines; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Warfarin | 2019 |
Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Differentiation; Cell Line, Tumor; Cell Survival; Diterpenes; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Molecular Structure | 2019 |
A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Monitoring, Physiologic; Neoplasm, Residual; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Withholding Treatment; Young Adult | 2019 |
Discontinuation of imatinib in children with chronic myeloid leukaemia in sustained deep molecular remission: results of the STOP IMAPED study.
Topics: Adolescent; Antineoplastic Agents; Child; Drug Substitution; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Registries; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation.
Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HLA-A24 Antigen; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Phosphatase 2; Quinolones; Thiophenes; Young Adult | 2019 |
Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
Topics: Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lotus | 2019 |
Exome, transcriptome and miRNA analysis don't reveal any molecular markers of TKI efficacy in primary CML patients.
Topics: Adult; Aged; Biomarkers, Tumor; Exome; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Transcriptome; Treatment Outcome; Young Adult | 2019 |
A Large Gray-Blue Macule on the Hard Palate as an Adverse Effect of Imatinib.
Topics: Aged; Antineoplastic Agents; Female; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Palate, Hard; Skin | 2019 |
Differential gene expression changes and their implication on the disease progression in patients with Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Prognosis; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2019 |
Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Topics: Adolescent; Adult; Animals; Antigens, CD; Antineoplastic Agents; Carcinogenesis; Cell Line, Tumor; Child, Preschool; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Oligoribonucleotides; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Transferrin; RNA, Long Noncoding; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Epstein-Barr virus-associated lymphoproliferative disease during imatinib mesylate treatment for chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epstein-Barr Virus Infections; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Lymphoproliferative Disorders; Male; Prednisone; Protein Kinase Inhibitors; Splenomegaly; Tomography, X-Ray Computed; Vincristine | 2019 |
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Chronic Disease; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Time Factors; Transcription, Genetic | 2019 |
Is DNA a better assay for residual disease in chronic myeloid leukemia?
Topics: DNA; Genomics; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Polymerase Chain Reaction | 2018 |
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function?
Topics: Adult; Aged; Antineoplastic Agents; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nephroblastoma Overexpressed Protein; Promoter Regions, Genetic; Protein Kinase Inhibitors | 2019 |
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Autophagy; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; Mice, Transgenic; Protein Kinase Inhibitors | 2019 |
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia?
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2019 |
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aniline Compounds; Antineoplastic Agents; Brain Ischemia; Dasatinib; Disease Susceptibility; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myocardial Infarction; Nitriles; Peripheral Vascular Diseases; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Retrospective Studies | 2019 |
Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute - Mexico, from 2000 to 2016.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mexico; Middle Aged; National Cancer Institute (U.S.); Prognosis; Survival Analysis; Treatment Outcome; United States; Young Adult | 2019 |
First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Registries; Retrospective Studies; Survival Rate | 2019 |
Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Hydrazones; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2019 |
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; RNA, Messenger; Treatment Outcome | 2019 |
Prosurvival kinase PIM2 is a therapeutic target for eradication of chronic myeloid leukemia stem cells.
Topics: Animals; bcl-Associated Death Protein; Biphenyl Compounds; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; STAT Transcription Factors; Thiazolidines | 2019 |
HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
Topics: Acetylation; Apoptosis; CRISPR-Cas Systems; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockout Techniques; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Panobinostat | 2019 |
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Epigenesis, Genetic; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Rate; Treatment Failure; Young Adult | 2019 |
Economic modeling to evaluate the impact of chronic myeloid leukemia therapy management on the oncology care model in the US.
Topics: Antineoplastic Agents; Biosimilar Pharmaceuticals; Health Expenditures; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Economic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Reimbursement, Incentive | 2019 |
RNA Sequencing Analysis for the Identification of a PCM1/PDGFRB Fusion Gene Responsive to Imatinib.
Topics: Autoantigens; Cell Cycle Proteins; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Sequence Analysis, RNA; Translocation, Genetic | 2019 |
[Pre-therapeutic and evolutive characteristics of patients suffering from chronic myeloid leukemia, in Abidjan, Ivory Coast].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Blood Cell Count; Chromosome Aberrations; Cote d'Ivoire; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Cells, Circulating; Philadelphia Chromosome; Prognosis; Remission Induction; Retrospective Studies; Socioeconomic Factors; Young Adult | 2019 |
The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Topics: Aurora Kinase A; Benzamides; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrazoles; Signal Transduction; Thiostrepton; Up-Regulation | 2019 |
Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia.
Topics: Aniline Compounds; Computer Simulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Pyrimidines; Quinolines; Software; Stochastic Processes | 2019 |
Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B/Bcl-2 pathway.
Topics: Animals; Apoptosis; Bone Marrow; Cell Line, Tumor; Cysteine-Rich Protein 61; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Up-Regulation | 2019 |
Age, gender and efflux transporter activity influence imatinib efficacy in chronic myeloid leukemia patients.
Topics: Adult; Age Factors; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Biological Transport; Biomarkers, Tumor; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Primary Cell Culture; Progesterone; Proto-Oncogene Proteins c-abl; Sex Factors; Treatment Outcome | 2019 |
Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Withholding Treatment | 2019 |
Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon.
Topics: Antineoplastic Agents; Dasatinib; Disease-Free Survival; Economics; Female; Health Expenditures; Humans; Imatinib Mesylate; Lebanon; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lost to Follow-Up; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2019 |
Discovery of novel Bcr-Abl
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Mutation; Piperazines; Pliability; Protein Binding; Protein Kinase Inhibitors | 2019 |
Dasatinib-induced nephrotic syndrome: a case of phenoconversion.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nephrotic Syndrome; Pharmacogenomic Testing; Phenotype; Protein Kinase Inhibitors; Pyrimidines | 2019 |
Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cohort Studies; Female; Genes, abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Polymerase Chain Reaction; Repetitive Sequences, Nucleic Acid; Young Adult | 2019 |
[Effect of Stably Down-regulating FMI Expression of K562 Cells on Sensitivity of K562 cells to Imatinib Mesylate].
Topics: Apoptosis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear | 2019 |
[Values of Different Prognostical Score Systems in Evaluation of Clinical Efficacy for Patients with Newly Diagnosed Chronic Myeloid Leukemia].
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Risk Factors; Treatment Outcome | 2019 |
The true value of second-generation TKIs as first-line therapy in chronic myeloid leukaemia.
Topics: Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2019 |
Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drugs, Generic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Quality-Adjusted Life Years; Remission Induction | 2019 |
The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients.
Topics: Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pancreatic alpha-Amylases; Pancreatitis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Salivary alpha-Amylases; Treatment Outcome | 2019 |
Knockdown of ribonucleotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib‑based therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Case-Control Studies; Cell Proliferation; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Cells, Cultured; Young Adult | 2019 |
Generic Imatinib in Chronic Myeloid Leukemia Treatment: Long-Term Follow-up.
Topics: Adult; Aged; Antineoplastic Agents; Drugs, Generic; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Protein Kinase Inhibitors; Treatment Outcome | 2019 |
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
Topics: Aged; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intervertebral Disc Degeneration; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelitis, Transverse; Optic Neuritis; Protein Kinase Inhibitors | 2019 |
Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
Topics: Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cyclin D1; Glycolysis; Humans; Imatinib Mesylate; Lactic Acid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oxidative Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-myc; STAT3 Transcription Factor | 2019 |
The tolerability issue of generic imatinib in patients with chronic myeloid leukemia
Topics: Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2019 |
MicroRNA signature refine response prediction in CML.
Topics: Adult; Aged; Biomarkers, Tumor; Cell Transformation, Neoplastic; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Prognosis; Protein Kinase Inhibitors; Survival Rate; Tumor Cells, Cultured | 2019 |
Lack of association between functional polymorphism of DNA repair genes (XRCC1, XPD) and clinical response in Indian chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymorphism, Genetic; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2019 |
Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission.
Topics: Aged; Antineoplastic Agents; Biomarkers; Female; Genetic Variation; Genotype; Haplotypes; Humans; Imatinib Mesylate; Immunophenotyping; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Receptors, KIR; Receptors, KIR2DL5; Remission Induction; Treatment Outcome; Withholding Treatment | 2019 |
Imatinib-induced platelet dysfunction and hypofibrinogenemia in chronic myeloid leukemia.
Topics: Afibrinogenemia; Blood Platelet Disorders; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Pyrimidines | 2019 |
Imatinib Mesylate Induced Erythroderma.
Topics: Antineoplastic Agents; Dermatitis, Exfoliative; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged | 2018 |
Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene.
Topics: Antineoplastic Agents; Cytoskeletal Proteins; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic | 2019 |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
Topics: Apoptosis; Cell Line, Tumor; Cyclopentanes; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; S Phase Cell Cycle Checkpoints; Signal Transduction; Ubiquitin-Activating Enzymes | 2019 |
Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia.
Topics: Chromatography, High Pressure Liquid; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tandem Mass Spectrometry | 2019 |
Current treatment of myeloproliferative neoplasias: three scenarios.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Niacinamide; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Recurrence; Remission Induction; Thrombocythemia, Essential; Time Factors; Withholding Treatment | 2020 |
Hyaluronan abrogates imatinib-induced senescence in chronic myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hymecromone; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2019 |
Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.
Topics: Dasatinib; Echocardiography; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lupus Erythematosus, Systemic; Male; Middle Aged; Pericardial Effusion; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines | 2020 |
Chronic myeloid leukemia: advances in diagnosis and management.
Topics: Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles | 2013 |
Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Fatigue Syndrome, Chronic; Female; Health Surveys; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Muscle Cramp; Musculoskeletal Pain; Piperazines; Pyrimidines; Quality of Life; Social Behavior; Young Adult | 2013 |
Successful management of imatinib despite alopecia and nail necrosis.
Topics: Alopecia; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Necrosis; Paronychia; Piperazines; Pyrimidines | 2013 |
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Benzamides; Biological Transport; Bone Marrow Cells; Cell Line, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Nuclear Proteins; Osmolar Concentration; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2013 |
Allogeneic hematopoietic stem cell transplantation for the treatment of chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetics; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mexico; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Topics: Benzamides; Blast Crisis; Clone Cells; Dasatinib; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Substitution; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sequence Analysis, DNA; Thiazoles | 2013 |
The roles of macromolecules in imatinib resistance of chronic myeloid leukemia cells by Fourier transform infrared spectroscopy.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macromolecular Substances; Piperazines; Pyrimidines; Spectroscopy, Fourier Transform Infrared | 2013 |
Arginine homozygosity in codon 72 of p53 correlates with failure to imatinib response in chronic myeloid leukemia.
Topics: Adult; Alleles; Antineoplastic Agents; Arginine; Benzamides; Codon; Female; Genetic Predisposition to Disease; Genotype; Heterozygote; Homozygote; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymorphism, Genetic; Proline; Pyrimidines; Tumor Suppressor Protein p53 | 2013 |
Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Topics: Animals; Apoptosis; Base Pairing; Base Sequence; Benzamides; Catalysis; Cell Line, Tumor; Cell Survival; DNA, Catalytic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Point Mutation; Pyrimidines; Transcription, Genetic | 2013 |
A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor.
Topics: Benzamides; Biosensing Techniques; Cell-Penetrating Peptides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2013 |
Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome; Young Adult | 2013 |
High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Diagnosis, Differential; Humans; Imatinib Mesylate; Intestinal Neoplasms; Intestine, Small; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Thiazoles; Vimentin | 2013 |
Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2013 |
Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Topics: Adenine; Animals; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzamides; Cell Line, Tumor; Down-Regulation; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Phagosomes; Piperazines; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Pyrimidines; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Overcoming chronic myeloid leukemia stem cell resistance to imatinib by also targeting JAK2.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfilament Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Administration, Oral; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Biological Availability; Blotting, Western; Cell Proliferation; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoprecipitation; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Microfilament Proteins; Mutation; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Sulfonamides; Up-Regulation | 2013 |
New concepts for CML clonality.
Topics: Base Sequence; Benzamides; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyridazines; Pyrimidines | 2013 |
Pseudoporphyria induced by imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Hand Dermatoses; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Porphyrins; Pyrimidines; Skin Diseases, Vesiculobullous | 2014 |
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib.
Topics: Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Cohort Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peripheral Arterial Disease; Piperazines; Pyrimidines | 2013 |
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.
Topics: Aged; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Pyrimidines; Retrospective Studies | 2013 |
[Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].
Topics: Benzamides; Dasatinib; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Medicine. (De)personalized medicine.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Myocardial Infarction; Piperazines; Precision Medicine; Pyrimidines | 2013 |
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.
Topics: Absorptiometry, Photon; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers; Bone Density; Bone Resorption; Collagen Type I; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Osteocalcin; Osteogenesis; Peptides; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Survival Rate; Young Adult | 2013 |
Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Benzamides; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome; Virus Activation | 2013 |
HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Agents; Benzamides; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Silencing; Homeodomain Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Promoter Regions, Genetic; Pyrimidines; Transcription Factors | 2013 |
Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
[Chronic myeloid leukemia maintained major molecular response with intermittent dosage of imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Vomiting | 2013 |
Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Clinical Trials as Topic; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Prognosis; Pyrimidines; Remission Induction; Sex Factors; Withholding Treatment | 2013 |
Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence.
Topics: Animals; Apoptosis; Benzamides; Cell Cycle; Down-Regulation; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Hematopoietic Stem Cells; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyrimidines; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2013 |
Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, abl; HSP90 Heat-Shock Proteins; Humans; Hydroxyurea; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Survivin | 2013 |
Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers; Child; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation Rate; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2013 |
EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Treatment Outcome; Young Adult | 2013 |
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cells, Cultured; DNA Damage; Drug Resistance, Neoplasm; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplastic Stem Cells; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species | 2013 |
Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
The treatment of children suffering from chronic myelogenous leukemia: a comparison of the result of treatment with imatinib mesylate and allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Cross-Sectional Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Time Factors; Transplantation, Homologous; Treatment Outcome | 2013 |
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
Topics: Apoptosis; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2013 |
Imatinib induces body mass changes in women with chronic myeloid leukemia.
Topics: Adult; Benzamides; Body Mass Index; Cohort Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Retrospective Studies; Weight Gain | 2013 |
Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Comorbidity; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
Multiple skin chloromas: a rare presentation of chronic myelogenous leukaemia in chronic stable phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sarcoma, Myeloid; Skin Neoplasms | 2013 |
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Asian People; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Young Adult | 2013 |
Study of Abl1 tyrosine kinase inhibitors by liquid chromatography-electrospray ionization-mass spectrometry.
Topics: Amino Acid Sequence; Benzamides; Biological Products; Caffeic Acids; Catechin; Chromatography, Liquid; Drug Discovery; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spectrometry, Mass, Electrospray Ionization | 2013 |
Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice.
Topics: Animals; Antineoplastic Agents; Antioxidants; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin Receptor Common gamma Subunit; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Piperazines; Pyrimidines; Vitamin E | 2013 |
Perforating folliculitis in a patient treated with nilotinib: a further evidence of C-kit involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Eruptions; Folliculitis; Hair Follicle; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thiazoles | 2014 |
Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Deletion; Humans; Imatinib Mesylate; Lactones; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; NF-kappa B; Piperazines; Pyrimidines; Sesquiterpenes, Eudesmane; Signal Transduction | 2013 |
Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thrombocythemia, Essential | 2013 |
Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Topics: Aclarubicin; Apoptosis; bcl-X Protein; Benzamides; Caspase 3; Cell Differentiation; Cell Proliferation; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Erythroid Cells; fas Receptor; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2013 |
A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Thiazoles; United Kingdom; Young Adult | 2013 |
Phosphorylation of serine palmitoyltransferase long chain-1 (SPTLC1) on tyrosine 164 inhibits its activity and promotes cell survival.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Nucleus; Cell Survival; Ceramides; Dogs; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Golgi Apparatus; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microsomes; Peptide Fragments; Phosphorylation; Phosphotyrosine; Piperazines; Protein Processing, Post-Translational; Protein Transport; Proteome; Pyrimidines; RNA, Small Interfering; Serine C-Palmitoyltransferase; Transcription, Genetic | 2013 |
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Monitoring of imatinib targeted delivery in human leukocytes.
Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
Periungual pyogenic granuloma following imatinib therapy in a patient with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Female; Granuloma, Pyogenic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Nail Diseases; Piperazines; Pyrimidines | 2013 |
Cancer of cervical stump diagnosed in a woman with chronic myelogenous leukaemia.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Uterine Cervical Neoplasms | 2013 |
Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Structure, Tertiary; Pyrimidines; Translocation, Genetic | 2013 |
Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines | 2013 |
[Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2013 |
Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Structure, Tertiary; Pyrimidines; Young Adult | 2013 |
Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Drug Resistance, Neoplasm; Egypt; Female; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
The occurrence of second neoplasms after treatment with tyrosine kinase inhibitors for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Young Adult | 2014 |
Imatinib results in better outcomes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Cohort Studies; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Siblings; Treatment Outcome; Young Adult | 2013 |
Multiple skin lesions caused by imatinib mesylate treatment of chronic myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Piperazines; Pyrimidines | 2013 |
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Validation Studies as Topic; Young Adult | 2013 |
Identification of Annexin A1 interacting proteins in chronic myeloid leukemia KCL22 cells.
Topics: Annexin A1; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Chromatography, Liquid; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Binding; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proteome; Proteomics; Pyrimidines; Signal Transduction; Tandem Mass Spectrometry; Treatment Outcome | 2013 |
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib.
Topics: Benzamides; CD8-Positive T-Lymphocytes; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome; Up-Regulation | 2013 |
The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-α in CML cell line, KT-1 cells.
Topics: Antiviral Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Pyrimidines; RNA, Small Interfering; Signal Transduction; STAT1 Transcription Factor; Tumor Cells, Cultured | 2013 |
A novel 5-way translocation t(9;11;13;19;22) in a case of chronic-phase chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Spectral Karyotyping; Translocation, Genetic; Treatment Outcome | 2013 |
Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?
Topics: Amantadine; Analgesics, Non-Narcotic; Antineoplastic Agents; Benzamides; Biological Transport, Active; Cell Line, Tumor; HEK293 Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Pyrimidines | 2013 |
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2013 |
BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance.
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies | 2013 |
Leukaemia.
Topics: Benzamides; Child; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2013 |
Perspective: combined forces.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins v-abl; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors | 2013 |
Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;).
Topics: Adult; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Sirolimus | 2013 |
Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult | 2013 |
[The combination of chronic myeloid leukemia and multiple myeloma in one patient].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Boronic Acids; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Induction Chemotherapy; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Piperazines; Polyneuropathies; Pyrazines; Pyrimidines; Recurrence; Watchful Waiting | 2013 |
[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Topics: Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2013 |
MDM2 promoter polymorphism and p53 codon 72 polymorphism in chronic myeloid leukemia: the association between MDM2 promoter genotype and disease susceptibility, age of onset, and blast-free survival in chronic phase patients receiving imatinib.
Topics: Adult; Age of Onset; Asian People; Benzamides; Case-Control Studies; Codon; Female; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Tumor Suppressor Protein p53 | 2014 |
Is Imatinib Maintenance Required for Patients with Relapse Chronic Myeloid Leukemia Post-Transplantation Obtaining CMR? A Pilot Retrospective Investigation.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Recurrence; Retrospective Studies; Survival Analysis; Young Adult | 2013 |
Fifteenth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Dasatinib; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Staging; Piperazines; Platelet Transfusion; Prednisone; Primary Prevention; Procarbazine; Pyrimidines; Randomized Controlled Trials as Topic; Rituximab; Stem Cell Transplantation; Survival Analysis; Thiazoles; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Vincristine; Vindesine | 2013 |
Nilotinib-induced interstitial lung disease.
Topics: Aged; Benzamides; Diagnosis, Differential; Drug Substitution; Female; Glucocorticoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Lung Diseases, Interstitial; Piperazines; Prednisolone; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Radiography, Thoracic; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Endogenous erythroid colony formation in chronic myeloid leukemia: a recurrent finding associated with persistent minimal residual disease under imatinib.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biopsy; Bone Marrow; Case-Control Studies; Cell Proliferation; Colony-Forming Units Assay; Erythroid Cells; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; STAT5 Transcription Factor; Treatment Outcome; Young Adult | 2013 |
Endoplasmic reticulum stress-mediated apoptosis in imatinib-resistant leukemic K562-r cells triggered by AMN107 combined with arsenic trioxide.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Time Factors; Treatment Outcome | 2013 |
TWIST it but don't spin it.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Withholding Treatment | 2013 |
KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.
Topics: Animals; Antigens, CD34; Apoptosis; Benzamides; Blotting, Western; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stem Cell Factor; Stromal Cells; Tumor Cells, Cultured | 2013 |
XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Cell Survival; Child; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; Survivin; X-Linked Inhibitor of Apoptosis Protein; Young Adult | 2013 |
What challenges remain in chronic myeloid leukemia research?
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Translational Research, Biomedical | 2013 |
Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Sex Factors; Treatment Outcome | 2014 |
Kinase inhibitor therapy in CML: it's what's inside that counts.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Bone Marrow Transplantation; Cell Transformation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Oxides; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Survival Rate; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2014 |
Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Administration Schedule; Drug Utilization Review; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; United States; Veterans | 2013 |
Imatinib induces demethylation of miR-203 gene: an epigenetic mechanism of anti-tumor effect of imatinib.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; CpG Islands; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Epigenesis, Genetic; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Piperazines; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger | 2013 |
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; DNA Damage; DNA Repair; DNA, Mitochondrial; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genome, Mitochondrial; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Topics: Apoptosis; Autophagy; Benzamides; Calcium; Calcium Signaling; Cell Line, Tumor; Chromones; Drug Synergism; Egtazic Acid; Humans; Imatinib Mesylate; Inositol Phosphates; Intracellular Space; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; src-Family Kinases; Thapsigargin | 2013 |
Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report.
Topics: Adolescent; Adult; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Young Adult | 2014 |
Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Flow Cytometry; gamma Catenin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 4; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Tumor Cells, Cultured; Wnt Proteins; Wnt-5a Protein | 2013 |
EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers, Tumor; Diagnostic Techniques and Procedures; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Survival Rate; Young Adult | 2013 |
[Effect of bortezomib on reverse multidrug resistance and XIAP expression in imatinib-resistant primary cells of chronic myeloid leukemia in blastic crisis].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proteasome Inhibitors; Pyrazines; Pyrimidines; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Young Adult | 2013 |
Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation.
Topics: Apoptosis; Benzamides; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Phosphatase 2; Pyrimidines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Langerhans Cell Sarcoma in a Chronic Myelogenous Leukemia Patient Undergoing Imatinib Mesylate Therapy: A Case Study and Review of the Literature.
Topics: Aged; Female; Humans; Imatinib Mesylate; Langerhans Cell Sarcoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2014 |
miRNA expression correlated with morphological findings in chronic myeloid leukemia treated with imatinib mesylate.
Topics: Benzamides; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Piperazines; Pyrimidines | 2014 |
The conformational control inhibitor of tyrosine kinases DCC-2036 is effective for imatinib-resistant cells expressing T674I FIP1L1-PDGFRα.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Cell Proliferation; Codon; Disease Models, Animal; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Quinolines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Casein Kinase II; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Naphthyridines; Phenazines; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction | 2013 |
Proteomic-based identification of Apg-2 as a therapeutic target for chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP110 Heat-Shock Proteins; Hydrogen Peroxide; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Piperazines; Proteome; Proteomics; Pyrimidines; RNA Interference; RNA, Small Interfering | 2013 |
Fenretinide targets chronic myeloid leukemia stem/progenitor cells by regulation of redox signaling.
Topics: Antigens, CD34; Benzamides; Fenretinide; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Oxidation-Reduction; Piperazines; Pyrimidines; Signal Transduction | 2014 |
International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Health Status Indicators; Humans; Imatinib Mesylate; International Cooperation; Interviews as Topic; Karnofsky Performance Status; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Psychometrics; Pyrimidines; Quality of Life; Residence Characteristics; Social Class; Surveys and Questionnaires; Young Adult | 2014 |
Imatinib-associated melanosis of the palate.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanosis; Palate; Piperazines; Pyrimidines | 2014 |
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Risk Factors; Treatment Outcome; Young Adult | 2013 |
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.
Topics: Benzamides; Biomarkers, Pharmacological; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Statistical; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2013 |
Unravelling survival pathways: the road to next-generation chronic myeloid leukaemia drugs?
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; gamma Catenin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 4; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Wnt Proteins; Wnt-5a Protein | 2013 |
Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2014 |
Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
Topics: Activins; Antineoplastic Agents; Benzamides; Cell Differentiation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins | 2014 |
Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Topics: Benzamides; Dasatinib; Europe; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Patient Satisfaction; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States | 2013 |
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Heterografts; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Mutation; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrimidines; Quinolines; TOR Serine-Threonine Kinases | 2014 |
Cross talk between Wnt/β-catenin and Irf8 in leukemia progression and drug resistance.
Topics: Animals; Benzamides; Blast Crisis; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunophenotyping; Interferon Regulatory Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Cells; Neoplastic Stem Cells; Piperazines; Pyrimidines; Side-Population Cells; Wnt Signaling Pathway | 2013 |
[Effects of imatinib mesylate on the levels of endocrine hormones].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Thyrotropin; Triiodothyronine; Young Adult | 2013 |
Parameterized SVM for personalized drug concentration prediction.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Piperazines; Precision Medicine; Pyrimidines; Support Vector Machine; Time Factors | 2013 |
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Alternative Splicing; Antineoplastic Agents; Benzamides; Biological Transport; Codon, Nonsense; Drug Resistance; Exons; Female; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis, Insertional; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Protein Isoforms; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Deletion | 2013 |
Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Sectional Studies; Drug Substitution; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
CUEDC2 sensitizes chronic myeloid leukemic cells to imatinib treatment.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Carrier Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; NF-kappa B; Piperazines; Pyrimidines; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2013 |
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligodeoxyribonucleotides, Antisense; Oxides; Piperazines; Pyrimidines; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
First-line treatment for patients with CML in chronic phase: why imatinib is an appropriate choice.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines | 2013 |
CML patients in the molecular era - report of five years experience of diagnosis and treatment in a single center.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Piperazines; Pyrimidines; Thiazoles; Vincristine | 2014 |
Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Health Knowledge, Attitudes, Practice; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Outpatients; Piperazines; Pyrimidines; Taiwan; Young Adult | 2014 |
Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Pyrimidines; Retrospective Studies; Treatment Outcome | 2014 |
Increasing access to care for chronic myeloid leukemia patients: assessment of a scaling-up program.
Topics: Antineoplastic Agents; Benzamides; Developing Countries; Health Services Accessibility; Humans; Imatinib Mesylate; International Cooperation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Program Evaluation; Pyrimidines; Quality Improvement; Surveys and Questionnaires | 2013 |
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
Topics: Benzamides; Female; Genes, abl; Health Expenditures; Health Services; Hospitalization; Humans; Imatinib Mesylate; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; RNA, Messenger; United States | 2014 |
Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MCF-7 Cells; Middle Aged; Phosphorylation; Piperazines; Protein Kinases; Proto-Oncogene Proteins c-crk; Pyrimidines; Young Adult | 2013 |
OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Benzamides; Gene Expression; Gene Frequency; Genetic Variation; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.
Topics: Adult; Aged; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Biomarkers, Pharmacological; Case-Control Studies; Child; Child, Preschool; Female; Fusion Proteins, bcr-abl; Gene Expression; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Membrane Proteins; Middle Aged; Mutation Rate; Piperazines; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins; Pyrimidines; RNA, Messenger | 2013 |
Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Developing Countries; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Health Status; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Physicians; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Self Report; Surveys and Questionnaires; Young Adult | 2014 |
Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan.
Topics: Adult; Antineoplastic Agents; Benzamides; Cohort Studies; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Taiwan; Treatment Outcome | 2014 |
Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Dasatinib; Drug Substitution; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Single-cell analysis of K562 cells: an imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
Topics: Benzamides; Cell Adhesion; Cell Survival; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrimidines; RNA, Messenger; Single-Cell Analysis; Up-Regulation | 2014 |
Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Topics: Apoptosis; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2013 |
EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Young Adult | 2014 |
Functional polymorphism of CYP2B6 G15631T is associated with hematologic and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Alleles; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Benzamides; Case-Control Studies; Cytochrome P-450 CYP2B6; Cytogenetic Analysis; Female; Gene Expression Regulation, Leukemic; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morocco; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
What does a deep molecular response signify?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
[Detection of BCR-ABL1 chimeric gene-positive neutrophils in a patient with mixed phenotype acute leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutrophils; Phenotype; Piperazines; Pyrimidines; Thiazoles | 2013 |
The matricellular protein CCN3 regulates NOTCH1 signalling in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nephroblastoma Overexpressed Protein; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptor, Notch1; RNA, Small Interfering; Signal Transduction; Transfection | 2013 |
Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cohort Studies; Comorbidity; Drug Interactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polypharmacy; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2014 |
[Particular evolution of complex cytogenetic variants of chronic myeloid leukemia treated with imatinib].
Topics: Adult; Benzamides; Cytogenetic Analysis; Disease Progression; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Translocation, Genetic; Young Adult | 2013 |
Multiple eruptive dermatofibromas related to imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Female; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Skin; Treatment Outcome | 2014 |
Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.
Topics: Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line; Cell Membrane; Dasatinib; Genetic Variation; Genotype; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nitriles; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles; Transduction, Genetic | 2014 |
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Administration Schedule; Female; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2014 |
Restoration of INK4a/ARF gene inhibits cell growth and cooperates with imatinib mesylate in Philadelphia chromosome-positive leukemias.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p16; Genes, p16; Humans; Imatinib Mesylate; Lentivirus; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Pyrimidines; Transduction, Genetic; Tumor Suppressor Protein p14ARF | 2013 |
Imatinib treatment and Aβ42 in humans.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Benzamides; Cells, Cultured; Cerebral Cortex; Down Syndrome; Embryonic Stem Cells; Female; HEK293 Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neurons; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Caspases; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Monocytes; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrimidines; Xanthones; Xenograft Model Antitumor Assays | 2014 |
Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Body Mass Index; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Plasma; Pyrimidines | 2014 |
21st-century oncology: a tangled web.
Topics: Antineoplastic Agents; Benzamides; Biomedical Research; Drug Industry; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Biological Transport; Drug Resistance, Neoplasm; Female; Gene Expression; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Knockout; Middle Aged; Organic Cation Transporter 1; Piperazines; Pyrimidines; Xenopus laevis | 2014 |
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2014 |
Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Electrolytes; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins; Piperazines; Pyrimidines | 2014 |
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Cost Sharing; Drug Costs; Female; Health Expenditures; Humans; Imatinib Mesylate; Insurance Coverage; Insurance, Health; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; United States | 2014 |
Targeted cancer therapy: from bench to bedside to patient.
Topics: Antineoplastic Agents; Benzamides; Cost Sharing; Drug Costs; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2014 |
Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Topics: Animals; B-Lymphocytes; Benzamides; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Vectors; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Retroviridae; Sorting Nexins; Thiazoles; Transfection | 2014 |
Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Administration Schedule; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Immunologic Factors; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Polyethylene Glycols; Prospective Studies; Pyrimidines; Recombinant Proteins; Recurrence; Remission Induction; Time Factors | 2014 |
p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Case-Control Studies; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphorylation; Piperazines; Protein Kinases; Pyrimidines; STAT3 Transcription Factor | 2014 |
A limited but necessary indication of stem cell transplantation for chronic myelogeneous leukemia in the era of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Myelodysplastic Syndromes; Pancytopenia; Patient Selection; Phenotype; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2014 |
Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Down-Regulation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Transketolase | 2014 |
Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Mutation; Piperazines; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyridazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Tumor Microenvironment | 2014 |
Early molecular response in chronic myeloid leukemia patients predicts future response status.
Topics: Adolescent; Adult; Benzamides; Child; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2014 |
Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptor, EphB4; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2014 |
[Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
Topics: Adolescent; Adult; Benzamides; Child; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
[Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetics; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Young Adult | 2013 |
The challenge of the 'C' in CML.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Sex Factors; Treatment Outcome | 2014 |
The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Case-Control Studies; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multidrug Resistance-Associated Proteins; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2014 |
IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Topics: Benzamides; Catalysis; Cell Line, Tumor; Cell Proliferation; Etoposide; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon Regulatory Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Transcriptional Activation; Tumor Stem Cell Assay | 2014 |
Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Diarrhea; Fatigue; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Nausea; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2014 |
Janet Rowley (1925-2013).
Topics: Benzamides; Genetics, Medical; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Neoplasms; Piperazines; Pyrimidines; Translocation, Genetic; United States | 2014 |
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Topics: Adolescent; Adult; Aged; Asian People; Benzamides; Catalytic Domain; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Young Adult | 2014 |
Imatinib-induced postoperative periorbital purpura: GASP (Gleevec-Associated Surgical Purpura) in a woman with imatinib-treated chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Blepharoplasty; Drug Administration Schedule; Ecchymosis; Edema; Eyelid Diseases; Female; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Postoperative Complications; Postoperative Hemorrhage; Preoperative Care; Protein Kinase Inhibitors; Purpura; Pyrimidines; Retrospective Studies; Skin Transplantation | 2014 |
EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Pyrimidines; Quinoxalines | 2014 |
Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Hypopigmentation; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melanins; Melanocytes; Middle Aged; Piperazines; Pyrimidines; Skin Pigmentation | 2014 |
Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Organic Cation Transporter 1; Piperazines; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Pyrimidines; Remission Induction; RNA, Messenger | 2014 |
Inhibitory effects of imatinib mesylate on human epidermal melanocytes.
Topics: Benzamides; Cell Proliferation; Cell Survival; Epidermal Cells; Fibroblasts; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanins; Melanocytes; Microphthalmia-Associated Transcription Factor; Models, Biological; Monophenol Monooxygenase; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Stem Cell Factor; Tumor Cells, Cultured | 2014 |
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Phenotype; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
[Intestinal bleeding in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Aged; Benzamides; Capsule Endoscopy; Dasatinib; Drug Substitution; Endoscopes, Gastrointestinal; Female; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2014 |
Best treatment option for infantile chronic myeloid leukemia patients: imatinib or hematopoietic stem cell transplantation?
Topics: Benzamides; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2014 |
Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Disease Models, Animal; Drug Synergism; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitochondria; Oligopeptides; Piperazines; Proto-Oncogene Mas; Pyrimidines; Receptors, CXCR4; Signal Transduction; Stromal Cells; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |
Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thiazoles; Young Adult | 2015 |
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Myeloproliferative Disorders; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinoxalines; STAT5 Transcription Factor; Tumor Suppressor Proteins | 2014 |
Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Interviews as Topic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Physician-Patient Relations; Qualitative Research; Risk Factors | 2015 |
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; White People; Young Adult | 2014 |
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.
Topics: Analysis of Variance; Benzamides; Cloning, Molecular; DNA Primers; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Dynamics Simulation; Mutation; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines | 2014 |
Effectiveness of imatinib therapy for sickle cell anemia and chronic myeloid leukemia.
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pain; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
Clinical efficacy of generic imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Child; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2015 |
[Chronic myeloid leukemia treatment and human immunodeficiency virus infection].
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents; Benzamides; Drug Interactions; HIV Infections; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
Optimizing tolerability of TKI therapy in CML.
Topics: Aniline Compounds; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines | 2014 |
Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzamides; Benzylamines; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Pyrimidines; Quinazolines | 2014 |
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Female; Genotype; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metabolic Clearance Rate; Middle Aged; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines | 2014 |
Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy.
Topics: Abortion, Spontaneous; Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Young Adult | 2015 |
Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Ponatinib circumvents FGF2-driven resistance to imatinib in CML.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance, Neoplasm; Fibroblast Growth Factor 2; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Piperazines; Protein Kinase Inhibitors; Pyridazines; Pyrimidines | 2014 |
[Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Transplantation, Homologous; Young Adult | 2014 |
A dimorphic blast population demonstrates Philadelphia-positive mixed phenotype acute leukaemia.
Topics: Adult; Benzamides; Biopsy, Needle; Bone Marrow; Diagnosis, Differential; Female; Flow Cytometry; Granulocyte Precursor Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Induction Chemotherapy; Karyotyping; Leukemia, Biphenotypic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenotype; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2014 |
BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Risk Factors; Treatment Outcome; Young Adult | 2014 |
Imatinib and ruxolitinib association: first experience in two patients.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrazoles; Pyrimidines | 2014 |
Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Topics: Budgets; Cost-Benefit Analysis; Dasatinib; Drug Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Markov Chains; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quality-Adjusted Life Years; Thailand | 2014 |
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chronic Disease; Cohort Studies; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies | 2014 |
Low level of TERC gene amplification between chronic myeloid leukaemia patients resistant and respond to imatinib mesylate treatment.
Topics: Benzamides; Cross-Sectional Studies; DNA Copy Number Variations; Drug Resistance, Neoplasm; Gene Amplification; Gene Dosage; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA; Telomerase | 2014 |
Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brazil; Cross-Sectional Studies; Data Collection; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Quality of Life; Work | 2014 |
Methylation and decreased expression of SHP-1 are related to disease progression in chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Child; Disease Progression; DNA Methylation; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Mitogen-Activated Protein Kinases; Piperazines; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrimidines; RNA, Messenger; STAT5 Transcription Factor; Young Adult | 2014 |
The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chemistry, Pharmaceutical; Cost-Benefit Analysis; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzothiazoles; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Models, Molecular; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Tumor Burden; Urea | 2014 |
Decreased frequency, but normal functional integrity of mesenchymal stromal cells derived from untreated and Imatinib-treated chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; Phenotype; Piperazines; Pyrimidines | 2014 |
Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humans.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Case-Control Studies; Cold Temperature; Female; Hot Temperature; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nociception; Pain; Pain Perception; Pain Threshold; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Skin | 2014 |
Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Benzamides; Caspase 3; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Piperazines; Pyrimidines | 2014 |
Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Cell Culture Techniques; Cell Proliferation; Culture Media, Conditioned; Drug Resistance, Neoplasm; Flavonoids; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Piperazines; Plant Roots; Pyrimidines; Scutellaria baicalensis; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
Patient empowerment in the management of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Power, Psychological; Professional-Patient Relations; Protein Kinase Inhibitors; Pyrimidines; Quality of Life | 2014 |
RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Ribosomal Proteins; Signal Transduction; Up-Regulation | 2014 |
Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Topics: Animals; Apoptosis; Benzamides; Cell Hypoxia; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Neoplastic Stem Cells; Oxygen; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tumor Cells, Cultured | 2014 |
VEGF in chronic myeloid leukemia treated with interferon and imatinib.
Topics: Benzamides; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Vascular Endothelial Growth Factor A | 2014 |
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Female; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Interferon Regulatory Factors; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Middle Aged; Molecular Sequence Data; Piperazines; Promoter Regions, Genetic; Pyrimidines; STAT5 Transcription Factor; Transcription, Genetic; Tumor Suppressor Proteins | 2014 |
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tyrosine; Vorinostat | 2014 |
Neutrophil numerals.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neutrophils; Piperazines; Pyrimidines; Translocation, Genetic | 2014 |
[Efficacy and safety analysis of interferon combined with imatinib in treating chronic myeloid leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Benzamides; Cell Line; Cell Survival; Coculture Techniques; Cytokines; Drug Synergism; Feeder Cells; Female; Humans; Imatinib Mesylate; Immunoblotting; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Pyrrolidines; RNA Interference; STAT5 Transcription Factor; Sulfonamides | 2014 |
Dipeptidylpeptidase IV (CD26) defines leukemic stem cells (LSC) in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Dipeptidyl Peptidase 4; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Interleukin Receptor Common gamma Subunit; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Transplantation, Heterologous; Tumor Cells, Cultured; Young Adult | 2014 |
Successful treatment of Chronic Myelogenic Leukemia (CML) with imatinib after renal transplantation.
Topics: Antineoplastic Agents; Benzamides; Cyclosporine; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prednisolone; Pyrimidines | 2014 |
A case of isolated lymphoblastic relapse of the central nervous system in a patient with chronic myelogenous leukemia treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines | 2014 |
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
Topics: Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Black People; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; White People | 2014 |
The anti-apoptotic form of tyrosine kinase Lyn that is generated by proteolysis is degraded by the N-end rule pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Caspases; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutagenesis, Site-Directed; Piperazines; Proteasome Endopeptidase Complex; Proteolysis; Pyrimidines; RNA, Small Interfering; src-Family Kinases; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2014 |
Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2014 |
Long-term imatinib treatment does not cause testicular toxicity in male adolescents with chronic myeloid leukemia and in a juvenile rat model.
Topics: Adolescent; Animals; Antineoplastic Agents; Benzamides; Child; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Inhibins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Long-Term Care; Male; Piperazines; Protein Kinase Inhibitors; Puberty; Pyrimidines; Rats; Rats, Wistar; Sperm Count; Testis; Testosterone | 2014 |
H2AX phosphorylation regulated by p38 is involved in Bim expression and apoptosis in chronic myelogenous leukemia cells induced by imatinib.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Histones; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Pyrimidines | 2014 |
A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; DNA Methylation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; HEK293 Cells; Hep G2 Cells; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MCF-7 Cells; Mice; Mice, Nude; Mice, Transgenic; MicroRNAs; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Pyrimidines; RNA, Long Noncoding; RNA, Messenger; Transplantation, Heterologous | 2015 |
Large-scale imatinib dose-concentration-effect study in CML patients under routine care conditions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
Therapy: This time it's personal.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biological Evolution; Biopsy; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; Drug Delivery Systems; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Genetics, Medical; Genomics; Humans; Imatinib Mesylate; Immunotherapy; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Nanoparticles; Neoplasms; Pharmacogenetics; Piperazines; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyrimidines; RNA Interference; RNA, Small Interfering; Sulfonamides; Time Factors; Transcriptome; Vemurafenib | 2014 |
Biology: Three known unknowns.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biological Evolution; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Immunity; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Metastasis; Neoplasms; Piperazines; Pyrimidines; Tumor Microenvironment | 2014 |
Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
Topics: Apoptosis; Blotting, Western; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Drugs, Chinese Herbal; Eukaryotic Initiation Factor-4E; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenanthrenes; Phosphorylation; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2015 |
Adherence to imatinib among patients attending Saskatchewan Cancer Agency Pharmacies.
Topics: Adult; Aged; Antineoplastic Agents; Electronic Health Records; Endpoint Determination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Oncology Service, Hospital; Pharmacies; Pharmacy Service, Hospital; Retrospective Studies; Saskatchewan; Young Adult | 2015 |
Complex/variant translocations in chronic myelogenous leukemia (CML): genesis and prognosis with 4 new cases.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic | 2014 |
Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Division; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA, Small Interfering | 2014 |
Arsenic trioxide and bortezomib interact synergistically to induce apoptosis in chronic myelogenous leukemia cells resistant to imatinib mesylate through Bcr/Abl‑dependent mechanisms.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Poly(ADP-ribose) Polymerases; Pyrazines; Pyrimidines; Reactive Oxygen Species; RNA, Messenger | 2014 |
Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Cell Survival; Daunorubicin; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Pyrimidines | 2014 |
Response to imatinib therapy in adult patients with chronic myeloid leukemia in Saudi population: a single-center study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Disease-Free Survival; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Recurrence; Remission Induction; Retrospective Studies; Saudi Arabia; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
[Chronic myeloid Leukemia - clinical practice according to the JSH guideline for hematological malignancies].
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2014 |
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Topics: ADP-ribosyl Cyclase 1; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; Dasatinib; DNA Damage; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Sirtuin 1; Thiazoles; Tretinoin | 2014 |
Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Gene Silencing; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins | 2014 |
International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Global Health; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; United States; Young Adult | 2014 |
[A patient with acute Philadelphia-chromosome-positive mixed phenotype leukemia developing ecthyma gangrenosum while undergoing combined imatinib mesylate chemotherapy].
Topics: Aged; Antineoplastic Agents; Benzamides; Ecthyma; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orbit; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrimidines | 2014 |
[Treatment of two chronic myeloid leukemia patients with V299L mutation by using nilotinib].
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines | 2014 |
Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Benzamides; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Imatinib Mesylate; Immunosuppressive Agents; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation, Homologous; Treatment Outcome; Young Adult | 2014 |
[Chronic myeloid leukemia].
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Nitriles; Piperazines; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Quinolines | 2014 |
CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.
Topics: Adult; Aged; Apoptosis; Autoantigens; Benzamides; Case-Control Studies; Cell Proliferation; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Proteins; Middle Aged; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; Young Adult | 2014 |
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2014 |
Cultural factors related to adherence to imatinib in CML: a Mexican perspective.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Health Services Accessibility; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mexico; Middle Aged; Patient Compliance; Piperazines; Pyrimidines; Remission Induction; Surveys and Questionnaires | 2015 |
In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cell Proliferation; Cyclophosphamide; Drug Interactions; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transplantation Conditioning; Tumor Cells, Cultured | 2014 |
Exposure of chronic myelogenous leukemia cells to imatinib results in the post-transcriptional induction of manganese superoxide dismutase.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Enzyme Induction; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Reverse Transcriptase Polymerase Chain Reaction; Superoxide Dismutase; Time Factors | 2015 |
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Topics: Age Factors; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Comorbidity; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Piperazines; Practice Patterns, Physicians'; Pyrimidines; Treatment Outcome | 2014 |
Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients.
Topics: Adult; Alleles; Antineoplastic Agents; ATP-Binding Cassette Transporters; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Solute Carrier Organic Anion Transporter Family Member 1B3; Treatment Outcome | 2015 |
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
Topics: Benzamides; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Substitution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Watchful Waiting | 2014 |
Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents; Asian People; Benzamides; Child; Cross-Sectional Studies; Drug Resistance, Neoplasm; Female; Genotype; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Young Adult | 2014 |
Molecular response in CML: where is the bar?
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2014 |
Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.
Topics: Antineoplastic Agents; Apoptosis; Azepines; Benzamides; Cell Proliferation; Drug Synergism; Gene Expression; HeLa Cells; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; Interferon Type I; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quinazolines | 2014 |
The RNA editing enzyme APOBEC1 induces somatic mutations and a compatible mutational signature is present in esophageal adenocarcinomas.
Topics: Adenocarcinoma; Animals; APOBEC-1 Deaminase; Benzamides; Cell Line; Chickens; Cytidine Deaminase; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gene Expression Regulation; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Rats | 2014 |
Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Iraq; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Treatment Outcome | 2014 |
Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biological Transport; Cell Survival; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Azacitidine; Benzamides; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Piperazines; Promoter Regions, Genetic; Pyrimidines | 2014 |
Development of myelodysplastic syndrome in a patient with chronic myelogenous leukemia treated with imatinib.
Topics: Antineoplastic Agents; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 20; Chromosomes, Human, Pair 7; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2015 |
Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.
Topics: Adult; Benzamides; Cytogenetic Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Electronic Health Records; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis | 2014 |
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.
Topics: Antioxidants; Benzamides; Cyclin-Dependent Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Oxidants; Pharmacological Phenomena; Piperazines; Pluripotent Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Mas; Pyrimidines; Signal Transduction; Tumor Stem Cell Assay | 2014 |
Elderly CML patients' treatment: considering not only physician's judgment but also co-morbidity indexes.
Topics: Animals; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Practice Patterns, Physicians'; Pyrimidines | 2014 |
Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Topics: Aminosalicylic Acids; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Discovery; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, Reporter; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Luciferases; Molecular Docking Simulation; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor; Sulfonamides; Thiazoles | 2015 |
Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prevalence; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Survival Analysis | 2015 |
Kinesin spindle protein inhibitor SB743921 induces mitotic arrest and apoptosis and overcomes imatinib resistance of chronic myeloid leukemia cells.
Topics: Apoptosis; Benzamides; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Chromones; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinesins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured | 2015 |
Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Cycle Checkpoints; Cell Differentiation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erythroid Cells; Extracellular Signal-Regulated MAP Kinases; Female; Flavanones; GATA1 Transcription Factor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Erythroblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Mice, Inbred NOD; Mice, SCID; Nuclear Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; Signal Transduction; Time Factors; Transcription Factors; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Reactive Oxygen Species | 2014 |
[Correlation between point mutation in ABL kinase and clinical outcome of chronic myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Benzamides; Child; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Prognosis; Proto-Oncogene Proteins c-abl; Pyrimidines; Young Adult | 2014 |
Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia.
Topics: Adolescent; Benzamides; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction | 2015 |
Remission status should not be treated as a base-line covariate--reply to Etienne et al.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Genes, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase C; Protein Kinase Inhibitors; Pyrimidines; raf Kinases; RNA, Small Interfering; Survival Analysis; Up-Regulation | 2014 |
Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Case-Control Studies; Down-Regulation; Female; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Statistics, Nonparametric | 2014 |
Rapid sequential gain of ABL1 kinase domain mutations with a complex karyotype in the progression of chronic myelogenous leukemia.
Topics: Base Sequence; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles; Translocation, Genetic | 2014 |
Dual glutathione-S-transferase-θ1 and -μ1 gene deletions determine imatinib failure in chronic myeloid leukemia.
Topics: Benzamides; Cell Line, Tumor; Gene Deletion; Gene Dosage; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure | 2014 |
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.
Topics: Animals; Antineoplastic Agents; Antirheumatic Agents; Apoptosis; Auranofin; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reactive Oxygen Species; Thioredoxin-Disulfide Reductase; Transplantation, Heterologous; Ubiquitin Thiolesterase | 2014 |
Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
Topics: Antineoplastic Agents; Cell Adhesion; Cell Line, Tumor; Dasatinib; Fibronectins; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Protein Transport; src-Family Kinases | 2014 |
Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2014 |
Inhibition of 32Dp210 cells harboring T315I mutation by a novel derivative of emodin correlates with down-regulation of BCR-ABL and its downstream signaling pathways.
Topics: Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Colony-Forming Units Assay; Down-Regulation; Drug Resistance, Neoplasm; Emodin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2015 |
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Nuclear Proteins; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Thiazoles; Time Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Safranal, a Crocus sativus L constituent suppresses the growth of K-562 cells of chronic myelogenous leukemia. In silico and in vitro study.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Carotenoids; Cell Line, Tumor; Computer Simulation; Crocus; Cyclohexenes; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Piperazines; Pyrimidines; Terpenes | 2014 |
Grb10 is involved in BCR-ABL-positive leukemia in mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Cell Cycle; Cell Proliferation; Disease Models, Animal; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; GRB10 Adaptor Protein; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; MicroRNAs; Piperazines; Primary Cell Culture; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2015 |
PTCH1 expression at diagnosis predicts imatinib failure in chronic myeloid leukaemia patients in chronic phase.
Topics: Benzamides; Cohort Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Patched Receptors; Patched-1 Receptor; Pilot Projects; Piperazines; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Receptors, Cell Surface; Sensitivity and Specificity; Transcriptome; Treatment Failure | 2015 |
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib.
Topics: Adult; Aged; Antineoplastic Agents; B-Lymphocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Young Adult | 2015 |
Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Patient Compliance; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2015 |
Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Antineoplastic Agents; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2015 |
Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
Topics: Adult; Antineoplastic Agents; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Liver Transplantation; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
[Efficacy of tyrosine kinase inhibitor in treatment of chronic myeloid leukemia patients].
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2014 |
Generics in chronic myeloid leukemia: current arguments for and against and the established evidence.
Topics: Antineoplastic Agents; Benzamides; Drug Substitution; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2014 |
ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Retrospective Studies; Treatment Failure; Young Adult | 2015 |
ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cohort Studies; Egypt; Female; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrimidines; Retrospective Studies; Treatment Failure; Treatment Outcome; Young Adult | 2014 |
MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2015 |
Trachyonychia in a patient with chronic myeloid leukaemia after imatinib mesylate.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Nail Diseases; Piperazines; Pyrimidines | 2014 |
Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Time Factors; Transcription, Genetic; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quaternary Ammonium Compounds; RNA Interference; RNA, Messenger; RNA, Small Interfering; Treatment Outcome | 2015 |
The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Tumor Stem Cell Assay | 2014 |
Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib.
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Chronic Disease; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reticulocytes; Severity of Illness Index; Sex Factors; Survival Analysis | 2015 |
Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Computational Biology; Female; Fusion Proteins, bcr-abl; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
Nonhematologic toxicity of imatinib mesylate in pediatric patients with chronic myelogenous leukemia: a predominance of musculoskeletal pain.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Musculoskeletal Pain; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Young Adult | 2015 |
A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B induced enhanced proliferation inhibition and apoptosis in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p15; Down-Regulation; Drug Combinations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA, Small Interfering | 2014 |
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia.
Topics: Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; beta Catenin; Carrier Proteins; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Nuclear Proteins; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins | 2015 |
Expression of multidrug resistance 1 gene in association with CXCL12 in chronic myelogenous leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Cell Line, Tumor; Chemokine CXCL12; Coculture Techniques; Female; Gene Expression Regulation, Leukemic; Genes, MDR; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction | 2014 |
Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphorylation; Piperazines; Pyrimidines; STAT3 Transcription Factor; Up-Regulation; Young Adult | 2014 |
[Evolution of chronic myeloid leukemia on nilotinib after failure of imatinib].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Failure; Young Adult | 2014 |
Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Topics: Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Dasatinib; Drug Costs; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Odds Ratio; Outcome Assessment, Health Care; Patient Care; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; United States | 2015 |
Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
Topics: Adult; Antineoplastic Agents; Australia; Benzamides; Canada; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Therapy Management; Middle Aged; Piperazines; Practice Patterns, Physicians'; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Republic of Korea; Retrospective Studies; Thiazoles; Treatment Outcome | 2015 |
Role of glutathione-S-transferase M1 (GSTM1) and T1 (GSTT1) genes in the development and progress of chronic myeloid leukemia and in the formation of response to imatinib therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Cytogenetic Analysis; Gene Deletion; Genetic Predisposition to Disease; Genotype; Glutathione Transferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Odds Ratio; Piperazines; Pyrimidines; Risk Factors; Russia | 2014 |
Coexistent BCR-ABL1 and JAK2 V617F: converting CML dwarves to ET staghorns with imatinib therapy.
Topics: Aged; Amino Acid Substitution; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Megakaryocytes; Piperazines; Pyrimidines | 2014 |
Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA, Small Interfering; Sirtuin 1; Tumor Cells, Cultured; Valproic Acid | 2015 |
Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Topics: Apoptosis; bcl-X Protein; Benzamides; Bone Marrow Cells; Cell Adhesion Molecules; Cell Proliferation; Clone Cells; Focal Adhesion Protein-Tyrosine Kinases; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfilament Proteins; Phosphoproteins; Phosphorylation; Phosphoserine; Piperazines; Protein Binding; Pyrimidines; Zyxin | 2015 |
Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN.
Topics: Antagomirs; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotides; Phosphoinositide-3 Kinase Inhibitors; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; PTEN Phosphohydrolase; RNA Interference; RNA, Small Interfering; Up-Regulation | 2014 |
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Body Height; Body Mass Index; Child; Child, Preschool; Female; Growth Disorders; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retrospective Studies | 2014 |
Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; United States; Young Adult | 2015 |
Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.
Topics: Adiponectin; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Adiponectin; RNA, Small Interfering; Time Factors | 2015 |
HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Mutation; Piperazines; Random Allocation; Signal Transduction; Urea; Xenograft Model Antitumor Assays | 2015 |
Dasatinib-induced immunosuppression and recurrent respiratory tract infections.
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2015 |
Molecular response to nilotinib in a patient with imatinib-intolerant e19a2-positive chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Xenograft Model Antitumor Assays | 2015 |
Identifying and validating a combined mRNA and microRNA signature in response to imatinib treatment in a chronic myeloid leukemia cell line.
Topics: Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Protein Kinase Inhibitors; RNA, Messenger | 2014 |
Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia.
Topics: Adult; Aged; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelopoiesis; Primary Myelofibrosis | 2015 |
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Topics: Adolescent; Adult; Benzamides; Blast Crisis; Case-Control Studies; Chromosome Breakpoints; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult | 2014 |
Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission.
Topics: Adult; Antineoplastic Agents; Back Pain; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction; Sarcoma, Myeloid; Spine | 2014 |
[Nilotinib treatment for patients with imatinib-resistant or intolerant chronic myeloid leukemia].
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2014 |
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Dihydrolipoyllysine-Residue Acetyltransferase; Disease Models, Animal; Female; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Ketone Oxidoreductases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mitochondria; Mitochondrial Proteins; Mitochondrial Proton-Translocating ATPases; Oligomycins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; RNA Interference; RNA, Small Interfering; Superoxides | 2015 |
A method for screening and validation of resistant mutations against kinase inhibitors.
Topics: Animals; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines | 2014 |
[Allo-geneic hematopoietic stem cell transplantation in treatment with T315I mutation of chronic myelogenous leukemia].
Topics: Adult; Allografts; Benzamides; Cord Blood Stem Cell Transplantation; Cyclosporine; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Mycophenolic Acid; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Retrospective Studies; Siblings | 2014 |
shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.
Topics: Active Transport, Cell Nucleus; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exportin 1 Protein; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Gene Library; Humans; Hydrazines; Imatinib Mesylate; K562 Cells; Karyopherins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; ran GTP-Binding Protein; Receptors, Cytoplasmic and Nuclear; RNA, Small Interfering; Signal Transduction; Triazoles; Tumor Stem Cell Assay | 2015 |
Drug transporters play a key role in the complex process of Imatinib resistance in vitro.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tumor Cells, Cultured | 2015 |
Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
Topics: Aged; Antineoplastic Agents; Base Sequence; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction | 2015 |
Squamous cell carcinoma in a chronic myelogenous leukemia patient treated with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Skin Neoplasms | 2015 |
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Cardiovascular Diseases; Dasatinib; Databases, Factual; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Lung Diseases; Middle Aged; Piperazines; Product Surveillance, Postmarketing; Pyrimidines; Thiazoles; United States; United States Food and Drug Administration; Young Adult | 2015 |
Secondary thrombotic microangiopathy in two patients with Philadelphia-positive hematological malignancies treated with imatinib mesylate.
Topics: Aged; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Thrombotic Microangiopathies | 2016 |
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mast Cells; Mice, Inbred BALB C; Mice, Inbred C57BL; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Time Factors; Treatment Outcome; Tryptases; Xenograft Model Antitumor Assays | 2015 |
Ph-negative isolated myeloid sarcoma with NPM1 gene mutation in adolescent with Ph-positive chronic myeloid leukemia in remission after treatment with allogeneic bone marrow transplantation and imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Combined Modality Therapy; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Nuclear Proteins; Nucleophosmin; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Sarcoma, Myeloid; Transplantation, Homologous | 2015 |
Possible implication of IKAROS gene deletion and BCR-ABL1 variants in progression of chronic myeloid leukemia to lymphoid blast crisis in childhood: a single-institution experience.
Topics: Antineoplastic Agents; Blast Crisis; Child; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Deletion; Genetic Variation; Humans; Ikaros Transcription Factor; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Drug target optimization in chronic myeloid leukemia using innovative computational platform.
Topics: Algorithms; Apoptosis; bcl-X Protein; Computational Biology; Computer Simulation; Fusion Proteins, bcr-abl; Gene Knockout Techniques; Gene Regulatory Networks; Humans; Imatinib Mesylate; Interleukin-3; Interleukin-6; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; ras Proteins | 2015 |
Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
Topics: Antineoplastic Agents; Apoptosis; Benzophenanthridines; Cell Differentiation; Down-Regulation; Drug Resistance, Neoplasm; Erythroid Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Phosphorylation; Proteolysis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Threonine | 2015 |
Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Body Mass Index; Case-Control Studies; Confounding Factors, Epidemiologic; Enzyme-Linked Immunosorbent Assay; Female; Fusion Proteins, bcr-abl; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leptin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenotype; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sex Factors; Time Factors; Treatment Outcome; Up-Regulation | 2014 |
An analysis of strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia with imatinib-resistant mutations.
Topics: Antineoplastic Agents; Computer Simulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mathematical Concepts; Models, Biological; Mutation; Protein Kinase Inhibitors | 2015 |
Morgana acts as an oncosuppressor in chronic myeloid leukemia.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Carrier Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Mice, Knockout; Molecular Chaperones; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; RNA, Messenger; Tumor Cells, Cultured | 2015 |
Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Time Factors; Young Adult | 2015 |
[Clinical efficacy of switching to 2nd generation of tyrosine kinase inhibitor on CML patients at poor responses to imatinib].
Topics: Benzamides; Blast Crisis; Cytogenetics; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2015 |
[Clinical analysis of acute heart failure's risk factor for chronic myelogenous leukemia patient during the early stage of allogeneic hematopoietic stem cell transplantation].
Topics: Acute Disease; Allografts; Antilymphocyte Serum; Benzamides; Heart Failure; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Retrospective Studies; Risk Factors | 2015 |
Spred2 modulates the erythroid differentiation induced by imatinib in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Erythroid Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Phosphorylation; Repressor Proteins; RNA Interference | 2015 |
Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Cell Growth Processes; Combined Modality Therapy; Down-Regulation; Fusion Proteins, bcr-abl; HeLa Cells; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Piperazines; Pyrimidines; Transfection | 2015 |
Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Proto-Oncogene Mas; Signal Transduction | 2015 |
Another piece of the puzzle--optimal TKI selection before treatment discontinuation in CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction; Thiazoles; Treatment Outcome | 2015 |
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; Recombinant Proteins; Remission Induction; Survival Rate; Young Adult | 2015 |
gDNA Q-PCR for clinical monitoring of CML.
Topics: Disease Progression; Genetic Markers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymerase Chain Reaction; Protein Kinase Inhibitors; Recurrence; Remission Induction; RNA, Messenger; Treatment Outcome | 2015 |
Apoptosis-related gene expression profile in chronic myeloid leukemia patients after imatinib mesylate and dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Thiazoles; Transcriptome | 2015 |
Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
Topics: Adult; Aged; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morocco; Neoplasm, Residual; Pathology, Molecular; Real-Time Polymerase Chain Reaction; Retrospective Studies | 2015 |
Successful maintenance of molecular remission in chronic myelogenous leukaemia during pregnancy with transition from imatinib to pegylated interferon.
Topics: Adult; Drug Substitution; Female; Humans; Imatinib Mesylate; Infant, Newborn; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polyethylene Glycols; Pregnancy; Pregnancy Complications, Neoplastic; Recombinant Proteins; Remission Induction; Treatment Outcome | 2015 |
Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Iran; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Prevalence; Sequence Analysis, DNA; Treatment Outcome | 2015 |
[Sustained deep molecular response over eight years after discontinuation of imatinib for chronic myeloid leukemia].
Topics: Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Remission Induction; RNA, Messenger; Time Factors | 2014 |
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Substitution; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retreatment; Retrospective Studies; Time Factors; Transcription, Genetic; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Comparative study of the anti-leukemic effects of imatinib mesylate, Glivec™ tablet and its generic formulation, OHK9511.
Topics: Animals; Antineoplastic Agents; Apoptosis; Drug Resistance, Neoplasm; Drugs, Generic; Fusion Proteins, bcr-abl; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Mesylates; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Tablets | 2015 |
The tyrosine kinase inhibitors imatinib and dasatinib reduce myeloid suppressor cells and release effector lymphocyte responses.
Topics: Adult; Aged; CD11b Antigen; Dasatinib; Female; Humans; Imatinib Mesylate; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopolysaccharide Receptors; Male; Middle Aged; Myeloid Cells; Protein Kinase Inhibitors; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes | 2015 |
[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Combined Modality Therapy; Gene Deletion; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Proteins; Middle Aged; Piperazines; Polymorphism, Genetic; Proto-Oncogene Proteins; Pyrimidines; Recurrence; Remission Induction | 2015 |
Functional activity of CD34-positive cells in chronic myeloid leukemia patients with different response to imatinib therapy.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Blood Cells; Bone Marrow; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2015 |
E255K and G250E mutation appearing in a patient with e19a2 chronic myeloid leukemia resistant to imatinib.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines | 2015 |
[Pro-survival signaling pathways activated by BCR-ABL oncogene in chronic myelogenous leukemia cells: the role of the perk-EIF2α signal path and acetylation of p53].
Topics: Benzamides; Drug Resistance, Neoplasm; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Fusion Proteins, bcr-abl; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; Translocation, Genetic; Tumor Cells, Cultured | 2014 |
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Risk; RNA, Messenger; Survival Analysis; Treatment Outcome | 2015 |
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response.
Topics: Antineoplastic Agents; Chromosome Aberrations; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies; Time Factors; Treatment Outcome | 2015 |
Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.
Topics: Antigens, CD34; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Cycle; Cell Proliferation; Fusion Proteins, bcr-abl; Homeodomain Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Receptor, Notch2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factor HES-1; Tumor Cells, Cultured | 2015 |
Korean Red Ginseng Extract Enhances the Anticancer Effects of Imatinib Mesylate Through Abrogation p38 and STAT5 Activation in KBM-5 Cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Cell Line, Tumor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; p38 Mitogen-Activated Protein Kinases; Panax; Phosphorylation; Piperazines; Plant Extracts; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Tumor Suppressor Protein p53 | 2015 |
[Induction of hospital indebtedness due to medicine purchases under monopoly conditions: the case of imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Brazil; Budgets; Drug Costs; Health Expenditures; Health Policy; Hospital Costs; Hospitals, Public; Hospitals, University; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2015 |
Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
Topics: Adult; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 20; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Remission Induction; Treatment Outcome | 2016 |
A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Erlotinib Hydrochloride; Female; Follow-Up Studies; Hospitals, University; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib.
Topics: Antineoplastic Agents; Benzamides; Body Surface Area; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2015 |
Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Body Surface Area; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Survival Rate | 2015 |
A novel compound against oncogenic Aurora kinase A overcomes imatinib resistance in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Aurora Kinase A; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Polyploidy; Pyrazoles; Pyrimidines | 2015 |
Impact of imatinib interruption and duration of prior hydroxyurea on the treatment outcome in patients with chronic myeloid leukemia: Single institution experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Mucosal pigmentation of the hard palate in a patient taking imatinib.
Topics: Antineoplastic Agents; Female; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mouth Diseases; Mouth Mucosa; Palate, Hard | 2015 |
A newborn with teratogenic effect of imatinib mesylate: a very rare case report.
Topics: Abnormalities, Drug-Induced; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Infant, Low Birth Weight; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pregnancy; Pregnancy Complications, Neoplastic | 2015 |
Endoscopic management of esophago-mediastinal fistula secondary to mediastinal tuberculosis infection.
Topics: Antineoplastic Agents; Esophageal Fistula; Esophagoscopy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mediastinal Diseases; Mediastinitis; Middle Aged; Radiography; Stents; Tuberculosis | 2015 |
A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML).
Topics: Adult; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Exons; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Insertional; Nucleotides; Piperazines; Pyrimidines; RNA, Messenger; Sequence Analysis, DNA; Thiazoles | 2015 |
Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Threonine | 2015 |
A rare case of chronic myelogenous leukemia and plasma cell myeloma in the same patient.
Topics: Aged; Antineoplastic Agents; Bone Marrow; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Multiple Myeloma; Platelet Count; Polymerase Chain Reaction; Thrombocytosis | 2015 |
Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.
Topics: Aged; Exons; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Oncogene Proteins, Fusion; Proto-Oncogene Proteins c-bcr; Receptor, Platelet-Derived Growth Factor alpha | 2015 |
[Clinical Efficacy of Dasatinib, Nilotinib and Imatinib in Newly Diagnosed Patients with Chronic-Phase Chronic Myeloid Leukemia: A Three-year Retrospective Analysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Dasatinib; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome | 2015 |
[A case report of refractory pleural effusion associated with dasatinib in the treatment of chronic myeloied leukemia].
Topics: Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pleural Effusion; Prognosis; Recurrence; Remission Induction | 2015 |
Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genome, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; STAT5 Transcription Factor; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2015 |
CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Lactones; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liriodendron; Mice; Plant Extracts; Point Mutation; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
[A female chronic myeloid leukemia patient who gave birth after stopping imatinib intentionally but who maintained a major molecular response with interferon].
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Outcome; Pyrimidines; Quality of Life | 2015 |
Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Curcumin; Down-Regulation; Drug Synergism; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Differential expression and alternative splicing of cell cycle genes in imatinib-treated K562 cells.
Topics: Alternative Splicing; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Drug Resistance, Neoplasm; Genes, cdc; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2015 |
K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Topics: Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutagenesis, Insertional; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2012 |
Low educational level but not low income impairs the achievement of cytogenetic remission in chronic myeloid leukemia patients treated with imatinib in Brazil.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Brazil; Child; Cytogenetic Analysis; Disease-Free Survival; Educational Status; Female; Health Services Accessibility; Humans; Imatinib Mesylate; Income; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Patient Education as Topic; Piperazines; Primary Health Care; Pyrimidines; Remission Induction; Socioeconomic Factors; Treatment Outcome; Young Adult | 2015 |
Imatinib for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Allografts; Bronchiolitis Obliterans; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2015 |
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Alternative Splicing; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Recurrence; Retrospective Studies; RNA, Messenger; Sex Factors; Treatment Outcome | 2016 |
Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro.
Topics: Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; GA-Binding Protein Transcription Factor; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proto-Oncogene Proteins c-ets; rac GTP-Binding Proteins; RAC2 GTP-Binding Protein | 2015 |
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Cell Line, Tumor; Chromosome Aberrations; Chromosome Breakage; Clonal Evolution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Proteolysis; Separase; Young Adult | 2015 |
Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Topics: Adolescent; Adult; Aged; Dasatinib; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
Resolution of Roth spots in chronic myeloid leukaemia after treatment with imatinib.
Topics: Adult; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Ophthalmoscopes; Protein Kinase Inhibitors; Retinal Diseases; Tomography, Optical Coherence; Treatment Outcome | 2015 |
Inhibition of human chronic myelogenous leukemia K562 cell growth following combination treatment with resveratrol and imatinib mesylate.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Resveratrol; Stilbenes | 2015 |
Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Female; Gastric Antral Vascular Ectasia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2015 |
Adiponectin enhances Imatinib anti-tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients.
Topics: Adiponectin; Adult; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice, Inbred BALB C; Piperazines; Pyrimidines; Receptors, Adiponectin; Recombinant Proteins | 2015 |
[Imatinib is effective in a 12-month-old boy with chronic myelogenous leukemia: case report and literature review].
Topics: Anemia; Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Retrospective Studies | 2015 |
[Watermelon stomach: Chronic renal failure and/or imatinib?].
Topics: Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Protein Kinase Inhibitors; Renal Dialysis | 2015 |
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Drug Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Protein Kinase Inhibitors; Treatment Outcome | 2015 |
Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib.
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Time Factors | 2016 |
Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines.
Topics: Apoptosis; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Purines; Pyridines; Signal Transduction; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2015 |
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Topics: Aged; Chronic Disease; Diagnosis, Differential; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polycythemia; Polycythemia Vera; Protein Kinase Inhibitors | 2015 |
Should vascular effects of newer treatments be addressed more completely?
Topics: Antineoplastic Agents; Cardiovascular Diseases; Clinical Trials as Topic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyridazines | 2015 |
Detailed study of imatinib metabolization using high-resolution mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Molecular Weight; Software | 2015 |
[Leukostasis during Chronic Myelogenous Leukemia Resolved Following Leukapheresis].
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukostasis; Piperazines; Pyrimidines; Remission Induction | 2015 |
β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: beta Catenin; Cadherins; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Wnt Proteins; Wnt-5a Protein | 2015 |
Preclinical model for identification of therapeutic targets for CML offers clues for handling imatinib resistance.
Topics: Animals; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude | 2015 |
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Aged, 80 and over; Creatinine; Dasatinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Incidence; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Coupled delivery of imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Biodegradable Plastics; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Doxorubicin; Fusion Proteins, bcr-abl; Humans; Hydrogen-Ion Concentration; Hypolipidemic Agents; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nanoparticles; Polyelectrolytes; Polymers | 2015 |
Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia.
Topics: Adult; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2016 |
Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Apoptosis; Child; Female; Gene Silencing; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Neoplastic Stem Cells; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Signal Transduction; Transfection; Young Adult | 2015 |
Concurrent effects of ABCB1 C3435T, ABCG2 C421A, and XRCC1 Arg194Trp genetic polymorphisms with risk of cancer, clinical output, and response to treatment with imatinib mesylate in patients with chronic myeloid leukemia.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Case-Control Studies; Cytogenetics; DNA-Binding Proteins; Female; Gene Expression Regulation, Leukemic; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms; Polymorphism, Restriction Fragment Length; Prevalence; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2016 |
UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; DNA Damage; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mice; Oxidative Stress; Point Mutation; Tumor Cells, Cultured; Ultraviolet Rays | 2015 |
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Young Adult | 2015 |
Chronic myeloid leukaemia with extreme thrombocytosis.
Topics: Aged; Antineoplastic Agents; Child; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Thrombocytosis | 2015 |
Genetic variations of hOCT1 gene and CYP3A4/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Child; Child, Preschool; Cohort Studies; Cytochrome P-450 CYP3A; Female; Genetic Association Studies; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Treatment Outcome; Young Adult | 2015 |
[The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].
Topics: Antineoplastic Agents; Disease-Free Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Retrospective Studies; Risk Factors | 2015 |
Sex correlates with differences in long-term outcome in chronic myeloid leukaemia patients treated with imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Sex Factors; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2016 |
[Effect of Recombinant Adenovirus AdE-SH2-Caspase 8 on the Apoptosis of Imatinib-resistant K562/G01 Cell Line].
Topics: Adenoviridae; Apoptosis; Caspase 8; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2015 |
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Humans; Imatinib Mesylate; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Interleukins; Keratinocytes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mast Cells; Protein Kinase Inhibitors; Pruritus | 2015 |
Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment.
Topics: Aged, 80 and over; Antineoplastic Agents; Blast Crisis; Bone Marrow; Female; Granulocyte Precursor Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2015 |
Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Serine-Threonine Kinases; Ribavirin; Signal Transduction; TOR Serine-Threonine Kinases | 2015 |
WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; WT1 Proteins | 2015 |
ABL SH3 mutant inhibits BCR-ABL activity and increases imatinib sensitivity by targeting RIN1 protein in CML cell.
Topics: Amino Acid Sequence; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Data; Mutation, Missense; Peptide Fragments; src Homology Domains; Xenograft Model Antitumor Assays | 2015 |
DBS sampling in imatinib therapeutic drug monitoring: from method development to clinical application.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Monitoring; Female; Hematocrit; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Acceptance of Health Care; Reproducibility of Results; Surveys and Questionnaires; Tandem Mass Spectrometry; Young Adult | 2015 |
Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Benzamides; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Pioglitazone; Piperazines; PPAR gamma; Pyrimidines; Repressor Proteins; STAT5 Transcription Factor; Thiazolidinediones; Trans-Activators | 2015 |
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Genetic; Polycomb Repressive Complex 1; Polycomb-Group Proteins; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase.
Topics: Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Organic Cation Transporter 1; RNA, Messenger | 2015 |
Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
Topics: Antineoplastic Agents; Cell Differentiation; Clone Cells; Computer Simulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunologic Surveillance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Protein Kinase Inhibitors; Remission Induction; RNA, Messenger; RNA, Neoplasm; Transcription, Genetic; Treatment Outcome; Tumor Burden | 2015 |
A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cholesterol; Drug Resistance, Neoplasm; G1 Phase; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipids; Membrane Potential, Mitochondrial; Nucleic Acids; Phosphatidylserines; Protein Kinase Inhibitors; Proteins; Pyridazines | 2016 |
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias.
Topics: Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Proto-Oncogene Proteins c-pim-1; Pyridazines; Tumor Cells, Cultured | 2015 |
Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Topics: Adult; Aged; Aged, 80 and over; Anthropometry; Blood Glucose; C-Peptide; Cohort Studies; Dasatinib; Female; Glucose; Humans; Imatinib Mesylate; Insulin; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Metabolism; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Young Adult | 2015 |
Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Agents; Biomarkers; Blood Platelets; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Platelet Aggregation; Platelet Function Tests; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Response and Adverse Effects of Nilotinib in Imatinib-resistant Chronic Myeloid Leukemia Patients: Data From a Developing Country.
Topics: Adolescent; Adult; Antineoplastic Agents; Blast Crisis; Cohort Studies; Cross-Sectional Studies; Developing Countries; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Probability; Prognosis | 2016 |
Impact of oncology pharmacist-managed oral anticancer therapy in patients with chronic myelogenous leukemia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Management; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Medication Adherence; Middle Aged; Pharmacists; Retrospective Studies; Young Adult | 2016 |
Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations.
Topics: Blast Crisis; Clone Cells; Complementarity Determining Regions; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Proto-Oncogene Proteins c-abl; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction | 2015 |
Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia.
Topics: Adult; Aged; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Real-Time Polymerase Chain Reaction; Treatment Outcome; WT1 Proteins | 2015 |
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Topics: ADP-ribosyl Cyclase 1; Antigens, CD34; Antineoplastic Agents; Apoptosis; bcl-X Protein; Biphenyl Compounds; Blast Crisis; Cell Proliferation; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sulfonamides; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report.
Topics: Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Protein Kinase Inhibitors | 2015 |
Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isothiocyanates; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Molecular Targeted Therapy; Phosphorylation; Protein Kinase C; Proto-Oncogene Proteins c-raf | 2015 |
[Impact of age on the clinical response of patients with CML treated with imatinib].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Killing two birds with one stone: a case of GIST and supervening CML.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Neoplasms, Multiple Primary | 2015 |
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Line, Tumor; Cell Survival; Culture Media; Cytochromes c; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Mitochondria; Proto-Oncogene Proteins; Pyrimidines | 2015 |
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Severity of Illness Index; Sex Factors; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biphenyl Compounds; Cell Line, Tumor; Dasatinib; Fusion Proteins, bcr-abl; Gene Deletion; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Nitrophenols; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Sulfonamides | 2016 |
Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Recurrence; Retreatment; Retrospective Studies; Treatment Outcome | 2016 |
The Importance of Being Cured: A Chronic Myeloid Leukemia Perspective.
Topics: Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Protein Kinase Inhibitors | 2016 |
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chromatography, Liquid; Female; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Male; Middle Aged; Neoplasm Proteins; Organic Cation Transporter 1; Polymorphism, Single Nucleotide; Tandem Mass Spectrometry; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
Modulating the Growth and Imatinib Sensitivity of Chronic Myeloid Leukemia Stem/Progenitor Cells with Pullulan/MicroRNA Nanoparticles In Vitro.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Glucans; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Nanomedicine; Nanoparticles; Neoplastic Stem Cells; Transfection; Young Adult | 2015 |
The reality of cancer treatment in a developing country: the effects of delayed TKI treatment on survival, cytogenetic and molecular responses in chronic myeloid leukaemia patients.
Topics: Aged; Antineoplastic Agents; Bosnia and Herzegovina; Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2016 |
Targeting Stem Cells in Chronic Myeloid Leukemia with a PPAR-γ Agonist.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Protein Kinase Inhibitors; Stem Cells | 2015 |
Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Dasatinib; Disease-Free Survival; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pregnancy; Primary Ovarian Insufficiency; Transplantation Conditioning; Treatment Outcome; Young Adult | 2016 |
Hyaluronan oligomers sensitize chronic myeloid leukemia cell lines to the effect of Imatinib.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cellular Senescence; Cytoprotection; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Hyaluronic Acid; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice | 2016 |
[Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 3; Caspase 9; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenanthrenes | 2015 |
The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anxiety; Depression; Diarrhea; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Maintenance Chemotherapy; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quality of Life; Time Factors | 2017 |
Isolated polyglobulia as an uncommon presentation of chronic myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Polycythemia | 2016 |
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics.
Topics: Computational Biology; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Dynamics Simulation; Mutagenesis, Site-Directed; Thermodynamics | 2015 |
Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Synergism; Energy Metabolism; Fatty Acids; Fusion Proteins, bcr-abl; Glycolysis; Heterocyclic Compounds, 1-Ring; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Imatinib Mesylate; K562 Cells; Ketones; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Neoplastic Stem Cells; Oxidation-Reduction; Polypyrimidine Tract-Binding Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyruvate Kinase; RNA Interference; Transfection | 2016 |
Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Health Services; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Middle Aged; Models, Econometric; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line; Doxorubicin; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression; Genes, Mitochondrial; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitochondria; RNA, Messenger | 2015 |
Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Iran; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Splenomegaly; Survival Rate; Treatment Outcome; Young Adult | 2015 |
[The expression and role of the transcription factor C/EBPα in chronic myeloid leukemia].
Topics: Blast Crisis; Bone Marrow; Case-Control Studies; CCAAT-Enhancer-Binding Protein-alpha; Cell Cycle; Cell Proliferation; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Transfection | 2015 |
Comprehensive Molecular Analyses in a Case of Masked Philadelphia Chronic Myeloid Leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Philadelphia Chromosome; Polymerase Chain Reaction | 2015 |
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; DNA Damage; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein-Tyrosine Kinases | 2015 |
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.
Topics: Adult; Aged; Controlled Clinical Trials as Topic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2017 |
First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Chemistry Tests; Female; Hair; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Reproducibility of Results; Treatment Outcome; Young Adult | 2016 |
Cutaneous adverse reactions of imatinib therapy in patients with chronic myeloid leukemia: A six-year follow up.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Cheilitis; Cross-Sectional Studies; Drug Eruptions; Edema; Exanthema; Female; Follow-Up Studies; Humans; Hyperhidrosis; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pigmentation Disorders; Stomatitis, Aphthous; Time Factors; Young Adult | 2016 |
Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Female; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 7; NF-kappa B; Signal Transduction | 2016 |
Treatment-free remission after stopping second-line dasatinib.
Topics: Antineoplastic Agents; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2015 |
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials as Topic; Cytogenetic Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Cytochrome P-450 CYP3A; Female; Humans; Imatinib Mesylate; Isoenzymes; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2016 |
Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at "La Raza" Medical Center in Mexico.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mexico; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quality of Life; Treatment Outcome; Young Adult | 2016 |
Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
Topics: Animals; Apoptosis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Mice; Neoplastic Stem Cells; Protein Methyltransferases | 2016 |
FZD7 regulates BMSCs-mediated protection of CML cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Case-Control Studies; Cell Proliferation; Down-Regulation; Frizzled Receptors; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; RNA, Small Interfering; Transfection; Wnt Signaling Pathway | 2016 |
Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cholestenones; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Protein Binding; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proteolysis; Saponins; Signal Transduction; Time Factors; Ubiquitination | 2016 |
[Achievement of deep molecular response in an elderly chronic myeloid leukemia patient intolerant to imatinib and nilotinib].
Topics: Aged, 80 and over; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines | 2015 |
Gastric Antral Vascular Ectasia during the Treatment of Chronic Myelogenous Leukemia with Imatinib Mesylate.
Topics: Aged; Antineoplastic Agents; Female; Gastric Antral Vascular Ectasia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Recurrence; Treatment Outcome | 2016 |
Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medicare; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; United States | 2016 |
Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Molecular Targeted Therapy; Monitoring, Physiologic; Multivariate Analysis; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2016 |
[Targeted treatment of chronic myeloid leukemia in the elderly patients].
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2015 |
[Tyrosine kinase inhibitors in the elderly patients with chronic myeloid leukemia].
Topics: Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2015 |
Imatinib Increases Serum Creatinine by Inhibiting Its Tubular Secretion in a Reversible Fashion in Chronic Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Case-Control Studies; Creatinine; Drug Substitution; Female; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Kidney Function Tests; Kidney Tubules; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nanoscavenger for inducing cytotoxicity in imatinib resistant cells.
Topics: Antineoplastic Agents; Cell Death; Cell Proliferation; Drug Carriers; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nanoparticles; Oxidation-Reduction; Particle Size; Polyglactin 910; Reactive Oxygen Species; Structure-Activity Relationship; Surface Properties; Tumor Cells, Cultured | 2016 |
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Female; Fibrosis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Reticulin; Treatment Outcome; Young Adult | 2016 |
Structure-Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Molecular Structure; Peptides, Cyclic; Structure-Activity Relationship | 2016 |
MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Sarcosine; Signal Transduction; Sulfonamides; Tubulin Modulators | 2016 |
Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
Topics: Antineoplastic Agents; Blotting, Western; Carrier Proteins; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Niemann-Pick C1 Protein; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2016 |
Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Movement; Chemokine CXCL11; Coculture Techniques; Culture Media, Conditioned; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interleukin-1beta; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Stromal Cells; Up-Regulation | 2016 |
BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Clinical Decision-Making; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Pyrimidines; Real-Time Polymerase Chain Reaction | 2016 |
Impact of Imatinib Adherence on the Cytogenetic Response in Pediatric Chronic Myeloid Leukemia - Chronic Phase.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Treatment Outcome | 2016 |
What Happens When Imatinib Goes Generic?
Topics: Antineoplastic Agents; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2016 |
Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
Topics: Antioxidants; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Energy Metabolism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metabolic Networks and Pathways; Mutation; Oxidation-Reduction; Reactive Oxygen Species | 2016 |
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Iron Chelating Agents; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Signal Transduction; Triazoles | 2016 |
[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
Topics: Blast Crisis; Cytogenetics; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Pyrimidines | 2016 |
Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Recurrence; Retreatment; Time Factors; Treatment Outcome | 2016 |
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein-1 Homolog; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Pyridines; Signal Transduction; TOR Serine-Threonine Kinases | 2016 |
Heme oxygenase-1 contributes to imatinib resistance by promoting autophagy in chronic myeloid leukemia through disrupting the mTOR signaling pathway.
Topics: Adult; Aged; Autophagy; Drug Resistance, Neoplasm; Female; Gene Silencing; Heme Oxygenase-1; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Young Adult | 2016 |
Fear of Progression in Outpatients With Chronic Myeloid Leukemia on Oral Tyrosine Kinase Inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Disease Progression; Fear; Germany; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Outpatients; Prospective Studies; Protein-Tyrosine Kinases; Surveys and Questionnaires | 2016 |
ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells.
Topics: Apoptosis; Bone Marrow; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2016 |
[Effect of A Novel Emodin Derivative on Chronic Myelogenous Leukemia K562 Cells and Imatinib-resistant K562/G01 Cells].
Topics: Apoptosis; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Emodin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation | 2016 |
How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
Topics: Antineoplastic Agents; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors; Recurrence; Treatment Outcome | 2017 |
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Casein Kinase II; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; Ribosomal Protein S6; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured | 2016 |
Novel Acylguanidine Derivatives Targeting Smoothened Induce Antiproliferative and Pro-Apoptotic Effects in Chronic Myeloid Leukemia Cells.
Topics: Apoptosis; Autophagy; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor | 2016 |
Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3.
Topics: Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Ribosomal Proteins; STAT3 Transcription Factor; Transcriptional Activation; Ubiquitins | 2016 |
NUMB inactivation confers resistance to imatinib in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression; Genes, Dominant; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Nerve Tissue Proteins; Signal Transduction | 2016 |
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
Topics: Adult; Aged; Antineoplastic Agents; Cost-Benefit Analysis; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Markov Chains; Middle Aged; Models, Econometric; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality-Adjusted Life Years; Survival Analysis; Treatment Outcome; United States | 2016 |
Dasatinib induces severe hemorrhagic colitis in a patient with accelerated phase of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Colitis; Dasatinib; Fusion Proteins, bcr-abl; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Thiazoles | 2018 |
A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclosporine; Drug Interactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Young Adult | 2016 |
Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Humans; Imatinib Mesylate; Laryngeal Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Neoplasm Staging; Neoplasms, Multiple Primary; Tomography, X-Ray Computed | 2016 |
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Topics: Adult; Aged; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Retrospective Studies | 2016 |
CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p18; Cyclin-Dependent Kinase Inhibitor p57; Dasatinib; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein Transport; Resting Phase, Cell Cycle | 2016 |
Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Lymphocytosis; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Retrospective Studies; T-Lymphocytes, Cytotoxic | 2016 |
Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2016 |
Identification of Genes That Modulate Susceptibility to Formaldehyde and Imatinib by Functional Genomic Screening in Human Haploid KBM7 Cells.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Formaldehyde; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Haploidy; High-Throughput Screening Assays; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; RNA Interference; Transfection | 2016 |
Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; Child; Demography; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Prognosis; Reproducibility of Results; Signal Transduction; Treatment Outcome; Young Adult | 2016 |
The Impact of Variant Philadelphia Chromosome Translocations on the Clinical Course of Chronic Myeloid Leukemia.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
BM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Marrow; Cell Line; Cell Line, Tumor; Culture Media, Conditioned; Drug Resistance, Neoplasm; Drug Synergism; Flavanones; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; NF-kappa B; Signal Transduction; STAT5 Transcription Factor; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
The predictive value of early molecular response in chronic myeloid leukaemia patients treated with imatinib in a single real-world medical centre in a developing country.
Topics: Academic Medical Centers; Adult; Antineoplastic Agents; Cytogenetics; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies; Treatment Outcome; Universities | 2017 |
Assessment of Imatinib in the treatment of chronic myeloid leukemia in Gabon: a cohort of 17 cases.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Female; Gabon; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Young Adult | 2016 |
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Topics: Apoptosis; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Forkhead Box Protein O1; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Tumor Cells, Cultured | 2016 |
Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quality of Life; Quinolines | 2016 |
Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Health Care Surveys; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Risk Factors; Treatment Outcome; Young Adult | 2016 |
Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2016 |
Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Exosomes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2016 |
Reversible skin telangiectasia induced by imatinib mesylate in chronic myeloid leukemia.
Topics: Adult; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission, Spontaneous; Skin Diseases; Telangiectasis; Withholding Treatment | 2016 |
Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib.
Topics: Antineoplastic Agents; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2016 |
Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Salvage Therapy | 2016 |
Racial Differences in Survival of Elderly Adults with Chronic Myeloid Leukemia Before and After the Introduction of Imatinib in the United States.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; SEER Program; Survival Rate; United States | 2016 |
GABP is necessary for stem/progenitor cell maintenance and myeloid differentiation in human hematopoiesis and chronic myeloid leukemia.
Topics: Adult; Aged, 80 and over; Antigens, CD34; Bone Marrow Cells; Cell Proliferation; Cells, Cultured; GA-Binding Protein Transcription Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Myeloid Cells; Myelopoiesis; RNA Interference; RNA, Small Interfering | 2016 |
Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Cohort Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2016 |
Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: The Challenge That Lies Ahead.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2016 |
Longitudinal Study to Assess the Clinical Significance of MSI2 Expression in Chronic Myeloid Leukemia Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Disease Progression; Female; Fusion Proteins, bcr-abl; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Mutation; Pyrimidines; Retrospective Studies; RNA-Binding Proteins; RNA, Messenger; Survival Analysis | 2016 |
Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2016 |
Overexpression of CCAAT Enhancer-Binding Protein α Inhibits the Growth of K562 Cells via the Foxo3a-Bim Pathway.
Topics: Apoptosis; Benzamides; CCAAT-Enhancer-Binding Protein-alpha; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transfection | 2016 |
Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells.
Topics: Acetylation; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylases; Histones; HSP70 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Panobinostat; Phosphorylation; Pyridazines; Signal Transduction | 2016 |
Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplastic Stem Cells; Protein Kinase Inhibitors; Remission Induction | 2016 |
Deep molecular response in chronic myeloid leukemia.
Topics: Bayes Theorem; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2016 |
Reporting results for deep molecular responses in chronic myeloid leukemia.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2016 |
In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; G1 Phase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Triazines | 2016 |
[Clinical observation of chromosomal abnormalities in Ph negative cells of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors].
Topics: Adult; Aged; Chromosome Aberrations; Chromosome Banding; Dasatinib; Female; Humans; Imatinib Mesylate; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines | 2016 |
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Topics: Animals; Antineoplastic Agents; cdc42 GTP-Binding Protein; Cell Movement; Cytoskeletal Proteins; Drug Resistance, Neoplasm; Ephrin-B2; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phosphorylation; rac1 GTP-Binding Protein; Receptor, EphB4; rhoA GTP-Binding Protein; Xenograft Model Antitumor Assays | 2016 |
MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Phosphorylation; RNA, Small Interfering; Tumor Cells, Cultured | 2016 |
Comparison of Branded and Generic Imatinib Plasma Concentrations in Patients With Chronic Myelogenous Leukemia: Unicentric Study.
Topics: Adult; Aged; Antineoplastic Agents; Drug Costs; Drug Monitoring; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Protein Kinase Inhibitors; Therapeutic Equivalency; Young Adult | 2016 |
High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia.
Topics: Apoptosis; Blast Crisis; Bone Marrow; Cells, Cultured; Coculture Techniques; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interleukin-7; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; Signal Transduction | 2016 |
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.
Topics: Acetamides; Animals; Antigens, CD34; Azepines; Cell Death; Cell Differentiation; DNA-Binding Proteins; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Imidazolines; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Proteomics; Proto-Oncogene Proteins c-myc; Reproducibility of Results; Signal Transduction; Transcriptome; Tumor Suppressor Protein p53 | 2016 |
Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia.
Topics: Cardiotoxicity; Cardiovascular Abnormalities; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2016 |
Multiple Causes of Cardiotoxic Effects in Patients With Chronic Myeloid Leukemia-Reply.
Topics: Cardiotoxicity; Cardiovascular Abnormalities; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2016 |
EphB4-VAV1 signaling pathway is associated with imatinib resistance in chronic myeloid leukemia cells.
Topics: Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Proto-Oncogene Proteins c-vav; Receptor, EphB4; Signal Transduction | 2016 |
TP53 codon 72 polymorphism predicts chronic myeloid leukemia susceptibility and treatment outcome.
Topics: Biomarkers, Tumor; Case-Control Studies; Codon; Disease-Free Survival; Female; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Treatment Failure; Treatment Outcome; Tumor Suppressor Protein p53 | 2016 |
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Discoidin Domain Receptor 1; Focal Adhesion Kinase 1; Glioblastoma; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Paxillin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction | 2016 |
MEF2C and CEBPA: Possible co-regulators in chronic myeloid leukemia disease progression.
Topics: CCAAT-Enhancer-Binding Proteins; Disease Progression; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MEF2 Transcription Factors; Neoplasm Staging; Up-Regulation | 2016 |
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
Topics: Animals; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Vectors; GRB2 Adaptor Protein; Humans; Imatinib Mesylate; K562 Cells; Lentivirus; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Point Mutation; Recombinant Fusion Proteins; Signal Transduction; src Homology Domains; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2016 |
A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Polymerization; Sulfones; Tubulin; Tubulin Modulators | 2016 |
Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion.
Topics: Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pyrimidines; RNA, Messenger | 2016 |
Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Cost of Illness; Delayed Diagnosis; Developing Countries; Disease Management; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Senegal; Socioeconomic Factors; Treatment Outcome; Young Adult | 2016 |
Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease.
Topics: Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Sclerosis; Treatment Outcome | 2016 |
Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Blood Cell Count; Drug Hypersensitivity Syndrome; Drug Substitution; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Skin; Treatment Outcome | 2017 |
Skin lesions in patients treated with imatinib mesylate: a 5-year prospective study.
Topics: Antineoplastic Agents; Carcinoma, Basal Cell; Dermatitis, Seborrheic; Dermatomycoses; Drug Eruptions; Eczema; Edema; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Histiocytoma, Benign Fibrous; Humans; Imatinib Mesylate; Keratosis, Actinic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Orbital Diseases; Prospective Studies; Pruritus; Psoriasis; Skin Neoplasms | 2016 |
The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; RNA, Messenger | 2017 |
Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nigeria; Pharmacogenetics; Polymorphism, Genetic; Young Adult | 2016 |
Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target.
Topics: Calcium; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Homeostasis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Proteome; Proteomics; Signal Transduction | 2016 |
Biophysical differences between chronic myelogenous leukemic quiescent and proliferating stem/progenitor cells.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Protein-Tyrosine Kinases | 2016 |
Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL-directed chemotherapy combined with continuous imatinib.
Topics: Antineoplastic Agents; Blast Crisis; Child; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 2016 |
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasms, Experimental; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines | 2016 |
Molecular Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib - Single Centre Experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Remission Induction; Republic of North Macedonia; Time Factors; Treatment Outcome; Young Adult | 2015 |
Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colforsin; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; HEK293 Cells; Hep G2 Cells; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Protein Kinase Inhibitors; Pyridazines; src-Family Kinases | 2016 |
Changes from imatinib mesylate to second generation tyrosine kinase inhibitors improve renal impairment with imatinib mesylate in chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Creatine; Dasatinib; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Renal Insufficiency | 2016 |
Pancytopenia during tyrosine kinase inhibitor treatment - coexistence of chronic myeloid leukemia and visceral leishmaniasis: a case report.
Topics: Adult; Humans; Imatinib Mesylate; Leishmaniasis, Visceral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pancytopenia; Protein Kinase Inhibitors | 2016 |
Metabolite Profiling of the Plasma and Leukocytes of Chronic Myeloid Leukemia Patients.
Topics: Amino Acids; Citric Acid Cycle; Drug Monitoring; Glycolysis; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Metabolome; Metabolomics; Plasma; Protein Kinase Inhibitors | 2016 |
Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Polymerase Chain Reaction; Remission Induction; Telomere; Telomere Shortening; Withholding Treatment | 2016 |
Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.
Topics: Aged; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Male; Mutation | 2016 |
Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.
Topics: Antineoplastic Agents; Drug Industry; Drugs, Generic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Quality Control | 2016 |
CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment.
Topics: Adolescent; Adult; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies; Spermatozoa; Young Adult | 2016 |
The Rho-ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia.
Topics: Amides; Antigens, CD1d; Cell Differentiation; Dendritic Cells; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunity, Innate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cells; Natural Killer T-Cells; Protein Kinase Inhibitors; Pyridines; rho-Associated Kinases | 2016 |
miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; NF-kappa B; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2016 |
Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Retrospective Studies; Withholding Treatment; Young Adult | 2016 |
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atherosclerosis; Cross-Sectional Studies; Cytokines; Dyslipidemias; Female; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Incidence; Inflammation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oxidation-Reduction; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Scavenger Receptors, Class E; Thrombosis | 2016 |
[Comparative Analysis of Efficacy and Drug Resistance of Imatinib in Patients with Chronic Myeloid Leukemia at Chronic and Advanced Phases].
Topics: Antineoplastic Agents; Blast Crisis; Cytogenetics; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Remission Induction; Survival Rate | 2016 |
Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
Topics: Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CXCL12; Coculture Techniques; Drug Resistance, Neoplasm; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Receptors, CXCR; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
[The impact of Glivec related side effects on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; China; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Quality of Life; Young Adult | 2016 |
[A survey on tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia in China: from patients'perspective].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Quality of Life; Surveys and Questionnaires; Young Adult | 2016 |
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction | 2016 |
Adverse effects of imatinib in children with chronic myelogenous leukemia.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Retrospective Studies; Treatment Outcome | 2017 |
Horizontal melanonychia.
Topics: Aged, 80 and over; Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melanosis; Nail Diseases; Nails, Malformed; Protein Kinase Inhibitors | 2017 |
CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Naphthoquinones; Protein Kinase Inhibitors; Signal Transduction; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2017 |
Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors | 2016 |
Response: Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting.
Topics: Antineoplastic Agents; Benzamides; Cyclosporine; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2016 |
Depletion of γ-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Topics: Animals; Antineoplastic Agents; Cell Survival; Desmoplakins; Disease Models, Animal; gamma Catenin; Heterografts; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Treatment Outcome; Tumor Cells, Cultured | 2016 |
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Polypharmacy; Treatment Outcome | 2016 |
The Culture Repopulation Ability (CRA) Assay and Incubation in Low Oxygen to Test Antileukemic Drugs on Imatinib-Resistant CML Stem-Like Cells.
Topics: Antineoplastic Agents; Bortezomib; Cell Culture Techniques; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Neoplastic Stem Cells; Oxygen | 2016 |
A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.
Topics: Apoptosis; Blast Crisis; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Mutation; Pyrimidines | 2016 |
High-Throughput Screening of Tyrosine Kinase Inhibitor Resistant Genes in CML.
Topics: Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Library; High-Throughput Screening Assays; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; RNA, Small Interfering; Sequence Analysis, DNA | 2016 |
Identification and functional characterization of the miRNA-gene regulatory network in chronic myeloid leukemia lineage negative cells.
Topics: 3' Untranslated Regions; Adaptor Proteins, Signal Transducing; Base Sequence; cdc25 Phosphatases; Cell Lineage; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Regulatory Networks; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Neoplastic Stem Cells; Nuclear Proteins; Phosphorylation; Real-Time Polymerase Chain Reaction; Reproducibility of Results; RNA, Messenger | 2016 |
Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphoproteins; Porphyrins; Transcription Factors; Up-Regulation; Verteporfin; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
[Efficacy of three prognostic scoring systems on evaluating the prognosis for patients with chronic myeloid leukemia].
Topics: Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Retrospective Studies | 2016 |
Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transport Proteins; Organic Cation Transporter 1; Protein Kinase Inhibitors; RNA Interference | 2016 |
Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2017 |
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Topics: 1-Naphthylamine; Aminoquinolines; Animals; Antineoplastic Agents; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Induction; Female; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HEK293 Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Neoplastic Stem Cells; Protein-Arginine N-Methyltransferases; Pyrimidines; RNA, Small Interfering; STAT5 Transcription Factor; Xenograft Model Antitumor Assays | 2016 |
Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.
Topics: Adult; Apoptosis; Autophagy; Celecoxib; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Male; Middle Aged; Necrosis; Neoplasm Staging | 2016 |
The anti-leukemic and lipid lowering effects of imatinib are not hindered by statins in CML: a retrospective clinical study and in vitro assessment of lipid-genes transcription.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lipid Metabolism; Lipids; Protein Kinase Inhibitors; Transcription, Genetic; Treatment Outcome | 2017 |
Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS).
Topics: Adolescent; Adult; Aged; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Retrospective Studies; RNA Splicing; Sequence Analysis, DNA; Treatment Failure; Young Adult | 2016 |
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Topics: Antigens, CD34; Apoptosis; Cell Line, Tumor; Cell Survival; Etoposide; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Signal Transduction; Topoisomerase II Inhibitors; Tumor Stem Cell Assay | 2017 |
[The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations].
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Retrospective Studies | 2016 |
Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
Topics: Antineoplastic Agents; Apoptosis; Biological Products; Cell Proliferation; Drug Resistance, Neoplasm; Emodin; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction | 2017 |
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.
Topics: Adult; Aged; Blood Proteins; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neovascularization, Pathologic; Pilot Projects; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Th1 Cells | 2016 |
4-methylumbelliferone and imatinib combination enhances senescence induction in chronic myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Extracellular Signal-Regulated MAP Kinases; Humans; Hymecromone; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt | 2017 |
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azulenes; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Mutation; Oxidative Stress; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Time Factors; Transfection | 2016 |
Successful management of chronic myeloid leukemia with a complication of anti-SRP antibody-associated myopathy.
Topics: Autoantibodies; Autoantigens; Biomarkers; Disease Management; Humans; Imatinib Mesylate; Immunoglobulins, Intravenous; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscular Diseases; Signal Recognition Particle; Treatment Outcome | 2017 |
Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; CSK Tyrosine-Protein Kinase; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases | 2016 |
Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers; Cytogenetic Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Time Factors; Treatment Outcome; Young Adult | 2017 |
Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience From a Tertiary Oncology Center in Southern India.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Translocation, Genetic; Young Adult | 2017 |
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Purines; Quinazolinones | 2016 |
Changing Treatment May Affect the Predictive Ability of European Treatment Outcome Study Scoring for the Prognosis of Patients with Chronic Myeloid Leukemia.
Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Humans; Hydroxyurea; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome | 2017 |
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Skin Neoplasms | 2017 |
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line.
Topics: Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Low ABCB1 and high OCT1 levels play a favorable role in the molecular response to imatinib in CML patients in the community clinical practice.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Drug Resistance, Neoplasm; Female; Hospitals, Community; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Prognosis; Remission Induction; Risk Factors; RNA, Messenger; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Survival Pattern of Chronic Myeloid Leukemia in a Pediatric Population in the United States.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Prognosis; SEER Program; Survival Rate; United States; Young Adult | 2017 |
[Chylothorax Related with Dasatinib in the Treatment of Chronic Myeloid Leukemia: Report of 3 Cases].
Topics: Chylothorax; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pleural Effusion; Prognosis; Protein Kinase Inhibitors | 2016 |
Imatinib Mesylate Versus Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic Myelogenous Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Retrospective Studies; Transplantation, Homologous; Young Adult | 2016 |
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Mutation; Pyrazoles; Pyrimidines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |
Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance.
Topics: Antineoplastic Agents; Base Sequence; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; MicroRNAs; Middle Aged; Proto-Oncogene Proteins c-myc; Real-Time Polymerase Chain Reaction; Tunisia | 2017 |
A deletion polymorphism in the RIZ gene is associated with increased progression of imatinib treated chronic myeloid leukemia patients.
Topics: Adult; Aged; Alleles; Case-Control Studies; Disease Progression; DNA-Binding Proteins; Female; Fusion Proteins, bcr-abl; Genotype; Histone-Lysine N-Methyltransferase; Humans; Imatinib Mesylate; INDEL Mutation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Polymorphism, Genetic; Sequence Deletion; Transcription Factors; Translocation, Genetic; Treatment Outcome | 2017 |
Celecoxib inhibits proliferation and survival of chronic myelogeous leukemia (CML) cells via AMPK-dependent regulation of β-catenin and mTORC1/2.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Celecoxib; Cell Cycle Checkpoints; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2016 |
Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.
Topics: Aged; Antineoplastic Agents; Cost-Benefit Analysis; Dasatinib; Disease-Free Survival; Fees, Pharmaceutical; Female; Health Expenditures; Health Services; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Econometric; Philadelphia Chromosome; Pyrimidines; Quality-Adjusted Life Years; Time Factors | 2017 |
lncRNA UCA1 Contributes to Imatinib Resistance by Acting as a ceRNA Against miR-16 in Chronic Myeloid Leukemia Cells.
Topics: ATP Binding Cassette Transporter, Subfamily B; Base Sequence; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; RNA, Long Noncoding; Up-Regulation | 2017 |
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Topics: Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridazines; Receptor Protein-Tyrosine Kinases; Small Molecule Libraries; Triazoles | 2017 |
Imatinib resistance in chronic myeloid leukemia due to a rare mutation.
Topics: Adult; Alleles; Antineoplastic Agents; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Protein Kinase Inhibitors | 2017 |
The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Topics: Adult; Aged; Antineoplastic Agents; Drug Resistance, Multiple; Female; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Young Adult | 2017 |
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Topics: Apoptosis; Caspases; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heterografts; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nickel; Proteasome Inhibitors; Pyridines; Thiones | 2016 |
Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pyrimidines; Salvage Therapy | 2016 |
Twisting IL-1 signaling to kill CML stem cells.
Topics: Humans; Imatinib Mesylate; Interleukin-1; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Signal Transduction; Stem Cells | 2016 |
Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.
Topics: Antineoplastic Agents; China; Cost-Benefit Analysis; Decision Support Techniques; Humans; Imatinib Mesylate; Insurance Coverage; Insurance, Health; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Pyrimidines; Quality-Adjusted Life Years | 2017 |
The impact of medical insurance coverage and molecular monitoring frequency on outcomes in chronic myeloid leukemia: real-world evidence in China.
Topics: Adult; Age Factors; Antineoplastic Agents; China; Female; Fusion Proteins, bcr-abl; Hematologic Tests; Humans; Imatinib Mesylate; Insurance Coverage; Insurance, Health; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Sex Factors | 2017 |
Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cantharidin; Cell Cycle Checkpoints; DNA Damage; Drug Synergism; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2016 |
CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials, Phase II as Topic; Cytochrome P-450 CYP2C8; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases | 2017 |
[Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Asian People; China; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Reported Outcome Measures; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quality of Life; Surveys and Questionnaires; Young Adult | 2016 |
The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice, SCID; Mutation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-mdm2; Time Factors; Tryptamines; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Belgium; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies | 2017 |
[A New Goal for Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: Treatment-free Remission -Review].
Topics: Goals; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases | 2016 |
Concomitant AID Expression and BCL7A Loss Associates With Accelerated Phase Progression and Imatinib Resistance in Chronic Myeloid Leukemia.
Topics: Aged; Cytidine Deaminase; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotype; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Microfilament Proteins; Oncogene Proteins; Protein Kinase Inhibitors | 2017 |
Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Cell Count; Cohort Studies; Dasatinib; Female; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Machine Learning; Male; Middle Aged; Models, Theoretical; Predictive Value of Tests; Pyrimidines; Saudi Arabia; Treatment Outcome; Young Adult | 2017 |
Evaluation of Long-Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dasatinib; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Time Factors; United States; United States Department of Veterans Affairs; Veterans; Young Adult | 2017 |
Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2017 |
Long noncoding RNA HULC promotes cell proliferation by regulating PI3K/AKT signaling pathway in chronic myeloid leukemia.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, myc; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Signal Transduction | 2017 |
Effects of Deeper Molecular Responses on Outcomes in Chronic Myeloid Leukemia Patients in Chronic Phase Treated With Imatinib Mesylate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytogenetics; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Prognosis; Retrospective Studies; Young Adult | 2017 |
CML stem cells: evasion for better invasion.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Stem Cells | 2017 |
Response: upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Pyrimidines | 2017 |
Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Pyrimidines | 2017 |
Pioglitazone with imatinib in CML may reduce residual disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Pioglitazone; Protein Kinase Inhibitors; Thiazolidinediones; Treatment Outcome | 2017 |
Chronic myelogenous leukemia evolving after treatment of multiple myeloma.
Topics: Antineoplastic Agents; Bone Marrow; Bortezomib; Dexamethasone; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Multiple Myeloma | 2016 |
miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Biomarkers, Tumor; Child; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2017 |
Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence.
Topics: Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2017 |
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasm, Residual; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.
Topics: Adaptor Proteins, Signal Transducing; Down-Regulation; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Hippo Signaling Pathway; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Phosphoproteins; Platelet Glycoprotein GPIb-IX Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction; SOXB1 Transcription Factors; Transcription Factors; YAP-Signaling Proteins | 2017 |
Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.
Topics: Adult; Aged; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome | 2017 |
Long-term treatment effects in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Time | 2017 |
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Cysteine; Diterpenes, Kaurane; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Deletion; Heat Shock Transcription Factors; HL-60 Cells; HSP70 Heat-Shock Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Molecular Chaperones; Oxidation-Reduction; Proteasome Endopeptidase Complex; Proteolysis; Ubiquitin | 2017 |
[Sudden bilateral decreased vision in a 14-year-old boy].
Topics: Adolescent; Emergency Service, Hospital; Fundus Oculi; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Retinal Hemorrhage; Tomography, Optical Coherence; Vision Disorders; Vision, Binocular; Vision, Low | 2017 |
Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Leukocytes, Mononuclear; Organic Cation Transporter 1; PPAR gamma | 2017 |
A case report of rare palmoplantar keratosis and nail dystrophy with imatinib.
Topics: Antineoplastic Agents; Female; Foot; Hand; Humans; Imatinib Mesylate; Keratoderma, Palmoplantar; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Nail Diseases; Skin | 2017 |
Population Pharmacokinetics of Imatinib and its application to the therapeutic drug monitoring: Middle East CML population.
Topics: Antineoplastic Agents; Drug Monitoring; Humans; Imatinib Mesylate; Iran; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle East; Population Surveillance | 2016 |
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
Topics: Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged | 2018 |
Does the frequency of molecular monitoring after tyrosine kinase inhibitor discontinuation affect outcomes of patients with chronic myeloid leukemia?
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Dasatinib; Deprescriptions; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Protein Kinase Inhibitors; Quinolines; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Watchful Waiting; Young Adult | 2017 |
Editorial: CML HSCs: Are the True Enemies for the Patient?
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Treatment Outcome | 2017 |
Nrf-2/Gst-α mediated imatinib resistance through rapid 4-HNE clearance.
Topics: Adult; Aldehydes; Bone Marrow Cells; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Glutathione Transferase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; NF-E2-Related Factor 2 | 2017 |
A Retrospective Study of Clinical Profile and Long Term Outcome to Imatinib Mesylate Alone in Childhood Chronic Myeloid Leukemia in Chronic Phase.
Topics: Antineoplastic Agents; Benzamides; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2017 |
Myeloid Sarcoma as the First Sign of Progression of Chronic Myeloid Leukemia in Medullary Chronic Phase: Experience from a Tertiary Cancer Centre in Southern India.
Topics: Adult; Disease Progression; Female; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Sarcoma, Myeloid | 2017 |
Hodgkin Lymphoma in a Case of Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors.
Topics: Centrosome; Chromosome Aberrations; Dose-Response Relationship, Drug; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Time Factors | 2019 |
The Efficacy of Generic Imatinib as First- and Second-line Therapy: 3-Year Follow-up of Patients With Chronic Myeloid Leukemia.
Topics: Adult; Antineoplastic Agents; Bosnia and Herzegovina; Drugs, Generic; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Retrospective Studies | 2017 |
hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents; Biomarkers, Tumor; Down-Regulation; Exons; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Octamer Transcription Factor-1; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; RNA, Messenger; Tunisia; Young Adult | 2017 |
Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dasatinib; Female; Health Services; Humans; Imatinib Mesylate; Insurance Claim Review; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Economic; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Vascular Diseases; Young Adult | 2017 |
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Edema; Factor Analysis, Statistical; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Octamer Transcription Factor-1; Pharmacogenetics; Polymorphism, Genetic; Prognosis; Sex Characteristics | 2017 |
Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.
Topics: Aged; Benzamides; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Case-Control Studies; Female; Giant Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Phosphates; Piperazines; Pyrimidines; Remission Induction; Time Factors | 2008 |
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins | 2008 |
Part I: Milestones in personalised medicine--imatinib.
Topics: Antineoplastic Agents; Benzamides; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2008 |
[Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2008 |
[Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2008 |
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrroles | 2008 |
Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
Topics: Aged; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Erythrocytes; Fatal Outcome; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Megakaryocytes; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Division; Cell Line, Tumor; Centrosome; CHO Cells; Cricetinae; Cricetulus; Fibroblasts; G1 Phase; Genes, abl; Genes, src; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Osteosarcoma; Piperazines; Pyrimidines; Skin Physiological Phenomena | 2008 |
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Topics: Adult; Agammaglobulinemia; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; gamma-Globulins; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunoglobulins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies | 2008 |
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cohort Studies; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Diagnosis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proportional Hazards Models; Pyrimidines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2008 |
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Drug Resistance, Neoplasm; Female; Gene Frequency; Genes, MDR; Genotype; Homozygote; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Pyrimidines | 2008 |
Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Patient Compliance; Piperazines; Pyrimidines | 2009 |
No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; RNA, Messenger; Treatment Failure; Treatment Outcome | 2008 |
Imatinib-lnduced agranulocytosis in a patient with chronic myelogenous leukemia in remission.
Topics: Adult; Agranulocytosis; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2008 |
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport; Dasatinib; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Temperature; Thiazoles; Tumor Cells, Cultured | 2008 |
Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2008 |
Proteomic analysis of an imatinib-resistant K562 cell line highlights opposing roles of heat shock cognate 70 and heat shock 70 proteins in resistance.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; HSP70 Heat-Shock Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proteomics; Pyrimidines | 2008 |
Dynamics and potential impact of the immune response to chronic myelogenous leukemia.
Topics: Benzamides; Computer Simulation; Humans; Imatinib Mesylate; Immunity, Innate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Immunological; Piperazines; Pyrimidines; T-Lymphocytes | 2008 |
Leukemic cells with increased telomerase activity exhibit resistance to imatinib.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Pyrimidines; Telomerase; Telomere; Transcription, Genetic; Tumor Cells, Cultured | 2008 |
Clinical imatinib mesylate treatment induces early normalisation of aberrant neutrophil leukotriene C4 synthase expression and activity in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Glutathione Transferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2008 |
Disease progression in some cancers may be due to low blood levels of targeted therapies.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Biological Availability; Dasatinib; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
STI571 reduces NER activity in BCR/ABL-expressing cells.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Survival; Comet Assay; DNA Repair; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2008 |
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Child; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Prognosis; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2008 |
Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?
Topics: Adolescent; Adult; Aged; Benzamides; Child; Cost-Benefit Analysis; Developing Countries; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mexico; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2008 |
Chronic phase of ETV6-ABL1 positive CML responds to imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2008 |
Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty.
Topics: Antineoplastic Agents; Benzamides; Bone Density; Child; Follicle Stimulating Hormone; Gynecomastia; Humans; Imatinib Mesylate; Inhibins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Puberty; Pyrimidines | 2008 |
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interleukin-11; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pilot Projects; Piperazines; Platelet Count; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thrombocytopenia; Treatment Outcome | 2008 |
PU.1 expression is restored upon treatment of chronic myeloid leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Middle Aged; Myeloid Cells; Piperazines; Polycythemia Vera; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Recombinant Proteins; RNA Interference; RNA, Messenger; RNA, Small Interfering; Thrombocythemia, Essential; Trans-Activators; Transfection; Treatment Outcome | 2008 |
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chronic Disease; Disease Progression; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines | 2008 |
A PDE model for imatinib-treated chronic myelogenous leukemia.
Topics: Algorithms; Antineoplastic Agents; Apoptosis; Benzamides; Cell Count; Cell Differentiation; Cell Proliferation; Computer Simulation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2008 |
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Registries; Treatment Outcome | 2008 |
Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; RNA, Messenger; Transcription, Genetic | 2008 |
Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Cohort Studies; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2008 |
Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Cell Separation; Dasatinib; Dogs; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles | 2008 |
Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia.
Topics: Adult; Arthritis, Rheumatoid; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2008 |
[Imatinib therapy in chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2008 |
Acetylation of FOXO3a transcription factor in response to imatinib of chronic myeloid leukemia.
Topics: Acetylation; Benzamides; Cell Line, Tumor; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Processing, Post-Translational; Pyrimidines | 2009 |
ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts.
Topics: Antineoplastic Agents; Benzamides; Exons; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutagenesis, Insertional; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines; Transcription, Genetic | 2008 |
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.
Topics: Aniline Compounds; Apoptosis; Benzamides; Cell Cycle; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Eukaryotic Initiation Factor-4F; Feedback, Physiological; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Peptide Chain Initiation, Translational; Phosphorylation; Piperazines; Polyribosomes; Protein Kinases; Purines; Pyrimidines; Ribosomal Protein S6; RNA Caps; RNA Transport; RNA, Messenger; Signal Transduction; Substrate Specificity; TOR Serine-Threonine Kinases | 2008 |
Use of imatinib mesylate in elderly patients in Northern Ireland: evidence of comparable haematological and molecular responses to younger patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Northern Ireland; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis | 2008 |
Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Transplantation Chimera; Transplantation, Homologous | 2008 |
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Disease Progression; HSP70 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Prognosis; Pyrimidines; Young Adult | 2009 |
Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Treatment Outcome; Tretinoin | 2008 |
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Agents; Benzamides; Databases, Factual; Drug Resistance, Neoplasm; Europe; Female; Health Planning Guidelines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Treatment Failure; Treatment Outcome; Young Adult | 2008 |
[SphK-1/S1P signal pathway in CML cells].
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysophospholipids; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Pyrimidines; RNA, Messenger; Signal Transduction; Sphingosine | 2008 |
Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.
Topics: Base Sequence; Benzamides; Bone Marrow Cells; DNA Primers; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Receptors, Erythropoietin; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Allogeneic stem cell transplantation for chronic myeloid leukemia-status in 2007.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transplantation, Homologous | 2008 |
Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Multiple Myeloma; Piperazines; Pyrimidines | 2009 |
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Colony-Forming Units Assay; Drug Resistance; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2008 |
EVI1, BAALC and AME: prevalence of the secondary mutations in chronic and accelerated phases of chronic myeloid leukemia patients from eastern India.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; DNA-Binding Proteins; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Mutation; Neoplasm Proteins; Piperazines; Polymerase Chain Reaction; Prevalence; Proto-Oncogenes; Pyrimidines; Transcription Factors | 2009 |
A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate | 2008 |
Chronic myeloid leukemia in two patients with gastrointestinal stromal tumor.
Topics: Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines | 2008 |
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels.
Topics: Adult; Benzamides; Cytogenetic Analysis; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Risk Assessment | 2009 |
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Drug Approval; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; United States; United States Food and Drug Administration | 2008 |
Successful use of National Cancer Registry data to monitor the effective use of imatinib for treating chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Registries; Scotland | 2008 |
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Topics: Adolescent; Adult; Antineoplastic Agents; Bangladesh; Benzamides; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Tretinoin | 2008 |
Is imatinib safe during pregnancy?
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Prenatal Exposure Delayed Effects; Pyrimidines | 2009 |
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Adhesion; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Cells; Extracellular Matrix; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Neovascularization, Pathologic; NF-kappa B; Piperazines; Propiophenones; Pyrimidines; Reactive Oxygen Species; Tumor Suppressor Protein p53; U937 Cells; Vascular Endothelial Growth Factor A | 2008 |
Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease.
Topics: Adolescent; Benzamides; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Localized | 2008 |
Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Parturition; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines | 2008 |
Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia.
Topics: Aged; Analgesics, Non-Narcotic; Anemia, Aplastic; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Benzamides; Cyclosporine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mycoses; Piperazines; Pyrimidines; Remission Induction; Respiratory Tract Infections | 2009 |
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Dasatinib; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2008 |
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Topics: Animals; Benzamides; beta Catenin; Bone Marrow; Cell Survival; Drug Resistance, Neoplasm; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Wnt Proteins | 2009 |
[Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects].
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Piperazines; Pyrimidines; Treatment Outcome | 2008 |
Modulation of reactive oxygen species by antioxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation.
Topics: Amitrole; Antineoplastic Agents; Antioxidants; Benzamides; Buthionine Sulfoximine; Dose-Response Relationship, Drug; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; Neoplasm Proteins; Piperazines; Pyrimidines; Reactive Oxygen Species; Survivin | 2008 |
What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Thiazoles | 2008 |
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Dasatinib; Drug Resistance, Neoplasm; Female; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pyrimidines; Thiazoles | 2008 |
Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Poly(ADP-ribose) Polymerases; Pyrimidines; Signal Transduction; Thiazoles | 2008 |
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Renal Insufficiency; Thiazoles | 2009 |
Supplemental results of the detection of splicing variant with c-ABL exon 7 deletion by direct sequencing Comment on "A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients" by Curvo et al. [Leuk. Res.].
Topics: Alternative Splicing; Benzamides; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sequence Analysis, DNA; Sequence Deletion | 2009 |
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Topics: Benzamides; Bone Marrow; Cell Death; Cell Line, Tumor; Culture Media, Conditioned; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Small Interfering; STAT3 Transcription Factor; Thiazoles | 2008 |
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Benzamides; Blotting, Western; Cell Line; Cell Transformation, Neoplastic; DNA Primers; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunoprecipitation; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2008 |
Persistence of molecular remission throughout pregnancy in CML after imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Remission Induction | 2009 |
Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib.
Topics: Adenosine Triphosphate; Benzamides; Cell Line; Cloning, Molecular; Collagen; Dasatinib; Discoidin Domain Receptor 1; Discoidin Domain Receptors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Mitogen; Structural Homology, Protein; Thiazoles | 2008 |
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK.
Topics: Apoptosis; Benzamides; Caspase 8; Ceramides; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Phosphatase 2; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2008 |
BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Topics: Aged; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2009 |
Current and future perspectives on the TARGET system: the registration system for Glivec established by the JSH.
Topics: Antineoplastic Agents; Benzamides; Female; Hematology; Humans; Imatinib Mesylate; Internet; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Registries; Societies, Medical; User-Computer Interface | 2008 |
The era of personalized medicine: back to basics.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Targeting; Genes, erbB-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Panitumumab; Patient-Centered Care; Piperazines; Pyrimidines; Treatment Outcome | 2008 |
[Chronic myeloid leukemia:specific characteristics and targeted therapy].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Piperazines; Pyrimidines | 2007 |
Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.
Topics: Animals; Antineoplastic Agents, Alkylating; Base Sequence; Benzamides; Blood Cells; Bone Marrow Cells; Cell Proliferation; Cells, Cultured; Chlorambucil; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Biological; Nylons; Piperazines; Pyrimidines; Substrate Specificity; Transduction, Genetic | 2008 |
Imatinib resistance in multidrug-resistant K562 human leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Benzamides; Blotting, Western; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Nitriles; Oligodeoxyribonucleotides; Piperazines; Pyrimidines; Sulfones | 2009 |
Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 3; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Pyrimidines | 2009 |
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cancer Vaccines; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Forkhead Transcription Factors; Imatinib Mesylate; Immunohistochemistry; Immunotherapy, Active; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Phosphorylation; Piperazines; Pyrimidines; STAT3 Transcription Factor; STAT5 Transcription Factor; T-Lymphocytes, Regulatory | 2008 |
Transient trisomy 8 abnormality in Philadelphia-negative cells during imatinib mesylate treatment of chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Trisomy | 2008 |
[Chronic myeloproliferative diseases. Current therapeutic standards and new developments].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Prognosis; Pyrimidines; Thrombocytosis | 2008 |
Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Flow Cytometry; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2008 |
c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Topics: Apoptosis; Benzamides; Cell Differentiation; Cell Proliferation; Enzyme Inhibitors; Erythroid Cells; Globins; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Mas; Proto-Oncogene Proteins c-jun; Pyrimidines | 2009 |
[Tolerability of imatinib for patients with chronic myelogeneous leukemia (CML)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease Progression; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Survival Rate; Young Adult | 2008 |
The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Carbamates; Cell Line, Tumor; Down-Regulation; Drug Synergism; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potentials; Oxazepines; Piperazines; Pyrimidines; Up-Regulation | 2009 |
OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Octamer Transcription Factor-1; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Young Adult | 2008 |
In vitro anti-leukaemia activity of sphingosine kinase inhibitor.
Topics: Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors | 2009 |
Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2009 |
Skin and oral lesions associated to imatinib mesylate therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Eruptions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oral Ulcer; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Pyrimidines; Transcription, Genetic | 2008 |
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Topics: Adult; Benzamides; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm; Time Factors | 2008 |
C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases | 2009 |
Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy.
Topics: Adult; Aged; Antigens, CD34; Benzamides; Biomarkers, Tumor; Female; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Fluorescence in situ hybridization dissection of a chronic myeloid leukemia case bearing the apparently balanced translocations (9;22)(q34;q11.2) and (11;11)(p15;q13).
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Deletion; Chromosome Mapping; Chromosome Painting; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic; Tumor Cells, Cultured | 2009 |
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; ErbB Receptors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2008 |
Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction | 2009 |
Has the time come for induction and maintenance imatinib therapy in chronic myeloid leukemia?
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nitriles; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Thiazoles | 2009 |
EUTOS for chronic myeloid leukemia shows improved management and dose optimization is required.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Laboratories, Hospital; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Registries | 2008 |
Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Topics: Adult; Antineoplastic Agents; Benzamides; Electrophoresis, Agar Gel; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2009 |
Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.
Topics: Benzamides; Chromosomes, Human, Pair 7; Clone Cells; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Young Adult | 2009 |
Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Conjunctival Diseases; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Spontaneous spinal epidural hematoma as the initial presentation of leukemia.
Topics: Antineoplastic Agents; Benzamides; Decompression, Surgical; Hematoma, Epidural, Spinal; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Compound 48, a novel dual PPAR alpha/gamma ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzopyrans; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; Piperazines; PPAR alpha; PPAR gamma; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Nucleus; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Growth deceleration in a girl treated with imatinib.
Topics: Benzamides; Bone Density; Bone Development; Child; Female; Growth; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
Topics: Acetylcysteine; Annexin A5; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Free Radical Scavengers; Fusion Proteins, bcr-abl; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Nitric Oxide; Nitric Oxide Synthase Type III; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species; Up-Regulation | 2009 |
Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Proteasome proteolytic profile is linked to Bcr-Abl expression.
Topics: Apoptosis; Benzamides; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrimidines; Tumor Cells, Cultured | 2009 |
The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.
Topics: Apoptosis; Benzamides; Cytokines; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Stem Cell Factor; Tumor Cells, Cultured | 2009 |
Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic | 2009 |
[Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Early Detection of Cancer; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines | 2009 |
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Reproducibility of Results; Research Design; Threonine | 2009 |
Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2008 |
Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes.
Topics: Adult; Aged; Antigens; Benzamides; Bone Marrow Cells; Female; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phenotype; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.
Topics: Adult; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger | 2009 |
Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
Topics: Apoptosis; Benzamides; CASP8 and FADD-Like Apoptosis Regulating Protein; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Peritoneal tuberculosis after imatinib therapy.
Topics: Adult; Antineoplastic Agents; Antitubercular Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphopenia; Male; Opportunistic Infections; Peritonitis; Peritonitis, Tuberculous; Piperazines; Pyrimidines | 2009 |
Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Disease-Free Survival; Female; Heart Diseases; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2009 |
A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia.
Topics: Animals; Arsenicals; Benzamides; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Piperazines; Proteasome Endopeptidase Complex; Protein Kinases; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Sulfides; Survival Rate; Systems Biology; TOR Serine-Threonine Kinases; Ubiquitins | 2009 |
Is anticancer drug development heading in the right direction?
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Drug Therapy; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Presentation of childhood CML mimicking bone sarcoma.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Neoplasms; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Osteosarcoma; Piperazines; Pyrimidines | 2009 |
The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzodioxoles; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinazolines; src-Family Kinases | 2009 |
A pulse at the heart of targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
[Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nucleic Acid Amplification Techniques; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2009 |
Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Case-Control Studies; Cell Line, Tumor; Cell Proliferation; DNA Primers; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Genes, abl; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Valproic Acid | 2009 |
Vitiligo-like lesions in an adult patient treated with Imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Vitiligo | 2009 |
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
Topics: Animals; Apoptosis; Benzamides; Chromosomal Proteins, Non-Histone; Cyclohexanes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Histone Chaperones; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; Piperazines; Protein Phosphatase 2; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Pyrimidines; src-Family Kinases; Transcription Factors; Tyrphostins | 2009 |
Recurrence of lymphoid blast crisis over 20 years after successful sibling allo-SCT for CML: short lived complete cytogenetic response to imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Pyrimidines | 2009 |
The structure of the leukemia drug imatinib bound to human quinone reductase 2 (NQO2).
Topics: Antineoplastic Agents; Benzamides; Crystallography, X-Ray; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; NAD(P)H Dehydrogenase (Quinone); Phosphorylation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Quinone Reductases; Structure-Activity Relationship; Thiazoles | 2009 |
Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Diterpenes; Drug Resistance, Neoplasm; Epoxy Compounds; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Phenanthrenes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Transcription, Genetic; Tripterygium; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays; Young Adult | 2009 |
Tuberculosis complicating imatinib treatment for chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Antitubercular Agents; Benzamides; CD8-Positive T-Lymphocytes; Humans; Imatinib Mesylate; Immune System; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mycobacterium tuberculosis; Piperazines; Pyrimidines; Signal Transduction; Treatment Outcome; Tuberculosis | 2009 |
Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ovulation Induction; Piperazines; Pregnancy; Pregnancy Outcome; Pyrimidines; Withholding Treatment | 2009 |
Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.
Topics: Animals; Antibodies; Benzamides; Cysteine; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indium Radioisotopes; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phosphotyrosine; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Radioimmunodetection; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutagenesis; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles; Treatment Failure | 2009 |
Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
Topics: Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 3; Drug Resistance, Neoplasm; Female; Glutamic Acid; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation, Missense; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic; Trisomy; Valine | 2009 |
[Pharmacogenetics and tailored drug therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Pharmacogenetics; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Body Size; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Time Factors | 2009 |
Berbamine exhibits potent antitumor effects on imatinib-resistant CML cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Benzamides; Benzylisoquinolines; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2009 |
Analysis of Bcr-Abl kinase domain mutations in Korean chronic myeloid leukaemia patients: poor clinical outcome of P-loop and T315I mutation is disease phase dependent.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Korea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzamides; Blotting, Western; Caspase Inhibitors; Caspases; Cell Nucleus; Checkpoint Kinase 2; DNA-Binding Proteins; Drug Resistance, Neoplasm; HL-60 Cells; Humans; Imatinib Mesylate; Immunoprecipitation; Interferon-alpha; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Promyelocytic Leukemia Protein; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; RNA, Small Interfering; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2009 |
Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Small Interfering | 2009 |
Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Benzamides; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Down-Regulation; Fusion Proteins, bcr-abl; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quinolines; RNA, Small Interfering | 2009 |
t(5;6;12) associated with resistance to imatinib mesylate in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 6; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
C3G silencing enhances STI-571-induced apoptosis in CML cells through p38 MAPK activation, but it antagonizes STI-571 inhibitory effect on survival.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Survival; Enzyme Activation; Gene Expression Regulation, Neoplastic; Gene Silencing; Guanine Nucleotide-Releasing Factor 2; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; p38 Mitogen-Activated Protein Kinases; Piperazines; Pyrimidines; rap1 GTP-Binding Proteins; Signal Transduction; Transcription, Genetic | 2009 |
Hypolipemiant besides antileukemic effect of imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Hypolipidemic Agents; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2009 |
Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Chromatin Immunoprecipitation; DNA Primers; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Promoter Regions, Genetic; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S-Phase Kinase-Associated Proteins; Transcriptional Activation | 2009 |
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Topics: Benzamides; Biopsy, Needle; Bone Marrow; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Gene Expression; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Transcription, Genetic | 2009 |
Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspase 9; Caspase Inhibitors; Enzyme Activation; Erythropoiesis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Sulfonamides | 2009 |
The CML stem cell: evolution of the progenitor.
Topics: Animals; Benzamides; Biological Evolution; Blast Crisis; Granulocyte-Macrophage Progenitor Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2009 |
Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays | 2009 |
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Case-Control Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Prevalence; Pyrimidines; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2009 |
Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; China; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Outcome | 2009 |
The toxicities of modern targeted therapies: learning from the price of progress.
Topics: Benzamides; Dasatinib; Drug Delivery Systems; ErbB Receptors; Hemorrhage; Humans; Imatinib Mesylate; Interdisciplinary Communication; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Sirolimus; Skin; Thiazoles; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzamides; Calcium; Cell Death; Cell Line, Tumor; Chloroquine; Dasatinib; Endoplasmic Reticulum; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Mice; Mice, Inbred C3H; Microtubule-Associated Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; Thiazoles; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2009 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
Dasatinib overcomes imatinib and nilotinib failure in Philadelphia chromosome positive chronic myeloid leukemia with different mechanisms of resistance.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2009 |
Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dasatinib; Dexamethasone; Female; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Radiotherapy; Recurrence; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Outcome | 2009 |
Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Topics: Base Sequence; Benzamides; Binding Sites; Cohort Studies; DNA Mutational Analysis; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines | 2009 |
Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel.
Topics: Adult; Benzamides; Colon; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Intestinal Absorption; Intestinal Mucosa; Intestines; Jejunum; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; CD4 Antigens; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance; Flow Cytometry; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Neutrophils; Nuclear Proteins; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2009 |
NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Fluorescent Antibody Technique; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Mutation; NF-kappa B; Piperazines; Pyrimidines | 2009 |
[Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Guidelines as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results.
Topics: Adolescent; Adult; Aged; Benzamides; Chromosome Aberrations; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Analysis; Treatment Outcome | 2009 |
Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML.
Topics: Benzamides; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction | 2009 |
Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Risk Assessment | 2009 |
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Carbon Isotopes; Cell Line, Tumor; Deoxyglucose; Drug Resistance, Neoplasm; Gas Chromatography-Mass Spectrometry; Glucose; Glucose Transporter Type 1; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Spectroscopy; Piperazines; Protein Transport; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Ribose; RNA, Neoplasm; Time Factors | 2009 |
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Cell Count; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles; Time Factors; Young Adult | 2009 |
Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Bcl-2-Like Protein 11; Benzamides; Cell Proliferation; Decitabine; DNA Methylation; DNA Modification Methylases; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Proteins; Middle Aged; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2009 |
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Introns; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials, Phase II as Topic; Disease-Free Survival; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
Topics: Benzamides; Blood Coagulation; Blood Platelet Disorders; Dasatinib; Health; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet Aggregation; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
The therapeutic benefits of heme oxygenase (HO-1) inhibition in the management of systemic malignancies besides hepatocellular carcinomas.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Hepatocellular; Enzyme Inhibitors; Heme Oxygenase-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Nasopharyngeal Neoplasms; Neoplasms; Piperazines; Protoporphyrins; Pyrimidines; Sarcoma, Kaposi | 2009 |
New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma.
Topics: Antineoplastic Agents; Benzamides; Calibration; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Thiazoles | 2009 |
Exploiting the promiscuity of imatinib.
Topics: Animals; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinone Reductases; Structure-Activity Relationship; Substrate Specificity | 2009 |
Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Mutation; Piperazines; Pyrimidines | 2009 |
Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Erythrocyte Indices; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2009 |
Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2009 |
Cutaneous lichenoid eruption caused by imatinib mesylate in a Japanese patient with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Piperazines; Pyrimidines | 2009 |
Karyotype changes during long-term targeted therapy of chronic myeloid leukemia with imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Risk Factors; Time Factors; Translocation, Genetic; Treatment Outcome | 2009 |
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome; Young Adult | 2009 |
Deletion of the der(9q) in chronic myeloid leukemia: the controversy continues.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Risk Factors; Translocation, Genetic; Treatment Outcome | 2009 |
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Chronic myelogenous leukaemia market.
Topics: Benzamides; Dasatinib; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Marketing; Piperazines; Pyrimidines; Thiazoles | 2009 |
Imatinib: a designer drug, another cutaneous complication.
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Piperazines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines | 2009 |
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
Topics: Benzamides; Cause of Death; Cohort Studies; Cytogenetics; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Probability; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Severity of Illness Index; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Piperazines; Pyrimidines; Radiation-Sensitizing Agents; Taxoids | 2009 |
Diminished alpha2-plasmin inhibitor activity associated with the use of imatinib mesylate in patients with Philadelphia chromosome-positive haematologic cancer.
Topics: Adult; Aged; Aged, 80 and over; alpha-2-Antiplasmin; Antineoplastic Agents; Benzamides; Blood Coagulation Tests; Cross-Sectional Studies; Female; Follow-Up Studies; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Thrombocytopenia; Treatment Outcome; Withholding Treatment | 2009 |
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.
Topics: Analysis of Variance; Benzamides; Blast Crisis; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Pharmacogenetics; Piperazines; Probability; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2009 |
Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells.
Topics: Animals; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, IGF Type 1 | 2010 |
Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.
Topics: Adult; Benzamides; Drug Resistance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Still's Disease, Adult-Onset; Treatment Outcome | 2009 |
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase.
Topics: Adolescent; Adult; Aged; Benzamides; Clinical Trials as Topic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Failure; Treatment Outcome | 2009 |
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines | 2009 |
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Cytarabine; Dasatinib; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Fusion Proteins, bcr-abl; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Rate; Thiazoles; Vincristine | 2009 |
Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Longitudinal growth retardation in a prepuberal girl with chronic myeloid leukemia on long-term treatment with imatinib.
Topics: Benzamides; Child; Female; Growth Disorders; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzylisoquinolines; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; G1 Phase; Genes, abl; Humans; I-kappa B Proteins; Imatinib Mesylate; Indicators and Reagents; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Piperazines; Pyrimidines; RNA, Messenger; Signal Transduction; Survivin; Tetrazolium Salts | 2009 |
S-phase fraction as response marker in patients with chronic myeloid leukemia.
Topics: Benzamides; Biomarkers, Tumor; Case-Control Studies; DNA; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; RNA, Messenger; S Phase | 2009 |
A fertile XY/XX chimeric male with chronic myeloid leukemia in a minor 46,XX cell line and a history of polycythemia vera and trisomy 9 in the major 46,XY cell line.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chimera; Chromosomes, Human, Pair 9; Chromosomes, Human, X; Chromosomes, Human, Y; Disease Progression; Fertility; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Incidental Findings; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Piperazines; Polycythemia Vera; Pyrimidines; Sex Chromosome Aberrations; Trisomy | 2009 |
Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-fyn; Pyridines; Pyrimidines; RNA, Small Interfering; Tumor Cells, Cultured | 2009 |
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Hospitals, Public; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Life Expectancy; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Spain; Survival Rate; Thiazoles | 2009 |
ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Genes, abl; Humans; Imatinib Mesylate; Immunohistochemistry; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Piperazines; Point Mutation; Pyrimidines; Signal Transduction | 2009 |
[Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Nucleic Acid Amplification Techniques; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reagent Kits, Diagnostic; RNA, Messenger | 2009 |
WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Ki-67 Antigen; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; RNA, Messenger; WT1 Proteins | 2009 |
Response to treatment in women with chronic myeloid leukemia during pregnancy and after delivery.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Delivery, Obstetric; Female; Humans; Imatinib Mesylate; Interferons; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Thiazoles | 2009 |
Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; von Willebrand Diseases | 2009 |
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cytochrome P-450 CYP3A; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glycoproteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Octamer Transcription Factor-1; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Pyrimidines; Treatment Outcome; Young Adult | 2009 |
JAK2 inhibitors: not the next imatinib but researchers see other possibilities.
Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Point Mutation; Polycythemia Vera; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Thrombocytosis | 2009 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Thiazoles | 2009 |
Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Topics: Aged; Aniline Compounds; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nitriles; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Stem Cell Transplantation; Thiazoles | 2009 |
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protease Inhibitors; Proteasome Inhibitors; Pyrimidines; RNA Interference | 2009 |
Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure.
Topics: Adolescent; Adult; Aged; Amylases; Benzamides; Child; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipase; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; Young Adult | 2009 |
Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Topics: Adult; Aged; Anemia; Antineoplastic Agents; Benzamides; Erythrocyte Indices; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Pyrimidines; Retrospective Studies | 2009 |
The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
Topics: Benzamides; Canada; Data Collection; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Physicians; Piperazines; Practice Patterns, Physicians'; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Siblings; Tissue Donors; Transplantation, Homologous; United States | 2009 |
New directions in the treatment of patients with chronic myeloid leukemia: introduction.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Optimizing first-line therapy for patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2009 |
Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Practical considerations for the management of patients in the tyrosine kinase inhibitor era.
Topics: Antineoplastic Agents; Benzamides; Exanthema; Fatigue; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medication Adherence; Muscular Diseases; Nausea; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
New directions in the treatment of imatinib failure and/or resistance.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles | 2009 |
The role of tyrosine kinase inhibitors in tuberous sclerosis.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure; Tuberous Sclerosis | 2009 |
RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Retrospective Studies; WT1 Proteins; Young Adult | 2009 |
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phosphotransferases; Piperazines; Prognosis; Protein Structure, Tertiary; Pyrimidines; Retrospective Studies; RNA, Messenger; Up-Regulation; Young Adult | 2009 |
Imatinib mesylate causes growth plate closure in vivo.
Topics: Animals; Antineoplastic Agents; Benzamides; Child; Female; Growth Disorders; Growth Plate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Rats; Rats, Sprague-Dawley | 2009 |
Nilotinib post-liver transplantation for acute hepatic failure related to imatinib.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Liver Transplantation; Middle Aged; Piperazines; Pyrimidines | 2009 |
Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA-Binding Proteins; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; LIM Domain Proteins; Male; Metalloproteins; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Survival Rate; Young Adult | 2009 |
Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Topics: Adult; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Rearrangement; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2009 |
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Separation; Everolimus; Flow Cytometry; Gene Expression; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microscopy, Confocal; Piperazines; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins c-abl; Pyrimidines; Sirolimus; TOR Serine-Threonine Kinases | 2010 |
Does imatinib mesylate therapy cause growth hormone deficiency?
Topics: Adult; Benzamides; Female; Glucagon; Human Growth Hormone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Levodopa; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
The role of heterogeneous nuclear ribonucleoprotein K in the progression of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Fusion Proteins, bcr-abl; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Ribonucleoproteins; Signal Transduction; Young Adult | 2010 |
Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
Topics: Arthritis, Rheumatoid; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Topics: Animals; Benzamides; Benzylamines; Cell Adhesion; Cell Line; Cell Line, Tumor; Chemokine CXCL12; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Stromal Cells | 2009 |
A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Topics: Antineoplastic Agents; Aphasia; Ataxia; Benzamides; Blast Crisis; Confusion; Cytarabine; Diagnosis, Differential; Hearing Loss; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2009 |
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Glycolysis; Humans; Imatinib Mesylate; K562 Cells; Lactic Acid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Spectroscopy; Phospholipids; Piperazines; Pyrimidines | 2009 |
Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Remission Induction; Treatment Outcome; Young Adult | 2009 |
Influence of late treatment on how chronic myeloid leukemia responds to imatinib.
Topics: Adult; Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Time Factors; Treatment Outcome; Young Adult | 2009 |
Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Benzamides; Female; Gastrectomy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Obesity, Morbid; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2009 |
[Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases].
Topics: Adult; Benzamides; Bone Marrow Cells; Chromosomes, Human, Pair 8; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors; Trisomy | 2009 |
Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.
Topics: Benzamides; DNA; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines; RNA, Messenger | 2009 |
Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Biological Transport, Active; Carrier Proteins; Cell Line, Tumor; Dogs; Humans; Imatinib Mesylate; Kidney; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Bilayers; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines | 2009 |
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Survival Rate; Transcription, Genetic | 2009 |
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2010 |
[Immunological evaluation for CML and its possibility for an immunotherapy].
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Dendritic Cells; Drug Delivery Systems; Humans; Imatinib Mesylate; Immunotherapy; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations.
Topics: Antineoplastic Agents; Benzamides; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Topics: Antigens, CD34; Antineoplastic Agents, Alkylating; Apoptosis; Benzamides; Blast Crisis; Blotting, Western; Cell Line, Tumor; Diterpenes; Epoxy Compounds; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenanthrenes; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times.
Topics: Algorithms; Benzamides; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Monitoring; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Tumor; Cytidine Deaminase; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Mutation; Piperazines; Pyrimidines | 2009 |
The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia.
Topics: Animals; B-Lymphocytes; Benzamides; Blast Crisis; Cell Line, Tumor; Cytidine Deaminase; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases, Renilla; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, SCID; Mice, Transgenic; Mutation; Piperazines; Pyrimidines; Xenograft Model Antitumor Assays | 2009 |
Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tumor Lysis Syndrome | 2009 |
Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Neoplasm Proteins; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Pyrimidines | 2010 |
Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods' comparison.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Chemical Analysis; Calibration; Chromatography, High Pressure Liquid; Chromatography, Liquid; Circadian Rhythm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tandem Mass Spectrometry | 2010 |
Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190(BCR-ABL) oncoprotein and JAK2V617F mutation.
Topics: Aged; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Differentiation; Computer Simulation; Drug Synergism; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2009 |
Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.
Topics: Antiviral Agents; Benzamides; Benzylamines; Bone Marrow; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Drug Resistance, Neoplasm; Heterocyclic Compounds; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Secondary Prevention; Stromal Cells | 2009 |
Attacking cancer at its root.
Topics: Antineoplastic Protocols; Awards and Prizes; Benzamides; Clinical Trials, Phase I as Topic; History, 21st Century; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Republic of Korea; Salvage Therapy; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
Topics: Adult; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction | 2010 |
Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Antigens, CD34; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2009 |
Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2009 |
Chronic myelogenous leukemia clinical practice guidelines in oncology.
Topics: Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Update: chronic myelogenous leukemia clinical practice guidelines.
Topics: Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines | 2003 |
Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: the Japan Marrow Donor Program.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Child; Child, Preschool; Donor Selection; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2009 |
Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; DNA Damage; Flow Cytometry; Fusion Proteins, bcr-abl; Genes, bcl-2; Hemin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-E2-Related Factor 2; Piperazines; Pyrimidines | 2009 |
Lasker Awards and papal portraiture: turning fields upside down.
Topics: Awards and Prizes; Benzamides; Cellular Reprogramming; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orientation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2009 |
Shifting paradigms: the seeds of oncogene addiction.
Topics: Awards and Prizes; Benzamides; Clinical Trials as Topic; DNA, Complementary; Drug Resistance; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Sequence Analysis, DNA; United States | 2009 |
Comparison of the cytogenetic and molecular analyses in the assessment of imatinib response in chronic myelocytic leukemia.
Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2009 |
Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; Pentacyclic Triterpenes; Piperazines; Pyrimidines; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays | 2010 |
The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Topics: 5-Lipoxygenase-Activating Proteins; Animals; Benzamides; Carrier Proteins; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipoxygenase Inhibitors; Membrane Proteins; Mice; Mice, Knockout; Myeloproliferative Disorders; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
A thrombocytosis occurring in Philadelphia positive CML in molecular response to imatinib can reveal an underlying JAK2(V617F) myeloproliferative neoplasm.
Topics: Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Phenylalanine; Piperazines; Pyrimidines; Thrombocytosis; Valine | 2010 |
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Topics: Adult; Benzamides; Cohort Studies; Cytogenetic Analysis; Dasatinib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Remission Induction; Reproducibility of Results; RNA, Messenger | 2010 |
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Philadelphia Chromosome; Piperazines; Pyrimidines | 2010 |
Peripheral neuropathy on imatinib treatment for chronic myeloid leukaemia: suspected adverse drug interaction with amlodipine.
Topics: Aged; Amlodipine; Benzamides; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peripheral Nervous System Diseases; Piperazines; Pyrimidines | 2009 |
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
Topics: Benzamides; Blood Chemical Analysis; Blood Proteins; Chromatography, High Pressure Liquid; Electric Conductivity; Female; Humans; Imatinib Mesylate; Laboratories, Hospital; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Linear Models; Male; Middle Aged; Piperazines; Pyrimidines; Reproducibility of Results; Tandem Mass Spectrometry; Temperature; Time Factors; Ultraviolet Rays | 2010 |
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Bone Marrow Cells; Cells, Cultured; Cluster Analysis; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; Imatinib Mesylate; Interleukin Receptor Common gamma Subunit; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous | 2009 |
The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy.
Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Benzamides; Drug Resistance, Neoplasm; Drug Therapy, Combination; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Young Adult | 2009 |
Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2010 |
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Pyrimidines; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2010 |
Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Dasatinib; Hematopoietic Stem Cell Transplantation; Humans; Iatrogenic Disease; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Treatment Outcome | 2010 |
A gene expression signature of primary resistance to imatinib in chronic myeloid leukemia.
Topics: Benzamides; Cytogenetic Analysis; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Leukocyte Count; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Remission Induction | 2010 |
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2009 |
ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.
Topics: ATP-Binding Cassette Transporters; Benzamides; Cell Line, Tumor; Drug Resistance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Piperazines; Pyrimidines | 2009 |
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phospholipase C gamma; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2010 |
The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia.
Topics: Antigens, CD34; Base Sequence; Benzamides; Blast Crisis; DNA Primers; DNA-Binding Proteins; Gene Expression; Genes, abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Neoplastic Stem Cells; Piperazines; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Stem Cell Transplantation; Transcription Factors | 2010 |
Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Topics: Benzamides; Computational Biology; Drug Design; Drug Resistance; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Purines; Pyrimidines; Structure-Activity Relationship | 2010 |
Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Health Care Costs; Health Care Rationing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Pyrimidines | 2010 |
Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells.
Topics: Acrylamides; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2009 |
Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Cathepsin B; Cell Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Neoplastic Stem Cells; Permeability; Piperazines; Pyrimidines | 2010 |
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Topics: Adult; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
Skin fragility and blistering with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Blister; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Skin | 2010 |
Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by differential modulation of p53 transcriptional and proapoptotic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; bcl-X Protein; Benzamides; Cell Cycle; Cell Cycle Proteins; Cisplatin; DNA Damage; DNA-Binding Proteins; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Cells; Piperazines; Protein Serine-Threonine Kinases; Pyrimidines; Transcription, Genetic; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2009 |
Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Topics: Adolescent; Adult; Aged; Base Sequence; Benzamides; Biomarkers, Tumor; Child; Child, Preschool; DNA Primers; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Saudi Arabia; Treatment Outcome; Young Adult | 2010 |
[Expression of hOCT1 in patients with chronic myelogeneous leukemia treated by imatinib mesylate].
Topics: Adolescent; Adult; Aged; Benzamides; Child; Child, Preschool; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Octamer Transcription Factor-1; Piperazines; Pyrimidines; RNA, Messenger; Young Adult | 2009 |
[Influence of hOCT1 polymorphism on imatinib mesylate effectiveness in chronic myelogenous leukemia patients].
Topics: Benzamides; Female; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Organic Cation Transporter 1; Piperazines; Polymorphism, Genetic; Pyrimidines; Treatment Outcome | 2009 |
Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Multiple Myeloma; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2009 |
Introduction: CML in the imatinib era.
Topics: Antineoplastic Agents; Benzamides; Cancer Vaccines; Drug Delivery Systems; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2009 |
Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Case-Control Studies; Cohort Studies; Creatine Kinase; Edema; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscular Diseases; Piperazines; Pyrimidines; Up-Regulation; Young Adult | 2010 |
SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oligonucleotide Array Sequence Analysis; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Chromosome Aberrations; Cytogenetic Analysis; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2009 |
Diffuse pigmentation of the palate.
Topics: Aged; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melanosis; Mouth Mucosa; Palate, Hard; Piperazines; Pyrimidines | 2009 |
Bartonella henselae neuroretinitis in a 15-year-old girl with chronic myelogenous leukemia.
Topics: Adolescent; Anti-Bacterial Agents; Antibodies, Bacterial; Antineoplastic Agents; Bartonella henselae; Benzamides; Cat-Scratch Disease; Doxycycline; Eye Infections, Bacterial; Female; Fluorescein Angiography; Humans; Imatinib Mesylate; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macular Edema; Magnetic Resonance Imaging; Papilledema; Piperazines; Pyrimidines; Retinitis; Tomography, Optical Coherence | 2009 |
Chronic myeloid leukemia: where do we go now?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survival Rate | 2009 |
Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.
Topics: Benzamides; Cohort Studies; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Time Factors | 2010 |
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Line; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoprecipitation; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Reactive Oxygen Species; RNA, Small Interfering | 2010 |
Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Poland; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2009 |
A diagnostically difficult case of chronic myeloid neoplasm with eosinophilia and abnormalities of PDGFRA effectively treated with imatinib in accelerated phase: case report.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha | 2009 |
CML mouse model in translational research.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Line; Cell Transplantation; Disease Models, Animal; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Transduction, Genetic; Translational Research, Biomedical | 2010 |
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Topics: 14-3-3 Proteins; Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cell Line; Cell Proliferation; Drug Interactions; Drug Resistance; Everolimus; Exonucleases; Exoribonucleases; Fusion Proteins, bcr-abl; Hematopoiesis; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Lethal Dose 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Myeloid Progenitor Cells; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Sirolimus; TOR Serine-Threonine Kinases; Trans-Activators; Transcription Factors; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2010 |
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Blood Glucose; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2010 |
Allo-SCT in a rare t(8;21) evolution of CML.
Topics: Adult; Benzamides; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Translocation, Genetic; Transplantation, Homologous | 2010 |
Rapid synthesis of Abelson tyrosine kinase inhibitors using click chemistry.
Topics: Benzamides; Drug Evaluation, Preclinical; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines | 2009 |
Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia.
Topics: Adult; Alcian Blue; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Coloring Agents; Humans; Hyaluronic Acid; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction | 2010 |
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Topics: Analgesics; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2010 |
AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance.
Topics: Adenine; Animals; Benzamides; Binding Sites; Cell Line; Computer Simulation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2010 |
Molecular characterization and prognostic significance of FLT3 in CML progression.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Disease Progression; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotide Array Sequence Analysis; Piperazines; Prognosis; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
[A patient with acute Philadelphia-chromosome-positive mixed phenotype leukemia developing ecthyma gangrenosum while undergoing combined imatinib mesylate chemotherapy].
Topics: Aged; Antineoplastic Agents; Benzamides; Ecthyma; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrimidines | 2009 |
p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; G2 Phase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polycythemia Vera; Pyrimidines | 2010 |
CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.
Topics: Benzamides; Cytochrome P-450 CYP3A; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pilot Projects; Piperazines; Pyrimidines; Remission Induction | 2010 |
Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Tertiary; Pyrimidines; Time Factors; Treatment Outcome | 2010 |
T-regulatory cell response in psoriasis and changes with imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immunity, Cellular; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Psoriasis; Pyrimidines; T-Lymphocytes, Regulatory | 2009 |
BCR-ABL1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Nuclear Proteins; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Treatment Outcome; Young Adult | 2010 |
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Binding Sites; Bone Marrow Transplantation; Cell Line, Tumor; Crystallization; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mass Spectrometry; Mice; Models, Molecular; Mutation; Piperazines; Protein Structure, Tertiary; Pyrimidines; Transplantation, Heterologous | 2010 |
Managing relapse of CML using therapeutic imatinib plasma level.
Topics: Benzamides; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2009 |
Is there any relationship between imatinib mesylate medication and hypothalamic-pituitary-adrenal axis dysfunction?
Topics: Adrenocorticotropic Hormone; Adult; Aged; Antineoplastic Agents; Benzamides; Cosyntropin; Endocrine System Diseases; Female; Glucagon; Glucocorticoids; Hormones; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pituitary-Adrenal System; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Drug plasma monitoring in CML and GIST: A case-based discussion.
Topics: Adult; Benzamides; Drug Monitoring; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Patient Compliance; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Rate; Treatment Outcome | 2009 |
Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Chloromethyl Ketones; AMP-Activated Protein Kinases; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Autophagy; Benzamides; Blotting, Western; Caspase Inhibitors; Caspases; Cell Survival; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Microscopy, Confocal; Microscopy, Electron; Piperazines; Pyrimidines; Resveratrol; RNA Interference; Sequestosome-1 Protein; Stilbenes; Tumor Cells, Cultured; Vacuolar Proton-Translocating ATPases | 2010 |
WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.
Topics: Antineoplastic Agents; Benzamides; Cancer Vaccines; Combined Modality Therapy; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Peptide Fragments; Piperazines; Prognosis; Pyrimidines; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Vaccination; WT1 Proteins | 2011 |
Kaposi's sarcoma in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; DNA, Viral; Fusion Proteins, bcr-abl; Herpesvirus 8, Human; HIV Seronegativity; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Kaposi; Skin | 2009 |
Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example.
Topics: Benzamides; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Pharmacogenetics; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
[Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Sensitivity and Specificity; Tumor Burden; Young Adult | 2010 |
Hypopigmentation of the skin due to imatinib mesylate in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Pigmentation; Treatment Outcome; Young Adult | 2009 |
Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
Topics: Antineoplastic Agents; Benzamides; Biomarkers; Bone Marrow Transplantation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reagent Kits, Diagnostic; Recurrence; Remission Induction | 2011 |
Bilateral toxoplasma retinochoroiditis in a patient with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Chorioretinitis; DNA; Genome; Humans; Imatinib Mesylate; Immune Tolerance; Immunoglobulin G; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Toxoplasma; Toxoplasmosis, Ocular; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Visual Acuity | 2010 |
TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Disease Models, Animal; Enzyme Activation; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Transport; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; Transforming Growth Factor beta; Tumor Stem Cell Assay | 2010 |
Whither the bone marrow transplant?
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Developed Countries; Developing Countries; Drug Costs; Drug Utilization; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Mexico; Multiple Myeloma; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spain; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; United States | 2010 |
[Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Topics: Adult; Aged; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult | 2010 |
[Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2010 |
Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment.
Topics: Animals; Benzamides; beta Catenin; Cell Hypoxia; Cell Line, Tumor; Dasatinib; Humans; Imatinib Mesylate; Lactoylglutathione Lyase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Heterologous | 2010 |
The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.
Topics: Aluminum Silicates; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytotoxicity, Immunologic; Dasatinib; Down-Regulation; Fusion Proteins, bcr-abl; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; Interferon-gamma; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2010 |
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Cycle Proteins; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines | 2010 |
Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.
Topics: Adolescent; Benzamides; Child; Child, Preschool; Cohort Studies; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Transcription, Genetic; Treatment Outcome | 2010 |
Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses.
Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines | 2010 |
Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity.
Topics: Adrenergic alpha-Antagonists; Antigens, CD34; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Bone Marrow Cells; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Prazosin; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2010 |
Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells.
Topics: Adrenergic alpha-Antagonists; Benzamides; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Prazosin; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tetraethylammonium; Tumor Cells, Cultured | 2010 |
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib.
Topics: Antigens, CD19; Antineoplastic Agents; Benzamides; Bone Marrow Cells; CD56 Antigen; Female; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Phenotype; Piperazines; Plasma Cells; Pyrimidines | 2010 |
Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell Line; Computer Simulation; Diterpenes; Down-Regulation; Drug Design; Drug Resistance, Neoplasm; Epoxy Compounds; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phenanthrenes; Piperazines; Pyrimidines; RNA, Messenger; Signal Transduction; Water; Xenograft Model Antitumor Assays | 2010 |
Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidental Findings; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; RNA, Messenger; RNA, Neoplasm | 2010 |
Spred2 is involved in imatinib-induced cytotoxicity in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Repressor Proteins | 2010 |
Reproductive fitness advantage of BCR-ABL expressing leukemia cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Division; Cell Movement; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Fitness; Hematopoiesis; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Oncogenes; Phenotype; Piperazines; Probability; Pyrimidines | 2010 |
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
Topics: Adult; Animals; Benzamides; Cells, Cultured; Coculture Techniques; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Mice; Mice, SCID; Piperazines; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes, Cytotoxic; Zoledronic Acid | 2010 |
Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.
Topics: Animals; Apoptosis; Benzamides; Bone Marrow Cells; Chemokine CXCL12; Coculture Techniques; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cells; Mice; Mice, SCID; Piperazines; Pyrimidines; Receptors, CXCR4; Stromal Cells; Tumor Cells, Cultured | 2010 |
Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pleural Effusion; Protein Kinase Inhibitors; Pyrimidines; Substance Withdrawal Syndrome; Thiazoles | 2010 |
Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era.
Topics: Adolescent; Adult; Age Factors; Aged; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pakistan; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies | 2009 |
Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Topics: Benzamides; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2010 |
Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; China; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2010 |
Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Drug Resistance, Neoplasm; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Genetic; Prognosis; Pyrimidines; Survival Rate; Young Adult | 2011 |
Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubule-Associated Proteins; Oxazepines; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Survivin | 2010 |
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Ribose; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Child; Cord Blood Stem Cell Transplantation; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Megakaryoblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2010 |
Generation of iPSCs from cultured human malignant cells.
Topics: Benzamides; Cell Differentiation; Cells, Cultured; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Induced Pluripotent Stem Cells; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-3; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; SOXB1 Transcription Factors | 2010 |
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Prognosis; Pyrimidines; Translocation, Genetic | 2010 |
Bcl2 is not required for the development and maintenance of leukemia stem cells in mice.
Topics: Animals; Antigens, Ly; Benzamides; Disease Models, Animal; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2010 |
[Nilotinib treatment for imatinib resistant or intolerant chronic myelogenous leukemia.].
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Treatment Outcome | 2010 |
Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Female; Humans; Imatinib Mesylate; Indonesia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspases; Cell Growth Processes; Cell Line, Tumor; Electrophoretic Mobility Shift Assay; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Phosphorylation; Piperazines; Pyrazines; Pyrimidines; Retinoblastoma Protein | 2010 |
Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Young Adult | 2010 |
Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caspase 3; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Piperazines; Pyrimidines; Vidarabine | 2010 |
A flow-based synthesis of imatinib: the API of Gleevec.
Topics: Antineoplastic Agents; Benzamides; Dimethylamines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazine; Piperazines; Pyrimidines | 2010 |
Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Female; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Thiazoles; Translocation, Genetic | 2010 |
Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity.
Topics: Adult; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Dietary Supplements; Herb-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Panax; Piperazines; Pyrimidines | 2010 |
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome | 2010 |
[An elderly case of chronic myeloid leukemia in which BCR/ABL decreased or disappeared, following imatinib therapy after each episode of blast crisis].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.
Topics: Adult; Antineoplastic Agents; Benzamides; Cancer Vaccines; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2010 |
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Death; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Reactive Oxygen Species; Simvastatin | 2011 |
Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Warfarin | 2010 |
Studies on lipid peroxidation and non-enzymatic antioxidant status as indices of oxidative stress in patients with chronic myeloid leukaemia.
Topics: Adult; Antioxidants; Benzamides; Biomarkers; Case-Control Studies; Disease Progression; Female; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sulfhydryl Compounds | 2010 |
Counterpoint: Data first.
Topics: Antineoplastic Agents; Benzamides; Drug Discovery; Fusion Proteins, bcr-abl; Genome, Human; Genomics; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Precision Medicine; Pyrimidines | 2010 |
Mutations in ABL kinase domain are associated with inferior progression-free survival.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Binding Sites; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Young Adult | 2010 |
A case of acute colitis with severe rectal bleeding in a patient with chronic myeloid leukemia after dasatinib use.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Colitis; Cytarabine; Dasatinib; Female; Gastrointestinal Hemorrhage; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Rectal Diseases; Thiazoles | 2010 |
Imatinib (Gleevec) as a paradigm of targeted cancer therapies.
Topics: Antineoplastic Agents; Benzamides; Biomedical Research; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines | 2010 |
Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Cathepsin B; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Oligopeptides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Clone Cells; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Antigen, T-Cell, alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; T-Lymphocytes; Treatment Outcome | 2010 |
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cytogenetic Analysis; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Medication Adherence; Micro-Electrical-Mechanical Systems; Middle Aged; Mutation; Octamer Transcription Factor-1; Piperazines; Polymorphism, Genetic; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Risk Factors; RNA, Messenger; Time Factors; Treatment Outcome; Young Adult | 2010 |
[A rare complication of imatinib mesylate therapy: drug-induced pneumonitis].
Topics: Aged; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed | 2010 |
Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Cadherins; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Snail Family Transcription Factors; Transcription Factors | 2010 |
Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Capsules; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Chronic myelogenous leukemia therapy beyond imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2010 |
Knockdown of SOD1 sensitizes the CD34+ CML cells to imatinib therapy.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Separation; Cell Survival; Flow Cytometry; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Superoxide Dismutase; Superoxide Dismutase-1; Transfection | 2011 |
Postimatinib therapy emergence of a new JAK2V617F clone and subsequent development of overt polycythemia vera in a patient with chronic myelogenous leukaemia.
Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Genes, abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation, Missense; Piperazines; Polycythemia Vera; Pyrimidines; Time Factors | 2010 |
Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia.
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Decitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunity, Humoral; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines | 2010 |
Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.
Topics: Benzamides; Child; Child, Preschool; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2010 |
Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CD8-Positive T-Lymphocytes; Clonal Anergy; Clone Cells; Cytomegalovirus; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Imatinib Mesylate; Immunologic Surveillance; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Thiazoles; Virus Activation; Young Adult | 2010 |
Treating imatinib resistance in the few in CML-A key step towards cure in all.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: a comparative proteomic approach.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blotting, Western; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NADP; Piperazines; Proteome; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2010 |
Clonal evolution with double Ph followed by tetraploidy in imatinib-treated chronic myeloid leukemia with e19a2 transcript in transformation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Base Sequence; Benzamides; Bone Marrow; Cell Transformation, Neoplastic; Clone Cells; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Philadelphia Chromosome; Piperazines; Polyploidy; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Time Factors | 2010 |
Drug developers unveil strategies aimed at imatinib-resistant CML.
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Design; Drug Industry; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2010 |
Resistance to imatinib in chronic myelogenous leukemia: mechanisms and clinical implications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2008 |
Molecular monitoring in patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines | 2008 |
Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
Topics: Adult; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Practice Guidelines as Topic; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Splenomegaly; Treatment Failure | 2010 |
Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult | 2010 |
Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.
Topics: Adult; Antineoplastic Agents; Benzamides; Carrier State; Disease-Free Survival; Hepatitis B; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Transplantation; Living Donors; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2010 |
Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.
Topics: Benzamides; Chromosome Aberrations; Chromosomes, Human, Y; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis | 2010 |
Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher plasma le
Topics: Antineoplastic Agents; Benzamides; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Piperazines; Pyrimidines; RNA, Messenger; Treatment Outcome | 2010 |
Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Cattle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Transplantation; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; Transplantation, Heterologous | 2010 |
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Cell Proliferation; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinolines; src-Family Kinases; Tumor Cells, Cultured | 2010 |
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.
Topics: Adenosine Triphosphate; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutant Proteins; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases | 2010 |
Bone marrow or peripheral blood.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Disease-Free Survival; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recurrence; Survival Analysis | 2010 |
Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
Topics: Animals; Apoptosis; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Genetic; Mutation; Phosphorylation; Piperazines; Protein Conformation; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases | 2010 |
Chakalaka-induced vasodilatation in patients with chronic myeloid leukaemia on tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cucumis sativus; Follow-Up Studies; Food Additives; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Spices; Vasodilation | 2009 |
Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Cells, Cultured; Female; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2010 |
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Stem Cell Transplantation; Young Adult | 2010 |
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2010 |
Sustained molecular remissions are achievable with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia and additional cytogenetic clonal evolution.
Topics: Adult; Benzamides; Clone Cells; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Treatment Outcome | 2010 |
Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2010 |
Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
Topics: Benzamides; Health Planning Guidelines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2010 |
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cell Separation; Child; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Activation; Flow Cytometry; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Nude; Middle Aged; NF-kappa B; Pentacyclic Triterpenes; Piperazines; Point Mutation; Pyrimidines; RNA, Small Interfering; Signal Transduction; Transcription, Genetic; Transfection; Triterpenes; Xenograft Model Antitumor Assays; Young Adult | 2010 |
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Topics: Antineoplastic Agents; Benzamides; DNA, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity | 2010 |
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2010 |
Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.
Topics: Antineoplastic Agents; Benzamides; Chromosome Breakpoints; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
The best frontline therapy for CML: imatinib?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Hematology. Imatinib--should we have more of a good thing?
Topics: Benzamides; Hematologic Tests; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cell Line; Cohort Studies; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Molecular; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; src Homology Domains; Young Adult | 2010 |
Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Platelet Disorders; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Platelet Function Tests; Pyrimidines | 2009 |
[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)].
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; Erythropoietin; Fertility; Food-Drug Interactions; France; Granulocyte Colony-Stimulating Factor; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metabolic Diseases; Neutropenia; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins | 2010 |
[Treatment of chronic myeloid leukemia with imatinib. A case of translational medicine].
Topics: Antineoplastic Agents; Benzamides; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2010 |
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles | 2010 |
Strategic treatment interruptions during imatinib treatment of chronic myelogenous leukemia.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Computer Simulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Models, Biological; Piperazines; Pyrimidines; Secondary Prevention; T-Lymphocytes; Time Factors | 2011 |
Imatinib mesylate-induced pseudoporphyria.
Topics: Antineoplastic Agents; Benzamides; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Porphyria Cutanea Tarda; Pyrimidines | 2010 |
Granulocytic sarcoma of the stomach: relapse after hematopoietic stem-cell transplantation for chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines; Sarcoma, Myeloid; Stomach Neoplasms; Transplantation, Homologous | 2010 |
[Case of pediatric chronic myeloid leukemia with bilateral visual loss onset].
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome; Vision, Low | 2010 |
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Urea | 2010 |
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Benzamides; Cytogenetic Analysis; Europe; Follow-Up Studies; Humans; Imatinib Mesylate; Immunotherapy; In Situ Hybridization, Fluorescence; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Thrombocytosis; Treatment Outcome | 2010 |
Imatinib-resistant lymphoid clone of chronic myelogenous leukemia in blast phase arising from B cell-committed progenitor leukemic stem cells.
Topics: Adult; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Clone Cells; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Neoplastic Stem Cells; Piperazines; Precursor Cells, B-Lymphoid; Pyrimidines | 2011 |
Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays.
Topics: Amino Acid Substitution; Benzamides; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Acute kidney injury presenting a feature of leukemic infiltration during therapy for chronic myelogenous leukemia.
Topics: Acute Kidney Injury; Aged, 80 and over; Benzamides; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Male; Piperazines; Pyrimidines | 2010 |
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Topics: Adult; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2010 |
Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapy.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Burden | 2010 |
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies | 2010 |
Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate.
Topics: Adult; Aged; Antigens, CD34; Benzamides; Cells, Cultured; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Piperazines; Prognosis; Pyrimidines; Stem Cells; Young Adult | 2010 |
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Topics: Benzamides; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytes; Leukocytes, Mononuclear; Neutrophils; Organic Cation Transporter 1; Piperazines; Pyrimidines; RNA, Messenger; RNA, Neoplasm | 2010 |
Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Biosensing Techniques; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Fluorescence; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Thiazoles | 2010 |
Membranoproliferative glomerulonephritis secondary to chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Diuretics; Glomerulonephritis, Membranoproliferative; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Improved outcome in patients with chronic myelogenous leukemia after allogeneic hematopoietic stem cell transplantation over the past 25 years: a single-center experience.
Topics: Adult; Benzamides; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Recurrence; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Vinblastine | 2010 |
Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Chromosome Aberrations; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2010 |
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Calcium; Cell Proliferation; Cyclosporine; Cytokines; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Wnt Proteins | 2010 |
Knee pain: ACL, MCL, or CML?
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Knee Joint; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Pain; Piperazines; Pyrimidines | 2010 |
Overdose with 16,000 mg of imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Drug Overdose; Electrocardiography; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines | 2010 |
WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient.
Topics: Aged; Antineoplastic Agents; Benzamides; Cancer Vaccines; Combined Modality Therapy; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; T-Lymphocytes, Cytotoxic; Vaccines, Subunit; WT1 Proteins | 2010 |
The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Myeloid Progenitor Cells; Neoplastic Stem Cells; Organic Cation Transporter 1; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2010 |
How cells respond to interferons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins | 2010 |
Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Opportunistic Infections; Piperazines; Pyrimidines | 2010 |
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzamides; Feasibility Studies; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome | 2010 |
Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Antigens, Surface; Benzamides; Blood Cells; Bone Marrow Cells; Cell Count; Cytotoxicity, Immunologic; Dasatinib; Female; Flow Cytometry; Humans; Imatinib Mesylate; Immune System; Immunologic Memory; Immunophenotyping; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Young Adult | 2010 |
Current patient management of chronic myeloid leukemia in Latin America: a study by the Latin American Leukemia Net (LALNET).
Topics: Antineoplastic Agents; Benzamides; Health Services Accessibility; Health Surveys; Humans; Imatinib Mesylate; Latin America; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Standard of Care; Surveys and Questionnaires; Treatment Failure | 2010 |
Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Middle Aged; Piperazines; Practice Patterns, Physicians'; Pyrimidines; SEER Program; Social Class; United States | 2010 |
A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Biosensing Techniques; Blotting, Western; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescence Resonance Energy Transfer; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luminescent Agents; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; Sensitivity and Specificity | 2010 |
Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Cell Line, Tumor; Dasatinib; DNA Primers; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Cytogenetic and molecular characterization of double inversion 3 associated with a cryptic BCR-ABL1 rearrangement and additional genetic changes.
Topics: Adult; Benzamides; Chromosome Aberrations; Chromosome Inversion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Loss of Heterozygosity; Male; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines | 2010 |
Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger; Thiazoles | 2010 |
Chronic myeloid leukemia with a novel four-way t(6;13;9;22)(p21;q32;q34;q11.2) successfully treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Spectral Karyotyping; Translocation, Genetic | 2010 |
Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 7; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Gene Dosage; Genes, abl; Genome-Wide Association Study; Humans; Ikaros Transcription Factor; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; T-Lymphocytes | 2011 |
Relationship of serum imatinib trough level and response in CML patients: long term follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Jordan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; ROC Curve | 2010 |
Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Benzamides; Busulfan; Child; Cyclophosphamide; Female; Fusion Proteins, bcr-abl; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precision Medicine; Protein-Tyrosine Kinases; Pyrimidines; Risk; RNA, Messenger; Siblings; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2011 |
The use of imatinib mesylate has no adverse effects on the heart function. Results of a pilot study in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Echocardiography; Electrocardiography; Female; Follow-Up Studies; Heart; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; No-Observed-Adverse-Effect Level; Pilot Projects; Piperazines; Prospective Studies; Pyrimidines; Survival Rate; Treatment Outcome; Troponin I | 2011 |
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Oxonic Acid; Piperazines; Pyrimidines; Stomach Neoplasms; Tegafur | 2010 |
Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphotransferases; Piperazines; Point Mutation; Protein Structure, Tertiary; Pyrimidines; Young Adult | 2011 |
E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Poor outcome after reintroduction of imatinib in patients with chronic myeloid leukemia who interrupt therapy on account of pregnancy without having achieved an optimal response.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Treatment Failure | 2010 |
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.
Topics: Adult; Age Factors; Aged; Benzamides; Comorbidity; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2010 |
Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma.
Topics: Benzamides; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Flow Injection Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reproducibility of Results; Tandem Mass Spectrometry | 2010 |
Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; src-Family Kinases; Thiazoles | 2011 |
Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genome, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Phenotype; Piperazines; Point Mutation; Prognosis; Protein Structure, Tertiary; Pyrimidines | 2010 |
Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia.
Topics: Benzamides; Child; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Treatment Outcome | 2010 |
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; DNA, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2010 |
OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.
Topics: Antineoplastic Agents; Benzamides; Heterozygote; Homozygote; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Pyrimidines | 2010 |
[Dynamic observations of beta-catenin in chronic myeloid leukemia and its relationship with cytogenetic response].
Topics: Adolescent; Adult; Benzamides; beta Catenin; Blast Crisis; Case-Control Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Young Adult | 2010 |
Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib.
Topics: Benzamides; Cell Line; Cell Survival; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship | 2010 |
Real-time fluorescent resonance energy transfer analysis to monitor drug resistance in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Biosensing Techniques; Cells, Cultured; Chlorocebus aethiops; Computer Systems; COS Cells; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorescence Resonance Energy Transfer; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines; Thiazoles; Time Factors | 2010 |
Role of symmetric and asymmetric division of stem cells in developing drug resistance.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2010 |
Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Electrophoresis, Gel, Two-Dimensional; Fibronectins; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microscopy, Fluorescence; Paxillin; Piperazines; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tropomyosin | 2010 |
Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-abl; Pyrimidines; Small Molecule Libraries | 2010 |
Early prediction of a long-term outcome by neutrophil-FISH in patients with CML receiving imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Piperazines; Pyrimidines; Treatment Outcome | 2010 |
Association of the GSTP1 gene (Ile105Val) polymorphism with chronic myeloid leukemia.
Topics: Adult; Benzamides; Case-Control Studies; Female; Genotype; Glutathione S-Transferase pi; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Survival Rate; Young Adult | 2010 |
The duration of the use of imatinib mesylate is only weakly related to elevated BNP levels in chronic myeloid leukaemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Case-Control Studies; Cross-Sectional Studies; Drug Administration Schedule; Echocardiography; Female; Heart; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Natriuretic Peptide, Brain; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
Hematology: Nilotinib and dasatinib--new 'magic bullets' for CML?
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome | 2010 |
Long-term follow-up of patients with chronic myeloid leukemia having received autologous stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2011 |
Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland | 2010 |
Clofarabine-based regimen as useful bridge therapy for allogeneic transplantation in myeloid blast crisis of Philadelphia-positive chronic myeloid leukemia resistant to imatinib and dasatinib.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzamides; Blast Crisis; Clofarabine; Combined Modality Therapy; Dasatinib; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transplantation, Homologous | 2010 |
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses.
Topics: Adult; Antineoplastic Agents; Benzamides; Case-Control Studies; Drug Resistance, Neoplasm; Gas Chromatography-Mass Spectrometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Pyrimidines | 2010 |
Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in K562 human chronic myeloid leukemia cells.
Topics: Acetylation; Benzamides; Cell Differentiation; Gene Expression Regulation; Histones; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proteomics; Pyrimidines | 2010 |
Can grapefruit juice decrease the cost of imatinib for the treatment of chronic myelogenous leukemia?
Topics: Antineoplastic Agents; Benzamides; Beverages; Citrus; Drug Costs; Food-Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2011 |
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p57; Dasatinib; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Transcription, Genetic | 2011 |
Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Cirrhosis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
The IFNG (IFN-gamma) genotype predicts cytogenetic and molecular response to imatinib therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Cohort Studies; Cytogenetic Analysis; Female; Genotype; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Young Adult | 2010 |
[The 2nd generation of TKIs for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2010 |
Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies | 2010 |
Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Drug Administration Schedule; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Cardiotoxicity of imatinib: At the heart of the problem.
Topics: Antineoplastic Agents; Benzamides; Heart; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2011 |
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Myeloproliferative Disorders; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Structure-Activity Relationship | 2011 |
Suboptimal response to imatinib according to 2006-2009 European LeukaemiaNet criteria: a 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukaemia patients who need early intervention.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Selection; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2011 |
A prospective evaluation of cardiac function in patients with chronic myeloid leukaemia treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Echocardiography; Female; Heart Function Tests; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines | 2011 |
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Oxidation-Reduction; Piperazines; Pyrimidines; Reactive Oxygen Species; Triazoles | 2011 |
A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib.
Topics: 14-3-3 Proteins; Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell Death; Cell Line; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Sequence Data; Piperazines; Pyrazoles; Pyrimidines | 2011 |
Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib.
Topics: Antineoplastic Agents; Benzamides; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; Exons; Fusion Proteins, bcr-abl; Gene Deletion; Gene Frequency; Genetic Association Studies; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nucleic Acid Denaturation; Piperazines; Protein Isoforms; Pyrimidines; Temperature | 2010 |
Hematopathologic and cytogenetic findings in imatinib mesylate treated chronic myelogenous leukemia patients: 2.5 years' experience.
Topics: Aged; Benzamides; Blood Cell Count; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2010 |
Dasatinib, even at low doses, is an effective second-line therapy for chronic myeloid leukemia patients resistant or intolerant to imatinib. Results from a real life-based Italian multicenter retrospective study on 114 patients.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2010 |
Glucose availability in hypoxia regulates the selection of chronic myeloid leukemia progenitor subsets with different resistance to imatinib-mesylate.
Topics: Apoptosis; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Glucose; Humans; Hypoxia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sweetening Agents; Tumor Cells, Cultured | 2011 |
[Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Liver Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Nilotinib for the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Pattern of pediatric chronic myeloid leukemia in Sudan and hematological response to imatinib.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Female; Fusion Proteins, bcr-abl; Hemoglobins; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Piperazines; Platelet Count; Pyrimidines; Sudan; Survival Rate; Treatment Outcome | 2011 |
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Treatment Outcome | 2010 |
The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinases; Azepines; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Topics: Adult; Aged; Antineoplastic Agents; Attitude to Health; Benzamides; Causality; Drug Prescriptions; Female; Health Knowledge, Attitudes, Practice; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Perception; Piperazines; Pyrimidines | 2011 |
Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunoblotting; Intracellular Space; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Osteonectin; Piperazines; Proto-Oncogene Proteins c-fyn; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Cells, Cultured; Up-Regulation | 2010 |
Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Proliferation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Piperazines; Pyrimidines | 2011 |
[Chronic myeloid leukemia and targeted therapies: too many choices?].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Tolerance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Time Factors; Treatment Outcome | 2010 |
A case of chronic myeloid leukemia with eosinophilic interstitial pneumonitis after administration of imatinib mesylate for 11 months.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Piperazines; Pulmonary Eosinophilia; Pyrimidines; Radiography; Treatment Outcome | 2010 |
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Topics: Animals; Benzamides; Cell Line, Tumor; Crystallography, X-Ray; Drug Resistance, Neoplasm; Fluoroimmunoassay; Fusion Proteins, bcr-abl; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Structure-Activity Relationship | 2011 |
Deregulation of TWIST-1 in the CD34+ compartment represents a novel prognostic factor in chronic myeloid leukemia.
Topics: Antigens, CD34; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Twist-Related Protein 1 | 2011 |
Autophagy induction by Bcr-Abl-expressing cells facilitates their recovery from a targeted or nontargeted treatment.
Topics: Animals; Autophagy; Benzamides; Cell Line, Tumor; DNA Damage; Doxorubicin; Etoposide; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Targeted Therapy; Piperazines; Pyrimidines; RNA, Small Interfering; Transfection | 2011 |
Reduction of imatinib absorption after gastric bypass surgery.
Topics: Antineoplastic Agents; Benzamides; Biliopancreatic Diversion; Female; Gastric Bypass; Humans; Imatinib Mesylate; Intestinal Absorption; Intestinal Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Obesity; Piperazines; Pyrimidines | 2011 |
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Protocols; Benzamides; Clone Cells; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Thiazoles; Withholding Treatment | 2011 |
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Databases, Factual; Follow-Up Studies; Humans; Imatinib Mesylate; Internet; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoadjuvant Therapy; Online Systems; Piperazines; Pyrimidines; Registries; Time Factors; Young Adult | 2011 |
GSTT1 copy number gain is a poor predictive marker for escalated-dose imatinib treatment in chronic myeloid leukemia: genetic predictive marker found using array comparative genomic hybridization.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Comparative Genomic Hybridization; Female; Fusion Proteins, bcr-abl; Gene Dosage; Gene Expression Regulation, Leukemic; Genetic Markers; Glutathione Transferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Pyrimidines | 2010 |
BCR-ABL kinase is dead; long live the CML stem cell.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Cell Survival; Cytokines; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
[A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia].
Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosomes, Human, Pair 3; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2010 |
Imatinib trough levels in chronic myelogenous leukemia: does one dose fit all?
Topics: Antineoplastic Agents; Benzamides; Gastric Bypass; Humans; Imatinib Mesylate; Intestinal Absorption; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2011 |
[Clinical analysis about the management and the perinatal outcomes of pregnancy with chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy, Needle; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; Infant, Low Birth Weight; Infant, Newborn; Leukapheresis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Piperazines; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy Trimester, Third; Prognosis; Pyrimidines; Retrospective Studies | 2010 |
Chronic myeloid leukemia--from the National to the European Registry--limited experience of a single center.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cohort Studies; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Registries; Retrospective Studies; Romania; Young Adult | 2010 |
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Pyrimidines | 2010 |
ETV6-ABL1-positive "chronic myeloid leukemia": clinical and molecular response to tyrosine kinase inhibition.
Topics: Adult; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; DNA, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Oncogene Proteins, Fusion; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2011 |
Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrimidines | 2011 |
Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; C-Reactive Protein; Complement System Proteins; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunity, Innate; Immunoglobulins; Immunologic Factors; Interferon-alpha; Interleukin-6; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Thiazoles; Treatment Outcome | 2010 |
Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cytarabine; DNA Damage; Drug Synergism; Gene Expression; Genes, abl; Humans; Hydroxyurea; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Piperazines; Pyrimidines; Tumor Stem Cell Assay | 2011 |
Second-generation tyrosine kinase inhibitors in chronic myelogenous leukemia: before or after imatinib?
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Salvage Therapy; Treatment Outcome | 2011 |
Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Gene Expression Regulation; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Organic Anion Transporters, Sodium-Independent; Piperazines; Polymorphism, Genetic; Pyrimidines; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2011 |
Novel variant Ph translocation t(9;22;11)(q34;q11.2;p15)inv(9)(p13q34) in chronic myeloid leukemia involving a one-step mechanism.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Inversion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dasatinib; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-gamma; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Philadelphia Chromosome; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2011 |
Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia.
Topics: Acetaminophen; Adult; Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; Half-Life; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cells, Cultured; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Piperazines; Prognosis; Pyrimidines; STAT5 Transcription Factor; Treatment Failure; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein Isoforms; Protein Structure, Tertiary; Pyrimidines; Real-Time Polymerase Chain Reaction; Young Adult | 2012 |
Amiloride modulates alternative splicing in leukemic cells and resensitizes Bcr-AblT315I mutant cells to imatinib.
Topics: Alternative Splicing; Amiloride; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzamides; Cell Cycle; Drug Synergism; Exons; Fusion Proteins, bcr-abl; Heterogeneous-Nuclear Ribonucleoproteins; HL-60 Cells; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Piperazines; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA-Binding Proteins; Serine-Arginine Splicing Factors | 2011 |
Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome | 2011 |
A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells.
Topics: Antineoplastic Agents; Benzamides; Biological Assay; Gas Chromatography-Mass Spectrometry; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Piperazines; Pyrimidines | 2011 |
BCR-ABL1 mutations in patients with imatinib-resistant Philadelphia chromosome-positive leukemia by use of the PCR-Invader assay.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phosphotransferases; Piperazines; Polymerase Chain Reaction; Prognosis; Protein Structure, Tertiary; Pyrimidines; Survival Analysis; Young Adult | 2011 |
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cyanoacrylates; Drug Resistance, Neoplasm; Endopeptidases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Nitriles; Phosphorylation; Piperazines; Protein Transport; Pyridines; Pyrimidines; Reactive Oxygen Species; Signal Transduction; Substrate Specificity; Ubiquitin Thiolesterase; Ubiquitination | 2011 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
[Chronic myeloid leukemia complicated with cerebellar hemorrhage and acute hydrocephalus successfully treated with imatinib and intensive supportive care].
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Cerebellum; Cerebral Hemorrhage; Combined Modality Therapy; Critical Care; Cytarabine; Drug Therapy, Combination; Female; Humans; Hydrocephalus; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukostasis; Mannitol; Middle Aged; Piperazines; Pyrimidines; Respiration, Artificial | 2010 |
[Therapeutic choice for the chronic myeloid leukemia patients in chronic phase showing late suboptimal response to imatinib].
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Time Factors; Young Adult | 2010 |
Peripheral neuropathy as an adverse effect of imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Nervous System Diseases; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2011 |
Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.
Topics: Animals; Benzamides; Cell Line, Tumor; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Isoxazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutagenesis; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Resorcinols | 2011 |
Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic; Treatment Outcome | 2011 |
Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.
Topics: Aged; Benzamides; Cell Line, Tumor; Cells, Cultured; Female; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2011 |
Role of Pten in leukemia stem cells.
Topics: Animals; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, Tumor Suppressor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice; Neoplastic Stem Cells; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Signal Transduction; Thiazoles | 2010 |
Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy.
Topics: Benzamides; Child; Dasatinib; Diseases in Twins; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance.
Topics: Apoptosis; Benzamides; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2011 |
Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.
Topics: Acute Kidney Injury; Adult; Age Factors; Antineoplastic Agents; Benzamides; Creatinine; Female; Glomerular Filtration Rate; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2011 |
Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
Topics: Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver-Specific Organic Anion Transporter 1; Male; Membrane Transport Proteins; Middle Aged; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Solute Carrier Organic Anion Transporter Family Member 1B3; Young Adult | 2011 |
Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
Topics: Benzamides; Disease Progression; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Telomerase; WT1 Proteins | 2011 |
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Secondary pulmonary alveolar proteinosis in a patient with chronic myeloid leukemia in the accelerated phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Bronchoalveolar Lavage; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pulmonary Alveolar Proteinosis; Pyrimidines | 2008 |
Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanosis; Middle Aged; Palate, Hard; Piperazines; Pyrimidines | 2011 |
[Recurrent neutrophilic panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib mesilate and dasatinib].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Panniculitis; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Skin; Thiazoles | 2011 |
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Pyrimidines; Remission Induction; Time Factors; Treatment Failure | 2011 |
Nilotinib and dasatinib first-line: are we ready for imatinib replacement?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoadjuvant Therapy; Piperazines; Pyrimidines; Safety-Based Drug Withdrawals; Thiazoles | 2011 |
Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Topics: Adult; Benzamides; Blast Crisis; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Disease Progression; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Transplantation Conditioning; Transplantation, Homologous | 2011 |
Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Blast Crisis; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; STAT5 Transcription Factor; Telomerase; Transcription, Genetic; Transcriptional Activation | 2011 |
[Preliminary analysis of therapeutic efficacy and prognosis of allogeneic hematopoietic stem cell transplantation in patients with advanced chronic myeloid leukemia].
Topics: Adolescent; Adult; Benzamides; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Young Adult | 2011 |
hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Enzymologic; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Telomerase; Transcription, Genetic; Tretinoin | 2011 |
Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Benzamides; CCAAT-Enhancer-Binding Proteins; Cell Proliferation; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mitogen-Activated Protein Kinase Kinases; Phosphopeptides; Phosphorylation; Piperazines; Proteome; Proto-Oncogene Proteins c-akt; Pyrimidines; Ribosomal Protein S6 Kinases, 90-kDa; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2010 |
Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Cytogenetic Analysis; Drug Administration Schedule; Female; Hematologic Tests; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Staging; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines; Retrospective Studies; Young Adult | 2011 |
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid.
Topics: Acetylation; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Valproic Acid | 2011 |
Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Gene Deletion; Genome, Human; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Treatment Outcome; Young Adult | 2011 |
Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Comparative Genomic Hybridization; Gene Dosage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Mutation; Piperazines; Pyrimidines; Young Adult | 2011 |
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Blotting, Northern; Blotting, Western; DNA Primers; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2011 |
Down-regulation of Thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Topics: Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fusion Proteins, bcr-abl; Genes, myc; Hematopoietic Stem Cells; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Repressor Proteins | 2012 |
[Loss of Philadelphia chromosome after graft failure following cord blood transplantation for Philadelphia chromosome-positive acute myeloid leukemia].
Topics: Benzamides; Fetal Blood; Graft Rejection; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
[Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow].
Topics: Benzamides; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Myeloproliferative Disorders; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocytosis; Translocation, Genetic | 2011 |
Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Benzamides; Cell Line, Tumor; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Microtubule-Associated Proteins; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Targeting; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA, Small Interfering; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Survival Analysis; Treatment Outcome | 2011 |
Interview with Jürg Zimmermann, global head of oncology & exploratory chemistry at Novartis.
Topics: Antineoplastic Agents; Benzamides; Chemistry, Pharmaceutical; Combinatorial Chemistry Techniques; Drug Discovery; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Research Personnel; Workforce | 2009 |
[Clinical significance of CRKL protein phosphorylation level in the treatment of chronic myeloid leukemia with imatinib].
Topics: Adaptor Proteins, Signal Transducing; Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; Young Adult | 2011 |
Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294.
Topics: Adolescent; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Male; Mutagenesis, Insertional; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?
Topics: Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
MYC in chronic myeloid leukemia: induction of aberrant DNA synthesis and association with poor response to imatinib.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Disease Progression; DNA Replication; Fusion Proteins, bcr-abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-myc; Pyrimidines | 2011 |
Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; DNA Probes; Female; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retrospective Studies; Translocation, Genetic | 2012 |
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Banding; Chromosome Duplication; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Counseling; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Patient Education as Topic; Piperazines; Prognosis; Program Evaluation; Pyrimidines; Republic of Korea; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, SCID; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Xenograft Model Antitumor Assays | 2011 |
Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematologic Tests; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cross Reactions; Dasatinib; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2011 |
Explaining the in vitro and in vivo differences in leukemia therapy.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 2011 |
Stochastic dynamics of leukemic cells under an intermittent targeted therapy.
Topics: Benzamides; Computer Simulation; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stochastic Processes | 2011 |
Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?
Topics: Adult; Anemia, Sickle Cell; Antineoplastic Agents; Arterial Occlusive Diseases; Benzamides; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Compliance; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence | 2011 |
Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?
Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Does pretreatment fluorescence in situ hybridization for BCR-ABL predict imatinib-associated hematologic toxicity in chronic myeloid leukemia?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins v-abl; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2011 |
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinolines | 2011 |
Fatherhood during imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Fathers; Female; Fertility; Humans; Imatinib Mesylate; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines | 2011 |
Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Analysis; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Child; Child, Preschool; Female; Flow Cytometry; Humans; Imatinib Mesylate; Infant; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Piperazines; Pyrimidines; RNA, Messenger; Young Adult | 2011 |
Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysophospholipids; Mice; Mice, SCID; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Phosphatase 2; Pyrimidines; Receptors, Lysosphingolipid; RNA, Small Interfering; Signal Transduction; Sphingosine; Ubiquitination | 2011 |
Is there any protective effect on organs upon higher uric acid level in tumor lysis syndrome?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tumor Lysis Syndrome; Uric Acid | 2011 |
Imatinib treatment induces CD5+ B lymphocytes and IgM natural antibodies with anti-leukemic reactivity in patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; B-Cell Activating Factor; B-Lymphocytes; Benzamides; CD4 Antigens; Chemokine CXCL12; Enzyme-Linked Immunosorbent Assay; Female; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunoglobulin M; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Treatment of consecutive patients with chronic myeloid leukaemia in the cooperating centres from the Czech Republic and the whole of Slovakia after 2000--a report from the population-based CAMELIA Registry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Czech Republic; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Registries; Retrospective Studies; Slovakia; Transplantation, Homologous; Young Adult | 2011 |
Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome.
Topics: Antineoplastic Agents; Benzamides; Cloning, Molecular; Cytogenetics; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Translocation, Genetic | 2011 |
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Basophils; Benzamides; Disease Progression; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Statistical; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Registries; Risk Assessment; Risk Factors; Spleen; Young Adult | 2011 |
Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Aurora Kinases; Benzamides; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Piperazines; Polyploidy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; Signal Transduction | 2011 |
AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Blotting, Western; Cells, Cultured; Cytidine Deaminase; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Female; Fusion Proteins, bcr-abl; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Oxides; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+/H+ exchanger.
Topics: Adolescent; Adult; Aged; Benzamides; Cell Line, Tumor; Child; Child, Preschool; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Female; Guanidines; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitogen-Activated Protein Kinases; Piperazines; Pyrimidines; Sodium-Hydrogen Exchangers; Sulfones; Young Adult | 2011 |
Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Mortality; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sex Factors; Sweden; Treatment Outcome; Young Adult | 2011 |
The GLIVEC international patient assistance programme: the Nairobi experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Developing Countries; Female; Gastrointestinal Stromal Tumors; Health Services Accessibility; Humans; Imatinib Mesylate; Kenya; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Young Adult | 2009 |
Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Body Height; Child; Child, Preschool; Female; Follow-Up Studies; Growth Disorders; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Puberty; Pyrimidines; Retrospective Studies | 2011 |
Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles | 2011 |
The significance of quantifiable residual normal karyotype hematopoietic cells for toxicity and outcome.
Topics: Benzamides; Female; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2011 |
Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia.
Topics: Benzamides; Coronary Artery Disease; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Brian Druker and Charles Sawyers receive the 2011 ASCI/Stanley J. Korsmeyer Award.
Topics: Antineoplastic Agents; Awards and Prizes; Benzamides; Clinical Medicine; History, 20th Century; History, 21st Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Piperazines; Pyrimidines; Societies, Medical; United States | 2011 |
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2011 |
Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.
Topics: Algorithms; Antineoplastic Agents; Antioxidants; Benzamides; Blotting, Western; Caco-2 Cells; DNA; Epithelium; Flavanones; Genotype; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Anion Transporters; Piperazines; Polymorphism, Genetic; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Topics: Benzamides; Cell Growth Processes; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; raf Kinases; ras Proteins | 2011 |
[Chronic myelogenous leukemia complicated by drug-induced agranulocytosis].
Topics: Aged; Agranulocytosis; Benzamides; Butylscopolammonium Bromide; Colonoscopy; Female; Flumazenil; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Piperazines; Premedication; Pyrimidines; Treatment Outcome | 2011 |
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells.
Topics: Algorithms; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Molecular Targeted Therapy; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription, Genetic; Treatment Outcome | 2011 |
Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Argentina; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2011 |
Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Cation Transporter 1; Piperazines; Pyrimidines; Thiazoles; Vault Ribonucleoprotein Particles | 2011 |
Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.
Topics: Animals; Benzamides; Bone Marrow Cells; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Osteolysis; Piperazines; Placenta Growth Factor; Pregnancy Proteins; Pyrimidines | 2011 |
Choosing the right TKI for chronic myeloid leukemia: when the truth lies in "long-term" safety and efficacy.
Topics: Adult; Aged; Benzamides; Blood Glucose; Cohort Studies; Constriction, Pathologic; Coronary Artery Disease; Drug Resistance, Neoplasm; Fasting; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Imatinib sensitivity in BCR-ABL1-positive chronic myeloid leukemia cells is regulated by the remaining normal ABL1 allele.
Topics: Alleles; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chromosome Banding; Comparative Genomic Hybridization; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines | 2011 |
Plasma tyrosine kinase activity as a potential biomarker in BCR-ABL1-targeted therapy.
Topics: Adaptor Proteins, Signal Transducing; Benzamides; Biomarkers, Tumor; Dasatinib; Dose-Response Relationship, Drug; Enzyme Assays; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; STAT5 Transcription Factor; Thiazoles | 2010 |
[Treatment of chronic myeloid leukemia with imatinib].
Topics: Antineoplastic Agents; Benzamides; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Survival Rate | 2011 |
[Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Pyrimidines | 2011 |
Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Monitoring; Drug Stability; Electrophoresis, Capillary; Female; Humans; Imatinib Mesylate; Least-Squares Analysis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity | 2011 |
[The role of allogenic hematopoietic stem cell transplantation for chronic myeloid leukemia in imatinib era].
Topics: Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Transplantation Conditioning; Transplantation, Homologous | 2011 |
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
Topics: Activating Transcription Factors; Animals; Antineoplastic Agents; Autophagy; Benzamides; Blotting, Western; Cell Transformation, Neoplastic; Chromatin Immunoprecipitation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luciferases; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; TOR Serine-Threonine Kinases; Transcription, Genetic | 2011 |
[Hematologic malignancies/ pediatric malignancies-chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Child; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Presence of complex t(6;9;22;15) four-way chromosome rearrangement plus rare t(1;6) translocation with favorable response to imatinib therapy in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome | 2011 |
Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Cell Line, Tumor; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2011 |
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines | 2012 |
α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients.
Topics: alpha-Defensins; Antineoplastic Agents; Benzamides; Biomarkers; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Peptides, Cyclic; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Simultaneous chronic myeloid leukemia and chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Multiple Primary; Piperazines; Pyrimidines | 2011 |
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Young Adult | 2011 |
Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Female; Health Status; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Male; Middle Aged; Piperazines; Population; Pyrimidines; Quality of Life; Time Factors; Young Adult | 2011 |
Fibrosis, regeneration, and aging: playing chess with evolution.
Topics: Aging; Animals; Antineoplastic Agents; Benzamides; Biological Evolution; Cytokines; Disease Progression; Fibrosis; Humans; Imatinib Mesylate; Immune System; Inflammation; Kidney Failure, Chronic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrophages; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Regeneration | 2011 |
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Benzamides; Cell Line, Tumor; Disease Progression; DNA Methylation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Genes, Neoplasm; Genome, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Sequence Analysis, DNA; Survival Analysis; Treatment Outcome; Young Adult | 2011 |
Long-term durability of molecular and chimerism responses in patients treated with imatinib for chronic myeloid leukemia relapse after allogeneic transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Young Adult | 2011 |
Inhibition of protein-tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl protein.
Topics: Benzamides; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysosomes; Piperazines; Protein Kinase Inhibitors; Protein Stability; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Pyrimidines; Reactive Oxygen Species; RNA, Small Interfering; Ubiquitination | 2011 |
Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase II as Topic; Female; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic | 2011 |
Bringing prognostic scores for chronic myeloid leukemia patients up to date.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2011 |
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Transcription Factors; Transfection | 2012 |
Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
Topics: Alanine; Benzamides; Binding Sites; Glutamic Acid; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; Lysine; Molecular Dynamics Simulation; Mutagenesis; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Salts; Thermodynamics | 2012 |
Severe peripheral arterial disease during nilotinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Drug Tolerance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Risk Factors; Severity of Illness Index; Stents | 2011 |
Leukocytosis: the mysteries within.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytosis; Male; Piperazines; Pyrimidines; Remission Induction | 2012 |
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.
Topics: Aged; Apoptosis; Basophils; Benzamides; Boronic Acids; Bortezomib; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrimidines | 2011 |
Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2012 |
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrimidines; Young Adult | 2011 |
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.
Topics: Benzamides; Fusion Proteins, bcr-abl; HeLa Cells; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Kinase D2; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Receptor, Interferon alpha-beta; Signal Transduction | 2011 |
Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Ceramides; Drug Resistance, Neoplasm; Glucosyltransferases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Piperazines; Pyrimidines | 2011 |
KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Receptors, KIR; Remission Induction; Survival Analysis | 2012 |
Successful treatment of childhood Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Cytarabine; Daunorubicin; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Induction Chemotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maintenance Chemotherapy; Piperazines; Pyrimidines | 2011 |
[H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience].
Topics: Adult; Benzamides; Biomarkers, Tumor; Female; Gene Expression Regulation, Leukemic; Genetic Markers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
First-line therapy for CML: nilotinib comes of age.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2011 |
Methyl-β-cyclodextrin induces programmed cell death in chronic myeloid leukemia cells and, combined with imatinib, produces a synergistic downregulation of ERK/SPK1 signaling.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; beta-Cyclodextrins; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Membrane Microdomains; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Binding Sites; Blast Crisis; Catalytic Domain; Dasatinib; DNA, Neoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mutation, Missense; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2011 |
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Topics: Adolescent; Adult; Aged; Apoptosis; Basic-Leucine Zipper Transcription Factors; Benzamides; Blotting, Western; Female; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Janus Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitogen-Activated Protein Kinases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrphostins; Young Adult | 2011 |
Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymorphism, Single Nucleotide; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Slovakia | 2011 |
BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2011 |
NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice.
Topics: Adolescent; Adult; Aged; Animals; Antineoplastic Agents; Benzamides; Cell Degranulation; Child; Disease Models, Animal; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2012 |
Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65--a novel Wnt/β-catenin signaling inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; beta Catenin; Cell Growth Processes; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; S Phase; Wnt Proteins; Wnt Signaling Pathway | 2011 |
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Topics: Adult; Aged; Base Sequence; Benzamides; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; INDEL Mutation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Young Adult | 2011 |
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ ALL resolution after decitabine therapy.
Topics: Azacitidine; Benzamides; Child, Preschool; Chromosome Aberrations; Decitabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cell Transplantation | 2012 |
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
Topics: Animals; Antigens, CD34; Benzamides; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Forkhead Transcription Factors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-6; Pyrimidines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tandem Mass Spectrometry; Young Adult | 2011 |
Roth spots in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow Cells; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retina; Retinal Hemorrhage | 2011 |
Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasm Transplantation; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Pyrimidines; Remission Induction; Substance Withdrawal Syndrome; Time Factors; Xenograft Model Antitumor Assays | 2011 |
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of β-catenin and STAT1 in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzamides; beta Catenin; Cell Line, Tumor; Chromones; COP9 Signalosome Complex; Down-Regulation; Enzyme Inhibitors; Flavonoids; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Oncogene Protein v-akt; Peptide Hydrolases; Piperazines; Promoter Regions, Genetic; Pyrimidines; STAT1 Transcription Factor; Transcription Factor 4; Transcription Factors | 2011 |
Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Calcium; Case-Control Studies; Cell Membrane; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Endoplasmic Reticulum; Female; Humans; Imatinib Mesylate; Inositol 1,4,5-Trisphosphate Receptors; Interleukin-6; Interleukin-8; Italy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; NF-kappa B; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Purinergic; Transcription Factor AP-1; Treatment Outcome | 2012 |
Hydroxychavicol, a Piper betle leaf component, induces apoptosis of CML cells through mitochondrial reactive oxygen species-dependent JNK and endothelial nitric oxide synthase activation and overrides imatinib resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Drug Resistance, Neoplasm; Eugenol; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; MAP Kinase Kinase 4; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mice, SCID; Mitochondria; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphorylation; Piper betle; Piperazines; Plant Extracts; Plant Leaves; Pyrimidines; Reactive Oxygen Species; Tumor Cells, Cultured | 2012 |
Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2011 |
Will imatinib compromise reproductive capacity?
Topics: Adolescent; Animals; Antineoplastic Agents; Benzamides; Cryopreservation; Female; Fertility Preservation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oocytes; Ovary; Ovulation Induction; Piperazines; Prognosis; Pyrimidines; Reproduction; Treatment Outcome | 2011 |
Durable molecular response despite F317L and E255K mutations: Successful treatment of chronic myeloid leukemia with sequential imatinib, nilotinib and dasatinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Dasatinib; Female; Fusion Proteins, bcr-abl; Glutamic Acid; Humans; Imatinib Mesylate; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysine; Mutation, Missense; Phenylalanine; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Remission Induction; Thiazoles; Time Factors; Treatment Outcome | 2012 |
Chronic myeloid leukemia within a year of kidney transplant with elevated alkaline phosphatase correlated with imatinib therapy.
Topics: Adolescent; Alkaline Phosphatase; Antineoplastic Agents; Benzamides; Biomarkers; Drug Therapy, Combination; Humans; Imatinib Mesylate; Immunosuppressive Agents; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mycophenolic Acid; Piperazines; Pyrimidines; Tacrolimus; Time Factors; Up-Regulation | 2011 |
[Roles of the 2nd generation TKIs for CML].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2011 |
Development of acute myeloid leukemia with NPM1 mutation, in Ph-negative clone, during treatment of CML with imatinib.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Philadelphia Chromosome; Piperazines; Pyrimidines | 2012 |
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Computer Simulation; Czech Republic; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Statistical; Piperazines; Prevalence; Pyrimidines; Statistics, Nonparametric; Young Adult | 2011 |
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2011 |
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Topics: Amino Acid Sequence; Animals; Base Sequence; Benzamides; Cells, Cultured; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Molecular Sequence Data; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; src Homology Domains | 2011 |
Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Stability; Humans; Hydrogen-Ion Concentration; Imatinib Mesylate; Least-Squares Analysis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2011 |
Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Topics: Adult; Antigens, CD; Antineoplastic Agents; Benzamides; Blast Crisis; Boronic Acids; Bortezomib; Cadherins; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Nucleus; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Female; Gene Expression; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrazines; Pyrimidines; RNA Interference; S-Phase Kinase-Associated Proteins; Young Adult | 2012 |
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Chemokine CXCL12; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Microdomains; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Phosphorylation; Piperazines; Protein Binding; Pyrimidines; Receptors, CXCR4; Signal Transduction; src-Family Kinases; Stromal Cells | 2012 |
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors.
Topics: Antigens, CD34; Apoptosis; Benzamides; Biphenyl Compounds; Blast Crisis; Cell Line, Tumor; Diterpenes; Epoxy Compounds; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitrophenols; Phenanthrenes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA, Messenger; Signal Transduction; Sulfonamides | 2012 |
CML: live long and prosper.
Topics: Benzamides; Female; Health Status; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Quality of Life | 2011 |
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
Topics: Antineoplastic Agents; Benzamides; Calibration; Cells, Cultured; Chromatography, High Pressure Liquid; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Limit of Detection; Mass Spectrometry; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reference Standards; Reproducibility of Results; Thiazoles | 2012 |
Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger | 2011 |
Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.
Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Computational Biology; Drug Resistance, Neoplasm; Exons; Gene Deletion; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Biology; Molecular Sequence Data; Piperazines; Polymerase Chain Reaction; Protein Isoforms; Protein Structure, Secondary; Proto-Oncogene Proteins c-abl; Pyrimidines; Sequence Deletion | 2012 |
Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Iran; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome | 2011 |
Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Surveys and Questionnaires; Treatment Outcome | 2012 |
Chronic myelogenous leukemia. Preface.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Transplantation, Homologous; Treatment Outcome | 2011 |
Clinical molecular medicine has finally arrived.
Topics: Benzamides; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2011 |
Increased natural killer cells and decreased CD3(+)CD8(+)CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.
Topics: Antineoplastic Agents; Benzamides; CD3 Complex; CD8 Antigens; CD8-Positive T-Lymphocytes; Female; Humans; Imatinib Mesylate; Killer Cells, Natural; L-Selectin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Piperazines; Pyrimidines; Remission Induction | 2012 |
Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Myeloid Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2012 |
[Serum α1-acid glycoprotein, imatinib concentration and efficacy in chronic myeloid leukemia patients].
Topics: Adolescent; Adult; Aged; Benzamides; Case-Control Studies; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Orosomucoid; Piperazines; Pyrimidines; Young Adult | 2011 |
Dasatinib overrides imatinib resistance mediated by the F359I residue mutation in two patients with chronic myeloid leukemia.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Mechanism of action of the multikinase inhibitor Foretinib.
Topics: Amino Acid Chloromethyl Ketones; Anilides; Anisomycin; Antigens, CD34; Antineoplastic Agents; Benzamides; Caspase 2; Caspase Inhibitors; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Death; Cell Size; Cell Survival; Cyclin B1; Cysteine Endopeptidases; Enzyme Activation; Enzyme Assays; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Melanocytes; Mitosis; Phenotype; Piperazines; Ploidies; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines; Quinolines; RNA, Small Interfering; Transfection | 2011 |
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457.
Topics: Animals; Aurora Kinases; Benzamides; Drug Resistance, Neoplasm; Histones; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines | 2012 |
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model.
Topics: Apoptosis; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Dasatinib; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitosis; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Second primary head and neck squamous cell cancers with aggressive behavior in patients with chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cause of Death; Disease-Free Survival; Follow-Up Studies; Gingival Neoplasms; Humans; Hydroxyurea; Hypopharyngeal Neoplasms; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Neoplasms; Neoplasms, Second Primary; Palliative Care; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Tongue Neoplasms | 2012 |
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
Topics: Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Gene Frequency; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Treatment Outcome | 2012 |
Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; RNA Interference; Signal Transduction; Transfection; Up-Regulation | 2011 |
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.
Topics: Antineoplastic Agents; Benzamides; Down-Regulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microarray Analysis; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Telomerase; Tumor Cells, Cultured | 2011 |
Bone marrow with gelatinous transformation associated with residual disease in imatinib mesylate-treated chronic myelogenous leukaemia (CML).
Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy, Needle; Bone Marrow; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Pancytopenia; Piperazines; Pyrimidines | 2012 |
Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antineoplastic Agents; Benzamides; Female; Flow Cytometry; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2012 |
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis; Young Adult | 2012 |
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K+ channels in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Down-Regulation; Ether-A-Go-Go Potassium Channels; Flow Cytometry; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patch-Clamp Techniques; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2012 |
Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; International Classification of Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Outcome; Young Adult | 2012 |
Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
Topics: Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Transcription, Genetic; Treatment Outcome; Young Adult | 2012 |
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Genes, ras; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Piperazines; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrimidines; raf Kinases; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.
Topics: Aniline Compounds; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Thiazoles; Time Factors; Transcription, Genetic; Treatment Outcome | 2012 |
AHI1 gene expression levels and BCR-ABL1 T315I mutations in chronic myeloid leukemia patients.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Time Factors; Young Adult | 2011 |
[Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2011 |
Bilateral hip pain caused by adductor pyomyositis as the initial presentation of chronic myeloid leukemia in a 17-year-old child.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Benzamides; Drainage; Hip; Humans; Imatinib Mesylate; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Oxacillin; Piperazines; Pyomyositis; Pyrimidines | 2011 |
Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.
Topics: Animals; Benzamides; Cell Communication; Cell Differentiation; Collagen; Culture Media, Conditioned; Dasatinib; Drug Combinations; Endocytosis; Exosomes; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; K562 Cells; Laminin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Nanotubes; Neovascularization, Physiologic; Piperazines; Proteoglycans; Pyrimidines; Reproducibility of Results; Signal Transduction; src-Family Kinases; Thiazoles; Time Factors | 2012 |
Imatinib in chronic myeloid leukemia elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2011 |
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Knockout; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sirtuin 1; STAT5 Transcription Factor; Stress, Physiological; Transcriptional Activation; Transfection | 2012 |
Mucosal pigmentation caused by imatinib: report of three cases.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Mucosa; Palate, Hard; Pigmentation Disorders; Piperazines; Pyrimidines | 2012 |
Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile.
Topics: Benzamides; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sequence Analysis, DNA; Thiazoles | 2012 |
How I treat childhood CML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Combined Modality Therapy; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Practice Guidelines as Topic; Pyrimidines; Stem Cell Transplantation; Translocation, Genetic | 2012 |
Photoinduced dermatitis and oral lichenoid reaction in a chronic myeloid leukemia patient treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Middle Aged; Mouth Diseases; Photosensitivity Disorders; Piperazines; Pyrimidines; Skin Pigmentation | 2012 |
Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; DNA Primers; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2011 |
Five-year follow-up of patients treated with imatinib mesylate for chronic myeloid leukaemia in Trinidad and Tobago.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Trinidad and Tobago; Young Adult | 2011 |
Skin fragility and blistering secondary to imatinib.
Topics: Antineoplastic Agents; Benzamides; Blister; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Skin Diseases | 2012 |
Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib-resistant chronic myeloid leukaemia patient harbouring the BCR-ABL1 T315I gatekeeper mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Resistance; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Pyrimidines | 2012 |
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Young Adult | 2012 |
Imatinib trough plasma levels do not correlate with the response to therapy in patients with chronic myeloid leukemia in routine clinical setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Pharmacological; Blood Chemical Analysis; Clinical Laboratory Techniques; Diagnostic Tests, Routine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Antineoplastic Agents; Benzamides; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Nuclear Proteins; Piperazines; Pyrimidines; Signal Transduction; Treatment Outcome | 2012 |
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; High-Temperature Requirement A Serine Peptidase 2; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mitochondrial Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Serine Endopeptidases; Sulfonamides; X-Linked Inhibitor of Apoptosis Protein | 2012 |
MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Neoplasm Proteins; Piperazines; Pyrimidines | 2012 |
Anti-leukemic effects of gallic acid on human leukemia K562 cells: downregulation of COX-2, inhibition of BCR/ABL kinase and NF-κB inactivation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cyclooxygenase 2; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gallic Acid; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; NF-kappa B; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
International reporting scale of BCR-ABL1 fusion transcript in chronic myeloid leukemia: first report from India.
Topics: Antineoplastic Agents; Benzamides; Clinical Chemistry Tests; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reference Standards | 2012 |
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Benzamides; Cytoplasm; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; NM23 Nucleoside Diphosphate Kinases; Piperazines; Pyrimidines; RNA Processing, Post-Transcriptional | 2012 |
An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia.
Topics: Academic Medical Centers; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetics; Disease-Free Survival; Female; Hospitals, Teaching; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2012 |
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
Topics: Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Pyrimidines; Treatment Outcome | 2012 |
Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Topics: Antigens, CD34; Apoptosis; Benzamides; beta Catenin; Blotting, Western; Cell Nucleus; Cells, Cultured; Cyclin D1; Cytokines; Dasatinib; Drug Synergism; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maleimides; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Signal Transduction; Thiazoles | 2012 |
Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Benzamides; Bone Marrow; DNA Mutational Analysis; DNA Probes; Drug Resistance, Neoplasm; Female; Fluorescence Resonance Energy Transfer; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Nucleic Acid Denaturation; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Retrospective Studies | 2012 |
Clinical cardiac safety profile of nilotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Coronary Artery Disease; Electrocardiography; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Heart; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Risk Factors; Ventricular Function, Left | 2012 |
Chronic myeloid leukemia: the race is yet to be won.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
Topics: Adult; Benzamides; Comorbidity; Dasatinib; Disease Management; HIV Infections; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; South Africa; Thiazoles; Treatment Outcome | 2011 |
Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Clonal Evolution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Translocation, Genetic | 2011 |
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Fusion Proteins, bcr-abl; HEK293 Cells; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; U937 Cells | 2012 |
Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2012 |
Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptors, Cytokine; RNA, Messenger | 2012 |
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Topics: Adult; Antineoplastic Agents; Asia, Southeastern; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro.
Topics: Antineoplastic Agents; Aurora Kinases; Benzamides; Benzimidazoles; Cell Line, Tumor; Cell Survival; Cells, Cultured; Humans; Imatinib Mesylate; Janus Kinases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Urea | 2012 |
[Rapamycin for myeloid blast crisis in refractory chronic myeloid leukemia with imatinib-resistance].
Topics: Adult; Antibiotics, Antineoplastic; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Sirolimus | 2011 |
Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.
Topics: Acetylation; Apoptosis; Benzamides; Drug Therapy, Combination; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; RNA, Small Interfering; Sirtuin 1; Transcription, Genetic; Tumor Suppressor Protein p53 | 2012 |
BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; DNA-Binding Proteins; Enzyme Activation; Female; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Regulation, Leukemic; Gene Order; Gene Silencing; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MDS1 and EVI1 Complex Locus Protein; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogenes; Pyrimidines; Transcription Factors | 2012 |
Imatinib resistance due to a novel tri-nucleotide insertion in the SH2/C lobe interface of BCR/ABL kinase domain between position K357 and N358.
Topics: Adult; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutagenesis, Insertional; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Indirubin derivatives induce apoptosis of chronic myelogenous leukemia cells involving inhibition of Stat5 signaling.
Topics: Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Survival; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Humans; Imatinib Mesylate; Immunoprecipitation; Indoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oximes; Piperazines; Pyridones; Pyrimidines; Signal Transduction; STAT5 Transcription Factor | 2012 |
Imatinib induces H2AX phosphorylation and apoptosis in chronic myelogenous leukemia cells in vitro via caspase-3/Mst1 pathway.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Cell Line, Tumor; Hepatocyte Growth Factor; Histones; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Pyrimidines; Signal Transduction | 2012 |
Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression.
Topics: Adolescent; Adult; Benzamides; Bone Marrow Cells; Cell Cycle Proteins; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2012 |
Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; MicroRNAs; Microtubule-Associated Proteins; Mitochondria; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2012 |
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Benzamides; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hedgehog Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Resveratrol; RNA Interference; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Stilbenes; Up-Regulation | 2012 |
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Feasibility Studies; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Neoadjuvant Therapy; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Withholding Treatment | 2012 |
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Dasatinib; Delivery of Health Care; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; United Kingdom | 2012 |
Trial by media.
Topics: Amyotrophic Lateral Sclerosis; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Media; Patient Education as Topic; Patients; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Research Personnel | 2012 |
Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Topics: Adult; Aged; Benzamides; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Unrelated Donors | 2012 |
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.
Topics: Benzamides; Cell Line, Tumor; DNA Repair; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Knockdown Techniques; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Sirtuin 1 | 2013 |
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Treatment Outcome | 2012 |
Oral mucosal hyperpigmentation and horizontal melanonychia caused by imatinib.
Topics: Antineoplastic Agents; Benzamides; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mouth Diseases; Mouth Mucosa; Nail Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Epigenetic therapy with hydralazine and magnesium valproate reverses imatinib resistance in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Humans; Hydralazine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Valproic Acid | 2012 |
Retention of CD34+ CML stem/progenitor cells during imatinib treatment and rapid decline after treatment with second-generation BCR-ABL inhibitors.
Topics: Aftercare; Antigens, CD34; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Prospective Studies; Pyrimidines | 2012 |
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Blast Crisis; Disease Management; Disease Progression; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Medication Adherence; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; RNA, Messenger; RNA, Neoplasm; Time Factors | 2012 |
NICE backs leukaemia drug after manufacturer drops price.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Thiazoles; United Kingdom | 2012 |
Extramedullary blastic crisis in abdominal lymph nodes in a patient with chronic myelogenous leukemia on imatinib.
Topics: Abdomen; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Middle Aged; Piperazines; Pyrimidines; Tomography, Emission-Computed | 2012 |
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.
Topics: Adenosine; Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Benzamides; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Transcription, Genetic | 2012 |
[Sustained complete molecular remission after cessation of imatinib mesylate treatment in a patient with relapsed chronic myelogenous leukemia after allogeneic stem cell transplantation].
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation, Homologous; Withholding Treatment | 2012 |
Pulmonary arterial hypertension in patients treated by dasatinib.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antineoplastic Agents; Benzamides; Bone Morphogenetic Protein Receptors, Type II; Calcium Channel Blockers; Dasatinib; Drug Utilization; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hydroxyurea; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Registries; Thiazoles; Treatment Outcome | 2012 |
Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Dasatinib; Female; Fusion Proteins, bcr-abl; Germany; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome; United Kingdom; United States | 2012 |
Imatinib-induced aplastic anemia in a patient with chronic myeloid leukemia.
Topics: Anemia, Aplastic; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2012 |
Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness.
Topics: Animals; Benzamides; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Imatinib Mesylate; Integrin alphaVbeta3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesoderm; Mice; Phenotype; Piperazines; Pyrimidines | 2012 |
The first case of Philadelphia chromosome-negative acute promyelocytic leukemia following imatinib for chronic myelogenous leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Promyelocytic, Acute; Male; Piperazines; Pyrimidines; Remission Induction; Translocation, Genetic | 2012 |
Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Benzamides; Bone Marrow Cells; Child; China; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Piperazines; Pyrimidines; RNA, Messenger; Treatment Outcome; Young Adult | 2012 |
DNA damage response in imatinib resistant chronic myeloid leukemia K562 cells.
Topics: Antineoplastic Agents; Benzamides; Cell Survival; Deoxyribonuclease (Pyrimidine Dimer); DNA Damage; Drug Resistance, Neoplasm; Endodeoxyribonucleases; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Hydrogen Peroxide; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxidants; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML.
Topics: Animals; Antineoplastic Agents; Benzamides; beta Catenin; Cyclooxygenase Inhibitors; Drug Resistance, Neoplasm; Gene Deletion; Humans; Imatinib Mesylate; Indomethacin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplastic Stem Cells; Piperazines; Prostaglandins; Pyrimidines | 2012 |
Imatinib mesylate-induced neutrophilic folliculitis in a teenager.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Facial Dermatoses; Female; Folliculitis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Piperazines; Pyrimidines | 2012 |
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
Topics: Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Disease Progression; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Topics: Aniline Compounds; Benzamides; Binding Sites; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isomerism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Nitriles; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Recombinant Proteins; Spectrophotometry, Infrared; Static Electricity; Thiazoles; X-Ray Diffraction | 2012 |
CML treatment in Asia-Pacific region.
Topics: Adult; Antineoplastic Agents; Asia; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia.
Topics: Animals; Benzamides; Cell Cycle; Chemokines; Cytokines; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Microenvironment | 2012 |
Increased financial burden among patients with chronic myelogenous leukaemia receiving imatinib in Japan: a retrospective survey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Health Care Costs; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Socioeconomic Factors; Surveys and Questionnaires; Young Adult | 2012 |
Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Diclofenac; Drug Interactions; Humans; Ibuprofen; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Pyrimidines | 2012 |
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anxiety; Benzamides; Edema; Europe; Fatigue; Female; Health Personnel; Humans; Imatinib Mesylate; Iraq; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Muscle Cramp; Patients; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Social Support; Surveys and Questionnaires; Taiwan; Young Adult | 2012 |
Chronic myeloid leukemia arising from acute myeloid leukemia: response to imatinib mesylate with favorable outcome.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2013 |
[Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles; Treatment Outcome | 2012 |
A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Codon, Nonsense; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Molecular; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines | 2012 |
Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.
Topics: Benzamides; Fas Ligand Protein; Flow Cytometry; Humans; Imatinib Mesylate; Interferon-alpha; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Natural Killer T-Cells; Perforin; Piperazines; Promyelocytic Leukemia Zinc Finger Protein; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Chronic myeloid leukemia in children and adolescents: results of treatment with imatinib mesylate.
Topics: Adolescent; Anemia; Antineoplastic Agents; Benzamides; Child; Exanthema; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Nausea; Neutropenia; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
microRNA 30A promotes autophagy in response to cancer therapy.
Topics: Apoptosis; Autophagy; Benzamides; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Models, Biological; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Nilotinib-associated vascular events.
Topics: Aged; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Risk Factors; Vascular Diseases | 2012 |
CML cells expressing the TEL/MDS1/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737.
Topics: Adult; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 3; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ETS Translocation Variant 6 Protein; Female; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MDS1 and EVI1 Complex Locus Protein; Nitrophenols; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ets; Proto-Oncogenes; Pyrimidines; Repressor Proteins; RNA Interference; Sulfonamides; Transcription Factors; Translocation, Genetic | 2012 |
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Comparative Genomic Hybridization; DNA Breaks, Double-Stranded; DNA End-Joining Repair; DNA Ligase ATP; DNA Ligases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly-ADP-Ribose Binding Proteins; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Xenopus Proteins | 2013 |
Chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Translocation, Genetic; United States | 2012 |
A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Dioxoles; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-cbl; Pyrimidines; Receptor Cross-Talk; Receptors, Transforming Growth Factor beta; Signal Transduction; src-Family Kinases; Transforming Growth Factor beta1; Ubiquitination | 2012 |
Phosphoprotein profiling predicts response to tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Cell Line, Tumor; Cluster Analysis; Female; HSP27 Heat-Shock Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Pyrimidines; STAT5 Transcription Factor; Treatment Outcome; Young Adult | 2012 |
A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Topics: Adolescent; Adult; Aged; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells.
Topics: Animals; Antigens, CD; Antigens, Ly; Apoptosis; Arachidonate 5-Lipoxygenase; Benzamides; Cell Lineage; Cell Survival; Fluorouracil; Fusion Proteins, bcr-abl; Gamma Rays; Hematopoietic Stem Cells; HSP90 Heat-Shock Proteins; Imatinib Mesylate; Interferon Regulatory Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Neoplastic Stem Cells; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Cell Surface; Signal Transduction; Signaling Lymphocytic Activation Molecule Family Member 1; src-Family Kinases; Time Factors | 2012 |
Peroxisome proliferator-activated receptor activation increases imatinib uptake and killing of chronic myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents; Benzamides; Female; Gene Expression Regulation, Leukemic; Hepatocytes; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Male; Mice; Octamer Transcription Factor-1; Piperazines; PPAR alpha; PPAR gamma; Pyrimidines; Up-Regulation | 2012 |
Pretreatment with IFN-α increases resistance to imatinib mesylate in patients with chronic myelocytic leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies | 2012 |
Recurrent imatinib-induced hepatotoxicity in a chronic myeloid leukaemia patient successfully managed with prednisone.
Topics: Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisone; Pyrimidines; Recurrence; Remission Induction; Young Adult | 2011 |
Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function.
Topics: ADP-ribosyl Cyclase 1; Anticarcinogenic Agents; Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; beta Catenin; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation; Glutathione; Glutathione S-Transferase pi; Humans; Imatinib Mesylate; Isothiocyanates; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Sulfoxides; Thiocyanates; Wnt Signaling Pathway | 2012 |
MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
Topics: Antineoplastic Agents; Benzamides; beta-Globins; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Dasatinib; Down-Regulation; Erythroid Cells; Gene Expression; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; S-Phase Kinase-Associated Proteins; Thiazoles | 2013 |
Hyperpigmentation of the hard palate associated with imatinib therapy for chronic myeloid leukemia with a genetic variation in the proto-oncogene c-KIT.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Female; Genetic Variation; Heterozygote; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Palate, Hard; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines | 2013 |
[Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Patient Compliance; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Thiazoles | 2012 |
Apoptotic effects of resveratrol, a grape polyphenol, on imatinib-sensitive and resistant K562 chronic myeloid leukemia cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Caspase 7; Cell Growth Processes; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Piperazines; Pyrimidines; Resveratrol; Stilbenes | 2012 |
Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Metabolism; Lipid Peroxidation; Male; Mass Spectrometry; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Proteomics; Pyrimidines; Wnt Signaling Pathway; Young Adult | 2012 |
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Diagnostic Techniques and Procedures; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Research Design; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
[Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; CpG Islands; DNA Methylation; Down-Regulation; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrimidines; RNA, Messenger; Trans-Activators | 2012 |
[Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Bone Marrow Cells; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Piperazines; Plasma; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
[Analysis of plasma trough level of imatinib in Chinese CML patients].
Topics: Adolescent; Adult; Aged; Asian People; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
[The effects of imatinib mesylate on immune globulin and T cell subset in patients with chronic myelocytic leukemia].
Topics: Adult; Aged; Benzamides; Case-Control Studies; Female; Humans; Imatinib Mesylate; Immunoglobulins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; T-Lymphocyte Subsets | 2012 |
Nilotinib and imatinib inhibit cytarabine cellular uptake: implications for combination therapy.
Topics: Benzamides; Cytarabine; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thymidine; Tumor Cells, Cultured | 2012 |
Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells.
Topics: Annexin A5; Apoptosis; ATP-Binding Cassette Transporters; Benzamides; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Intracellular Space; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction; Time Factors | 2012 |
[Long-term outcomes of nilotinib treatment for chronic myelogenous leukemia patients with imatinib resistance or intolerance].
Topics: Adult; Benzamides; Drug Resistance, Neoplasm; Drug Tolerance; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines | 2012 |
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cats; Disease Models, Animal; Dogs; Female; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mast-Cell Sarcoma; Neoplasms; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Thiazoles; Transcriptome | 2012 |
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Dasatinib; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; MAP Kinase Signaling System; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinolines; RNA, Small Interfering; Thiazoles; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2013 |
The proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Cycle Proteins; Cyclin B1; Drug Resistance, Neoplasm; Endopeptidases; Fusion Proteins, bcr-abl; Genomic Instability; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Phosphatase 2; Proteolysis; Pyrimidines; Securin; Separase; U937 Cells | 2012 |
Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Benzamides; Fatigue; Female; Humans; Imatinib Mesylate; Information Seeking Behavior; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Medication Adherence; Middle Aged; Odds Ratio; Piperazines; Pyrimidines; Quality of Life; Risk Factors; Social Support; Treatment Outcome | 2012 |
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cation Transport Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transport Proteins; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Symporters; Treatment Outcome; Young Adult | 2013 |
Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Exosomes; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Interleukin-8; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neovascularization, Pathologic; Orotic Acid; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate.
Topics: Adult; Benzamides; Hepatitis B virus; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Virus Replication | 2012 |
[Effects of hOCT1 and ABCB1 gene on the efficacy of imatinib mesylate in chronic myelocytic leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Child; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Organic Cation Transporter 1; Piperazines; Pyrimidines; RNA, Messenger; Treatment Outcome; Young Adult | 2012 |
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML.
Topics: Animals; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzylamines; Blotting, Western; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Dasatinib; Female; Flow Cytometry; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Nervous System Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Thiazoles | 2012 |
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzamides; Cell Proliferation; Cell Survival; Diterpenes, Kaurane; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; raf Kinases; RNA, Messenger; Signal Transduction; src-Family Kinases; STAT5 Transcription Factor; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2012 |
Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Bcl-2-Like Protein 11; Beclin-1; Benzamides; Caspase 3; Cell Cycle Checkpoints; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Oligopeptides; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA Interference; RNA, Small Interfering; Ubiquitin-Activating Enzymes | 2012 |
Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.
Topics: Adult; Aged; Antigens, Neoplasm; Benzamides; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; Female; Fusion Proteins, bcr-abl; HLA Antigens; Humans; Imatinib Mesylate; Immunotherapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peptides; Piperazines; Pyrimidines | 2012 |
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates.
Topics: Adolescent; Allopurinol; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Therapy, Combination; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Male; Piperazines; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retina; Retinal Neoplasms; Retinal Vein Occlusion; Vision Disorders; Visual Acuity | 2012 |
Measurement of imatinib uptake by flow cytometry.
Topics: Antineoplastic Agents; Benzamides; Cell Shape; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorescence; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sensitivity and Specificity; Ultraviolet Rays | 2012 |
Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response.
Topics: Aged; Aged, 80 and over; Benzamides; Drug Administration Schedule; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2012 |
MLPA is a powerful tool for detecting lymphoblastic transformation in chronic myeloid leukemia and revealing the clonal origin of relapse in pediatric acute lymphoblastic leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Child; Clonal Evolution; Cohort Studies; DNA Copy Number Variations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Nucleic Acid Amplification Techniques; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence | 2012 |
Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biopsy; Bone and Bones; Bone Marrow; Female; Homeostasis; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2012 |
Why are patients with chronic myeloid leukaemia (non-)adherent?
Topics: Antineoplastic Agents; Benzamides; Fatigue; Female; Humans; Imatinib Mesylate; Information Seeking Behavior; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Piperazines; Pyrimidines; Quality of Life; Social Support | 2012 |
10 years of progress in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Thiazoles | 2012 |
Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Chlorocebus aethiops; COS Cells; Drug Synergism; Female; Fibroblasts; Flow Cytometry; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mammary Neoplasms, Animal; Mice; Mitochondria; Oxidative Stress; Phosphorylation; Piperazines; Pyrimidines | 2012 |
Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2012 |
The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Cytogenetics; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2012 |
Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Nanomedicine; Nanoparticles; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptors, Transferrin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serum Albumin; Sorafenib; STAT5 Transcription Factor; Transferrin; Tumor Cells, Cultured | 2012 |
Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; National Cancer Institute (U.S.); Piperazines; Pyrimidines; Regression Analysis; SEER Program; United States | 2012 |
Imatinib increases apoptosis index through modulation of survivin subcellular localization in the blast phase of CML cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Blast Crisis; Blotting, Western; Cell Nucleus; Cell Survival; Cytoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Inhibitor of Apoptosis Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Survivin | 2012 |
Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Membrane; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Phosphotyrosine; Piperazines; Pyrimidines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Tyrosine | 2013 |
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Biomarkers; Bone and Bones; Child; Female; Growth Charts; Hormones; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Puberty; Pyrimidines | 2013 |
Oral and maxillofacial pathology case of the month. Palatal melanosis associated with imatinib mesylate therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melanosis; Mouth Mucosa; Palate, Hard; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Metastasis; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatases; Pyrimidines; Signal Transduction; STAT Transcription Factors | 2012 |
Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment?
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Dasatinib; Female; Flow Cytometry; Genome, Human; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Progenitor Cells; Myeloid Progenitor Cells; Neoplasms, Second Primary; Neoplastic Stem Cells; Piperazines; Pyrimidines; Thiazoles | 2012 |
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Jordan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Structure, Tertiary; Pyrimidines; Treatment Outcome | 2012 |
Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nitriles; Piperazines; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Quinolines; Structure-Activity Relationship; Systems Biology | 2012 |
Can we safely discontinue imatinib? Searching for new endpoints in CML: a standardized definition of "cure".
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Endpoint Determination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloablative Agonists; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Risk Factors; Treatment Outcome | 2012 |
Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Limit of Detection; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Solid Phase Extraction; Tandem Mass Spectrometry | 2013 |
Disappearance of both the BCR/ABL1 fusion gene and the JAK2V617F mutation with dasatinib therapy in a patient with imatinib-resistant chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines; Thiazoles; Translocation, Genetic | 2012 |
Emerging kinetics of BCR-ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure.
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Failure | 2013 |
Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome.
Topics: Abnormal Karyotype; Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Brazil; Chromosomes, Human; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Translocation, Genetic; Treatment Outcome; Young Adult | 2013 |
CaMKII γ, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Benzamides; Benzylisoquinolines; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinase Type 1; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Models, Molecular; Mutation; Neoplastic Stem Cells; Piperazines; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Synergistic killing effect of imatinib and simvastatin on imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Pyrimidines; Simvastatin; Xenograft Model Antitumor Assays | 2013 |
Dengue virus infection in a patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Dengue; Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2012 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Threonine | 2012 |
Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Gene Silencing; Heme Oxygenase-1; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reactive Oxygen Species | 2013 |
The PERK-eIF2α phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Survival; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; STAT5 Transcription Factor | 2012 |
Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory.
Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Female; Follow-Up Studies; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; Treatment Outcome | 2013 |
The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Chromosome Banding; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Introns; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Molecular Targeted Therapy; Patient Selection; Piperazines; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Recurrence; Remission Induction; Sequence Deletion; Time Factors | 2013 |
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Female; Gene Frequency; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Organic Cation Transport Proteins; Organic Cation Transporter 2; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Treatment Outcome; Young Adult | 2013 |
Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
Topics: Administration, Oral; Animals; Benzamides; Benzylisoquinolines; beta Catenin; Cell Growth Processes; Citrates; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Fusion Proteins, bcr-abl; G1 Phase Cell Cycle Checkpoints; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Neoplastic Stem Cells; Piperazines; Pyrimidines; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Xenograft Model Antitumor Assays | 2012 |
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Audit; Middle Aged; Monitoring, Physiologic; Piperazines; Pyrimidines; Treatment Outcome | 2012 |
Rare frameshift mutation Cys475Tyrfs(*)11 in the BCR/ABL kinase domain contributes to imatinib mesylate resistance in 2 Korean patients with chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Asian People; Base Sequence; Benzamides; Drug Resistance, Neoplasm; Female; Frameshift Mutation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Republic of Korea; Sequence Analysis, DNA; Young Adult | 2012 |
[Treatment for de novo chronic myeloid leukemia in chronic phase].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2012 |
[Treatment of imatinib-intolerant or -resistant CML patients].
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2012 |
[Detection of Abl kinase domain point mutations in chronic myeloid leukemia patients with imatinib resistance and its clinical significance].
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Point Mutation; Pyrimidines | 2012 |
Design, synthesis and preclinical evaluation of NRC-AN-019.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Injections, Intraperitoneal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2013 |
Vocal fold hemorrhage in a CML patient after Glivec treatment.
Topics: Antineoplastic Agents; Benzamides; Female; Hemorrhage; Humans; Imatinib Mesylate; Laryngeal Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Vocal Cords | 2013 |
Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells.
Topics: Benzamides; Drug Interactions; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrimidines | 2013 |
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Prognosis; Pyrimidines; Young Adult | 2013 |
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Neoplasm Recurrence, Local; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors | 2013 |
Front-line TKI therapy for chronic-phase CML: the luxury of choice.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Is imatinib still an acceptable first-line treatment for CML in chronic phase?
Topics: Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2012 |
Which TKI should be recommended as initial treatment for CML in chronic phase?
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2012 |
Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Case-Control Studies; Dasatinib; Depression; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Outcome Assessment, Health Care; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Surveys and Questionnaires; Thiazoles; United States; Young Adult | 2013 |
Disparities in chronic myeloid leukemia survival by age, gender, and ethnicity in pre- and post-imatinib eras in the US.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Ethnicity; Female; Health Status Disparities; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; SEER Program; Sex Characteristics; Survival Rate; United States | 2013 |
Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Monitoring; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Orosomucoid; Piperazines; Protein Binding; Pyrimidines | 2013 |
Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
Topics: Antimalarials; Apoptosis; Artemisinins; Benzamides; Caspase 3; Caspase 9; Cell Line, Tumor; Cytochromes c; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mitochondria; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger | 2013 |
Complete clearance of Ph+ metaphases after 3 months is a very early indicator of good response to imatinib as front-line treatment in chronic myelogenous leukemia.
Topics: Aged; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metaphase; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2013 |
BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Binding Sites; Carcinogenesis; Cell Proliferation; Down-Regulation; Fusion Proteins, bcr-abl; G1 Phase Cell Cycle Checkpoints; GATA1 Transcription Factor; Gene Expression; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Open Reading Frames; Piperazines; Promoter Regions, Genetic; Pyrimidines; RNA Interference | 2014 |
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.
Topics: Benzamides; Cloning, Molecular; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines | 2013 |
The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Female; Gene Expression; Gene Expression Regulation, Leukemic; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Models, Molecular; Organic Cation Transporter 1; Piperazines; Polymorphism, Single Nucleotide; Protein Conformation; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2013 |
Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
Topics: Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Profiling; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters; Organic Cation Transport Proteins; Piperazines; Polymorphism, Genetic; Pyrimidines; RNA, Messenger; Statistics, Nonparametric; Vault Ribonucleoprotein Particles; Young Adult | 2013 |
Downregulation of γ-catenin inhibits CML cell growth and potentiates the response of CML cells to imatinib through β-catenin inhibition.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Benzamides; beta Catenin; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Fusion Proteins, bcr-abl; gamma Catenin; Gene Expression Regulation, Leukemic; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; STAT5 Transcription Factor | 2013 |
PECAM-1 is involved in BCR/ABL signaling and may downregulate imatinib-induced apoptosis of Philadelphia chromosome-positive leukemia cells.
Topics: Apoptosis; Benzamides; Cell Adhesion; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Pyrimidines; Signal Transduction | 2013 |
All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Signal Transduction; Thiazoles; Tumor Cells, Cultured | 2012 |
Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Body Mass Index; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Obesity; Piperazines; Pyrimidines; Weight Gain | 2012 |
Chronic myeloid leukemia and ankylosing spondylitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Spondylitis, Ankylosing | 2012 |
[Successful treatment for Hodgkin's lymphoma in a female patient with Ph+ chronic myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hodgkin Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prednisone; Procarbazine; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine | 2012 |
[Role of Lyn kinase in imatinib-resistant chronic myelogenous leukemia].
Topics: Benzamides; Case-Control Studies; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; src-Family Kinases | 2012 |
Bosutinib in the treatment of chronic myelogenous leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinolines | 2012 |
SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Female; Haplotypes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linkage Disequilibrium; Malaysia; Male; Middle Aged; Organic Cation Transporter 1; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome; Young Adult | 2012 |
Bone metabolism during long-term treatment with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers; Bone and Bones; Bone Density; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2013 |
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Body Mass Index; Chromosome Aberrations; Cytogenetic Analysis; DNA Mismatch Repair; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2013 |
Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
Topics: Abnormal Karyotype; Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Treatment Outcome | 2013 |
As leukemia options grow, drugs jockey to be first-line therapies.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridazines; Pyrimidines; Thiazoles | 2013 |
A case with coexistence of major and minor BCR/ABL fusion transcript at lymphoblastic crisis of chronic myelogenous leukemia in patients with major BCR/ABL positivity during chronic phase.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Real-Time Polymerase Chain Reaction | 2013 |
Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Topics: Benzamides; Binding Sites; Binding, Competitive; Crystallography, X-Ray; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Thermodynamics | 2013 |
Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
Topics: Adolescent; Anthropometry; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Cross-Sectional Studies; Female; Growth Disorders; Human Growth Hormone; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2013 |
Rapid recognition of drug-resistance/sensitivity in leukemic cells by Fourier transform infrared microspectroscopy and unsupervised hierarchical cluster analysis.
Topics: Animals; Benzamides; Cluster Analysis; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyrimidines; Spectroscopy, Fourier Transform Infrared; Thiazoles; Tumor Cells, Cultured | 2013 |
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Biological; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Signal Transduction | 2013 |
5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
Topics: Apoptosis; Benzamides; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2013 |
A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Homologous Recombination; Humans; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Docking Simulation; Mutation; Neoplastic Stem Cells; Piperazines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Multimerization; Protein Processing, Post-Translational; Protein-Tyrosine Kinases; Pyrimidines; Rad51 Recombinase; RNA Interference; Tetrahydroisoquinolines; Time Factors; Transfection; Tumor Burden | 2013 |
GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Cycle; GA-Binding Protein Transcription Factor; Gene Expression; Hematopoietic Stem Cells; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Transgenic; Piperazines; Protein Kinase D2; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines | 2013 |
Imatinib-induced Stevens-Johnsons syndrome.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stevens-Johnson Syndrome | 2013 |
Preliminary validation of self-assessment tool to measure imatinib adherence in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cohort Studies; Diagnostic Self Evaluation; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Surveys and Questionnaires; Treatment Outcome | 2013 |
Adherence to tyrosine kinase inhibitor therapy for chronic myeloid leukemia: a Brazilian single-center cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Brazil; Child; Cohort Studies; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medication Adherence; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2013 |
The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzamides; Benzofurans; Benzophenones; Bone Marrow Cells; Cell Line, Tumor; Colony-Forming Units Assay; Cyclin D1; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; G1 Phase; Gene Expression Regulation, Neoplastic; Genes, bcl-1; Genes, bcl-2; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Necrosis; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Resting Phase, Cell Cycle; STAT5 Transcription Factor | 2013 |
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Substitution; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Treatment Failure; Treatment Outcome | 2013 |
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Osteonectin; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; RNA, Messenger; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Up-Regulation | 2013 |
From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biological Transport; Humans; Imatinib Mesylate; Intracellular Space; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Organic Cation Transporter 1; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2013 |
Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cytochrome P-450 CYP3A; Egypt; Genetic Predisposition to Disease; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Organic Anion Transporters, Sodium-Independent; Piperazines; Polymorphism, Single Nucleotide; Prospective Studies; Pyrimidines; Solute Carrier Organic Anion Transporter Family Member 1B3; Treatment Outcome; Young Adult | 2013 |
The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; Epigenomics; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins; Pyrimidines | 2013 |
Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.
Topics: Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Hematopoietic Stem Cells; Humans; Hydrogen Peroxide; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Oxidative Stress; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; STAT5 Transcription Factor; Tumor Suppressor Proteins | 2013 |
Lichenoid eruption to STI 571.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Piperazines; Pyrimidines | 2002 |
FDA approves Novartis' Gleevec.
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United States; United States Food and Drug Administration | 2001 |
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
Topics: Antineoplastic Agents; Benzamides; Blood Cell Count; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Middle Aged; Philadelphia Chromosome; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines; Remission Induction; T-Lymphocytes; Treatment Outcome | 2002 |
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
Topics: Alleles; Amino Acid Substitution; Benzamides; Cell Division; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies | 2002 |
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines | 2002 |
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Biomarkers, Tumor; Caspase 3; Caspases; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
[Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
Topics: Antineoplastic Agents; Benzamides; Dermatofibrosarcoma; Florida; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Skin Neoplasms | 2002 |
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenylalanine; Phosphorylation; Piperazines; Point Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Tyrosine | 2002 |
Imatinib mesylate and gray hair.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Hair; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pigmentation; Piperazines; Pyrimidines | 2002 |
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Synergism; Harringtonines; Homoharringtonine; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Survival Analysis | 2002 |
Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2002 |
Complete molecular remission in chronic myelogenous leukemia after imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; RNA, Messenger | 2002 |
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Topics: Androstadienes; Antineoplastic Agents; Benzamides; Caspase 3; Caspases; Chromones; Drug Synergism; Enzyme Inhibitors; Flavonoids; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrimidines; Reference Values; Tumor Cells, Cultured; Wortmannin | 2002 |
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Topics: Alleles; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Neoplasm Recurrence, Local; Piperazines; Protein Structure, Tertiary; Pyrimidines; Recurrence; Time Factors | 2002 |
Severe periorbital edema secondary to STI571 (Gleevec).
Topics: Benzamides; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Middle Aged; Orbit; Orbital Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Oral lichenoid reaction to imatinib (STI 571, Gleevec).
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Mouth Diseases; Piperazines; Pyrimidines | 2002 |
Pityriasis rosea associated with imatinib (STI571, Gleevec).
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pityriasis Rosea; Pyrimidines | 2002 |
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Topics: Apoptosis; Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Phosphorylation; Piperazines; Piperidines; Protein Processing, Post-Translational; Pyrimidines; Signal Transduction; U937 Cells | 2002 |
Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Piperazines; Pyrimidines | 2002 |
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Pyrimidines | 2002 |
Cardiac tamponade associated with imatinib mesylate therapy of chronic myelogenous leukemia.
Topics: Benzamides; Cardiac Tamponade; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Piperazines; Pyrimidines; Radiography; Weight Gain | 2002 |
a suitable case for treatment. The National Institute for Clinical Excellence's change of heart over cancer drug Glivec has been applauded by clinicians--and patients.
Topics: Academies and Institutes; Antineoplastic Agents; Benzamides; Drug Approval; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United Kingdom | 2002 |
Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.
Topics: Benzamides; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Hepatitis, Viral, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Diseases; Middle Aged; Piperazines; Pyrimidines | 2002 |
Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.
Topics: Adenosine Triphosphate; Adult; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Position paper on imatinib mesylate in chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Drug Costs; Forecasting; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Failure | 2002 |
Sti571-induced Stevens-Johnson Syndrome.
Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Stevens-Johnson Syndrome | 2002 |
Tyrosine kinase inhibitor STI571 in the treatment of Philadelphia chromosome-positive leukaemia failing myeloablative stem cell transplantation.
Topics: Adolescent; Adult; Benzamides; Drug Evaluation; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Remission Induction; RNA, Neoplasm; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2002 |
Hypersensitivity pneumonitis related to imatinib mesylate.
Topics: Adult; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2002 |
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Topics: Benzamides; Benzoquinones; Blast Crisis; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidines; Rifabutin; src-Family Kinases; STAT5 Transcription Factor; Trans-Activators | 2002 |
NICE widens patient group for leukaemia drug.
Topics: Antineoplastic Agents; Benzamides; England; Guidelines as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Pyrimidines | 2002 |
Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Topics: Benzamides; Case-Control Studies; DNA Fingerprinting; Female; Gene Expression Regulation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Monocytes; Myeloblastin; Piperazines; Promoter Regions, Genetic; Pyrimidines; Remission Induction; Serine Endopeptidases; T-Lymphocytes, Cytotoxic; Transcription, Genetic | 2003 |
[Resistance to tumor specific therapy with imatinib by clonal selection of mutated cells].
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Histidine; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Point Mutation; Pyrimidines; Selection, Genetic; Tyrosine | 2002 |
Gleevec for the treatment of chronic myelogenous leukemia: US. Food and Drug Administration regulatory mechanisms, accelerated approval, and orphan drug status.
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orphan Drug Production; Piperazines; Pyrimidines; United States; United States Food and Drug Administration | 2002 |
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Benzamides; Blood Cells; Bone Marrow Cells; Clone Cells; Cohort Studies; Cytarabine; Dosage Compensation, Genetic; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Idarubicin; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Receptors, Androgen; Remission Induction | 2003 |
[Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy].
Topics: Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pancytopenia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Severity of Illness Index | 2002 |
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Binding Sites; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2002 |
Severe tumor lysis syndrome during treatment with STI 571 in a patient with chronic myelogenous leukemia accelerated phase.
Topics: Adolescent; Benzamides; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Risk Assessment; Severity of Illness Index; Tumor Lysis Syndrome | 2002 |
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Skin Diseases, Papulosquamous | 2002 |
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Camptothecin; Child; Combined Modality Therapy; Edema; Enzyme Inhibitors; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Lung Neoplasms; Male; Neoplasm Proteins; Neuroectodermal Tumors, Primitive; Piperazines; Pleural Effusion; Proto-Oncogene Proteins c-kit; Pyrimidines; Remission Induction; Sarcoma, Ewing; Testis; Topotecan | 2002 |
Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma, Ewing; Treatment Outcome; Tumor Cells, Cultured | 2002 |
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle Proteins; Computer Systems; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Disease Progression; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Processing, Post-Translational; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Vorinostat | 2003 |
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Caspase 3; Caspases; Cell Division; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Philadelphia Chromosome; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2002 |
A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells.
Topics: Animals; Benzamides; Cell Cycle; Cell Line; DNA-Binding Proteins; Forkhead Box Protein O1; Forkhead Box Protein O3; Forkhead Transcription Factors; Fusion Proteins, bcr-abl; G1 Phase; G2 Phase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; Transcription Factors; Transfection; Tumor Cells, Cultured | 2003 |
[Treatment of chronic myelogenous leukemia with imatinib mesylate resulting in hematological remission and marked regression of myelofibrosis].
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Primary Myelofibrosis; Prognosis; Pyrimidines; Remission Induction | 2002 |
Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Piperazines; Primary Myelofibrosis; Pyrimidines | 2002 |
[Chronic myeloid leukemia--case report].
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Cytarabine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Piperazines; Prognosis; Pyrimidines; Remission Induction | 2002 |
Telomere length in peripheral blood granulocytes reflects response to treatment with imatinib in patients with chronic myeloid leukemia.
Topics: Benzamides; Biomarkers; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Telomere; Treatment Outcome | 2003 |
STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy; Transplantation, Homologous | 2002 |
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Division; Cells, Cultured; Culture Media, Conditioned; Densitometry; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphokines; Mice; Neovascularization, Pathologic; Piperazines; Precipitin Tests; Pyrimidines; Time Factors; Transfection; Umbilical Veins; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutagenesis, Site-Directed; Piperazines; Protein Isoforms; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyridones; Pyrimidines; Transfection | 2002 |
Decitabine has promising clinical activity in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials, Phase I as Topic; Decitabine; DNA Modification Methylases; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Failure | 2002 |
TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Regulatory Proteins; Arabidopsis Proteins; Benzamides; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 1; Death Domain Receptor Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fas Ligand Protein; Fatty Acid Desaturases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leupeptins; Membrane Glycoproteins; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Peptides; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Orbital Diseases; Piperazines; Pyrimidines | 2003 |
[Treatment of residual disease in chronic myeloid leukemia with STI-571 (Glivec)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2002 |
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Topics: Benzamides; Blast Crisis; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Selection, Genetic; src-Family Kinases | 2003 |
Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy.
Topics: Benzamides; Cell Lineage; Cell Transformation, Neoplastic; Clone Cells; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Myelodysplastic Syndromes; Piperazines; Pyrimidines | 2003 |
Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.
Topics: Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Transplantation, Homologous | 2003 |
Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
Topics: Benzamides; Clone Cells; Disease Progression; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines | 2002 |
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA, Complementary; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA; Treatment Outcome | 2003 |
BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Chromosome Banding; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2002 |
Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stem Cell Transplantation; Vidarabine; Whole-Body Irradiation | 2002 |
Thrombocytopenia induced by imatinib mesylate (Glivec) in patients with chronic myelogenous leukemia: is 400 mg daily of imatinib mesylate an optimal starting dose for Japanese patients?
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Thrombocytopenia | 2003 |
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Topics: Adult; Aged; Antigens, CD34; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Translocation, Genetic; Trisomy | 2003 |
Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Eruptions; Edema; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Piperazines; Prospective Studies; Pruritus; Pyrimidines | 2003 |
Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line.
Topics: Alkyl and Aryl Transferases; Apoptosis; Benzamides; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Piperidines; Pyridines; Pyrimidines; Research Design; Tumor Cells, Cultured | 2003 |
BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Northern; Blotting, Western; Case-Control Studies; DNA Primers; DNA, Complementary; Fetal Blood; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Vectors; Green Fluorescent Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luminescent Proteins; Neoplasm Proteins; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transduction, Genetic; Transfection | 2003 |
Inverse relationship between myeloid maturation and leukotriene C4 synthase expression in normal and leukemic myelopoiesis-consistent overexpression of the enzyme in myeloid cells from patients with chronic myeloid leukemia.
Topics: Antigens, CD34; Benzamides; Case-Control Studies; Cell Differentiation; Gene Expression Regulation, Leukemic; Glutathione Transferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lewis X Antigen; Myeloid Cells; Myelopoiesis; Neutrophils; Piperazines; Pyrimidines; Receptors, IgG | 2003 |
Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Follow-Up Studies; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2003 |
Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Time Factors | 2003 |
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.
Topics: Animals; Benzamides; Blood-Brain Barrier; Bone Marrow; Brain Neoplasms; Central Nervous System Diseases; Genes, abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Piperazines; Pyrimidines; Spinal Cord Neoplasms; Transfection | 2003 |
Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Benzamides; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Thrombocytopenia | 2003 |
Chromosomal abnormalities in Philadelphia (Ph)-negative cells of patients with chronic myeloide leukemia treated with Imatinib (ST1571).
Topics: Adult; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Death; Cell Division; Colony-Forming Units Assay; Cyclosporins; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression; Genes, MDR; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotyrosine; Piperazines; Pyrimidines; Transfection; Tumor Cells, Cultured; Verapamil | 2003 |
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy.
Topics: Adult; Aged; Benzamides; Bone Marrow Examination; Cytogenetic Analysis; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity | 2002 |
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Topics: Aged; Benzamides; Blast Crisis; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Humans; Hydroxyurea; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2002 |
Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retinal Hemorrhage; Retinal Neoplasms; Visual Acuity | 2003 |
Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Stem Cell Transplantation; Time Factors; Treatment Outcome | 2003 |
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Topics: Adenosine Triphosphate; Adult; Aged; Benzamides; Binding Sites; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Prognosis; Protein Structure, Tertiary; Pyrimidines; Survival Analysis | 2003 |
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chickenpox; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
Gleevec: tailoring to fit.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyridones; Pyrimidines | 2003 |
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Salvage Therapy | 2003 |
Imatinib mesylate--the new gold standard for treatment of chronic myeloid leukemia.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation | 2003 |
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
Topics: Adult; Aged; Benzamides; Case-Control Studies; Chromosomes, Human, Pair 8; Clone Cells; Cytogenetic Analysis; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Philadelphia Chromosome; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Trisomy | 2003 |
Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Genetic Markers; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2003 |
Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Eruptions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Photosensitivity Disorders; Piperazines; Pyrimidines | 2003 |
Current use of imatinib in the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines; Treatment Outcome | 2003 |
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Genetic Variation; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Sequence Data; Mutagenesis, Site-Directed; Piperazines; Point Mutation; Protein Conformation; Protein Structure, Secondary; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment.
Topics: Age Factors; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cocarcinogenesis; Coronary Disease; Drug Eruptions; Dyspnea; Enzyme Inhibitors; Facial Neoplasms; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Pancytopenia; Piperazines; Pleural Effusion; Pyrimidines; Sunlight; Ultraviolet Rays | 2003 |
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Topics: Aneuploidy; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Chromosome Aberrations; Chromosome Painting; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fatal Outcome; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous | 2003 |
[A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Transplantation; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction | 2003 |
Intramuscular edema as a complication of treatment with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Edema; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Muscular Diseases; Piperazines; Pyrimidines; Thigh | 2003 |
G-CSF for imatinib-induced neutropenia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines | 2003 |
Is another bcr-abl inhibitor needed for chronic myelogenous leukemia?
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyridines; Pyrimidines | 2003 |
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation Chimera; Transplantation, Homologous | 2003 |
Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Binding, Competitive; Clone Cells; DNA Probes; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Nucleic Acid Hybridization; Peptide Nucleic Acids; Piperazines; Polymerase Chain Reaction; Pyrimidines; Retrospective Studies; Sensitivity and Specificity | 2003 |
Precipitation of porphyria cutanea tarda by imatinib mesylate?
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Porphyria Cutanea Tarda; Pyrimidines | 2003 |
Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation.
Topics: Benzamides; Fatal Outcome; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Steroids; Stevens-Johnson Syndrome; Transplantation, Homologous | 2003 |
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Topics: Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Survival Rate; Treatment Failure; Treatment Outcome | 2003 |
Imatinib restores expression of CD62L in BCR-ABL-positive cells.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; L-Selectin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2003 |
Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration.
Topics: Adult; Antineoplastic Agents; Benzamides; Busulfan; Cardiomegaly; Cyclophosphamide; Echocardiography, Doppler; Electrocardiography; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Male; Piperazines; Pyrimidines; Radiography; Reoperation; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous | 2003 |
Prediction of sensitivity to STI571 among chronic myeloid leukemia patients by genome-wide cDNA microarray analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gene Expression Regulation, Neoplastic; Genome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Treatment Outcome | 2002 |
Imatinib for chronic myelogenous leukaemia: a 9 or 24 carat gold standard?
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2003 |
Prolonged treatment with imatinib mesylate in patients with advanced chronic myeloid leukemia causes a reduction of bcr/abl mRNA levels independent of cytogenetic response.
Topics: Antineoplastic Agents; Benzamides; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2003 |
Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperazines; Pyrimidines; ras Proteins; Secondary Prevention; Signal Transduction | 2003 |
Imatinib Mesylate (Gleevec) is a useful agent in the salvage treatment of adults with relapsed/refractory Philadelphia positive acute leukemias.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Benzamides; Cytarabine; Daunorubicin; Doxorubicin; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Hepatitis B; Humans; Imatinib Mesylate; Immunosuppressive Agents; Lamivudine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Methotrexate; Middle Aged; Neoplasm Proteins; Peripheral Blood Stem Cell Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Pyrimidines; Remission Induction; Salvage Therapy; Vincristine | 2003 |
Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).
Topics: Antineoplastic Agents; Benzamides; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA, Small Interfering; Tumor Cells, Cultured | 2003 |
Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Blood Component Removal; Cohort Studies; Enzyme Inhibitors; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2003 |
Histological features of acute hepatitis after imatinib mesylate treatment.
Topics: Adult; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stem Cell Transplantation | 2003 |
Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Blotting, Western; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Rifabutin | 2003 |
Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase.
Topics: Benzamides; Blood Vessels; Bone Marrow; Case-Control Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neovascularization, Pathologic; Piperazines; Pyrimidines | 2003 |
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Division; Diphosphonates; Drug Synergism; Hematopoietic Stem Cells; HL-60 Cells; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Monomeric GTP-Binding Proteins; Pamidronate; Piperazines; Protein Prenylation; Pyrimidines; Zoledronic Acid | 2003 |
In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Caspases; Cell Division; Cytarabine; DNA; DNA-Binding Proteins; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Phosphorylation; Piperazines; Poly(ADP-ribose) Polymerases; Precipitin Tests; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Tyrosine; U937 Cells | 2003 |
Questioning the aim of CML therapy in the era of Imatinib?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2003 |
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Middle Aged; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recurrence | 2003 |
A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Prediction of response to imatinib by cDNA microarray analysis.
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Oligonucleotide Array Sequence Analysis; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
Cytogenetic and molecular mechanisms of resistance to imatinib.
Topics: Benzamides; Chromosome Aberrations; Clone Cells; Cytogenetic Analysis; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Pyrimidines; RNA, Neoplasm; Treatment Outcome | 2003 |
[Successful treatment with imatinib mesylate for Philadelphia chromosome-positive refractory acute myeloid leukemia].
Topics: Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger; Treatment Outcome | 2003 |
Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome; Treatment Refusal | 2003 |
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
Gynaecomastia in men with chronic myeloid leukaemia after imatinib.
Topics: Antineoplastic Agents; Benzamides; Gynecomastia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Progesterone; Pyrimidines; Testosterone | 2003 |
The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia.
Topics: Antigen Presentation; Antigens, CD; Benzamides; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Dendritic Cells; DNA Probes; Enzyme Inhibitors; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2003 |
[Targeted therapy with imatinib has reformed the treatment of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
[Successful attainment of the third chronic phase by autologous peripheral blood stem cell transplantation and imatinib in a patient with chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Remission Induction; Transplantation, Autologous | 2003 |
Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Enzyme Inhibitors; Fatal Outcome; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence | 2003 |
Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Membrane; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; KB Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukotrienes; Multidrug Resistance-Associated Proteins; Phosphorylation; Photoaffinity Labels; Piperazines; Pyrimidines; Tyrosine | 2003 |
Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma?
Topics: Antineoplastic Agents; Benzamides; Child; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Chronic myeloid leukemia in a patient with chronic idiopathic thrombocytopenic purpura: rapid response to imatinib mesylate (STI571).
Topics: Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines | 2003 |
Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Histocytochemistry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Skin Diseases | 2003 |
Minimal residual disease-based role of imatinib as a first-line interim therapy prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Risk; RNA; RNA, Messenger; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2003 |
Salvage chemotherapy with donor lymphocyte infusion and STI 571 in a patient relapsing with B-lymphoblastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
Topics: Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Bone Marrow Transplantation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Tissue Donors; Transplantation, Homologous; Treatment Outcome | 2003 |
[Treatment of 54 chronic myelogenous leukemia with Gleevec].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Mutation; Piperazines; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Imatinib or transplant for chronic myeloid leukaemia?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2003 |
Imatinib or transplant for chronic myeloid leukaemia?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2003 |
Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
Topics: Adult; Aged; Benzamides; Cytogenetic Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; RNA, Neoplasm | 2003 |
[Imatinib--en epoch-making new drug against chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Clinical heterogeneity in chronic myeloid leukaemia reflecting biological diversity in normal persons.
Topics: Adult; Benzamides; Case-Control Studies; Cell Division; Female; Fusion Proteins, bcr-abl; Genetic Variation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Diagnostic Techniques; Orosomucoid; Piperazines; Prognosis; Pyrimidines; Recurrence; Remission Induction; RNA, Messenger; Time Factors | 2003 |
[Successful induction of complete cytogenetic response with high-dose imatinib mesylate and subsequent allogeneic stem cell transplantation for CML blastic crisis].
Topics: Adult; Benzamides; Blast Crisis; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pulse Therapy, Drug; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Drug Evaluation; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Risk Assessment; Salvage Therapy; Severity of Illness Index; Survival Analysis; Treatment Failure | 2003 |
The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Butyrates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protease Inhibitors; Pyrazines; Pyrimidines; Reactive Oxygen Species; Signal Transduction; Tumor Cells, Cultured; Vorinostat | 2003 |
A case of myelodysplastic syndrome developed blastic crisis of chronic myelogenous leukemia with acquisition of major BCR/ABL.
Topics: Aged; Benzamides; Blast Crisis; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger; Translocation, Genetic | 2003 |
A hope for the future.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reproducibility of Results | 2003 |
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pancytopenia; Philadelphia Chromosome; Piperazines; Pyrimidines; Trisomy | 2003 |
From bedside to bench: treatment for rare blood disorder yields clues to disease mechanism.
Topics: Antineoplastic Agents; Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 4; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2003 |
[Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ].
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quality of Life; Recombinant Proteins; Treatment Outcome | 2003 |
Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Topics: Acute Kidney Injury; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
[Relationship between cytopenia and cytogenetic response in imatinib mesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients].
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Risk Factors; Thrombocytopenia; Treatment Outcome | 2003 |
ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
Topics: Adenosine Triphosphate; Adult; Amino Acid Sequence; Base Sequence; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Molecular Sequence Data; Piperazines; Point Mutation; Proto-Oncogene Proteins c-abl; Pyrimidines; Sequence Homology, Nucleic Acid | 2003 |
Effects of lower dose of imatinib to CML patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; RNA, Messenger | 2003 |
Successful treatment of extramedullary blast crisis of chronic myelogenous leukemia with imatinib mesylate (STI571).
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Examination; Bone Marrow Transplantation; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Node Excision; Male; Neck; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome | 2003 |
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Azacitidine; Base Sequence; Benzamides; Cell Division; Cell Line, Tumor; Decitabine; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Transplantation, Homologous | 2003 |
A 41-year-old woman with chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Decision Making; Fatigue; Female; Headache; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Stem Cell Transplantation | 2003 |
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; G1 Phase; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microfilament Proteins; Multienzyme Complexes; Muscle Proteins; Piperazines; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Pyridones; Pyrimidines; Tumor Cells, Cultured | 2003 |
Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
Topics: Animals; Benzamides; Binding Sites; Bleomycin; DNA Damage; DNA Helicases; Enzyme Inhibitors; Exodeoxyribonucleases; HeLa Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; Piperazines; Protein Transport; Proto-Oncogene Proteins c-abl; Pyrimidines; Recombinant Proteins; RecQ Helicases; Signal Transduction; src Homology Domains; Tumor Cells, Cultured; Tyrosine; Werner Syndrome Helicase | 2003 |
Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec.
Topics: Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Fusion Proteins, bcr-abl; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Translocation, Genetic | 2003 |
Emergence of Ph negative clones in chronic myeloid leukemia (CML) patients in complete cytogenetic remission after therapy with imatinib mesylate (STI).
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 7; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Translocation, Genetic | 2003 |
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; RNA, Messenger | 2003 |
Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2003 |
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Cell Line; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mutagenesis, Site-Directed; Mutation; Phosphorylation; Piperazines; Pyrimidines; STAT5 Transcription Factor; Trans-Activators; Transfection; Tyrosine | 2003 |
Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Transplantation, Homologous; Treatment Outcome | 2003 |
Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.
Topics: Adult; Antineoplastic Agents; Benzamides; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Topics: Administration, Oral; Age Factors; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
Scientists probe cancer cell resistance: new insights may help development of new drugs.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Chaperones; Mutation; Piperazines; Pyrimidines; Signal Transduction; Tamoxifen | 2003 |
Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2003 |
Chromosomal abnormalities in Ph- cells of patients on imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines | 2003 |
[The early efficacy of imatinib in the treatment of 54 cases of chronic myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Female; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Benzamides; Case-Control Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Piperazines; Probability; Prognosis; Pyrimidines; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway.
Topics: Apoptosis; Benzamides; Biomarkers; Cell Cycle; Cell Line, Transformed; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytosol; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction | 2003 |
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carrier Proteins; Cell Cycle Proteins; Drug Synergism; Eukaryotic Initiation Factors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Pyrimidines; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2003 |
Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Recurrence; Time Factors; Transplantation, Homologous; Transplantation, Isogeneic; Treatment Outcome | 2003 |
Concomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Benzamides; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Treatment Outcome | 2003 |
Minimal residual disease in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cytarabine; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2003 |
Residual disease in chronic myeloid leukemia after induction of molecular remission.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Sensitivity and Specificity | 2003 |
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
Topics: Animals; Apoptosis; Benzamides; Cell Division; Cell Line, Transformed; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines | 2003 |
Autologous peripheral blood stem cell transplantation of stem cells harvested in imatinib-induced complete cytogenetic remission: an example of in vivo purging in CML.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2003 |
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Division; Cladribine; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines; Tumor Stem Cell Assay; Vidarabine | 2003 |
Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign.
Topics: Adult; Benzamides; Biopsy, Needle; Dermatitis, Exfoliative; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Risk Assessment; Saudi Arabia; Severity of Illness Index | 2003 |
Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Porphyria Cutanea Tarda; Pyrimidines | 2004 |
Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Arthritis, Rheumatoid; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pain Measurement; Piperazines; Pyrimidines; Range of Motion, Articular; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2003 |
[Efficacy and pharmacokinetics of imatinib mesylate in a child with chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Child; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction | 2003 |
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Deletion; Chromosome Mapping; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; Clinical Trials as Topic; DNA Mutational Analysis; Female; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Metastasis; Phenotype; Piperazines; Prognosis; Pyrimidines; Risk; Risk Factors; Time Factors; Treatment Outcome | 2003 |
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Metaphase; Middle Aged; Piperazines; Pyrimidines | 2003 |
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation toward the erythroid lineage.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Differentiation; Cell Lineage; Enzyme Inhibitors; Erythroid Precursor Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Models, Biological; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction | 2003 |
Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cell Division; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase C; Protein-Tyrosine Kinases; Pyrimidines; Telomerase; Tumor Cells, Cultured | 2003 |
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orosomucoid; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2003 |
[New oncological treatment principle with imatinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dermatofibrosarcoma; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Skin Neoplasms; Stromal Cells; Treatment Outcome | 2003 |
Disseminated erythematous and pityriasiform plaques caused by imatinib mesylate.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Erythema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methylprednisolone; Middle Aged; Piperazines; Pityriasis; Pyrimidines | 2003 |
Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.
Topics: Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Trisomy | 2004 |
Does early imatinib-induced myelosuppression predict hematologic responses in patients with advanced-phase chronic myeloid leukemia?
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2003 |
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports.
Topics: Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Chromosome Aberrations; Cytogenetic Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Skin Neoplasms | 2003 |
Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Stem Cell Transplantation; Stem Cells | 2003 |
EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate.
Topics: Aged; B-Lymphocytes; Benzamides; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Immunosuppression Therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoproliferative Disorders; Neoplasms, Second Primary; Piperazines; Pyrimidines; Skin Neoplasms | 2003 |
[STI 571 for treating 19 patients with chronic-phase chronic myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Pyrimidines | 2003 |
Imatinib mesylate causes hypopigmentation in the skin.
Topics: Adult; Aged; Benzamides; Enzyme Inhibitors; Female; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-kit; Pyrimidines | 2003 |
A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: caspase-independent, necrosis-like programmed cell death mediated by serine protease activity.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Benzamides; Caspase 3; Caspase 9; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cell Nucleus; Cysteine Proteinase Inhibitors; Flavoproteins; Fusion Proteins, bcr-abl; High-Temperature Requirement A Serine Peptidase 2; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potentials; Membrane Proteins; Mitochondria; Mitochondrial Proteins; Necrosis; Nucleosomes; Piperazines; Pyrimidines; Reactive Oxygen Species; Serine Endopeptidases | 2004 |
David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
Topics: Antineoplastic Agents; Awards and Prizes; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2003 |
[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Erythema; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2003 |
[The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Topics: Adenosine Triphosphate; Adult; Aged; Benzamides; Binding Sites; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm, Residual; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase.
Topics: Animals; Apoptosis; Benzamides; Calcium; Caspase 12; Caspases; Cell Line, Transformed; Down-Regulation; Endoplasmic Reticulum; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Temperature; Transduction, Genetic | 2004 |
Imatinib-associated pulmonary alveolar proteinosis.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pulmonary Alveolar Proteinosis; Pyrimidines | 2003 |
Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2.
Topics: Animals; Apoptosis; Benzamides; Cell Line; Cell Line, Transformed; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon Regulatory Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Multipotent Stem Cells; Piperazines; Promoter Regions, Genetic; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Repressor Proteins; Transfection | 2004 |
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
Topics: Administration, Oral; Aged; Benzamides; Biological Availability; Chromatography, High Pressure Liquid; Half-Life; HL-60 Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metabolic Clearance Rate; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2004 |
Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Flow Cytometry; Humans; Imatinib Mesylate; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; T-Lymphocytes; Time Factors | 2002 |
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Survival Rate; Treatment Outcome | 2003 |
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Division; Cell Survival; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2003 |
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2004 |
[Autogeneic peripheral blood hemopoietic stem cell transplantation for chronic myeloid leukemia with imatinib mesylate-induced negative Philadelphia chromosome].
Topics: Adult; Antigens, CD34; Benzamides; Follow-Up Studies; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous | 2003 |
Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Caspases; Drug Synergism; Enzyme Inhibitors; Genes, abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Peptides, Cyclic; Piperazines; Pyrimidines | 2004 |
Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
Topics: Amino Acid Substitution; Benzamides; Clone Cells; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Mutation, Missense; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein Structure, Tertiary; Pyrimidines; Treatment Outcome | 2003 |
Pulmonary nocardiosis in a patient with CML relapse undergoing imatinib therapy after bone marrow transplantation.
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Benzamides; Bone Marrow Transplantation; Bronchiolitis Obliterans; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Nocardia asteroides; Nocardia Infections; Piperazines; Pneumonia, Bacterial; Pyrimidines; Tomography, X-Ray Computed; Transplantation, Homologous; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Fibrous dysplasia masquerading as extramedullary relapse after bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Benzamides; Bone Marrow Transplantation; Exophthalmos; Female; Fibrous Dysplasia of Bone; Humans; Hyperthyroidism; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Orbital Neoplasms; Piperazines; Pyrimidines | 2003 |
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dendritic Cells; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2004 |
[Synergism of As2S2 and STI 571 in inducing apoptosis of K562 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenicals; Benzamides; Cell Division; Dose-Response Relationship, Drug; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2003 |
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Division; Cyclosporine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunosuppressive Agents; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Piperazines; Pyrimidines; Rhodamines | 2004 |
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Examination; Drug Evaluation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microcirculation; Neovascularization, Pathologic; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Retrospective Studies | 2004 |
A novel t(6;7)(p24;q21) in a chronic myelocytic leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 6; Chromosomes, Human, Pair 7; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction; Translocation, Genetic | 2004 |
Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Pyrimidines; Stem Cell Transplantation | 2004 |
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Topics: Antineoplastic Agents; Benzamides; Case-Control Studies; Follow-Up Studies; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2004 |
Testing the prognostic model of Marin et al in an independent chronic myelogenous leukemia study group.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2004 |
Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
Topics: Aminopeptidases; Anti-Bacterial Agents; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspases; Cell Division; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Protease Inhibitors; Pyrimidines; Serine; Signal Transduction | 2003 |
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Blotting, Northern; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Terminal Repeat Sequences | 2004 |
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Topics: Benzamides; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm Proteins; Oncogene Proteins; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Recurrence | 2004 |
Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
Topics: Adult; Aged; Benzamides; Bone Marrow; Cytogenetic Analysis; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; DNA Primers; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2004 |
Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
[Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report].
Topics: Aged; Antineoplastic Agents; Benzamides; Biopsy; Diagnosis, Differential; Edema; Eyelid Diseases; Eyelids; Female; Humans; Iatrogenic Disease; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2004 |
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Topics: Adult; Aged; Benzamides; Chromatography, High Pressure Liquid; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins v-abl; Piperazines; Protein Structure, Tertiary; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2004 |
Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; DNA-Binding Proteins; Gene Expression; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Promoter Regions, Genetic; Pyrimidines; RNA, Messenger; Sp1 Transcription Factor; Sp3 Transcription Factor; Transcription Factors; Transcriptional Activation; Vascular Endothelial Growth Factor A | 2004 |
Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Differentiation; Cell Line, Tumor; Dendritic Cells; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Immunotherapy; Interleukin-4; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha | 2004 |
Antiproliferative efficacy of the third-generation bisphosphonate, zoledronic acid, combined with other anticancer drugs in leukemic cell lines.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cell Division; Cell Line, Tumor; Cytarabine; Daunorubicin; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Hydroxyurea; Imatinib Mesylate; Imidazoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Pyrimidines; Vincristine; Zoledronic Acid | 2004 |
As targeted therapies evolve, challenges remain.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quinazolines | 2004 |
C-myc expression in cell lines derived from chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Busulfan; Cell Division; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines | 2004 |
Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib.
Topics: Benzamides; Blast Crisis; Bone Marrow; Genes, abl; Humans; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2004 |
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Survival; Cytosine; Dioxolanes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
[Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Bone Marrow Transplantation; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neovascularization, Pathologic; Piperazines; Pyrimidines; Reference Values | 2004 |
Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
Topics: Adult; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger | 2004 |
Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Dendritic Cells; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopolysaccharide Receptors; Male; Middle Aged; Piperazines; Pyrimidines | 2004 |
[Chronic myeloid leukemia and imatinib mesylate therapy].
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Adjunctive chromosomal abnormalities in Philadelphia-negative cells of CML patients treated with Imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2004 |
Novel chromosomal aberrations in Philadelphia negative cells of chronic myelogenous leukemia patients on imatinib: report of three cases.
Topics: Adult; Benzamides; Chromosome Aberrations; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines | 2004 |
Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biological Assay; Caspases; Cell Line, Tumor; Cell Survival; Fluorescence; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luminescent Measurements; Microscopy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate.
Topics: Benzamides; Child, Preschool; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Remission Induction; Translocation, Genetic | 2004 |
Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib.
Topics: Aged; Benzamides; Blast Crisis; Cell Transformation, Neoplastic; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines; Remission Induction | 2004 |
Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; Humans; I-kappa B Proteins; Imatinib Mesylate; In Vitro Techniques; JNK Mitogen-Activated Protein Kinases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitochondria; Mitogen-Activated Protein Kinases; NF-kappa B; Nuclear Proteins; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Piperidines; Pyrazines; Pyrimidines; RNA Polymerase II; src-Family Kinases; STAT3 Transcription Factor; STAT5 Transcription Factor; Trans-Activators | 2004 |
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2004 |
[Imatinib. An anticancer agents indicated in the treatment of chronic myeloid leukemia]].
Topics: Adult; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse-Patient Relations; Piperazines; Pyrimidines | 2004 |
[Clonal Ph-negative hematopoiesis with trisomy 8 in chronic myeloid leukemia during imatinib therapy].
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Trisomy | 2004 |
Chk2 drives late G1/early S phase arrest of clonal myeloid progenitors expressing the p210 BCR-ABL tyrosine kinase in response to STI571.
Topics: Animals; Antineoplastic Agents; Benzamides; cdc25 Phosphatases; Cell Line; Checkpoint Kinase 2; Cyclin-Dependent Kinases; DNA; Fusion Proteins, bcr-abl; G1 Phase; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Progenitor Cells; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrimidines; S Phase | 2004 |
Ascorbic acid restores sensitivity to imatinib via suppression of Nrf2-dependent gene expression in the imatinib-resistant cell line.
Topics: Antineoplastic Agents; Ascorbic Acid; Benzamides; Blast Crisis; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Glutamate-Cysteine Ligase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-E2-Related Factor 2; Oxidative Stress; Piperazines; Protein Transport; Pyrimidines; Regulatory Sequences, Nucleic Acid; RNA, Neoplasm; Trans-Activators | 2004 |
Favorable early response of secondary chronic myeloid leukemia to imatinib.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Piperazines; Pyrimidines | 2004 |
Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetics; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Translocation, Genetic; Treatment Outcome | 2004 |
Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Molecular Chaperones; Phosphorylation; Piperazines; Pyrimidines; T-Lymphocytes, Cytotoxic | 2004 |
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drugs, Investigational; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Therapies, Investigational | 2004 |
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2004 |
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Chromosomes, Human, Pair 15; Disease Progression; Genotype; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Models, Genetic; Multivariate Analysis; Phenotype; Piperazines; Polymorphism, Genetic; Pyrimidines; Time Factors; Treatment Outcome | 2004 |
Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
Topics: Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy | 2004 |
Visual disturbance due to retinal edema as a complication of imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Papilledema; Piperazines; Pyrimidines; Vision Disorders | 2004 |
Clonal chromosomal abnormalities in the Philadelphia chromosome negative cells of chronic myeloid leukemia patients treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Piperazines; Pyrimidines | 2004 |
[Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia].
Topics: Adolescent; Adult; Benzamides; Child; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2004 |
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Topics: Animals; Benzamides; Burkitt Lymphoma; Cell Division; Drug Therapy, Combination; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-hck; Pyrimidines; Pyrroles; src-Family Kinases | 2004 |
Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Central Nervous System Neoplasms; Cytarabine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Recurrence; Remission Induction | 2004 |
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2004 |
Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Fusion Proteins, bcr-abl; Hematopoietic System; Humans; Hypoxanthine Phosphoribosyltransferase; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phenotype; Piperazines; Pyrimidines | 2004 |
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic | 2004 |
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Interleukin-11; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Count; Protein-Tyrosine Kinases; Pyrimidines; Thrombocytopenia; Time Factors | 2004 |
Hypopigmentation from imatinib mesylate (Gleevec).
Topics: Antineoplastic Agents; Benzamides; Black People; Child; Cord Blood Stem Cell Transplantation; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Missouri; Piperazines; Pyrimidines | 2004 |
Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia.
Topics: Apoptosis; Benzamides; Biliverdine; Carbon Monoxide; Cell Line, Transformed; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Imatinib Mesylate; Iron; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Pyrimidines; RNA, Messenger; Transcriptional Activation | 2004 |
Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
Topics: Benzamides; Cytogenetic Analysis; Disease-Free Survival; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Salvage Therapy | 2004 |
Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Female; Gene Rearrangement; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcr; Pyrimidines; Remission Induction | 2004 |
Interstitial pneumonitis during imatinib therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Glucocorticoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Lung Diseases, Interstitial; Piperazines; Prednisolone; Pyrimidines; Tomography, X-Ray Computed | 2004 |
Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
Topics: Alkyl and Aryl Transferases; Androstadienes; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Division; Cells, Cultured; Chromones; Drug Therapy, Combination; Farnesyltranstransferase; Humans; Imatinib Mesylate; Interferon-gamma; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines; Signal Transduction; Stem Cells; Tyrphostins; Wortmannin | 2004 |
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells.
Topics: Antigens, CD19; Antigens, CD34; Antineoplastic Agents; Benzamides; Burkitt Lymphoma; Cell Death; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Liposomes; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured | 2004 |
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Topics: Anemia; Antineoplastic Agents; Benzamides; Erythropoietin; Female; Humans; Imatinib Mesylate; Injections, Subcutaneous; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins; Survival Rate; Treatment Outcome | 2004 |
Imatinib mesylate causes hypopigmentation in the skin.
Topics: Benzamides; Enzyme Inhibitors; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Antibodies; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Carrier Proteins; Caspases; Co-Repressor Proteins; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Inhibitors; fas Receptor; Fusion Proteins, bcr-abl; Gene Expression; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Glycoproteins; Molecular Chaperones; Myeloid Cells; Nuclear Proteins; Piperazines; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Up-Regulation | 2004 |
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Topics: Adult; Aged; Aneuploidy; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 8; Clone Cells; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies | 2004 |
Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Cell Line, Tumor; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Oncogene Proteins v-abl; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, ErbB-2; Trastuzumab | 2004 |
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Topics: Aged; Antineoplastic Agents; Benzamides; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Philadelphia Chromosome; Piperazines; Proportional Hazards Models; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2004 |
Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Topics: Animals; Benzamides; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; Treatment Outcome | 2004 |
Telomere shortening correlates with prognostic score at diagnosis and proceeds rapidly during progression of chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cells, Cultured; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Pyrimidines; T-Lymphocytes; Telomere; Time Factors | 2004 |
Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Chromosome Aberrations; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Neutropenia; Piperazines; Platelet Count; Pyrimidines; Remission Induction; RNA, Messenger | 2004 |
Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.
Topics: Animals; Apoptosis; Benzamides; Biomarkers; Bone Marrow Cells; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cytokines; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mitogen-Activated Protein Kinases; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA, Small Interfering | 2004 |
Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Exons; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Amino Acids; Apoptosis; Benzamides; Cell Cycle; Cell Division; DNA-Binding Proteins; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Models, Molecular; Mutation; Nuclear Proteins; Phosphorylation; Phosphotyrosine; Piperazines; Protein Structure, Tertiary; Pyridones; Pyrimidines; STAT5 Transcription Factor; Trans-Activators | 2004 |
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Topics: Benzamides; DNA Mutational Analysis; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Predictive Value of Tests; Protein Structure, Tertiary; Pyrimidines; RNA, Messenger | 2004 |
Cancer. Gleevec, chapter two: new leukemia drug aims to overcome resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Pyrimidines; Thiazoles | 2004 |
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Topics: Amino Acid Substitution; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Cell Division; Cell Line; Clinical Trials, Phase I as Topic; Dasatinib; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Mutation; Piperazines; Protein Conformation; Pyrimidines; Thiazoles; Transfection | 2004 |
Response of prostate cancer during imatinib therapy in a patient with chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Multiple Primary; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Testis; Testosterone | 2004 |
Unusual extramedullary relapse of CML.
Topics: Antineoplastic Agents; Benzamides; Bone Neoplasms; Genes, abl; Humans; Ilium; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Tomography, X-Ray Computed | 2004 |
Contemporaneous pulmonary sarcoidosis and chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Sarcoidosis, Pulmonary | 2004 |
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Failure | 2004 |
Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Body Height; Body Weight; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Genes, abl; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recurrence; Remission Induction; Transplantation Chimera; Transplantation, Homologous | 2004 |
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetics; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome | 2004 |
Chronic myelogenous leukemia--identifying the hydra's heads.
Topics: Antineoplastic Agents; Benzamides; beta Catenin; Blast Crisis; Cytoskeletal Proteins; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multipotent Stem Cells; Piperazines; Pyrimidines; Trans-Activators | 2004 |
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; beta Catenin; Blast Crisis; Colony-Forming Units Assay; Cytoskeletal Proteins; DNA-Binding Proteins; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Granulocytes; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoid Enhancer-Binding Factor 1; Macrophages; Male; Microscopy, Confocal; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Trans-Activators; Transcription Factors | 2004 |
[Efficacy and safety evaluation of imatinib in the treatment of patients with chronic granulocytic leukemia in accelerated phase].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
Indian patients go to court over cancer drug.
Topics: Antineoplastic Agents; Benzamides; Drug Industry; Drugs, Generic; Humans; Imatinib Mesylate; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Marketing; Piperazines; Pyrimidines | 2004 |
SRCircumventing imatinib resistance.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Conformation; Pyrimidines | 2004 |
Imatinib mesylate in conjunction with allogeneic hematopoietic stem cell transplantation in patients with Philadelphia chromosome positive leukemias: report of 4 cases.
Topics: Adult; Antineoplastic Agents; Benzamides; Cyclosporine; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Transplantation, Homologous; Treatment Outcome | 2004 |
Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Transfection; WT1 Proteins | 2004 |
Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Stem Cell Transplantation; Transplantation, Homologous | 2004 |
Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow; Cytogenetic Analysis; Disease Progression; Fibrosis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2004 |
Re: Lange T et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Leukemia 2004; 89: 49-57.
Topics: Antineoplastic Agents; Benzamides; Cytogenetics; DNA, Complementary; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm | 2004 |
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Benzamides; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sulfides | 2004 |
Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate.
Topics: Adult; Aged; Antigens, Surface; Antineoplastic Agents; Benzamides; Blood Cells; Dendritic Cells; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloid Cells; Neuropilin-1; Piperazines; Prospective Studies; Pyrimidines; Th1 Cells; Th2 Cells; Vascular Endothelial Growth Factor A | 2004 |
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Topics: Adult; Aged; Antigens, CD34; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm, Residual; Neoplastic Stem Cells; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger | 2005 |
Assessment of the response to imatinib in chronic myeloid leukemia patients--comparison between the FISH, multiplex and RT-PCR methods.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Cytogenetic and fluorescence in situ hybridization monitoring in Ph+ Chronic Myeloid Leukemia patients treated with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Chromosome Banding; Cytogenetic Analysis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Metaphase; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Salvage Therapy; Survival Rate | 2004 |
Pretransplant imatinib can improve the outcome of nonmyeloablative stem cell transplantation without increasing the morbidity in Philadelphia chromosome-positive chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morbidity; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2004 |
Detection of trisomy 8 in donor-derived Ph- cells in a patient with Ph+ chronic myeloid leukemia successfully treated with Imatinib (STI571) in relapse after allogeneic transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Transplantation Chimera; Transplantation, Homologous; Trisomy | 2004 |
Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2004 |
Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cranial Irradiation; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2004 |
Megakaryocyte features and bcr/abl translocation in chronic myeloid leukemia following imatinib mesylate (STI571) therapy--a fluorescence in-situ hybridization study.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Megakaryocytes; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2004 |
Subdural hematomas during CML therapy with imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Hematoma, Subdural; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Risk Factors; Thrombocytopenia; Treatment Outcome | 2004 |
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Topics: Aged; Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Dyspnea; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukostasis; Lung; Male; Piperazines; Pyrimidines; Remission Induction; Tomography, X-Ray Computed | 2004 |
Massive bone marrow necrosis in a patient with chronic myelocytic leukemia following imatinib mesylate therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Benzamides; Bone Marrow; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Necrosis; Neoplasm Proteins; Piperazines; Pneumonia; Protein Kinase Inhibitors; Pyrimidines | 2004 |
Discontinuation of imatinib therapy after achieving a molecular response.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Time Factors; Treatment Outcome | 2004 |
Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Cells, Cultured; Drug Resistance; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines; Sequence Analysis, Protein; Stem Cells; Structure-Activity Relationship; Tumor Cells, Cultured | 2004 |
Establishment and characterization of an STI571-resistant human myelogenous leukemia cell line, SR-1.
Topics: Adult; Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Translocation, Genetic | 2004 |
An 85-year-old Japanese woman with Philadelphia chromosome-positive chronic myelogenous leukemia with del (5q) successfully treated by intermittent imatinib therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2004 |
New generation leukaemia drugs are on their way.
Topics: Animals; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Pyrimidines; Thiazoles | 2004 |
[Target-oriented tumor therapy -- proof of the principle].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines | 2004 |
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Topics: Animals; Benzamides; Cell Culture Techniques; Cell Line; Cell Line, Transformed; Cells, Cultured; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Transfection | 2005 |
The Scotland Leukaemia Registry audit of incidence, diagnosis and clinical management of new patients with chronic myeloid leukaemia in 1999 and 2000.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Humans; Hydroxyurea; Imatinib Mesylate; Incidence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Registries; Scotland; Surveys and Questionnaires | 2004 |
Treatment of chronic myeloid leukemia cells with imatinib (STI571) impairs p53 accumulation in response to DNA damage.
Topics: Antineoplastic Agents; Benzamides; Cell Line; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; DNA Damage; Down-Regulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phosphorylation; Piperazines; Protein Kinases; Protein Serine-Threonine Kinases; Pyrimidines; Serine; Tumor Suppressor Protein p53 | 2004 |
Rapid detection of phosphotyrosine proteins by flow cytometric analysis in Bcr-Abl-positive cells.
Topics: Animals; Benzamides; Biomarkers, Tumor; Bone Marrow Cells; Cell Line, Tumor; Cell Separation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Mice; Phosphorylation; Phosphotyrosine; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Establishment and characterization of a new human erythroleukemic cell line, ERY-1.
Topics: Aged; Aged, 80 and over; Antigens, CD; Benzamides; Cell Line, Tumor; Chromosomes, Human, Pair 8; Female; Fusion Proteins, bcr-abl; Gene Duplication; Globins; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Erythroblastic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenotype; Piperazines; Pyrimidines; Receptors, Erythropoietin; Transforming Growth Factor beta; Transforming Growth Factor beta1; Translocation, Genetic; Trisomy | 2004 |
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Carbon Isotopes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Glucose; Glutamates; Humans; Imatinib Mesylate; K562 Cells; Lactates; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Spectroscopy; Nucleotides; Phospholipids; Piperazines; Pyrimidines | 2004 |
Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.
Topics: Benzamides; Cell Line; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxyglucose; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Jurkat Cells; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monosaccharide Transport Proteins; Phloretin; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinases; Pyrimidines; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Tyrosine; Up-Regulation | 2005 |
Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Cytarabine; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Survival Analysis; Treatment Outcome | 2004 |
Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Cost-Benefit Analysis; Cytarabine; Health Care Costs; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Retrospective Studies; Survival Analysis | 2004 |
Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Piperazines; Pyrimidines | 2005 |
[Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Clone Cells; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2004 |
[Emergence and decrement of Ph-negative clone with trisomy 8 in CML during imatinib therapy].
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Trisomy | 2004 |
Severe hepatitis and complete molecular response caused by imatinib mesylate: possible association of its serum concentration with clinical outcomes.
Topics: Adult; Antineoplastic Agents; Benzamides; Biopsy; Female; Hepatitis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Piperazines; Prothrombin Time; Pyrimidines; Remission Induction; Seasons; Time Factors; Treatment Outcome | 2004 |
Reduced dose imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2004 |
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Topics: Acute Disease; Apoptosis; Benzamides; Benzoquinones; Blast Crisis; Cell Line, Tumor; Drug Combinations; Drug Synergism; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Gene Deletion; Gene Expression Regulation; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Panobinostat; Piperazines; Point Mutation; Polyubiquitin; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; Rifabutin | 2005 |
[Imatinib mesylate-induced acute cytolytic hepatitis].
Topics: Acute Disease; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines | 2004 |
CML resistance to tyrosine kinase inhibitors: how is the laboratory to tell?
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2004 |
Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Benzamides; Bone Marrow Transplantation; Community Networks; Cross-Sectional Studies; Databases, Factual; Disease Progression; Female; France; Health Services Accessibility; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins | 2005 |
Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Catalytic Domain; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Treatment Outcome | 2005 |
A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Phosphorylation; Piperazines; Protein Tyrosine Phosphatase, Non-Receptor Type 2; Protein Tyrosine Phosphatases; Pyrimidines; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Transduction, Genetic | 2004 |
Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Comorbidity; Diabetes Mellitus; Female; Glucose; Humans; Imatinib Mesylate; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2004 |
Targeted therapy with imatinib: hits and misses?
Topics: Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Development of c-Kit-expressing small-cell lung cancer in a chronic myeloid leukemia patient during imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Bronchoscopy; Carcinoma, Small Cell; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines | 2004 |
[Imatinib mesylate plus G-CSF therapy for chronic myelogenous leukemia in the blastic crisis].
Topics: Bacterial Infections; Benzamides; Blast Crisis; Drug Therapy, Combination; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Remission Induction | 2004 |
Reciprocal relationship between a Ph-negative clone with trisomy 8 associated with severe myelodysplasia and a Ph-positive clone following imatinib treatment in a patient with accelerated-phase chronic myelogenous leukemia (CML).
Topics: Benzamides; Chromosomes, Human, Pair 8; Clone Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines; Trisomy | 2004 |
Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2005 |
Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prednisolone; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines; Remission Induction | 2004 |
Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation.
Topics: Adolescent; Adult; Aged; Benzamides; Graft Rejection; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stem Cell Transplantation; Time Factors; Treatment Outcome | 2004 |
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2004 |
[Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Remission Induction; Survival Rate | 2004 |
Follicular mucinosis associated with imatinib (STI571).
Topics: Antineoplastic Agents; Benzamides; Drug Eruptions; Facial Dermatoses; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mucinosis, Follicular; Piperazines; Pyrimidines | 2004 |
Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.
Topics: Antineoplastic Agents; Benzamides; Female; Hidradenitis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines | 2005 |
CML cytogenetic relapse after cessation of imatinib therapy.
Topics: Adult; Benzamides; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Every case of essential thrombocythemia should be tested for the Philadelphia chromosome.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Chronic Disease; Diagnosis, Differential; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential | 2005 |
Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pericardial Effusion; Piperazines; Pleural Effusion; Pyrimidines | 2005 |
Selective effect of imatinib on serum IgM in a patient with CML.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Immunoglobulin M; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2004 |
Gene expression profiling of Philadelphia chromosome (Ph)-negative CD34+ hematopoietic stem and progenitor cells of patients with Ph-positive CML in major molecular remission during therapy with imatinib.
Topics: Adult; Aged; Antigens, CD34; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Philadelphia Chromosome; Phylogeny; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2005 |
Clonal aberrations in Philadelphia chromosome negative hematopoiesis in patients with chronic myeloid leukemia treated with imatinib or interferon alpha.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clone Cells; Female; Hematopoiesis; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines | 2005 |
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Survival; DNA-Binding Proteins; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Kinase Kinases; Milk Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligonucleotides, Antisense; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; raf Kinases; ras Proteins; RNA, Small Interfering; STAT5 Transcription Factor; Trans-Activators; Tumor Cells, Cultured | 2005 |
[Experimental research on tyrosine-kinase inhibitor STI571 and P21WAF gene clone to treat chronic myeloid leukemia].
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Cloning, Molecular; Cyclin-Dependent Kinase Inhibitor p21; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transfection | 2004 |
Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Drug Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Models, Economic; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Survival Analysis; Treatment Outcome | 2004 |
Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2005 |
Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma; Drug Eruptions; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Pyrimidines; Skin Neoplasms; Vomiting; Weight Gain | 2005 |
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Mutation; Phosphorylation; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Stem Cell Factor; Survival Rate; Time Factors | 2005 |
Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr/abl + CML.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Clinical Trials as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; WT1 Proteins | 2005 |
Trisomy 8 finding treatment of imatinib mesylate in chronic myeloid leukemia cases.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Trisomy | 2005 |
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Benzene Derivatives; Cell Death; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Molecular Structure; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Proteins | 2005 |
Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Blindness; Central Nervous System; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 6; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Retina; Trisomy | 2005 |
Imatinib does not inhibit neutrophil oxidative burst function in patients with chronic myelogenous leukemia.
Topics: Benzamides; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutrophils; Oxygen Consumption; Piperazines; Pyrimidines; Respiratory Burst | 2005 |
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Prognosis; Pyrimidines; Recurrence; Remission Induction; Risk Factors | 2005 |
Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.
Topics: Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 9; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; T-Lymphocytes | 2005 |
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Line; Cell Line, Tumor; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Biological; Models, Chemical; Mutation; Mycoplasma; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Retroviridae; Time Factors | 2005 |
Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Cells; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Outcome | 2005 |
Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32).
Topics: Adolescent; Base Sequence; Benzamides; Blotting, Western; Cell Line; Cell Survival; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 9; Cyclin-Dependent Kinase Inhibitor p16; DNA-Binding Proteins; DNA, Complementary; Female; Fusion Proteins, bcr-abl; Gene Deletion; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, T-Cell; Microtubules; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Genetic; Molecular Sequence Data; Oncogene Proteins, Fusion; Open Reading Frames; Phenotype; Phosphorylation; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT5 Transcription Factor; Time Factors; Trans-Activators; Translocation, Genetic | 2005 |
Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 11; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; RNA Helicases | 2005 |
The Philadelphia translocation and pre-existing myeloproliferative disorders.
Topics: Antineoplastic Agents; Benzamides; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic | 2005 |
Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation.
Topics: Annexin A5; Apoptosis; Benzamides; Biological Transport; Blotting, Western; Cell Survival; Cytokines; Deoxyglucose; Dose-Response Relationship, Drug; Doxycycline; Enzyme Inhibitors; Flow Cytometry; Fusion Proteins, bcr-abl; Glucose; Glucose Transporter Type 1; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunohistochemistry; Interleukin-3; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monosaccharide Transport Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Temperature; Time Factors | 2005 |
The role of alpha-interferon in chronic myelogenous leukaemia in Imatinib era.
Topics: Aged; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Metastasis; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2004 |
[STI571 used in treating acute myeloid leukemia with Philadelphia chromosome].
Topics: Acute Disease; Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2005 |
Baseline disease risk and response to therapy in chronic myeloid leukemia: necessary predictive tools then and now.
Topics: Benzamides; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Prognosis; Pyrimidines | 2005 |
Oral BMS-354825 rescues Gleevec-resistant CML.
Topics: Administration, Oral; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
Imatinib and regression of type 2 diabetes.
Topics: Aged; Antineoplastic Agents; Benzamides; Diabetes Mellitus, Type 2; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
New agent overcomes resistance to imatinib.
Topics: Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; src-Family Kinases | 2005 |
Diabetes research. Researchers puzzle over possible effect of Gleevec.
Topics: Aged; Antineoplastic Agents; Benzamides; Diabetes Mellitus, Type 2; Female; Humans; Imatinib Mesylate; Insulin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2005 |
Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Biopsy, Needle; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Risk Assessment; Severity of Illness Index; Sweet Syndrome | 2005 |
Treatment with cyclosporin A cream for the cutaneous reactions associated with imatinib therapy.
Topics: Administration, Topical; Antineoplastic Agents; Benzamides; Cyclosporine; Drug Hypersensitivity; Female; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Piperazines; Pyrimidines | 2005 |
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; G1 Phase; Gene Expression Regulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinases; Pyrimidines; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2005 |
Untreated essential thrombocythemia evolving to biphenotypic leukemia, Philadelphia chromosome positive with monosomy 7: response to imatinib and reduced-intensity allogeneic stem cell transplant.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monosomy; Piperazines; Pyrimidines; Thrombocytosis; Transplantation, Homologous | 2005 |
Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.
Topics: 5' Untranslated Regions; Androstadienes; Benzamides; Cell Line; Cell Line, Tumor; Cell Survival; Eukaryotic Initiation Factor-4E; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Granulocytes; Humans; Imatinib Mesylate; Immunoblotting; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Biosynthesis; Protein Kinases; Pyrimidines; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; Signal Transduction; Sirolimus; Stem Cells; Time Factors; TOR Serine-Threonine Kinases; Wortmannin | 2005 |
p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
Topics: Animals; Antigens, CD34; Benzamides; Blast Crisis; Cell Line; Chemokine CXCL12; Chemokines, CXC; Down-Regulation; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; NIH 3T3 Cells; Piperazines; Pluripotent Stem Cells; Pyrimidines; Receptors, CXCR4; Signal Transduction; Transcription, Genetic | 2005 |
Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
Topics: Benzamides; Cell Nucleus; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; HLA Antigens; Humans; Imatinib Mesylate; Immunotherapy, Adoptive; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Signal Transduction; Transfection | 2005 |
Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
Topics: Anterior Chamber; Antineoplastic Agents; Aqueous Humor; Benzamides; Eye Neoplasms; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemic Infiltration; Middle Aged; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction; Uveitis, Anterior | 2005 |
New leukemia drug shows promise against Gleevec resistance.
Topics: Antineoplastic Agents; Benzamides; Benzene Derivatives; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2005 |
Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Piperazines; Pyrimidines | 2005 |
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Signal Transduction | 2005 |
Gene expression analysis fails to identify patients with chronic myeloid leukemia who will achieve cytogenetic response to imatinib.
Topics: Antineoplastic Agents; Benzamides; Chromosomes; Cytogenetic Analysis; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2005 |
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Male; Microarray Analysis; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; RNA, Neoplasm; RNA, Ribosomal | 2005 |
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, Pair 9; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Transformation, Genetic | 2005 |
Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Piperazines; Pyrimidines | 2005 |
Chronic myelogenous leukemia manifested as bilateral proliferative retinopathy.
Topics: Adult; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fluorescein Angiography; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retinal Neoplasms; Retinal Neovascularization | 2005 |
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Topics: Benzamides; Carrier Proteins; Cell Cycle; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p27; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Pyrimidines; Retinoblastoma Protein; S-Phase Kinase-Associated Proteins; Transcription, Genetic | 2005 |
After imatinib: new hopes for chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Technology, Pharmaceutical | 2005 |
Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Topics: Adult; Antineoplastic Agents; Apoptosis; Ascorbic Acid; Benzamides; Comet Assay; DNA Damage; DNA Repair; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Piperazines; Plasmids; Protein-Tyrosine Kinases; Pyrimidines; Statistics, Nonparametric; Vitamin A; Vitamin E | 2005 |
Bone marrow changes in chronic myelogenous leukaemia after long-term treatment with the tyrosine kinase inhibitor STI571: an immunohistochemical study on 75 patients.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Integrin beta3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors | 2005 |
Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Chronic Disease; Cost-Benefit Analysis; Decision Support Techniques; Health Care Costs; Humans; Imatinib Mesylate; Insurance, Health, Reimbursement; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Markov Chains; Monte Carlo Method; Piperazines; Pyrimidines | 2005 |
Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Cell Count; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphatic Diseases; Middle Aged; Piperazines; Pleural Effusion; Pyrimidines; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Dyspnea; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Oxygen Inhalation Therapy; Piperazines; Pyrimidines; Radiography, Thoracic; Treatment Outcome | 2005 |
[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Durability of molecular remission in chronic myeloid leukemia patients treated with imatinib vs allogeneic stem cell transplantation.
Topics: Antineoplastic Agents; Benzamides; Cohort Studies; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Stem Cell Transplantation; Transplantation, Homologous | 2005 |
How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2005 |
Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia.
Topics: Anemia, Aplastic; Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Middle Aged; Pancytopenia; Piperazines; Pyrimidines; Singapore; Time Factors | 2005 |
Two new agents effective in Gleevec-resistant CML.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2004 |
Imatinib in pregnancy.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Hematologic; Pyrimidines | 2005 |
CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
Topics: Adult; Benzamides; Cytogenetic Analysis; Exons; Fusion Proteins, bcr-abl; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin | 2005 |
Cost effectiveness of imatinib compared with interferon-alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Markov Chains; Models, Economic; Piperazines; Pyrimidines | 2005 |
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Translocation, Genetic | 2005 |
Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL--Inhibition of P-glycoprotein function by 17-AAG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Benzoquinones; Cell Proliferation; Drug Synergism; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rifabutin; RNA, Messenger; Tumor Stem Cell Assay | 2005 |
Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Central Nervous System Neoplasms; Clone Cells; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2005 |
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Clone Cells; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Multivariate Analysis; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
Inhibition of c-fms by imatinib: expanding the spectrum of treatment.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction | 2005 |
Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tissue Distribution | 2005 |
The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biological Transport; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tyrphostins | 2005 |
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Dasatinib; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2005 |
Analysis of total phosphotyrosine levels in CD34+ cells from CML patients to predict the response to imatinib mesylate treatment.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Proliferation; Cryopreservation; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Imatinib Mesylate; Immunomagnetic Separation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Phosphotyrosine; Pilot Projects; Piperazines; Pyrimidines; Remission Induction; Reproducibility of Results; Time Factors; Treatment Outcome | 2005 |
CMV-induced hemorrhagic cystitis as a complication of peripheral blood stem cell transplantation: case report.
Topics: Benzamides; Biopsy; Bone Marrow; Cystitis; Cytomegalovirus; Hemoglobins; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Platelet Count; Pneumonia; Pyrimidines; Time Factors; Transplantation Conditioning | 2005 |
[Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Disease Progression; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Young Adult | 2005 |
[Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Clone Cells; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Treatment Outcome | 2005 |
Coexistence of different clonal populations harboring the b3a2 (p210) and e1a2 (p190) BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib.
Topics: Aged; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Rearrangement; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA, Messenger | 2005 |
In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Proliferation; Chromosomes, Human, Pair 9; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; In Vitro Techniques; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Oncogene Proteins; Phosphorylation; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Time Factors; Treatment Outcome | 2005 |
RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.
Topics: Anthracyclines; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Cell Line, Tumor; DNA Transposable Elements; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA, Small Interfering; Trans-Activators | 2005 |
An amino-acid switch in the BCR-ABL kinase domain modifies sensitivity to imatinib mesylate.
Topics: Amino Acid Substitution; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutagenesis, Site-Directed; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity | 2005 |
Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Infant, Newborn; Labor, Induced; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines; Recurrence; Remission Induction; Treatment Outcome; Withholding Treatment | 2005 |
Drug resistance in cancer: principles of emergence and prevention.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Pyrimidines | 2005 |
Dermatological toxicity of imatinib mesylate.
Topics: Adult; Benzamides; Erythema; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Blood Component Removal; Cell Survival; Cells, Cultured; Chromosome Banding; Colony-Forming Units Assay; Cytogenetic Analysis; Feasibility Studies; Filgrastim; Flow Cytometry; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Piperazines; Pyrimidines; Recombinant Proteins; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2005 |
Cancer biology: summing up cancer stem cells.
Topics: Benzamides; Cell Differentiation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Point Mutation; Pyrimidines; Recurrence; Stem Cells; Time Factors; Treatment Outcome | 2005 |
Dynamics of chronic myeloid leukaemia.
Topics: Benzamides; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Point Mutation; Pyrimidines; Recurrence; Retrospective Studies; Stem Cells; Time Factors; Treatment Outcome | 2005 |
Isolated central nervous system blast crisis in chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Combined Modality Therapy; Cranial Irradiation; Cytarabine; Humans; Hydrocortisone; Imatinib Mesylate; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Meninges; Methotrexate; Neoplasm Invasiveness; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction | 2004 |
Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Treatment Outcome | 2005 |
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow Transplantation; Disease Progression; Europe; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Risk Factors; Societies, Scientific; Survival Rate; Transplantation Conditioning; Treatment Outcome | 2005 |
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Models, Molecular; Phosphorylation; Piperazines; Pyrimidines; Survival Analysis; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Bone Marrow Transplantation; Cell Survival; Cell Transplantation; Disease Models, Animal; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Knockout; Piperazines; Pyrimidines; Survival Analysis | 2005 |
Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Early Diagnosis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2005 |
Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines | 2005 |
Isolated central nervous system relapse in patients with chronic myeloid leukemia on imatinib mesylate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Central Nervous System Neoplasms; Chronic Disease; Fatal Outcome; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Piperazines; Pyrimidines; Recurrence; Remission Induction | 2005 |
Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Busulfan; Fatal Outcome; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mucormycosis; Piperazines; Pyrimidines | 2005 |
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Primary Myelofibrosis; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Treatment Outcome | 2005 |
Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Topics: Antineoplastic Agents; Ascites; Benzamides; Blast Crisis; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2005 |
Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.
Topics: Alkaloids; Apoptosis; Benzamides; Benzylisoquinolines; Bone Marrow Cells; Caspase 3; Caspases; Dose-Response Relationship, Drug; Down-Regulation; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
[Molecular signal transduction inhibitor for treatment of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Signal Transduction; Stem Cell Transplantation | 2005 |
[Nonmyleoablative allogeneic stem cell transplantation combined with imatinib in treatment of chronic myeloid leukemia: a clinical study].
Topics: Adult; Benzamides; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines | 2005 |
hOCT 1 and resistance to imatinib.
Topics: ATP-Binding Cassette Transporters; Benzamides; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Octamer Transcription Factor-1; Piperazines; Pyrimidines; Transcription Factors | 2005 |
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.
Topics: Base Sequence; Benzamides; DNA Primers; Drug Monitoring; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Pyrimidines; Retrospective Studies; RNA, Messenger | 2005 |
Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Case-Control Studies; Cell Cycle; Cell Death; Cell Differentiation; Cell Line, Tumor; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myeloid Progenitor Cells; Piperazines; Pyrimidines | 2005 |
Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Dacarbazine; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Temozolomide | 2005 |
e6a2 BCR/ABL1 fusion with cryptic der(9)t(9;22) deletions in a patient with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; DNA Primers; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Sequence Deletion | 2005 |
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Topics: Antineoplastic Agents; Benzamides; Computational Biology; Computer Simulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Threonine | 2005 |
Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diphosphonates; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Pregnancy outcome of two patients treated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Infant, Newborn; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Remission Induction | 2005 |
Chronic myeloid leukemia CD34+ cells have elevated levels of phosphatidylinositol 3,4,5 trisphosphate (PtdIns(3,4,5)P3) and lack a PtdIns(3,4,5)P3 response to cytokines and chemotactic factors; effects reversed by imatinib.
Topics: Antigens, CD34; Benzamides; Chemotactic Factors; Cytokines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Phosphatidylinositol Phosphates; Piperazines; Pyrimidines | 2005 |
E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
Topics: Aged; Benzamides; Exons; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2005 |
Ph-Chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis.
Topics: Adult; Benzamides; Bone Marrow; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis, Systemic; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2005 |
Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
Topics: Benzamides; Cell Proliferation; Cells, Cultured; Colony-Forming Units Assay; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Predictive Value of Tests; Pyrimidines; Recovery of Function; Remission Induction; Transplantation, Homologous | 2006 |
[Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Topics: Adolescent; Adult; Aged; Benzamides; Biopsy; Bone Marrow; Cytogenetic Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2005 |
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2005 |
Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib.
Topics: Aged; Antibodies, Antinuclear; Antineoplastic Agents; Benzamides; Eosinophilia; Fasciitis; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mycosis Fungoides; Piperazines; Pseudolymphoma; Pyrimidines | 2005 |
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutagenesis; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Messenger; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2005 |
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Arginine; Benzamides; Blood Donors; Case-Control Studies; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines | 2005 |
Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Case-Control Studies; CD4-Positive T-Lymphocytes; Cell Culture Techniques; Cell Proliferation; Cytokines; Enterotoxins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tyrosine; ZAP-70 Protein-Tyrosine Kinase | 2005 |
Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
Topics: Antineoplastic Agents; Benzamides; Core Binding Factor Alpha 2 Subunit; DNA-Binding Proteins; Drug Resistance, Neoplasm; Genes, abl; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Proto-Oncogene Proteins; Pyrimidines; Transcription Factors | 2005 |
Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
Topics: Adult; Aged; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Remission Induction | 2005 |
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, MDR; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors | 2005 |
Differential tyrosine phosphorylation of leukemic cells during apoptosis as a result of treatment with imatinib mesylate.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Electrophoresis, Gel, Two-Dimensional; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proteome; Pyrimidines; Transcription, Genetic; Tyrosine | 2005 |
Does early stem-cell transplantation have a role in chronic myeloid leukaemia? Against the proposal.
Topics: Benzamides; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Survival Rate | 2005 |
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Proliferation; Diphosphonates; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Genes, abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Evaluation of CML model cell lines and imatinib mesylate response: determinants of signaling profiles.
Topics: Animals; Benzamides; Cell Line, Tumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2005 |
Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; CpG Islands; Disease Progression; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; DNA Methyltransferase 3B; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Long Interspersed Nucleotide Elements; Male; Middle Aged; Multivariate Analysis; Open Reading Frames; Piperazines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrimidines; Regression Analysis; Retroelements; Transcription, Genetic; Treatment Outcome | 2005 |
CML clonal evolution with resistance to single agent imatinib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Transformation, Neoplastic; Clone Cells; Cytarabine; Drug Resistance, Neoplasm; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Trisomy | 2005 |
Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Interferons; Leukemia, Hairy Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm, Residual; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Rituximab; Treatment Outcome | 2006 |
Resistance to pretransplant imatinib therapy may adversely affect the outcome of allogeneic stem cell transplantation in CML.
Topics: Adult; Aged; Benzamides; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Transplantation, Homologous; Treatment Outcome | 2005 |
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cytogenetic Analysis; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Transplantation, Homologous | 2006 |
Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Combined Modality Therapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Neoplasm Recurrence, Local; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2005 |
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Dasatinib; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genetic Vectors; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Immunoblotting; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Phosphotyrosine; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases; Stem Cells; Thiazoles; Time Factors | 2005 |
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Phosphorylation; Piperazines; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; STAT5 Transcription Factor; Stem Cells | 2005 |
Imatinib synergizes with donor lymphocyte infusions to achieve rapid molecular remission of CML relapsing after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Benzamides; Drug Synergism; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Transfusion; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Transplantation, Homologous | 2005 |
Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Bryostatins; Drug Antagonism; G1 Phase; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macrolides; Piperazines; Protein Kinase C; Pyrimidines; Resting Phase, Cell Cycle | 2005 |
Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Base Sequence; Benzamides; Chromosome Breakage; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Sequence Data; Piperazines; Pyrimidines | 2005 |
Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.
Topics: Adult; Aged; Benzamides; Clone Cells; DNA Mutational Analysis; DNA Primers; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Methods; Middle Aged; Piperazines; Point Mutation; Polymerase Chain Reaction; Pyrimidines | 2005 |
Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pityriasis Rosea; Pyrimidines | 2005 |
Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects.
Topics: Apoptosis; Benzamides; Gene Expression; Genes, abl; Genes, p53; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Suppressor Protein p53 | 2005 |
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Bone Marrow Cells; Cell Growth Processes; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leupeptins; MAP Kinase Signaling System; Membrane Proteins; Piperazines; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Transfection | 2005 |
Complete cytogenietic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Follow-Up Studies; Humans; Imatinib Mesylate; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2005 |
The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzamides; Blood Component Removal; Child; Female; Graft vs Host Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Treatment Outcome | 2005 |
Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
Topics: Adult; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Therapy; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Homologous; Treatment Outcome; United Kingdom | 2005 |
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Fatty Acids, Unsaturated; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2006 |
Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Microtubule-Associated Proteins; Neoplasm Proteins; Piperazines; Pyrimidines; Survivin | 2006 |
Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2003 |
Update on the use of imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Is imatinib a cost-effective treatment for newly diagnosed chronic myeloid leukemia patients?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quality-Adjusted Life Years; Retrospective Studies; Survival Analysis | 2005 |
Reduction of glycosylated hemoglobin with stable insulin levels in a diabetic patient with chronic myeloid leukemia responsive to imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hydroxyurea; Imatinib Mesylate; Insulin; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
Mobilization of autologous hematopoietic progenitors and subsequent transplantation is a safe and feasible procedure in chronic phase chronic myelogenous leukemia patients with cytogenetic resistance to imatinib.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; Interferons; Lenograstim; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Autologous | 2005 |
Binding of alpha-1-acid glycoprotein to imatinib following increased dosage of drug.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orosomucoid; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines | 2005 |
Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
Topics: Anti-Bacterial Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukopenia; Meningitis, Listeria; Middle Aged; Monocytes; Piperazines; Pyrimidines | 2005 |
Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
Topics: Adult; Benzamides; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Variation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2006 |
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Binding Sites; Blotting, Western; Bone Marrow Cells; Cell Proliferation; Cell Survival; Cells, Cultured; Combined Modality Therapy; DNA; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; NF-kappa B; Piperazines; Pyridines; Pyrimidines; Tumor Stem Cell Assay | 2006 |
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Benzamides; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genetic Therapy; Genetic Vectors; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; K562 Cells; Lentivirus; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Phosphoproteins; Piperazines; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatases; Pyrimidines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor | 2006 |
Trends in the management of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation | 2005 |
Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Benzamides; CD4-Positive T-Lymphocytes; Child; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Immunity, Cellular; Immunization; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; T-Lymphocytes | 2006 |
D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients.
Topics: Benzamides; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Prognosis; Pyrimidines | 2005 |
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Cell Line, Transformed; Chromosomal Proteins, Non-Histone; Colforsin; DNA-Binding Proteins; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Histone Chaperones; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Neoplasm Transplantation; Phosphoprotein Phosphatases; Piperazines; Protein Phosphatase 2; Pyrimidines; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
Topics: Adult; Antifungal Agents; Antineoplastic Agents; Aspergillosis; Benzamides; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Eruptions; Drug Interactions; Enzyme Inhibitors; Exanthema; Humans; Imatinib Mesylate; Irritants; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Fungal; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Triazoles; Voriconazole | 2005 |
Pregnancy on imatinib: fatal outcome with meningocele.
Topics: Adult; Antineoplastic Agents; Benzamides; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Meningocele; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Treatment Outcome | 2006 |
Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib.
Topics: Adult; Aged; Benzamides; Cohort Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasms, Second Primary; Piperazines; Product Surveillance, Postmarketing; Pyrimidines; Time | 2006 |
Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase.
Topics: Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Female; Humans; Hypercalcemia; Hyperplasia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Parathyroid Hormone-Related Protein; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Liver Diseases; Middle Aged; Piperazines; Prednisolone; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Management of early stage disease.
Topics: Antineoplastic Agents; Benzamides; Disease-Free Survival; Gene Expression Profiling; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Staging; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Time Factors; Treatment Outcome | 2005 |
Loss of response to imatinib: mechanisms and management.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cell Transplantation; Thiazoles; Transplantation, Homologous; Treatment Failure | 2005 |
Pathobiology of lymphoid and myeloid blast crisis and management issues.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of imatinib mesylate: implication for vaccination regimens.
Topics: Antigens, CD; Benzamides; Cell Survival; Cells, Cultured; Dendritic Cells; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunization; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Vaccination | 2006 |
Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients.
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Nucleic Acid Amplification Techniques; Piperazines; Pyrimidines; RNA, Neoplasm | 2005 |
Chronic myelogenous leukemia.
Topics: Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Cell Transformation, Neoplastic; Chromosome Breakage; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytarabine; Cytogenetic Analysis; Disease Progression; Drug Interactions; Gene Fusion; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interferons; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; Recombinant Fusion Proteins; Remission Induction; Secondary Prevention; Translocation, Genetic; Transplantation, Homologous | 2005 |
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
Topics: Adult; Aged; Aged, 80 and over; Alleles; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phenotype; Phosphotransferases; Piperazines; Polymerase Chain Reaction; Protein Structure, Tertiary; Pyrimidines; Retrospective Studies; RNA, Messenger; Sensitivity and Specificity | 2005 |
Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment.
Topics: Antineoplastic Agents; Benzamides; Fatal Outcome; Hepatitis B virus; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Time Factors; Virus Activation | 2006 |
Chronic myeloid leukemia after treatment of lymphoid malignancies: response to imatinib mesylate and favorable outcomes in three patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Time Factors; Transplantation, Homologous | 2006 |
Identification of differentially expressed proteins in imatinib mesylate-resistant chronic myelogenous cells.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mass Spectrometry; Piperazines; Proteomics; Pyrimidines; Recombinant Fusion Proteins | 2005 |
Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines | 2005 |
A simulation study using validated prognostic factors to assess expected long-term survival.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Computer Simulation; Cross-Over Studies; Female; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Probability; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Risk Factors; Survival Analysis; Time Factors | 2005 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Radiography; Sarcoma, Myeloid | 2006 |
Imatinib and hyperlipidemia.
Topics: Benzamides; Humans; Hypereosinophilic Syndrome; Hyperlipidemias; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
[Disease transformation in imatinib mesylate treated Philadelphia chromosome-positive chronic myelogenous leukemia patients achieved cytogenetic remissions].
Topics: Adult; Antineoplastic Agents; Benzamides; Disease Progression; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2005 |
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Topics: Adult; Aged; Alleles; Base Sequence; Benzamides; Biomarkers, Tumor; Diarrhea; DNA Mutational Analysis; Edema; Exanthema; Female; Gastrointestinal Stromal Tumors; Gene Frequency; Genotype; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Natriuretic Peptide, Brain; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2006 |
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Topics: Antibiotics, Antineoplastic; Benzamides; Blotting, Western; DNA Damage; DNA Repair; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2006 |
BCRABL transcript detection by quantitative real-time PCR : are correlated results possible from homebrew assays?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Transplantation; Genes, abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Middle Aged; Molecular Diagnostic Techniques; Piperazines; Polymerase Chain Reaction; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity | 2005 |
The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cytotoxicity, Immunologic; Fusion Proteins, bcr-abl; G(M1) Ganglioside; Genes, abl; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; In Vitro Techniques; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Microdomains; NK Cell Lectin-Like Receptor Subfamily K; Piperazines; Pyrimidines; Receptors, Immunologic; Receptors, Natural Killer Cell; Transfection | 2006 |
[A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Topics: Antigens, CD34; Benzamides; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPARalpha/gamma ligand TZD18.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Ligands; NF-kappa B; Phenyl Ethers; Piperazines; PPAR alpha; PPAR gamma; Pyrimidines; Thiazolidinediones | 2006 |
[Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Base Sequence; Benzamides; DNA Mutational Analysis; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2005 |
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cardiomyopathies; Eosinophil Cationic Protein; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Serine Endopeptidases; Tryptases; World Health Organization | 2006 |
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line; Cell Line, Transformed; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
[Hematological side effects of tyrosine kinase inhibition using imatinib].
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Gastrointestinal Diseases; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.
Topics: Aurora Kinases; Benzamides; Catalytic Domain; Crystallography; Dasatinib; Drug Resistance, Neoplasm; Escherichia coli; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Thiazoles | 2006 |
Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Culture Media, Serum-Free; Drug Combinations; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Granulocyte Colony-Stimulating Factor; RNA, Messenger; Tumor Cells, Cultured | 2006 |
Looking beyond imatinib: next line of targeted drugs for CML shows promise.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts.
Topics: Antigens, CD; Antigens, CD34; Antineoplastic Agents; Benzamides; Bone Marrow Purging; Cell Separation; Cell Survival; Cyclophosphamide; Flow Cytometry; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Cells, Circulating; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Autologous | 2006 |
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pilot Projects; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vincristine | 2006 |
[Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
Topics: Adult; Antineoplastic Agents; Benzamides; Colonic Diseases; Female; Gastrointestinal Hemorrhage; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2005 |
[Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Male; Middle Aged; Piperazines; Psoriasis; Pyrimidines; Th1 Cells | 2005 |
[Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib].
Topics: Antineoplastic Agents; Basophils; Benzamides; Erythema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Leukopenia; Middle Aged; Piperazines; Pyrimidines; Severity of Illness Index | 2005 |
Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Drug Interactions; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tumor Cells, Cultured; Valproic Acid | 2006 |
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Topics: Abortion, Spontaneous; Adult; Antineoplastic Agents; Benzamides; Congenital Abnormalities; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Records; Metaphase; Philadelphia Chromosome; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Retrospective Studies; Teratogens | 2006 |
Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis.
Topics: Aged; Antineoplastic Agents; Benzamides; Comorbidity; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung; Lung Diseases, Interstitial; Male; Piperazines; Pulmonary Fibrosis; Pyrimidines; Tomography, X-Ray Computed | 2008 |
Prognostic variables in patients with chronic myeloid leukemia treated with imatinib.
Topics: Benzamides; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Prognosis; Pyrimidines; Secondary Prevention | 2006 |
The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Phosphotransferases; Piperazines; Predictive Value of Tests; Pyrimidines; RNA, Neoplasm | 2006 |
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome; World Health Organization | 2006 |
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sensitivity and Specificity; Sequence Analysis, DNA; Transcription, Genetic | 2006 |
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Dosage; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; RNA, Neoplasm; Thiazoles | 2006 |
Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macular Edema; Male; Middle Aged; Phacoemulsification; Piperazines; Pyrimidines; Tomography, Optical Coherence | 2005 |
Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzamides; Cohort Studies; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transcription, Genetic; Treatment Outcome | 2005 |
Gene expression changes associated with progression and response in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Disease Progression; DNA-Binding Proteins; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Imatinib Mesylate; Kruppel-Like Transcription Factors; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peptide Elongation Factor 1; Piperazines; Pyrimidines; Recurrence; Transcription Factors | 2006 |
Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.
Topics: Adolescent; Adult; Aged; Benzamides; Bone Marrow; Chromosome Aberrations; Cloning, Molecular; Cytogenetic Analysis; Disease Progression; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Predictive Value of Tests; Pyrimidines; Reproducibility of Results; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Treatment Outcome | 2006 |
Pulmonary arterial hypertension after childhood cancer therapy and bone marrow transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Female; Humans; Hyperplasia; Hypertension, Pulmonary; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Vasodilator Agents | 2006 |
Imatinib mesylate as a cause of acute liver failure.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Liver Transplantation; Middle Aged; Necrosis; Piperazines; Pyrimidines | 2006 |
Monolateral renal infarction and erythromelalgia in a case of chronic myelogenous leukemia.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Erythromelalgia; Etoposide; Female; Humans; Hydroxyurea; Imatinib Mesylate; Infarction; Interferon-alpha; Kidney; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Radiography | 2006 |
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diagnosis, Differential; Disease Progression; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Irinotecan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Piperazines; Pyrimidines; Remission Induction; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Identification of transcriptional targets associated with the expression of p210 Bcr-Abl.
Topics: Animals; Benzamides; Cell Line; Cell Proliferation; Cells, Cultured; Chromones; Class I Phosphatidylinositol 3-Kinases; Clone Cells; Fusion Proteins, bcr-abl; Gene Expression Profiling; Glycolysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Morpholines; Oligonucleotide Array Sequence Analysis; Phenotype; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Transcription, Genetic | 2006 |
A common phosphotyrosine signature for the Bcr-Abl kinase.
Topics: Benzamides; Biomarkers, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Phosphotyrosine; Piperazines; Protein Kinase Inhibitors; Proteomics; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction | 2006 |
hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzamides; Carrier Proteins; Cell Cycle Proteins; Disease Progression; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-myc; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA-Binding Proteins; Sensitivity and Specificity; Tankyrases; Telomerase; Telomeric Repeat Binding Protein 1; Telomeric Repeat Binding Protein 2; Transcription, Genetic; Tumor Suppressor Proteins | 2006 |
Detection of BCR-ABL mutations and resistance to imatinib mesylate.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Mutation, Missense; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2006 |
Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
Topics: Adult; Apoptosis Regulatory Proteins; Benzamides; Bone Marrow Cells; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Beyond Gleevec--the next generation in CML.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2006 |
Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Combined Modality Therapy; Dose-Response Relationship, Drug; Fatal Outcome; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Risk Factors; Transplantation, Autologous; Treatment Outcome | 2006 |
[Disappearance of a Philadelphia chromosome-positive clone and appearance of a -negative clone following treatment with imatinib mesylate in acute myelomonocytic leukemia].
Topics: Benzamides; Clone Cells; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Acute; Middle Aged; Piperazines; Pyrimidines | 2006 |
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Panobinostat; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2006 |
Multiple joint effusions associated with high-dose imatinib therapy in a patient with chronic myelogenous leukaemia.
Topics: Aged; Benzamides; Dose-Response Relationship, Drug; Edema; Female; Follow-Up Studies; Hip Joint; Humans; Imatinib Mesylate; Joint Diseases; Knee Joint; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Piperazines; Pyrimidines; Treatment Outcome | 2006 |
Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase Inhibitors; Caspases; Celecoxib; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Hydroxyurea; Imatinib Mesylate; Interleukin-1; Intracellular Signaling Peptides and Proteins; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Pyrazoles; Pyrimidines; S Phase; Sulfonamides | 2006 |
Exploiting oxidative damage to overcome resistance.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymorphism, Single Nucleotide; Pyrimidines; Reactive Oxygen Species | 2006 |
BCR-ABL activity and its response to drugs can be determined in CD34+ CML stem cells by CrkL phosphorylation status using flow cytometry.
Topics: Adaptor Proteins, Signal Transducing; Antigens, CD34; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; HL-60 Cells; Humans; Imatinib Mesylate; In Vitro Techniques; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Phosphorylation; Piperazines; Pyrimidines; Sensitivity and Specificity; Tumor Cells, Cultured | 2006 |
Addition of sargramostim (GM-CSF) to imatinib results in major cytogenetic response in a patient with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Female; Fusion Proteins, bcr-abl; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Recombinant Proteins | 2006 |
BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Benzamides; Female; Gene Expression Regulation, Neoplastic; Genes, abl; Histocompatibility Antigens Class I; Humans; Imatinib Mesylate; K562 Cells; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; NK Cell Lectin-Like Receptor Subfamily K; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinases; Pyrimidines; Receptors, Immunologic; Receptors, Natural Killer Cell; RNA Interference; RNA, Messenger; RNA, Neoplasm; Signal Transduction; T-Lymphocytes; TOR Serine-Threonine Kinases | 2006 |
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Benzamides; Carbon Isotopes; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Octamer Transcription Factor-1; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2006 |
Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Interstitial; Male; Middle Aged; Piperazines; Pyrimidines; Risk Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.
Topics: Adolescent; Adult; Aged; Benzamides; Cytogenetic Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Profiling; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment | 2006 |
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Topics: Adult; Benzamides; Blast Crisis; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Graft Survival; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2006 |
Genzyme launches diagnostic to monitor Gleevec resistance.
Topics: Antineoplastic Agents; Benzamides; Drug Industry; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines | 2006 |
Despite inhibition of hematopoietic progenitor cell growth in vitro, the tyrosine kinase inhibitor imatinib does not impair engraftment of human CD133+ cells into NOD/SCIDbeta2mNull mice.
Topics: AC133 Antigen; Animals; Antigens, CD; Apoptosis; Benzamides; Blood Cells; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Fetal Blood; Fibronectins; Glycoproteins; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Integrin alpha4beta1; Integrin alpha5beta1; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred NOD; Mice, SCID; Peptides; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, CXCR4; Receptors, Platelet-Derived Growth Factor; Xenograft Model Antitumor Assays | 2006 |
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
Topics: Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines | 2006 |
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Topics: Alleles; Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Bone Marrow Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Genes, abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Interleukin-7; Leukemia, Lymphoid; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Transplantation; Piperazines; Pyrimidines; Tumor Cells, Cultured; Tumor Suppressor Protein p14ARF | 2006 |
[Study on the mechanisms of imatinib-resistance of cancer stem-like cells in K562/Vp16 cell line].
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Drug Resistance, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2005 |
A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Living Donors; Lymphocyte Transfusion; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Salvage Therapy; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2006 |
Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Genetic Testing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Point Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyrimidines; Sensitivity and Specificity; Sequence Analysis, DNA; Time Factors | 2006 |
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate.
Topics: Antigens, CD34; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Cytarabine; Disease Progression; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Splenomegaly; Survival Analysis; Treatment Failure; Treatment Outcome | 2006 |
Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon.
Topics: Adenocarcinoma; Benzamides; Cytogenetic Analysis; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Rectal Neoplasms; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Transcription, Genetic; Treatment Outcome | 2006 |
A Src-like inactive conformation in the abl tyrosine kinase domain.
Topics: Amino Acid Motifs; Antineoplastic Agents; Benzamides; Binding Sites; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Protein Binding; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Pyrimidines; src-Family Kinases | 2006 |
Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).
Topics: Adolescent; Adult; Aged; Benzamides; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; France; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Predictive Value of Tests; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Imatinib-induced erythrodermia in a patient with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Dermatitis, Exfoliative; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines | 2006 |
The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines.
Topics: Adolescent; Apoptosis; Benzamides; Blast Crisis; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Imatinib Mesylate; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Piperazines; Protease Inhibitors; Proteasome Inhibitors; Pyrimidines; Saquinavir | 2006 |
Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.
Topics: Animals; Benzamides; Blast Crisis; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocytes; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
Topics: Aged; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Pyrimidines; Remission Induction | 2006 |
Successful treatment of chronic myeloid leukemia with imatinib mesylate in a patient with chronic renal failure on hemodialysis.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Renal Dialysis; Renal Insufficiency; Treatment Outcome | 2006 |
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Chronic Disease; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Fusion Proteins, bcr-abl; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes; Piperazines; Pyrimidines; Quinazolines; Thrombocythemia, Essential; Time Factors; Translocation, Genetic; Treatment Outcome | 2006 |
Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Topics: Benzamides; Biomarkers; Bone and Bones; Bone Remodeling; Calcitriol; Calcium; Female; Gastrointestinal Stromal Tumors; Humans; Hypophosphatemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Phosphates; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Vitamin D | 2006 |
Imatinib mesylate causes palmoplantar hyperkeratosis and nail dystrophy in three patients with chronic myeloid leukaemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Eruptions; Female; Humans; Imatinib Mesylate; Keratoderma, Palmoplantar; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nail Diseases; Piperazines; Pyrimidines | 2006 |
Imatinib-associated neutropenia may not be overcome by filgrastim treatment in patients with blastic phase of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neutropenia; Piperazines; Pyrimidines; Recombinant Proteins | 2006 |
Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Brain Neoplasms; Fatal Outcome; Female; Hematopoiesis, Extramedullary; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Skin Neoplasms | 2006 |
[Treatment strategies for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Benzamides; Genes, abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2005 |
Hypoxia suppresses BCR/Abl and selects imatinib-insensitive progenitors within clonal CML populations.
Topics: Antineoplastic Agents; Benzamides; Cell Hypoxia; Clone Cells; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxygen; Piperazines; Pyrimidines | 2006 |
Clone wars in CML.
Topics: Alleles; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasm, Residual; Piperazines; Pyrimidines | 2006 |
Kinase inhibitors in chronic myelogenous leukemia.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Dasatinib; Disease Progression; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinolines; Signal Transduction; Thiazoles | 2006 |
Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
Topics: Antineoplastic Agents; Benzamides; Centrosome; Disease Progression; DNA Repair; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotide Array Sequence Analysis; Oxidative Stress; Piperazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
[Study on mismatch repair genes of chronic myeloid leukemia].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; DNA Mismatch Repair; Female; Fusion Proteins, bcr-abl; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience].
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2006 |
Circumventing resistance to kinase-inhibitor therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
[Further improving the standard of treatment for chronic myeloid leukemia].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Azacitidine; Benzamides; Cancer Vaccines; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Tumor Necrosis Factor-alpha | 2006 |
Tumour lysis syndrome with acute renal failure during imatinib therapy.
Topics: Acute Kidney Injury; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Lysis Syndrome | 2007 |
[Chronic neutrophilic leukemia: a long-term analysis of seven cases and review of the literature].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diagnosis, Differential; Humans; Hungary; Hydroxyurea; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Neutrophilic, Chronic; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Splenomegaly; Treatment Outcome | 2006 |
Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantation.
Topics: Adult; Benzamides; Bronchiolitis Obliterans; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Treatment Failure; Treatment Outcome | 2006 |
Corticosteroids can reverse severe imatinib-induced hepatotoxicity.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Benzamides; Chemical and Drug Induced Liver Injury; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Liver Diseases; Methylprednisolone; Piperazines; Prednisone; Pyrimidines | 2006 |
[Ph+ acute lymphoblastic leukemia combined with lung and brain invasive aspergillosis].
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Benzamides; Brain Diseases; Humans; Imatinib Mesylate; Itraconazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases, Fungal; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2006 |
Ongoing challenges of a global international patient assistance program.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Developing Countries; Gastrointestinal Stromal Tumors; Global Health; Health Services Accessibility; Humans; Imatinib Mesylate; International Cooperation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Program Development; Program Evaluation; Public Health; Pyrimidines; Thailand | 2006 |
Effect of imatinib mesylate combined with granulocyte colony-stimulating factor on leukaemic blast cells derived from advanced-stage chronic myelogenous leukaemia patients.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Proliferation; Drug Antagonism; Drug Evaluation, Preclinical; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Leukemic; Genes, abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Piperazines; Pyrimidines | 2006 |
Fluorescence in situ hybridization analysis of minimal residual disease and the relevance of the der(9) deletion in imatinib-treated patients with chronic myeloid leukemia.
Topics: Benzamides; Chromosome Deletion; Chromosomes, Human, Pair 9; Follow-Up Studies; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Piperazines; Pyrimidines | 2006 |
Janus kinase 2: a critical target in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; NF-kappa B; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrimidines; RNA, Small Interfering; Signal Transduction; Transfection; Tyrphostins | 2006 |
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Topics: Adamantane; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Humans; Hydroquinones; Imatinib Mesylate; Inhibitory Concentration 50; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Phosphorylation; Piperazines; Pyrimidines; Tyrosine | 2006 |
Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient.
Topics: Aged; Benzamides; Cytogenetic Analysis; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Multiple Primary; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Gene Expression; Glucuronidase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Diagnostic Techniques; Neoplasm, Residual; Piperazines; Polymerase Chain Reaction; Pyrimidines; Reference Standards; Sample Size | 2006 |
Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells.
Topics: Antineoplastic Agents; Benzamides; Dendritic Cells; Flow Cytometry; Humans; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2006 |
Successful outcome of pregnancy in a patient with chronic myelogenous leukemia exposed to imatinib during the first trimester.
Topics: Adult; Benzamides; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Pyrimidines; Treatment Outcome | 2006 |
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Cytogenetics; Drug Administration Schedule; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Binding; Pyrimidines; Retrospective Studies; Time Factors | 2006 |
Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
Topics: Administration, Oral; Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Body Weight; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Intestinal Absorption; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Orosomucoid; Piperazines; Pyrimidines; Sex Factors | 2006 |
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Basophils; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Multivariate Analysis; Piperazines; Point Mutation; Prognosis; Pyrimidines; Survival Rate | 2006 |
Gene expression signatures associated with the resistance to imatinib.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; RNA, Messenger | 2006 |
Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isotope Labeling; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Oncogene Protein v-cbl; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoproteins; Phosphoric Monoester Hydrolases; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrimidines; Tyrosine | 2006 |
Imatinib-induced cytogenetic remission in chronic eosinophilic leukaemia.
Topics: Benzamides; Chronic Disease; Cytogenetic Analysis; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2006 |
Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Agents; Benzamides; Chronic Disease; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Graft vs Host Disease; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Retrospective Studies; Stem Cell Transplantation; Time Factors; Transplantation, Homologous | 2006 |
Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2006 |
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Topics: Amino Acid Sequence; Animals; Benzamides; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Disease Models, Animal; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Mutation; Myeloid Progenitor Cells; Phosphotransferases; Phosphotyrosine; Piperazines; Protein Structure, Tertiary; Pyrimidines; Signal Transduction; Substrate Specificity | 2006 |
Eph tumour suppression: the dark side of Gleevec.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Breast Neoplasms; Cell Movement; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mammary Neoplasms, Experimental; Mice; Models, Biological; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Receptor, EphA1 | 2006 |
Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotides; Oligonucleotides, Antisense; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Ribonuclease H; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 2006 |
Targeted cancer therapeutics: the heartbreak of success.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Drug Delivery Systems; Enzyme Inhibitors; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplasms; Piperazines; Pyrimidines; src-Family Kinases; Ventricular Dysfunction, Left | 2006 |
Imatinib and pregnancy.
Topics: Abortion, Spontaneous; Adult; Animals; Antineoplastic Agents; Benzamides; Congenital Abnormalities; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimesters; Protein-Tyrosine Kinases; Pyrimidines; Teratogens | 2006 |
Tyrosine kinase inhibitors: the next generation.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2006 |
Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Benzamides; Blast Crisis; Cytarabine; Daunorubicin; Feasibility Studies; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; In Vitro Techniques; Interferons; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines; Vincristine | 2006 |
Differentiation therapy as an effective strategy for the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Differentiation; Cellular Senescence; Guanosine Triphosphate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2006 |
Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells.
Topics: Animals; Benzamides; Cell Differentiation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Galactosylceramides; Humans; Imatinib Mesylate; Interferon-gamma; Interleukin-12; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Mice; Monocytes; Neoplasms; Piperazines; Pyrimidines; T-Lymphocytes, Regulatory | 2006 |
Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cerebellum; Drug Administration Schedule; Fatal Outcome; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Injections, Spinal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2006 |
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Densitometry; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Sex Factors; Time Factors | 2006 |
Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia.
Topics: Adenomatoid Tumor; Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Testicular Neoplasms | 2006 |
Successful management of liver injury caused by imatinib mesylate in a patient with previously untreated chronic myelogenous leukemia in the chronic phase.
Topics: Antineoplastic Agents; Benzamides; Biopsy; Blast Crisis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Middle Aged; Piperazines; Pyrimidines | 2006 |
Activity of AMN107 in gleevec-resistant leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2006 |
Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Thiazoles | 2006 |
Mobilization of Ph chromosome-negative peripheral blood stem cells in a child with chronic myeloid leukemia after imatinib-induced complete molecular remission.
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Marrow Purging; Child; Filgrastim; Forecasting; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Peripheral Blood Stem Cell Transplantation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins; Remission Induction | 2008 |
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
Topics: Antineoplastic Agents; Benzamides; Drug Monitoring; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genetic Heterogeneity; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Plasma; Pyrimidines; Reproducibility of Results; RNA, Messenger; Sensitivity and Specificity | 2006 |
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibiotics, Antineoplastic; Benzamides; Carrier Proteins; Cell Cycle Proteins; Cyclin D3; Cyclins; Eukaryotic Initiation Factor-4F; Eukaryotic Initiation Factor-4G; Eukaryotic Initiation Factors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Phosphoproteins; Phosphorylation; Piperazines; Protein Biosynthesis; Proteins; Pyrimidines; Sirolimus; TOR Serine-Threonine Kinases; Transcription Factors; Tumor Cells, Cultured | 2007 |
Desensitization to imatinib in patients with leukemia.
Topics: Administration, Oral; Adolescent; Aged; Antineoplastic Agents; Benzamides; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2006 |
Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
Topics: Active Transport, Cell Nucleus; Apoptosis; Benzamides; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Fusion Proteins, bcr-abl; G1 Phase; Genes, Transgenic, Suicide; Genetic Engineering; Genetic Therapy; Genetic Vectors; Herpesvirus 4, Human; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Phosphorylation; Piperazines; Point Mutation; Pyrimidines; Retinoblastoma; RNA Interference; RNA, Small Interfering; S Phase; Tumor Cells, Cultured | 2006 |
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Brain; Cyclosporine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Injections; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Neoplasm Transplantation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Random Allocation; src-Family Kinases | 2007 |
Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome?
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines | 2006 |
Dasatinib in chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2006 |
Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Hematopoiesis; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Piperazines; Pyrimidines; Risk Factors | 2006 |
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Child; Disease Progression; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Basophilic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
Topics: Benzamides; Blast Crisis; Cell Line; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; Signal Transduction; Transfection | 2006 |
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance.
Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Kinesins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Piperazines; Pyrimidines; Transplantation, Heterologous | 2006 |
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A new class of agents with high apoptotic activity in chronic myelogenous leukemia K562 cells and in cells from patients at onset and who were imatinib-resistant.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Caspase 3; Caspase 8; Caspase 9; Caspases; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Thiazepines; Tumor Cells, Cultured | 2006 |
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Benzamides; Biphenyl Compounds; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; Fetus; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Membrane Proteins; Mice; Myeloid Progenitor Cells; Nitrophenols; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides | 2006 |
Glivec and beyond.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Thiazoles | 2006 |
Imatinib spells BAD news for Bcr/abl-positive leukemias.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Benzamides; Cytotoxicity, Immunologic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrimidines | 2006 |
A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Topics: Aged; Alternative Splicing; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Point Mutation; Pyrimidines | 2006 |
Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
Topics: Adult; Antineoplastic Agents; Apoptosis; Benzamides; CD8-Positive T-Lymphocytes; Cell Proliferation; Dose-Response Relationship, Drug; Epitopes, T-Lymphocyte; Extracellular Matrix Proteins; Female; Hematopoietic Stem Cell Transplantation; Humans; Hyaluronan Receptors; Imatinib Mesylate; Immunomagnetic Separation; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Transplantation, Homologous | 2007 |
Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate.
Topics: Anemia, Aplastic; Benzamides; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Immunoglobulins; Injections, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prednisone; Pyrimidines; Time Factors; Treatment Outcome | 2007 |
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications.
Topics: Algorithms; Antineoplastic Agents; Benzamides; Cell Proliferation; Clinical Trials as Topic; Cohort Studies; Computer Simulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Theoretical; Piperazines; Pyrimidines; Remission Induction; Time Factors | 2006 |
Bone marrow aplasia--a rare complication of imatinib therapy in CML patients.
Topics: Adolescent; Adult; Anemia, Aplastic; Benzamides; Blast Crisis; Bone Marrow Examination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pancytopenia; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Atypical chronic myeloid leukaemia with CD117-positive blast cells treated with imatinib: A report of two cases.
Topics: Aged; Antineoplastic Agents; Benzamides; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines | 2006 |
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; src-Family Kinases; STAT5 Transcription Factor; Thiazoles; Tumor Cells, Cultured; Vorinostat | 2006 |
Varying response to escalating the dose of imatinib in patients with CML who "acquire" a BCR-ABL M244V mutant allele.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Polymerase Chain Reaction; Pyrimidines; Time Factors; Transcription, Genetic | 2006 |
Targeted cancer treatment: resisting arrest.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Differentiation; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Models, Theoretical; Piperazines; Pyrimidines; Recurrence; Stem Cells; Time Factors | 2006 |
Antituberculosis therapy and imatinib for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Antitubercular Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines | 2006 |
Imatinib mesylate-induced acute hepatitis with autoimmune features.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents; Antineoplastic Agents; Antiviral Agents; Benzamides; Drug Therapy, Combination; Female; Hepatitis, Autoimmune; Humans; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Piperazines; Polyethylene Glycols; Prednisone; Pyrimidines; Recombinant Proteins | 2006 |
Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzamides; Dermatomyositis; Diagnosis, Differential; Drug Eruptions; Exanthema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2006 |
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Topics: Apoptosis; Benzamides; Caspase Inhibitors; Caspases; Cell Differentiation; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Erythroid Cells; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines | 2007 |
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Topics: Antineoplastic Agents; Basic-Leucine Zipper Transcription Factors; Benzamides; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Heterochromatin; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maleates; Piperazines; Pyrimidines; Time Factors; Transcription, Genetic; U937 Cells | 2007 |
Follicular acneiform eruption induced by imatinib.
Topics: Acne Vulgaris; Adult; Antineoplastic Agents; Benzamides; Drug Eruptions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2006 |
The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.
Topics: Adult; Benzamides; Chemical and Drug Induced Liver Injury; Drug Evaluation; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Retrospective Studies; Survival Analysis; Transplantation, Homologous | 2007 |
[Effects of Imatinib mesylate on the development of dendritic cells derived from bone marrow mononuclear cells of patients with chronic myeloid leukemia].
Topics: Adult; Antigens, CD; B7-1 Antigen; B7-2 Antigen; Benzamides; Bone Marrow Cells; CD83 Antigen; Cell Line, Tumor; Dendritic Cells; Female; Granulocyte-Macrophage Colony-Stimulating Factor; HLA-DR Antigens; Humans; Imatinib Mesylate; Immunoglobulins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Membrane Glycoproteins; Middle Aged; NF-kappa B; Piperazines; Pyrimidines | 2006 |
Complete cytogenetic and molecular response to treatment with imatinib mesylate for philadelphia chromosome positive acute myeloid leukemia with multilineage dysplasia.
Topics: Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2006 |
Expression analysis of PCNA gene in chronic myelogenous leukemia--combined application of siRNA silencing and expression arrays.
Topics: Apoptosis; Benzamides; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotide Array Sequence Analysis; Piperazines; Proliferating Cell Nuclear Antigen; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2007 |
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Topics: Animals; Antineoplastic Agents; B-Lymphocytes; Benzamides; Blast Crisis; Burkitt Lymphoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Thiazoles | 2006 |
Reconstitution of T cell subset repertoire diversity following multiple antigen-mismatched bone marrow transplantation.
Topics: Adult; Animals; Antilymphocyte Serum; Benzamides; Blast Crisis; Bone Marrow Transplantation; Cell Lineage; Combined Modality Therapy; Female; Gene Rearrangement, T-Lymphocyte; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Lymphocyte Depletion; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Rabbits; Remission Induction; T-Lymphocyte Subsets; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2006 |
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Topics: Acyltransferases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Hematopoietic Stem Cells; Humans; Hydrocarbons, Halogenated; Imatinib Mesylate; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Pyrimidines; Triazines | 2006 |
Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation.
Topics: Benzamides; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Progenitor Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Signal Transduction; STAT5 Transcription Factor; Tumor Cells, Cultured | 2007 |
[Combination of imatinib and anagrelide in treatment of chronic myeloid leukemia in blastic phase].
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thrombocytosis | 2006 |
Chemotherapy and imatinib-induced molecular remission in lymphoid blast crisis after 20 years of "untreated" chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Survivors; Treatment Refusal; Vincristine | 2007 |
[The anti-tumoral effect of PI3K inhibitor and MEK inhibitor combined with STI571 on chronic myeloid leukemia cells in a bone marrow stromal cell co-culture system].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Bone Marrow Cells; Cell Proliferation; Chromones; Coculture Techniques; Flavonoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Piperazines; Pyrimidines; Stromal Cells | 2006 |
Dual PPARalpha/gamma ligand TZD18 either alone or in combination with imatinib inhibits proliferation and induces apoptosis of human CML cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phenyl Ethers; Piperazines; PPAR alpha; PPAR gamma; Pyrimidines; Thiazolidinediones | 2006 |
Chlordiazepoxide for imatinib-induced muscular cramps.
Topics: Antineoplastic Agents; Benzamides; Chlordiazepoxide; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; GABA Modulators; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Muscle Cramp; Piperazines; Pyrimidines | 2006 |
Changes in expression of apoptosis-related genes are linked to the molecular response to imatinib treatment in chronic-phase chronic myeloid leukemia patients.
Topics: Adult; Aged; Apoptosis; bcl-Associated Death Protein; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia.
Topics: Benzamides; Biopsy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Time Factors; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2006 |
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Synergism; Flavonoids; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyrimidines; RNA, Neoplasm | 2006 |
Pure red cell aplasia in a patient of chronic granulocyte leukemia associated with imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Blood Cell Count; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Red-Cell Aplasia, Pure | 2007 |
[Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2006 |
Monitoring molecular response by BCR-ABL, JH and WT-1 in Ph+ all treated with imatinib containing regimen: preliminary report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Monitoring; Female; Fusion Proteins, bcr-abl; Gene Rearrangement; Humans; Imatinib Mesylate; Immunoglobulin J-Chains; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; WT1 Proteins | 2006 |
Presentation of extramedullary Philadelphia chromosome-positive biphenotypic acute leukemia as testicular mass: Response to imatinib-combined chemotherapy.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Cells; Flow Cytometry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Homologous | 2006 |
Promyelocytic crisis of chronic myelogenous leukaemia during imatinib mesylate treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Flow Cytometry; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Oral and cutaneous lichenoid reaction secondary to imatinib: report of two cases.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Mouth Diseases; Piperazines; Pyrimidines; Tongue Diseases | 2006 |
Usefulness of quantitative assessment of JunB gene expression as a marker for monitoring chronic myeloid leukemia patients undergoing imatinib therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Piperazines; Predictive Value of Tests; Proto-Oncogene Proteins c-jun; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome | 2006 |
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Frequency; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mutation; Neoplasm Staging; Piperazines; Protein Kinases; Protein Structure, Tertiary; Pyrimidines | 2006 |
[A case of chronic myeloid leukemia following TS-1 therapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fusion Proteins, bcr-abl; Gastrectomy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplasms, Second Primary; Oxonic Acid; Piperazines; Pyrimidines; Stomach Neoplasms; Tegafur | 2006 |
Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells.
Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Cell Line, Tumor; Cyanoacrylates; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Tumor Stem Cell Assay | 2007 |
Comparative proteomic analysis of chronic myelogenous leukemia cells: inside the mechanism of imatinib resistance.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gene Expression Regulation, Leukemic; Humans; Image Processing, Computer-Assisted; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Proteomics; Pyrimidines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines | 2007 |
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines | 2007 |
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines | 2007 |
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
Topics: Antineoplastic Agents; Benzamides; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Pyrimidines | 2007 |
Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis.
Topics: Adult; Benzamides; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Recurrence; Transplantation, Homologous | 2007 |
FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Topics: AC133 Antigen; Antigens, CD; Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Lineage; Chronic Disease; Clone Cells; Drug Resistance; Eosinophils; Erythrocytes; Fusion Proteins, bcr-abl; Glycophorins; Glycoproteins; Granulocytes; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Subsets; Megakaryocytes; Monocytes; mRNA Cleavage and Polyadenylation Factors; Myeloid Cells; Neoplastic Stem Cells; Oncogene Proteins, Fusion; Peptides; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tumor Stem Cell Assay; X Chromosome Inactivation | 2007 |
Chronic myeloid leukemia blast crisis arises from progenitors.
Topics: Benzamides; Blast Crisis; Disease Progression; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Immunological; Mutation; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2007 |
Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Benzamides; Bleomycin; Blotting, Western; Bromodeoxyuridine; Caspase 3; Cell Line, Tumor; Cells, Cultured; Collagen; DNA, Single-Stranded; Dose-Response Relationship, Drug; Epithelial Cells; Fibroblasts; Fibrosis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Immunohistochemistry; Indicators and Reagents; Injections, Intraperitoneal; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Diseases; Mesenchymal Stem Cells; Mice; Phenotype; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction | 2007 |
Imatinib mesylate (gleevec) hepatotoxicity.
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Bilirubin; Blood Cell Count; Erythrocyte Indices; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure; Male; Necrosis; Piperazines; Protein Kinase Inhibitors; Prothrombin Time; Pyrimidines; Time Factors | 2007 |
Dasatinib (Sprycel) for CML and Ph + ALL.
Topics: Benzamides; Clinical Trials as Topic; Dasatinib; Drug Interactions; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Autologous stem cells collected after debulking by high dose chemotherapy in late phase chronic myeloid leukemia may improve Imatinib efficacy.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous | 2007 |
Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
Topics: Antigens, Nuclear; Antineoplastic Agents; bcl-2-Associated X Protein; Benzamides; BRCA1 Protein; Camptothecin; Cell Line, Tumor; DNA Repair Enzymes; DNA-Activated Protein Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Ku Autoantigen; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Radiation Tolerance | 2007 |
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Codon; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutant Proteins; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Treatment Refusal | 2007 |
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Butyrates; Cell Cycle; Cell Differentiation; Cell Survival; Drug Synergism; Enzyme Inhibitors; Erythroid Cells; Flow Cytometry; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Immunoblotting; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Novel compounds with antiproliferative activity against imatinib-resistant cell lines.
Topics: Alkynes; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Furans; Fusion Proteins, bcr-abl; gamma-Aminobutyric Acid; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fyn; Pyrimidines; src-Family Kinases; Tumor Cells, Cultured | 2007 |
The tyrosine-kinase inhibitor imatinib induces long-term remission in a patient with chronic myelogenous leukemia with translocation t(4;22).
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 4; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2007 |
Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment.
Topics: Adult; Apoptosis; Benzamides; Cell Growth Processes; Female; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines | 2007 |
Imatinib concentrations in human milk.
Topics: Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk, Human; Piperazines; Pyrimidines | 2007 |
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States | 2007 |
Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose.
Topics: Benzamides; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Stevens-Johnson Syndrome | 2007 |
Introduction: chronic myelogenous leukemia (CML).
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Cell Line, Tumor; CpG Islands; DEAD-box RNA Helicases; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Proteins; Piperazines; Prognosis; Promoter Regions, Genetic; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Testis | 2007 |
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Case-Control Studies; DNA Primers; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monitoring, Physiologic; Piperazines; Pyrimidines; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; RNA, Neoplasm | 2007 |
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin | 2007 |
[Innovation of clinical trials for anti-cancer drugs in Japan--proposals from academia with special reference to the development of novel Bcr-Abl/Lyn tyrosine kinase inhibitor INNO-406 (NS-187) for imatinib-resistant chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles | 2007 |
Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Polycythemia; Pyrimidines | 2007 |
Insufficient outcomes with imatinib mesylate: case report of Ph-positive acute myeloid leukemia evolving from myelodysplastic syndrome.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 3; Cytogenetic Analysis; Disease Progression; Fatal Outcome; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Recurrence; Treatment Failure | 2007 |
Inv (11)(p15q21) in donor-derived Ph-negative cells in a patient with chronic myeloid leukemia in relapse successfully treated with imatinib mesylate post allogeneic stem cell transplantation.
Topics: Adult; Benzamides; Chromosomes, Human, Pair 11; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence; Stem Cell Transplantation; Tissue Donors; Transplantation, Homologous | 2007 |
Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells.
Topics: Apoptosis; Benzamides; Ceramides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lysophospholipids; Membrane Potential, Mitochondrial; Membrane Proteins; Piperazines; Pyrimidines; RNA, Small Interfering; Sphingosine; Sphingosine N-Acyltransferase; Time Factors; Up-Regulation | 2007 |
Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
Topics: Antineoplastic Agents; Benzamides; Diabetic Nephropathies; Female; Humans; Imatinib Mesylate; Kidney Failure, Chronic; Kidney Transplantation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Time Factors | 2007 |
Promyelocytic blast crisis of chronic myelogenous leukemia during imatinib treatment.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Genes, abl; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Colorimetry; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Longitudinal Studies; Male; Middle Aged; Piperazines; Pyrimidines; Skin Pigmentation; Statistics, Nonparametric | 2007 |
Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe--impact of cost considerations.
Topics: Antineoplastic Agents; Benzamides; Developed Countries; Drug Costs; Europe; Health Care Costs; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Income; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Societies, Medical; Transplantation, Homologous | 2007 |
Do affluent societies have the only options for the best therapy?
Topics: Adolescent; Age of Onset; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Catastrophic Illness; Child; China; Developed Countries; Developing Countries; Drug Costs; Granulocyte Colony-Stimulating Factor; Health Care Costs; Health Care Rationing; Health Services Accessibility; Human Rights; Humans; Imatinib Mesylate; Income; India; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Social Justice; State Medicine; Therapeutics | 2007 |
Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Cytogenetic Analysis; Developing Countries; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pakistan; Piperazines; Pyrimidines; Quality of Life; Treatment Outcome | 2007 |
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
Topics: Apoptosis; Benzamides; beta Catenin; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Fusion Proteins, bcr-abl; Glycogen Synthase Kinase 3; Humans; Imatinib Mesylate; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Phosphorylation; Piperazines; Protein Binding; Protein-Tyrosine Kinases; Pyrimidines; RNA, Small Interfering; Signal Transduction; Transcription, Genetic; Tyrosine | 2007 |
Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Blood-Brain Barrier; Central Nervous System Neoplasms; Cytarabine; Dexamethasone; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Methotrexate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma, Myeloid; Treatment Outcome | 2007 |
Unusual fluid retention with imatinib therapy for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Water-Electrolyte Imbalance | 2007 |
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pilot Projects; Piperazines; Pyrimidines; Survival Rate; Treatment Outcome | 2007 |
Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Fusion Proteins, bcr-abl; Graft vs Leukemia Effect; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Stem Cell Transplantation; Survival Rate; Transplantation, Homologous; Treatment Outcome | 2007 |
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
Topics: Aged; Benzamides; Europe; Female; Fusion Proteins, bcr-abl; Health Surveys; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Surveys and Questionnaires; United States | 2007 |
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
Topics: Adolescent; Aged; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Topics: Adaptor Proteins, Signal Transducing; ADP-ribosyl Cyclase 1; Antigens, CD34; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Nuclear Proteins; Octamer Transcription Factor-1; Phosphorylation; Piperazines; Pyrimidines | 2007 |
Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Binding Sites; Cross-Over Studies; Cytarabine; Disease-Free Survival; Drug Design; Drug Resistance, Neoplasm; Drugs, Investigational; Europe; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Neoplasm Proteins; Piperazines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; src Homology Domains; Transplantation, Homologous; Treatment Outcome | 2007 |
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Prognosis; Pyrimidines | 2007 |
Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Topics: Antigens, CD34; Benzamides; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Plasmids; Promoter Regions, Genetic; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta; Up-Regulation | 2007 |
An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
Topics: Aged; Benzamides; Chromosome Inversion; Chromosomes, Human, Pair 16; Core Binding Factor beta Subunit; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines | 2007 |
Follow-up study of patients diagnosed with chronic myelogenous leukemia treated with STI 571 in Ecuador.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Ecuador; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |
Blastoid mantle cell lymphoma occurring in a patient in complete remission of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Mantle-Cell; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2007 |
Imatinib-induced dental hyperpigmentation in childhood chronic myeloid leukemia.
Topics: Adolescent; Benzamides; Female; Gingival Diseases; Humans; Hyperpigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Tooth Diseases; Treatment Outcome | 2007 |
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line; Core Binding Factor Alpha 2 Subunit; Core Binding Factor Alpha 3 Subunit; Drug Resistance, Neoplasm; Genetic Techniques; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mutagenesis; Mutagenesis, Site-Directed; Piperazines; Pyrimidines; Retroviridae | 2007 |
Imatinib-induced immune hepatitis: case report and literature review.
Topics: Adolescent; Alanine Transaminase; Antibodies, Antinuclear; Antibody Specificity; Antineoplastic Agents; Aspartate Aminotransferases; Autoantibodies; Autoantigens; Benzamides; DNA; Female; Hepatitis, Autoimmune; Humans; Imatinib Mesylate; Immunosuppressive Agents; Jaundice, Obstructive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Muscle, Smooth; Piperazines; Prednisolone; Pyrimidines | 2007 |
Total CD34+ cells per 10 HPF in bone marrow trephines of patients with chronic myeloid leukaemia correlates with probability of complete cytogenetic response following imatinib treatment.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Biopsy, Needle; Bone Marrow Cells; Cell Count; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Predictive Value of Tests; Pyrimidines; Treatment Outcome | 2007 |
Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
Topics: Antineoplastic Agents; Benzamides; Female; Fetal Blood; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk, Human; Piperazines; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines | 2007 |
Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.
Topics: Adult; Aged; Benzamides; Blood Glucose; Drug Resistance, Neoplasm; Female; Humans; Hypoglycemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |
The receptor for hyaluronic acid-mediated motility induces specific CD8+ T cell response in healthy donors and patients with chronic myeloid leukemia after allogeneic stem cell transplantation.
Topics: Benzamides; CD8-Positive T-Lymphocytes; Cell Movement; Cohort Studies; Epitopes; Extracellular Matrix Proteins; Female; Flow Cytometry; Humans; Hyaluronan Receptors; Hyaluronic Acid; Imatinib Mesylate; Immunophenotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous | 2007 |
Chronic myeloid leukemia-associated membranoproliferative glomerulonephritis that responded to imatinib mesylate therapy.
Topics: Benzamides; Biopsy; Bone Marrow; Disease Progression; Follow-Up Studies; Glomerular Basement Membrane; Glomerulonephritis, Membranoproliferative; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesangial Cells; Microscopy, Electron; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
Topics: Adult; Antineoplastic Agents; Base Sequence; Benzamides; DNA Primers; DNA, Complementary; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Piperazines; Pyrimidines | 2007 |
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia.
Topics: Adult; Agammaglobulinemia; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2008 |
Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis.
Topics: Aged; Benzamides; Blast Crisis; Bone Marrow Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Necrosis; Piperazines; Pyrimidines | 2007 |
Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Feeding; Cytarabine; Embryonic Development; Female; Humans; Imatinib Mesylate; Immunologic Factors; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Recurrence; Remission Induction | 2007 |
Cocaine abuse may influence the response to imatinib in CML patients.
Topics: Adult; Antineoplastic Agents; Benzamides; Cocaine; Cocaine-Related Disorders; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hydroxyurea; Imatinib Mesylate; Inactivation, Metabolic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Liver; Male; Piperazines; Pyrimidines; Substrate Specificity | 2007 |
Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy.
Topics: Adult; Animals; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pregnancy; Pregnancy Outcome; Pyrimidines; Rats; Spermatogenesis | 2007 |
Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Glucocorticoids; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Optic Neuritis; Piperazines; Prednisolone; Pyrimidines; Treatment Outcome; Vision Disorders | 2007 |
Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles | 2008 |
Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Computer Simulation; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2007 |
Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Drug Resistance, Neoplasm; Gene Silencing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; RNA, Small Interfering | 2007 |
Dasatinib is effective in imatinib-resistant CML.
Topics: Benzamides; Dasatinib; Drug Approval; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome; United Kingdom | 2007 |
Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
Topics: Adult; Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; Female; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; src-Family Kinases | 2007 |
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation, Missense; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Translocation, Genetic | 2007 |
Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2007 |
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Banding; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Transcription, Genetic; Treatment Outcome | 2007 |
Isodicentric Philadelphia chromosomes in imatinib mesylate (Gleevec)-resistant patients.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Centromere; Chromosome Aberrations; Chromosome Banding; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines | 2007 |
The daunting task of modeling response to imatinib therapy in patients with chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Theoretical; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cells; Thiazoles; Treatment Outcome | 2007 |
Use of imatinib mesylate in a 15-month old with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Protocols; Databases, Factual; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Patient Selection; Piperazines; Pyrimidines; Registries; Transplantation, Homologous; United States | 2007 |
Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia.
Topics: Adult; Anemia, Aplastic; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2008 |
Imatinib in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Survival Analysis | 2007 |
Comparison between molecularly defined and conventional therapeutics in a conditional BCR-ABL cell culture model.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Genetic Therapy; Imatinib Mesylate; Inhibitory Concentration 50; Interleukin-3; Intracellular Signaling Peptides and Proteins; Lentivirus; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Biological; Phosphoproteins; Piperazines; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatases; Pyrimidines; RNA Interference; RNA, Small Interfering; STAT5 Transcription Factor; Tumor Cells, Cultured | 2007 |
Chronic myelogenous leukemia progenitors display a genetically unstable personality.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Stem Cells | 2007 |
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Topics: Benzamides; Colony-Forming Units Assay; DNA Mutational Analysis; DNA Primers; Genes, abl; Genomic Instability; Humans; Imatinib Mesylate; Immunomagnetic Separation; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Stem Cells; Tumor Cells, Cultured | 2007 |
Chromosomal abnormalities in chronic myeloid leukemia: evidence of a hierarchy in imatinib treated cells.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Chromosome Aberrations; Cytogenetics; Hematopoietic Stem Cells; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Philadelphia Chromosome; Piperazines; Pyrimidines | 2007 |
Targeted therapy and the T315I mutation in Philadelphia-positive leukemias.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Benzene Derivatives; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Hydrogen Bonding; Hydroxamic Acids; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Naphthalenes; Panobinostat; Philadelphia Chromosome; Piperazines; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Remission Induction; Structure-Activity Relationship; Threonine; Vorinostat | 2007 |
Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aneuploidy; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chromosome Deletion; Clone Cells; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Monosomy; Neoplastic Cells, Circulating; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Remission Induction; Trisomy | 2007 |
[Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
Topics: Adult; Aged; Benzamides; Bone Marrow Cells; DNA-Activated Protein Kinase; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; RNA, Messenger | 2007 |
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
Topics: Animals; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Mutation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Recurrence; Risk Factors | 2007 |
Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
Topics: Benzamides; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Male; Middle Aged; Piperazines; Pyrimidines; Risk Assessment | 2007 |
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Biphenyl Compounds; Boronic Acids; Bortezomib; Cell Line, Transformed; Cell Line, Tumor; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-bcr; Pyrazines; Pyrimidines; Sulfonamides | 2007 |
Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Binding Sites; Drug Resistance, Neoplasm; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Transduction, Genetic | 2007 |
Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Drug Costs; Drug Prescriptions; Female; Health Care Costs; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Managed Care Programs; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Treatment Refusal; United States | 2007 |
Familial adenomatous polyposis complicated by chronic myelogenous leukemia: response to imatinib mesylate.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosome Breakage; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |
[Effects of ST1571 on the development of dendritic cells derived from bone marrow mononuclear cells in patients with chronic myeloid leukemia].
Topics: Adult; Antigens, CD; Benzamides; Bone Marrow Cells; Cell Proliferation; Cells, Cultured; Dendritic Cells; Female; Flow Cytometry; Fusion Proteins, bcr-abl; HLA-DR Antigens; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; T-Lymphocytes; Vascular Endothelial Growth Factor A | 2006 |
Farnesyl transferase inhibitor resistance probed by target mutagenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutagenesis; Mutagenesis, Site-Directed; Mutation; Pilot Projects; Piperazines; Piperidines; Protein Conformation; Protein Prenylation; Pyridines; Pyrimidines; Tumor Cells, Cultured | 2007 |
Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines.
Topics: Animals; Antigens, CD34; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Cytokines; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Mice; Models, Biological; Piperazines; Proto-Oncogene Proteins; Pyrimidines | 2007 |
BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Pyrimidines; Time Factors; Treatment Outcome | 2007 |
EBV-positive lymphoproliferative disease with medullary, splenic and hepatic infiltration after imatinib mesylate therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kidney Medulla; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Lymphoproliferative Disorders; Middle Aged; Piperazines; Pyrimidines; Recurrence; Spleen; Translocation, Genetic | 2007 |
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Dendritic Cells; Down-Regulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Activation; Piperazines; Pyrimidines; RNA, Small Interfering; T-Lymphocytes, Cytotoxic | 2007 |
Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
Topics: Aneuploidy; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 6; Cytogenetic Analysis; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Proteins; Proteomics; Pyrimidines | 2007 |
Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells.
Topics: Arsenic Trioxide; Arsenicals; Benzamides; Buthionine Sulfoximine; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oxides; Piperazines; Pyrimidines | 2007 |
The rho-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34(+) CML progenitor cells.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Antigens, CD34; Benzamides; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; rho-Associated Kinases; Stem Cells; Tumor Cells, Cultured | 2007 |
Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Fluorescein Angiography; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Macular Edema; Piperazines; Pyrimidines; Tomography, Optical Coherence | 2007 |
Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome.
Topics: Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 7; Disease Progression; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Monosomy; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Treatment Outcome | 2007 |
[Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
Topics: Adult; Antineoplastic Agents; Benzamides; beta 2-Microglobulin; Biomarkers, Tumor; Bone Marrow; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm, Residual; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity | 2007 |
Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Disease Progression; Drug Administration Schedule; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Stem Cells | 2008 |
Appearance of bone marrow lymphocytosis predicts an optimal response to imatinib therapy in patients with chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Bone Marrow; Bone Marrow Cells; Chromosome Banding; Female; Humans; Imatinib Mesylate; Immunophenotyping; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Lymphocytosis; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines | 2007 |
Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
Topics: Acylation; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Processing, Post-Translational; Pyrimidines; Up-Regulation | 2007 |
A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients.
Topics: Alternative Splicing; Benzamides; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2008 |
Imatinib mesylate therapy in chronic myeloid leukaemia: the floodgates opened.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Gene Targeting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic; Treatment Outcome | 2007 |
Hematological and molecular response evaluation of CML patients on imatinib.
Topics: Adult; Age Factors; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Targeting; Hematology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Piperazines; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Translocation, Genetic; Treatment Outcome | 2007 |
Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Benzamides; Child; Cytogenetic Analysis; Cytogenetics; Female; Fusion Proteins, bcr-abl; Gene Targeting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Piperazines; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Translocation, Genetic; Treatment Outcome | 2007 |
Durable responses in chronic myeloid leukemia patients maintained with lower doses of imatinib mesylate after achieving molecular remission.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Monitoring, Physiologic; Neoplasm, Residual; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; STAT5 Transcription Factor | 2007 |
Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells.
Topics: Animals; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; NIH 3T3 Cells; Phosphatidylinositol 3-Kinases; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA, Small Interfering; Signal Transduction; Up-Regulation | 2007 |
Optimal control of treatment in a mathematical model of chronic myelogenous leukemia.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Cytarabine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mathematics; Models, Biological; Piperazines; Pyrimidines; T-Lymphocytes | 2007 |
Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Benzamides; Chromosomes, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Piperazines; Pyrimidines; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2007 |
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.
Topics: Benzamides; Blood Cell Count; Blood Platelets; Cell Line; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; RNA, Small Interfering; Transcription, Genetic; Transfection | 2007 |
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line; Cell Proliferation; Depsipeptides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Inhibitor of Apoptosis Proteins; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitogen-Activated Protein Kinases; Piperazines; Pyrimidines; Telomerase; Tumor Cells, Cultured | 2007 |
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Chromosome Aberrations; Chronic Disease; DNA Mutational Analysis; Genes, abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2007 |
Severe periorbital edema secondary to imatinib mesylate for chronic myelogenous leukemia.
Topics: Aged; Benzamides; Edema; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Orbital Diseases; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Imatinib mesylate in the treatment of chronic myeloid leukemia: a local experience.
Topics: Antineoplastic Agents; Benzamides; Cytogenetics; Disease Progression; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Malaysia; Male; Piperazines; Prognosis; Prospective Studies; Pyrimidines; Treatment Outcome | 2006 |
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Clinical Trials as Topic; Cytogenetic Analysis; Female; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Metaphase; Middle Aged; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
[Current status and future perspectives of the Glivec Registration System established by JSCH/JSH-TARGET].
Topics: Antineoplastic Agents; Benzamides; Databases, Factual; Female; Fusion Proteins, bcr-abl; Hematology; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Registries; Societies, Medical | 2007 |
[Reappearance of t(12;17)-positive primary myelofibrosis following Ph+ CML cell reduction by imatinib].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 17; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Primary Myelofibrosis; Pyrimidines; Recurrence; Translocation, Genetic | 2007 |
Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mass Spectrometry; Middle Aged; Particle Accelerators; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2007 |
BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia.
Topics: Antigens, CD34; Benzamides; Cell Adhesion; Cell Proliferation; Cell Transformation, Neoplastic; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcr; Pyrimidines; ras Proteins; Retroviridae; Tyrosine | 2007 |
A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Cytogenetic Analysis; Disease Progression; Exons; Female; Gene Expression Regulation, Leukemic; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Time Factors; Translocation, Genetic; Treatment Outcome | 2007 |
Monosomy 7 in t(9;22)-negative cells during nilotinib therapy in an imatinib-resistant chronic myeloid leukemia case.
Topics: Adult; Aneugens; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 7; Chromosomes, Human, Pair 9; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Monosomy; Piperazines; Pyrimidines; Translocation, Genetic | 2007 |
[Physiopathology, diagnosis and treatment of chronic myeloproliferative diseases: discussion].
Topics: Benzamides; Chronic Disease; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Polymerase Chain Reaction; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
[Imatinib . Sunitinib].
Topics: Angiogenesis Inhibitors; Benzamides; Carcinoma, Renal Cell; Dermatofibrosarcoma; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Kidney Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms; Sunitinib; Survival Rate | 2007 |
A karyometric study on ageing and butyrate or imatinib treated human leukemic myeloblasts represented by K562 cells originated from chronic myeloid leukaemia.
Topics: Aging; Benzamides; Butyrates; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate.
Topics: Adult; Aged; Benzamides; Bone Marrow; Cell Count; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2008 |
Drugs offer new hope for patients with CML who are resistant to imatinib.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Interactions; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nurse's Role; Oncology Nursing; Patient Education as Topic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles | 2007 |
Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Topics: Alleles; Amino Acid Motifs; Animals; Benzamides; Cell Line; Dasatinib; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fusion Proteins, bcr-abl; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Sensitivity and Specificity; Thiazoles; Valine | 2007 |
Therapeutic drug monitoring in CML patients on imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Piperazines; Pyrimidines; Remission Induction | 2007 |
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Topics: Animals; Benzamides; Blast Crisis; Cell Survival; Dasatinib; Drug Resistance, Neoplasm; Fingolimod Hydrochloride; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Molecular Structure; Phosphoprotein Phosphatases; Phosphorylation; Piperazines; Propylene Glycols; Protein Phosphatase 2; Pyrimidines; Signal Transduction; Sphingosine; Thiazoles; Time Factors; Tumor Cells, Cultured | 2007 |
[Clinical observation of Gleevec combined with myeloablative allogeneic stem cells transplantation in treatment of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Piperazines; Pyrimidines; Transplantation Conditioning; Treatment Outcome | 2007 |
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Topics: Benzamides; Dasatinib; Discoidin Domain Receptor 1; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proteomics; Pyrimidines; Quinone Reductases; Receptor Protein-Tyrosine Kinases; Thiazoles | 2007 |
[No influence of imatinib on type 2 diabetes].
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Imatinib Mesylate; Insulin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metformin; Middle Aged; Piperazines; Pyrimidines | 2007 |
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Benzamides; Central Nervous System Neoplasms; Cytarabine; Dasatinib; Drug Therapy, Combination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liposomes; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Treatment Outcome | 2007 |
Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cells, Cultured; Chromones; Drug Resistance, Neoplasm; Etoposide; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Genes, Wilms Tumor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Inositol; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Recombinant Fusion Proteins; RNA, Neoplasm; Signal Transduction; Transduction, Genetic; WT1 Proteins | 2007 |
Combination of SK-7041, one of novel histone deacetylase inhibitors, and STI571-induced synergistic apoptosis in chronic myeloid leukemia.
Topics: Amides; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Cell Cycle; Cell Cycle Proteins; Drug Resistance, Neoplasm; Drug Synergism; Histone Deacetylase Inhibitors; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies | 2007 |
Simultaneous regression of Philadelphia chromosome and multiple nonrecurrent clonal chromosomal abnormalities with imatinib mesylate in a patient autografted 22 years before for chronic myelogenous leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Chromosome Aberrations; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Philadelphia Chromosome; Piperazines; Pyrimidines; Transplantation, Autologous; Whole-Body Irradiation | 2007 |
Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pregnancy; Pregnancy Outcome; Pyrimidines | 2008 |
Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzamides; Biomarkers; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Histamine; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monitoring, Physiologic; Neoplasm, Residual; Piperazines; Probability; Prognosis; Pyrimidines; Radioimmunoassay; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2007 |
Safety of imatinib in chronic myeloid leukemia in blastic crisis presenting as cholestatic jaundice.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Humans; Imatinib Mesylate; Jaundice, Obstructive; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Neoplasms; Male; Piperazines; Pyrimidines | 2007 |
Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Non-Hodgkin; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Rituximab | 2008 |
Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Survival Analysis; Time Factors | 2008 |
FDG PET findings of chronic myeloid leukemia in the chronic phase before and after treatment.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Radiopharmaceuticals; Treatment Outcome | 2007 |
Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Dasatinib; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Middle Aged; Mutation; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Overdose with 6400 mg of imatinib: is it safe?
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Overdose; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2007 |
Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Thiazoles; Time Factors | 2007 |
Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Forkhead Transcription Factors; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines; TNF-Related Apoptosis-Inducing Ligand; Transfection | 2007 |
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Benzamides; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nuclear Proteins; Phosphorylation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor; Survival Rate | 2008 |
Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
Topics: Aged; Antineoplastic Agents; Benzamides; Female; Heart Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2008 |
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
Topics: Adaptor Proteins, Signal Transducing; Adult; Analysis of Variance; Antineoplastic Agents; Benzamides; Biomarkers; Dose-Response Relationship, Drug; Drug Monitoring; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Nuclear Proteins; Piperazines; Predictive Value of Tests; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Imatinib mesylate induced skin hypopigmentation.
Topics: Antineoplastic Agents; Benzamides; Genes, abl; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Diseases | 2007 |
Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Psoriasis; Pyrimidines; Skin | 2007 |
Effect of cellular quiescence on the success of targeted CML therapy.
Topics: Antineoplastic Agents; Benzamides; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Models, Biological; Models, Theoretical; Mutation; Piperazines; Probability; Pyrimidines; Stochastic Processes | 2007 |
The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Differentiation; Cell Proliferation; Chromatography, Liquid; DEAD-box RNA Helicases; Hematopoietic Stem Cells; HSP110 Heat-Shock Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Peptides; Peroxidases; Peroxiredoxin III; Peroxiredoxins; Piperazines; Protein Kinase Inhibitors; Proteome; Proteomics; Pyrimidines; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2007 |
Restoration of insulin sensitivity following treatment with imatinib mesylate (Gleevec) in non-diabetic patients with chronic myelogenic leukemia (CML).
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Insulin Resistance; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2008 |
Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Molecular Probes; Phosphotyrosine; Piperazines; Pyrimidines; ras Proteins; Triazoles | 2008 |
Chronic myeloid leukemia and gastrointestinal stromal tumor: simultaneous presentation.
Topics: Antineoplastic Agents; Benzamides; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasms, Second Primary; Piperazines; Pyrimidines; Stomach Neoplasms; Treatment Outcome | 2007 |
Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Chromosome Aberrations; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mosaicism; Philadelphia Chromosome; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2007 |
Imatinib mesylate induced immune thrombocytopenia.
Topics: Adult; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Purpura, Thrombocytopenic, Idiopathic; Pyrimidines | 2007 |
(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Topics: Apoptosis; bcl-X Protein; Benzamides; Caspase 3; Cell Proliferation; Cytochromes c; Down-Regulation; Drug Evaluation, Preclinical; Enzyme Activation; Fusion Proteins, bcr-abl; Gossypol; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2007 |
[Recovery of polyclonial hemopoiesis in females with chronic myeloid leukemia with a complete cytogenetic response].
Topics: Adolescent; Adult; Aged; Alleles; Antineoplastic Agents; Benzamides; DNA, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Hematopoiesis; Humans; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Polymerase Chain Reaction; Polymorphism, Genetic; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Recovery of Function; Remission Induction; Treatment Outcome | 2007 |
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib | 2007 |
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
Topics: Benzamides; Bone Marrow Examination; Drug Monitoring; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Cytogenetics; DNA Mutational Analysis; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Reproducibility of Results; RNA, Neoplasm; Time Factors; Treatment Outcome | 2007 |
Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzamides; Cell Differentiation; Cell Division; DNA Primers; Doxorubicin; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Polymerase Chain Reaction; Pyrimidines | 2007 |
Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Topics: Animals; Apoptosis; Benzamides; Cell Line, Transformed; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Knockout; Paclitaxel; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retroviridae; Transduction, Genetic; Tubulin Modulators | 2008 |
Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; B-Lymphocytes; Benzamides; CD4-CD8 Ratio; Female; Hematopoiesis; Humans; Imatinib Mesylate; Immunoglobulin A; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Killer Cells, Natural; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Monocytes; Piperazines; Pyrimidines; Recovery of Function; Remission Induction | 2007 |
[STI571 enhances the effect of arsenic trioxide and Velcade on bcr/abl+-CD34+ cell proliferation and apoptosis].
Topics: Adult; Aged; Apoptosis; Arsenic Trioxide; Arsenicals; Benzamides; Boronic Acids; Bortezomib; Cell Proliferation; Drug Synergism; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Oxides; Piperazines; Pyrazines; Pyrimidines; Tumor Cells, Cultured | 2007 |
Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Division; Drug Resistance, Neoplasm; Female; Heme Oxygenase-1; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2008 |
Effects of the mean daily doses of imatinib during the first year on survival of patients with chronic myeloid leukemia in Japan: a study of the Hokkaido Hematology Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Child; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Japan; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Pyrimidines; Retrospective Studies; Treatment Outcome | 2008 |
Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bile Ducts; Blast Crisis; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cytarabine; Drug Eruptions; Hepatocytes; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Function Tests; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2007 |
Erythroid variant of chronic myelogenous leukemia.
Topics: Adult; Benzamides; Diagnosis, Differential; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Remission Induction; Thrombocytopenia | 2008 |
Long-term imatinib therapy promotes bone formation in CML patients.
Topics: Adipogenesis; Adult; Aged; Antineoplastic Agents; Benzamides; Calcification, Physiologic; Calcium; Cell Proliferation; Enzyme Activation; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesenchymal Stem Cells; Middle Aged; Organ Size; Osteogenesis; Phosphates; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-crk; Pyrimidines; Time Factors | 2008 |
Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Topics: Aniline Compounds; Antineoplastic Agents; Benzamides; Fetal Blood; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Quinolines; src-Family Kinases | 2008 |
Chronic myeloid leukemia. Introduction.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Transplantation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Thiazoles | 2007 |
Leukemia. Q&A highlights.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Dasatinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Piperazines; Pyrimidines; Thiazoles | 2007 |
Reduced dose of imatinib for patients with chronic myeloid leukemia and low body surface area.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzamides; Body Surface Area; Dose-Response Relationship, Drug; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neutropenia; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction; Retrospective Studies; Thrombocytopenia | 2007 |
Subcellular distribution of p210(BCR-ABL) in CML cell lines and primary CD34+ CML cells.
Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Antibody Specificity; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cellular Senescence; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytes, Mononuclear; Microscopy, Confocal; Neoplastic Stem Cells; Nuclear Proteins; Phosphorylation; Piperazines; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyrimidines; Subcellular Fractions | 2008 |
Modeling imatinib-treated chronic myelogenous leukemia: reducing the complexity of agent-based models.
Topics: Antineoplastic Agents; Benzamides; Computer Simulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Philadelphia Chromosome; Piperazines; Pyrimidines | 2008 |
Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Edema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Orbital Diseases; Piperazines; Pyrimidines | 2008 |
Chronic myeloid leukemia--therapy in the 20th and 21st centuries.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Time Factors | 2007 |
Pregnancy in patients with chronic myeloid leukemia treated with imatinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pyrimidines | 2007 |
Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Dasatinib; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; RNA, Messenger; Thiazoles | 2008 |
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Survival Analysis; Time Factors; Transcription, Genetic; Translocation, Genetic; Treatment Outcome | 2008 |
Complete response to imatinib mesylate treatment in a 12-month-old patient with chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2008 |
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Topics: Antineoplastic Agents; Benzamides; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoassay; Immunoprecipitation; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity | 2008 |
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Benzamides; Benzodiazepines; Blast Crisis; Caspase 3; Cell Death; Cell Survival; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Farnesyltranstransferase; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Thiazoles | 2008 |
Imatinib-induced fatal acute liver failure.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Antineoplastic Agents; Benzamides; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Middle Aged; Pain; Piperazines; Pyrimidines | 2007 |
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; RNA, Messenger; RNA, Neoplasm; Survival Rate; Time Factors; Treatment Outcome | 2008 |
Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.
Topics: Animals; Benzamides; Bone Marrow; Cytogenetics; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Immunophenotyping; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mastocytosis, Systemic; Mice; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2008 |
BCR-ABL1 mediates up-regulation of Fyn in chronic myelogenous leukemia.
Topics: Animals; Benzamides; Blast Crisis; Cell Proliferation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, SCID; Piperazines; Proto-Oncogene Proteins c-fyn; Pyrimidines; Up-Regulation | 2008 |
Gene expression analysis of BCR/ABL1-dependent transcriptional response reveals enrichment for genes involved in negative feedback regulation.
Topics: Benzamides; Biomarkers, Tumor; Blotting, Northern; Blotting, Western; Feedback, Physiological; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Oligonucleotide Array Sequence Analysis; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Transcription, Genetic; Tumor Cells, Cultured | 2008 |
Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2008 |
Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cisplatin; Etoposide; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mesenchymoma; Piperazines; Pyrimidines | 2008 |
Prolonged imatinib-induced myelosuppression in chronic myeloid leukaemia with an unusually long survival.
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Busulfan; Fatal Outcome; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrimidines; Survivors; Thrombocytopenia | 2008 |
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Topics: Adult; Apoptosis; Benzamides; Blotting, Western; Bone Marrow; Case-Control Studies; Cell Cycle; Cell Proliferation; Cells, Cultured; Chromones; Colony-Forming Units Assay; Dasatinib; DNA Primers; Female; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Homeobox A10 Proteins; Homeodomain Proteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Thiazoles; Transfection | 2008 |
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
Topics: Benzamides; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Tumor Cells, Cultured | 2008 |
Conjunctival hemorrhagic events associated with imatinib mesylate.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Conjunctival Diseases; Drug Hypersensitivity; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Hemorrhage; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2007 |
Successful combined use of tranexamic acid and unfractionated heparin for life-threatening bleeding associated with intravascular coagulation in a patient with chronic myelogenous leukemia in blast crisis.
Topics: Acute Disease; Adult; alpha-2-Antiplasmin; Antifibrinolytic Agents; Antineoplastic Agents; Antithrombin III; Benzamides; Blast Crisis; Blood Transfusion; Bone Marrow Transplantation; Colon; Colonic Diseases; Disseminated Intravascular Coagulation; Fibrinolysin; Gastrointestinal Hemorrhage; Genes, abl; Heparin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Peptide Hydrolases; Piperazines; Pyrimidines; Shock; Tranexamic Acid; Transplantation, Homologous | 2007 |
Pregnancy complicated with chronic myelogeneous leukemia (CML) successfully treated with imatinib: a case report.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Treatment Outcome | 2008 |
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Topics: Antigens, CD34; Benzamides; Bone Marrow; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Phosphorylation; Piperazines; Pyrimidines; Receptors, CXCR4; Up-Regulation | 2008 |
Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
Topics: Antineoplastic Agents; Benzamides; Fanconi Syndrome; Female; Humans; Hypophosphatemia; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Phosphates; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Irreversible sensorineural hearing loss due to Imatinib.
Topics: Adult; Benzamides; Hearing Loss, Sensorineural; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Topics: Adult; Aged; Amino Acid Substitution; Benzamides; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Recurrence; Retrospective Studies | 2008 |
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Topics: Adaptor Proteins, Signal Transducing; Benzamides; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiprotein Complexes; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Pyrimidines; Signal Transduction; src-Family Kinases | 2008 |
Prognosis of pediatric patients transplanted for Ph+ chronic myeloid leukemia in the period from 1989 to 2006 in the Czech Republic.
Topics: Adolescent; Benzamides; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Pyrimidines; Time Factors | 2008 |
Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones.
Topics: Benzamides; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2008 |
Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Caspases; Cell Differentiation; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Resveratrol; Stilbenes | 2008 |
Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Creatine Kinase; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Phosphates; Piperazines; Pyrimidines; Retrospective Studies | 2008 |
Bcr-Abl induces autocrine IGF-1 signaling.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Insulin-Like Growth Factor I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-hck; Pyrimidines; RNA, Messenger; Signal Transduction; STAT5 Transcription Factor | 2008 |
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD34; Apoptosis; Aurora Kinase B; Aurora Kinases; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; G2 Phase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mitosis; Mutant Proteins; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines | 2008 |
Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.
Topics: Benzamides; Cell Proliferation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 2008 |
Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells.
Topics: Apoptosis; Benzamides; Cell Proliferation; Cell Survival; Cellular Senescence; Combined Modality Therapy; Drug Evaluation, Preclinical; G2 Phase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Necrosis; Piperazines; Pyrimidines; Radiation-Sensitizing Agents; S Phase | 2008 |
JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders.
Topics: Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Polycythemia Vera; Pyrimidines | 2008 |
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Cohort Studies; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Retrospective Studies; Transplantation, Homologous | 2008 |
Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biological Evolution; Biological Transport; Fluorescent Dyes; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multidrug Resistance-Associated Proteins; Piperazines; Pyrimidines; Rhodamine 123 | 2008 |
Trisomy 6 in a CML patient receiving imatinib mesylate therapy.
Topics: Adult; Benzamides; Blast Crisis; Chromosomes, Human, Pair 6; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome; Trisomy | 2008 |
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzamides; Blood Component Removal; Bone Marrow; Cytogenetic Analysis; Female; Filgrastim; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Transplantation, Autologous; Treatment Outcome | 2008 |
CML: imatinib mesylate (Glivec) or something else?
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2007 |
Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Bone Marrow; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Glucuronidase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Reference Standards; RNA Stability; RNA, Neoplasm | 2008 |
Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Dasatinib; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Polymerase Chain Reaction; Pyrimidines; Remission Induction; Thiazoles | 2008 |
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Cardiotoxins; Female; Heart Function Tests; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Natriuretic Peptide, Brain; Piperazines; Pyrimidines | 2008 |
Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Topics: Benzamides; Chromosome Aberrations; Cytogenetic Analysis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Sarcoma, Myeloid | 2008 |
Regression of cutaneous squamous cell carcinoma in a patient with chronic myeloid leukaemia on imatinib mesylate treatment.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasms, Multiple Primary; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Skin Neoplasms | 2008 |
The effects of imatinib on pregnancy outcome.
Topics: Abnormalities, Multiple; Abortion, Spontaneous; Antineoplastic Agents; Benzamides; Craniofacial Abnormalities; Female; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrimidines; Retrospective Studies; Risk Factors | 2008 |
Primary ovarian insufficiency associated with imatinib therapy.
Topics: Adult; Amenorrhea; Antineoplastic Agents; Benzamides; Female; Follicle Stimulating Hormone; Humans; Imatinib Mesylate; Infertility, Female; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Primary Ovarian Insufficiency; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Development and dynamics of robust T-cell responses to CML under imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Clone Cells; Female; Flow Cytometry; Humans; Imatinib Mesylate; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2008 |
Additional rearrangements affecting the derivative chromosome 9 involved in the standard Philadelphia translocation after imatinib therapy in a patient with chronic myeloid leukemia.
Topics: Adult; Benzamides; Chromosome Aberrations; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Translocation, Genetic | 2008 |
Transporter pumps and imatinib: a cause of pharmacokinetic resistance?
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Benzamides; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Binding; Pyrimidines | 2008 |
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; src-Family Kinases | 2008 |
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzamides; Child; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Imatinib Mesylate; International Cooperation; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Multicenter Studies as Topic; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Program Development; Protein Kinase Inhibitors; Pyrimidines; Survival Analysis; Time Factors | 2008 |
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Topics: Adult; Aged; Benzamides; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Phosphorylation; Piperazines; Precursor Cells, B-Lymphoid; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sequence Deletion; Tyrosine | 2008 |
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Central Nervous System Neoplasms; Cyclophosphamide; Cytogenetic Analysis; Dexamethasone; Doxorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome; Vincristine | 2008 |
Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.
Topics: Antineoplastic Agents; Benzamides; Fatal Outcome; Hepatitis B, Chronic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver Failure, Acute; Male; Middle Aged; Piperazines; Pyrimidines | 2008 |
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nuclear Proteins; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2008 |
Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
Topics: Adult; Benzamides; Bone Marrow; Bone Marrow Examination; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2008 |
RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Topics: Animals; Benzamides; Benzoquinones; Blotting, Western; Cell Proliferation; Cell Survival; Colony-Forming Units Assay; Fusion Proteins, bcr-abl; Hematopoiesis; Imatinib Mesylate; Lactams, Macrocyclic; Lentivirus; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT5 Transcription Factor | 2008 |
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Differentiation; Cell Line, Tumor; Drug Resistance, Neoplasm; Flavonoids; G1 Phase; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Resting Phase, Cell Cycle | 2008 |
Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia.
Topics: Adrenergic beta-Antagonists; Adult; Antineoplastic Agents; Asian People; Benzamides; Cytochrome P-450 CYP2D6; Drug Interactions; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Metoprolol; Middle Aged; Piperazines; Polymorphism, Genetic; Pyrimidines; Statistics as Topic | 2008 |
Imatinib-associated hyperpigmentation, a side effect that should be recognized.
Topics: Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Pigmentation Disorders; Piperazines; Pyrimidines | 2009 |
Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation.
Topics: Adult; Aged; Benzamides; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction | 2008 |
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Topics: Aldehyde Dehydrogenase; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Benzamides; Caspase 3; Cells, Cultured; Drug Resistance, Neoplasm; Enzyme Activation; Fusion Proteins, bcr-abl; Glutathione; Humans; Imatinib Mesylate; Immunoblotting; Isothiocyanates; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mutation; Oxidation-Reduction; Piperazines; Precursor Cells, B-Lymphoid; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species | 2008 |
Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction | 2008 |
Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Benzoquinones; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphotransferases (Alcohol Group Acceptor); Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Signal Transduction | 2008 |
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Topics: Adult; Aged; Benzamides; Dasatinib; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Survival Rate; Thiazoles; Treatment Outcome | 2008 |
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Benzamides; Child; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2008 |
Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.
Topics: Benzamides; Cytogenetic Analysis; Female; Gene Deletion; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-bcr; Pyrimidines; Retrospective Studies; Survival Rate; Translocation, Genetic | 2008 |
Twin pregnancy in a patient of chronic myeloid leukemia on imatinib therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy, Multiple; Pyrimidines; Twins | 2008 |
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Topics: Animals; Benzamides; Cell Line, Tumor; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Silencing; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multiprotein Complexes; Nerve Growth Factor; PC12 Cells; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Receptor, trkA; RNA, Small Interfering; Signal Transduction | 2008 |
Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Topics: Antineoplastic Agents; Benzamides; Dasatinib; Drug Resistance, Neoplasm; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Point Mutation; Pyrimidines; Thiazoles; Treatment Outcome | 2008 |
Chronic myeloid leukemia and HIV-infection.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; CD4 Lymphocyte Count; Flow Cytometry; Follow-Up Studies; HIV Infections; HIV-1; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; Treatment Outcome; Viral Load | 2008 |
Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis.
Topics: Adult; Benzamides; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocytosis; Magnetic Resonance Imaging; Muscle, Skeletal; Piperazines; Pyrimidines | 2008 |
Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
Topics: Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Telomerase | 2008 |
Occurrence of colon adenocarcinoma in chronic myeloid leukemia patients treated with imatinib: report of two cases and review of the literature.
Topics: Adenocarcinoma; Aged; Benzamides; Colonic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines | 2009 |
[Imatinib-induced DRESS].
Topics: Aged; Antineoplastic Agents; Benzamides; Drug Hypersensitivity; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Skin; Skin Diseases | 2008 |
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib.
Topics: Adult; Benzamides; Dasatinib; Edema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retinal Diseases; Thiazoles | 2008 |
Bedside to bench: interfering with leukemic stem cells.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Progenitor Cells; Piperazines; Pyrimidines; Recombinant Proteins | 2008 |
Bench to bedside: BRCA: from therapeutic target to therapeutic shield.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Interferon Type I; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Progenitor Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recombinant Proteins | 2008 |
Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
Topics: Adult; Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 17; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Deletion; Genes, abl; Genes, p53; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mutation; Piperazines; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2008 |
Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzamides; Female; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2008 |
[Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; CD11b Antigen; Cell Proliferation; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopolysaccharide Receptors; NADPH Oxidases; Piperazines; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Oleanolic Acid; Oxidation-Reduction; Oxygen; Piperazines; Pyrimidines; Reactive Oxygen Species | 2008 |
An evaluation of the cardiotoxicity of imatinib mesylate.
Topics: Aged; Antineoplastic Agents; Atrial Fibrillation; Atrial Function, Left; Atrial Function, Right; Benzamides; Blood Pressure; Cardiotoxins; Electrocardiography; Heart Rate; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines | 2008 |
Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 16; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Translocation, Genetic | 2008 |
[Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment].
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Drug Resistance; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Molecular Sequence Data; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines | 2008 |
Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Aurora Kinase A; Aurora Kinases; Bcl-2-Like Protein 11; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Humans; Hydroxamic Acids; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Proteins; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrimidines; Vorinostat | 2008 |
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Topics: Animals; Benzamides; Blood Cells; Bone Marrow; Dose-Response Relationship, Drug; Enzyme Inhibitors; Evaluation Studies as Topic; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Stem Cells; Tumor Cells, Cultured | 1996 |
The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells.
Topics: Adult; Benzamides; Cell Differentiation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 1997 |
Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors.
Topics: Benzamides; Cell Cycle; Cell Division; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Growth Substances; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 1998 |
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Topics: Apoptosis; Benzamides; Cell Division; Cell Survival; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Pyrimidines; Tumor Cells, Cultured | 1998 |
The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL.
Topics: Antigens, CD34; Apoptosis; Benzamides; Enzyme Inhibitors; fas Receptor; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 1998 |
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 1999 |
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Tumor Cells, Cultured | 1999 |
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Topics: Apoptosis; Benzamides; Caspases; Enzyme Activation; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retinoblastoma Protein; Tumor Cells, Cultured; U937 Cells | 1998 |
Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors.
Topics: Antineoplastic Agents; Benzamides; Coculture Techniques; Colony-Forming Units Assay; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stromal Cells; Tumor Cells, Cultured | 1999 |
BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.
Topics: Animals; Benzamides; Cell Movement; Cell Transformation, Neoplastic; Down-Regulation; Fusion Proteins, bcr-abl; Half-Life; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Philadelphia Chromosome; Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases; Phosphoric Monoester Hydrolases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; src Homology Domains | 1999 |
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Topics: Animals; Apoptosis; bcl-X Protein; Benzamides; Caspase 3; Caspases; Cell Count; Cell Division; Chromones; Cytochrome c Group; Cytosol; Down-Regulation; Enzyme Activation; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Flavonoids; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Glycoproteins; Morpholines; Piperazines; Poly(ADP-ribose) Polymerases; Protein Binding; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Tumor Cells, Cultured; Tyrphostins | 2000 |
Molecular biology. Cancer fighter's modus operandi revealed.
Topics: Antineoplastic Agents; Benzamides; Catalytic Domain; Clinical Trials as Topic; Enzyme Activation; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Conformation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines | 2000 |
Dragons 'round the fleece again: STI571 versus alpha1 acid glycoprotein.
Topics: Animals; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orosomucoid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2000 |
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Erythromycin; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Orosomucoid; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Tumor Cells, Cultured | 2000 |
A cancer 'smart bomb'. A new drug shows hope of conquering a form of leukemia by targeting the misbehaving cells.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United States | 2000 |
Inviting leukemic cells to waltz with the devil.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Benzamides; Cell Nucleus; Enzyme Inhibitors; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2001 |
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.
Topics: Active Transport, Cell Nucleus; Animals; Apoptosis; Benzamides; Bone Marrow Cells; Cell Line, Transformed; Cell Nucleus; Cytoplasm; Enzyme Inhibitors; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2001 |
Hope for leukemia.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Translocation, Genetic | 2001 |
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Harringtonines; Homoharringtonine; Humans; Hydroxyurea; Imatinib Mesylate; Interferon-alpha; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Microbial Sensitivity Tests; Neoplasm Proteins; Neoplasms; Piperazines; Pyrimidines; Tumor Cells, Cultured; Vincristine | 2001 |
Leukemia cells fall on their swords.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Fatty Acids, Unsaturated; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Translocation, Genetic | 2001 |
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease.
Topics: Adult; Aged; Benzamides; Blast Crisis; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2001 |
Promising clinical trials on kinase inhibitor.
Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Cancer's mechanics. Targeting errant cells.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United States | 2001 |
Quick success for cancer kinase treatment.
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines | 2001 |
Gleevec (STI-571) for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2001 |
ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blast Crisis; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Oncogene Proteins v-abl; Phosphorylation; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Processing, Post-Translational; Pyrimidines; Substrate Specificity; Tumor Cells, Cultured | 2001 |
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Blast Crisis; Cell Line; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Amplification; Genes, abl; Humans; Hydrogen Bonding; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Philadelphia Chromosome; Phosphorylation; Piperazines; Point Mutation; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-crk; Pyrimidines; Recurrence; Signal Transduction | 2001 |
Cancer research. Why some leukemia cells resist STI-571.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Binding Sites; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Amplification; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Point Mutation; Proto-Oncogene Proteins c-abl; Pyrimidines | 2001 |
The oncologic four-minute mile.
Topics: Antineoplastic Agents; Benzamides; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Medical Oncology; Piperazines; Pyrimidines | 2001 |
New leukemia drug receives FDA approval.
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United States; United States Food and Drug Administration | 2001 |
From the Food and Drug Administration.
Topics: Antineoplastic Agents; Atrasentan; Benzamides; Drug Approval; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Orphan Drug Production; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrrolidines; United States; United States Food and Drug Administration | 2001 |
After 30 years of laboratory work, a quick approval for STI571.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Time Factors; United States; United States Food and Drug Administration | 2001 |
STI571 revolution: can the newer targeted drugs measure up?
Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Industry; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Neoplasms; Piperazines; Pyrimidines | 2001 |
New-age drug meets resistance.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Drug Approval; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Recurrence; United States | 2001 |
New drug targets genetic malfunction in chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Drug Delivery Systems; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.
Topics: Antineoplastic Agents; Benzamides; Carbon; Enzyme Inhibitors; Fatty Acids; Glucose; Glucosephosphate Dehydrogenase; Hexokinase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nucleic Acids; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transketolase; Tumor Cells, Cultured | 2001 |
[Anti-tyrosine kinase: the beginning of molecular therapies of cancer and initial results].
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Oncogene Proteins, Fusion; Philadelphia Chromosome; Piperazines; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Stomach Neoplasms; Treatment Outcome | 2001 |
Clinical trials referral resource. ST1571.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2001 |
Cancer treatment. New drugs, new hope.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Sarcoma | 2001 |
Cancer in the crosshairs.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2001 |
Implications of signal transduction inhibition for the treatment of chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2001 |
Cutaneous reactions to STI571.
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Drug Eruptions; Exanthema; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Topics: Acute Disease; Adult; Antineoplastic Agents; Benzamides; Diagnosis, Differential; Drug Eruptions; Enzyme Inhibitors; Exanthema; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Cancer treatment in the STI571 era: what will change?
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Evidence-Based Medicine; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Patient Selection; Piperazines; Pyrimidines; Stromal Cells | 2001 |
Roots of clinical resistance to STI-571 cancer therapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Proto-Oncogene Proteins c-abl; Pyrimidines | 2001 |
Chronic myeloid leukemia: current treatment options.
Topics: Antineoplastic Agents; Benzamides; Decision Making; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Prognosis; Pyrimidines; Risk Factors; Survival Rate; Transplantation, Homologous | 2001 |
Roots of clinical resistance to STI-571 cancer therapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Proto-Oncogene Proteins c-abl; Pyrimidines | 2001 |
Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2001 |
[New target-aimed molecular cancer treatment of chronic myeloid leukemia and gastrointestinal stromal tumor].
Topics: Antineoplastic Agents; Benzamides; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Improving the management of chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines | 2001 |
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo.
Topics: Antineoplastic Agents; Area Under Curve; Benzamides; Case-Control Studies; Cell Division; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Progenitor Cells; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Pyrimidines | 2001 |
Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.
Topics: Apoptosis; B-Lymphocytes; Benzamides; Cell Line; Cell Survival; Cysteine Endopeptidases; Down-Regulation; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Megakaryocytes; Mitogen-Activated Protein Kinases; Multienzyme Complexes; Nuclear Proteins; Oligonucleotides, Antisense; Piperazines; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Transfection | 2001 |
[STI571: the resistance organizes!].
Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gastrointestinal Neoplasms; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Pyrimidines; Recurrence | 2001 |
Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Bone Marrow Transplantation; Disease Models, Animal; DNA-Binding Proteins; Fusion Proteins, bcr-abl; Imatinib Mesylate; Immediate-Early Proteins; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Mice; Mice, Inbred BALB C; Milk Proteins; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Retroviridae; RNA, Messenger; Spleen; STAT5 Transcription Factor; Suppressor of Cytokine Signaling Proteins; Survival Rate; Trans-Activators; Transduction, Genetic | 2001 |
Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours.
Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Sensitivity and Specificity; Treatment Outcome | 2001 |
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Ploidies; Pyrimidines | 2001 |
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Topics: Benzamides; Blast Crisis; Cyclin D2; Cyclins; Down-Regulation; Fusion Proteins, bcr-abl; G1 Phase; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Phosphatidylinositol 3-Kinases; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; S Phase; Signal Transduction; Transfection | 2001 |
Imatinib.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2001 |
Imatinib for chronic myeloid leukaemia: a NICE mess.
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; National Health Programs; Piperazines; Pyrimidines; United Kingdom | 2001 |
Research on resistance to cancer drug Gleevec.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Amplification; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinases; Protein Structure, Tertiary; Pyrimidines; Reproducibility of Results | 2001 |
Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells.
Topics: Animals; Benzamides; Caspase 3; Caspases; Cell Division; Cell Survival; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Phosphorylation; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2001 |
Imatinib for chronic myeloid leukaemia: a NICE mess.
Topics: Antineoplastic Agents; Benzamides; Financing, Government; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; National Health Programs; Piperazines; Pyrimidines; United Kingdom | 2001 |
Imatinib for chronic myeloid leukaemia: a NICE mess.
Topics: Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; National Health Programs; Piperazines; Pyrimidines; Treatment Outcome; United Kingdom | 2001 |
Imatinib for chronic myeloid leukaemia: a NICE mess.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lichenoid Eruptions; Mouth Mucosa; National Health Programs; Piperazines; Pyrimidines; United Kingdom | 2001 |
Breakthrough of the year. The runners-up.
Topics: Animals; Antineoplastic Agents; Axons; Benzamides; Carbon; Climate; Ecosystem; Electronics; Genome, Human; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Physical Phenomena; Physics; Piperazines; Pyrimidines; Research; RNA; Science | 2001 |
BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.
Topics: Animals; Apoptosis; Benzamides; Blast Crisis; Carrier Proteins; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Proteins; Cells, Cultured; DNA-Binding Proteins; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Myeloid Cells; Neoplasm Proteins; Neoplastic Stem Cells; Oligodeoxyribonucleotides; Piperazines; Protein Biosynthesis; Protein Isoforms; Pyrimidines; Receptors, Granulocyte Colony-Stimulating Factor; RNA-Binding Proteins; RNA, Messenger; Sequence Alignment; Sequence Homology, Nucleic Acid; Transcription Factors; Transcription, Genetic; Transfection | 2002 |
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
Topics: Antigens, CD34; Antineoplastic Agents; Benzamides; Cell Division; Culture Media, Serum-Free; Enzyme Inhibitors; Flow Cytometry; Growth Substances; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2002 |
Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Enzyme Inhibitors; Erythropoiesis; Female; Granulocytes; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Megakaryocytes; Middle Aged; Piperazines; Primary Myelofibrosis; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction | 2002 |
Imatinib mesylate.
Topics: Antineoplastic Agents; Benzamides; Drug Costs; Drug Interactions; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
[Introduction: chronic myelogenous leukemia leading advanced clinical oncology].
Topics: Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2001 |
ST1571: a paradigm for clinical trials of molecularly targeted agents.
Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Gene Targeting; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines | 2001 |
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Topics: Adamantane; Apoptosis; Benzamides; Caspase 9; Caspases; Drug Synergism; Enzyme Induction; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Hydroquinones; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphorylation; Piperazines; Protein Biosynthesis; Protein Processing, Post-Translational; Proteins; Pyrimidines; Recombinant Fusion Proteins; Serpins; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay; Viral Proteins; X-Linked Inhibitor of Apoptosis Protein | 2002 |
Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Orosomucoid; Piperazines; Pyrimidines | 2002 |
Chronic myeloid leukemia. Sceptical scientists.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Thriving with chronic myeloid leukaemia.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; History, 20th Century; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2001 |
Autotransplantation for chronic myeloid leukemia: is it useful?
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow Purging; Busulfan; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melphalan; Multicenter Studies as Topic; Piperazines; Pyrimidines; Retrospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2002 |
Challenges in oncology. Case 3. Depigmentation in a chronic myeloid leukemia patient treated with STI-571.
Topics: Antineoplastic Agents; Benzamides; Humans; Hypopigmentation; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines | 2002 |
[STI571: a new dimension in the treatment of chronic myeloid leukemia].
Topics: Adult; Antineoplastic Agents; Benzamides; Blast Crisis; Clinical Trials as Topic; Drug Approval; Enzyme Inhibitors; Europe; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction; United States | 2002 |
[Molecular therapy of chronic myeloid leukemia--a new era in the treatment of malignant diseases].
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines | 2002 |
[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
[Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Clinical Trials as Topic; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Treatment Outcome | 2002 |
[Drug therapy of chronic myeloid leukemia].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Treatment Outcome | 2002 |
Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia.
Topics: Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzamides; Cell Division; Cytarabine; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stem Cells; Tretinoin; Tyrphostins | 2002 |
[Chronic myeloid leukemia as a model for modern noncytostatic therapy of malignant diseases. From Virchow to STI 571].
Topics: Animals; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Resistance to targeted therapy in leukaemia.
Topics: Benzamides; Drug Resistance; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmacogenetics; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2002 |
Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study.
Topics: Adult; Aged; Benzamides; Female; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.
Topics: Benzamides; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Prospective Studies; Protein-Tyrosine Kinases; Pyrimidines; Sequence Analysis, DNA | 2002 |
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Topics: Alternative Splicing; Antineoplastic Agents; Benzamides; Case-Control Studies; Cell Division; DNA-Binding Proteins; Enzyme Inhibitors; Feedback, Physiological; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Proteins; Pyrimidines; Repressor Proteins; Suppressor of Cytokine Signaling Proteins; Tissue Distribution; Trans-Activators; Tumor Cells, Cultured | 2002 |
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Topics: Antineoplastic Agents; Base Sequence; Benzamides; Bone Marrow Cells; DNA, Complementary; Drug Resistance; Fusion Proteins, bcr-abl; Genetic Testing; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
What is the dose of STI-571 needed to induce a molecular remission in chronic myeloid leukemia?
Topics: Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; RNA, Messenger | 2002 |
Adverse events after imatinib mesylate therapy.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Necrosis; Piperazines; Pyrimidines | 2002 |
Is red tape stifling the progress of new anticancer drugs?
Topics: Antineoplastic Agents; Benzamides; Drug Approval; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United States; United States Food and Drug Administration | 2002 |
FDA licences imatinib mesylate for CML.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; United States; United States Food and Drug Administration | 2002 |
Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.
Topics: Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Renal Insufficiency | 2002 |
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.
Topics: Adenosine Triphosphate; Adult; Aged; Benzamides; Binding Sites; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Point Mutation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines | 2002 |
STI-stop transplanting immediately?
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2002 |
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloid Progenitor Cells; Piperazines; Pyrimidines | 2002 |
Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzamides; Cytogenetic Analysis; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Neoplasm Recurrence, Local; Piperazines; Pyrimidines; Transplantation, Homologous | 2002 |
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.
Topics: Antineoplastic Agents; Benzamides; Cell Death; Cytarabine; Enzyme Inhibitors; Etoposide; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Tumor Cells, Cultured | 2002 |
Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Busulfan; Cell Division; Combined Modality Therapy; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Radiotherapy; Tumor Cells, Cultured | 2002 |
Unable to resist.
Topics: Antineoplastic Agents; Benzamides; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Translocation, Genetic; Up-Regulation | 2002 |
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Drug Approval; Exanthema; Headache; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nausea; Piperazines; Pyrimidines; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting | 2002 |
Stevens-Johnson syndrome after treatment with STI571: a case report.
Topics: Adult; Antineoplastic Agents; Benzamides; Drug Eruptions; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Stevens-Johnson Syndrome | 2002 |
Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Enzyme Inhibitors; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Topics: Animals; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Marrow Cells; Bone Marrow Transplantation; Cell Division; Cloning, Molecular; Disease Models, Animal; Disease Progression; Fusion Proteins, bcr-abl; Green Fluorescent Proteins; Homeodomain Proteins; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Luminescent Proteins; Mice; Nuclear Pore Complex Proteins; Oncogene Proteins, Fusion; Piperazines; Proviruses; Pyrimidines; Tumor Cells, Cultured | 2002 |
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Nucleus; Daunorubicin; DNA Fragmentation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potentials; Mitochondria; Phosphatidylserines; Piperazines; Pyrimidines; Tumor Cells, Cultured | 2002 |
Cerebral oedema as a possible complication of treatment with imatinib.
Topics: Aged; Benzamides; Brain Edema; Enzyme Inhibitors; Fatal Outcome; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Tomography, X-Ray Computed | 2002 |
Decrease of resistance to imatinib in leukaemia.
Topics: Benzamides; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Point Mutation; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Doctors condemn NICE's guidance on leukaemia drug.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Government Agencies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Practice Guidelines as Topic; Pyrimidines; United Kingdom | 2002 |
Cancer studies explore targeted therapy, researchers seek new prevention strategies.
Topics: Antineoplastic Agents; Antioxidants; Benzamides; Breast Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Genes, BRCA1; Genes, BRCA2; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Male; Mastectomy; Ovarian Neoplasms; Ovariectomy; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Retinoic Acid; Smoking; Tobacco Smoke Pollution; Tretinoin; Vitamins | 2002 |
Not so NICE for CML.
Topics: Antineoplastic Agents; Benzamides; Cytarabine; Drug Approval; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Treatment Outcome | 2002 |
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
Topics: Adenosine Triphosphate; Benzamides; Binding Sites; Cloning, Molecular; Enzyme Inhibitors; Humans; Imatinib Mesylate; Kinetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Piperazines; Point Mutation; Protein Conformation; Protein-Tyrosine Kinases; Pyrimidines; Recombinant Fusion Proteins; Recombinant Proteins; Sensitivity and Specificity; Substrate Specificity | 2002 |
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Topics: Adult; Aged; Benzamides; Blood Cells; Bone Marrow Cells; Cytogenetic Analysis; Drug Resistance; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Remission Induction; Retrospective Studies; Time Factors; Treatment Outcome | 2002 |
Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 8; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Philadelphia Chromosome; Piperazines; Pyrimidines; Trisomy | 2002 |
Imatinib and chronic-phase leukemias.
Topics: Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2002 |
Infusion of peripheral blood stem cells collected at diagnosis, with maintenance of the treatment, resulted in Ph-negative recovery in a chronic myeloid leukaemia patient in persisting aplasia on STI-571 therapy.
Topics: Benzamides; Combined Modality Therapy; Cryopreservation; Enzyme Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Transplantation, Autologous | 2002 |